<DOC>
<DOCNO>WT18-B27-1</DOCNO>
<DOCOLDNO>IA017-000177-B047-191</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-post.html 192.33.214.13 19970106035637 text/html 1650
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:56:59 GMT
Last-modified: Friday, 19-Jul-96 15:59:15 GMT
Content-length: 1462
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HivNet: Juristische Informationen</TITLE></HEAD>
<BODY>

<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-forum.html"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>

<UL>
<H2>Juristische Informationen</H2>

<P>
<H3><I>Stellung einer Frage</I></H3><BR CLEAR>
<HR>

<P>
Ihre Frage wird  <B><I>vertraulich</I></B> von einem Jurist des &quot;Groupe Sida Gen&egrave;ve&quot; bearbeitet.
<P>
<B>Vergessen Sie nicht</B> die bischer erteilte Ratschl&auml;ge zu konsultieren und reservieren Sie diesen Dienst f&uuml;r die juristische Fragen (<B>exklusiv Schweizer Recht</B>).
<P>
<UL>
<form action="Legal-post.cgi" method="POST">
<b>
Objekt der Frage<br>
<INPUT TYPE=text NAME=sujet SIZE=60 MAXLENGTH=60>
<P>
Frage<br>
<textarea wrap=virtual name=question rows=10 cols=60></textarea>
<P>
</B>
</UL>
<CENTER><I><input type=submit value="      Senden !      "></I></center>
</FORM>
<H3>Achtung ! :</H3>
<UL>
<LI>Wenn Sie auf <I>Senden !</I> dr&uuml;cken garantieren wir Ihnen dass nur das Objekt und die Frage dem Juristen  gesendet werden, ausschliesslich aller anderen Daten.
<P>
<LI>Wenn m&ouml;glich, stellen Sie eine Frage auf ein Mal ! 
</UL>



<P>
<CENTER> 
<A HREF="/d/index.html"><IMG SRC="/d/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/d/search/index.html"><IMG SRC="/d/gif/suchen2.gif" BORDER=0 ALT="Suchen"></A>
<A HREF="/d/hivnet/index.html"><IMG SRC="/d/gif/kontakte2.gif" BORDER=0 ALT="Kontakte"></A>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-2</DOCNO>
<DOCOLDNO>IA017-000177-B047-203</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/index.html 192.33.214.13 19970106035648 text/html 6466
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:57:07 GMT
Last-modified: Monday, 23-Dec-96 16:29:46 GMT
Content-length: 6278
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>HIVNet CH: Organisations</TITLE></HEAD>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/organisations.gif" WIDTH="130" HEIGHT="106" >
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Artworks"></A>
</CENTER>
<BR CLEAR>
<PRE>

 

</PRE>
<UL>
<UL>


<H2>Organisations actives dans le domaine HIV/SIDA</H2>

<P>
<B>Organisations pr&eacute;sentes sur ce serveur</B><P>



<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/dialogai/index.html">Dialogai</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/gsg/index.html">Groupe Sida Gen&egrave;ve<BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/pwa/index.html">PWA</A> - F&eacute;d&eacute;ration suisse PWA (People With Aids) et <A HREF="/pvage/index.html">PVA Gen&egrave;ve</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/sids/index.html">Sida Info Doc Suisse</A><BR><IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>Lettre mensuelle d'information <A HREF="/migrants/index.html">Migrants contre le Sida / VIH</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/fdp/index.html">La Fondation du Pr&eacute;sent - Gen&egrave;ve</A><BR>
<P>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/geneve/collectif/index.html">Programme du 1er D&eacute;cembre 1996, Gen&egrave;ve</A><BR>

<P>
<HR WIDTH=150>
<P>

<B>Organisations suisses - Index</B>
<P>
<TABLE BORDER=2 CELLPADDING=10>

<TR>

<TD ALIGN=CENTER><H1>A</H1>
<TD><LI><A HREF="ass.html"><B>AHS</B> (ASS)</A></B><I> - Aids Hilfe Schweiz und Kantonale Aids-Hilfen</I><BR>
<LI><A HREF="relig.html#bls"><B>Aidspfarramt</B> (Aum&ocirc;niers Sida)</A><I> beider Basel</I><BR>
<LI><A HREF="relig.html#zh"><B>Aidspfarramt</B> (Aum&ocirc;niers Sida)</A><I> (Z&uuml;rich)</I><BR>
<LI><B><A HREF="home.html#zh">Anker-Huus</A></B><I> (Wohnprojekte, Z&uuml;rich)</I><BR>
<LI><A HREF="ass.html"><B>ASS</B> (AHS)</A> - Aide Suisse contre le Sida, Antennes cantonales de l'ASS<BR>
<LI><B>Fondation <A HREF="child.html#vd">As'Trame</A></B><I> (Sida et enfants, Vaud)</I><BR>
<LI><A HREF="relig.html"><B>Aum&ocirc;niers Sida</B></A>
</TR>

<TR>
<TD ALIGN=CENTER><H1>B</H1>
<TD>
<LI><B><A HREF="home.html#bls">Basler Lighthouse</A></B><I> (Wohnprojekte, B&acirc;le)</I><BR>
<LI><B><A HREF="ofsp.html">BAG</A></B><I> - Budesamtes f&uuml;r Gesundheitswesen</I><BR>
</TR>

<TR>
<TD ALIGN=CENTER><H1>D</H1>
<TD><LI><B><A HREF="/dialogai/index.html">Dialogai</A></B><I> (Association homosexuelle, GE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>E</H1>
<TD><LI><B><A HREF="home.html#ju">Espace Bleu</A></B><I> (Lieu d'accueil, JU)</I><BR>
<LI><B>Association <A HREF="child.html#ge">ESPER</A></B><I> (Sida et enfants, GE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>G</H1>
<TD><LI><B><A HREF="child.html#ju">GSE</A> - Groupe Sida Enfants</B><I> (JU)</I>
<LI><B><A HREF="/gsg/index.html">GSG</A> - Groupe Sida Gen&egrave;ve</B><I> (Antenne de l'ASS)</I>
<LI><B><A HREF="child.html#ge">GSG</A> - Groupe Sida Gen&egrave;ve</B><I> (Sida et enfants)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>H</H1>
<TD><LI><B><A HREF="home.html#bls">Haus Gilgamesch</A></B><I> (Wohnprojekte, BS)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>K</H1>
<TD><LI><B><A HREF="child.html#zh">Aids</A> und Kind <I>(ZH)</I> 
</TR>


<TR>
<TD ALIGN=CENTER><H1>L</H1>
<TD><LI><B>Fondation du <A HREF="home.html#vd">Levant</A></B><I> (Lieu d'accueil, VD)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>M</H1>
<TD><LI><B>La <A HREF="home.html#ge">Maison</A></B><I> (Lieu d'accueil, GE)</I>
<LI><B><A HREF="/migrants/index.html">Migrants contre le Sida/VIH</A></B><I>
<LI><B><A HREF="/ministere-sida/">Minist&egrave;re Sida</A></B><I> (Aum&ocirc;niers sida, GE)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>O</H1>
<TD><LI><B><A HREF="ofsp.html">OFSP</A></B><I> - Office F&eacute;d&eacute;ral de la Sant&eacute; Publique</I>
</TR>



<TR>
<TD ALIGN=CENTER><H1>P</H1>
<TD><LI><B><A HREF="relig.html#ge">Pasteure:</A> Mme Dominique Roulin</B><I> (GE)</I><BR><UL> et aupr&egrave;s de <B><A HREF="/ministere-sida/">Minist&egrave;re Sida</A></B><I> (Aum&ocirc;niers sida, GE)</I></UL>
<LI><B><A HREF="child.html#ge">Plateforme</A> 'Sida et Enfants'</B><I> (GE)</I>
<LI><B>Fondation du <A HREF="/f/fdp/index.html">Pr&eacute;sent</A></B><I>(Information, GE)</I>
<LI><B><A HREF="/pvage/index.html">PVA</A> - Gen&egrave;ve</B><I> (Antenne de PWA Suisse)</I>
<LI><B><A HREF="/pwa/index.html">PWA</A> Schweiz</B><I> (Schw. Verein der </i>People With Aids<i>)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>S</H1>
<TD><LI><B><A HREF="relig.html#bls">Seelsorge:</A> Herr Benedict H&auml;nggi</B><I> (BS)</I>
<LI><B><A HREF="/sids/index.html">SIDS</A> Sida Info Doc Suisse</B><I></I>
<LI><B><A HREF="home.html#zh">Sune-Egge</A></B><I> (Wohnprojekte, ZH)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>W</H1>
<TD><LI><B><A HREF="home.html#sg">Wohngemeinschaft</A> 'Arche'</B><I> (Wohnprojekte, SG)</I>
<LI><B><A HREF="home.html#be">Wohngemeinschaft</A> St&ouml;ckli</B><I> (Wohnprojekte, BE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>Z</H1>
<TD><LI><B><A HREF="home.html#zh">Z&uuml;rcher Aids Projekte</A></B><I> (Wohnprojekte, ZH)</I>
<LI><B><A HREF="home.html#zh">Z&uuml;rcher Lighthouse</A></B><I> (Wohnprojekte, ZH)</I>
</TR>
</TABLE>
</UL>
</UL>
<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" WIDTH="100" HEIGHT="100"   BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" WIDTH="100" HEIGHT="100"   BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-3</DOCNO>
<DOCOLDNO>IA017-000177-B047-214</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/ass.html 192.33.214.13 19970106035657 text/html 8320
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:57:19 GMT
Last-modified: Friday, 06-Sep-96 17:10:53 GMT
Content-length: 8132
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Organisations: Swiss AIDS Help</TITLE></HEAD>



<BODY BGCOLOR="FFFFFF">

<A HREF="../organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Aide Suisse contre le Sida</H1><HR>


<IMG ALIGN=right HSPACE=30 BORDER=0 SRC="/gif/ass_l.gif">

Postfach 141, CH-8031 Z&uuml;rich,<br><i>t&eacute;l (01) 273 42 42, fax (01) 273 42 62</i><br clear>

<B><i>e-mail:</i> <A HREF="mailto:aids@aids.ch">aids@aids.ch</A></B>



<P><HR><center>



<H3>Antennes Cantonales de l'Aide Suisse contre le Sida</H3>

<A HREF="#ag">AG</A> / <A HREF="#sg">AI,AR</A> / <A HREF="#bls">BL,BS</A> / <A HREF="#be">BE</A> / <A HREF="#fl">FL</A> / <A HREF="#ge">GE</A> / <A HREF="#gr">GR</A> / <A HREF="#ju">JU</A> / <A HREF="#lu">LU</A><br>

<A HREF="#ne">NE</A> / <A HREF="#sg">SG</A> / <A HREF="#sh">SH</A> / <A HREF="#so">SO</A> / <A HREF="#sh">TG</A> / <A HREF="#ti">TI</A> / <A HREF="#vd">VD</A> / <A HREF="#vs">VS</A> / <A HREF="#zg">ZG</A> / <A HREF="#zh">ZH</A>
<P>
</center>
<HR>
<A NAME="ag"><H3>Aargau</H3></A>

<UL>

<LI><B>Aids-Hilfe Aargau</B><br>

Entfelderstr. 17<br>

CH-5000 Aarau<br>

<I>tel (064) 244 450<br>

fax (064) 244 409<br></I>

<UL>Beratung: Mo 8 bis 12 Uhr, Mi und Do 14 bis 17 Uhr; (064) 243 050</UL>

</UL>



<A NAME="air"><H3>Appenzell : Siehe unter AHS <A HREF="#sg">St. Gallen</A></H3></A>



<A NAME="bls"><H3>Basel</H3></A>

<UL>

<LI><B>Aids-Hilfe Beider Basel</B><br>

Claragraben 160<br>

CH-4057 Basel<br>

<I>tel (061) 692 21 22 oder 692 73 92<br>

fax (061) 692 50 75<br></I>

<UL>Mo-Fr 9 bis 5 Uhr, durchgehend</UL>

</UL>



<A NAME="be"><H3>Bern</H3></A>

<UL>

<LI><B>Aids-Hilfe Bern</B><br>

Wylerstr. 109<br>

Postfach 16<br>

CH-3000 Bern 12<br>

<I>tel (031) 331 33 34<br>

fax (031) 331 33 36<br></I>

<UL>Beratung: Mo 9 bis 16 Uhr, Di 9 bis 12 Uhr, Mi-Fr 9 bis 16 Uhr<br>

<B>Jeden Di ab. 1700 Uhr bis in den Abend:</B><br>

Pers. Beratung ohne Vorhanmeldung im Caf&eacute;-Anderland, am M&uuml;hlepltaz 11</UL><P>

<LI><B>Aids-Hilfe Biel<br>Aide Sida Bienne</B><br>

Freiestr. 37<br>

Postfach/Case Postale 3605<br>

CH-2500 Biel/Bienne<br>

<I>tel (032) 424 342 (deutsch)<br>

tel (032) 412 141 (fran&ccedil;ais)<br>

fax (032) 412 161<br></I>

<UL>&Ouml;ffnungszeiten laut Telefonbeantworter /<br>Heures d'ouverture sur r&eacute;pondeur t&eacute;l&eacute;phonique</UL>

</UL>



<A NAME="fl"><H3>F&uuml;rstenturm Liechtenstein</H3></A>

<UL>

<LI><B>Aids-Hilfe Liechtenstein</B><br>

Postfach 207<br>

FL-9494 Schaan<br>

<I>tel (075) 232 05 20<br></I>

<UL>Mo 18 bis 20 Uhr; Do 8 bis 9 Uhr</UL>

</UL>



<A NAME="ge"><H3>Gen&egrave;ve</H3></A>

<UL>

<LI><B><A HREF="/dialogai/">Dialogai</A></B><br>

57, av. Wendt (entr&eacute;e rue Liotard)<br>

CH-1203 Gen&egrave;ve<br>

<UL>(Case Postale 27, CH-1211 Gen&egrave;ve 7)<br></UL>

<I>tel (022) 340 00 00<br>

fax (022) 340 03 98</I>

<UL>Permanence t&eacute;l&eacute;phonique me 19 &agrave; 22 heures<br>Portes ouvertes me et je de 20 &agrave; 22 heures</UL><P>

<LI><B><A HREF="/gsg/">Groupe Sida Gen&egrave;ve</A></B><br>

17, rue Pierre-Fatio<br>

CH-1204 Gen&egrave;ve<br>

<I>tel (022) 700 15 00<br>

fax (022) 700 15 47<br></I>

<UL>lu-ve 9 &agrave; de 12 heures et 14 &agrave; 16 heures<br>Portes ouverte me de 19 &agrave; 21 heures 30</UL>

</UL>



<A NAME="gr"><H3>Grisons</H3></A>

<UL>

<LI><B><A HREF="http://www.spin.ch/aidshelp/">Aids-Hilfe Gra&uuml;bunden</A></B><br>

Lurlibadstrasse 15<br>

CH-7002 Coire<br>

<I>tel (081) 224 900<br>

fax (081) 224 901<br></I>

<UL>Conseils aux heures de bureau</UL>

</UL>



<A NAME="ju"><H3>Jura</H3></A>

<UL>

<LI><B>Groupe Sida Jura</B><br>

Case Postale 2201<br>

CH-2800 Del&eacute;mont<br>

<I>tel (066) 222 868<br>

fax (066) 231 339<br></I>

<UL>lu au ve de 9 &agrave; 17 heures</UL>

</UL>



<A NAME="lu"><H3>Luzern</H3></A>

<UL>

<LI><B>Aids-Hilfe Luzern</B><br>

Wesemlinrain 20<br>

Postfach 6183<br>

CH-6000 Luzern 6<br>

<I>tel (041) 516 960<br>

fax (041) 516 848<br></I>

Mo-Do 9 bis 12 und 14 bis 17<br>

<UL>Beratung: Mo 17 bis 19 Uhr, Mi 9.30 bis 11.30 Uhr, Do 15 bis 17 Uhr, <I>tel (041) 516 848</I></UL>

</UL>



<A NAME="ne"><H3>Neuch&acirc;tel</H3></A>

<UL>

<LI><B>Groupe Sida Neuch&acirc;tel</B><br>

6, rue du Verger<br>

CH-2034 Peseux<br>

<I>tel (038) 314 924<br>

fax (038) 301 750<br>

lu-ve de 8 &agrave; 11 heures 30<br></I>

<UL>Info-Sida: lu, me de 19 &agrave; 21 heures; ma, je et ve de 9 &agrave; 11 heures 30 au<I> (038) 311 313</I></UL><P>

<LI><B>Homologai</B><br>

Permanence homosexuelle,<br>

Case Postale 1719<br>

CH-2002 Neuch&acirc;tel<br>

<UL> je de 20 &agrave; 22 heures au <I>(038) 315 726</I></UL>

</UL>



<A NAME="sh"><H3>Schaffhausen / Thurgau</H3></A>

<UL>

<LI><B>Aids-Hilfe Schaffhausen / Thurgau</B><br>

Rathausbogen 15<br>

CH-8200 Schaffhausen<br>

<I>tel (053) 259 338<br></I>

<UL>Mo-Fr 8 bis 12 Uhr, Mi 14 bis 17 Uhr</UL>

</UL>



<A NAME="so"><H3>Solothurn</H3></A>

<UL>

<LI><B>Aids-Hilfe Solothurn</B><br>

Postfach 155<br>

CH-4502 Solothurn<br>

<I>tel (065) 229 411 oder 553 134<br>

fax (065) 553 134<br></I>

<UL>Mo-Fr 8 bis 12 Uhr und 15 bis 18 Uhr</UL>

</UL>



<A NAME="sg"><H3>St. Gallen / Appenzell</H3></A>

<UL>

<LI><B>Aids-Hilfe St. Gallen / Appenzell</B><br>

Tellstr. 4, 2. Stock<br>

CH-9001 St. Gallen<br>

<UL>(Postfach 8, CH-9001 St. Gallen)</UL>

<I>tel (071) 236 808<br>

fax (071) 236 607<br></I>

<UL>Mo-Do 9 bis 12 Uhr und 14 bis 17 Uhr, Fr 9 bis 12 Uhr<br>Beratung: Zeiten bitte jeweils vom Telefonbeantworter abh&ouml;ren,<br><I>tel (071) 233 868</I></UL>

</UL>



<H3>Thurgau : Siehe unter AHS <A HREF="#sh">Schaffhausen</A></H3>



<A NAME="ti"><H3>Ticino</H3></A>

<UL>

<LI><B>Aiuto Aids Ticino</B><br>

Via Zurigo<br>

Casella Postale 34<br>

CH-6904 Lugano<br>

<I>tel e fax (091) 238 040<br></I>

<UL>lu-gi 9:30-17:30<br>informazione: lu-gi 14-17 ore, <I>tel (091) 231 717</I></UL>

</UL>



<A NAME="vs"><H3>Valais / Wallis</H3></A>

<UL>

<LI><B>Antenne Sida du Valais romand</B><br>

10, av. du Midi<br>

CH-1950 Sion<br>

<UL>lu et ma de 8 &agrave; 12 heures et de 14 &agrave; 18 heures; je de 8 &agrave; 12 heures<br>Permanence t&eacute;l&eacute;phonique ma de 18 &agrave; 22 heures au <I>tel (027) 228 757</I><br>Portes ouvertes ma de 19 &agrave; 21 heures</UL><P>

<LI><B>Aids-Hilfe Oberwallis</B><br>

St. Martiniplatz 1,<br>

Postfach 30<br>

CH-3930 Visp<br>

<I>tel (028) 464 668<br></I>

<UL>di 19 bis 21 Uhr</UL>

</UL>



<A NAME="vd"><H3>Vaud</H3></A>

<UL>

<LI><B>Point Fixe</B><br>

14, rue Louis-Curtat<br>

CH-1005 Lausanne<br>

<I>tel et fax (021) 320 40 60</I>

</UL>



<A NAME="zg"><H3>Zug</H3></A>

<UL>

<LI><B>Fachstelle f&uuml;r Aidsfragen</B><br>

Zeughausgasse 9, 6. Stock<br>

CH-6300 Zug<br>

<I>tel (042) 224 865<br></I>

<UL>Mo und Do 10 bis 13 Uhr und 14 bis 17 Uhr</UL>

</UL>



<A NAME="zh"><H3>Z&uuml;rich</H3></A>

<UL>

<LI><B>Z&uuml;rcher Aids-Hilfe</B><br>

Birmendorferstr. 169<br>

CH-8003 Z&uuml;rich<br>

<UL>(Postfach 690, CH-8026 Z&uuml;rich)</UL>

Allgemeine Telefonberatung, Mo-Fr 9 bis 13 Uhr und 14 bis 17 Uhr,<br><i>tel (01) 461 15 16<br>fax (01) 461 46 69</i><br>

<UL>Beratung: Frauentel. am Mo, Jugendtel. am Mi und Schwulentel. am Di,<br>jeweils von 14 bis 17 Uhr, <I>tel (01) 461 15 16</I></UL><P>

<LI><B>Aids-Informationsstelle Winterthur</B><br>

Lagerhausstr. 5<br>

Postfach 1251<br>

CH-8401 Winterthur<br>

<I>tel (052) 212 81 41<br>

fax (052) 212 80 95<br></I>

<UL>Di-Do 14 bis 17 Uhr</UL><P>

<LI><B>Aids-Hilfe Bezirk Horgen</B><br>

Dorfstr. 7<br>

CH-8800 Thalwil<br>

<I>tel (01) 721 20 50<br></I>

<UL>Jeden 1. und 3. Montag Positiven-Treffen genauere Informationen bei:<br>

Susi Hoffmann, <I>tel (01) 729 94 53</I>; Mia Huber, <I>tel (01) 720 83 64</I></UL>

</UL>



<HR>

Source: Aide Suisse contre le Sida, 5.95

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-4</DOCNO>
<DOCOLDNO>IA017-000177-B047-229</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/ofsp.html 192.33.214.13 19970106035709 text/html 1029
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:57:28 GMT
Last-modified: Saturday, 13-Apr-96 19:16:30 GMT
Content-length: 840
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Organisations: OFSP</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Office F&eacute;d&eacute;ral de la Sant&eacute; Publique</H1><HR>

<IMG ALIGN=right HSPACE=30 BORDER=0 SRC="/gif/ofsp_l.gif">

<H3>Division Promotion de la Sant&eacute; / Section Sida</H3><P>

Hess-strasse 27E, CH-3097 Liebefeld, <br><i>t&eacute;l (031) 970 87 13/88 11, fax (031) 970 87 89</i><br clear>


<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-5</DOCNO>
<DOCOLDNO>IA017-000177-B047-240</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/pwa/ 192.33.214.13 19970106035719 text/html 2857
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:57:41 GMT
Last-modified: Friday, 03-May-96 18:40:40 GMT
Content-length: 2669
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Organisations: People with AIDS</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>People With Aids - Suisse</H1><HR>

<H2><IMG ALIGN=right HSPACE=30 BORDER=0 SRC="/gif/pwa_l.gif">P.W.A-Suisse</H2><P>

Theaterstr. 3, CH-8400 Winterthur, <br><i>tel (052) 212 47 47, fax (052)</i>



<P><HR><center>



<H3><A HREF="pwachf.html">Pr&eacute;sentation</A> de P.W.A Suisse</H3>



<HR WIDTH=250>



<H3>Antennes cantonales de P.W.A-Suisse</H3>

<A HREF="#ag">AG</A> / <A HREF="#sg">AI,AR</A> / <A HREF="#be">BE</A> / <A HREF="#bls">BL,BS</A> / <A HREF="#fl">FL</A> / <A HREF="#ge">GE</A> / <A HREF="#gr">GR</A> / <A HREF="#ju">JU</A> / <A HREF="#lu">LU</A><br>

<A HREF="#ne">NE</A> / <A HREF="#sg">SG</A> / <A HREF="#sh">SH</A> / <A HREF="#so">SO</A> / <A HREF="#sh">TG</A> / <A HREF="#ti">TI</A> / <A HREF="#vd">VD</A> / <A HREF="#vs">VS</A> / <A HREF="#zg">ZG</A> / <A HREF="#zh">ZH</A>

<P>



</center><HR>



<A NAME="ag"><H3>Aargau</H3></A>

<UL>

</UL>



<A NAME="bls"><H3>Basel</H3></A>

<UL>

</UL>



<A NAME="be"><H3>Bern</H3></A>

<UL>

<LI><B>P.W.A-Bern</B><br>

Cecilienstr. 7<br>

CH-3007 Bern<br>

<I>tel (031) 371 17 85</I>

</UL>



<A NAME="ge"><H3>Gen&egrave;ve</H3></A>

<UL>

<LI><B><A HREF="/pvage/index.html">PVA Gen&egrave;ve</A></B><br>

17, rue Pierre-Fatio<br>

CH-1204 Gen&egrave;ve<br>

<I>tel (022) 700 15 31<br>

fax (022) 700 15 41</I>

</UL>



<A NAME="gr"><H3>Graub&uuml;nden</H3></A>

<UL>

</UL>



<A NAME="ju"><H3>Jura</H3></A>

<UL>

</UL>



<A NAME="lu"><H3>Luzern</H3></A>

<UL>

</UL>



<A NAME="ne"><H3>Neuch&acirc;tel</H3></A>

<UL>

</UL>



<A NAME="sh"><H3>Schaffhausen / Thurgau</H3></A>

<UL>

</UL>



<A NAME="so"><H3>Solothurn</H3></A>

<UL>

</UL>



<A NAME="sg"><H3>St. Gallen / Appenzell</H3></A>

<UL>

</UL>



<A NAME="ti"><H3>Ticino</H3></A>

<UL>

</UL>



<A NAME="vs"><H3>Valais / Wallis</H3></A>

<UL><LI><B>P.V.A. Valais</B><BR>
Case postale<BR>
1951 SION<BR>


</UL>



<A NAME="vd"><H3>Vaud</H3></A>

<UL>

</UL>



<A NAME="zg"><H3>Zug</H3></A>

<UL>

</UL>



<A NAME="zh"><H3>Z&uuml;rich</H3></A>

<UL>

<LI><B>ACT-HIV</B><br>

Hallwylstr. 78<br>

CH-8004 Z&uuml;rich<br>

<I>tel (01) 291 37 20</I>

</UL>



<P><HR>

Source:  P.W.A-Suisse, 11.95

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-6</DOCNO>
<DOCOLDNO>IA017-000177-B047-255</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/dialogai/ 192.33.214.13 19970106035734 text/html 13579
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:57:55 GMT
Last-modified: Monday, 24-Jun-96 16:36:42 GMT
Content-length: 13390
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Organisations: Dialogai</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Dialogai</H1><HR>

<IMG ALIGN=right HSPACE=0 WIDTH=250 SRC="/gif/dialog_l.gif">
57 av. Wendt<BR>
(entr&eacute;e rue Liotard),<BR>
Case postale 27,<BR>
1211 Gen&egrave;ve 7<br>
<i>t&eacute;l&eacute;phone (022) 340 00 00,<BR> 

t&eacute;l&eacute;fax (022) 340 03 98</i><br clear>


<HR WIDTH=550>
<UL>



<LI><A HREF="#presentation">Pr&eacute;sentation</A> de Dialogai

<LI><A HREF="#phone">Permanence t&eacute;l&eacute;phonique, entretiens...</A>

<LI><A HREF="#cafeplus">Caf&eacute;+</A><I> (groupe solidarit&eacute;-sida)</I>

<LI><A HREF="#publications">Publications de Dialogai</A>

<LI>Publications sur <A HREF="#prevention">la pr&eacute;vention et la maladie</A>

<LI><A HREF="#biblio">Biblioth&egrave;que</A>



</UL><HR WIDTH=550>

<UL>



<A NAME="presentation"><H3>Association 'Dialogai'</H3></A>
<P>
L'association Dialogai a &eacute;t&eacute; cr&eacute;&eacute;e &agrave; Gen&egrave;ve en 1982. Depuis, l'association offre une structure d'accueil, d'&eacute;coute, de convivialit&eacute; et d'information. Elle se propose en outre de favoriser le dialogue avec toutes les composantes de la soci&eacute;t&eacute;, d'agir dans le cadre de la lutte contre le sida et de d&eacute;fendre les personnes victimes de discriminations fond&eacute;es sur leur orientation sexuelle.
<P>
Pour atteindre ses buts, Dialogai offre plusieurs activit&eacute;s: f&ecirc;tes annuelles, brunchs (les dimanches d'hiver, de 12 &agrave; 14 heures). Le mercredi de 19 &agrave; 22 heures, nous offrons un service de <A HREF="#biblio">biblioth&egrave;que</A> et une <A HREF="#phone">permanence t&eacute;l&eacute;phonique</A>, ainsi qu'un repas dans une ambiance sympa, &agrave; partir de 20 heures.
<P>
Un bar macho-cuir-drag-queen compl&egrave;te la liste de nos rendez-vous, les premiers et avant-derniers vendredi du mois, de 22 heures &agrave; l'aube.
<P>
En outre, de nombreux groupes constitu&eacute;s au sein de l'association s'articulent autour de th&egrave;mes pr&eacute;cis: les gais randos (marche, ski), les gais mari&eacute;s, <A HREF="#cafeplus"><B>caf&eacute;+</B></A><B> (groupe solidarit&eacute;-sida)</B>, les gais motards, le groupe C+H (chr&eacute;tiens et homosexuels), le groupe jeunes gais (pour les moins de 25 ans), l'Organisation suisse des enseignants et &eacute;ducateurs homosexuels (OSEEH), les Gais Etudiants du Bouddhisme et enfin le choeur homog&egrave;ne (chorale gaie).
<P>
En 1985, Dialogai est devenue la premi&egrave;re antenne de l'<A HREF="/f/organs/ass.html">Aide Suisse contre le Sida</A> (ASS). A ce titre, nous tenons &agrave; disposition des personnes int&eacute;ress&eacute;es une riche <A HREF="#prevention">documentation</A> sur la pratique du sexe sans risques (safer sex) - et le mat&eacute;riel aux normes permettant de le pratiquer!



</UL><HR WIDTH=550>

<UL>



<A NAME="cafeplus"><H3>Caf&eacute;+ <I>(groupe solidarit&eacute;-sida)</I></H3></A>
<P>
A raison de trois mardis par mois, les personnes concern&eacute;es par le sida (s&eacute;ropositifs, malades, proches...) se r&eacute;unissent au local de Dialogai. C'est l'occasion de se retrouver, dans le respect mutuel de la confidentialit&eacute;. Nous &eacute;voquons nos exp&eacute;riences, nos vies, cherchons des soutiens, des r&eacute;ponses... et nous entraidons.
<P>
De mani&egrave;re g&eacute;n&eacute;rale, les rencontres sont plut&ocirc;t informelles. Cela permet en effet &agrave; chacun d'&eacute;voquer des exp&eacute;riences qui, souvent impr&eacute;visibles, doivent &ecirc;tre relat&eacute;es "&agrave; chaud". Cette souplesse est en effet un atout lorsque l'on est confront&eacute; &agrave; des &eacute;v&eacute;nements, des &eacute;motions peu ma&icirc;trisables. Mais cela permet aussi, bien souvent, de discuter dans une ambiance conviviale. C'est la raison d'&ecirc;tre du nom du groupe: caf&eacute; +.
<P>
Caf&eacute; + action (le deuxi&egrave;me mardi du mois) est centr&eacute; autour d'une revue de presse, d'un th&egrave;me d'actualit&eacute; ou d'une rencontre avec un invit&eacute;.<BR>
Caf&eacute; + soutien (le troisi&egrave;me mardi du mois) est anim&eacute; par un psychologue; il permet &agrave; chacun de parler en groupe, de soi et de sa situation. Pour plus d'informations, appeler Dialogai ou Alain au (022) 305.51.21.<BR>
Caf&eacute; + repas (le dernier mardi du mois) nous r&eacute;unit autour d'une table. L'ambiance chaleureuse d'un repas permet &agrave; chacun d'&eacute;voquer son v&eacute;cu de mani&egrave;re plus informelle, plus sociale...
<P>
<B>Fonds de solidarit&eacute; sida:</B> en activit&eacute; depuis 1988, ce fonds permet d'apporter une aide ponctuelle, individuelle ou collective &agrave; toute personne touch&eacute;e par le sida ou toute institution s'occupant de s&eacute;ropositifs ou de malades.
<P>
Un grand merci &agrave; ceux qui nous soutiennent. Nous vous rappelons que Dialogai, &eacute;tant consid&eacute;r&eacute; comme une association d'utilit&eacute; publiques, selon l'art. 21U, LPC, que vos dons sont d&eacute;ductibles d'imp&ocirc;ts.Voil&agrave;! 
<P>
Ce bref aper&ccedil;u vous aura, nous l'esp&eacute;rons, donn&eacute; une petite id&eacute;e du contenu, du but de nos rencontres. Mais il y a bien des choses qui ne sauraient &ecirc;tre mises sur papier: la solidarit&eacute;, les contacts qui se nouent, le plaisir de se retrouver, les rires et les &eacute;motions. Alors pourquoi ne pas venir partager un de ces moments en notre compagnie ?
<P>
A bient&ocirc;t!



</UL><HR WIDTH=550>

<UL>



<A NAME="publications"><H3>Publications</H3></A>

<LI><A HREF="#dialinfo">Dialogai-infos

<LI><A HREF="#decoudre"><I>"Pour en d&eacute;coudre avec..."</I></A>

<LI>Les <A HREF="#blackbook"><I>"Cahiers Noirs"</I></A>

</UL><HR WIDTH=200><UL>

<A NAME="dialinfo"><H4>Dialogai-infos</H4></A>
<P>
Dialogai-Infos para&icirc;t six fois l'an. Son tirage est de 6000 exemplaires, il est envoy&eacute; &agrave; tous les membres de l'association, aux abonn&eacute;s, correspondants et distribu&eacute; dans les commerces gais de Suisse et de France voisine. Cette publication est une tribune de toute premi&egrave;re importance pour le milieu Gai suisse-romand et les personnes concern&eacute;es par le VIH/Sida. Elle permet la diffusion de l'information sur le VIH/Sida et sur les th&egrave;mes homosexuels, avec une ligne r&eacute;dactionnelle dans le respect des sensibilit&eacute;s gaies. Information sur l'association, la vie gaie locale, nationale et internationale, virus-infos (informations m&eacute;dicales, l&eacute;gales adresses destin&eacute;es aux s&eacute;ropos, malades et leurs proches), petites annonces...



<A NAME="decoudre"><H4><I>"Pour en d&eacute;coudre avec..."</I></H4></A>
<P>
La troisi&egrave;me &eacute;dition de <I><B>Pour en d&eacute;coudre avec...</B></I> se propose, comme &agrave; l'origine, de r&eacute;pondre aux interrogations pratiques les plus courantes et les plus l&eacute;gitimes des personnes concern&eacute;es par le sida. Elle n'a ni ambition th&eacute;orique, ni pr&eacute;tentions encyclop&eacute;diques. Elle veut surtout tenir compte de l'environnement social sp&eacute;cifique de la Suisse romande.
<P>
Les sujets abord&eacute;s sont les suivants: Infection VIH / Pr&eacute;vention / Institutions, politique, &eacute;conomie / Soins, aide, solidarit&eacute; / Emploi, assurances, social / Ethique, droits de l'homme, droit / Droits de l'homme et &eacute;thique / Le secret m&eacute;dical / Le droit des patients / Droit p&eacute;nal et sida / Succession et couple gay / Voyages et infection &agrave; VIH / Code p&eacute;nal, police et gays / etc...
<P>
La prochaine &eacute;dition, actualis&eacute;e dans le domaine de l'assurance maladie et des nouveaux traitements et augment&eacute;e de nouveaux chapitres, sera disponible aux alentours de l'automne 1996
 

<A NAME="blackbook"><H4>Les<I> "Cahiers Noirs"</I></H4></A>
<P>
Les <B><I>Cahiers Noirs de l'HCUG</I></B> fut la premi&egrave;re &eacute;tape d'un effort d'am&eacute;lioration des conditions d'hospitalisation &agrave; Gen&egrave;ve. Entretiens et t&eacute;moignages avec des patients, r&eacute;flexion sur les probl&egrave;mes rencontr&eacute;s, analyse de la situation et propositions concr&egrave;tes constituent l'essentiel de ce document. Un suivi de ce travail devrait avoir lieu dans le courant de l'ann&eacute;e 96, n'h&eacute;sitez pas &agrave; nous contacter...



</UL><HR WIDTH=550>

<UL>



<A NAME="biblio"><H3>Biblioth&egrave;que</H3></A>
<P>
D'ann&eacute;e en ann&eacute;e le fond d'ouvrages qui constitue notre biblioth&egrave;que s'&eacute;toffe. Constitu&eacute; par des livres, publications, documents audiovisuels, traitant de litt&eacute;rature, m&eacute;decine, sexualit&eacute;, psychologie, sociologie, et droits  etc..., notre biblioth&egrave;que constitue une source importante de documentation pour nombres d'&eacute;tudiants, journalistes, membres de l'association, etc... Le pr&ecirc;t est r&eacute;serv&eacute; aux membres de l'association et aux &eacute;tudiants en cours de recherche. Unique en son genre en Suisse comme m&eacute;moire d'un patrimoine, elle vient de recevoir un legs de documents important sur l'homosexualit&eacute; en Suisse couvrant la p&eacute;riode des ann&eacute;es cinquante &agrave; nos jours.
<P>
Une mise en commun de catalogues entre le Groupe Sida Gen&egrave;ve et Dialogai et la cr&eacute;ation d'un centre d'information sida, nomm&eacute; Sidoc, est maintenant r&eacute;alis&eacute;e.
<P>
Le pr&ecirc;t de livres est ouvert les mercredi de 19 &agrave; 22 heures.<P>



</UL><HR WIDTH=550>

<UL>



<A NAME="phone"><H3>Permanence t&eacute;l&eacute;phonique; entretiens individuels</H3></A>
<P>
<B>Permanence t&eacute;l&eacute;phonique:</B> l'entretien t&eacute;l&eacute;phonique est le pr&eacute;alable le plus courant &agrave; la relation d'aide. Tous types confondus, les appels sont nombreux le mercredi soir, et ce sont quelque 1400 appels qui arrivent chaque ann&eacute;e sur notre ligne. N'h&eacute;sitez pas &agrave; recourir &agrave; ce service, que votre souci soit d'ordre affectif, social, juridique: vos interlocuteurs sauront &ecirc;tre d'une &eacute;coute attentive et de bon conseil.
<P>
<B>Entretiens individuels:</B> l'association vous offre &eacute;galement la possibilit&eacute;, pour des cas ne pouvant &ecirc;tre r&eacute;solus ou discut&eacute;s au t&eacute;l&eacute;phone, de vous entretenir de mani&egrave;re individuelle avec un interlocuteur. Dans ce cas &eacute;galement, l'&eacute;coute vous est assur&eacute;e, et des solutions correspondant &agrave; votre difficult&eacute; pourront certainement &ecirc;tre trouv&eacute;es.



</UL><HR WIDTH=550>

<UL>



<A NAME="prevention"><H3>Publications sur la <I>pr&eacute;vention</I> et la<I> maladie</I></H3></A>
<P>
Parmi de nombreux documents de pr&eacute;vention sp&eacute;cialement &eacute;dit&eacute;s pour les gays, Dialogai diffuse les brochures de la s&eacute;rie <B><I>Hommes entre eux</I></B>, publi&eacute;es par l'Agence fran&ccedil;aise contre le sida.<br>
Ces brochures sont disponibles &agrave; l'association, ou peuvent &ecirc;tre envoy&eacute;es sous pli discret.
<P>
<H4>Sur le th&egrave;me du VIH/sida:<I> (disponibles &agrave; l'association)</I></H4>
<UL>
<li><I>Pour en d&eacute;coudre avec (la maladie, les soins, la pr&eacute;vention, les droits sociaux, l'isolement, les assurances...)</I><br>
La 'bible' sida de Dialogai, 128 p. 3e &eacute;dition, <I>Fr. 10.-</I>
<li><I>Soigner &agrave; domicile les personnes vivant avec le VIH et le sida</I><br>
Une brochure de l'<A HREF="/f/organs/ass.html">ASS</A> pour aider les proches et accompagnants des personnes s&eacute;ropositives et malades, <I>60 p., Fr. 10.-</I>
<li><I>Nutrition et VIH</I><br>
Comment manger de mani&egrave;re &eacute;quilibr&eacute;e, en pr&eacute;venant les infections alimentaires et comment faire face aux probl&egrave;mes li&eacute;s au VIH, <I>Aides, 60 p., Fr. 10.-</I>
<li><I>Manger positivement</I><br>
Brochure &eacute;dit&eacute;e par l'ASS et l'association suisse des di&eacute;t&eacute;ticiens, <I>50 p, Fr. 10.-</I>
<li><I>Infection par le VIH et sida</I><br>
Le point sur l'&eacute;pid&eacute;mie, les risques et modes de contamination, l'infection... Avec t&eacute;moignages, illustrations. Un bref et bon tour d'horizon. <I>Arcat sida, 60 p., Fr. 10.-</I>
<li><I>Safer Sexe pour jeunes homosexuels</I><br>
Pour r&eacute;pondre aux questions sur le sexe en g&eacute;n&eacute;ral et le safer en particulier,<I> ASS et Spot 25, 30 p., Fr. 10.-</I>
<li><I>Horizons th&eacute;rapeutiques</I><br>
Le classeur qui recense tous les traitements. Mise &agrave; jour r&eacute;guli&egrave;re.<I> ASS, PWA - Suisse et industries pharmaceutiques, Fr. 80.-</I>
</UL>
</UL>

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-7</DOCNO>
<DOCOLDNO>IA017-000177-B047-267</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/aidsmin.html 192.33.214.13 19970106035743 text/html 1629
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:05 GMT
Last-modified: Saturday, 13-Apr-96 16:53:32 GMT
Content-length: 1439
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>MINISTERE SIDA</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Minist&egrave;re sida</H1><HR>

<I>Minist&egrave;re Sida,<BR>
5 pl. Jargonnant, 1207 Gen&egrave;ve<br>
Tel: 022/ 736 24 26  Fax: 022/736 10 10</I><P>

<UL>

L'association <B>Minist&egrave;re sida</B> s'adresse aux personnes s&eacute;ropositives ou malades et &agrave; leurs proches, ainsi qu'aux professionnels dans le cadre d'une formation, d'une information ou d'une activit&eacute; li&eacute;e au sida. La pr&eacute;sence aupr&egrave;s des personnes s&eacute;ropositives ou malades et leurs proches s'envisage comme un accompagnement, souvent men&eacute; jusqu'&agrave; la fin de vie et au del&agrave; pour les proches en deuil. L'association est un espace de soutien, de recherche et de paroles, libre de tout jugement et ouvert &agrave; toute croyance.<P>

Elle est soutenue par l'Eglise Nationale Protestante de Gen&egrave;ve et par l'Etat de Gen&egrave;ve. Dominique ROULIN, Pasteure en est la responsable.
</UL>

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-8</DOCNO>
<DOCOLDNO>IA017-000177-B047-281</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/child.html 192.33.214.13 19970106035801 text/html 2381
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:21 GMT
Last-modified: Saturday, 13-Apr-96 19:13:05 GMT
Content-length: 2191
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Organisations: AIDS and Children</TITLE>
</HEAD>




<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Organisations actives dans le domaine 'Sida et enfants'</H1><HR>

<center>
<A HREF="#ge">GE</A> / <A HREF="#ju">JU</A> / <A HREF="#vd">VD</A> / <A HREF="#zh">ZH</A>
<P></center><HR>



<A NAME="ge"><H3>Gen&egrave;ve</H3></A>

<UL>

<LI><B>Association ESPER</B><br>

<I>Association d'aide aux enfants touch&eacute;s par le sida</I><br>

c/o Isabelle Lamm<br>

10, rue du Mil&eacute;ant<br>

CH-1203 Gen&egrave;ve<br>

<I>tel (022) 344 47 03</I><P>

<LI><B>Plateforme <I>'Sida et Enfant'</I></B><br>

<i>Groupe de travail pluridisciplinaire pour l'accueil des enfants et des familles touch&eacute;s par le sida</i><br>

Mme D. Fournier<br>

c/o Service de Protection de la Jeunesse<br>

Case Postale 638<br>

CH-1211 Gen&egrave;ve 3<br>

<I>tel (022) 787 69 60</I><P>

<LI><B><A HREF="/gsg/index.html">Groupe Sida Gen&egrave;ve</A></B><br>

Brigitte Studer<br>

<I>tel (022) 700 15 00<br></I>

</UL>



<A NAME="ju"><H3>Jura</H3></A>

<UL>

<LI><B>Groupe sida-enfants</B><br>

c/o Groupe Sida Jura<br>

Case Postale 2201<br>

CH-2800 Del&eacute;mont<br>

<I>tel (066) 222 868<br>

fax (066) 231 339<br></I>

</UL>



<A NAME="vd"><H3>Vaud</H3></A>

<UL>

<LI><B>Fondation As'Trame</B><br>

<i>L'enfant la famille le sida</i><br>

Av. de la Gare 52<br>

Case Postale 644<br>

CH-1001 Lausanne<br>

<I>tel (021) 329 04 34</I>

</UL>



<A NAME="zh"><H3>Z&uuml;rich</H3></A>

<UL>

<LI><B>AIDS und Kind</B><br>

<i>Schweizerische Stiftung f&uuml;r Direkthilfe an betroffene Kinder</i><br>

Seefeldstr. 219<br>

CH-8008 Z&uuml;rich<br>

<i>tel (01) 422 57 57<br>

fax (01) 422 62 92</i><br>

</UL><P>
<HR>
Source: Aide Suisse contre le Sida, 5.95

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-9</DOCNO>
<DOCOLDNO>IA017-000177-B047-292</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/gsg/mywishes.html 192.33.214.13 19970106035811 text/html 4331
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:33 GMT
Last-modified: Saturday, 13-Apr-96 16:14:05 GMT
Content-length: 4141
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>GSG et Minist&egrave;re Sida: 'Mes Volont&eacute;s'</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Groupe Sida Gen&egrave;ve</H1><HR>


<H2>Dossier <i>'Mes Volont&eacute;s'</i></H2>

<H4>R&eacute;alis&eacute; par le <A HREF="index.html">Groupe Sida Gen&egrave;ve</A> et <A HREF="/f/organs/aidsmin.html">Minist&egrave;re Sida</A></H4>

<HR WIDTH=550><UL>



<LI><A HREF="#pourquoi">Pourquoi</A> un tel dossier?

<LI>Fiche 1: <A HREF="sec1.html#fiche1">Testament biologique</A>

<LI>Fiche 2: <A HREF="sec2.html">Succession et testament</A>

<LI>Fiche 3: <A HREF="sec1.html#fiche3">Enfants</A>

<LI>Fiche 4: <A HREF="sec1.html#fiche4">Assurances</A>

<LI>Fiche 5: <A HREF="sec1.html#fiche5">Bail</A>

<LI>Fiche 6: <A HREF="sec1.html#fiche6">Questions frontali&egrave;res</A>

<LI>Fiche 7: <A HREF="sec1.html#fiche7">Service fun&egrave;bre et fun&eacute;railles</A>

<LI><A HREF="#index">Index</A> des th&egrave;mes abord&eacute;s



</UL><HR WIDTH=550><UL>



<A NAME="pourquoi"><H3>Pourquoi un tel dossier?</H3></A>

<H4><I>"Il faut que l'imagination prenne trop pour que le pass&eacute; ait assez. Il faut que la volont&eacute; imagine trop pour r&eacute;aliser assez."</I> - Gaston Bachelard</H4>

Nous avons constat&eacute; que la majorit&eacute; des personnes vivant avec le virus du sida se posent des questions sur leurs diff&eacute;rents droits: droit d'&ecirc;tre un patient respect&eacute;, droit vis-&agrave;-vis de ses enfants, droit face &agrave; ses assurances ou son bail, etc. En fait, tout ce qui permet de se prendre en charge le plus globalement possible sans occulter la r&eacute;alit&eacute; du virus.<P>

Nous avons tent&eacute; de r&eacute;pondre &agrave; ces questions &agrave; travers les fiches que vous trouverez dans ce dossier. Elles essaient d'&ecirc;tre le plus clair et le plus lisible possible, sans pour autant &ecirc;tre exhaustives.

Si vous avez des questions, des remarques ou si vous avez besoin d'une assistance, n'h&eacute;sitez pas &agrave; vous adresser &agrave;:<P>

<A HREF="index.html">Groupe Sida Gen&egrave;ve</A>, Florian H&uuml;bner, <I>tel: (022)700 15 00</I><br>

Dominique Roulin, <A HREF="/f/organs/aidsmin.html">Minist&egrave;re Sida</A>, <I>tel: (022) 736 24 26</I><P>



Le GSG vous propose &eacute;galement des <A HREF="/f/consult/legal.html">consultations juridiques <I>anonymes</I></A> on-line.<P>



</UL><HR WIDTH=550><UL>



<A NAME="index"><H3>Index des th&egrave;mes abord&eacute;s</H3></A>

<UL>

<A HREF="sec1.html#fiche1">testament biologique</A><br>

<A HREF="sec2.html">succession et testament</A><br>

<UL><i>

<A HREF="sec2.html">h&eacute;ritiers</A><br>

<A HREF="sec2.html#par2">h&eacute;ritiers r&eacute;servataires, r&eacute;serve</A><br>

<A HREF="sec2.html#par3">testament</A><br>

<A HREF="sec2.html#par4">pacte successoral</A><br>

<A HREF="sec2.html#par5">succession d'&eacute;trangers</A><br>

</i></UL>

<A HREF="sec1.html#fiche3">enfants</A><br>

<A HREF="sec1.html#fiche4">assurances</A><br>

<UL><i>

<A HREF="sec1.html#fiche4par1">pr&eacute;voyance professionnelle</A><br>

<A HREF="sec1.html#fiche4par2">assurance-vie</A><br>

</i></UL>

<A HREF="sec1.html#fiche5">bail</A><br>

<A HREF="sec1.html#fiche6">questions frontali&egrave;res</A><br>

<UL><i>

<A HREF="sec1.html#fiche6par1">succession</A><br>

<A HREF="sec1.html#fiche6par2">adresses utiles</A><br>

</i></UL>

<A HREF="sec1.html#fiche7">service fun&egrave;bres et fun&eacute;railles</A><br>

<UL><i>

<A HREF="sec1.html#fiche7">derni&egrave;res volont&eacute;s</A><br>

<A HREF="sec1.html#fiche7par2">fun&eacute;railles</A><br>

<A HREF="sec1.html#fiche7par3">d&eacute;c&egrave;s &agrave; l'&eacute;tranger</A><P>

</i></UL>
</UL>
</UL>

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-10</DOCNO>
<DOCOLDNO>IA017-000177-B047-305</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/index.html 192.33.214.13 19970106035820 text/html 1946
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:41 GMT
Last-modified: Wednesday, 11-Dec-96 09:31:59 GMT
Content-length: 1755
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>HivNet.ch</TITLE>
<BODY BGCOLOR="#FFFFFF">
</HEAD>
<P><FONT SIZE=-1>[ <A HREF="/d/">Deutsch</A> ] [ <A HREF="/e/">English</A> ] [ <FONT COLOR="#0000FF">Fran&ccedil;ais</FONT> ]</FONT></P><UL>
<CENTER><P><IMG SRC="/gif/hivnet.gif" HEIGHT=95 WIDTH=316>
<P><IMG SRC="/f/gif/titref.gif" HEIGHT=27 WIDTH=488></P></CENTER>

<CENTER><TABLE WIDTH="80%" >
<TR ALIGN=CENTER>
<TD><A HREF="/f/biblio/"><IMG SRC="/f/gif/bibliotheque.gif" ALT="Bibliotheque" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/f/webforum/"><IMG SRC="/f/gif/webforum.gif" ALT="Webforum" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/f/consult/"><IMG SRC="/f/gif/consultation.gif" ALT="Consultations anonymes" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>
</TR>

<TR ALIGN=CENTER>
<TD><A HREF="/f/organs/"><IMG SRC="/f/gif/organisations.gif" ALT="Organisations" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/f/art/"><IMG SRC="/f/gif/artworks.gif" ALT="Artworks" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/f/search/"><IMG SRC="/f/gif/search.gif" ALT="Rechercher" BORDER=0 HEIGHT=100 WIDTH=100 ALIGN=CENTER></A></TD>
</TR>

<TR ALIGN=CENTER>
<TD>
</TD>

<TD><A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" ALT="Info" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><P><FONT SIZE=-1>Avec le soutien de l'Office f&eacute;d&eacute;ral
de la sant&eacute; publique, de la Fondation Sida Info Doc Suisse et de
l'Etat de Gen&egrave;ve </FONT></P></CENTER>

<CENTER><P><FONT SIZE=-1>Copyright 1991-1996 <A HREF="http://www.hivnet.ch/fdp/">Fondation
du Pr&eacute;sent</A> et les Auteurs </FONT></P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-11</DOCNO>
<DOCOLDNO>IA017-000177-B047-314</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/search/index.html 192.33.214.13 19970106035829 text/html 2023
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:50 GMT
Last-modified: Monday, 02-Dec-96 09:43:42 GMT
Content-length: 1835
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>HIVNet: Rechercher</TITLE>

</HEAD>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/search.gif">
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<UL>
<H2>Recherche de documents</H2>
<FORM ACTION="/anais/f/bin/search.cgi" METHOD=post>

<B>contenant</B> le ou les mots suivants
<BR>
<UL><I>(exemple: DDI 3TC SAQUINAVIR)</I><BR>
<INPUT NAME=and SIZE=40></UL><BR>

contenant <B>au moins</B> un des mots suivants,

<BR><UL><INPUT NAME=or SIZE=40></UL><BR>

<B>ne contenant pas</B> le ou les mots suivants,

<UL><INPUT NAME=not SIZE=40></UL>

<P>

dans les publications suivantes (à sélectionner)
<P>
<UL>
<TABLE BORDER=0>
<TR>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="ATN"> AIDS TREATMENT NEWS</TD>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="SUMM-96"> AIDS Daily Summary</TD>
</TR>
<TR>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="INFOTHEQUE"> INFOTHEQUE SIDA</TD>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="VON-AIDS"> Von Aids bis Z</TD>
</TR>
</TABLE>
</UL>
<P>

<I><INPUT TYPE="submit" VALUE="     Recherche!     "></I><P>
</UL>
</FORM>


<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>
</CENTER>

</BODY>
</HTML>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-12</DOCNO>
<DOCOLDNO>IA017-000177-B047-326</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/hivnet/index.html 192.33.214.13 19970106035836 text/html 1353
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:58:59 GMT
Last-modified: Monday, 03-Jun-96 13:43:05 GMT
Content-length: 1165
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>HIVNet CH: Contact</TITLE></HEAD>

<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/intouch.gif" ALT="Contact">
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
<A HREF="/f/infomed/index.html"><IMG ALIGN=top SRC="/f/gif/info_med2.gif" BORDER=0 ALT="Info_Med"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<UL>


<H2>Contact - HIVnet</H2>
<HR>
<CENTER>
<P>
Ecrivez-nous<BR>
<A HREF="mailto:info@hivnet.ch">info@hivnet.ch</A>
<P>
<HR>
<P>

</UL><CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
</CENTER></BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-13</DOCNO>
<DOCOLDNO>IA017-000177-B047-341</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/index.html 192.33.214.13 19970106035849 text/html 1788
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 03:59:11 GMT
Last-modified: Tuesday, 03-Dec-96 16:04:01 GMT
Content-length: 1599
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet CH -Artworks'</title></head>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/artworks.gif">
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<hr>
<UL>

<table CELLPADDING=10>
<tr>
<td>
<img src="anim/neuf.cgi"><P>
Les aventures du Latex,<br>
Petit-Roulet
</td>
<td>
<B>Les Aventures du Latex <I>(extraits)</I></B>
<UL>
<LI><I>Les Aventures de Lord Latex</I>,<A HREF="latex/avril.html"> Avril</A> (~136 K).

<LI><I>Danger ! Corps C&eacute;leste</I>, <A HREF="latex/denis.html">Jean-Claude Denis</A> (~247 K).

<LI><A HREF="latex/petitr.html">Petit-Roulet</A>, ( <A HREF="anim/petitr.html">avec animation</a> ).

<LI><A HREF="latex/vaninnis.html">Beno&icirc;t van Innis</A> (~112 K).

</UL><P>

<B><I>MUSIQUE</I></B>

<UL>
<LI><A HREF="music/sarclo.html">Sarcloret</A>, <I>La petite laine</I>
</UL>
</td>
</tr>
</table>
</UL>
<HR>
<P>

<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-14</DOCNO>
<DOCOLDNO>IA017-000177-B048-281</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/info/index.html 192.33.214.13 19970106040443 text/html 5376
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:04 GMT
Last-modified: Monday, 09-Dec-96 10:35:10 GMT
Content-length: 5188
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Info @ HivNet.ch</TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#FF0000" VLINK="#0000FF" ALINK="#FF0000">
<CENTER><P><IMG SRC="/gif/hivnet.gif" ALT="logo" HEIGHT=95 WIDTH=316> <BR>
<IMG SRC="/gif/titred.gif" HEIGHT=25 WIDTH=440></P></CENTER>
<BR CLEAR>



<TABLE CELLPADDING=2 WIDTH="80%" HEIGHT="100%" >
<TR ALIGN=CENTER VALIGN=top>
<TD NOWRAP><IMG SRC="/d/gif/intouch.gif" alt="Info" HEIGHT=106 WIDTH=130 ALIGN=CENTER></TD>

<TD>
<TABLE>
<TR ALIGN=LEFT VALIGN=TOP>
<TD><B><FONT SIZE=+1><A HREF="#Participer">Beteiligung</A></FONT></B></TD>

<TD ALIGN=LEFT VALIGN=TOP>F&uuml;llen Sie bitte das <A HREF="form6d.html">Anmeldungsformular</A>
<BR>
aus um von den Diensten <BR>
von HivNet.ch zu profitieren</TD>

<TD></TD>

<TD></TD>
</TR>

<TR>
<TD></TD>

<TD><B><FONT SIZE=+1><A HREF="#Services">Dienste</A></FONT></B></TD>

<TD></TD>

<TD></TD>
</TR>

<TR>
<TD></TD>

<TD></TD>

<TD><B><FONT SIZE=+1><A HREF="#Accès">Zugang</A></FONT></B></TD>

<TD></TD>
</TR>

<TR>
<TD>
<CENTER><P><A HREF="mailto:info@hivnet.ch">E-mail<BR>
</A>info@hivnet.ch</P></CENTER>
</TD>

<TD></TD>

<TD></TD>

<TD><B><FONT SIZE=+1><A HREF="#Audience">Zielpublikum</A></FONT></B></TD>
</TR>
</TABLE>

<TABLE CELLSPACING=2 CELLPADDING=10 WIDTH="25%" HEIGHT="10%" >
<TR VALIGN=CENTER>
<TD></TD>

<TD></TD>

<TD></TD>

<TD></TD>

<TD></TD>
</TR>
</TABLE>

<P>
<HR WIDTH="100%"></P>
</TD>

<TD></TD>
</TR>

<TR>
<TD></TD>

<TD>
<H3><BR>
<A NAME="HivNet.ch"></A><FONT SIZE=+0>HivNet.ch</FONT></H3>

<UL>
<LI>HivNet.ch ist der schweizerischer elektronischen Dienst f&uuml;r Information
und Austausch &uuml;ber das Thema HIV und Aids. Er wurde von der Fondation
du Pr&eacute;sent in Genf, gegr&uuml;ndet.<BR>
</LI>

<LI>HivNet.ch ist der Diffusionszweig auf Internet der Aids Info Docu Schweiz
(Bern).<BR>
</LI>

<LI>HivNet.ch ist der Internet Site f&uuml;r Organisationen die im Kampf
gegen HIV/AIDS t&auml;tig sind.<BR>
</LI>

<LI>HivNet.ch ist Mitglied des europ&auml;ischen <A HREF="http://www.hivnet.org">HIVNET</A>
Informationsnetz &uuml;ber HIV und Aids.</LI>
</UL>

<H3><A NAME="Accès"></A><FONT SIZE=+0>Zugang </FONT></H3>

<UL>
<P>Zugang zu HivNet.ch ist frei und kostenlos. </P>
</UL>

<H3><A NAME="Audience"></A><FONT SIZE=+0>Zielpublikum</FONT></H3>

<UL>
<P>HivNet.ch bietet allen Menschen ein Gespr&auml;chsforum und ein Solidarit&auml;tsnetz
dar; sei es f&uuml;r Menschen die sich um ihre Gesundheit k&uuml;mmern
oder &uuml;ber dessen von anderen, HIV-Positiven oder Aids-Kranken, Familien
und/oder Ihr Umfeld, Forschern, Aertze. Alle interessierte Person kann
sich &uuml;ber die medizinische Fortschritte auf dem laufende halten. Jeder
Benutzer hat ausserdem die Wahl seine anonymit&auml;t zu bewahren. </P>
</UL>

<H3><A NAME="Services"></A><FONT SIZE=+0>Vorgeschlagte Dienste</FONT></H3>

<UL>
<P>HivNet.ch erm&ouml;glicht ihrer Organization :</P>

<LI>Dokumente auf den World Wide Web zu publizieren</LI>

<LI>Projekte auf Internet selbst zu entwickeln </LI>

<LI>eine E-mail Mailingliste herzustellen um ihren Mitglieder von den schweizerischen
und ausl&auml;ndische Neuigkeiten auf dem laufende zu halten</LI>

<LI>Ihre Datenbanken und Bibliotheken zu ver&ouml;ffentlichen</LI>

<LI>Ausk&uuml;nfte und anonyme Ratschl&auml;ge zu erteilen um neue Kontakte
zwischen Mitglieder und Publikum zu schliessen </LI>

<LI>nationale und internationale Konferenzen &uuml;ber HIV/Aids aktiv zu
vorbereiten oder sich an Ihnen zu beteiligen </LI>

<LI>eine pers&ouml;nliche E-mail Adresse zu bekommen f&uuml;r die Organisation
und dessen Mitglieder</LI>
</UL>

<H3><A NAME="Participer"></A><FONT SIZE=+0>Beteiligung</FONT></H3>

<UL>
<P>Wenn sie von den Diensten von HivNet.ch profitieren m&ouml;chten, f&uuml;llen
Sie bitte den <A HREF="form6d.html">Anmeldungsformular</A> aus.</P>
</UL>

<H3><A NAME="Soutiens"></A><FONT SIZE=+0>Unterst&uuml;zung </FONT></H3>

<UL>
<P>HivNet.ch ist von der Stiftung Aids Info Docu Schweiz (Bern), dem Bundesamt
f&uuml;r Gesundheit und vom Staat Genf unterst&uuml;tzt. </P>

<P>Ein spezieller Dank geht auch an die wertvolle Unterst&uuml;ztung der
Vereine, den freiwilligen und der Organisationen, u.a. :</P>
</UL>

<UL>
<LI>Aids Hilfe Schweiz (AHS) </LI>

<LI>Centre Hospitalier Universitaire Vaudois, Division des maladies infectieuses
</LI>

<LI>Global Network of People living with HIV/AIDS </LI>

<LI>Groupe Sida Gen&egrave;ve </LI>

<LI>H&ocirc;pital Cantonal Universitaire de Gen&egrave;ve, Division des
maladies infectieuses </LI>

<LI>Universit&auml;tsspital Zurich, Abteilung Infektionskrankheiten ud
Spitalhygiene</LI>

<LI>Loterie romande </LI>

<LI>People With AIDS Switzerland </LI>

<LI>Personnes Vivant Avec (PVA Gen&egrave;ve) </LI>

<LI>SUN Microsystem (Gland) </LI>

<LI>Universit&auml;t Freiburg, Psychologisches Institut </LI>

<LI>Universit&eacute; de Gen&egrave;ve, Services Informatiques</LI>
</UL>
</TD>
</TR>
</TABLE>

<P>
<HR WIDTH="100%"></P>

<CENTER><P><A HREF="/d/info/"><IMG SRC="/d/gif/home.gif" ALT="Home" BORDER=0></A><A HREF="/d/search/"><IMG SRC="/d/gif/suchen.gif" ALT="Suchen" BORDER=0></A><A HREF="/d/info/"><IMG SRC="/d/gif/intouch.gif" ALT="Info" BORDER=0></A></P></CENTER>
</UL>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-15</DOCNO>
<DOCOLDNO>IA017-000177-B048-290</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/pwa/pwachf.html 192.33.214.13 19970106040452 text/html 3106
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:13 GMT
Last-modified: Tuesday, 12-Nov-96 12:10:40 GMT
Content-length: 2917
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Organisations: P.W.A-Suisse</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>People With Aids - Suisse</H1><HR>

<H2><IMG ALIGN=right HSPACE=30 BORDER=0 SRC="/gif/pwa_l.gif">P.W.A-Suisse</H2><P>

35, rue des P&acirc;quis,<BR>
CH-1202 Gen&egrave;ve,<BR>
<I>tel (022) 908.01.50,<BR>
fax (022) 908.01.51<BR>
E-Mail: PWA-Suisse@hivnet.ch</I><P>

<i><b>Z&uuml;rcher B&uuml;ro:</b><br>Theaterstr. 3, CH-8400 Winterthur, <br>tel (052) 212 47 47, fax (052) 212 47 57<br clear></i>

<P><HR>

<CENTER><H3>P.W.A-Suisse</H3></CENTER><P>

L'association <B>P.W.A-Suisse</B> fond&eacute;e en f&eacute;vrier 1991 se compose de <I>groupes de personnes vivant avec le sida</I> de toute la Suisse. Les personnes vivant avec le VIH/sida se sont ainsi regroup&eacute;es pour d&eacute;fendre leur <I>droit &agrave; une vie digne</I> et <I>combattre la discrimination et la r&eacute;pression</I>.<P>

L'association P.W.A-Suisse repr&eacute;sente au niveau national les personnes directement touch&eacute;es. Elle <I>g&egrave;re diff&eacute;rents projets</I>, notamment <a href="projet_ecoles/finhaut.html">le Projet Ecoles</a> qui consiste en l'intervention directe de personnes vivant avec le sida aupr&egrave;s de jeunes ou moins jeunes afin de renforcer le discours de pr&eacute;vention primaire.<br>

Elle participe &eacute;galement &agrave; l'<B>European Aids Treatment Group</B> qui recense en Europe les diff&eacute;rentes <I>d&eacute;marches th&eacute;rapeutiques</I>.<br>

Elle administre enfin le <B>'Names-Project Suisse'</B> ou <I>projet des quilts</I> r&eacute;alis&eacute;s &agrave; la <I>m&eacute;moire</I> des personnes d&eacute;c&eacute;d&eacute;es.<P>

<HR>

<CENTER><H3>Antennes romandes de P.W.A-Suisse</H3>

<A HREF="#ge">GE</A> / <A HREF="#ju">JU</A> / <A HREF="#ne">NE</A> / <A HREF="#vd">VD</A> / <A HREF="#vs">VS</A></CENTER>

<P><HR WIDTH=200>

<A NAME="ge"><H3>Gen&egrave;ve</H3></A>

<UL>

<LI><B><A HREF="/pvage/index.html">PVA Gen&egrave;ve</A></B><br>

35, rue des P&acirc;quis<br>

CH-1201 Gen&egrave;ve<br>

<I>tel (022) 906.40.30<br>

fax (022) 906.40.33<br>

E-Mail: PVA-Geneve@hivnet.ch</I>

</UL>



<A NAME="ju"><H3>Jura</H3></A>

<UL>

</UL>



<A NAME="ne"><H3>Neuch&acirc;tel</H3></A>

<UL>

</UL>



<A NAME="vs"><H3>Valais / Wallis</H3></A>

<UL>

</UL>



<A NAME="vd"><H3>Vaud</H3></A>

<UL>

</UL>



<HR>

<i>Source: P.W.A-Suisse, 11.96
<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-16</DOCNO>
<DOCOLDNO>IA017-000177-B048-306</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/pvage/joanne.html 192.33.214.13 19970106040459 text/html 2497
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:22 GMT
Last-modified: Thursday, 22-Aug-96 14:03:18 GMT
Content-length: 2307
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Joanne </TITLE>
</HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=
"0" ALT="Organisations" ALIGN="RIGHT"></A><ALIGN=BASELINE> 
<H1>Joanne</H1>
<HR SIZE="3" WIDTH="90%">
<TABLE BORDER=0 WIDTH=93%>
<TR><TD VALIGN=BOTTOM><FONT SIZE=6><B>Bonjour !</B></FONT>
<TD ALIGN=RIGHT><IMG SRC="joanne.jpg">
</TABLE>
<BR>
<BR>
<BR>
<BLOCKQUOTE>
<P>
Je m'appelle Joanne D'Amico. Je suis mari&eacute;e et j'ai deux gar&ccedil;ons
de 25 et 13 ans.
<P>
Passionn&eacute;e de musique, je chante dans un choeur mixte et je joue
de la guitare. J'aime aussi &eacute;crire (des po&egrave;mes, des nouvelles,
des chansons) et, d&egrave;s septembre 96, j'enseignerai l'Art Dramatique
&agrave; des ados.
<P>
Jusqu'en ao&ucirc;t 95, je travaillais au sein d'une association genevoise
charg&eacute;e de l'assistance et de l'h&eacute;bergement des requ&eacute;rants
d'asile. 
<P>
Dans ce milieu parfois difficile, j'ai appris &agrave; mettre des nuances
entre mes &eacute;tats d'&acirc;me et l'aide r&eacute;elle que je pouvais
apporter aux autres. 
<P>
J'ai accept&eacute; l'id&eacute;e que jamais je ne pourrai soulager
tous les maux de tous les hommes. Par contre, j'ai compris qu'un sourire
ou une &eacute;coute attentive suffisent parfois pour adoucir, ne serait-ce
qu'un instant, le chagrin d'un seul. 
<P>
Voil&agrave; ! Mon ambition, c'est cela: &ecirc;tre assez humble pour
ne pas pr&eacute;tendre r&eacute;ussir &agrave; tous les coups; &ecirc;tre
assez forte pour essayer quand m&ecirc;me; &ecirc;tre assez g&eacute;n&eacute;reuse
pour garder toujours les bras ouverts et assez attentive pour entendre
et comprendre, m&ecirc;me ce que l'on ne me dit pas. 
<P>
<TABLE BORDER=0 WIDTH=70%><TR><TD ALIGN=RIGHT><I>Joanne</I></TABLE>
</BLOCKQUOTE>
<P>
<br>
<center><font size=4><a href="index.html">Retour &agrave; la page de PVA - Gen&egrave;ve</a></font></center>
<p>
<br>
<HR SIZE="3" WIDTH="90%"><BR>
<P><CENTER><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER="0"
ALT="Home" ALIGN="BOTTOM"></A> <A HREF="/f/search/index.html"><IMG SRC=
"/f/gif/search2.gif" BORDER="0" ALT="Rechercher" ALIGN="BOTTOM"></A> <A HREF="/f/hivnet/index.html"><IMG SRC=
"/f/gif/intouch2.gif" ALIGN="TOP" BORDER="0" ALT="Contact"></A> </CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-17</DOCNO>
<DOCOLDNO>IA017-000177-B048-317</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/consult/index.html 192.33.214.13 19970106040507 text/html 2247
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:29 GMT
Last-modified: Tuesday, 03-Dec-96 16:04:58 GMT
Content-length: 2058
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet CH - Conseils</title></head>







<BODY BGCOLOR="FFFFFF">



<IMG ALIGN=left SRC="/f/gif/consultation.gif">

<CENTER>

<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>

<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>

<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>

<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>

</CENTER>

<BR CLEAR>

<PRE>



</PRE>

<UL>



<H1>Conseils</H1>





<UL>
Conseils de sant&eacute;, informations juridiques et dialogue avec les associations en lutte contre le Sida. 
<P>
Ce service traite les questions et les r&eacute;ponses de <B>fa&ccedil;on anonyme</B>.



<UL>

<P>

<B>

<LI><A HREF="Medic-forum.html">Conseils de sant&eacute;</A>

<P>

<LI><A HREF="Legal-forum.html">Informations juridiques</A>

<P>

<LI><A HREF="pvage-forum.html">Dialogue</A> avec l'association "Personnes Vivant Avec", Gen&egrave;ve 

</B>

</UL>

<P>



Les conseils sont donn&eacute;s uniquement &agrave; titre informatif.<B> Ils ne remplacent en aucun cas une consultation médicale ou juridique aupr&egrave;s d'un praticien autoris&eacute;</B>.

<P>

</UL>

<A HREF="http://expasy2.hcuge.ch/dmi/">La Division des Maladies Infectieuses</A> de l'Hôpital Cantonal Universitaire de Genève donne les conseils de sant&eacute;. 
<P>
L'association <A HREF="/gsg/">Groupe Sida Genève</A> donne les informations juridiques.
<P>
L'association <A HREF="/pvage/index.html">"Personnes Vivant Avec"</A> &agrave; Gen&egrave;ve r&eacute;pond aux demandes faites sur son espace.
<P>

<HR>



<CENTER>

<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>

<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" BORDER=0 ALT="Rechercher"></A>

<A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>

</CENTER>



</UL>



</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT18-B27-18</DOCNO>
<DOCOLDNO>IA017-000177-B048-341</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi 192.33.214.13 19970106040526 text/html 49046
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:46 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/anais/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - <A HREF="INFOTHEQUE.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<H3>Aids Infotheque 4/95, Jul 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:1">Kommentar, Prof. Dr. med. Beat Roos</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>10 Jahre Aids-Hilfe Schweiz / 10 Ans Aide Suisse contre le Sida</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.1">10 Jahre Aids-Hilfe Schweiz, Christian Schneeberger</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.2">Wie man den Kampf gegen Aids bei schwulen M&auml;nnern doch noch verliert Roger Staub</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.3">Den Fixerinnen und Fixern fehlte eine Lobby, Prof. Dr. med. Peter Grob</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.4">'Et les personnes touch&eacute;es commen&ccedil;aient &agrave; parler', Philippe Esnault</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.5">Les malades du sida sont indociles, Dr m&eacute;d. Bernard Hirschel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.6">L'Aiuto Aids Svizzero compie 10 anni, Christian Schneeberger</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.1">Bibliothek: 10 Jahre AHS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.2">Neue Publikationen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.3">Graue Literatur</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Bibliographie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.1">Nouvelles parutions</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.2">Litt&eacute;rature grise</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.3">Revues, journaux</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.4">Mat&eacute;riel d'information</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:5">Videos (Deutsch)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:6">Vid&eacute;os (Fran&ccedil;ais)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:7">Theater</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.1">Medikalische Tests</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.2">Eine Studie aus dem Programm der Kommission zur Kontrolle der Aids-Forschung, Luc Perrin</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.3">Resultate einiger Projekte aus dem Nationalen Aids-Forschungs-Programm</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.4">Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection, Y. Cao et al.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.5">Europ&auml;ische Parlamentarische Konferenz &uuml;ber HIV und Aids: Fortsetzung dringend n&ouml;tig, Dr. Therese Stutz Steiger</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 01/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.1">Commentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.2">Kommentar</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Stress et Syst&egrave;me immunitaire</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.1">Immunit&eacute;, syst&egrave;me nerveux et psychisme - le point des connaissances.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.2">Immunit&auml;t, Nervensystem und Psyche  was weiss man heute?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.3">Interventions psychologiques et syst&egrave;me immunitaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.4">Immunit&agrave;, sistema nervoso e psiche  cosa ne sappiamo oggi?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek ;Stress</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.1">Psychoimmunologie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.2">Biopsychologie von Stress und emotionalen Reaktionen.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.3">Immunantwort und Psyche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.4">Der Einflu&szlig; von Hypnose und Stre&szlig; auf das Blutbild.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.5">Stress und Stressbew&auml;ltigung / Hinweis</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.6">Verhaltenstraining zur Stressbew&auml;ltigung / Stress und Stressbew&auml;ltigung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Unterricht</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.1">Kondome quer durchs Curriculum</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.2">Sexualerziehung in den deutschsprachigen Schulen des Kantons Bern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.3">Freundschaft, Liebe, Sexualit&auml;t...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.4">Sexualp&auml;dagogische Jungenarbeit</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.1">Mein Kind ist so und nicht anders...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.2">Mitten ins Herz...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.3">Sexualit&auml;t, Lebensformen, Liebe / Bisexualit&auml;t</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.4">Abschied von der sexuellen Revolution... / Strichpunkt...</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD>Medizin</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.1">Bittere Naturmedizin</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.2">Kooperation und Rivalit&auml;t... / The Cellular Basis of Central Nervous... / Neuropsychologische Untersuchungen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>4,Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.1">Menschen mit Aids pflegen: i.v. DrogengebraucherInnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.2">Arbeit, Ausbildung und Qualifikation f&uuml;r Drogengebraucher in Substitutionsbehandlung / Die Berner Drogenszene</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Vermischtes</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.5.1">Mein Gott AIDS</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.1">Le sida et les fragilit&eacute;s fran&ccedil;aises: nos r&eacute;actions face &agrave; l'&eacute;pid&eacute;mie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.2">Le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.3">Les sciences sociales face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.4">Comment vivre avec une personne atteinte par le virus du sida ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.5">Un amour s&eacute;rodiff&eacute;rent</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.6">Ev&eacute;nements quotidiens et bien-&ecirc;tre &agrave; l'adolescence...</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.7">Le mort et moi et nous</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.8">Vivre le deuil au jour le jour: la perte d'une personne proche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.9">Couples homophiles: le droit &agrave; l'existence ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.10">L'amour et le pr&eacute;servatif</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.11">Essais th&eacute;rapeutiques et  &eacute;tudes cliniques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.12">Vivre son mourir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.13</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.13">Le t&eacute;moin myope Regards sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.14</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.14">Une mort africaine Le sida au quotidien</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.15</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.15">Sang contamin&eacute; Priorit&eacute;s d'Etat et d&eacute;cisions politiques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.16</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.16">De la syphilis au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.17</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.17">Un mal imaginaire</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9601:6">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.1">Les homosexuels face au sida: enqu&ecirc;te 1993 sur les modes de vie et la gestion du risque VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.2">Rapport de la commission &quot;maladies sexuellement transmissibles et sida&quot;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.3">Soins et sida. Les chiffres cl&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.4">Pertinence, redondance et red&eacute;finition ...</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Mat&eacute;riel d'information</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.1">Guide - Sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.2">Sant&eacute;, sexualit&eacute;, sida. Une p&eacute;dagogie adapt&eacute;e.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.3">Infection par le VIH et sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.4">Sida et &eacute;ducation sexuelle</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:9.1">Pr&eacute;venir. In&eacute;galit&eacute;s, sant&eacute;, exclusions</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Videos</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.1">Forscher, Fakten, Visionen. Auf Tod und Leben!</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.2">E tempo de agir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.3">Sida: paroles de familles</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Forschung und Therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.1">Aids und Traditionelle Chinesische Medizin: Eine Studie in Z&uuml;rich</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.2">Das Forscherportrait: Dr. med. Pietro Vernazza Kantonsspital St. Gallen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.3">Portrait: Dr med. Pietro Vernazza, H&ocirc;pital cantonal de St-Gall</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.1">9. Internationale Konferenz &uuml;ber Aids und Geschlechtskrankheiten in Afrika (ICASA)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.2">Wird mit UNAIDS alles anders ?</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 02/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Kommentar / Commentaires</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.1">Kommentar deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.2">Commentaire fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:2">Infection par le VIH/SIDA et alimentation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>HIV und Ern&auml;hrung</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.1">Nahrung f&uuml;r Menschen mit Aids in der Dritten Welt</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.2">Aidskrank als Frau in Nepal: Kann man das noch &quot;leben&quot; nennen ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:4">Infezione da HIV, AIDS e alimentazione</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Ern&auml;hrung + HIV</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.1">Ern&auml;hrung, HIV-Infektion und Aids: Ein Blick &uuml;ber den Tellerrand.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.2">Wie positiv essen.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.3">Healthy Eating Makes A Difference. A Food Resource Book for People Living with HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.4">Food for those with HIV/Aids (Ern&auml;hrung f&uuml;r Menschen mit HIV/Aids)</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.5">Das grosse Buch der Vitamine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.6">Nutrition and HIV (Ern&auml;hrung und HIV). A New Model for Treatment.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.7">Immune Power. Combining Holistic  Standard Medical Therapies into the Optimal Treatment Program for HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.8">Staying Healthy with HIV. A Guide to Alternative and Complementary Therapies</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.9">Vitamine, Vitamine! Eine Brosch&uuml;re mit Rezepten &uuml;ber Vitamine und Mineralstoffe f&uuml;r Menschen mit HIV und AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.10</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.10">Unkonventionelle Medizin bei HIV und Aids</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>Ern&auml;hrung allgemein</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.1">Die Psychologie des Essens</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.2">Bioaktive Substanzen in Lebensmitteln</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.3">Die Jutta-Poschet-Immundi&auml;t / Immun</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.4">St&auml;rken Sie ihr Immunsystem.Leben Sie besser durch nat&uuml;rliche Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.5">&Ouml;ko Test - Ratgeber Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.6">Ern&auml;hrungssprechstunde.Grundlagen einer gesunden Lebensf&uuml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.7">K&uuml;chengeheimnisse der Hildegard-Medizin.Ratschl&auml;ge und Erkenntnisse der hl. Hildegard von Bingen &uuml;ber die Heilkraft unserer Nahrungsmittel</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.8">Die pflanzlichen Heilmittel bei Hildegard von Bingen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.9">SVE Medienverzeichnis. Catalogue des publications et du mat&eacute;riel m&eacute;diatique ASA. ASA elenco di pubblicazioni e della mediateca.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3">Di&eacute;t&eacute;tique</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3.1">Di&eacute;t&eacute;tique: ouvrages g&eacute;n&eacute;raux de base et sp&eacute;cialis&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Nutrition et sida</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.1">Nutitional Care for HIV+ persons: a manual for individuals and their caregivers</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.2">Nutrition et VIH</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.3">Etre mieux en mangeant mieux</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.4">Manger positivement</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.5">D&eacute;pliant &quot;Nutrition et immunit&eacute;&quot; / Branle-bas de combat dans la cuisine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.6">Probl&egrave;mes sp&eacute;cifiques</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.7">1&egrave;re conf&eacute;rence internationale nutrition et infection par le VIH</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD>Pr&auml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.1">Doppelcharakter der Pr&auml;vention</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.2">HIV-Beratung und -Pr&auml;vention in der Arztpraxis. Stellenwert und Wirksamkeit der &auml;rztlichen Fortbildung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.3">Jugend und Gesundheit. Interventionsfelder und Pr&auml;ventionsbereiche</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.4">Diskriminierungsbereitschaft Jugendlicher gegen&uuml;ber Menschen mit HIV/Aids.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.2.1">Stigma-Management und schwules Selbstbewusstsein.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.3</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.1">Geld und Gef&uuml;hle um HIV und Aids.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.2">Die medizinische Betreuung HIV-infizierter Kinder und Jugendlicher</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.4</TD>
	 <TD>Sterben</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.1">Leben- und Sterbenk&ouml;nnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.2">W&auml;rme, die nur Feuer geben kann</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.1">Sant&eacute;, guide des associations, L'Impatient - Alternative Sant&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.2">Histoire de la recherche sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.3">La sociologie du risque</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.4">L'infection au VIH de la m&egrave;re et de l'enfant</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.5">L'Eglise et l'homosexualit&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.6">J'accuse... Les mensonges qui tuent les drogu&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.7">Nouveaux d&eacute;fis des soins palliatifs: philosophie palliative et m&eacute;decine compl&eacute;mentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.8">Douleur et m&eacute;decine, la fin d'un oubli</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.9">Douleur et plaisir, maladie et sant&eacute;: une perception subjective</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.10">Le deuil &agrave; vivre</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.11">Vivre, seulement vivre. Quatre regards photographiques pour la vie</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:8">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.1">L'infection par le virus de l'immunod&eacute;ficience humaine (VIH)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.2">Plan de communication publique sur l'infection &agrave; VIH - SIDA</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.3">Les politiques publiques face au d&eacute;fi du sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.4">L'&eacute;valuation &eacute;conomique du d&eacute;pistage sida chez les femmes enceintes</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.5">Le steribox et la r&eacute;duction des risques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.6">Programme de r&eacute;duction des risques &agrave; l'usage des personnes toxicomanes usagers de drogues par voie intraveineuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.7">Les biblioth&egrave;ques face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.8">Approche biopsychosociale de l'infection au virus VIH: une revue de la litt&eacute;rature</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.9">La question du sida dans la relation psychoth&eacute;rapeutique</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:10">Mat&eacute;riel d'information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:11.1">Tabula</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:12">Videos</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.1">Whose problem? An HIV/AIDS education package</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.2">Unmasking AIDS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.3">Living on the edge. Coping with HIV and drug misuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.4">HIV pre-test counselling. How to conduct pre-test counselling in confidence</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD>Forschung et therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.1">Les choix des th&eacute;rapies</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.2">Trials</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.3">Das Forscherportrait: Dr. phil. II Markus Thali</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.4">Le portrait d'un chercheur: Dr. Markus Thali</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.1">Der Schweizerische Verband diplomierter Ern&auml;hrungsberaterInnen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.2">Wissenschaftliche Begleitung des Modellprojektes &quot;Infektionsprophylaxe im Nieders&auml;chsischen Strafvollzug&quot;</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Annoncen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:15.1">Der gute Tip: Mittagstisch f&uuml;r Menschen mit HIV und Aids</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:16">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 03/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.1">Editorial Deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.2">Editorial Fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Der HIV-Antik&ouml;rpertest / Le test de d&eacute;pistage VIH</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.1">Der HIV-Antik&ouml;rpertest - 1996 (noch) ein Thema?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.2">Le test des anticorps anti-VIH -- (encore) un sujet de discussion en 1996?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.3">Du nouveau sur le test de d&eacute;pistage du VIH?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.4">Neues zum HIV-Antik&ouml;rpertest?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.5">Recht und Unrecht beim HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.6">Aspects juridiques du test VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.7">Les curieuses m&eacute;thodes de Sida Information Suisse.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.8">Die seltsamen Methoden der Aids-Aufkl&auml;rung Schweiz</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.9">Il test HIV - nel 1996 (ancora) un tema ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.1">Handbuch HIV-Test, Arbeitshilfen zur Beratung und Testdurchf&uuml;hrung</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.2">Sentinel-Surveillance von HIV und anderen sexuell &uuml;bertragbaren Krankheiten.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.3">Der HIV-Test in Spital und Praxis / Das Testen auf die HIV-Infektion</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Prauuml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.1">Aids in Europe - The Behavioural Aspect</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.2">La Flottille de l'Espoir</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.3">Gesundheit durch Projekte f&ouml;rdern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.4">Gesundheitsf&ouml;rderung und Public Health</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Kinder/Jugendliche</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.1">Ein kurzes Leben lang / Wir sprechen &uuml;ber AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.2">Wir sprechen &uuml;ber Drogen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.3">&quot;Schwanger werd' ich nicht alleine ...&quot;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3">Homosexualit&auml;tektion</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.1">V&ouml;llig normal</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.2">Kahn, Knaben, schnelle Fahrt</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.3">Handbuch zu lesbischen und schwulen Studien in der Schweiz</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.4.1">Methadon Standards</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Betroffene</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.1">Ann&auml;herungen. Meine ersten 10 Jahre im Zeichen von AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.2">Aids hat viele Gesichter</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.3">Farbige Trauer. Gedenkt&uuml;cher f&uuml;r Menschen, die an den Folgen von Aids gestorben sind. Signes d'amour. Panneaux comm&eacute;moratifs &agrave; la m&eacute;moire de personnes d&eacute;c&eacute;d&eacute;es du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.4">Leben ohne Grenzen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.5">Mut zum Tr&auml;umen, Kraft zum K&auml;mpfen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.6</TD>
	 <TD>Epidemiologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.6.1">Ansteckend. Berichte und Informationen zum Thema Infektionskrankheiten</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.7</TD>
	 <TD>Therapie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.1">Aids-Management der Erkrankung. Szenarien zur Verbesserung von Diagnose und Behandlung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.2">AIDS ist besiegbar</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.8</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.1">Krankheits- und Sterbebegleitung. Ausbildung, Krisenintervention, Training</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.2">Trauma AIDS. Eine psychoanalytische Studie &uuml;ber die Auswirkungen der HIV-Infektion</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Histoire, Epid&eacute;miologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.1">Les maux &eacute;pid&eacute;miques dans l'Empire chinois</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.2">Ces virus qui d&eacute;truisent les hommes</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>G&eacute;n&eacute;ralit&eacute;s</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.1">VIH/sida Une approche multidisciplinaire</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.2">Efficacit&eacute; du pr&eacute;servatif</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD>Sexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.1">Sexualit&eacute; et sida. Recherches en sciences sociales</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.2">La drague ou les rencontres difficiles</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.3">L'&eacute;ducation sexuelle</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.4">La sexualit&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.5">L'&eacute;ducation sexuelle des enfants</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Homosexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.4.1">L'amour du semblable: questions sur l'homosexualit&eacute;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD>Toxicomanie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.1">La double rencontre: toxicomanie et sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.2">Drogue, la guerre chim&eacute;rique</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.3">La m&eacute;thadone, mode d'emploi</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD>T&eacute;moignages</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.1">Le poids du silence</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.2">Infirmi&egrave;re aux portes de la mort</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD>M&eacute;decine et sant&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.1">Infiniment m&eacute;decins: les g&eacute;n&eacute;ralistes entre la science et l'humain</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.2">Le praticien face au sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.3">ABC du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.4">Cent question sur l'h&eacute;patite C</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD>Accompagnement, soins palliatifs, douleur</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.1">Soigner... le premier art de la vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.2">Instant de vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.3">La douleur: entre modernit&eacute; et tradition</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.4">La douleur. Ses m&eacute;canismes et les bases de ses traitements</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.5">Non &agrave; la douleur</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD>M&eacute;decines alternatives</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.9.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.9.1">G&eacute;n&eacute;alogie des m&eacute;decines douces: de l'Inde &agrave; l'Occident</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD>Ethique</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.1">Ethique, sida et soci&eacute;t&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.2">...mais tous &eacute;taient frapp&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD>S&eacute;curit&eacute; transfusionelle</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.11.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.11.1">Le sang et le droit. Essai sur la transfusion sanguine</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:5.12">Publications r&eacute;centes</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Mat&eacute;riel de pr&eacute;vention</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.1">Le sida. R&eacute;ponses aux questions du personnel de sant&eacute; sur l'infection par le VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.2">La th&eacute;rapie g&eacute;nique de l'infection par le VIH</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:7">Litt&eacute;rature grise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Zeitschriften /Journaux/Revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.1">R&eacute;flexe : journal du groupe sida neuch&acirc;tel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.2">Sida: information et rumeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.3">Exp&eacute;riences de mort imminente</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.4">Psychologues au temps du sida, dossier N#186;2</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Video</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.1">AIDS - Die Sache mit dem HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.2">J'ai besoin de savoir. Tests VIH: pr&eacute;vention et counselling</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.3">L'Instit. Aimer par coeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.4">Une vie menac&eacute;e, une vie cr&eacute;ative</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.5">Drogue: r&eacute;duire les risques?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Tonkassetten</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:10.1">Douleur, je t'abandonne</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Recherche et th&eacute;rapie / Forschung und Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.1">Le portrait du chercheur: Dr m&eacute;d. Pascal R. Meylan</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.2">Das Forscherportr&auml;t: Dr. med. Pascal R. Meylan</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.1">Thema Informed Consent - nur eine Kaffeeunterhaltung?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.2">Schlechtes Beispiel macht immer noch Schule</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.3">Der  HIV-Test  - Segen oder Katastrophe f&uuml;r Menschen der Dritten Welt?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.4">Interview mit Dr. Kurt Meyer, Pr&auml;sident GELIKO von Kurth W. Kocher</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:13">Neue Medikamente gegen das HIV in der Schweiz : Fragen und Antworten</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:14">Nouveaux m&eacute;dicaments contre le VIH : Questions et r&eacute;ponses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Sida, agir ensemble / Antwort auf Aids</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.1">Soumission de projets pour l'octroi d'un financement</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.2">Ausschreibung f&uuml;r Projektfinanzierung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:16">Schweizerische Krebsliga</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>17.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:17">Offerta di lavoro</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>18.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:18">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-19</DOCNO>
<DOCOLDNO>IA017-000177-B048-352</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/ 192.33.214.13 19970106040533 text/html 1788
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:05:56 GMT
Last-modified: Tuesday, 03-Dec-96 16:04:01 GMT
Content-length: 1599
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet CH -Artworks'</title></head>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/artworks.gif">
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<hr>
<UL>

<table CELLPADDING=10>
<tr>
<td>
<img src="anim/neuf.cgi"><P>
Les aventures du Latex,<br>
Petit-Roulet
</td>
<td>
<B>Les Aventures du Latex <I>(extraits)</I></B>
<UL>
<LI><I>Les Aventures de Lord Latex</I>,<A HREF="latex/avril.html"> Avril</A> (~136 K).

<LI><I>Danger ! Corps C&eacute;leste</I>, <A HREF="latex/denis.html">Jean-Claude Denis</A> (~247 K).

<LI><A HREF="latex/petitr.html">Petit-Roulet</A>, ( <A HREF="anim/petitr.html">avec animation</a> ).

<LI><A HREF="latex/vaninnis.html">Beno&icirc;t van Innis</A> (~112 K).

</UL><P>

<B><I>MUSIQUE</I></B>

<UL>
<LI><A HREF="music/sarclo.html">Sarcloret</A>, <I>La petite laine</I>
</UL>
</td>
</tr>
</table>
</UL>
<HR>
<P>

<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-20</DOCNO>
<DOCOLDNO>IA017-000177-B048-363</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/migrants/contents.html 192.33.214.13 19970106040543 text/html 12213
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:06:05 GMT
Last-modified: Sunday, 08-Dec-96 22:28:36 GMT
Content-length: 12024
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<META name="description" content="Migrants against HIV/AIDS (Migrants contre le sida) Newsletter about AIDS organizing by Black and Third World communities in Europe">
<META name="keywords" content="AIDS, HIV, racism, Third World, people of color, antiracism, fascism, Europe, Fortress Europe, SIDA, VIH, Arab, Black, African, Asian, Surinamese">
<TITLE>Migrants against HIV/AIDS Migrants contre le sida/VIH</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<IMG SRC="http://www.hivnet.ch/migrants/cgi-bin/makelog.cgi?migrants_contents,http://www.hivnet.ch/migrants/contents.html" HEIGHT="1" WIDTH="1" ALIGN=LEFT>


<TABLE>
<TR><TD WIDTH=450 ALIGN=CENTER VALIGN=TOP >
<A HREF="index.html"><IMG SRC="images/logo.gif" ALT="Migrants against HIV/AIDS" ALIGN=MIDDLE WIDTH="273" HEIGHT="110" BORDER="0"></A>
<BR>
</TD></TR>
</TABLE>

<TABLE CELLPADDING=5 WIDTH=450>
<TR><TD WIDTH=210 ALIGN=LEFT VALIGN=TOP ><HR SIZE=1 NOSHADE ALIGN=LEFT><A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/BROCH96.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=LEFT WIDTH="53" HEIGHT="38" BORDER="0"></A>Brochure &amp; subscription info in
English (111K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)<P><HR SIZE=1 NOSHADE ALIGN=LEFT></TD>
<TD WIDTH=210 ALIGN=LEFT VALIGN=TOP ><HR SIZE=1 NOSHADE ALIGN=LEFT><A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/BROCH96F.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=LEFT WIDTH="53" HEIGHT="38" BORDER="0"></A>Brochure &amp; subscription info in
French (111K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)<p><HR SIZE=1 NOSHADE ALIGN=LEFT></TD>
</TR>
</TABLE>

<TABLE>
<TR><TD WIDTH=450 ALIGN=LEFT VALIGN=TOP >
<A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/MIG0896E.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=MIDDLE WIDTH="53" HEIGHT="38" BORDER="0"></A>August 1996 issue in English (208K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Norway's Africans united in anger. Board of Health issues racist and sexist warning to white population linking Africans and HIV.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>
Norway's African community has united in angry protest following a press conference held early July by Norwegian authorities to warn the white population that Africans are potential HIV carriers.
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>An astonishingly bad idea. Editorial by Mary Haour-Knipe on the Norwegian crisis.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>Medical sociologist Mary Haour-Knipe gives three reasons <I>why</I> the Norwegian public health campaign to stress "a risk of HIV transmission between Norwegian heterosexuals and African immigrants" is bad news.
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Switzerland. HIV+ African man jailed for transmission. A new HIV transmission conviction exposes the link between racism and public health.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>Following the condemnation of an HIV+ African man, AIDS organizations have been slow to respond, if at all. Why?
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>New film celebrates Surinamese community survival</B><HR SIZE=1 NOSHADE ALIGN=LEFT><I>Cause of Death: Nothing,</I> a new documentary about the Surinamese community's struggle with AIDS in the Netherlands. Director Andre Reeder talks about the making of this extraordinary film, and public health worker Mitra Rambaran tell of the extraordinary AIDS organizing work accomplished by the Surinamese community. Reviewed by Black British filmmaker Pratibha Parmar.
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>"Safe sex is beautiful," says Cheb Khaled.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>New Beur FM radio campaign talks about AIDS, but what does it say? Beur FM, a commercial French radio station with an ethnic audience, has launched a new radio campaign to "better inform the Maghrebi community" about HIV and AIDS. Migrants against HIV/AIDS takes a critical look at the campaign and recalls the history of the radio station which began as a militant project.
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Lots of up-to-date, original news from Europe's Third World communities and around the world</B><HR SIZE=1 NOSHADE ALIGN=LEFT>
Gay Moroccan man wins deportation appeal in Britain. Spain "needs a little push," say Migrants conference hosts. Positively Irish Action on AIDS shuts down. Swiss Migrants Project and police social workers develop joint project. A multilingual European AIDS Directory.
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>United States. HIV Positive, Church Negative.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>In the past, there have been times when the African-American church has stepped in to provide sustenance and safety from the hostility and hate of the dominant culture. What has been the role of the African-American Church during the AIDS crisis?<HR SIZE=1 NOSHADE ALIGN=LEFT>
</TD></TR>
</TABLE>

<TABLE>
<TR><TD WIDTH=450 ALIGN=LEFT VALIGN=TOP >

<A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/MIG0596E.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=MIDDLE WIDTH="53" HEIGHT="38" BORDER="0"></A>May 1996 <I>Migrants against HIV/AIDS</I> (111K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)
<HR SIZE=1 NOSHADE ALIGN=LEFT><IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Front page article: Ghosts in the Fortress, by Walid Taqatqa.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>

Taqatqa, a Palestinian street corner HIV & drug worker, has been on the streets of Rotterdam for the last six years. But this isn't his story. It's the story of the North African Arab youths who risk their lives to cross the Mediterranean into the "promised land" of Europe. "These youths," says Taqatqa, "are the lost generation in our modern society." Many die of AIDS. Taqatqa clears the ideological rubble about whether or not to "help" illegal immigrants, about the Double Penalty (prison + deportation), the impact of crack, and inability of white social work to find answers to such questions.<HR SIZE=1 NOSHADE ALIGN=LEFT>

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>London. Positively Irish Action on AIDS fights back against "market management"</B><HR SIZE=1 NOSHADE ALIGN=LEFT>

In April, the Health Commissioners who control AIDS funding in London announced that Positively Irish Action on AIDS, a self-help group established in 1989, would lose all its funding. PIAA's activists talk about the need for organizational self-determination and the responsibility of public health authorities for supporting community-based HIV care. In addition, we report on PIAA's contribution to building a strong European network of ethnic minority AIDS groups, and about PIAA's response to the anti-Irish racism of the London Times.<HR SIZE=1 NOSHADE ALIGN=LEFT>

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>International news</B><HR SIZE=1 NOSHADE ALIGN=LEFT> Blacks quit GMHC, Israel dumps Falasha blood, UN puts HIV & migration on human rights agenda. Miscellaneous news items.<HR SIZE=1 NOSHADE ALIGN=LEFT>

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>The Netherlands. African migrants face government discrimination, mandatory testing.</B> By AFAPAC.<HR SIZE=1 NOSHADE ALIGN=LEFT>

The racist mythology about AIDS and Africa, the mandatory HIV testing of asylum seekers, and access to health care for undocumented people with HIV. These are three of the crucial questions for AFAPAC, an African group working in Amsterdam.<HR SIZE=1 NOSHADE ALIGN=LEFT>

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Sweden. Swedish goodwill?</B><HR SIZE=1 NOSHADE ALIGN=LEFT>Africans arriving in Europe know more about HIV than do Africans long settled in Sweden, says Stockholm's African Health Team.<HR SIZE=1 NOSHADE ALIGN=LEFT>

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>United States. "Rest assured, we will mobilize again."</B> Faced with government discrimination, the New York Haitian community fought and won. An article reprinted from the weekly Haiti Progres.

</TD></TR>
</TABLE>

<TABLE CELLPADDING=5 WIDTH=450>
<TR><TD WIDTH=210 ALIGN=LEFT VALIGN=TOP ><HR SIZE=1 NOSHADE ALIGN=LEFT><A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/MIG1295E.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=LEFT WIDTH="53" HEIGHT="38" BORDER="0"></A>December 1995 <I>Migrants against HIV/AIDS</I> in
English (111K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)<P><HR SIZE=1 NOSHADE ALIGN=LEFT></TD>
<TD WIDTH=210 ALIGN=LEFT VALIGN=TOP ><HR SIZE=1 NOSHADE ALIGN=LEFT><A HREF="http://www.hivnet.ch/migrants/cgi-bin/byteserver.cgi/migrants/pdf/MIG1295F.PDF"><IMG SRC="images/pdficonarrow.gif" ALT="PDF" ALIGN=LEFT WIDTH="53" HEIGHT="38" BORDER="0"></A>December 1995 <I>Migrants contre le sida/VIH</I> in French (111K; <A HREF="http://w1000.mv.us.adobe.com/Acrobat/readstep.html">Acrobat</A>
PDF)<p><HR SIZE=1 NOSHADE ALIGN=LEFT></TD>
</TR>
</TABLE>

<TABLE>
<TR><TD WIDTH=450 ALIGN=LEFT VALIGN=TOP >

<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Fortress Europe or Europe Against AIDS? </B><HR SIZE=1 NOSHADE ALIGN=LEFT>A brief report on the Third European Meeting on Migrants, Ethnic Minorities, and HIV/AIDS, at Driebergen, The Netherlands.<HR SIZE=1 NOSHADE ALIGN=LEFT>
<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Sisyphus is not a myth</B><HR SIZE=1 NOSHADE ALIGN=LEFT> Arab community organization or French "exception"? The French model of "integration" does not recognize the existence of "communities" nor their right to self-organization. What have Arab AIDS activists done in the face of this, and what have been the consequences on the AIDS crisis in France?<HR SIZE=1 NOSHADE ALIGN=LEFT>
<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>The Euros are coming</B><HR SIZE=1 NOSHADE ALIGN=LEFT>European funding: Where do immigrant/Black communities fit into in the EU's 50-million "Euro" "Europe against AIDS" program? Can "Europe against AIDS" be useful to Black/Third World/migrant activists?<HR SIZE=1 NOSHADE ALIGN=LEFT>
<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>The adventures of Don Juan Latex in Switzerland.</B><HR SIZE=1 NOSHADE ALIGN=LEFT>The story of the Swiss "Projet Migrants" prevention efforts by the Latino community, initiated and supported financially by the Swiss government on the basis of the right to information.<HR SIZE=1 NOSHADE ALIGN=LEFT>
<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Demos, conferences, documents, books, news briefs</B><HR SIZE=1 NOSHADE ALIGN=LEFT>
<IMG SRC="images/copland_arrow.gif" WIDTH="7" HEIGHT="12" ALIGN="BOTTOM"> <B>Interview. Dr Zoubida Djelali, Medecins du Monde's "French Mission", Paris</B><HR SIZE=1 NOSHADE ALIGN=LEFT> "We tell undocumented people: Stay away from the hospital"
</B><HR SIZE=1 NOSHADE ALIGN=LEFT>
</TD>
</TR>
</TABLE>
<P>
<!---------- Cut Here ---------->
<SCRIPT LANGUAGE="JavaScript">
<!-- Beginning of JavaScript
var theDate = "";
theDate = document.lastModified;
document.writeln("<FONT SIZE=-2>Last Updated : ");
document.write(theDate+"</FONT>");
document.write();
// - End of JavaScript - -->
</SCRIPT>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-21</DOCNO>
<DOCOLDNO>IA017-000177-B049-20</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/info/index.html 192.33.214.13 19970106040601 text/html 5699
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:06:23 GMT
Last-modified: Monday, 09-Dec-96 10:23:00 GMT
Content-length: 5511
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>Info @ HivNet.ch</TITLE>
  </HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" LINK="#FF0000" VLINK="#0000FF" ALINK="#FF0000">

<CENTER><P><IMG SRC="/gif/hivnet.gif" ALT="logo" HEIGHT=95 WIDTH=316> <BR>
<IMG SRC="/f/gif/titref.gif" HEIGHT=27 WIDTH=488></P></CENTER>

<TABLE CELLPADDING=2 WIDTH="80%" HEIGHT="100%" >
<TR ALIGN=CENTER VALIGN=top>
<TD NOWRAP><IMG SRC="/f/gif/intouch.gif" HEIGHT=106 WIDTH=130 ALIGN=CENTER></TD>

<TD>
<TABLE CELLSPACING=2 CELLPADDING=3 WIDTH="20%" HEIGHT="10%" >
<TR ALIGN=LEFT VALIGN=TOP>
<TD><B><FONT SIZE=+1><A HREF="#Participer">Participer</A></FONT></B></TD>

<TD COLSPAN="8">(<FONT SIZE=-1>remplissez ce <A HREF="/f/info/form6F.html"<B>formulaire d'inscription</B></A> si vous
souhaitez obtenir un acc&egrave;s direct et b&eacute;n&eacute;ficier des
services de HivNet.ch)</FONT></TD>

<TD></TD>

<TD></TD>
</TR>

<TR>
<TD></TD>

<TD><B><FONT COLOR="#0000FF"><FONT SIZE=+1><A HREF="#Services">Services</A></FONT></FONT></B></TD>
</TR>

<TR>
<TD></TD>

<TD></TD>

<TD><B><FONT COLOR="#0000FF"><FONT SIZE=+1><A HREF="#Accès">Acc&egrave;s</A></FONT></FONT></B></TD>
</TR>

<TR>
<TD ALIGN=CENTER VALIGN=TOP></TD>

<TD></TD>

<TD></TD>

<TD><B><FONT SIZE=+1><A HREF="#Audience">Audience</A></FONT></B> </TD>

<TD></TD>

<TD></TD>

<TD></TD>
</TR>
</TABLE>

<P>
<HR WIDTH="100%"></P>
</TD>

<TD></TD>
</TR>

<TR>
<TD></TD>

<TD>
<H3><BR>
<A NAME="HivNet.ch"></A>HivNet.ch</H3>

<UL>
<LI>HivNet.ch est le service &eacute;lectronique suisse d'information et
d'&eacute;change sur le VIH et le Sida cr&eacute;&eacute; par la Fondation
du Pr&eacute;sent, &agrave; Gen&egrave;ve<BR>
</LI>

<LI>HivNet.ch est le relais de diffusion sur Internet de la Fondation Sida
Info Doc Suisse (Berne)<BR>
</LI>

<LI>HivNet.ch est le site Internet d&eacute;di&eacute; aux associations
en lutte contre le VIH/Sida<BR>
</LI>

<LI>HivNet.ch est rattach&eacute; au r&eacute;seau europ&eacute;en <A HREF="http://www.hivnet.org">HIVNET</A>,
le service europ&eacute;en d'information et d'&eacute;change sur le VIH/Sida</LI>
</UL>

<H3><A NAME="Accès"></A>Acc&egrave;s </H3>

<UL>
<P>L'acc&egrave;s &agrave; HivNet.ch est <B>libre et gratuit</B>. </P>
</UL>

<H3><A NAME="Audience"></A>Audience</H3>

<UL>
<P>HivNet.ch est un espace de dialogue et de solidarit&eacute; ouvert &agrave;
tous; aux personnes soucieuses de leur sant&eacute; et de celle des autres,
aux personnes s&eacute;ropositives ou malades, &agrave; leurs familles
et &agrave; leurs proches, aux chercheurs, aux m&eacute;decins, &agrave;
toute personne concern&eacute;e d&eacute;sirant se tenir inform&eacute;e
des progr&egrave;s en la mati&egrave;re, avec le choix dans tous les cas
de garder ou non l'anonymat. </P>
</UL>

<H3><A NAME="Services"></A>Services</H3>

<UL>
<P>HivNet.ch permet &agrave; votre associations ou &agrave; votre organisation;
</P>

<LI>de publier votre documentation sur le Web </LI>

<LI>d'h&eacute;berger votre serveur d'information et de d&eacute;velopper
librement des projets sur Internet </LI>

<LI>de cr&eacute;er vos listes de distribution e-mail (courrier &eacute;lectronique)
pour tenir vos membres inform&eacute;s des nouveaut&eacute;s en Suisse
et &agrave; l'&eacute;tranger </LI>

<LI>de rendre accessibles vos bases de donn&eacute;es et biblioth&egrave;ques
sp&eacute;cialis&eacute;es </LI>

<LI>de prodiguer informations et conseils anonymes afin d'&eacute;tablir
de nouvelles relations avec vos membres et avec le public </LI>

<LI>de pr&eacute;parer et de participer activement aux conf&eacute;rences
nationales et internationales sur le VIH/Sida. </LI>

<LI>d'obtenir vos adresses e-mail personnelles, etc.</LI>
</UL>

<H3><A NAME="Participer"></A>Participer</H3>

<UL>
<P>Compl&eacute;tez le<B> <FONT SIZE=+1><A HREF="/f/info/form6F.html"<B>formulaire d'inscription</B></A></FONT></B><FONT SIZE=+1>
</FONT>(demande d'acc&egrave;s) si vous souhaitez b&eacute;n&eacute;ficier
des services de HivNet.ch</P>
</UL>

<H3><A NAME="Soutiens"></A>Soutiens </H3>

<UL>
<P>HivNet.ch re&ccedil;oit le soutien de la Fondation Sida Info Doc Suisse
(Berne), de l'Office F&eacute;d&eacute;ral de la sant&eacute; publique
et de l'Etat de Gen&egrave;ve. </P>

<P>HivNet.ch b&eacute;n&eacute;ficie &eacute;galement du pr&eacute;cieux
soutien ddes asociations, des b&eacute;n&eacute;voles et des organisations
suivantes:</P>
</UL>

<UL>
<LI>Aide Suisse contre le Sida (ASS) </LI>

<LI>Centre Hospitalier Universitaire Vaudois, Division des maladies infectieuses
</LI>

<LI>Global Network of People living with HIV/AIDS </LI>

<LI>Groupe Sida Gen&egrave;ve </LI>

<LI>H&ocirc;pital Cantonal Universitaire de Gen&egrave;ve, Division des
maladies infectieuses </LI>

<LI>H&ocirc;pital Universitaire de Zurich, Division des Maladies Infectieuses
</LI>

<LI>Loterie romande </LI>

<LI>People With AIDS Switzerland </LI>

<LI>Personnes Vivant Avec (PVA Gen&egrave;ve) </LI>

<LI>SUN Microsystem (Gland) </LI>

<LI>Universit&eacute; de Fribourg, D&eacute;partement de Psychologie </LI>

<LI>Universit&eacute; de Gen&egrave;ve, Services Informatiques</LI>
</UL>
</TD>
</TR>
</TABLE>

<UL>
<UL>
<P>
<HR WIDTH="100%"></P>
</UL>

<CENTER><P><!--fin du corps du document-->
<A HREF="/f/"><IMG SRC="/f/gif/home2.gif" ALT="Home" BORDER=0 HEIGHT=100 WIDTH=100></A><A HREF="/f/search/"><IMG SRC="/f/gif/search2.gif" ALT="Rechercher" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="/f/info/"><IMG SRC="/f/gif/intouch.gif" ALT="Info" BORDER=0 ></A>

<!--pied de page avec logos-->
</P></CENTER>
</UL>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-22</DOCNO>
<DOCOLDNO>IA017-000177-B049-28</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+1 192.33.214.13 19970106040610 text/html 4490
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:06:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<H3>1. Allgemeine Fragen zum Arbeitsplatz und zu Versicherungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.1</TD>
 <TD><A HREF="VON-AIDS.cgi?1:1">Verhalten bei der Stellenbewerbung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>1.2</TD>
 <TD><A HREF="VON-AIDS.cgi?1:2">W&auml;hrend des Arbeitsverh&auml;ltnisses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>1.3</TD>
 <TD><A HREF="VON-AIDS.cgi?1:3">Wenn es zur Entlassung kommt</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>1.4</TD>
 <TD><A HREF="VON-AIDS.cgi?1:4">Was Sie im Umgang mit Versicherungen wissen sollten</A></TD>
</TR>
</TABLE>
</UL>
<H3>2. Krankenkasse</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>2.1</TD>
 <TD><A HREF="VON-AIDS.cgi?2:1">Leistungen der Grundversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.2</TD>
 <TD><A HREF="VON-AIDS.cgi?2:2">Zusatzversicherungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.3</TD>
 <TD><A HREF="VON-AIDS.cgi?2:3">Welche Kosten &uuml;bernimmt die Krankenkasse f&uuml;r Medikamente ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.4</TD>
 <TD><A HREF="VON-AIDS.cgi?2:4">Welche Kosten &uuml;bernimmt die Krankenkasse f&uuml;r Therapien der Komplement&auml;rmedizin ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.5</TD>
 <TD><A HREF="VON-AIDS.cgi?2:5">Soll ich der Krankenkasse meine HIV-Infektion melden ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.6</TD>
 <TD><A HREF="VON-AIDS.cgi?2:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>3. Kollektive Krankentaggeldversicherung</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>3.1</TD>
 <TD><A HREF="VON-AIDS.cgi?3:1">Aufnahme in die KKV eines neuen Arbeitgebers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.2</TD>
 <TD><A HREF="VON-AIDS.cgi?3:2">&Uuml;bertritt in die Einzelversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.3</TD>
 <TD><A HREF="VON-AIDS.cgi?3:3">Was tun bei bevorstehender Arbeitslosigkeit ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.4</TD>
 <TD><A HREF="VON-AIDS.cgi?3:4">Wenn bei Krankheit die K&uuml;ndigung droht</A></TD>
</TR>
</TABLE>
</UL>
<H3>4. Berufliche Vorsorge (BVG)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>4.1</TD>
 <TD><A HREF="VON-AIDS.cgi?4:1">Obligatorische berufliche Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.2</TD>
 <TD><A HREF="VON-AIDS.cgi?4:2">Freiwillige weitergehende Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.3</TD>
 <TD><A HREF="VON-AIDS.cgi?4:3">Nachteilige Aspekte der Pensionskasse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.4</TD>
 <TD><A HREF="VON-AIDS.cgi?4:4">Diskriminierende Auswirkungen f&uuml;r Menschen mit HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.5</TD>
 <TD><A HREF="VON-AIDS.cgi?4:5">Die Folgen einer Nichtaufnahme in die Zusatzversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.6</TD>
 <TD><A HREF="VON-AIDS.cgi?4:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>5. Invalidenversicherung (IV)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>5.1</TD>
 <TD><A HREF="VON-AIDS.cgi?5:1">Wann besteht Anspruch auf Leistungen der IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.2</TD>
 <TD><A HREF="VON-AIDS.cgi?5:2">Welche Leistungen erbringt die IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.3</TD>
 <TD><A HREF="VON-AIDS.cgi?5:3">Wie hoch sind die Renten und Entsch&auml;digungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.4</TD>
 <TD><A HREF="VON-AIDS.cgi?5:4">Ab welchem Zeitpunkt besteht ein Rentenanspruch ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.5</TD>
 <TD><A HREF="VON-AIDS.cgi?5:5">Wie und wann wird eine Rente beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+6"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-23</DOCNO>
<DOCOLDNO>IA017-000177-B049-45</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+2 192.33.214.13 19970106040620 text/html 4624
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:06:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>2. Krankenkasse</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>2.1</TD>
 <TD><A HREF="VON-AIDS.cgi?2:1">Leistungen der Grundversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.2</TD>
 <TD><A HREF="VON-AIDS.cgi?2:2">Zusatzversicherungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.3</TD>
 <TD><A HREF="VON-AIDS.cgi?2:3">Welche Kosten &uuml;bernimmt die Krankenkasse f&uuml;r Medikamente ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.4</TD>
 <TD><A HREF="VON-AIDS.cgi?2:4">Welche Kosten &uuml;bernimmt die Krankenkasse f&uuml;r Therapien der Komplement&auml;rmedizin ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.5</TD>
 <TD><A HREF="VON-AIDS.cgi?2:5">Soll ich der Krankenkasse meine HIV-Infektion melden ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.6</TD>
 <TD><A HREF="VON-AIDS.cgi?2:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>3. Kollektive Krankentaggeldversicherung</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>3.1</TD>
 <TD><A HREF="VON-AIDS.cgi?3:1">Aufnahme in die KKV eines neuen Arbeitgebers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.2</TD>
 <TD><A HREF="VON-AIDS.cgi?3:2">&Uuml;bertritt in die Einzelversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.3</TD>
 <TD><A HREF="VON-AIDS.cgi?3:3">Was tun bei bevorstehender Arbeitslosigkeit ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.4</TD>
 <TD><A HREF="VON-AIDS.cgi?3:4">Wenn bei Krankheit die K&uuml;ndigung droht</A></TD>
</TR>
</TABLE>
</UL>
<H3>4. Berufliche Vorsorge (BVG)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>4.1</TD>
 <TD><A HREF="VON-AIDS.cgi?4:1">Obligatorische berufliche Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.2</TD>
 <TD><A HREF="VON-AIDS.cgi?4:2">Freiwillige weitergehende Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.3</TD>
 <TD><A HREF="VON-AIDS.cgi?4:3">Nachteilige Aspekte der Pensionskasse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.4</TD>
 <TD><A HREF="VON-AIDS.cgi?4:4">Diskriminierende Auswirkungen f&uuml;r Menschen mit HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.5</TD>
 <TD><A HREF="VON-AIDS.cgi?4:5">Die Folgen einer Nichtaufnahme in die Zusatzversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.6</TD>
 <TD><A HREF="VON-AIDS.cgi?4:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>5. Invalidenversicherung (IV)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>5.1</TD>
 <TD><A HREF="VON-AIDS.cgi?5:1">Wann besteht Anspruch auf Leistungen der IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.2</TD>
 <TD><A HREF="VON-AIDS.cgi?5:2">Welche Leistungen erbringt die IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.3</TD>
 <TD><A HREF="VON-AIDS.cgi?5:3">Wie hoch sind die Renten und Entsch&auml;digungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.4</TD>
 <TD><A HREF="VON-AIDS.cgi?5:4">Ab welchem Zeitpunkt besteht ein Rentenanspruch ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.5</TD>
 <TD><A HREF="VON-AIDS.cgi?5:5">Wie und wann wird eine Rente beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>6. Erg&auml;nzungsleistungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>6.1</TD>
 <TD><A HREF="VON-AIDS.cgi?6:1">Ziel der Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.2</TD>
 <TD><A HREF="VON-AIDS.cgi?6:2">Wer erh&auml;lt Erg&auml;nzungsleistungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.3</TD>
 <TD><A HREF="VON-AIDS.cgi?6:3">Was ist versichert ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.4</TD>
 <TD><A HREF="VON-AIDS.cgi?6:4">Besonderheiten bei HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.5</TD>
 <TD><A HREF="VON-AIDS.cgi?6:5">Wie werden Erg&auml;nzungsleistungen beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+7"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-24</DOCNO>
<DOCOLDNO>IA017-000177-B049-57</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+3 192.33.214.13 19970106040629 text/html 4374
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:06:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>3. Kollektive Krankentaggeldversicherung</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>3.1</TD>
 <TD><A HREF="VON-AIDS.cgi?3:1">Aufnahme in die KKV eines neuen Arbeitgebers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.2</TD>
 <TD><A HREF="VON-AIDS.cgi?3:2">&Uuml;bertritt in die Einzelversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.3</TD>
 <TD><A HREF="VON-AIDS.cgi?3:3">Was tun bei bevorstehender Arbeitslosigkeit ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.4</TD>
 <TD><A HREF="VON-AIDS.cgi?3:4">Wenn bei Krankheit die K&uuml;ndigung droht</A></TD>
</TR>
</TABLE>
</UL>
<H3>4. Berufliche Vorsorge (BVG)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>4.1</TD>
 <TD><A HREF="VON-AIDS.cgi?4:1">Obligatorische berufliche Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.2</TD>
 <TD><A HREF="VON-AIDS.cgi?4:2">Freiwillige weitergehende Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.3</TD>
 <TD><A HREF="VON-AIDS.cgi?4:3">Nachteilige Aspekte der Pensionskasse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.4</TD>
 <TD><A HREF="VON-AIDS.cgi?4:4">Diskriminierende Auswirkungen f&uuml;r Menschen mit HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.5</TD>
 <TD><A HREF="VON-AIDS.cgi?4:5">Die Folgen einer Nichtaufnahme in die Zusatzversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.6</TD>
 <TD><A HREF="VON-AIDS.cgi?4:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>5. Invalidenversicherung (IV)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>5.1</TD>
 <TD><A HREF="VON-AIDS.cgi?5:1">Wann besteht Anspruch auf Leistungen der IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.2</TD>
 <TD><A HREF="VON-AIDS.cgi?5:2">Welche Leistungen erbringt die IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.3</TD>
 <TD><A HREF="VON-AIDS.cgi?5:3">Wie hoch sind die Renten und Entsch&auml;digungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.4</TD>
 <TD><A HREF="VON-AIDS.cgi?5:4">Ab welchem Zeitpunkt besteht ein Rentenanspruch ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.5</TD>
 <TD><A HREF="VON-AIDS.cgi?5:5">Wie und wann wird eine Rente beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>6. Erg&auml;nzungsleistungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>6.1</TD>
 <TD><A HREF="VON-AIDS.cgi?6:1">Ziel der Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.2</TD>
 <TD><A HREF="VON-AIDS.cgi?6:2">Wer erh&auml;lt Erg&auml;nzungsleistungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.3</TD>
 <TD><A HREF="VON-AIDS.cgi?6:3">Was ist versichert ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.4</TD>
 <TD><A HREF="VON-AIDS.cgi?6:4">Besonderheiten bei HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.5</TD>
 <TD><A HREF="VON-AIDS.cgi?6:5">Wie werden Erg&auml;nzungsleistungen beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>7. HIV-Test</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>7.1</TD>
 <TD><A HREF="VON-AIDS.cgi?7:1">Bevor Sie sich f&uuml;r einen HIV-Test entscheiden, empfiehlt es sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.2</TD>
 <TD><A HREF="VON-AIDS.cgi?7:2">Wenn der Entscheid f&uuml;r einen HIV-Test gefallen ist, raten wir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.3</TD>
 <TD><A HREF="VON-AIDS.cgi?7:3">Wenn der Test positiv ausf&auml;llt</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.4</TD>
 <TD><A HREF="VON-AIDS.cgi?7:4">Wenn der Test ohne Ihr Wissen oder ohne Ihre Zustimmung erfolgt ist</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+8"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-25</DOCNO>
<DOCOLDNO>IA017-000177-B049-69</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+4 192.33.214.13 19970106040638 text/html 4262
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:07:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>4. Berufliche Vorsorge (BVG)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>4.1</TD>
 <TD><A HREF="VON-AIDS.cgi?4:1">Obligatorische berufliche Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.2</TD>
 <TD><A HREF="VON-AIDS.cgi?4:2">Freiwillige weitergehende Vorsorge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.3</TD>
 <TD><A HREF="VON-AIDS.cgi?4:3">Nachteilige Aspekte der Pensionskasse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.4</TD>
 <TD><A HREF="VON-AIDS.cgi?4:4">Diskriminierende Auswirkungen f&uuml;r Menschen mit HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.5</TD>
 <TD><A HREF="VON-AIDS.cgi?4:5">Die Folgen einer Nichtaufnahme in die Zusatzversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.6</TD>
 <TD><A HREF="VON-AIDS.cgi?4:6">Verschiedene Fragen und Empfehlungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>5. Invalidenversicherung (IV)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>5.1</TD>
 <TD><A HREF="VON-AIDS.cgi?5:1">Wann besteht Anspruch auf Leistungen der IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.2</TD>
 <TD><A HREF="VON-AIDS.cgi?5:2">Welche Leistungen erbringt die IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.3</TD>
 <TD><A HREF="VON-AIDS.cgi?5:3">Wie hoch sind die Renten und Entsch&auml;digungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.4</TD>
 <TD><A HREF="VON-AIDS.cgi?5:4">Ab welchem Zeitpunkt besteht ein Rentenanspruch ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.5</TD>
 <TD><A HREF="VON-AIDS.cgi?5:5">Wie und wann wird eine Rente beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>6. Erg&auml;nzungsleistungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>6.1</TD>
 <TD><A HREF="VON-AIDS.cgi?6:1">Ziel der Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.2</TD>
 <TD><A HREF="VON-AIDS.cgi?6:2">Wer erh&auml;lt Erg&auml;nzungsleistungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.3</TD>
 <TD><A HREF="VON-AIDS.cgi?6:3">Was ist versichert ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.4</TD>
 <TD><A HREF="VON-AIDS.cgi?6:4">Besonderheiten bei HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.5</TD>
 <TD><A HREF="VON-AIDS.cgi?6:5">Wie werden Erg&auml;nzungsleistungen beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>7. HIV-Test</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>7.1</TD>
 <TD><A HREF="VON-AIDS.cgi?7:1">Bevor Sie sich f&uuml;r einen HIV-Test entscheiden, empfiehlt es sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.2</TD>
 <TD><A HREF="VON-AIDS.cgi?7:2">Wenn der Entscheid f&uuml;r einen HIV-Test gefallen ist, raten wir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.3</TD>
 <TD><A HREF="VON-AIDS.cgi?7:3">Wenn der Test positiv ausf&auml;llt</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.4</TD>
 <TD><A HREF="VON-AIDS.cgi?7:4">Wenn der Test ohne Ihr Wissen oder ohne Ihre Zustimmung erfolgt ist</A></TD>
</TR>
</TABLE>
</UL>
<H3>8. Antritt einer neuen Arbeitsstelle</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>8.1</TD>
 <TD><A HREF="VON-AIDS.cgi?8:1">Informationspflicht beim Antritt einer neuen Stelle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.2</TD>
 <TD><A HREF="VON-AIDS.cgi?8:2">Aufnahme in eine kollektive Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.3</TD>
 <TD><A HREF="VON-AIDS.cgi?8:3">Aufnahme in die Pensionskasse eines Arbeitgebers</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+9"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-26</DOCNO>
<DOCOLDNO>IA017-000177-B049-88</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+5 192.33.214.13 19970106040657 text/html 3955
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:07:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>5. Invalidenversicherung (IV)</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>5.1</TD>
 <TD><A HREF="VON-AIDS.cgi?5:1">Wann besteht Anspruch auf Leistungen der IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.2</TD>
 <TD><A HREF="VON-AIDS.cgi?5:2">Welche Leistungen erbringt die IV ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.3</TD>
 <TD><A HREF="VON-AIDS.cgi?5:3">Wie hoch sind die Renten und Entsch&auml;digungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.4</TD>
 <TD><A HREF="VON-AIDS.cgi?5:4">Ab welchem Zeitpunkt besteht ein Rentenanspruch ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.5</TD>
 <TD><A HREF="VON-AIDS.cgi?5:5">Wie und wann wird eine Rente beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>6. Erg&auml;nzungsleistungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>6.1</TD>
 <TD><A HREF="VON-AIDS.cgi?6:1">Ziel der Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.2</TD>
 <TD><A HREF="VON-AIDS.cgi?6:2">Wer erh&auml;lt Erg&auml;nzungsleistungen ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.3</TD>
 <TD><A HREF="VON-AIDS.cgi?6:3">Was ist versichert ?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.4</TD>
 <TD><A HREF="VON-AIDS.cgi?6:4">Besonderheiten bei HIV/Aids</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.5</TD>
 <TD><A HREF="VON-AIDS.cgi?6:5">Wie werden Erg&auml;nzungsleistungen beantragt ?</A></TD>
</TR>
</TABLE>
</UL>
<H3>7. HIV-Test</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>7.1</TD>
 <TD><A HREF="VON-AIDS.cgi?7:1">Bevor Sie sich f&uuml;r einen HIV-Test entscheiden, empfiehlt es sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.2</TD>
 <TD><A HREF="VON-AIDS.cgi?7:2">Wenn der Entscheid f&uuml;r einen HIV-Test gefallen ist, raten wir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.3</TD>
 <TD><A HREF="VON-AIDS.cgi?7:3">Wenn der Test positiv ausf&auml;llt</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.4</TD>
 <TD><A HREF="VON-AIDS.cgi?7:4">Wenn der Test ohne Ihr Wissen oder ohne Ihre Zustimmung erfolgt ist</A></TD>
</TR>
</TABLE>
</UL>
<H3>8. Antritt einer neuen Arbeitsstelle</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>8.1</TD>
 <TD><A HREF="VON-AIDS.cgi?8:1">Informationspflicht beim Antritt einer neuen Stelle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.2</TD>
 <TD><A HREF="VON-AIDS.cgi?8:2">Aufnahme in eine kollektive Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.3</TD>
 <TD><A HREF="VON-AIDS.cgi?8:3">Aufnahme in die Pensionskasse eines Arbeitgebers</A></TD>
</TR>
</TABLE>
</UL>
<H3>9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>9.1</TD>
 <TD><A HREF="VON-AIDS.cgi?9:1">Absenzen infolge einer ambulanten medizinischen Behandlung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.2</TD>
 <TD><A HREF="VON-AIDS.cgi?9:2">Lohnausfallentsch&auml;digung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.3</TD>
 <TD><A HREF="VON-AIDS.cgi?9:3">Invalidenrente</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+10"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-27</DOCNO>
<DOCOLDNO>IA017-000177-B049-105</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+7 192.33.214.13 19970106040713 text/html 3652
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:07:30 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+2"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>7. HIV-Test</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>7.1</TD>
 <TD><A HREF="VON-AIDS.cgi?7:1">Bevor Sie sich f&uuml;r einen HIV-Test entscheiden, empfiehlt es sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.2</TD>
 <TD><A HREF="VON-AIDS.cgi?7:2">Wenn der Entscheid f&uuml;r einen HIV-Test gefallen ist, raten wir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.3</TD>
 <TD><A HREF="VON-AIDS.cgi?7:3">Wenn der Test positiv ausf&auml;llt</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.4</TD>
 <TD><A HREF="VON-AIDS.cgi?7:4">Wenn der Test ohne Ihr Wissen oder ohne Ihre Zustimmung erfolgt ist</A></TD>
</TR>
</TABLE>
</UL>
<H3>8. Antritt einer neuen Arbeitsstelle</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>8.1</TD>
 <TD><A HREF="VON-AIDS.cgi?8:1">Informationspflicht beim Antritt einer neuen Stelle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.2</TD>
 <TD><A HREF="VON-AIDS.cgi?8:2">Aufnahme in eine kollektive Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.3</TD>
 <TD><A HREF="VON-AIDS.cgi?8:3">Aufnahme in die Pensionskasse eines Arbeitgebers</A></TD>
</TR>
</TABLE>
</UL>
<H3>9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>9.1</TD>
 <TD><A HREF="VON-AIDS.cgi?9:1">Absenzen infolge einer ambulanten medizinischen Behandlung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.2</TD>
 <TD><A HREF="VON-AIDS.cgi?9:2">Lohnausfallentsch&auml;digung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.3</TD>
 <TD><A HREF="VON-AIDS.cgi?9:3">Invalidenrente</A></TD>
</TR>
</TABLE>
</UL>
<H3>10. Beendigung des Arbeitsvertrags</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>10.1</TD>
 <TD><A HREF="VON-AIDS.cgi?10:1">Die ordentliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.2</TD>
 <TD><A HREF="VON-AIDS.cgi?10:2">Die missbr&auml;uchliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.3</TD>
 <TD><A HREF="VON-AIDS.cgi?10:3">Die fristlose K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.4</TD>
 <TD><A HREF="VON-AIDS.cgi?10:4">K&uuml;ndigung w&auml;hrend einer Krankheit</A></TD>
</TR>
</TABLE>
</UL>
<H3>11. Nach Beendigung des Arbeitsverh&auml;ltnisses</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>11.1</TD>
 <TD><A HREF="VON-AIDS.cgi?11:1">Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.2</TD>
 <TD><A HREF="VON-AIDS.cgi?11:2">Arbeitslosenversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.3</TD>
 <TD><A HREF="VON-AIDS.cgi?11:3">Pensionskassen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.4</TD>
 <TD><A HREF="VON-AIDS.cgi?11:4">Unfallversicherung</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+12"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-28</DOCNO>
<DOCOLDNO>IA017-000177-B049-117</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+8 192.33.214.13 19970106040723 text/html 3302
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:07:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+3"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>8. Antritt einer neuen Arbeitsstelle</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>8.1</TD>
 <TD><A HREF="VON-AIDS.cgi?8:1">Informationspflicht beim Antritt einer neuen Stelle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.2</TD>
 <TD><A HREF="VON-AIDS.cgi?8:2">Aufnahme in eine kollektive Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.3</TD>
 <TD><A HREF="VON-AIDS.cgi?8:3">Aufnahme in die Pensionskasse eines Arbeitgebers</A></TD>
</TR>
</TABLE>
</UL>
<H3>9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>9.1</TD>
 <TD><A HREF="VON-AIDS.cgi?9:1">Absenzen infolge einer ambulanten medizinischen Behandlung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.2</TD>
 <TD><A HREF="VON-AIDS.cgi?9:2">Lohnausfallentsch&auml;digung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.3</TD>
 <TD><A HREF="VON-AIDS.cgi?9:3">Invalidenrente</A></TD>
</TR>
</TABLE>
</UL>
<H3>10. Beendigung des Arbeitsvertrags</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>10.1</TD>
 <TD><A HREF="VON-AIDS.cgi?10:1">Die ordentliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.2</TD>
 <TD><A HREF="VON-AIDS.cgi?10:2">Die missbr&auml;uchliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.3</TD>
 <TD><A HREF="VON-AIDS.cgi?10:3">Die fristlose K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.4</TD>
 <TD><A HREF="VON-AIDS.cgi?10:4">K&uuml;ndigung w&auml;hrend einer Krankheit</A></TD>
</TR>
</TABLE>
</UL>
<H3>11. Nach Beendigung des Arbeitsverh&auml;ltnisses</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>11.1</TD>
 <TD><A HREF="VON-AIDS.cgi?11:1">Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.2</TD>
 <TD><A HREF="VON-AIDS.cgi?11:2">Arbeitslosenversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.3</TD>
 <TD><A HREF="VON-AIDS.cgi?11:3">Pensionskassen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.4</TD>
 <TD><A HREF="VON-AIDS.cgi?11:4">Unfallversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>12. Verschiedene Anmerkungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>12.1</TD>
 <TD><A HREF="VON-AIDS.cgi?12:1">Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.2</TD>
 <TD><A HREF="VON-AIDS.cgi?12:2">Krankenversicherung</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="VON-AIDS.cgi?+13"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-29</DOCNO>
<DOCOLDNO>IA017-000177-B049-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+9 192.33.214.13 19970106040732 text/html 3059
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:07:53 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+4"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>9.1</TD>
 <TD><A HREF="VON-AIDS.cgi?9:1">Absenzen infolge einer ambulanten medizinischen Behandlung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.2</TD>
 <TD><A HREF="VON-AIDS.cgi?9:2">Lohnausfallentsch&auml;digung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.3</TD>
 <TD><A HREF="VON-AIDS.cgi?9:3">Invalidenrente</A></TD>
</TR>
</TABLE>
</UL>
<H3>10. Beendigung des Arbeitsvertrags</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>10.1</TD>
 <TD><A HREF="VON-AIDS.cgi?10:1">Die ordentliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.2</TD>
 <TD><A HREF="VON-AIDS.cgi?10:2">Die missbr&auml;uchliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.3</TD>
 <TD><A HREF="VON-AIDS.cgi?10:3">Die fristlose K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.4</TD>
 <TD><A HREF="VON-AIDS.cgi?10:4">K&uuml;ndigung w&auml;hrend einer Krankheit</A></TD>
</TR>
</TABLE>
</UL>
<H3>11. Nach Beendigung des Arbeitsverh&auml;ltnisses</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>11.1</TD>
 <TD><A HREF="VON-AIDS.cgi?11:1">Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.2</TD>
 <TD><A HREF="VON-AIDS.cgi?11:2">Arbeitslosenversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.3</TD>
 <TD><A HREF="VON-AIDS.cgi?11:3">Pensionskassen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.4</TD>
 <TD><A HREF="VON-AIDS.cgi?11:4">Unfallversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>12. Verschiedene Anmerkungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>12.1</TD>
 <TD><A HREF="VON-AIDS.cgi?12:1">Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.2</TD>
 <TD><A HREF="VON-AIDS.cgi?12:2">Krankenversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>13. Pers&ouml;nliche Rechtsberatung lohnt sich</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>13.1</TD>
 <TD><A HREF="VON-AIDS.cgi?13:1">Pers&ouml;nliche Rechtsberatung lohnt sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.2</TD>
 <TD><A HREF="VON-AIDS.cgi?13:2">Adressen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-30</DOCNO>
<DOCOLDNO>IA017-000177-B049-142</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+10 192.33.214.13 19970106040743 text/html 2482
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:02 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+5"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>10. Beendigung des Arbeitsvertrags</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>10.1</TD>
 <TD><A HREF="VON-AIDS.cgi?10:1">Die ordentliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.2</TD>
 <TD><A HREF="VON-AIDS.cgi?10:2">Die missbr&auml;uchliche K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.3</TD>
 <TD><A HREF="VON-AIDS.cgi?10:3">Die fristlose K&uuml;ndigung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.4</TD>
 <TD><A HREF="VON-AIDS.cgi?10:4">K&uuml;ndigung w&auml;hrend einer Krankheit</A></TD>
</TR>
</TABLE>
</UL>
<H3>11. Nach Beendigung des Arbeitsverh&auml;ltnisses</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>11.1</TD>
 <TD><A HREF="VON-AIDS.cgi?11:1">Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.2</TD>
 <TD><A HREF="VON-AIDS.cgi?11:2">Arbeitslosenversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.3</TD>
 <TD><A HREF="VON-AIDS.cgi?11:3">Pensionskassen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.4</TD>
 <TD><A HREF="VON-AIDS.cgi?11:4">Unfallversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>12. Verschiedene Anmerkungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>12.1</TD>
 <TD><A HREF="VON-AIDS.cgi?12:1">Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.2</TD>
 <TD><A HREF="VON-AIDS.cgi?12:2">Krankenversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>13. Pers&ouml;nliche Rechtsberatung lohnt sich</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>13.1</TD>
 <TD><A HREF="VON-AIDS.cgi?13:1">Pers&ouml;nliche Rechtsberatung lohnt sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.2</TD>
 <TD><A HREF="VON-AIDS.cgi?13:2">Adressen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-31</DOCNO>
<DOCOLDNO>IA017-000177-B049-152</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+11 192.33.214.13 19970106040753 text/html 1878
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+6"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>11. Nach Beendigung des Arbeitsverh&auml;ltnisses</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>11.1</TD>
 <TD><A HREF="VON-AIDS.cgi?11:1">Krankentaggeldversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.2</TD>
 <TD><A HREF="VON-AIDS.cgi?11:2">Arbeitslosenversicherung</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.3</TD>
 <TD><A HREF="VON-AIDS.cgi?11:3">Pensionskassen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.4</TD>
 <TD><A HREF="VON-AIDS.cgi?11:4">Unfallversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>12. Verschiedene Anmerkungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>12.1</TD>
 <TD><A HREF="VON-AIDS.cgi?12:1">Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.2</TD>
 <TD><A HREF="VON-AIDS.cgi?12:2">Krankenversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>13. Pers&ouml;nliche Rechtsberatung lohnt sich</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>13.1</TD>
 <TD><A HREF="VON-AIDS.cgi?13:1">Pers&ouml;nliche Rechtsberatung lohnt sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.2</TD>
 <TD><A HREF="VON-AIDS.cgi?13:2">Adressen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-32</DOCNO>
<DOCOLDNO>IA017-000177-B049-161</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+12 192.33.214.13 19970106040801 text/html 1317
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+7"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>12. Verschiedene Anmerkungen</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>12.1</TD>
 <TD><A HREF="VON-AIDS.cgi?12:1">Erg&auml;nzungsleistungen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.2</TD>
 <TD><A HREF="VON-AIDS.cgi?12:2">Krankenversicherung</A></TD>
</TR>
</TABLE>
</UL>
<H3>13. Pers&ouml;nliche Rechtsberatung lohnt sich</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>13.1</TD>
 <TD><A HREF="VON-AIDS.cgi?13:1">Pers&ouml;nliche Rechtsberatung lohnt sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.2</TD>
 <TD><A HREF="VON-AIDS.cgi?13:2">Adressen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-33</DOCNO>
<DOCOLDNO>IA017-000177-B049-167</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?+13 192.33.214.13 19970106040811 text/html 997
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>Von Aids bis Z - <A HREF="VON-AIDS.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="VON-AIDS.cgi?+8"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>13. Pers&ouml;nliche Rechtsberatung lohnt sich</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>13.1</TD>
 <TD><A HREF="VON-AIDS.cgi?13:1">Pers&ouml;nliche Rechtsberatung lohnt sich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.2</TD>
 <TD><A HREF="VON-AIDS.cgi?13:2">Adressen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-34</DOCNO>
<DOCOLDNO>IA017-000177-B049-182</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?7:1 192.33.214.13 19970106040818 text/html 1459
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:41 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 7. HIV-Test</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+7"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "7.">
<CENTER>
<A HREF="VON-AIDS.cgi?6:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H1>HIV-Test, Arbeitsplatz, Versicherungen : <BR>
Das Wichtigste in K&uuml;rze</H1>
<P>
<H2>7. HIV-Test</H2>
<A NAME="1">
<H3>7.1 Bevor Sie sich f&uuml;r einen HIV-Test entscheiden, empfiehlt
es sich :</H3>
<P>
<B>Vorg&auml;ngig</B> mit mehreren sachverst&auml;ndigen Personen
(Arzt, &Auml;rztin, Freunden, Freundinnen, Betroffenen usw.) dar&uuml;ber
zu <B>sprechen</B> und sich mit einer kantonalen Aids-Hilfe in
Verbindung zu setzen.
<P>
Sich eine <B>Bedenkzeit</B> zuzugestehen (ausser in einem medizinischen
Notfall).
<P>
<B>Ihre Versicherungsleistungen zu &uuml;berpr&uuml;fen</B> und
allenfalls die n&ouml;tigen Zusatzversicherungen abzuschliessen
(siehe auch <A HREF="VON-AIDS.cgi?1:4#4">1.4</A>).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?6:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-35</DOCNO>
<DOCOLDNO>IA017-000177-B049-196</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?10:1 192.33.214.13 19970106040828 text/html 4362
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 10. Beendigung des Arbeitsvertrags</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+10"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "10.">
<CENTER>
<A HREF="VON-AIDS.cgi?9:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="1">
<H2>10. Beendigung des Arbeitsvertrags</H2>
<H3>10.1 Die ordentliche K&uuml;ndigung</H3>
<P>
<I><B>Ist die durch das Gesetz und durch den Arbeitsvertrag
vorgeschriebene
Form eingehalten worden ?</B></I>
<P>
Die K&uuml;ndigung kann Ihnen m&uuml;ndlich oder brieflich (normale
Post) er&ouml;ffnet werden. In der Praxis wird die K&uuml;ndigung
jedoch per Einschreibebrief ausgesprochen, um der Beweispflicht
zu gen&uuml;gen.
<P>
Sieht der Vertrag f&uuml;r die K&uuml;ndigung eine andere Formvorschrift
vor, so muss diese eingehalten werden, damit die K&uuml;ndigung
g&uuml;ltig ist.
<P>
<P>
<I><B>Wie lange dauert die K&uuml;ndigungsfrist ?</B></I>
<P>
Die K&uuml;ndigungsfrist schwankt je nach Dauer des
Arbeitsverh&auml;ltnisses
(OR) :
<P>
- Bis zu einem Jahr kann auf Ende des auf die K&uuml;ndigung folgenden
Monats gek&uuml;ndigt werden.
<BR>
- Von 2 bis 9 Jahren betr&auml;gt die K&uuml;ndigungsfrist zwei Monate auf
Ende des Monats.
<BR>
- Ab 10 Jahren betr&auml;gt die K&uuml;ndigungsfrist drei Monate
auf Ende des Monats.
<BR>
- Durch den Einzelarbeitsvertrag, den Gesamtarbeitsvertrag oder
das Beamtengesetz des Bundes, der Kantone oder Gemeinden kann
auch eine l&auml;ngere K&uuml;ndigungsfrist vereinbart werden.
<P>
Ausser wenn im Arbeitsvertrag ausdr&uuml;cklich anders vermerkt,
<B>beginnt die K&uuml;ndigungsfrist bei Erhalt des
K&uuml;ndigungsschreibens</B>
oder sp&auml;testens nach Ablauf der Postaufbewahrungsfrist (7
Tage), vorausgesetzt, dass der Empf&auml;nger bzw. die Empf&auml;ngerin
in der Lage war, die Sendung beim Postamt abzuholen.
<P>
<B>Eine brieflich erfolgte K&uuml;ndigung (auch wenn eingeschrieben)
w&auml;hrend eines gesch&auml;ftlichen Auslandaufenthalts oder
w&auml;hrend den Ferien,</B> von der Sie folglich nichts wissen
k&ouml;nnen, respektiert die vertraglich und gesetzlich festgelegte
K&uuml;ndigungsfrist nicht.
<P>
<P>
<I><B>Die K&uuml;ndigungsfrist ist eingehalten worden.</B></I>
<P>
Kl&auml;ren Sie ab, ob auch die vorgeschriebene Form eingehalten
worden ist.
<P>
Auch wenn die Frist und die Form eingehalten worden sind, <B>kann
Aufschluss &uuml;ber den K&uuml;ndigungsgrund verlangt werden</B>
(Art. 335 Abs. 2 OR).
<P>
<P>
<I><B>Die K&uuml;ndigungsfrist ist nicht eingehalten worden.</B></I>
<P>
<B>Die Nichtbeachtung der K&uuml;ndigungsfrist bedeutet nicht,
dass die K&uuml;ndigung ung&uuml;ltig ist. </B>
<P>
<B>Schreiben Sie unbedingt und unverz&uuml;glich einen eingeschriebenen
Brief an Ihren Arbeitgeber, in dem Sie :</B>
<BR>
ihm die Bedingungen Ihres Arbeitsvertrags oder des Gesetzes
(K&uuml;ndigungsfrist)
in Erinnerung rufen
<BR>
und ihm Ihre Dienste mindestens bis zum n&auml;chsten rechtm&auml;ssigen
K&uuml;ndigungstermin anbieten.
<P>
<B>Der letztere Punkt ist sehr wichtig im Hinblick auf Ihr Anrecht
auf Arbeitslosenunterst&uuml;tzung.</B> Wenn Sie dies nicht
ausdr&uuml;cklich
erw&auml;hnen, wird man aus Ihrem Verhalten schliessen, dass Sie
die K&uuml;ndigung angenommen haben (vorgezogene K&uuml;ndigung
im gegenseitigen Einverst&auml;ndnis), und Sie erhalten erst Anrecht
auf die Leistungen der Arbeitslosenkasse nach Ablauf der
gesetzm&auml;ssigen
K&uuml;ndigungsfrist, die aufgrund des Arbeitsvertrags und des
Gesetzes h&auml;tte eingehalten werden m&uuml;ssen !
<P>
<B>Wenn der Arbeitgeber auf seiner K&uuml;ndigung beharrt,</B>
wenden Sie sich an das zust&auml;ndige Gericht in Ihrer Region
oder Ihrem Bezirk und verlangen Sie den Lohn bis zum Ablauf der
gesetzlichen oder vertraglichen K&uuml;ndigungsfrist. Arbeitsrechtliche
Prozesse sind bis zu einem Streitwert von Fr. 20'000.-kostenlos.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?9:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-36</DOCNO>
<DOCOLDNO>IA017-000177-B049-208</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?10:2 192.33.214.13 19970106040839 text/html 2827
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:08:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 10. Beendigung des Arbeitsvertrags</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+10"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "10.">
<CENTER>
<A HREF="VON-AIDS.cgi?10:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="2">
<H3>10.2 Die missbr&auml;uchliche K&uuml;ndigung</H3>
<P>
<B>Wenn der Arbeitgeber eine HIV-Infektion, Drogensucht,
Homosexualit&auml;t
oder andere pers&ouml;nliche Eigenschaften als K&uuml;ndigungsgrund
angibt,</B> ist die K&uuml;ndigung missbr&auml;uchlich (Art. 336
OR) unter der Bedingung, dass der geltend gemachte Grund nicht
in einem Zusammenhang mit dem Arbeitsverh&auml;ltnis steht (beispielsweise
gilt der Konsum von Bet&auml;ubungsmitteln, wenn er die
Arbeitsf&auml;higkeit
vermindert, nicht als missbr&auml;uchlicher K&uuml;ndigungsgrund).
<P>
<B>Es ist unbedingt erforderlich, dass Sie bis sp&auml;testens
zum Ablauf der K&uuml;ndigungsfrist einen eingeschriebenen Brief
an Ihren Arbeitgeber richten</B>, in dem
<BR>
- Sie die K&uuml;ndigung anfechten
<BR>
- Sie den missbr&auml;uchlichen Grund oder die missbr&auml;uchlichen
Gr&uuml;nde f&uuml;r die K&uuml;ndigung pr&auml;zisieren
<BR>
- Sie ihn auffordern, die Weiterf&uuml;hrung des Arbeitsverh&auml;ltnisses
schriftlich zu best&auml;tigen.
<P>
<B>Wenn sich der Arbeitgeber einer Weiterf&uuml;hrung des
Arbeitsverh&auml;ltnisses
widersetzt</B>, wenden Sie sich innert 180 Tagen seit Beendigung
des Arbeitsverh&auml;ltnisses an das Arbeitsgericht (vgl. oben).
Die Entsch&auml;digung f&uuml;r eine missbr&auml;uchliche K&uuml;ndigung
betr&auml;gt maximal sechs Monatsl&ouml;hne.
<P>
<B>Wenn Sie die Gr&uuml;nde f&uuml;r Ihre K&uuml;ndigung nicht
kennen</B>, m&uuml;ssen Sie Ihren Arbeitgeber, Ihre Arbeitgeberin
auffordern, Ihnen diese schriftlich mitzuteilen. Dazu ist er gesetzlich
verpflichtet. Wenn sich seine Gr&uuml;nde als missbr&auml;uchlich
herausstellen, gehen Sie vor, wie oben ausgef&uuml;hrt.
<P>
Schiebt der Arbeitgeber, die Arbeitgeberin andere Gr&uuml;nde
vor, k&uuml;ndigt Ihrer Meinung nach aber wegen eines
missbr&auml;uchlichen
Grundes, so m&uuml;ssen Sie bei Gericht beweisen, dass ein
Missbrauchstatbestand
vorliegt, und der Arbeitgeber, die Arbeitgeberin muss beweisen,
dass seine schriftlich abgegebenen, vorgeschobenen Gr&uuml;nde
vorliegen.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?10:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-37</DOCNO>
<DOCOLDNO>IA017-000177-B049-222</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?10:3 192.33.214.13 19970106040858 text/html 1938
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:09:13 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 10. Beendigung des Arbeitsvertrags</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+10"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "10.">
<CENTER>
<A HREF="VON-AIDS.cgi?10:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="3">
<H3>10.3 Die fristlose K&uuml;ndigung</H3>
<P>
<B>Unter fristloser K&uuml;ndigung versteht man jene, die ohne
Frist und ohne Entsch&auml;digung ausgesprochen wird.</B>
<P>
<B>Sie ist g&uuml;ltig, wenn sie aufgrund eines wichtigen Grundes
gem&auml;ss OR erfolgt und wenn sich dieser Grund als tats&auml;chlich
gegeben herausstellt.</B> Die Gr&uuml;nde f&uuml;r eine fristlose
K&uuml;ndigung m&uuml;ssen eine schwere Verletzung der vertraglichen
Pflichten beinhalten, zum Beispiel Taten, die eine Strafverfolgung
nach sich ziehen k&ouml;nnen. Allerdings ist die Einsch&auml;tzung
der wahren Motive schwierig, und die Rechtsprechung ist nicht
immer einheitlich. Zur Abkl&auml;rung der pers&ouml;nlichen Situation
empfiehlt es sich deshalb, mit einer Gewerkschaft oder mit einer
Rechtsanw&auml;ltin bzw. einem Rechtsanwalt Kontakt aufzunehmen.

<P>
Wenn die vorgebrachten Gr&uuml;nde f&uuml;r eine fristlose K&uuml;ndigung
letztere missbr&auml;uchlich machen (siehe auch <A
HREF="VON-AIDS.cgi?10:2#2">10.2</A>), muss sie
ganz klar angefochten werden (siehe auch <A HREF="VON-AIDS.cgi?10:1#1">10.1</A> und
<A HREF="VON-AIDS.cgi?10:2#2">10.2</A>).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?10:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-38</DOCNO>
<DOCOLDNO>IA017-000177-B049-231</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?10:4 192.33.214.13 19970106040915 text/html 5029
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:09:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 10. Beendigung des Arbeitsvertrags</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+10"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "10.">
<CENTER>
<A HREF="VON-AIDS.cgi?10:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="4">
<H3>10.4 K&uuml;ndigung w&auml;hrend einer Krankheit</H3>
<P>
<I><B>K&uuml;ndigungsschutz bei Krankheit</B></I>
<P>
<B>Wenn Sie krank sind, geniessen Sie w&auml;hrend einer gewissen
Frist einen K&uuml;ndigungsschutz ; wenn Ihr Arbeitgeber Ihnen
innerhalb dieser Frist k&uuml;ndigt, ist die K&uuml;ndigung nichtig</B>.
Die Schutzfrist betr&auml;gt :
<P>
1. Dienstjahr : 30 Tage
<BR>
2. bis 5. Dienstjahr : 90 Tage
<BR>
Ab 6. Dienstjahr : 180 Tage
<P>
Erst nach Ablauf dieser Frist kann eine K&uuml;ndigung ausgesprochen
werden, wobei allerdings die gesetzlichen K&uuml;ndigungsfristen
weiterhin beachtet werden m&uuml;ssen und missbr&auml;uchliche
Gr&uuml;nde nicht g&uuml;ltig sind (siehe auch <A
HREF="VON-AIDS.cgi?1:2#2">1.2</A>).
<P>
Der K&uuml;ndigungsschutz tritt nur in Kraft, wenn eine Krankheit
erwiesen und durch ein &auml;rztliches Zeugnis best&auml;tigt
ist. <B>Eine symptomfreie HIV-Infektion gibt kein Anrecht auf
K&uuml;ndigungsschutz</B>, da diese gem&auml;ss Arbeitsrecht nicht
als Krankheit betrachtet wird.
<P>
<B>In einem Arbeitsvertrag oder einem Kollektivvertrag d&uuml;rfen
l&auml;ngere K&uuml;ndigungsschutzfristen vorgesehen werden</B>
oder andere Vereinbarungen, solange diese zugunsten des Arbeitnehmers,
bzw. der Arbeitnehmerin ausfallen.
<P>
<B>Schreiben Sie deshalb unbedingt und unverz&uuml;glich einen
eingeschriebenen Brief an Ihren Arbeitgeber</B>, in dem
<BR>
- Sie ihn darauf hinweisen, dass Sie K&uuml;ndigungsschutz geniessen
und dass die K&uuml;ndigung deshalb nichtig ist
<BR>
- Sie erw&auml;hnen, dass er damit rechnen muss, Ihnen den Lohn
bis zum n&auml;chstm&ouml;glichen rechtm&auml;ssigen K&uuml;ndigungstermin
weiterhin bezahlen zu m&uuml;ssen, falls er auf seinem Entscheid
beharrt
<BR>
- Sie ihn dazu auffordern, Ihnen die Weiterf&uuml;hrung des
Arbeitsverh&auml;ltnisses
schriftlich zu best&auml;tigen.
<P>
<B>Erscheinen Sie wieder an Ihrem Arbeitsplatz, sobald Ihre
Arbeitsf&auml;higkeit
wiederhergestellt ist.</B>
<P>
<B>Wenn Ihr Arbeitgeber die Weiterf&uuml;hrung des
Arbeitsverh&auml;ltnisses
ablehnt,</B> m&uuml;ssen Sie sich an das zust&auml;ndige Gericht
in Ihrem Kanton oder Bezirk wenden und sich durch eine Anw&auml;ltin
bzw. einen Anwalt oder eine sachverst&auml;ndige Person beraten
lassen.
<P>
<B>Ein Arbeitgeber, der einen Angestellten bzw. eine Angestellte
entlassen will, muss nach Ablauf der Schutzfrist nochmals eine
K&uuml;ndigung aussprechen</B> und die K&uuml;ndigungsfrist einhalten.
<P>
<P>
<I><B>Arbeitsunf&auml;higkeit w&auml;hrend der
K&uuml;ndigungsfrist</B></I>
<P>
<B>Wenn Sie w&auml;hrend der K&uuml;ndigungsfrist</B> (Zeitraum
zwischen der K&uuml;ndigung und der Beendigung des
Arbeitsverh&auml;ltnisses)
<B>arbeitsunf&auml;hig werden</B>, wird die K&uuml;ndigung zeitweilig
suspendiert, und die Frist l&auml;uft erst weiter, wenn Sie wieder
arbeitsf&auml;hig sind. Die K&uuml;ndigungsfrist wird jedoch maximal
um die Sperrfrist unterbrochen.
<P>
Das Arbeitsverh&auml;ltnis muss auf einen bestimmten Termin beendigt
werden (Monatsende). Wenn dieser Termin nun nicht mehr mit dem
Ende der K&uuml;ndigungsfrist zusammenf&auml;llt, die nach einem
Unterbruch wieder zu laufen begonnen hat, <B>wird die K&uuml;ndigungsfrist
bis zum n&auml;chsten K&uuml;ndigungstermin verl&auml;ngert</B>.
<P>
<B>Beispiel :</B> Die Arbeitnehmerin befindet sich im ersten Jahr
ihres Arbeitsverh&auml;ltnisses. Sie erh&auml;lt die K&uuml;ndigung
am 5. M&auml;rz. K&uuml;ndigungsfrist = ein Monat auf Ende des
folgenden Monats. Das Arbeitsverh&auml;ltnis wird demnach am 30.
April beendigt. Die Arbeitnehmerin ist nun vom 20. M&auml;rz bis
am 27. April krankheitsbedingt arbeitsunf&auml;hig. Der
K&uuml;ndigungsschutz
aufgrund von Krankheit betr&auml;gt 30 Tage. Also l&auml;uft die
K&uuml;ndigungsfrist ab 19. April weiter. Das Arbeitsverh&auml;ltnis
wird demnach am 31. Mai beendet.
<BR>
<B>In einem solchen Fall m&uuml;ssen Sie sich Ihrem Arbeitgeber
nach Ihrer Genesung unbedingt wieder zur Verf&uuml;gung stellen.</B>
Wenn Sie dies nicht tun, verlieren Sie nicht nur Ihr Anrecht auf
Lohn, sondern auch dasjenige auf die Leistungen der Arbeitslosenkasse
; diese leistet ihre Beitr&auml;ge erst nach Ablauf der
K&uuml;ndigungsfrist,
die h&auml;tte eingehalten werden m&uuml;ssen.
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?10:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-39</DOCNO>
<DOCOLDNO>IA017-000178-B001-2</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?11:2 192.33.214.13 19970106040926 text/html 3581
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:09:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 11. Nach Beendigung des Arbeitsverh&auml;ltnisses</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+11"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "11.">
<CENTER>
<A HREF="VON-AIDS.cgi?11:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="2">
<H3>11.2 Arbeitslosenversicherung</H3>
<P>
<B>Melden Sie sich am ersten Tag der Arbeitslosigkeit sofort auf
dem Arbeitsamt</B>. Beginnen Sie wenn m&ouml;glich mit der Suche
nach einer neuen Stelle bereits w&auml;hrend der ablaufenden
K&uuml;ndigungsfrist.

<P>
<B>Menschen mit HIV gelten bei den Arbeits&auml;mtern als voll
vermittlungsf&auml;hig.</B> Es besteht keine Verpflichtung, dem
Arbeitsamt die HIV-Infektion mitzuteilen (siehe auch <A
HREF="VON-AIDS.cgi?1:3#3">1.3</A>).
<P>
<B>Wenn Sie voll arbeitsf&auml;hig sind, haben Sie Anspruch auf
Arbeitslosenversicherung</B>, sofern Sie innerhalb der letzten
zwei Jahre mindestens 6 Monate gearbeitet haben. Ausnahme : nach
Ausbildungsabschluss, Scheidung, Teilinvalidit&auml;t.
<BR>
Nehmen Sie sofort nach der K&uuml;ndigung Kontakt mit dem zust&auml;ndigen
kantonalen Arbeitsamt auf.
<P>
<B>Wenn Sie nur teilweise arbeitsf&auml;hig sind,</B> haben Sie
ein beschr&auml;nktes Anrecht auf Arbeitslosenentsch&auml;digung.
Dies gilt auch dann, wenn ein Antrag auf Invalidenrente gestellt
worden ist, und zwar solange, bis der Entscheid der IV gef&auml;llt
ist.
<P>
<B>Wenn eine 100 prozentige Arbeitsunf&auml;higkeit besteht,
beschr&auml;nkt
sich Ihr Anspruch auf Arbeitslosenunterst&uuml;tzung auf ein Maximum
von 34 Taggeldern</B> innerhalb der gesetzlichen Rahmenfrist von
zwei Jahren. F&uuml;r jedes Krankheitsereignis werden die Taggelder
jedoch nur bis zum 30. Tag nach Krankheitsbeginn bezahlt. Da nur
f&uuml;r Arbeitstage bezahlt wird, werden f&uuml;r ein Krankheitsereignis,
das 30 Tage oder l&auml;nger dauert, maximal 20 bis 23 Taggelder
angerechnet (oder weniger, wenn die Krankheit vorher zu Ende geht).
Insgesamt werden jedoch maximal 34 Taggelder ausbezahlt. Es muss
mit einer Wartefrist von einer Woche gerechnet werden, ausser
bei einem Unfall, bei Schwangerschaft oder bei einer Behandlung
im Krankenhaus.
<P>
<B>Wenn die zeitweilige Arbeitsunf&auml;higkeit &uuml;ber diese
Zeitspanne hinaus andauert,</B> haben Sie Anspruch auf
<BR>
- das volle Taggeld, wenn die Arbeitsf&auml;higkeit mindestens
75 % betr&auml;gt.
<BR>
- die H&auml;lfte des Taggeldes, wenn die Arbeitsf&auml;higkeit
mindestens 50 % betr&auml;gt.
<P>
<B>Einige Kantone schlagen Zusatzversicherungen f&uuml;r den Verlust
der Arbeitslosenentsch&auml;digung bei Krankheit vor.</B> Wenn
Sie &uuml;ber keine Einzelversicherung verf&uuml;gen, empfiehlt
es sich dringend, eine solche Zusatzversicherung abzuschliessen,
deren Leistungen - etwa in Genf - bis zum Ablauf der Rahmenfrist
gew&auml;hrt werden k&ouml;nnen. Erkundigen Sie sich von Fall
zu Fall.
<P>
Wenn Sie sich im Rahmen einer Bewerbung weigern, einen HIV-Test
zu machen und die Stelle deshalb nicht erhalten, sind
Taggeldk&uuml;rzungen
der Arbeitslosenkasse nicht zul&auml;ssig.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?11:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-40</DOCNO>
<DOCOLDNO>IA017-000178-B001-17</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?9:2 192.33.214.13 19970106040937 text/html 4338
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:09:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+9"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "9.">
<CENTER>
<A HREF="VON-AIDS.cgi?9:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="2">
<H3>9.2 Lohnausfallentsch&auml;digung</H3>
<P>
<I><B>Welche Entsch&auml;digungen erhalten Sie f&uuml;r Lohnausfall
bei Krankheit, wenn Sie keine Krankentaggeldversicherung haben
?</B></I>
<P>
Diese Frage ist im Obligationenrecht (OR) Art. 324a Abs. 2 etwas
vage geregelt : Der Arbeitgeber, die Arbeitgeberin hat &quot;
im ersten Dienstjahr den Lohn f&uuml;r drei Wochen und nachher
f&uuml;r eine angemessene l&auml;ngere Zeit zu entrichten, je
nach der Dauer des Arbeitsverh&auml;ltnisses und den besonderen
Umst&auml;nden &quot;. In der Rechtsprechung haben sich sogenannte Skala
entwickelt, die von den ArbeitgeberInnen, Versicherungsgesellschaften,
aber auch von den Gerichten angewendet werden. Je nach Region
kommt die Berner-, die Basler- oder die Z&uuml;rcher-Skala zur
Anwendung. Versicherungsgesellschaften wenden in aller Regel die
Berner-Skala an :
<P>
<UL>
1. Dienstjahr : 3 Wochen Lohn
<BR>
2. Dienstjahr : 1 Monat Lohn
<BR>
3 bis 4 Dienstjahre : 2 Monate Lohn
<BR>
5 bis 9 Dienstjahre : 3 Monate Lohn
<BR>
10 bis 14 Dienstjahre : 4 Monate Lohn
<BR>
15 bis 19 Dienstjahre : 5 Monate Lohn
<BR>
20 bis 24 Dienstjahre : 6 Monate Lohn
<BR>
25 bis 29 Dienstjahre : 7 Monate Lohn
<BR>
30 bis 34 Dienstjahre : 8 Monate Lohn
<BR>
35 bis 39 Dienstjahre : 9 Monate Lohn
</UL>
<P>
<B>Die Berechnung der Dienstjahre</B> richtet sich nach dem
Eintrittsdatum.
Zum Beispiel befindet sich eine angestellte Person bei einer Anstellung
von einem Jahr und zwei Monaten im 2. Dienstjahr. Beginnt eine
Krankheit im 1. Dienstjahr und dauert bis ins 2. Dienstjahr hinein,
so beginnt die Lohnfortzahlungsdauer im 2. Dienstjahr neu zu laufen.

<P>
<B>W&auml;hrend der Probezeit</B> besteht kein Anspruch auf
Lohnfortzahlung.
Gem&auml;ss OR gilt die gesetzliche Lohnfortzahlung nur f&uuml;r
Arbeitsverh&auml;ltnisse, die f&uuml;r mehr als 3 Monate eingegangen
worden sind oder drei Monate gedauert haben.<I> </I>
<P>
<P>
<I><B>Welche Entsch&auml;digungen erhalten Sie bei Krankheit,
wenn Sie durch eine Krankentaggeldversicherung versichert sind
?</B></I>
<P>
Allgemein muss die <B>Arbeitsunf&auml;higkeit mindestens 50% </B>betragen,
damit der Lohnausfall durch die Versicherung gedeckt wird.
<P>
<B>Wenn die Krankheit an der Sie leiden Gegenstand eines Vorbehalts
ist und die Deckung durch eine Privatversicherung erfolgt</B>,
haben Sie kein Anrecht auf Krankentaggeld. Allerdings ist der
Arbeitgeber verpflichtet, den Lohn w&auml;hrend einer bestimmten
Zeitspanne weiterzubezahlen ( siehe Berner Skala weiter oben).

<P>
<B>Die Taggeldentsch&auml;digung betr&auml;gt meist 80% des Lohnausfalls
</B>(50 % Arbeitsunf&auml;higkeit = 40 % Entsch&auml;digung) ;
allerdings kann sie auch bis zu 100 % betragen.
<P>
<B>Wenn die Deckung &uuml;ber eine anerkannte Krankenkasse erfolgt,</B>
ist die Auszahlung gesetzlich auf eine Zeitspanne von 720 Tagen
w&auml;hrend einer Periode von 900 aufeinanderfolgenden Tagen
beschr&auml;nkt.
<P>
<B>Wenn die Deckung &uuml;ber eine private Versicherung erfolgt</B>,
kann die Zahlungsdauer variieren. In diesem Fall empfiehlt es
sich unbedingt die &quot; Allgemeinen Versicherungsbedingungen
&quot; zu konsultieren.
<P>
<B>Der Vertrag kann eine Karenzzeit</B> von 3, 7, 14, 30 oder
90 Tagen Arbeitsunf&auml;higkeit <B>vorsehen</B>, w&auml;hrend
der die Versicherungsleistungen nicht ausbezahlt werden. Die Verpflichtung
des Arbeitgebers, den Lohn zu bezahlen, bleibt dennoch bestehen
( siehe Berner Skala weiter oben).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?9:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-41</DOCNO>
<DOCOLDNO>IA017-000178-B001-30</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?8:2 192.33.214.13 19970106040949 text/html 7638
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 8. Antritt einer neuen Arbeitsstelle</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+8"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "8.">
<CENTER>
<A HREF="VON-AIDS.cgi?8:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="2">
<H3>8.2 Aufnahme in eine kollektive Krankentaggeldversicherung</H3>
<I><B>Ihr Arbeitgeber versichert Sie in einer kollektiven
Krankentaggeldversicherung.
Er verlangt aber nicht, dass Sie einen Fragebogen ausf&uuml;llen,
der Auskunft &uuml;ber Ihren gegenw&auml;rtigen Gesundheitszustand
gibt.</B></I>
<P>
Wenn die Deckung von einer <B>anerkannten Krankenkasse
</B>gew&auml;hrleistet
wird, sind Sie ohne Einschr&auml;nkung versichert, falls Sie bei
Eintritt in die Krankenkasse nicht bereits krankheitshalber
arbeitsunf&auml;hig
waren.
<P>
<B>Wenn die Deckung durch eine private Versicherungsgesellschaft
&uuml;bernommen wird, </B>m&uuml;ssen die allgemeinen
Versicherungsbedingungen
sorgf&auml;ltig studiert werden (diese k&ouml;nnen Sie von Ihrem
Arbeitgeber verlangen). In einigen F&auml;llen werden bereits
bestehende Krankheiten beim Eintritt in die Versicherung von der
Deckung ausgeschlossen, auch wenn Sie nicht durch den Fragebogen
oder durch einen Test abgekl&auml;rt worden sind. Im Zweifelsfall
obliegt es allerdings der Versicherungsgesellschaft zu beweisen,
dass Sie bei Vertragsabschluss tats&auml;chlich HIV-positiv waren.
<P>
<P>
<I><B>Ihr Arbeitgeber versichert Sie in einer kollektiven
Krankentaggeldversicherung
und verlangt, dass Sie einen Fragebogen ausf&uuml;llen oder eine
&auml;rztliche Untersuchung durchf&uuml;hren lassen. Sie verf&uuml;gen
bis zu diesem Zeitpunkt (zum Beispiel bei Ihrem fr&uuml;heren
Arbeitgeber) noch &uuml;ber keine Krankentaggeldversicherung.</B></I>
<P>
<B>Wenn Sie im Fragebogen angeben, dass Sie HIV-positiv sind und
die Deckung von einer anerkannten Krankenkasse &uuml;bernommen
wird, </B>wird die Krankentaggeldversicherung einen Vorbehalt
f&uuml;r eine &quot; HIV-Krankheit und deren Folgen &quot; anbringen,
der auf f&uuml;nf Jahre beschr&auml;nkt ist. Wenn die
Krankentaggeldversicherung
allerdings nicht freiwillig ist (vorgeschrieben durch den Arbeitsvertrag
oder durch einen Kollektivvertrag), sistiert die Krankenkasse
diesen Vorbehalt normalerweise w&auml;hrend der Dauer des
Arbeitsverh&auml;ltnisses
(Vorbehalt wird ausser Kraft gesetzt, aber die Frist von f&uuml;nf
Jahren beginnt dennoch zu laufen).
<P>
<B>Wenn Sie im Fragebogen angeben, dass Sie HIV-positiv sind und
die Deckung von einer privaten Versicherungsgesellschaft &uuml;bernommen
wird,</B> kann die Krankentaggeldversicherung die Aufnahme verweigern,
die Leistungen k&uuml;rzen oder einen zeitlich nicht begrenzten
Vorbehalt f&uuml;r eine &quot; HIV-Krankheit und deren Folgen
&quot; anbringen.
<P>
<B>Wenn Sie bei einer &auml;rztlichen Eintrittsuntersuchung, die
von einer Versicherungsgesellschaft verlangt wird, gebeten werden
einen HIV-Test zu machen, </B>k&ouml;nnen Sie diesen verweigern.
In diesem Fall wird die Versicherung Sie behandeln, als ob Sie
HIV-positiv w&auml;ren (Aufnahmeverweigerung, K&uuml;rzung der
Leistungen oder zeitlich nicht begrenzter Vorbehalt). Wenn Sie
wissen, dass Sie HIV-positiv sind, oder nicht sicher sind, ob
Sie HIV-negativ sind, sollten Sie einen in diesem Zusammenhang
verlangten HIV-Test unbedingt ablehnen.
<P>
<B>Wenn Sie wissen, dass Sie HIV-positiv sind, den Test aber anonym
oder im Ausland gemacht haben</B> und in der Schweiz keine &auml;rztliche
Behandlung durchgef&uuml;hrt haben, und Sie im Fragebogen eine
falsche Auskunft geben (zum Beispiel HIV-negativ anstelle von
HIV-positiv), dann riskieren Sie praktisch keine Nachteile, da
die Versicherung Ihre HIV-Infektion nicht nachweisen kann.
<P>
<B>Wenn Sie wissen, dass Sie HIV-positiv sind, den Test nicht
anonym in der Schweiz gemacht haben und/oder einer &auml;rztlichen
Behandlung in der Schweiz zugestimmt haben</B> und im Fragebogen
einen falsche Auskunft geben (zum Beispiel HIV-negativ anstelle
von HIV-positiv), laufen Sie Gefahr, dass die Versicherungsleistungen
gek&uuml;rzt werden oder dass Sie aus der Versicherung ausgeschlossen
werden.
<P>
<B>Wenn der Eintrittsfragebogen nicht explizit nach Ihrem HIV-Status
fragt, jedoch nach Ihrem Gesundheitszustand (zum Beispiel : Sind
Sie krank ?)</B> und Sie HIV-positiv sind und diese Tatsache durch
die Versicherung bewiesen werden k&ouml;nnte (durch eine
vertrauens&auml;rztliche
Untersuchung), laufen Sie Gefahr, dass Ihnen die Leistungen gek&uuml;rzt
werden - unabh&auml;ngig davon, ob Sie mit Ja oder Nein antworten.
Das Eidgen&ouml;ssische Versicherungsgericht hat 1990 die symptomlose
HIV-Infektion als &quot; Krankheit &quot; qualifiziert. Dies gilt
auch dann, wenn Sie HIV-positiv, gesund und voll arbeitsf&auml;hig
sind (siehe auch <A HREF="VON-AIDS.cgi?1:4#4">1.4</A>).
<P>
<B>Wenn der Fragebogen nicht vertraulich behandelt wird</B>
(beispielsweise
wenn er dem Arbeitgeber oder der Arbeitgeberin offen &uuml;bergeben
werden muss oder durch diesen ausgef&uuml;llt wird), k&ouml;nnen
Sie zum Schutz Ihrer Privatsph&auml;re l&uuml;gen (Notwehrrecht
der L&uuml;ge). Allerdings hat sich die Rechtsprechung noch nicht
klar zu diesem Punkt ge&auml;ussert. Wenn Sie sich weigern, die
Frage zu beantworten (und die Felder oder die Zeilen leer lassen),
werden Sie behandelt, als ob Sie HIV-positiv w&auml;ren, allerdings
mit dem Vorteil, dass die Diagnose f&uuml;r die Versicherung und/oder
den Arbeitgeber oder die Arbeitgeberin  nicht gesichert ist.
<P>
<P>
<I><B>Ihr neuer Arbeitgeber versichert Sie in einer kollektiven
Krankentaggeldversicherung, und Sie verf&uuml;gen durch Ihren
fr&uuml;heren Arbeitgeber bereits &uuml;ber eine solche
Versicherung.</B></I>
<P>
Informieren Sie Ihren neuen Arbeitgeber unverz&uuml;glich &uuml;ber
diese Tatsache. <B>Wenn sowohl Ihre bisherige als auch die neue
Kollektivversicherung durch eine anerkannte Krankenkasse gedeckt
sind, </B>dann haben Sie Anrecht auf einen freien &Uuml;bertritt.
Es darf kein neuer Vorbehalt angebracht werden, und Sie m&uuml;ssen
deshalb nicht bekanntgeben, dass Sie HIV-positiv sind, und Sie
brauchen auch keinen Fragebogen auszuf&uuml;llen (siehe auch
<A HREF="VON-AIDS.cgi?3:1#1">3.1</A>).
<P>
<B>Wenn Ihre bisherige und die neue Kollektivversicherung durch
eine Privatversicherung gedeckt sind, </B>besteht ein &Uuml;bertrittsrecht
nur aufgrund eines privatrechtlichen Abkommens zwischen diesen
Versicherungen und nur dann, wenn sie dem Abkommen beigetreten
sind. Es empfiehlt sich, diese Frage abzukl&auml;ren, eventuell
mit Hilfe eines Rechtsanwaltes oder einer Rechtsanw&auml;ltin
( siehe auch <A HREF="VON-AIDS.cgi?3:1#1">3.1</A>).
<P>
<B>F&uuml;r den Fall, dass der &Uuml;bertritt von einer Krankenkasse
zu einer Privatversicherung oder umgekehrt erfolgt</B>, gibt es
ein privatrechtliches Abkommen, das allerdings nur f&uuml;r diejenigen
Kassen bindend ist, die ihm beigetreten sind. Normalerweise wird
das &Uuml;bertrittsrecht gew&auml;hrt. Wenden Sie sich bei Schwierigkeiten
an einen Rechtsanwalt bzw. eine Rechtanw&auml;ltin ( siehe auch
<A HREF="VON-AIDS.cgi?3:1#1">3.1</A>).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?8:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-42</DOCNO>
<DOCOLDNO>IA017-000178-B001-46</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?8:3 192.33.214.13 19970106040959 text/html 5449
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 8. Antritt einer neuen Arbeitsstelle</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+8"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "8.">
<CENTER>
<A HREF="VON-AIDS.cgi?8:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="3">
<H3>8.3 Aufnahme in die Pensionskasse eines Arbeitgebers</H3>
<P>
<I><B>Die Leistungen der Pensionskasse Ihres zuk&uuml;nftigen
Arbeitgebers sind auf das obligatorische Minimum beschr&auml;nkt
(BVG-Minimum).</B></I>
<P>
<B>Im Aufnahmefragebogen darf keine Frage zu HIV, zu Aids oder
zu anderen Krankheiten gestellt werden.</B> Eine vertrauens&auml;rztliche
Untersuchung vor dem Eintritt ist ebenfalls ausgeschlossen.
<P>
<B>Auch wenn Sie HIV-positiv oder aidskrank sind,</B> m&uuml;ssen
Sie obligatorisch und ohne Vorbehalte in die Versicherung aufgenommen
werden (Ausnahme : im Falle einer Teilinvalidit&auml;t von mindestens
zwei Dritteln) (siehe auch <A HREF="VON-AIDS.cgi?4:1#1">4.1</A>).
<P>
<P>
<I><B>Die Leistungen der Pensionskasse Ihres zuk&uuml;nftigen
Arbeitgebers &uuml;bersteigen das obligatorische Minimum.</B></I>
<P>
<B>Informieren Sie sich &uuml;ber die Aufnahmebedingungen.</B>
<P>
<B>Wenn kein Fragebogen ausgef&uuml;llt werden muss</B> und keine
&auml;rztliche Untersuchung verlangt wird, sind Sie normal versichert,
auch bei einer bestehenden HIV-Infektion. Dies ist bei den meisten
&ouml;ffentlichen Kassen der Fall (Eidgenossenschaft, Kantone,
Gemeinden usw.).
<P>
<B>Wenn Sie in einem Fragebogen angeben, dass Sie HIV-positiv
sind</B>, kann die Pensionskasse jede Deckung ablehnen, die &uuml;ber
das gesetzlich festgelegte Minimum hinausgeht (BVG). Sie kann
die &uuml;berobligatorischen Leistungen k&uuml;rzen oder einen
zeitlich nicht begrenzten Vorbehalt f&uuml;r eine &quot; HIV-Krankheit
und deren Folgen &quot; anbringen.
<P>
Wenn Sie in einem Fragebogen angegeben haben, dass Sie HIV-positiv
sind, oder wenn Sie einem HIV-Test zugestimmt haben, der positiv
ausgefallen ist, <B>wird die Pensionskasse normalerweise Kenntnis
davon haben </B>(diese Diagnose muss bekannt sein, um einen Vorbehalt
anbringen zu k&ouml;nnen). Der Arbeitgeber, bzw. die Arbeitgeberin wird im
Normalfall &uuml;ber die Ablehnung eines Versicherungsschutzes oder die
Anbringung eines Vorbehalts informiert, ohne dass ihm/ihr aber die
medizinische Diagnose bekanntgegeben wird.
<P>
<B>Wenn Sie bei einer &auml;rztlichen Eintrittsuntersuchung, die
von der Pensionskasse verlangt wird, gebeten werden, einen HIV-Test
zu machen, haben Sie das Recht, diesen zu verweigern.</B> In diesem
Fall behandelt Sie die Pensionskasse, als ob Sie HIV-positiv w&auml;ren.
Wenn Sie wissen, dass Sie HIV-positiv sind, oder nicht sicher
sind, ob Sie HIV-negativ sind, sollten Sie einen in diesem Zusammenhang
verlangten HIV-Test ablehnen oder sich mit einer Beratungsstelle
absprechen.
<P>
<B>Wenn Sie wissen, dass Sie HIV-positiv sind, den Test aber anonym
oder im Ausland gemacht haben</B> und nie in der Schweiz in
&auml;rztlicher
Behandlung waren und Sie im Fragebogen eine falsche Auskunft geben
(zum Beispiel HIV-negativ anstelle von HIV-positiv), dann riskieren
Sie praktisch keine Nachteile, da diese Ihre HIV-Positivit&auml;t
nicht nachweisen kann.
<P>
<B>Wenn Sie wissen, dass Sie HIV-positiv sind, den Test nicht
anonym in der Schweiz gemacht haben und/oder einer &auml;rztlichen
Behandlung in der Schweiz zugestimmt haben</B> und im Fragebogen
eine falsche Auskunft geben (zum Beispiel HIV-negativ anstelle
von HIV-positiv), laufen Sie Gefahr, dass die Pensionskasse Ihre
HIV-Infektion nachweisen kann und in der Folge die Versicherungsleistungen
verweigert und Sie von einer Zusatzversicherung ausgeschlossen
werden.
<P>
<B>Wenn der Fragebogen nicht vertraulich behandelt wird</B>
(beispielsweise
wenn er dem Arbeitgeber, der Arbeitgeberin offen &uuml;bergeben
werden muss oder durch diesen ausgef&uuml;llt wird), k&ouml;nnen
Sie zum Schutz Ihrer Privatsph&auml;re l&uuml;gen (Notwehrrecht
der L&uuml;ge). Allerdings hat sich die Rechtsprechung noch nicht
klar zu diesem Punkt ge&auml;ussert. Wenn Sie sich weigern, die
Frage zu beantworten (und die Felder oder die Zeilen leer lassen),
werden Sie behandelt, als ob Sie HIV-positiv w&auml;ren, allerdings
mit dem Vorteil, dass die Diagnose f&uuml;r die Versicherung und/oder
den Arbeitgeber nicht gesichert ist.
<P>
<B>Wenn der Eintrittsfragebogen nicht explizit nach Ihrem HIV-Status
fragt, jedoch nach dem Gesundheitszustand</B> (zum Beispiel :
Sind Sie krank ?) und Sie HIV-positiv sind und diese Tatsache
durch die Pensionskasse bewiesen werden k&ouml;nnte (durch eine
vertrauens&auml;rztliche Untersuchung), laufen Sie - ob Sie nun
mit Ja oder Nein antworten - Gefahr, dass Ihnen letztlich die
Leistungen auf das BVG-Minimum gek&uuml;rzt werden. Das
Eidgen&ouml;ssische
Versicherungsgericht hat 1990 die HIV-Infektion als &#179;Krankheit&#147;
qualifiziert.  (siehe auch <A HREF="VON-AIDS.cgi?1:4#4">1.4</A>).
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?8:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-43</DOCNO>
<DOCOLDNO>IA017-000178-B001-54</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?11:3 192.33.214.13 19970106041007 text/html 5013
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:29 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 11. Nach Beendigung des Arbeitsverh&auml;ltnisses</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+11"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "11.">
<CENTER>
<A HREF="VON-AIDS.cgi?11:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<A NAME="3">
<H3>11.3 Pensionskassen</H3>
<P>
<I><B>Freiz&uuml;gigkeitsleistungen</B></I>
<P>
<B>Der Arbeitgeber ist verpflichtet, die Vorsorgeinstitution &uuml;ber
Ihre K&uuml;ndigung zu informieren. Diese wiederum muss Sie &uuml;ber
die M&ouml;glichkeiten informieren, wie Sie die Vorsorge gem&auml;ss
Gesetz und dem eigenen Reglement weiterf&uuml;hren k&ouml;nnen.</B>
Sie m&uuml;ssen der bisherigen Pensionskasse mitteilen, auf welche
neue Vorsorgeinstitution Ihr Guthaben &uuml;bertragen werden soll,
dies innerhalb von 30 Tagen. Wenn diese Frist nicht eingehalten
wird, ist die bisherige Pensionskasse berechtigt, selbst zu entscheiden,
wie die Weiterf&uuml;hrung der Vorsorge aufgrund des Gesetzes
und der eigenen Bestimmungen gestaltet wird (siehe auch <A
HREF="VON-AIDS.cgi?4:6#6">4.6</A>).
<P>
<I><B>Sie sind gegenw&auml;rtig arbeitslos.</B></I>
<P>
<B>Wenn Sie Stempelgelder beziehen</B>, werden Ihnen gem&auml;ss
dem neuen Bundesgesetz &uuml;ber die Arbeitslosenversicherung
(AVIG) von den Arbeitslosentaggeldern Pr&auml;mienbeitr&auml;ge
f&uuml;r die Risiken Tod und Invalidit&auml;t abgezogen und an
die Stiftung Auffangeinrichtung &uuml;berwiesen. <B>Diese Regelung
tritt am 1. Januar 1997 in Kraft.</B>
<P>
<B>Sie haben die Wahl zwischen den M&ouml;glichkeiten, die das
Reglement Ihrer Pensionskasse vorsieht.</B>
<P>
<B>Wenn das Reglement eine Weiterf&uuml;hrung des
Versicherungsverh&auml;ltnisses
vorsieht,</B>
<BR>
- wird das Altersguthaben nur noch durch die Zinsen erh&ouml;ht
<BR>
- bleibt die Versicherung f&uuml;r Todesfall oder Invalidit&auml;t
bestehen, wobei die Pr&auml;mien entweder von der Versicherungsnehmerin
bzw. dem Versicherungsnehmer erhoben oder vom Kapital abgezogen werden.
<BR>
<B>Wenn das Reglement keine Weiterf&uuml;hrung des
Versicherungsverh&auml;ltnisses
vorsieht, </B>
<BR>
- k&ouml;nnen Sie Ihr Guthaben auf ein Sperrkonto &uuml;bertragen
lassen, wobei dann allerdings bei Todesfall oder Invalidit&auml;t
keine Rente ausbezahlt wird (nur das Kapital kann bezogen werden)
<BR>
- k&ouml;nnen Sie Ihr Guthaben auf eine Lebensversicherung &uuml;bertragen
lassen, wobei die Rentenzahlungen bei Todesfall oder Invalidit&auml;t
den Bestimmungen der gew&auml;hlten Lebensversicherung unterliegen
<BR>
- k&ouml;nnen Sie Ihr Guthaben auf eine eidgen&ouml;ssische
Auffangeinrichtung
&uuml;bertragen lassen, womit die Versicherung weitergef&uuml;hrt
wird. Sie m&uuml;ssen dann allerdings die Arbeitgeber- und
Arbeitnehmerbeitr&auml;ge
bezahlen, was bis zu 20% Ihres Lohns ausmachen kann.
<P>
<B>Wenn Ihnen Ihr Arbeitgeber oder die Pensionskasse die verlangten
Informationen nicht bekanntgeben</B> oder wenn sie ihren Verpflichtungen
nicht nachkommen, k&ouml;nnen Sie sich an die kantonalen
BVG-Aufsichtsbeh&ouml;rden
wenden (Adressen auf der letzten Seite des Telefonbuchs).
<P>
<B>Bei der Freiz&uuml;gigkeit</B>, das heisst bei einem Transfer
Ihres Guthabens auf die Pensionskasse Ihres neuen Arbeitgebers
oder auf die Auffangeinrichtung, sieht das BVG vor, dass das gesamte
Altersguthaben (die eigenen Beitr&auml;ge und diejenigen des
Arbeitgebers),
das durch das Gesetz festgelegt ist (gesetzliches Minimum), an
den Arbeitnehmer bzw. die Arbeitnehmerin &uuml;bergehen. Wenn
die geleisteten Beitr&auml;ge das gesetzliche Minimum allerdings
&uuml;bersteigen oder wenn der Arbeitnehmer bzw. die Arbeitnehmerin
vor Inkraftsetzung des BVG (1.1.1985) bereits ein Guthaben einbezahlt
hat, betrifft die Freiz&uuml;gigkeit nicht die Gesamtsumme der
einbezahlten Beitr&auml;ge. Die Berechnung nach dem neuen
Freiz&uuml;gigkeitsgesetz
ist kompliziert. Lassen Sie sich von einer spezialisierten Anw&auml;ltin
oder einem spezialisierten Anwalt oder einer Beratungsstelle beraten.
<P>
<B>Der Betrag der Freiz&uuml;gigkeit kann in den folgenden durch
das Gesetz vorgesehenen F&auml;llen als Kapital &uuml;berwiesen
werden :</B>
<BR>
1. Wenn die Austrittsleistung weniger als Ihr Jahresbeitrag betr&auml;gt.
<BR>
2. Wenn Sie die Schweiz endg&uuml;ltig verlassen.
<BR>
3. Wenn Sie eine selbst&auml;ndige Erwerbst&auml;tigkeit aufnehmen.
<BR>
4. Wenn Sie eine ganze Invalidenrente der eidgen&ouml;ssischen
Invalidenversicherung beziehen und das Invalidit&auml;tsrisiko
nicht  versichert ist.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?11:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?11:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-44</DOCNO>
<DOCOLDNO>IA017-000178-B001-64</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?6:1 192.33.214.13 19970106041016 text/html 1637
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 6. Erg&auml;nzungsleistungen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+6"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "6.">
<CENTER>
<A HREF="VON-AIDS.cgi?5:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H2>6. Erg&auml;nzungsleistungen</H2>
<A NAME="1">
<H3>6.1. Ziel der Erg&auml;nzungsleistungen</H3>
Die Renten der AHV und IV sollen nach urspr&uuml;nglicher Meinung
der Bundesverfassung das Existenzminimum decken. Zur Zeit betr&auml;gt
die einfache maximale Invalidenrente f&uuml;r Alleinstehende Fr.
1'940.-pro Monat (Stand 1995). Dieser Betrag wird dem Verfassungsauftrag
nicht gerecht, wenn die Bez&uuml;gerinnen und Bez&uuml;ger ausschliesslich
davon leben m&uuml;ssen. 1965 wurde deshalb das Bundesgesetz &uuml;ber
die Erg&auml;nzungsleistungen geschaffen. Die Erg&auml;nzungsleistungen
(EL) sollen die Renten der AHV und IV &quot; aufstocken &quot;.
Sie sind beitragsfrei und werden vollumf&auml;nglich aus Steuergeldern
finanziert. Neben diesen EL des Bundes zahlen sowohl die Kantone
als auch die Gemeinden ebenfalls Erg&auml;nzungs- oder Zusatzleistungen.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?5:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-45</DOCNO>
<DOCOLDNO>IA017-000178-B001-77</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?6:2 192.33.214.13 19970106041024 text/html 1606
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:46 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 6. Erg&auml;nzungsleistungen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+6"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "6.">
<CENTER>
<A HREF="VON-AIDS.cgi?6:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>6.2. Wer erh&auml;lt Erg&auml;nzungsleistungen ?</H3>
In der Schweiz wohnhafte Schweizer B&uuml;rgerinnen und B&uuml;rger,
die eine Rente oder Hilflosenentsch&auml;digung der AHV oder mindestens
eine halbe Rente der IV beziehen, haben Anspruch auf EL, wenn
ihr j&auml;hrliches Einkommen kleiner ist als die folgenden
Einkommensgrenzen
(Stand 1995) :
<P>
- F&uuml;r Alleinstehende und Minderj&auml;hrige Fr. 15'060.--
<P>
- F&uuml;r Ehepaare Fr. 22'500.--
<P>
- F&uuml;r Waisen Fr. 7'530.--
<P>
Wer w&auml;hrend mindestens sechs Monaten Taggelder der IV bezieht
(z.B. w&auml;hrend einer Umschulung), hat ebenfalls Anspruch auf
EL. Ausl&auml;nder und Ausl&auml;nderinnen haben nur einen Anspruch,
wenn sie ununterbrochen w&auml;hrend 15 Jahren in der Schweiz
wohnten (Fl&uuml;chtlinge und Staatenlose w&auml;hrend f&uuml;nf
Jahren).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?6:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-46</DOCNO>
<DOCOLDNO>IA017-000178-B001-90</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?6:3 192.33.214.13 19970106041033 text/html 2659
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:10:55 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 6. Erg&auml;nzungsleistungen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+6"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "6.">
<CENTER>
<A HREF="VON-AIDS.cgi?6:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>6.3. Was ist versichert ?</H3>
Versichert ist die Differenz zwischen dem anrechenbaren Einkommen
und der jeweiligen Einkommensgrenze, das heisst, von der Einkommensgrenze
wird das Einkommen in Abzug gebracht. Beim anrechenbaren Einkommen
wird auch das Verm&ouml;gen anteilm&auml;ssig ber&uuml;cksichtigt,
soweit es eine gewisse Freigrenze &uuml;bersteigt.
<P>
Die Berechnung ist kompliziert und sollte nicht allein gemacht
werden. Nachstehend ein einfaches Beispiel zur Verdeutlichung
:
<P>
<B>Zum Beispiel eine alleinstehende Person mit :</B>
<BR>
<PRE>
IV-Rente / Monat                           Fr.    970.-<BR>
Mietzins / Monat                           Fr.    700.-<BR>
Zus&auml;tzliche Kosten f&uuml;r Arzt<BR>
und Medikamente/Jahr                       Fr.    600.-<BR>
Verm&ouml;gen (Freigrenze 25'000.--)            Fr.    30'000.-
<P>
<B>Einkommen :</B>
<BR>
IV-Rente (12 x 970.--)                     Fr.    11'640.-<BR>
Verm&ouml;gensertrag                            Fr.    1'500.-<BR>
1/15 Verm&ouml;gen                              Fr.    333.--<BR>
______________<BR>
<B>                                           Fr.    13'473.-</B>
<P>
<B>Abz&uuml;ge :</B>
<BR>
Miete (max. 11'200.--)                     Fr.    8'400.-<BR>
Selbstbehaltkosten                         Fr.    600.-<BR>
______________<BR>
<B>                                           Fr.    9'000.-</B>
<P>
Anrechenbares Einkommen                    Fr.    4'473.-<BR>
Anrechenbare Einkommensgrenze              Fr.    15'060.-<BR>
______________<BR>
<B>Erg&auml;nzungsleistungen                       Fr.    10'587.-</B>
</PRE>
<P>
<P>
<B>Wichtig</B>
<BR>
Nach Einf&uuml;hrung des neuen KVG (1. Januar 1996) wurde das
Bundesgesetz &uuml;ber die Erg&auml;nzungsleistungen ge&auml;ndert.
Seit 1. Januar 1996 k&ouml;nnen die Krankenkassenbeitr&auml;ge
nicht mehr vom Einkommen in Abzug gebracht werden.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?6:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-47</DOCNO>
<DOCOLDNO>IA017-000178-B001-100</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?6:4 192.33.214.13 19970106041047 text/html 1901
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:11:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 6. Erg&auml;nzungsleistungen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+6"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "6.">
<CENTER>
<A HREF="VON-AIDS.cgi?6:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>6.4. Besonderheiten bei HIV/Aids</H3>
Alle krankheitsbedingten, nicht von der Krankenkasse gedeckten
Kosten sind vom anrechenbaren Einkommen in Abzug zu bringen. Allerdings
nur f&uuml;r das Kalenderjahr, in dem die Behandlung vorgenommen
wurde. Diese Kosten k&ouml;nnen innert 15 Monaten seit Rechnungsstellung
geltend gemacht werden. Darunter fallen auch nicht gedeckte Kosten
f&uuml;r vor&uuml;bergehende Aufenthalte in einer Heilanstalt,
soweit vom Arzt/von der &Auml;rztin verordnet, sowie die Kosten
f&uuml;r ambulante Pflege, die von &ouml;ffentlichen oder
gemeinn&uuml;tzigen
Tr&auml;gern (z.B. Spitex) erbracht wird ( siehe auch 3. Teil
&#179;Heimpflege und Haushalthilfe&#147;, Seite QQ).
<P>
Behinderungsbedingte Mehrkosten f&uuml;r notwendige Hilfe durch
eine Drittperson im Haushalt, Transportkosten zu medizinischen
Behandlungsorten oder die Miete f&uuml;r eine rollstuhlg&auml;ngige
Wohnung sind ebenfalls abzugsf&auml;hig. Auch an Aufenthalte in
Lighth&auml;usern und Hospizen k&ouml;nnen Erg&auml;nzungsleistungen
bezahlt werden. Es gelten dann die Beitragss&auml;tze f&uuml;r
Heimbewohnerinnen und -bewohner.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?6:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?6:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-48</DOCNO>
<DOCOLDNO>IA017-000178-B001-110</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?6:5 192.33.214.13 19970106041059 text/html 1389
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:11:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 6. Erg&auml;nzungsleistungen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+6"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "6.">
<CENTER>
<A HREF="VON-AIDS.cgi?6:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>6.5. Wie werden Erg&auml;nzungsleistungen beantragt ?</H3>
<BR>
Die Adressen der Stellen, bei denen Sie sich f&uuml;r
Erg&auml;nzungsleistungen
anmelden k&ouml;nnen, finden Sie im Kapitel &#179;Anhang&#147;
auf Seite QQ.
<P>
<B>N&uuml;tzliche Merkbl&auml;tter</B>
<BR>
Bei den kantonalen Ausgleichskassen k&ouml;nnen verschiedene
Merkbl&auml;tter
bezogen werden. Wichtig sind vor allem :<BR>
- Merkblatt &uuml;ber die Erg&auml;nzungsleistungen der AHV/IV
<BR>
- Merkbl&auml;tter &uuml;ber kantonale und kommunale Zusatzleistungen
<P>
Die Adressen der Ausgleichskassen finden Sie auf den letzten Seiten
im Telefonbuch.
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?6:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-49</DOCNO>
<DOCOLDNO>IA017-000178-B001-122</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?7:2 192.33.214.13 19970106041118 text/html 1399
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:11:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 7. HIV-Test</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+7"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "7.">
<CENTER>
<A HREF="VON-AIDS.cgi?7:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>7.2 Wenn der Entscheid f&uuml;r einen HIV-Test gefallen ist,
raten wir :</H3>
<P>
Einen <B>anonymen</B> Test zu machen (die Adressen finden
Sie im Anhang dieser Brosch&uuml;re auf Seite QQ).
<P>
Mit Ihrem Arzt bzw. Ihrer &Auml;rztin zu vereinbaren<B>, dass
der Test anonymisiert wird</B> (in diesem Fall werden die Kosten
f&uuml;r den Test von der Krankenkasse nicht &uuml;bernommen)
und dass er nicht in Ihrer Krankengeschichte erscheint. Achtung
: Die Anonymit&auml;t muss vollumfassend sein, das bedeutet, dass
Ihr Name dem Labor nicht bekanntgegeben werden darf !
<P>
Den <B>Test im Ausland</B> zu machen, vorzugsweise ebenfalls
anonym.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?7:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-50</DOCNO>
<DOCOLDNO>IA017-000178-B001-135</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?7:3 192.33.214.13 19970106041131 text/html 1609
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:11:53 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 7. HIV-Test</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+7"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "7.">
<CENTER>
<A HREF="VON-AIDS.cgi?7:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>7.3 Wenn der Test positiv ausf&auml;llt</H3>
<P>
<B>Bevor Sie einer &auml;rztlichen Behandlung zustimmen</B>, die
die Aufhebung der Anonymit&auml;t mit sich bringt, sollten Sie
Ihre Versicherungsdeckung abkl&auml;ren (Krankheit, Krankentaggeld,
Lebensversicherung).
<P>
<B>Wenn Sie vorhaben, Ihre Arbeitsstelle in n&auml;chster Zukunft
zu wechseln</B>, sollten Sie mit einer &auml;rztlichen Behandlung
warten, bis alle notwendigen Formalit&auml;ten wie etwa die Aufnahme
in eine Pensionskasse oder in eine Kollektivversicherung (Krankheit,
Lohnausfall) erledigt sind. Wenn eine &auml;rztliche Behandlung
jedoch dringend notwendig ist, dann sprechen Sie sich mit Ihrer
&Auml;rztin bzw. Ihrem Arzt dahingehend ab, dass diese Behandlung
anonym erfolgt (was allerdings den Nachteil hat, dass die Kosten
von der Krankenkasse nicht &uuml;bernommen werden).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?7:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?7:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-51</DOCNO>
<DOCOLDNO>IA017-000178-B001-144</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?7:4 192.33.214.13 19970106041140 text/html 1622
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:12:01 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 7. HIV-Test</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+7"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "7.">
<CENTER>
<A HREF="VON-AIDS.cgi?7:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>7.4 Wenn der Test ohne Ihr Wissen oder ohne Ihre Zustimmung erfolgt
ist</H3>
<P>
Wenn der Test anonym war, ohne dass Ihr Name an das Labor weitergeleitet
wurde, dann verlangen Sie von Ihrem Arzt bzw. Ihrer &Auml;rztin,
dass <B>alle Passagen in Ihrer Krankengeschichte, die sich auf
diesen Test beziehen, vernichtet werden.</B>
<P>
<B>Nehmen Sie Kontakt mit einer kantonalen Aids-Hilfe auf. </B>Sie
haben die M&ouml;glichkeit, rechtlich gegen den f&uuml;r diesen
Test verantwortlichen Arzt bzw. die verantwortliche &Auml;rztin
vorzugehen.
<P>
<B>Wenn dieser ohne Ihr Wissen gemachte Test Ihnen finanzielle
Nachteile bringt</B> (beispielsweise bei Versicherungen), k&ouml;nnen
Sie auch einen Zivilprozess f&uuml;r Schadenersatz in Erw&auml;gung
ziehen. Nehmen Sie zuvor Kontakt mit einer Rechtsanw&auml;ltin
bzw. einem Rechtsanwalt oder einer kantonalen Aids-Hilfe auf.
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?7:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-52</DOCNO>
<DOCOLDNO>IA017-000178-B001-155</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?8:1 192.33.214.13 19970106041149 text/html 1956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:12:11 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 8. Antritt einer neuen Arbeitsstelle</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+8"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "8.">
<CENTER>
<A HREF="VON-AIDS.cgi?7:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H2>8. Antritt einer neuen Arbeitsstelle</H2>
<H3>8.1 Informationspflicht beim Antritt einer neuen Stelle</H3>
<P>
<I><B>Sie sind HIV-positiv und voll arbeitsf&auml;hig (nicht
aidskrank).</B></I>
<P>
<B>Sie m&uuml;ssen Ihrem zuk&uuml;nftigen Arbeitgeber Ihre
HIV-Positivit&auml;t
nicht bekanntgeben. </B>Sogar der Vertrauensarzt bzw. die
Vertrauens&auml;rztin
braucht nichts davon zu wissen.
<P>
<B>Sie haben das Recht zu l&uuml;gen</B>, wenn Sie direkt danach
gefragt werden (Notwehrrecht der L&uuml;ge) (siehe auch <A
HREF="VON-AIDS.cgi?1:1#1">1.1</A>).
<P>
<P>
<I><B>Sie sind aidskrank, und dies ist durch ein &auml;rztliches
Zeugnis belegt.</B></I>
<P>
<B>Sie d&uuml;rfen nicht abstreiten, dass Sie nicht voll arbeitsf&auml;hig
sind</B> oder dass Ihre Arbeitsf&auml;higkeit durch die Krankheit,
an der Sie leiden, beeintr&auml;chtigt werden k&ouml;nnte. <B>Allerdings
sind Sie nicht verpflichtet zu sagen, dass es sich bei dieser
Krankheit um Aids handelt</B>. Diese Information unterliegt Ihrer
Privatsph&auml;re.
<P>
<B>Wenn Sie jedoch abstreiten, krank zu sein</B>, kann Ihnen sp&auml;ter
die Entlassung drohen<B> </B>( siehe auch <A HREF="VON-AIDS.cgi?1:1#1">1.1</A>).
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?7:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?8:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-53</DOCNO>
<DOCOLDNO>IA017-000178-B001-164</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?9:1 192.33.214.13 19970106041159 text/html 1634
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:12:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+9"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "9.">
<CENTER>
<A HREF="VON-AIDS.cgi?8:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H2>9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge
einer medizinischen  Behandlung, einer Krankheit oder einer
Invalidit&auml;t</H2>
<H3>9.1 Absenzen infolge einer ambulanten medizinischen Behandlung</H3>
<P>
<B>Der Lohn ist normal f&auml;llig </B>f&uuml;r Absenzen im Zusammenhang
mit einer medizinischen Behandlung (keine Lohnk&uuml;rzung).
<P>
<B>Ihr Arbeitgeber darf von Ihnen</B> f&uuml;r Absenzen im Zusammenhang
mit einer medizinischen Behandlung <B>keine Kompensation verlangen
</B>(&Uuml;berstunden, Verl&auml;ngerung der Arbeitszeit).
<P>
Sie sind dazu verpflichtet, <B>die Arzttermine</B> soweit als
m&ouml;glich so zu vereinbaren, dass ein reibungsloser Arbeitsablauf
m&ouml;glichst wenig beeintr&auml;chtigt wird.
<P>
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?8:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?9:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-54</DOCNO>
<DOCOLDNO>IA017-000178-B001-171</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/VON-AIDS.cgi?9:3 192.33.214.13 19970106041208 text/html 3857
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:12:30 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Von Aids bis Z - 9. Aufgabe oder Verminderung der beruflichen T&auml;tigkeit infolge einer medizinischen Behandlung, einer Krankheit oder einer Invalidit&auml;t</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="VON-AIDS.cgi?+9"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>Von Aids bis Z (Auszug)<HR></H2>
<!% "9.">
<CENTER>
<A HREF="VON-AIDS.cgi?9:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>9.3 Invalidenrente</H3>
<P>
<I><B>Was tun, wenn Ihre Arbeitsunf&auml;higkeit voraussichtlich
l&auml;nger als 365 Tage dauert ?</B></I>
<P>
<B>Sie haben Anrecht auf eine Invalidenrente (IV), erg&auml;nzt
durch eine entsprechende Rente Ihrer Pensionskasse</B>
<P>
<B>Stellen Sie fr&uuml;hzeitig einen Antrag an die IV </B>- auch
wenn Sie nicht sicher sind, wie lange Ihre Arbeitsunf&auml;higkeit
dauern wird. Ihr Arzt bzw. Ihre &Auml;rztin kann die notwendigen
Schritte einleiten ( siehe auch <A HREF="VON-AIDS.cgi?5:1#1">5.1</A> und <A
HREF="VON-AIDS.cgi?5:5#5">5.5</A>).
<P>
Die Invalidenversicherung kl&auml;rt zuerst die M&ouml;glichkeiten
f&uuml;r eine Umschulung oder f&uuml;r berufliche Eingliederungsmassnahmen
f&uuml;r den Wiedereinstieg ins aktive Erwerbsleben ab. Die Bearbeitung
der Dossiers kann sich &uuml;ber mehrere Monate hinwegziehen.
<B>Z&ouml;gern Sie nicht, fachkundige Hilfe anzufordern, um das
Verfahren zu beschleunigen.</B>
<P>
<B>Das Recht auf Rente wird wirksam</B> fr&uuml;hestens nach einer
durchschnittlichen Arbeitsunf&auml;higkeit von 40% w&auml;hrend
eines Jahres. Diese Wartefrist beginnt zu laufen, sobald die
Arbeitsf&auml;higkeit
deutlich (nach Gerichtspraxis ab 20%) beeintr&auml;chtigt ist.
Das bedeutet zum Beispiel : Wer 6 Monate lang 20% und 6 Monate
lang 80% arbeitsunf&auml;hig war, hat w&auml;hrend eines Jahres
eine durchschnittliche Arbeitsunf&auml;higkeit von 50%. Die
Arbeitsunf&auml;higkeit
darf keinen wesentlichen Unterbruch erleiden. Unterbrochen wird
die Wartefrist durch eine volle Arbeitsf&auml;higkeit von mindestens
30 Tagen
<P>
Sie haben ebenfalls <B>Anrecht auf eine Invalidenrente von Ihrer
Pensionskasse</B>. Die Schritte sind mit dem Rentenantrag an die
IV koordiniert.
<P>
<B>Die H&ouml;he der Rente h&auml;ngt vom Grad der Invalidit&auml;t
ab.</B> Diese wird errechnet, indem das Einkommen, das mit der
gesundheitlichen Beeintr&auml;chtigung erzielt werden kann, in
Relation gesetzt wird zum Einkommen, das ohne diese Beeintr&auml;chtigung
erzielt werden k&ouml;nnte. Wenn die Rente nicht durch eine
betr&auml;chtliche
Rente Ihrer Pensionskasse erg&auml;nzt wird, deckt sie aber normalerweise
den Lebensunterhalt nicht.
<P>
<B>Wenn Ihre Invalidenrente nicht ausreicht</B>, um den Lebensunterhalt
zu decken, haben Sie Anrecht auf Erg&auml;nzungsleistungen.
<P>
<B>Bei finanziellen Schwierigkeiten</B> (zum Beispiel wenn keine
Lohnausfallversicherung besteht), haben Sie Anrecht auf Sozialhilfe.
Allerdings sind die Bedingungen f&uuml;r eine Gew&auml;hrung oftmals
drakonisch (Verm&ouml;gen wird auf ein Minimum reduziert, sogar
der Besitz eines Autos wird zuweilen als Luxus gewertet). Erkundigen
Sie sich bei den zust&auml;ndigen F&uuml;rsorgeinstitutionen Ihres
Kantons oder Ihrer Gemeinde. Wenden Sie sich auch an die kantonale
Aids-Hilfe, die gegebenenfalls einen Solidarit&auml;tsfonds heranziehen
kann ( siehe auch Teil 3, &#179;Solidarit&auml;tsfonds f&uuml;r
Menschen mit HIV/Aids&#147;, Seite QQ).
</UL>
<HR>
<CENTER>
<A HREF="VON-AIDS.cgi?9:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="VON-AIDS.cgi?10:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-55</DOCNO>
<DOCOLDNO>IA017-000178-B001-180</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/INFOTHEQUE.cgi?+9504 192.33.214.13 19970106041236 text/html 49038
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:12:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - <A HREF="INFOTHEQUE.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<H3>Aids Infotheque 4/95, Jul 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:1">Kommentar, Prof. Dr. med. Beat Roos</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>10 Jahre Aids-Hilfe Schweiz / 10 Ans Aide Suisse contre le Sida</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.1">10 Jahre Aids-Hilfe Schweiz, Christian Schneeberger</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.2">Wie man den Kampf gegen Aids bei schwulen M&auml;nnern doch noch verliert Roger Staub</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.3">Den Fixerinnen und Fixern fehlte eine Lobby, Prof. Dr. med. Peter Grob</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.4">'Et les personnes touch&eacute;es commen&ccedil;aient &agrave; parler', Philippe Esnault</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.5">Les malades du sida sont indociles, Dr m&eacute;d. Bernard Hirschel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:2.6">L'Aiuto Aids Svizzero compie 10 anni, Christian Schneeberger</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.1">Bibliothek: 10 Jahre AHS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.2">Neue Publikationen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:3.3">Graue Literatur</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Bibliographie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.1">Nouvelles parutions</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.2">Litt&eacute;rature grise</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.3">Revues, journaux</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:4.4">Mat&eacute;riel d'information</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:5">Videos (Deutsch)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:6">Vid&eacute;os (Fran&ccedil;ais)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9504:7">Theater</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.1">Medikalische Tests</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.2">Eine Studie aus dem Programm der Kommission zur Kontrolle der Aids-Forschung, Luc Perrin</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.3">Resultate einiger Projekte aus dem Nationalen Aids-Forschungs-Programm</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.4">Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection, Y. Cao et al.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9504:8.5">Europ&auml;ische Parlamentarische Konferenz &uuml;ber HIV und Aids: Fortsetzung dringend n&ouml;tig, Dr. Therese Stutz Steiger</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 01/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.1">Commentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.2">Kommentar</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Stress et Syst&egrave;me immunitaire</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.1">Immunit&eacute;, syst&egrave;me nerveux et psychisme - le point des connaissances.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.2">Immunit&auml;t, Nervensystem und Psyche  was weiss man heute?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.3">Interventions psychologiques et syst&egrave;me immunitaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.4">Immunit&agrave;, sistema nervoso e psiche  cosa ne sappiamo oggi?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek ;Stress</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.1">Psychoimmunologie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.2">Biopsychologie von Stress und emotionalen Reaktionen.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.3">Immunantwort und Psyche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.4">Der Einflu&szlig; von Hypnose und Stre&szlig; auf das Blutbild.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.5">Stress und Stressbew&auml;ltigung / Hinweis</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.6">Verhaltenstraining zur Stressbew&auml;ltigung / Stress und Stressbew&auml;ltigung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Unterricht</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.1">Kondome quer durchs Curriculum</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.2">Sexualerziehung in den deutschsprachigen Schulen des Kantons Bern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.3">Freundschaft, Liebe, Sexualit&auml;t...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.4">Sexualp&auml;dagogische Jungenarbeit</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.1">Mein Kind ist so und nicht anders...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.2">Mitten ins Herz...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.3">Sexualit&auml;t, Lebensformen, Liebe / Bisexualit&auml;t</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.4">Abschied von der sexuellen Revolution... / Strichpunkt...</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD>Medizin</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.1">Bittere Naturmedizin</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.2">Kooperation und Rivalit&auml;t... / The Cellular Basis of Central Nervous... / Neuropsychologische Untersuchungen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>4,Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.1">Menschen mit Aids pflegen: i.v. DrogengebraucherInnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.2">Arbeit, Ausbildung und Qualifikation f&uuml;r Drogengebraucher in Substitutionsbehandlung / Die Berner Drogenszene</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Vermischtes</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.5.1">Mein Gott AIDS</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.1">Le sida et les fragilit&eacute;s fran&ccedil;aises: nos r&eacute;actions face &agrave; l'&eacute;pid&eacute;mie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.2">Le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.3">Les sciences sociales face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.4">Comment vivre avec une personne atteinte par le virus du sida ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.5">Un amour s&eacute;rodiff&eacute;rent</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.6">Ev&eacute;nements quotidiens et bien-&ecirc;tre &agrave; l'adolescence...</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.7">Le mort et moi et nous</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.8">Vivre le deuil au jour le jour: la perte d'une personne proche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.9">Couples homophiles: le droit &agrave; l'existence ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.10">L'amour et le pr&eacute;servatif</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.11">Essais th&eacute;rapeutiques et  &eacute;tudes cliniques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.12">Vivre son mourir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.13</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.13">Le t&eacute;moin myope Regards sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.14</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.14">Une mort africaine Le sida au quotidien</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.15</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.15">Sang contamin&eacute; Priorit&eacute;s d'Etat et d&eacute;cisions politiques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.16</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.16">De la syphilis au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.17</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.17">Un mal imaginaire</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9601:6">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.1">Les homosexuels face au sida: enqu&ecirc;te 1993 sur les modes de vie et la gestion du risque VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.2">Rapport de la commission &quot;maladies sexuellement transmissibles et sida&quot;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.3">Soins et sida. Les chiffres cl&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.4">Pertinence, redondance et red&eacute;finition ...</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Mat&eacute;riel d'information</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.1">Guide - Sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.2">Sant&eacute;, sexualit&eacute;, sida. Une p&eacute;dagogie adapt&eacute;e.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.3">Infection par le VIH et sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.4">Sida et &eacute;ducation sexuelle</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:9.1">Pr&eacute;venir. In&eacute;galit&eacute;s, sant&eacute;, exclusions</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Videos</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.1">Forscher, Fakten, Visionen. Auf Tod und Leben!</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.2">E tempo de agir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.3">Sida: paroles de familles</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Forschung und Therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.1">Aids und Traditionelle Chinesische Medizin: Eine Studie in Z&uuml;rich</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.2">Das Forscherportrait: Dr. med. Pietro Vernazza Kantonsspital St. Gallen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.3">Portrait: Dr med. Pietro Vernazza, H&ocirc;pital cantonal de St-Gall</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.1">9. Internationale Konferenz &uuml;ber Aids und Geschlechtskrankheiten in Afrika (ICASA)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.2">Wird mit UNAIDS alles anders ?</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 02/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Kommentar / Commentaires</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.1">Kommentar deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.2">Commentaire fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:2">Infection par le VIH/SIDA et alimentation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>HIV und Ern&auml;hrung</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.1">Nahrung f&uuml;r Menschen mit Aids in der Dritten Welt</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.2">Aidskrank als Frau in Nepal: Kann man das noch &quot;leben&quot; nennen ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:4">Infezione da HIV, AIDS e alimentazione</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Ern&auml;hrung + HIV</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.1">Ern&auml;hrung, HIV-Infektion und Aids: Ein Blick &uuml;ber den Tellerrand.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.2">Wie positiv essen.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.3">Healthy Eating Makes A Difference. A Food Resource Book for People Living with HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.4">Food for those with HIV/Aids (Ern&auml;hrung f&uuml;r Menschen mit HIV/Aids)</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.5">Das grosse Buch der Vitamine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.6">Nutrition and HIV (Ern&auml;hrung und HIV). A New Model for Treatment.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.7">Immune Power. Combining Holistic  Standard Medical Therapies into the Optimal Treatment Program for HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.8">Staying Healthy with HIV. A Guide to Alternative and Complementary Therapies</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.9">Vitamine, Vitamine! Eine Brosch&uuml;re mit Rezepten &uuml;ber Vitamine und Mineralstoffe f&uuml;r Menschen mit HIV und AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.10</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.10">Unkonventionelle Medizin bei HIV und Aids</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>Ern&auml;hrung allgemein</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.1">Die Psychologie des Essens</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.2">Bioaktive Substanzen in Lebensmitteln</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.3">Die Jutta-Poschet-Immundi&auml;t / Immun</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.4">St&auml;rken Sie ihr Immunsystem.Leben Sie besser durch nat&uuml;rliche Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.5">&Ouml;ko Test - Ratgeber Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.6">Ern&auml;hrungssprechstunde.Grundlagen einer gesunden Lebensf&uuml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.7">K&uuml;chengeheimnisse der Hildegard-Medizin.Ratschl&auml;ge und Erkenntnisse der hl. Hildegard von Bingen &uuml;ber die Heilkraft unserer Nahrungsmittel</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.8">Die pflanzlichen Heilmittel bei Hildegard von Bingen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.9">SVE Medienverzeichnis. Catalogue des publications et du mat&eacute;riel m&eacute;diatique ASA. ASA elenco di pubblicazioni e della mediateca.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3">Di&eacute;t&eacute;tique</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3.1">Di&eacute;t&eacute;tique: ouvrages g&eacute;n&eacute;raux de base et sp&eacute;cialis&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Nutrition et sida</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.1">Nutitional Care for HIV+ persons: a manual for individuals and their caregivers</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.2">Nutrition et VIH</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.3">Etre mieux en mangeant mieux</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.4">Manger positivement</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.5">D&eacute;pliant &quot;Nutrition et immunit&eacute;&quot; / Branle-bas de combat dans la cuisine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.6">Probl&egrave;mes sp&eacute;cifiques</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.7">1&egrave;re conf&eacute;rence internationale nutrition et infection par le VIH</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD>Pr&auml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.1">Doppelcharakter der Pr&auml;vention</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.2">HIV-Beratung und -Pr&auml;vention in der Arztpraxis. Stellenwert und Wirksamkeit der &auml;rztlichen Fortbildung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.3">Jugend und Gesundheit. Interventionsfelder und Pr&auml;ventionsbereiche</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.4">Diskriminierungsbereitschaft Jugendlicher gegen&uuml;ber Menschen mit HIV/Aids.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.2.1">Stigma-Management und schwules Selbstbewusstsein.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.3</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.1">Geld und Gef&uuml;hle um HIV und Aids.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.2">Die medizinische Betreuung HIV-infizierter Kinder und Jugendlicher</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.4</TD>
	 <TD>Sterben</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.1">Leben- und Sterbenk&ouml;nnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.2">W&auml;rme, die nur Feuer geben kann</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.1">Sant&eacute;, guide des associations, L'Impatient - Alternative Sant&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.2">Histoire de la recherche sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.3">La sociologie du risque</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.4">L'infection au VIH de la m&egrave;re et de l'enfant</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.5">L'Eglise et l'homosexualit&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.6">J'accuse... Les mensonges qui tuent les drogu&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.7">Nouveaux d&eacute;fis des soins palliatifs: philosophie palliative et m&eacute;decine compl&eacute;mentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.8">Douleur et m&eacute;decine, la fin d'un oubli</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.9">Douleur et plaisir, maladie et sant&eacute;: une perception subjective</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.10">Le deuil &agrave; vivre</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.11">Vivre, seulement vivre. Quatre regards photographiques pour la vie</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:8">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.1">L'infection par le virus de l'immunod&eacute;ficience humaine (VIH)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.2">Plan de communication publique sur l'infection &agrave; VIH - SIDA</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.3">Les politiques publiques face au d&eacute;fi du sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.4">L'&eacute;valuation &eacute;conomique du d&eacute;pistage sida chez les femmes enceintes</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.5">Le steribox et la r&eacute;duction des risques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.6">Programme de r&eacute;duction des risques &agrave; l'usage des personnes toxicomanes usagers de drogues par voie intraveineuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.7">Les biblioth&egrave;ques face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.8">Approche biopsychosociale de l'infection au virus VIH: une revue de la litt&eacute;rature</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.9">La question du sida dans la relation psychoth&eacute;rapeutique</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:10">Mat&eacute;riel d'information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:11.1">Tabula</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:12">Videos</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.1">Whose problem? An HIV/AIDS education package</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.2">Unmasking AIDS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.3">Living on the edge. Coping with HIV and drug misuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.4">HIV pre-test counselling. How to conduct pre-test counselling in confidence</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD>Forschung et therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.1">Les choix des th&eacute;rapies</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.2">Trials</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.3">Das Forscherportrait: Dr. phil. II Markus Thali</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.4">Le portrait d'un chercheur: Dr. Markus Thali</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.1">Der Schweizerische Verband diplomierter Ern&auml;hrungsberaterInnen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.2">Wissenschaftliche Begleitung des Modellprojektes &quot;Infektionsprophylaxe im Nieders&auml;chsischen Strafvollzug&quot;</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Annoncen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:15.1">Der gute Tip: Mittagstisch f&uuml;r Menschen mit HIV und Aids</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:16">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 03/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.1">Editorial Deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.2">Editorial Fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Der HIV-Antik&ouml;rpertest / Le test de d&eacute;pistage VIH</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.1">Der HIV-Antik&ouml;rpertest - 1996 (noch) ein Thema?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.2">Le test des anticorps anti-VIH -- (encore) un sujet de discussion en 1996?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.3">Du nouveau sur le test de d&eacute;pistage du VIH?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.4">Neues zum HIV-Antik&ouml;rpertest?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.5">Recht und Unrecht beim HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.6">Aspects juridiques du test VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.7">Les curieuses m&eacute;thodes de Sida Information Suisse.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.8">Die seltsamen Methoden der Aids-Aufkl&auml;rung Schweiz</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.9">Il test HIV - nel 1996 (ancora) un tema ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.1">Handbuch HIV-Test, Arbeitshilfen zur Beratung und Testdurchf&uuml;hrung</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.2">Sentinel-Surveillance von HIV und anderen sexuell &uuml;bertragbaren Krankheiten.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.3">Der HIV-Test in Spital und Praxis / Das Testen auf die HIV-Infektion</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Prauuml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.1">Aids in Europe - The Behavioural Aspect</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.2">La Flottille de l'Espoir</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.3">Gesundheit durch Projekte f&ouml;rdern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.4">Gesundheitsf&ouml;rderung und Public Health</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Kinder/Jugendliche</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.1">Ein kurzes Leben lang / Wir sprechen &uuml;ber AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.2">Wir sprechen &uuml;ber Drogen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.3">&quot;Schwanger werd' ich nicht alleine ...&quot;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3">Homosexualit&auml;tektion</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.1">V&ouml;llig normal</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.2">Kahn, Knaben, schnelle Fahrt</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.3">Handbuch zu lesbischen und schwulen Studien in der Schweiz</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.4.1">Methadon Standards</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Betroffene</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.1">Ann&auml;herungen. Meine ersten 10 Jahre im Zeichen von AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.2">Aids hat viele Gesichter</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.3">Farbige Trauer. Gedenkt&uuml;cher f&uuml;r Menschen, die an den Folgen von Aids gestorben sind. Signes d'amour. Panneaux comm&eacute;moratifs &agrave; la m&eacute;moire de personnes d&eacute;c&eacute;d&eacute;es du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.4">Leben ohne Grenzen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.5">Mut zum Tr&auml;umen, Kraft zum K&auml;mpfen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.6</TD>
	 <TD>Epidemiologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.6.1">Ansteckend. Berichte und Informationen zum Thema Infektionskrankheiten</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.7</TD>
	 <TD>Therapie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.1">Aids-Management der Erkrankung. Szenarien zur Verbesserung von Diagnose und Behandlung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.2">AIDS ist besiegbar</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.8</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.1">Krankheits- und Sterbebegleitung. Ausbildung, Krisenintervention, Training</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.2">Trauma AIDS. Eine psychoanalytische Studie &uuml;ber die Auswirkungen der HIV-Infektion</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Histoire, Epid&eacute;miologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.1">Les maux &eacute;pid&eacute;miques dans l'Empire chinois</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.2">Ces virus qui d&eacute;truisent les hommes</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>G&eacute;n&eacute;ralit&eacute;s</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.1">VIH/sida Une approche multidisciplinaire</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.2">Efficacit&eacute; du pr&eacute;servatif</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD>Sexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.1">Sexualit&eacute; et sida. Recherches en sciences sociales</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.2">La drague ou les rencontres difficiles</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.3">L'&eacute;ducation sexuelle</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.4">La sexualit&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.5">L'&eacute;ducation sexuelle des enfants</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Homosexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.4.1">L'amour du semblable: questions sur l'homosexualit&eacute;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD>Toxicomanie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.1">La double rencontre: toxicomanie et sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.2">Drogue, la guerre chim&eacute;rique</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.3">La m&eacute;thadone, mode d'emploi</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD>T&eacute;moignages</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.1">Le poids du silence</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.2">Infirmi&egrave;re aux portes de la mort</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD>M&eacute;decine et sant&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.1">Infiniment m&eacute;decins: les g&eacute;n&eacute;ralistes entre la science et l'humain</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.2">Le praticien face au sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.3">ABC du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.4">Cent question sur l'h&eacute;patite C</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD>Accompagnement, soins palliatifs, douleur</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.1">Soigner... le premier art de la vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.2">Instant de vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.3">La douleur: entre modernit&eacute; et tradition</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.4">La douleur. Ses m&eacute;canismes et les bases de ses traitements</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.5">Non &agrave; la douleur</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD>M&eacute;decines alternatives</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.9.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.9.1">G&eacute;n&eacute;alogie des m&eacute;decines douces: de l'Inde &agrave; l'Occident</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD>Ethique</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.1">Ethique, sida et soci&eacute;t&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.2">...mais tous &eacute;taient frapp&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD>S&eacute;curit&eacute; transfusionelle</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.11.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.11.1">Le sang et le droit. Essai sur la transfusion sanguine</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:5.12">Publications r&eacute;centes</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Mat&eacute;riel de pr&eacute;vention</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.1">Le sida. R&eacute;ponses aux questions du personnel de sant&eacute; sur l'infection par le VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.2">La th&eacute;rapie g&eacute;nique de l'infection par le VIH</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:7">Litt&eacute;rature grise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Zeitschriften /Journaux/Revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.1">R&eacute;flexe : journal du groupe sida neuch&acirc;tel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.2">Sida: information et rumeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.3">Exp&eacute;riences de mort imminente</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.4">Psychologues au temps du sida, dossier N#186;2</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Video</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.1">AIDS - Die Sache mit dem HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.2">J'ai besoin de savoir. Tests VIH: pr&eacute;vention et counselling</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.3">L'Instit. Aimer par coeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.4">Une vie menac&eacute;e, une vie cr&eacute;ative</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.5">Drogue: r&eacute;duire les risques?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Tonkassetten</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:10.1">Douleur, je t'abandonne</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Recherche et th&eacute;rapie / Forschung und Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.1">Le portrait du chercheur: Dr m&eacute;d. Pascal R. Meylan</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.2">Das Forscherportr&auml;t: Dr. med. Pascal R. Meylan</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.1">Thema Informed Consent - nur eine Kaffeeunterhaltung?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.2">Schlechtes Beispiel macht immer noch Schule</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.3">Der  HIV-Test  - Segen oder Katastrophe f&uuml;r Menschen der Dritten Welt?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.4">Interview mit Dr. Kurt Meyer, Pr&auml;sident GELIKO von Kurth W. Kocher</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:13">Neue Medikamente gegen das HIV in der Schweiz : Fragen und Antworten</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:14">Nouveaux m&eacute;dicaments contre le VIH : Questions et r&eacute;ponses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Sida, agir ensemble / Antwort auf Aids</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.1">Soumission de projets pour l'octroi d'un financement</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.2">Ausschreibung f&uuml;r Projektfinanzierung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:16">Schweizerische Krebsliga</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>17.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:17">Offerta di lavoro</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>18.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:18">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-56</DOCNO>
<DOCOLDNO>IA017-000178-B001-191</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/INFOTHEQUE.cgi?+9601 192.33.214.13 19970106041247 text/html 45195
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:13:07 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - <A HREF="INFOTHEQUE.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="INFOTHEQUE.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Infoth&egrave;que SIDA 01/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.1">Commentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:1.2">Kommentar</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Stress et Syst&egrave;me immunitaire</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.1">Immunit&eacute;, syst&egrave;me nerveux et psychisme - le point des connaissances.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.2">Immunit&auml;t, Nervensystem und Psyche  was weiss man heute?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.3">Interventions psychologiques et syst&egrave;me immunitaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:2.4">Immunit&agrave;, sistema nervoso e psiche  cosa ne sappiamo oggi?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek ;Stress</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.1">Psychoimmunologie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.2">Biopsychologie von Stress und emotionalen Reaktionen.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.3">Immunantwort und Psyche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.4">Der Einflu&szlig; von Hypnose und Stre&szlig; auf das Blutbild.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.5">Stress und Stressbew&auml;ltigung / Hinweis</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:3.6">Verhaltenstraining zur Stressbew&auml;ltigung / Stress und Stressbew&auml;ltigung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Unterricht</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.1">Kondome quer durchs Curriculum</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.2">Sexualerziehung in den deutschsprachigen Schulen des Kantons Bern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.3">Freundschaft, Liebe, Sexualit&auml;t...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.1.4">Sexualp&auml;dagogische Jungenarbeit</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.1">Mein Kind ist so und nicht anders...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.2">Mitten ins Herz...</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.3">Sexualit&auml;t, Lebensformen, Liebe / Bisexualit&auml;t</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.2.4">Abschied von der sexuellen Revolution... / Strichpunkt...</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD>Medizin</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.1">Bittere Naturmedizin</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.3.2">Kooperation und Rivalit&auml;t... / The Cellular Basis of Central Nervous... / Neuropsychologische Untersuchungen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>4,Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.1">Menschen mit Aids pflegen: i.v. DrogengebraucherInnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.4.2">Arbeit, Ausbildung und Qualifikation f&uuml;r Drogengebraucher in Substitutionsbehandlung / Die Berner Drogenszene</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Vermischtes</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9601:4.5.1">Mein Gott AIDS</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.1">Le sida et les fragilit&eacute;s fran&ccedil;aises: nos r&eacute;actions face &agrave; l'&eacute;pid&eacute;mie</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.2">Le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.3">Les sciences sociales face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.4">Comment vivre avec une personne atteinte par le virus du sida ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.5">Un amour s&eacute;rodiff&eacute;rent</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.6">Ev&eacute;nements quotidiens et bien-&ecirc;tre &agrave; l'adolescence...</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.7">Le mort et moi et nous</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.8">Vivre le deuil au jour le jour: la perte d'une personne proche</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.9">Couples homophiles: le droit &agrave; l'existence ?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.10">L'amour et le pr&eacute;servatif</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.11">Essais th&eacute;rapeutiques et  &eacute;tudes cliniques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.12">Vivre son mourir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.13</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.13">Le t&eacute;moin myope Regards sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.14</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.14">Une mort africaine Le sida au quotidien</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.15</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.15">Sang contamin&eacute; Priorit&eacute;s d'Etat et d&eacute;cisions politiques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.16</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.16">De la syphilis au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.17</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:5.17">Un mal imaginaire</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9601:6">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.1">Les homosexuels face au sida: enqu&ecirc;te 1993 sur les modes de vie et la gestion du risque VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.2">Rapport de la commission &quot;maladies sexuellement transmissibles et sida&quot;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.3">Soins et sida. Les chiffres cl&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:7.4">Pertinence, redondance et red&eacute;finition ...</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Mat&eacute;riel d'information</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.1">Guide - Sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.2">Sant&eacute;, sexualit&eacute;, sida. Une p&eacute;dagogie adapt&eacute;e.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.3">Infection par le VIH et sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:8.4">Sida et &eacute;ducation sexuelle</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:9.1">Pr&eacute;venir. In&eacute;galit&eacute;s, sant&eacute;, exclusions</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Videos</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.1">Forscher, Fakten, Visionen. Auf Tod und Leben!</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.2">E tempo de agir</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:10.3">Sida: paroles de familles</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Forschung und Therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.1">Aids und Traditionelle Chinesische Medizin: Eine Studie in Z&uuml;rich</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.2">Das Forscherportrait: Dr. med. Pietro Vernazza Kantonsspital St. Gallen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:11.3">Portrait: Dr med. Pietro Vernazza, H&ocirc;pital cantonal de St-Gall</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.1">9. Internationale Konferenz &uuml;ber Aids und Geschlechtskrankheiten in Afrika (ICASA)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9601:12.2">Wird mit UNAIDS alles anders ?</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 02/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Kommentar / Commentaires</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.1">Kommentar deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.2">Commentaire fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:2">Infection par le VIH/SIDA et alimentation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>HIV und Ern&auml;hrung</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.1">Nahrung f&uuml;r Menschen mit Aids in der Dritten Welt</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.2">Aidskrank als Frau in Nepal: Kann man das noch &quot;leben&quot; nennen ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:4">Infezione da HIV, AIDS e alimentazione</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Ern&auml;hrung + HIV</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.1">Ern&auml;hrung, HIV-Infektion und Aids: Ein Blick &uuml;ber den Tellerrand.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.2">Wie positiv essen.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.3">Healthy Eating Makes A Difference. A Food Resource Book for People Living with HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.4">Food for those with HIV/Aids (Ern&auml;hrung f&uuml;r Menschen mit HIV/Aids)</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.5">Das grosse Buch der Vitamine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.6">Nutrition and HIV (Ern&auml;hrung und HIV). A New Model for Treatment.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.7">Immune Power. Combining Holistic  Standard Medical Therapies into the Optimal Treatment Program for HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.8">Staying Healthy with HIV. A Guide to Alternative and Complementary Therapies</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.9">Vitamine, Vitamine! Eine Brosch&uuml;re mit Rezepten &uuml;ber Vitamine und Mineralstoffe f&uuml;r Menschen mit HIV und AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.10</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.10">Unkonventionelle Medizin bei HIV und Aids</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>Ern&auml;hrung allgemein</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.1">Die Psychologie des Essens</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.2">Bioaktive Substanzen in Lebensmitteln</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.3">Die Jutta-Poschet-Immundi&auml;t / Immun</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.4">St&auml;rken Sie ihr Immunsystem.Leben Sie besser durch nat&uuml;rliche Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.5">&Ouml;ko Test - Ratgeber Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.6">Ern&auml;hrungssprechstunde.Grundlagen einer gesunden Lebensf&uuml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.7">K&uuml;chengeheimnisse der Hildegard-Medizin.Ratschl&auml;ge und Erkenntnisse der hl. Hildegard von Bingen &uuml;ber die Heilkraft unserer Nahrungsmittel</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.8">Die pflanzlichen Heilmittel bei Hildegard von Bingen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.9">SVE Medienverzeichnis. Catalogue des publications et du mat&eacute;riel m&eacute;diatique ASA. ASA elenco di pubblicazioni e della mediateca.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3">Di&eacute;t&eacute;tique</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3.1">Di&eacute;t&eacute;tique: ouvrages g&eacute;n&eacute;raux de base et sp&eacute;cialis&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Nutrition et sida</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.1">Nutitional Care for HIV+ persons: a manual for individuals and their caregivers</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.2">Nutrition et VIH</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.3">Etre mieux en mangeant mieux</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.4">Manger positivement</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.5">D&eacute;pliant &quot;Nutrition et immunit&eacute;&quot; / Branle-bas de combat dans la cuisine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.6">Probl&egrave;mes sp&eacute;cifiques</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.7">1&egrave;re conf&eacute;rence internationale nutrition et infection par le VIH</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD>Pr&auml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.1">Doppelcharakter der Pr&auml;vention</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.2">HIV-Beratung und -Pr&auml;vention in der Arztpraxis. Stellenwert und Wirksamkeit der &auml;rztlichen Fortbildung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.3">Jugend und Gesundheit. Interventionsfelder und Pr&auml;ventionsbereiche</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.4">Diskriminierungsbereitschaft Jugendlicher gegen&uuml;ber Menschen mit HIV/Aids.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.2.1">Stigma-Management und schwules Selbstbewusstsein.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.3</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.1">Geld und Gef&uuml;hle um HIV und Aids.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.2">Die medizinische Betreuung HIV-infizierter Kinder und Jugendlicher</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.4</TD>
	 <TD>Sterben</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.1">Leben- und Sterbenk&ouml;nnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.2">W&auml;rme, die nur Feuer geben kann</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.1">Sant&eacute;, guide des associations, L'Impatient - Alternative Sant&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.2">Histoire de la recherche sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.3">La sociologie du risque</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.4">L'infection au VIH de la m&egrave;re et de l'enfant</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.5">L'Eglise et l'homosexualit&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.6">J'accuse... Les mensonges qui tuent les drogu&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.7">Nouveaux d&eacute;fis des soins palliatifs: philosophie palliative et m&eacute;decine compl&eacute;mentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.8">Douleur et m&eacute;decine, la fin d'un oubli</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.9">Douleur et plaisir, maladie et sant&eacute;: une perception subjective</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.10">Le deuil &agrave; vivre</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.11">Vivre, seulement vivre. Quatre regards photographiques pour la vie</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:8">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.1">L'infection par le virus de l'immunod&eacute;ficience humaine (VIH)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.2">Plan de communication publique sur l'infection &agrave; VIH - SIDA</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.3">Les politiques publiques face au d&eacute;fi du sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.4">L'&eacute;valuation &eacute;conomique du d&eacute;pistage sida chez les femmes enceintes</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.5">Le steribox et la r&eacute;duction des risques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.6">Programme de r&eacute;duction des risques &agrave; l'usage des personnes toxicomanes usagers de drogues par voie intraveineuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.7">Les biblioth&egrave;ques face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.8">Approche biopsychosociale de l'infection au virus VIH: une revue de la litt&eacute;rature</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.9">La question du sida dans la relation psychoth&eacute;rapeutique</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:10">Mat&eacute;riel d'information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:11.1">Tabula</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:12">Videos</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.1">Whose problem? An HIV/AIDS education package</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.2">Unmasking AIDS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.3">Living on the edge. Coping with HIV and drug misuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.4">HIV pre-test counselling. How to conduct pre-test counselling in confidence</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD>Forschung et therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.1">Les choix des th&eacute;rapies</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.2">Trials</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.3">Das Forscherportrait: Dr. phil. II Markus Thali</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.4">Le portrait d'un chercheur: Dr. Markus Thali</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.1">Der Schweizerische Verband diplomierter Ern&auml;hrungsberaterInnen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.2">Wissenschaftliche Begleitung des Modellprojektes &quot;Infektionsprophylaxe im Nieders&auml;chsischen Strafvollzug&quot;</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Annoncen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:15.1">Der gute Tip: Mittagstisch f&uuml;r Menschen mit HIV und Aids</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:16">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 03/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.1">Editorial Deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.2">Editorial Fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Der HIV-Antik&ouml;rpertest / Le test de d&eacute;pistage VIH</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.1">Der HIV-Antik&ouml;rpertest - 1996 (noch) ein Thema?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.2">Le test des anticorps anti-VIH -- (encore) un sujet de discussion en 1996?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.3">Du nouveau sur le test de d&eacute;pistage du VIH?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.4">Neues zum HIV-Antik&ouml;rpertest?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.5">Recht und Unrecht beim HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.6">Aspects juridiques du test VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.7">Les curieuses m&eacute;thodes de Sida Information Suisse.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.8">Die seltsamen Methoden der Aids-Aufkl&auml;rung Schweiz</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.9">Il test HIV - nel 1996 (ancora) un tema ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.1">Handbuch HIV-Test, Arbeitshilfen zur Beratung und Testdurchf&uuml;hrung</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.2">Sentinel-Surveillance von HIV und anderen sexuell &uuml;bertragbaren Krankheiten.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.3">Der HIV-Test in Spital und Praxis / Das Testen auf die HIV-Infektion</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Prauuml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.1">Aids in Europe - The Behavioural Aspect</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.2">La Flottille de l'Espoir</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.3">Gesundheit durch Projekte f&ouml;rdern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.4">Gesundheitsf&ouml;rderung und Public Health</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Kinder/Jugendliche</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.1">Ein kurzes Leben lang / Wir sprechen &uuml;ber AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.2">Wir sprechen &uuml;ber Drogen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.3">&quot;Schwanger werd' ich nicht alleine ...&quot;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3">Homosexualit&auml;tektion</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.1">V&ouml;llig normal</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.2">Kahn, Knaben, schnelle Fahrt</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.3">Handbuch zu lesbischen und schwulen Studien in der Schweiz</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.4.1">Methadon Standards</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Betroffene</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.1">Ann&auml;herungen. Meine ersten 10 Jahre im Zeichen von AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.2">Aids hat viele Gesichter</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.3">Farbige Trauer. Gedenkt&uuml;cher f&uuml;r Menschen, die an den Folgen von Aids gestorben sind. Signes d'amour. Panneaux comm&eacute;moratifs &agrave; la m&eacute;moire de personnes d&eacute;c&eacute;d&eacute;es du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.4">Leben ohne Grenzen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.5">Mut zum Tr&auml;umen, Kraft zum K&auml;mpfen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.6</TD>
	 <TD>Epidemiologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.6.1">Ansteckend. Berichte und Informationen zum Thema Infektionskrankheiten</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.7</TD>
	 <TD>Therapie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.1">Aids-Management der Erkrankung. Szenarien zur Verbesserung von Diagnose und Behandlung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.2">AIDS ist besiegbar</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.8</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.1">Krankheits- und Sterbebegleitung. Ausbildung, Krisenintervention, Training</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.2">Trauma AIDS. Eine psychoanalytische Studie &uuml;ber die Auswirkungen der HIV-Infektion</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Histoire, Epid&eacute;miologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.1">Les maux &eacute;pid&eacute;miques dans l'Empire chinois</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.2">Ces virus qui d&eacute;truisent les hommes</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>G&eacute;n&eacute;ralit&eacute;s</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.1">VIH/sida Une approche multidisciplinaire</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.2">Efficacit&eacute; du pr&eacute;servatif</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD>Sexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.1">Sexualit&eacute; et sida. Recherches en sciences sociales</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.2">La drague ou les rencontres difficiles</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.3">L'&eacute;ducation sexuelle</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.4">La sexualit&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.5">L'&eacute;ducation sexuelle des enfants</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Homosexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.4.1">L'amour du semblable: questions sur l'homosexualit&eacute;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD>Toxicomanie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.1">La double rencontre: toxicomanie et sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.2">Drogue, la guerre chim&eacute;rique</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.3">La m&eacute;thadone, mode d'emploi</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD>T&eacute;moignages</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.1">Le poids du silence</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.2">Infirmi&egrave;re aux portes de la mort</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD>M&eacute;decine et sant&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.1">Infiniment m&eacute;decins: les g&eacute;n&eacute;ralistes entre la science et l'humain</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.2">Le praticien face au sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.3">ABC du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.4">Cent question sur l'h&eacute;patite C</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD>Accompagnement, soins palliatifs, douleur</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.1">Soigner... le premier art de la vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.2">Instant de vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.3">La douleur: entre modernit&eacute; et tradition</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.4">La douleur. Ses m&eacute;canismes et les bases de ses traitements</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.5">Non &agrave; la douleur</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD>M&eacute;decines alternatives</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.9.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.9.1">G&eacute;n&eacute;alogie des m&eacute;decines douces: de l'Inde &agrave; l'Occident</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD>Ethique</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.1">Ethique, sida et soci&eacute;t&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.2">...mais tous &eacute;taient frapp&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD>S&eacute;curit&eacute; transfusionelle</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.11.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.11.1">Le sang et le droit. Essai sur la transfusion sanguine</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:5.12">Publications r&eacute;centes</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Mat&eacute;riel de pr&eacute;vention</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.1">Le sida. R&eacute;ponses aux questions du personnel de sant&eacute; sur l'infection par le VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.2">La th&eacute;rapie g&eacute;nique de l'infection par le VIH</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:7">Litt&eacute;rature grise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Zeitschriften /Journaux/Revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.1">R&eacute;flexe : journal du groupe sida neuch&acirc;tel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.2">Sida: information et rumeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.3">Exp&eacute;riences de mort imminente</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.4">Psychologues au temps du sida, dossier N#186;2</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Video</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.1">AIDS - Die Sache mit dem HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.2">J'ai besoin de savoir. Tests VIH: pr&eacute;vention et counselling</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.3">L'Instit. Aimer par coeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.4">Une vie menac&eacute;e, une vie cr&eacute;ative</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.5">Drogue: r&eacute;duire les risques?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Tonkassetten</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:10.1">Douleur, je t'abandonne</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Recherche et th&eacute;rapie / Forschung und Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.1">Le portrait du chercheur: Dr m&eacute;d. Pascal R. Meylan</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.2">Das Forscherportr&auml;t: Dr. med. Pascal R. Meylan</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.1">Thema Informed Consent - nur eine Kaffeeunterhaltung?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.2">Schlechtes Beispiel macht immer noch Schule</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.3">Der  HIV-Test  - Segen oder Katastrophe f&uuml;r Menschen der Dritten Welt?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.4">Interview mit Dr. Kurt Meyer, Pr&auml;sident GELIKO von Kurth W. Kocher</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:13">Neue Medikamente gegen das HIV in der Schweiz : Fragen und Antworten</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:14">Nouveaux m&eacute;dicaments contre le VIH : Questions et r&eacute;ponses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Sida, agir ensemble / Antwort auf Aids</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.1">Soumission de projets pour l'octroi d'un financement</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.2">Ausschreibung f&uuml;r Projektfinanzierung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:16">Schweizerische Krebsliga</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>17.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:17">Offerta di lavoro</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>18.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:18">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-57</DOCNO>
<DOCOLDNO>IA017-000178-B001-199</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/INFOTHEQUE.cgi?+9602 192.33.214.13 19970106041256 text/html 33911
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:13:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - <A HREF="INFOTHEQUE.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="INFOTHEQUE.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Infoth&egrave;que SIDA 02/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Kommentar / Commentaires</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.1">Kommentar deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:1.2">Commentaire fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:2">Infection par le VIH/SIDA et alimentation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>HIV und Ern&auml;hrung</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.1">Nahrung f&uuml;r Menschen mit Aids in der Dritten Welt</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:3.2">Aidskrank als Frau in Nepal: Kann man das noch &quot;leben&quot; nennen ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:4">Infezione da HIV, AIDS e alimentazione</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Ern&auml;hrung + HIV</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.1">Ern&auml;hrung, HIV-Infektion und Aids: Ein Blick &uuml;ber den Tellerrand.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.2">Wie positiv essen.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.3">Healthy Eating Makes A Difference. A Food Resource Book for People Living with HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.4">Food for those with HIV/Aids (Ern&auml;hrung f&uuml;r Menschen mit HIV/Aids)</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.5">Das grosse Buch der Vitamine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.6">Nutrition and HIV (Ern&auml;hrung und HIV). A New Model for Treatment.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.7">Immune Power. Combining Holistic  Standard Medical Therapies into the Optimal Treatment Program for HIV</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.8">Staying Healthy with HIV. A Guide to Alternative and Complementary Therapies</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.9">Vitamine, Vitamine! Eine Brosch&uuml;re mit Rezepten &uuml;ber Vitamine und Mineralstoffe f&uuml;r Menschen mit HIV und AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.10</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.1.10">Unkonventionelle Medizin bei HIV und Aids</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>Ern&auml;hrung allgemein</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.1">Die Psychologie des Essens</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.2">Bioaktive Substanzen in Lebensmitteln</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.3">Die Jutta-Poschet-Immundi&auml;t / Immun</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.4">St&auml;rken Sie ihr Immunsystem.Leben Sie besser durch nat&uuml;rliche Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.5">&Ouml;ko Test - Ratgeber Ern&auml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.6">Ern&auml;hrungssprechstunde.Grundlagen einer gesunden Lebensf&uuml;hrung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.7">K&uuml;chengeheimnisse der Hildegard-Medizin.Ratschl&auml;ge und Erkenntnisse der hl. Hildegard von Bingen &uuml;ber die Heilkraft unserer Nahrungsmittel</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.8</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.8">Die pflanzlichen Heilmittel bei Hildegard von Bingen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.9</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.2.9">SVE Medienverzeichnis. Catalogue des publications et du mat&eacute;riel m&eacute;diatique ASA. ASA elenco di pubblicazioni e della mediateca.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3">Di&eacute;t&eacute;tique</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.3.1">Di&eacute;t&eacute;tique: ouvrages g&eacute;n&eacute;raux de base et sp&eacute;cialis&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Nutrition et sida</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.1">Nutitional Care for HIV+ persons: a manual for individuals and their caregivers</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.2">Nutrition et VIH</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.3">Etre mieux en mangeant mieux</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.4">Manger positivement</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.5">D&eacute;pliant &quot;Nutrition et immunit&eacute;&quot; / Branle-bas de combat dans la cuisine</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.6</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.6">Probl&egrave;mes sp&eacute;cifiques</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.7</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:5.4.7">1&egrave;re conf&eacute;rence internationale nutrition et infection par le VIH</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD>Pr&auml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.1">Doppelcharakter der Pr&auml;vention</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.2">HIV-Beratung und -Pr&auml;vention in der Arztpraxis. Stellenwert und Wirksamkeit der &auml;rztlichen Fortbildung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.3">Jugend und Gesundheit. Interventionsfelder und Pr&auml;ventionsbereiche</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.1.4">Diskriminierungsbereitschaft Jugendlicher gegen&uuml;ber Menschen mit HIV/Aids.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD>Sexualit&auml;t</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.2.1">Stigma-Management und schwules Selbstbewusstsein.</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.3</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.1">Geld und Gef&uuml;hle um HIV und Aids.</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.3.2">Die medizinische Betreuung HIV-infizierter Kinder und Jugendlicher</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.4</TD>
	 <TD>Sterben</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.1">Leben- und Sterbenk&ouml;nnen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>6.4.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9602:6.4.2">W&auml;rme, die nur Feuer geben kann</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.1">Sant&eacute;, guide des associations, L'Impatient - Alternative Sant&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.2">Histoire de la recherche sur le sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.3">La sociologie du risque</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.4">L'infection au VIH de la m&egrave;re et de l'enfant</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.5">L'Eglise et l'homosexualit&eacute;</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.6">J'accuse... Les mensonges qui tuent les drogu&eacute;s</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.7">Nouveaux d&eacute;fis des soins palliatifs: philosophie palliative et m&eacute;decine compl&eacute;mentaire</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.8">Douleur et m&eacute;decine, la fin d'un oubli</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.9">Douleur et plaisir, maladie et sant&eacute;: une perception subjective</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.10</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.10">Le deuil &agrave; vivre</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.11</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:7.11">Vivre, seulement vivre. Quatre regards photographiques pour la vie</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:8">Publications r&eacute;centes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Litt&eacute;rature grise</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.1">L'infection par le virus de l'immunod&eacute;ficience humaine (VIH)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.2">Plan de communication publique sur l'infection &agrave; VIH - SIDA</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.3">Les politiques publiques face au d&eacute;fi du sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.4">L'&eacute;valuation &eacute;conomique du d&eacute;pistage sida chez les femmes enceintes</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.5">Le steribox et la r&eacute;duction des risques</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.6">Programme de r&eacute;duction des risques &agrave; l'usage des personnes toxicomanes usagers de drogues par voie intraveineuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.7">Les biblioth&egrave;ques face au sida</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.8">Approche biopsychosociale de l'infection au virus VIH: une revue de la litt&eacute;rature</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:9.9">La question du sida dans la relation psychoth&eacute;rapeutique</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:10">Mat&eacute;riel d'information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Journaux,revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:11.1">Tabula</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:12">Videos</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.1">Whose problem? An HIV/AIDS education package</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.2">Unmasking AIDS</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.3">Living on the edge. Coping with HIV and drug misuse</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:12.4">HIV pre-test counselling. How to conduct pre-test counselling in confidence</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD>Forschung et therapie / Recherche et th&eacute;rapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.1">Les choix des th&eacute;rapies</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.2">Trials</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.3">Das Forscherportrait: Dr. phil. II Markus Thali</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>13.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:13.4">Le portrait d'un chercheur: Dr. Markus Thali</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.1">Der Schweizerische Verband diplomierter Ern&auml;hrungsberaterInnen</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>14.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:14.2">Wissenschaftliche Begleitung des Modellprojektes &quot;Infektionsprophylaxe im Nieders&auml;chsischen Strafvollzug&quot;</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Annoncen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9602:15.1">Der gute Tip: Mittagstisch f&uuml;r Menschen mit HIV und Aids</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9602:16">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
<H3>Infoth&egrave;que SIDA 03/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.1">Editorial Deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.2">Editorial Fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Der HIV-Antik&ouml;rpertest / Le test de d&eacute;pistage VIH</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.1">Der HIV-Antik&ouml;rpertest - 1996 (noch) ein Thema?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.2">Le test des anticorps anti-VIH -- (encore) un sujet de discussion en 1996?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.3">Du nouveau sur le test de d&eacute;pistage du VIH?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.4">Neues zum HIV-Antik&ouml;rpertest?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.5">Recht und Unrecht beim HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.6">Aspects juridiques du test VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.7">Les curieuses m&eacute;thodes de Sida Information Suisse.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.8">Die seltsamen Methoden der Aids-Aufkl&auml;rung Schweiz</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.9">Il test HIV - nel 1996 (ancora) un tema ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.1">Handbuch HIV-Test, Arbeitshilfen zur Beratung und Testdurchf&uuml;hrung</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.2">Sentinel-Surveillance von HIV und anderen sexuell &uuml;bertragbaren Krankheiten.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.3">Der HIV-Test in Spital und Praxis / Das Testen auf die HIV-Infektion</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Prauuml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.1">Aids in Europe - The Behavioural Aspect</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.2">La Flottille de l'Espoir</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.3">Gesundheit durch Projekte f&ouml;rdern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.4">Gesundheitsf&ouml;rderung und Public Health</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Kinder/Jugendliche</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.1">Ein kurzes Leben lang / Wir sprechen &uuml;ber AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.2">Wir sprechen &uuml;ber Drogen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.3">&quot;Schwanger werd' ich nicht alleine ...&quot;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3">Homosexualit&auml;tektion</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.1">V&ouml;llig normal</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.2">Kahn, Knaben, schnelle Fahrt</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.3">Handbuch zu lesbischen und schwulen Studien in der Schweiz</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.4.1">Methadon Standards</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Betroffene</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.1">Ann&auml;herungen. Meine ersten 10 Jahre im Zeichen von AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.2">Aids hat viele Gesichter</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.3">Farbige Trauer. Gedenkt&uuml;cher f&uuml;r Menschen, die an den Folgen von Aids gestorben sind. Signes d'amour. Panneaux comm&eacute;moratifs &agrave; la m&eacute;moire de personnes d&eacute;c&eacute;d&eacute;es du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.4">Leben ohne Grenzen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.5">Mut zum Tr&auml;umen, Kraft zum K&auml;mpfen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.6</TD>
	 <TD>Epidemiologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.6.1">Ansteckend. Berichte und Informationen zum Thema Infektionskrankheiten</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.7</TD>
	 <TD>Therapie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.1">Aids-Management der Erkrankung. Szenarien zur Verbesserung von Diagnose und Behandlung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.2">AIDS ist besiegbar</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.8</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.1">Krankheits- und Sterbebegleitung. Ausbildung, Krisenintervention, Training</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.2">Trauma AIDS. Eine psychoanalytische Studie &uuml;ber die Auswirkungen der HIV-Infektion</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Histoire, Epid&eacute;miologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.1">Les maux &eacute;pid&eacute;miques dans l'Empire chinois</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.2">Ces virus qui d&eacute;truisent les hommes</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>G&eacute;n&eacute;ralit&eacute;s</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.1">VIH/sida Une approche multidisciplinaire</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.2">Efficacit&eacute; du pr&eacute;servatif</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD>Sexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.1">Sexualit&eacute; et sida. Recherches en sciences sociales</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.2">La drague ou les rencontres difficiles</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.3">L'&eacute;ducation sexuelle</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.4">La sexualit&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.5">L'&eacute;ducation sexuelle des enfants</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Homosexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.4.1">L'amour du semblable: questions sur l'homosexualit&eacute;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD>Toxicomanie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.1">La double rencontre: toxicomanie et sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.2">Drogue, la guerre chim&eacute;rique</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.3">La m&eacute;thadone, mode d'emploi</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD>T&eacute;moignages</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.1">Le poids du silence</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.2">Infirmi&egrave;re aux portes de la mort</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD>M&eacute;decine et sant&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.1">Infiniment m&eacute;decins: les g&eacute;n&eacute;ralistes entre la science et l'humain</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.2">Le praticien face au sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.3">ABC du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.4">Cent question sur l'h&eacute;patite C</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD>Accompagnement, soins palliatifs, douleur</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.1">Soigner... le premier art de la vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.2">Instant de vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.3">La douleur: entre modernit&eacute; et tradition</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.4">La douleur. Ses m&eacute;canismes et les bases de ses traitements</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.5">Non &agrave; la douleur</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD>M&eacute;decines alternatives</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.9.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.9.1">G&eacute;n&eacute;alogie des m&eacute;decines douces: de l'Inde &agrave; l'Occident</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD>Ethique</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.1">Ethique, sida et soci&eacute;t&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.2">...mais tous &eacute;taient frapp&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD>S&eacute;curit&eacute; transfusionelle</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.11.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.11.1">Le sang et le droit. Essai sur la transfusion sanguine</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:5.12">Publications r&eacute;centes</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Mat&eacute;riel de pr&eacute;vention</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.1">Le sida. R&eacute;ponses aux questions du personnel de sant&eacute; sur l'infection par le VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.2">La th&eacute;rapie g&eacute;nique de l'infection par le VIH</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:7">Litt&eacute;rature grise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Zeitschriften /Journaux/Revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.1">R&eacute;flexe : journal du groupe sida neuch&acirc;tel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.2">Sida: information et rumeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.3">Exp&eacute;riences de mort imminente</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.4">Psychologues au temps du sida, dossier N#186;2</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Video</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.1">AIDS - Die Sache mit dem HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.2">J'ai besoin de savoir. Tests VIH: pr&eacute;vention et counselling</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.3">L'Instit. Aimer par coeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.4">Une vie menac&eacute;e, une vie cr&eacute;ative</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.5">Drogue: r&eacute;duire les risques?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Tonkassetten</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:10.1">Douleur, je t'abandonne</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Recherche et th&eacute;rapie / Forschung und Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.1">Le portrait du chercheur: Dr m&eacute;d. Pascal R. Meylan</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.2">Das Forscherportr&auml;t: Dr. med. Pascal R. Meylan</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.1">Thema Informed Consent - nur eine Kaffeeunterhaltung?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.2">Schlechtes Beispiel macht immer noch Schule</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.3">Der  HIV-Test  - Segen oder Katastrophe f&uuml;r Menschen der Dritten Welt?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.4">Interview mit Dr. Kurt Meyer, Pr&auml;sident GELIKO von Kurth W. Kocher</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:13">Neue Medikamente gegen das HIV in der Schweiz : Fragen und Antworten</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:14">Nouveaux m&eacute;dicaments contre le VIH : Questions et r&eacute;ponses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Sida, agir ensemble / Antwort auf Aids</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.1">Soumission de projets pour l'octroi d'un financement</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.2">Ausschreibung f&uuml;r Projektfinanzierung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:16">Schweizerische Krebsliga</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>17.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:17">Offerta di lavoro</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>18.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:18">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-58</DOCNO>
<DOCOLDNO>IA017-000178-B001-208</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/INFOTHEQUE.cgi?+9603 192.33.214.13 19970106041306 text/html 18758
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:13:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - <A HREF="INFOTHEQUE.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="INFOTHEQUE.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Infoth&egrave;que SIDA 03/96</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD>Editorial</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.1">Editorial Deutsch</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:1.2">Editorial Fran&ccedil;ais</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD>Der HIV-Antik&ouml;rpertest / Le test de d&eacute;pistage VIH</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.1">Der HIV-Antik&ouml;rpertest - 1996 (noch) ein Thema?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.2">Le test des anticorps anti-VIH -- (encore) un sujet de discussion en 1996?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.3">Du nouveau sur le test de d&eacute;pistage du VIH?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.4">Neues zum HIV-Antik&ouml;rpertest?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.5">Recht und Unrecht beim HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.6</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.6">Aspects juridiques du test VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.7</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.7">Les curieuses m&eacute;thodes de Sida Information Suisse.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.8</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.8">Die seltsamen Methoden der Aids-Aufkl&auml;rung Schweiz</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.9</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:2.9">Il test HIV - nel 1996 (ancora) un tema ?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD>Bibliothek</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.1">Handbuch HIV-Test, Arbeitshilfen zur Beratung und Testdurchf&uuml;hrung</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.2">Sentinel-Surveillance von HIV und anderen sexuell &uuml;bertragbaren Krankheiten.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:3.3">Der HIV-Test in Spital und Praxis / Das Testen auf die HIV-Infektion</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD>Neue Publikationen</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.1</TD>
	 <TD>Prauuml;vention</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.1">Aids in Europe - The Behavioural Aspect</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.2">La Flottille de l'Espoir</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.3">Gesundheit durch Projekte f&ouml;rdern</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.1.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.1.4">Gesundheitsf&ouml;rderung und Public Health</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.2</TD>
	 <TD>Kinder/Jugendliche</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.1">Ein kurzes Leben lang / Wir sprechen &uuml;ber AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.2">Wir sprechen &uuml;ber Drogen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.2.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.2.3">&quot;Schwanger werd' ich nicht alleine ...&quot;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3">Homosexualit&auml;tektion</A></TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.1">V&ouml;llig normal</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.2">Kahn, Knaben, schnelle Fahrt</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.3.3">Handbuch zu lesbischen und schwulen Studien in der Schweiz</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.4</TD>
	 <TD>Drogen</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.4.1">Methadon Standards</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.5</TD>
	 <TD>Betroffene</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.1">Ann&auml;herungen. Meine ersten 10 Jahre im Zeichen von AIDS</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.2">Aids hat viele Gesichter</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.3">Farbige Trauer. Gedenkt&uuml;cher f&uuml;r Menschen, die an den Folgen von Aids gestorben sind. Signes d'amour. Panneaux comm&eacute;moratifs &agrave; la m&eacute;moire de personnes d&eacute;c&eacute;d&eacute;es du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.4">Leben ohne Grenzen</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.5.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.5.5">Mut zum Tr&auml;umen, Kraft zum K&auml;mpfen</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.6</TD>
	 <TD>Epidemiologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.6.1">Ansteckend. Berichte und Informationen zum Thema Infektionskrankheiten</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.7</TD>
	 <TD>Therapie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.1">Aids-Management der Erkrankung. Szenarien zur Verbesserung von Diagnose und Behandlung</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.7.2">AIDS ist besiegbar</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>4.8</TD>
	 <TD>Betreuung</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.1">Krankheits- und Sterbebegleitung. Ausbildung, Krisenintervention, Training</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>4.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:4.8.2">Trauma AIDS. Eine psychoanalytische Studie &uuml;ber die Auswirkungen der HIV-Infektion</A></TD>
		</TR>
		</TABLE>
		</TD>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD>Nouvelles parutions</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.1</TD>
	 <TD>Histoire, Epid&eacute;miologie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.1">Les maux &eacute;pid&eacute;miques dans l'Empire chinois</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.1.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.1.2">Ces virus qui d&eacute;truisent les hommes</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.2</TD>
	 <TD>G&eacute;n&eacute;ralit&eacute;s</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.1">VIH/sida Une approche multidisciplinaire</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.2.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.2.2">Efficacit&eacute; du pr&eacute;servatif</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.3</TD>
	 <TD>Sexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.1">Sexualit&eacute; et sida. Recherches en sciences sociales</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.2">La drague ou les rencontres difficiles</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.3">L'&eacute;ducation sexuelle</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.4">La sexualit&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.3.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.3.5">L'&eacute;ducation sexuelle des enfants</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.4</TD>
	 <TD>Homosexualit&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.4.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.4.1">L'amour du semblable: questions sur l'homosexualit&eacute;</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.5</TD>
	 <TD>Toxicomanie</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.1">La double rencontre: toxicomanie et sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.2">Drogue, la guerre chim&eacute;rique</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.5.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.5.3">La m&eacute;thadone, mode d'emploi</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.6</TD>
	 <TD>T&eacute;moignages</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.1">Le poids du silence</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.6.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.6.2">Infirmi&egrave;re aux portes de la mort</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.7</TD>
	 <TD>M&eacute;decine et sant&eacute;</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.1">Infiniment m&eacute;decins: les g&eacute;n&eacute;ralistes entre la science et l'humain</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.2">Le praticien face au sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.3">ABC du sida</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.7.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.7.4">Cent question sur l'h&eacute;patite C</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.8</TD>
	 <TD>Accompagnement, soins palliatifs, douleur</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.1">Soigner... le premier art de la vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.2">Instant de vie</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.3</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.3">La douleur: entre modernit&eacute; et tradition</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.4</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.4">La douleur. Ses m&eacute;canismes et les bases de ses traitements</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.8.5</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.8.5">Non &agrave; la douleur</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.9</TD>
	 <TD>M&eacute;decines alternatives</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.9.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.9.1">G&eacute;n&eacute;alogie des m&eacute;decines douces: de l'Inde &agrave; l'Occident</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.10</TD>
	 <TD>Ethique</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.1">Ethique, sida et soci&eacute;t&eacute;</A></TD>
		</TR>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.10.2</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.10.2">...mais tous &eacute;taient frapp&eacute;s</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.11</TD>
	 <TD>S&eacute;curit&eacute; transfusionelle</TD>
	</TR>
	<TR>
		<TD></TD>
		<TD>
		<TABLE BORDER=0>
		<TR ALIGN=left VALIGN=top>
		 <TD>5.11.1</TD>
		 <TD><A HREF="INFOTHEQUE.cgi?9603:5.11.1">Le sang et le droit. Essai sur la transfusion sanguine</A></TD>
		</TR>
		</TABLE>
		</TD>
	<TR ALIGN=left VALIGN=top>
	 <TD>5.12</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:5.12">Publications r&eacute;centes</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD>Mat&eacute;riel de pr&eacute;vention</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.1">Le sida. R&eacute;ponses aux questions du personnel de sant&eacute; sur l'infection par le VIH</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:6.2">La th&eacute;rapie g&eacute;nique de l'infection par le VIH</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:7">Litt&eacute;rature grise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD>Zeitschriften /Journaux/Revues</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.1">R&eacute;flexe : journal du groupe sida neuch&acirc;tel</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.2">Sida: information et rumeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.3">Exp&eacute;riences de mort imminente</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>8.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:8.4">Psychologues au temps du sida, dossier N#186;2</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Video</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.1">AIDS - Die Sache mit dem HIV-Test</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.2">J'ai besoin de savoir. Tests VIH: pr&eacute;vention et counselling</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.3">L'Instit. Aimer par coeur</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.4">Une vie menac&eacute;e, une vie cr&eacute;ative</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.5</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:9.5">Drogue: r&eacute;duire les risques?</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD>Tonkassetten</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>10.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:10.1">Douleur, je t'abandonne</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD>Recherche et th&eacute;rapie / Forschung und Therapie</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.1">Le portrait du chercheur: Dr m&eacute;d. Pascal R. Meylan</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>11.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:11.2">Das Forscherportr&auml;t: Dr. med. Pascal R. Meylan</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD>Focus</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.1">Thema Informed Consent - nur eine Kaffeeunterhaltung?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.2">Schlechtes Beispiel macht immer noch Schule</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.3</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.3">Der  HIV-Test  - Segen oder Katastrophe f&uuml;r Menschen der Dritten Welt?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>12.4</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:12.4">Interview mit Dr. Kurt Meyer, Pr&auml;sident GELIKO von Kurth W. Kocher</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:13">Neue Medikamente gegen das HIV in der Schweiz : Fragen und Antworten</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:14">Nouveaux m&eacute;dicaments contre le VIH : Questions et r&eacute;ponses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD>Sida, agir ensemble / Antwort auf Aids</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.1</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.1">Soumission de projets pour l'octroi d'un financement</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>15.2</TD>
	 <TD><A HREF="INFOTHEQUE.cgi?9603:15.2">Ausschreibung f&uuml;r Projektfinanzierung</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>16.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:16">Schweizerische Krebsliga</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>17.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:17">Offerta di lavoro</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>18.</TD>
 <TD><A HREF="INFOTHEQUE.cgi?9603:18">Veranstaltungen</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-59</DOCNO>
<DOCOLDNO>IA017-000178-B001-218</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+261 192.33.214.13 19970106041313 text/html 9124
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:13:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS Issue #261, December 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?261:1">Viral Load Seminars in January and February, Eight U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?261:2">d4T+AZT -- Unexpected CD4 Drop Seen in Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?261:3">1592: Consensus Letter on Access to New Glaxo Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?261:4">Call for Research on Better Use of Existing Drugs in Advanced Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?261:5">National Conference on Women and HIV -- Late Breaker Deadline March 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?261:6">Geneva AIDS Conference Seeks Community Planning Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?261:7">Vaccine Report Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?261:8">Reminder: AIDS TREATMENT NEWS Reader Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?261:9">Medical Marijuana: Legal Issues for Physicians, Others</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?261:10">Marijuana and Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?261:11">AIDS TREATMENT NEWS 28-Page Index</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?261:12">AIDS TREATMENT NEWS Index, 1996</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?261:13">Notice</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #260, December 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?260:1">Buyers' Club Crisis -- Challenge for AIDS Community</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?260:2">Fewer AIDS Deaths: San Francisco Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?260:3">FDA Advisory Committee Deadlocks on Delavirdine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?260:4">Albendazole Free from Buyers' Club</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?260:5">Books: IMPURE SCIENCE</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?260:6">Buyers' Clubs List, December 1996</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?260:7">AIDS TREATMENT NEWS Reader Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?260:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS,Issue #259, November 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?259:1">Birmingham UK Drug Therapy Conference -- Early Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?259:2">Federal Team Developing Treatment Principles for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?259:3">1592: Two Studies Recruiting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?259:4">The New Antiretroviral Arsenal</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?259:5">Medical Marijuana Wins in California and Arizona</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?259:6">FDA Internet Regulation? Public Comment Accepted until December 16</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?259:7">AZT Twice-Daily Tablets Approved; Dosing Concerns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?259:8">Retroviruses Conference: Press Deadline December 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?259:9">Qigong Program on San Francisco KQED TV, Beginning December 7</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?259:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #258, November 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?258:1">HCG: New Kind of KS Treatment?</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?258:1.1">References</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?258:1.2">References</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?258:2">NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?258:3">International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?258:4">Retroviruses Conference -- Some Scholarships Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?258:5">Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?258:6">TREATMENT ISSUES Article on New Therapies After Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?258:7">AIDSACT, New Email List for Activists</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?258:8">Hepatitis C: Protease Structure of Virus Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?258:9">Bioethics: Major Meetings in San Francisco, November 20-25</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?258:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS - Issue #251,  July 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?251:1">Vancouver in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?251:2">What Is New?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?251:3">New View of Antiretroviral Treatment: Illustrations from &quot;Late Breaker&quot; Abstracts</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?251:3.1">Bi-Directional Inhibition of HIV-1 Drug Resistance</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?251:3.2">Potent and Sustained Antiretroviral Activity of Indinavir (IDV), Zidovudine (ZVD) and Lamivudine (3TC).</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="ATN.cgi?251:3.3">Triple Therapy with AZT and 3TC in Combination with Nelfinavir Mesylate in 12 Antiretroviral-Naive Subjects Chronically Infected with HIV-1.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="ATN.cgi?251:3.4">Triple Therapy with AZT, 3TC, and Ritonavir in 12 Subjects Newly Infected with HIV.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="ATN.cgi?251:3.5">How Long Should Treatment Be Given If We Had an Antiretroviral Regimen that Completely Blocks HIV Replication?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="ATN.cgi?251:3.6">Improved Survival and Decreased Progression of HIV in Patients Treated with Saquinavir (Invirase(TM), SQV) Plus HIVID (Zalcitabine, ddC).</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?251:4">Expert Panel's New Recommendations for Antiviral Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?251:5">After Vancouver: Documenting Improved Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?251:6">Other Vancouver News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?251:7">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?251:7.1">TERMS</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+250"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-60</DOCNO>
<DOCOLDNO>IA017-000178-B001-231</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+260 192.33.214.13 19970106041337 text/html 9657
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:13:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS Issue #260, December 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?260:1">Buyers' Club Crisis -- Challenge for AIDS Community</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?260:2">Fewer AIDS Deaths: San Francisco Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?260:3">FDA Advisory Committee Deadlocks on Delavirdine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?260:4">Albendazole Free from Buyers' Club</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?260:5">Books: IMPURE SCIENCE</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?260:6">Buyers' Clubs List, December 1996</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?260:7">AIDS TREATMENT NEWS Reader Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?260:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS,Issue #259, November 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?259:1">Birmingham UK Drug Therapy Conference -- Early Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?259:2">Federal Team Developing Treatment Principles for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?259:3">1592: Two Studies Recruiting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?259:4">The New Antiretroviral Arsenal</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?259:5">Medical Marijuana Wins in California and Arizona</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?259:6">FDA Internet Regulation? Public Comment Accepted until December 16</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?259:7">AZT Twice-Daily Tablets Approved; Dosing Concerns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?259:8">Retroviruses Conference: Press Deadline December 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?259:9">Qigong Program on San Francisco KQED TV, Beginning December 7</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?259:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #258, November 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?258:1">HCG: New Kind of KS Treatment?</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?258:1.1">References</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?258:1.2">References</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?258:2">NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?258:3">International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?258:4">Retroviruses Conference -- Some Scholarships Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?258:5">Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?258:6">TREATMENT ISSUES Article on New Therapies After Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?258:7">AIDSACT, New Email List for Activists</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?258:8">Hepatitis C: Protease Structure of Virus Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?258:9">Bioethics: Major Meetings in San Francisco, November 20-25</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?258:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS - Issue #251,  July 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?251:1">Vancouver in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?251:2">What Is New?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?251:3">New View of Antiretroviral Treatment: Illustrations from &quot;Late Breaker&quot; Abstracts</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?251:3.1">Bi-Directional Inhibition of HIV-1 Drug Resistance</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?251:3.2">Potent and Sustained Antiretroviral Activity of Indinavir (IDV), Zidovudine (ZVD) and Lamivudine (3TC).</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="ATN.cgi?251:3.3">Triple Therapy with AZT and 3TC in Combination with Nelfinavir Mesylate in 12 Antiretroviral-Naive Subjects Chronically Infected with HIV-1.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="ATN.cgi?251:3.4">Triple Therapy with AZT, 3TC, and Ritonavir in 12 Subjects Newly Infected with HIV.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="ATN.cgi?251:3.5">How Long Should Treatment Be Given If We Had an Antiretroviral Regimen that Completely Blocks HIV Replication?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="ATN.cgi?251:3.6">Improved Survival and Decreased Progression of HIV in Patients Treated with Saquinavir (Invirase(TM), SQV) Plus HIVID (Zalcitabine, ddC).</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?251:4">Expert Panel's New Recommendations for Antiviral Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?251:5">After Vancouver: Documenting Improved Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?251:6">Other Vancouver News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?251:7">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?251:7.1">TERMS</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #250, July 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?250:1">Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?250:2">NAC: First Controlled Trial, Positive Results</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="ATN.cgi?250:2.1">History</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="ATN.cgi?250:2.2">The Stanford Trial</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?250:3">Nevirapine Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?250:4">Vancouver Conference: Each Day Summarized Nightly on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?250:5">SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?250:6">CMV RETINITIS AND TREATMENT CME Course on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?250:7">Delavirdine Expanded Access Program Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?250:8">West Hollywood: AIDS and Chinese Medicine Conference, July 25-28</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Neuropathy: Nutrient Therapies</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="ATN.cgi?250:9.1">Neuropathy: Nutrient Therapies (part 1)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="ATN.cgi?250:9.2">Neuropathy: Nutrient Therapies (part 2)</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?250:10">World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?250:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?250:12">R&eacute;f&eacute;rences</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+249"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-61</DOCNO>
<DOCOLDNO>IA017-000178-B001-241</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+259 192.33.214.13 19970106041349 text/html 10760
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:14:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS,Issue #259, November 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?259:1">Birmingham UK Drug Therapy Conference -- Early Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?259:2">Federal Team Developing Treatment Principles for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?259:3">1592: Two Studies Recruiting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?259:4">The New Antiretroviral Arsenal</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?259:5">Medical Marijuana Wins in California and Arizona</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?259:6">FDA Internet Regulation? Public Comment Accepted until December 16</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?259:7">AZT Twice-Daily Tablets Approved; Dosing Concerns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?259:8">Retroviruses Conference: Press Deadline December 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?259:9">Qigong Program on San Francisco KQED TV, Beginning December 7</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?259:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #258, November 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?258:1">HCG: New Kind of KS Treatment?</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?258:1.1">References</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?258:1.2">References</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?258:2">NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?258:3">International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?258:4">Retroviruses Conference -- Some Scholarships Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?258:5">Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?258:6">TREATMENT ISSUES Article on New Therapies After Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?258:7">AIDSACT, New Email List for Activists</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?258:8">Hepatitis C: Protease Structure of Virus Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?258:9">Bioethics: Major Meetings in San Francisco, November 20-25</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?258:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS - Issue #251,  July 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?251:1">Vancouver in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?251:2">What Is New?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?251:3">New View of Antiretroviral Treatment: Illustrations from &quot;Late Breaker&quot; Abstracts</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?251:3.1">Bi-Directional Inhibition of HIV-1 Drug Resistance</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?251:3.2">Potent and Sustained Antiretroviral Activity of Indinavir (IDV), Zidovudine (ZVD) and Lamivudine (3TC).</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="ATN.cgi?251:3.3">Triple Therapy with AZT and 3TC in Combination with Nelfinavir Mesylate in 12 Antiretroviral-Naive Subjects Chronically Infected with HIV-1.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="ATN.cgi?251:3.4">Triple Therapy with AZT, 3TC, and Ritonavir in 12 Subjects Newly Infected with HIV.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="ATN.cgi?251:3.5">How Long Should Treatment Be Given If We Had an Antiretroviral Regimen that Completely Blocks HIV Replication?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="ATN.cgi?251:3.6">Improved Survival and Decreased Progression of HIV in Patients Treated with Saquinavir (Invirase(TM), SQV) Plus HIVID (Zalcitabine, ddC).</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?251:4">Expert Panel's New Recommendations for Antiviral Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?251:5">After Vancouver: Documenting Improved Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?251:6">Other Vancouver News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?251:7">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?251:7.1">TERMS</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #250, July 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?250:1">Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?250:2">NAC: First Controlled Trial, Positive Results</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="ATN.cgi?250:2.1">History</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="ATN.cgi?250:2.2">The Stanford Trial</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?250:3">Nevirapine Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?250:4">Vancouver Conference: Each Day Summarized Nightly on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?250:5">SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?250:6">CMV RETINITIS AND TREATMENT CME Course on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?250:7">Delavirdine Expanded Access Program Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?250:8">West Hollywood: AIDS and Chinese Medicine Conference, July 25-28</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Neuropathy: Nutrient Therapies</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="ATN.cgi?250:9.1">Neuropathy: Nutrient Therapies (part 1)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="ATN.cgi?250:9.2">Neuropathy: Nutrient Therapies (part 2)</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?250:10">World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?250:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?250:12">R&eacute;f&eacute;rences</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?249:1">New Optimism on Controlling HIV Infection</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?249:1.1">Today there is more data, and from different kinds of patients, suggesting that:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?249:1.2">Is Viral Eradication Possible?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.3</TD>
	 <TD><A HREF="ATN.cgi?249:1.3">Comment: Practical Concerns</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?249:2">Internet Free Speech Wins Court Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?249:3">Azithromycin Approved for Once-Weekly MAC Prophylaxis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?249:4">Nevirapine Recommended for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?249:5">Free Viral Load Tests: Remember to Dial 1 Before 888</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?249:6">Needlestick Exposure: CDC Recommends Three-Drug Regimen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?249:7">AIDS and Alternative Medicine: A Journalist's Perspective</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?249:7.1">What has been lost from failing to research alternative treatments?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="ATN.cgi?249:7.2">Major Problems in Drug Development</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="ATN.cgi?249:7.3">What Can Be Done?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="ATN.cgi?249:7.4">Appendix: ExtraMED Database</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?249:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+248"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-62</DOCNO>
<DOCOLDNO>IA017-000178-B001-249</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+258 192.33.214.13 19970106041358 text/html 11773
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:14:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS Issue #258, November 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?258:1">HCG: New Kind of KS Treatment?</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?258:1.1">References</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?258:1.2">References</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?258:2">NTZ for Cryptosporidiosis: Larger Expanded Access; Buyers' Club/FDA Conflict</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?258:3">International Treatment Access and Research, How You Can Help -- Interview with Dr. Peter Piot of UNAIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?258:4">Retroviruses Conference -- Some Scholarships Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?258:5">Starting and Changing HIV Treatment: Conference Call Nov. 5, Recording Later</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?258:6">TREATMENT ISSUES Article on New Therapies After Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?258:7">AIDSACT, New Email List for Activists</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?258:8">Hepatitis C: Protease Structure of Virus Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?258:9">Bioethics: Major Meetings in San Francisco, November 20-25</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?258:10">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS - Issue #251,  July 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?251:1">Vancouver in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?251:2">What Is New?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?251:3">New View of Antiretroviral Treatment: Illustrations from &quot;Late Breaker&quot; Abstracts</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?251:3.1">Bi-Directional Inhibition of HIV-1 Drug Resistance</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?251:3.2">Potent and Sustained Antiretroviral Activity of Indinavir (IDV), Zidovudine (ZVD) and Lamivudine (3TC).</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="ATN.cgi?251:3.3">Triple Therapy with AZT and 3TC in Combination with Nelfinavir Mesylate in 12 Antiretroviral-Naive Subjects Chronically Infected with HIV-1.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="ATN.cgi?251:3.4">Triple Therapy with AZT, 3TC, and Ritonavir in 12 Subjects Newly Infected with HIV.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="ATN.cgi?251:3.5">How Long Should Treatment Be Given If We Had an Antiretroviral Regimen that Completely Blocks HIV Replication?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="ATN.cgi?251:3.6">Improved Survival and Decreased Progression of HIV in Patients Treated with Saquinavir (Invirase(TM), SQV) Plus HIVID (Zalcitabine, ddC).</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?251:4">Expert Panel's New Recommendations for Antiviral Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?251:5">After Vancouver: Documenting Improved Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?251:6">Other Vancouver News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?251:7">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?251:7.1">TERMS</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #250, July 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?250:1">Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?250:2">NAC: First Controlled Trial, Positive Results</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="ATN.cgi?250:2.1">History</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="ATN.cgi?250:2.2">The Stanford Trial</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?250:3">Nevirapine Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?250:4">Vancouver Conference: Each Day Summarized Nightly on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?250:5">SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?250:6">CMV RETINITIS AND TREATMENT CME Course on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?250:7">Delavirdine Expanded Access Program Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?250:8">West Hollywood: AIDS and Chinese Medicine Conference, July 25-28</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Neuropathy: Nutrient Therapies</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="ATN.cgi?250:9.1">Neuropathy: Nutrient Therapies (part 1)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="ATN.cgi?250:9.2">Neuropathy: Nutrient Therapies (part 2)</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?250:10">World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?250:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?250:12">R&eacute;f&eacute;rences</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?249:1">New Optimism on Controlling HIV Infection</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?249:1.1">Today there is more data, and from different kinds of patients, suggesting that:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?249:1.2">Is Viral Eradication Possible?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.3</TD>
	 <TD><A HREF="ATN.cgi?249:1.3">Comment: Practical Concerns</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?249:2">Internet Free Speech Wins Court Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?249:3">Azithromycin Approved for Once-Weekly MAC Prophylaxis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?249:4">Nevirapine Recommended for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?249:5">Free Viral Load Tests: Remember to Dial 1 Before 888</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?249:6">Needlestick Exposure: CDC Recommends Three-Drug Regimen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?249:7">AIDS and Alternative Medicine: A Journalist's Perspective</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?249:7.1">What has been lost from failing to research alternative treatments?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="ATN.cgi?249:7.2">Major Problems in Drug Development</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="ATN.cgi?249:7.3">What Can Be Done?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="ATN.cgi?249:7.4">Appendix: ExtraMED Database</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?249:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?248:1">Viral Load Approved; Free Test Offered to All in U.S. with HIV</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?248:1.1">Comment</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?248:1.2">What You Can Do Now</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?248:2">Viral Load: New Recommendations for Clinical Practice</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?248:3">Viral Load: New Proof of Importance for Disease Staging and Prognosis</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?248:3.1">The data were looked at in several different ways:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?248:3.2">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?248:4">Op Ed: Viral Load FDA Approval Delays</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?248:5">PMPA: New Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?248:6">3TC: Glaxo Wellcome Broadens Patient Assistance</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="ATN.cgi?248:6.1">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?248:7">Prison: California Conference on HIV and Prison Issues, Oakland, June 27</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?248:8">AIDS TREATMENT NEWS New Index Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?248:9">Activist Communications, Activities at Vancouver Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?248:10">&quot;Access for All&quot;: Communication Strategy Proposal for Activists at International Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?248:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?248:12">References</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+244"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-63</DOCNO>
<DOCOLDNO>IA017-000178-B001-262</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+251 192.33.214.13 19970106041408 text/html 11557
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:14:28 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS - Issue #251,  July 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?251:1">Vancouver in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?251:2">What Is New?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?251:3">New View of Antiretroviral Treatment: Illustrations from &quot;Late Breaker&quot; Abstracts</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?251:3.1">Bi-Directional Inhibition of HIV-1 Drug Resistance</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?251:3.2">Potent and Sustained Antiretroviral Activity of Indinavir (IDV), Zidovudine (ZVD) and Lamivudine (3TC).</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.3</TD>
	 <TD><A HREF="ATN.cgi?251:3.3">Triple Therapy with AZT and 3TC in Combination with Nelfinavir Mesylate in 12 Antiretroviral-Naive Subjects Chronically Infected with HIV-1.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.4</TD>
	 <TD><A HREF="ATN.cgi?251:3.4">Triple Therapy with AZT, 3TC, and Ritonavir in 12 Subjects Newly Infected with HIV.</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.5</TD>
	 <TD><A HREF="ATN.cgi?251:3.5">How Long Should Treatment Be Given If We Had an Antiretroviral Regimen that Completely Blocks HIV Replication?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.6</TD>
	 <TD><A HREF="ATN.cgi?251:3.6">Improved Survival and Decreased Progression of HIV in Patients Treated with Saquinavir (Invirase(TM), SQV) Plus HIVID (Zalcitabine, ddC).</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?251:4">Expert Panel's New Recommendations for Antiviral Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?251:5">After Vancouver: Documenting Improved Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?251:6">Other Vancouver News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?251:7">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?251:7.1">TERMS</A></TD>
	</TR>
	</TABLE>
	</TD>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #250, July 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?250:1">Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?250:2">NAC: First Controlled Trial, Positive Results</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.1</TD>
	 <TD><A HREF="ATN.cgi?250:2.1">History</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>2.2</TD>
	 <TD><A HREF="ATN.cgi?250:2.2">The Stanford Trial</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?250:3">Nevirapine Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?250:4">Vancouver Conference: Each Day Summarized Nightly on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?250:5">SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?250:6">CMV RETINITIS AND TREATMENT CME Course on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?250:7">Delavirdine Expanded Access Program Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?250:8">West Hollywood: AIDS and Chinese Medicine Conference, July 25-28</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD>Neuropathy: Nutrient Therapies</TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.1</TD>
	 <TD><A HREF="ATN.cgi?250:9.1">Neuropathy: Nutrient Therapies (part 1)</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>9.2</TD>
	 <TD><A HREF="ATN.cgi?250:9.2">Neuropathy: Nutrient Therapies (part 2)</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?250:10">World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?250:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?250:12">R&eacute;f&eacute;rences</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?249:1">New Optimism on Controlling HIV Infection</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?249:1.1">Today there is more data, and from different kinds of patients, suggesting that:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?249:1.2">Is Viral Eradication Possible?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.3</TD>
	 <TD><A HREF="ATN.cgi?249:1.3">Comment: Practical Concerns</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?249:2">Internet Free Speech Wins Court Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?249:3">Azithromycin Approved for Once-Weekly MAC Prophylaxis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?249:4">Nevirapine Recommended for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?249:5">Free Viral Load Tests: Remember to Dial 1 Before 888</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?249:6">Needlestick Exposure: CDC Recommends Three-Drug Regimen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?249:7">AIDS and Alternative Medicine: A Journalist's Perspective</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?249:7.1">What has been lost from failing to research alternative treatments?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="ATN.cgi?249:7.2">Major Problems in Drug Development</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="ATN.cgi?249:7.3">What Can Be Done?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="ATN.cgi?249:7.4">Appendix: ExtraMED Database</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?249:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?248:1">Viral Load Approved; Free Test Offered to All in U.S. with HIV</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?248:1.1">Comment</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?248:1.2">What You Can Do Now</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?248:2">Viral Load: New Recommendations for Clinical Practice</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?248:3">Viral Load: New Proof of Importance for Disease Staging and Prognosis</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?248:3.1">The data were looked at in several different ways:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?248:3.2">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?248:4">Op Ed: Viral Load FDA Approval Delays</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?248:5">PMPA: New Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?248:6">3TC: Glaxo Wellcome Broadens Patient Assistance</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="ATN.cgi?248:6.1">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?248:7">Prison: California Conference on HIV and Prison Issues, Oakland, June 27</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?248:8">AIDS TREATMENT NEWS New Index Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?248:9">Activist Communications, Activities at Vancouver Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?248:10">&quot;Access for All&quot;: Communication Strategy Proposal for Activists at International Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?248:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?248:12">References</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #244, April 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?244:1">San Francisco: 3TC Available Now to Residents through ADAP Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?244:2">Protease Inhibitors: Patient Education Critical</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?244:3">Indinavir (Crixivan(R)) Access and Distribution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?244:4">AIDS Research at NIH: Study Panel Issues Major Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?244:5">Viral Load: Inconclusive FDA Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?244:6">AZT, ddI, and ddC Combinations at FDA Advisory Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?244:7">Cidofovir Recommended for Approval for CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?244:8">California: Clinical Trials Computer Service Now Available Statewide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?244:9">San Francisco Protest Against Meeting Disruptions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?244:10">California: AB 2812 Would Outlaw Anonymous Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?244:11">AIDS Medications Needed Abroad</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+243"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-64</DOCNO>
<DOCOLDNO>IA017-000178-B001-272</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+249 192.33.214.13 19970106041417 text/html 9300
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:14:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+260"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?249:1">New Optimism on Controlling HIV Infection</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?249:1.1">Today there is more data, and from different kinds of patients, suggesting that:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?249:1.2">Is Viral Eradication Possible?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.3</TD>
	 <TD><A HREF="ATN.cgi?249:1.3">Comment: Practical Concerns</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?249:2">Internet Free Speech Wins Court Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?249:3">Azithromycin Approved for Once-Weekly MAC Prophylaxis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?249:4">Nevirapine Recommended for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?249:5">Free Viral Load Tests: Remember to Dial 1 Before 888</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?249:6">Needlestick Exposure: CDC Recommends Three-Drug Regimen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?249:7">AIDS and Alternative Medicine: A Journalist's Perspective</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.1</TD>
	 <TD><A HREF="ATN.cgi?249:7.1">What has been lost from failing to research alternative treatments?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.2</TD>
	 <TD><A HREF="ATN.cgi?249:7.2">Major Problems in Drug Development</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.3</TD>
	 <TD><A HREF="ATN.cgi?249:7.3">What Can Be Done?</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>7.4</TD>
	 <TD><A HREF="ATN.cgi?249:7.4">Appendix: ExtraMED Database</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?249:8">AIDS TREATMENT NEWS</A></TD>
</TR>
</TABLE>
</UL>
<H3>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?248:1">Viral Load Approved; Free Test Offered to All in U.S. with HIV</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?248:1.1">Comment</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?248:1.2">What You Can Do Now</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?248:2">Viral Load: New Recommendations for Clinical Practice</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?248:3">Viral Load: New Proof of Importance for Disease Staging and Prognosis</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?248:3.1">The data were looked at in several different ways:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?248:3.2">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?248:4">Op Ed: Viral Load FDA Approval Delays</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?248:5">PMPA: New Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?248:6">3TC: Glaxo Wellcome Broadens Patient Assistance</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="ATN.cgi?248:6.1">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?248:7">Prison: California Conference on HIV and Prison Issues, Oakland, June 27</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?248:8">AIDS TREATMENT NEWS New Index Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?248:9">Activist Communications, Activities at Vancouver Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?248:10">&quot;Access for All&quot;: Communication Strategy Proposal for Activists at International Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?248:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?248:12">References</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #244, April 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?244:1">San Francisco: 3TC Available Now to Residents through ADAP Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?244:2">Protease Inhibitors: Patient Education Critical</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?244:3">Indinavir (Crixivan(R)) Access and Distribution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?244:4">AIDS Research at NIH: Study Panel Issues Major Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?244:5">Viral Load: Inconclusive FDA Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?244:6">AZT, ddI, and ddC Combinations at FDA Advisory Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?244:7">Cidofovir Recommended for Approval for CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?244:8">California: Clinical Trials Computer Service Now Available Statewide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?244:9">San Francisco Protest Against Meeting Disruptions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?244:10">California: AB 2812 Would Outlaw Anonymous Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?244:11">AIDS Medications Needed Abroad</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #243, March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?243:1">Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?243:2">Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?243:3">Protease Inhibitors at FDA Advisory Hearings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?243:4">FDA Antiviral Hearings: Community Perspectives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?243:5">FDA Hearings: For More Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?243:6">Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?243:7">Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?243:8">AIDS and Alternative Medicine, Seattle, April 28</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #242, March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?242:1">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?242:2">Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?242:3">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?242:4">Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating  HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?242:5">Protease Inhibitors at Retroviruses Conference: Agouron's Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?242:6">Retroviruses Conference: Obtaining Abstracts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?242:7">DHEA: Threat to Access?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+241"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-65</DOCNO>
<DOCOLDNO>IA017-000178-B001-284</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+248 192.33.214.13 19970106041434 text/html 7883
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:14:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+259"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?248:1">Viral Load Approved; Free Test Offered to All in U.S. with HIV</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.1</TD>
	 <TD><A HREF="ATN.cgi?248:1.1">Comment</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>1.2</TD>
	 <TD><A HREF="ATN.cgi?248:1.2">What You Can Do Now</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?248:2">Viral Load: New Recommendations for Clinical Practice</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?248:3">Viral Load: New Proof of Importance for Disease Staging and Prognosis</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.1</TD>
	 <TD><A HREF="ATN.cgi?248:3.1">The data were looked at in several different ways:</A></TD>
	</TR>
	<TR ALIGN=left VALIGN=top>
	 <TD>3.2</TD>
	 <TD><A HREF="ATN.cgi?248:3.2">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?248:4">Op Ed: Viral Load FDA Approval Delays</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?248:5">PMPA: New Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?248:6">3TC: Glaxo Wellcome Broadens Patient Assistance</A></TD>
</TR>
<TR>
	<TD></TD>
	<TD>
	<TABLE BORDER=0>
	<TR ALIGN=left VALIGN=top>
	 <TD>6.1</TD>
	 <TD><A HREF="ATN.cgi?248:6.1">Comment</A></TD>
	</TR>
	</TABLE>
	</TD>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?248:7">Prison: California Conference on HIV and Prison Issues, Oakland, June 27</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?248:8">AIDS TREATMENT NEWS New Index Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?248:9">Activist Communications, Activities at Vancouver Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?248:10">&quot;Access for All&quot;: Communication Strategy Proposal for Activists at International Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?248:11">AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?248:12">References</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #244, April 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?244:1">San Francisco: 3TC Available Now to Residents through ADAP Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?244:2">Protease Inhibitors: Patient Education Critical</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?244:3">Indinavir (Crixivan(R)) Access and Distribution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?244:4">AIDS Research at NIH: Study Panel Issues Major Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?244:5">Viral Load: Inconclusive FDA Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?244:6">AZT, ddI, and ddC Combinations at FDA Advisory Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?244:7">Cidofovir Recommended for Approval for CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?244:8">California: Clinical Trials Computer Service Now Available Statewide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?244:9">San Francisco Protest Against Meeting Disruptions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?244:10">California: AB 2812 Would Outlaw Anonymous Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?244:11">AIDS Medications Needed Abroad</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #243, March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?243:1">Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?243:2">Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?243:3">Protease Inhibitors at FDA Advisory Hearings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?243:4">FDA Antiviral Hearings: Community Perspectives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?243:5">FDA Hearings: For More Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?243:6">Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?243:7">Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?243:8">AIDS and Alternative Medicine, Seattle, April 28</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #242, March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?242:1">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?242:2">Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?242:3">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?242:4">Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating  HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?242:5">Protease Inhibitors at Retroviruses Conference: Agouron's Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?242:6">Retroviruses Conference: Obtaining Abstracts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?242:7">DHEA: Threat to Access?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #241</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?241:1">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?241:2">d4T Plus ddI Antiviral Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?241:3">Growing Crisis in Paying for Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?241:4">AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?241:5">Press Gag Rules at AIDS Conference</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+240"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-66</DOCNO>
<DOCOLDNO>IA017-000178-B001-297</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+244 192.33.214.13 19970106041445 text/html 6818
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:15:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+258"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #244, April 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?244:1">San Francisco: 3TC Available Now to Residents through ADAP Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?244:2">Protease Inhibitors: Patient Education Critical</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?244:3">Indinavir (Crixivan(R)) Access and Distribution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?244:4">AIDS Research at NIH: Study Panel Issues Major Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?244:5">Viral Load: Inconclusive FDA Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?244:6">AZT, ddI, and ddC Combinations at FDA Advisory Hearing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?244:7">Cidofovir Recommended for Approval for CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?244:8">California: Clinical Trials Computer Service Now Available Statewide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?244:9">San Francisco Protest Against Meeting Disruptions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?244:10">California: AB 2812 Would Outlaw Anonymous Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?244:11">AIDS Medications Needed Abroad</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #243, March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?243:1">Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?243:2">Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?243:3">Protease Inhibitors at FDA Advisory Hearings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?243:4">FDA Antiviral Hearings: Community Perspectives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?243:5">FDA Hearings: For More Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?243:6">Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?243:7">Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?243:8">AIDS and Alternative Medicine, Seattle, April 28</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #242, March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?242:1">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?242:2">Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?242:3">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?242:4">Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating  HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?242:5">Protease Inhibitors at Retroviruses Conference: Agouron's Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?242:6">Retroviruses Conference: Obtaining Abstracts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?242:7">DHEA: Threat to Access?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #241</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?241:1">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?241:2">d4T Plus ddI Antiviral Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?241:3">Growing Crisis in Paying for Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?241:4">AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?241:5">Press Gag Rules at AIDS Conference</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+239"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-67</DOCNO>
<DOCOLDNO>IA017-000178-B001-306</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+243 192.33.214.13 19970106041454 text/html 6560
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:15:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+251"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #243, March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?243:1">Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?243:2">Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?243:3">Protease Inhibitors at FDA Advisory Hearings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?243:4">FDA Antiviral Hearings: Community Perspectives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?243:5">FDA Hearings: For More Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?243:6">Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?243:7">Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?243:8">AIDS and Alternative Medicine, Seattle, April 28</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #242, March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?242:1">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?242:2">Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?242:3">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?242:4">Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating  HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?242:5">Protease Inhibitors at Retroviruses Conference: Agouron's Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?242:6">Retroviruses Conference: Obtaining Abstracts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?242:7">DHEA: Threat to Access?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #241</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?241:1">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?241:2">d4T Plus ddI Antiviral Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?241:3">Growing Crisis in Paying for Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?241:4">AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?241:5">Press Gag Rules at AIDS Conference</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+238"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-68</DOCNO>
<DOCOLDNO>IA017-000178-B001-317</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+242 192.33.214.13 19970106041505 text/html 6355
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:15:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+250"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #242, March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?242:1">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?242:2">Protease Inhibitor Approvals: Will People Be Cut Off Drug? Followup Studies Proposal Needs Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?242:3">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?242:4">Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating  HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?242:5">Protease Inhibitors at Retroviruses Conference: Agouron's Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?242:6">Retroviruses Conference: Obtaining Abstracts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?242:7">DHEA: Threat to Access?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #241</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?241:1">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?241:2">d4T Plus ddI Antiviral Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?241:3">Growing Crisis in Paying for Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?241:4">AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?241:5">Press Gag Rules at AIDS Conference</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+237"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-69</DOCNO>
<DOCOLDNO>IA017-000178-B002-11</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+241 192.33.214.13 19970106041521 text/html 6956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:15:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+249"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #241</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?241:1">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?241:2">d4T Plus ddI Antiviral Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?241:3">Growing Crisis in Paying for Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?241:4">AB 9: California Bill Would End County Mandate for Last-Resort Care, Including Communicable Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?241:5">Press Gag Rules at AIDS Conference</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+236"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-70</DOCNO>
<DOCOLDNO>IA017-000178-B002-22</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+240 192.33.214.13 19970106041541 text/html 7451
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:15:52 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+248"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+235"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-71</DOCNO>
<DOCOLDNO>IA017-000178-B002-38</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+239 192.33.214.13 19970106041555 text/html 6912
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:16:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+244"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #235, November 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?235:1">New AIDS Treatment Article Series Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?235:2">U.S./China AIDS Research Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?235:3">Protease Inhibitors: Drug Resistance and Cross Resistance Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?235:4">Grapefruit Juice and Saquinavir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?235:5">Vancouver Conference Internet Address</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?235:6">FDA Reform: New Senate Bill</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+234"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-72</DOCNO>
<DOCOLDNO>IA017-000178-B002-54</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+238 192.33.214.13 19970106041607 text/html 6989
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:16:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+243"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #235, November 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?235:1">New AIDS Treatment Article Series Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?235:2">U.S./China AIDS Research Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?235:3">Protease Inhibitors: Drug Resistance and Cross Resistance Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?235:4">Grapefruit Juice and Saquinavir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?235:5">Vancouver Conference Internet Address</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?235:6">FDA Reform: New Senate Bill</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #234, November 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?234:1">Project Inform's THE HIV DRUG BOOK Now Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?234:2">Thalidomide for Wasting Syndrome: Progress Toward Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?234:3">NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?234:4">NIH Role in Clinical Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?234:5">CMV: Oral Ganciclovir for Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?234:6">CMV: New Screening Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?234:7">Cryptosporidiosis Information Phone/Fax Line</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?234:8">Protease Inhibitor Trial Drops AZT-Only Arm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?234:9">Help Wanted: AIDS Treatment Activist, Atlanta</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?234:10">Peptide T: Negative Trial Result</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+233"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-73</DOCNO>
<DOCOLDNO>IA017-000178-B002-66</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+237 192.33.214.13 19970106041617 text/html 7642
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:16:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+242"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #235, November 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?235:1">New AIDS Treatment Article Series Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?235:2">U.S./China AIDS Research Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?235:3">Protease Inhibitors: Drug Resistance and Cross Resistance Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?235:4">Grapefruit Juice and Saquinavir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?235:5">Vancouver Conference Internet Address</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?235:6">FDA Reform: New Senate Bill</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #234, November 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?234:1">Project Inform's THE HIV DRUG BOOK Now Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?234:2">Thalidomide for Wasting Syndrome: Progress Toward Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?234:3">NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?234:4">NIH Role in Clinical Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?234:5">CMV: Oral Ganciclovir for Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?234:6">CMV: New Screening Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?234:7">Cryptosporidiosis Information Phone/Fax Line</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?234:8">Protease Inhibitor Trial Drops AZT-Only Arm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?234:9">Help Wanted: AIDS Treatment Activist, Atlanta</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?234:10">Peptide T: Negative Trial Result</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #233, October 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?233:1">Viral Load: New &quot;Strategy&quot; Trial in 15 U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?233:2">Guidelines for Clinical Management Using Plasma HIV RNA Quantitation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?233:3">White House Meeting on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?233:4">FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), November 6-8</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?233:5">International Conference, Vancouver 1996: Arrangements, Deadlines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?233:6">Thalidomide Conflict -- How to Help</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?233:7">Internet Newsgroup sci.med.aids -- New Addresses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?233:8">California: Governor Vetoes Cryptosporidium Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?233:9">San Francisco Area: Testosterone Replacement Study, Injection vs. Patch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?233:10">Women Prisoners: San Francisco Bay Area Events</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?233:11">Office of AIDS Research Announces Advisory Council</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+232"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-74</DOCNO>
<DOCOLDNO>IA017-000178-B002-80</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+236 192.33.214.13 19970106041625 text/html 7100
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:16:47 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+241"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #235, November 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?235:1">New AIDS Treatment Article Series Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?235:2">U.S./China AIDS Research Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?235:3">Protease Inhibitors: Drug Resistance and Cross Resistance Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?235:4">Grapefruit Juice and Saquinavir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?235:5">Vancouver Conference Internet Address</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?235:6">FDA Reform: New Senate Bill</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #234, November 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?234:1">Project Inform's THE HIV DRUG BOOK Now Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?234:2">Thalidomide for Wasting Syndrome: Progress Toward Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?234:3">NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?234:4">NIH Role in Clinical Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?234:5">CMV: Oral Ganciclovir for Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?234:6">CMV: New Screening Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?234:7">Cryptosporidiosis Information Phone/Fax Line</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?234:8">Protease Inhibitor Trial Drops AZT-Only Arm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?234:9">Help Wanted: AIDS Treatment Activist, Atlanta</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?234:10">Peptide T: Negative Trial Result</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #233, October 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?233:1">Viral Load: New &quot;Strategy&quot; Trial in 15 U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?233:2">Guidelines for Clinical Management Using Plasma HIV RNA Quantitation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?233:3">White House Meeting on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?233:4">FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), November 6-8</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?233:5">International Conference, Vancouver 1996: Arrangements, Deadlines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?233:6">Thalidomide Conflict -- How to Help</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?233:7">Internet Newsgroup sci.med.aids -- New Addresses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?233:8">California: Governor Vetoes Cryptosporidium Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?233:9">San Francisco Area: Testosterone Replacement Study, Injection vs. Patch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?233:10">Women Prisoners: San Francisco Bay Area Events</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?233:11">Office of AIDS Research Announces Advisory Council</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #232, October 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?232:1">Protease Inhibitors and Prevention of Cross Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?232:2">AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?232:3">Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?232:4">California: Marijuana Compassionate Use Statewide Initiative</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?232:5">New York, Ohio, Ontario: Health Promotion Workshops</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?232:6">Vaccine Research Meeting, Oct. 16, Near Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?232:7">ICAAC's Small Advances</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?232:8">AIDS Information Obstacles</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+231"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-75</DOCNO>
<DOCOLDNO>IA017-000178-B002-96</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+235 192.33.214.13 19970106041639 text/html 7736
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:16:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+240"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #235, November 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?235:1">New AIDS Treatment Article Series Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?235:2">U.S./China AIDS Research Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?235:3">Protease Inhibitors: Drug Resistance and Cross Resistance Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?235:4">Grapefruit Juice and Saquinavir</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?235:5">Vancouver Conference Internet Address</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?235:6">FDA Reform: New Senate Bill</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #234, November 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?234:1">Project Inform's THE HIV DRUG BOOK Now Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?234:2">Thalidomide for Wasting Syndrome: Progress Toward Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?234:3">NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?234:4">NIH Role in Clinical Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?234:5">CMV: Oral Ganciclovir for Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?234:6">CMV: New Screening Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?234:7">Cryptosporidiosis Information Phone/Fax Line</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?234:8">Protease Inhibitor Trial Drops AZT-Only Arm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?234:9">Help Wanted: AIDS Treatment Activist, Atlanta</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?234:10">Peptide T: Negative Trial Result</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #233, October 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?233:1">Viral Load: New &quot;Strategy&quot; Trial in 15 U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?233:2">Guidelines for Clinical Management Using Plasma HIV RNA Quantitation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?233:3">White House Meeting on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?233:4">FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), November 6-8</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?233:5">International Conference, Vancouver 1996: Arrangements, Deadlines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?233:6">Thalidomide Conflict -- How to Help</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?233:7">Internet Newsgroup sci.med.aids -- New Addresses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?233:8">California: Governor Vetoes Cryptosporidium Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?233:9">San Francisco Area: Testosterone Replacement Study, Injection vs. Patch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?233:10">Women Prisoners: San Francisco Bay Area Events</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?233:11">Office of AIDS Research Announces Advisory Council</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #232, October 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?232:1">Protease Inhibitors and Prevention of Cross Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?232:2">AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?232:3">Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?232:4">California: Marijuana Compassionate Use Statewide Initiative</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?232:5">New York, Ohio, Ontario: Health Promotion Workshops</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?232:6">Vaccine Research Meeting, Oct. 16, Near Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?232:7">ICAAC's Small Advances</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?232:8">AIDS Information Obstacles</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #231, September 29, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?231:1">ICAAC 1995: New Perspectives on Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?231:2">Major Study Shows AZT Monotherapy Inferior</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?231:3">Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?231:4">Agouron Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?231:5">Saquinavir (Roche Protease Inhibitor) At Higher Doses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?231:6">Ritonavir, Saquinavir Combination --  Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?231:7">Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?231:8">Saquinavir -- New Lottery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?231:9">Symptom-Reduction Trials at FDA Clinical Trials Workshop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?231:10">Medicaid in Congress: Serious Threat to Health Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?231:11">San Francisco: Nutrition and Wasting Seminar, October 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?231:12">San Francisco: Virology/Immunology Meeting, October 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?231:13">Drug Policy Reform: Ninth International Conference, October 18-21</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+230"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-76</DOCNO>
<DOCOLDNO>IA017-000178-B002-105</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+234 192.33.214.13 19970106041649 text/html 8048
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+239"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #234, November 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?234:1">Project Inform's THE HIV DRUG BOOK Now Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?234:2">Thalidomide for Wasting Syndrome: Progress Toward Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?234:3">NIH Research Evaluation: Last Meeting on Clinical Trials November 13, Public Comment Allowed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?234:4">NIH Role in Clinical Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?234:5">CMV: Oral Ganciclovir for Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?234:6">CMV: New Screening Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?234:7">Cryptosporidiosis Information Phone/Fax Line</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?234:8">Protease Inhibitor Trial Drops AZT-Only Arm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?234:9">Help Wanted: AIDS Treatment Activist, Atlanta</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?234:10">Peptide T: Negative Trial Result</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #233, October 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?233:1">Viral Load: New &quot;Strategy&quot; Trial in 15 U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?233:2">Guidelines for Clinical Management Using Plasma HIV RNA Quantitation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?233:3">White House Meeting on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?233:4">FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), November 6-8</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?233:5">International Conference, Vancouver 1996: Arrangements, Deadlines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?233:6">Thalidomide Conflict -- How to Help</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?233:7">Internet Newsgroup sci.med.aids -- New Addresses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?233:8">California: Governor Vetoes Cryptosporidium Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?233:9">San Francisco Area: Testosterone Replacement Study, Injection vs. Patch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?233:10">Women Prisoners: San Francisco Bay Area Events</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?233:11">Office of AIDS Research Announces Advisory Council</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #232, October 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?232:1">Protease Inhibitors and Prevention of Cross Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?232:2">AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?232:3">Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?232:4">California: Marijuana Compassionate Use Statewide Initiative</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?232:5">New York, Ohio, Ontario: Health Promotion Workshops</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?232:6">Vaccine Research Meeting, Oct. 16, Near Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?232:7">ICAAC's Small Advances</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?232:8">AIDS Information Obstacles</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #231, September 29, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?231:1">ICAAC 1995: New Perspectives on Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?231:2">Major Study Shows AZT Monotherapy Inferior</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?231:3">Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?231:4">Agouron Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?231:5">Saquinavir (Roche Protease Inhibitor) At Higher Doses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?231:6">Ritonavir, Saquinavir Combination --  Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?231:7">Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?231:8">Saquinavir -- New Lottery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?231:9">Symptom-Reduction Trials at FDA Clinical Trials Workshop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?231:10">Medicaid in Congress: Serious Threat to Health Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?231:11">San Francisco: Nutrition and Wasting Seminar, October 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?231:12">San Francisco: Virology/Immunology Meeting, October 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?231:13">Drug Policy Reform: Ninth International Conference, October 18-21</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #230, September 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?230:1">Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?230:2">Hydroxyurea and ddI: French Study Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?230:3">Thalidomide: New Expanded Access for Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?230:4">d4T Dose Clarification</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?230:5">San Francisco: Viral Load Trial Offers Free Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?230:6">National AIDS Treatment Advocates Forum, October 15-18, Los Angeles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?230:7">Next AIDS TREATMENT NEWS Delayed One Week</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?230:8">Health Insurance: Widespread Copayment Abuse</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+229"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-77</DOCNO>
<DOCOLDNO>IA017-000178-B002-111</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+233 192.33.214.13 19970106041657 text/html 7864
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+238"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #233, October 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?233:1">Viral Load: New &quot;Strategy&quot; Trial in 15 U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?233:2">Guidelines for Clinical Management Using Plasma HIV RNA Quantitation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?233:3">White House Meeting on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?233:4">FDA Antiviral Advisory Hearings on Lamivudine (Epivir(TM), 3TC), Saquinavir (Invirase(TM)), Stavudine (Zerit(TM), d4T), November 6-8</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?233:5">International Conference, Vancouver 1996: Arrangements, Deadlines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?233:6">Thalidomide Conflict -- How to Help</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?233:7">Internet Newsgroup sci.med.aids -- New Addresses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?233:8">California: Governor Vetoes Cryptosporidium Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?233:9">San Francisco Area: Testosterone Replacement Study, Injection vs. Patch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?233:10">Women Prisoners: San Francisco Bay Area Events</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?233:11">Office of AIDS Research Announces Advisory Council</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #232, October 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?232:1">Protease Inhibitors and Prevention of Cross Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?232:2">AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?232:3">Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?232:4">California: Marijuana Compassionate Use Statewide Initiative</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?232:5">New York, Ohio, Ontario: Health Promotion Workshops</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?232:6">Vaccine Research Meeting, Oct. 16, Near Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?232:7">ICAAC's Small Advances</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?232:8">AIDS Information Obstacles</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #231, September 29, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?231:1">ICAAC 1995: New Perspectives on Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?231:2">Major Study Shows AZT Monotherapy Inferior</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?231:3">Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?231:4">Agouron Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?231:5">Saquinavir (Roche Protease Inhibitor) At Higher Doses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?231:6">Ritonavir, Saquinavir Combination --  Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?231:7">Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?231:8">Saquinavir -- New Lottery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?231:9">Symptom-Reduction Trials at FDA Clinical Trials Workshop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?231:10">Medicaid in Congress: Serious Threat to Health Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?231:11">San Francisco: Nutrition and Wasting Seminar, October 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?231:12">San Francisco: Virology/Immunology Meeting, October 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?231:13">Drug Policy Reform: Ninth International Conference, October 18-21</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #230, September 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?230:1">Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?230:2">Hydroxyurea and ddI: French Study Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?230:3">Thalidomide: New Expanded Access for Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?230:4">d4T Dose Clarification</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?230:5">San Francisco: Viral Load Trial Offers Free Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?230:6">National AIDS Treatment Advocates Forum, October 15-18, Los Angeles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?230:7">Next AIDS TREATMENT NEWS Delayed One Week</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?230:8">Health Insurance: Widespread Copayment Abuse</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #229, August 18, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?229:1">&quot;Confirmatory&quot; Trials: Symptom Reduction As Efficacy Measure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?229:2">FDA Warning on Raw Oysters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?229:3">ICAAC Conference, September 17-20, in San Francisco</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?229:4">Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?229:5">Alternative Medicine and HIV/AIDS: Request for Applications</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?229:6">San Francisco: AIDS TREATMENT NEWS Needs Office Space</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?229:7">House Moves to Block Internet Censorship</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?229:8">Is NIH AIDS Research in Danger?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+228"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-78</DOCNO>
<DOCOLDNO>IA017-000178-B002-123</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+232 192.33.214.13 19970106041709 text/html 7326
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+237"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #232, October 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?232:1">Protease Inhibitors and Prevention of Cross Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?232:2">AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?232:3">Los Angeles, New York, Stanford University: HBY 097, New Drug May Weaken HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?232:4">California: Marijuana Compassionate Use Statewide Initiative</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?232:5">New York, Ohio, Ontario: Health Promotion Workshops</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?232:6">Vaccine Research Meeting, Oct. 16, Near Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?232:7">ICAAC's Small Advances</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?232:8">AIDS Information Obstacles</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #231, September 29, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?231:1">ICAAC 1995: New Perspectives on Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?231:2">Major Study Shows AZT Monotherapy Inferior</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?231:3">Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?231:4">Agouron Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?231:5">Saquinavir (Roche Protease Inhibitor) At Higher Doses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?231:6">Ritonavir, Saquinavir Combination --  Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?231:7">Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?231:8">Saquinavir -- New Lottery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?231:9">Symptom-Reduction Trials at FDA Clinical Trials Workshop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?231:10">Medicaid in Congress: Serious Threat to Health Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?231:11">San Francisco: Nutrition and Wasting Seminar, October 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?231:12">San Francisco: Virology/Immunology Meeting, October 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?231:13">Drug Policy Reform: Ninth International Conference, October 18-21</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #230, September 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?230:1">Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?230:2">Hydroxyurea and ddI: French Study Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?230:3">Thalidomide: New Expanded Access for Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?230:4">d4T Dose Clarification</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?230:5">San Francisco: Viral Load Trial Offers Free Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?230:6">National AIDS Treatment Advocates Forum, October 15-18, Los Angeles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?230:7">Next AIDS TREATMENT NEWS Delayed One Week</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?230:8">Health Insurance: Widespread Copayment Abuse</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #229, August 18, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?229:1">&quot;Confirmatory&quot; Trials: Symptom Reduction As Efficacy Measure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?229:2">FDA Warning on Raw Oysters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?229:3">ICAAC Conference, September 17-20, in San Francisco</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?229:4">Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?229:5">Alternative Medicine and HIV/AIDS: Request for Applications</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?229:6">San Francisco: AIDS TREATMENT NEWS Needs Office Space</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?229:7">House Moves to Block Internet Censorship</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?229:8">Is NIH AIDS Research in Danger?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #228, August 4, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?228:1">New Antiretroviral Strategies: Interview with Marcus Conant, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?228:2">3TC: Now Available Again Up To CD4 of 300</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?228:3">California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?228:4">Boston: Important Trial of Treatment Vaccine, CD4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?228:5">FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?228:6">Comment: Workable Clinical Trials [or, AIDS &quot;Confirmatory&quot; Trials: What's Wrong, and How to Move Forward Today]</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?228:7">FDA Reform: Activists' Proposals</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+227"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-79</DOCNO>
<DOCOLDNO>IA017-000178-B002-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+231 192.33.214.13 19970106041718 text/html 7154
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+236"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #231, September 29, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?231:1">ICAAC 1995: New Perspectives on Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?231:2">Major Study Shows AZT Monotherapy Inferior</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?231:3">Abbott Protease Inhibitor In Combination: Sustained Viral Load Drop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?231:4">Agouron Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?231:5">Saquinavir (Roche Protease Inhibitor) At Higher Doses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?231:6">Ritonavir, Saquinavir Combination --  Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?231:7">Boston, Galveston, Jackson County, Jefferson County, New York City, Portland -- New Saquinavir Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?231:8">Saquinavir -- New Lottery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?231:9">Symptom-Reduction Trials at FDA Clinical Trials Workshop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?231:10">Medicaid in Congress: Serious Threat to Health Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?231:11">San Francisco: Nutrition and Wasting Seminar, October 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?231:12">San Francisco: Virology/Immunology Meeting, October 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?231:13">Drug Policy Reform: Ninth International Conference, October 18-21</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #230, September 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?230:1">Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?230:2">Hydroxyurea and ddI: French Study Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?230:3">Thalidomide: New Expanded Access for Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?230:4">d4T Dose Clarification</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?230:5">San Francisco: Viral Load Trial Offers Free Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?230:6">National AIDS Treatment Advocates Forum, October 15-18, Los Angeles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?230:7">Next AIDS TREATMENT NEWS Delayed One Week</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?230:8">Health Insurance: Widespread Copayment Abuse</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #229, August 18, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?229:1">&quot;Confirmatory&quot; Trials: Symptom Reduction As Efficacy Measure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?229:2">FDA Warning on Raw Oysters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?229:3">ICAAC Conference, September 17-20, in San Francisco</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?229:4">Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?229:5">Alternative Medicine and HIV/AIDS: Request for Applications</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?229:6">San Francisco: AIDS TREATMENT NEWS Needs Office Space</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?229:7">House Moves to Block Internet Censorship</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?229:8">Is NIH AIDS Research in Danger?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #228, August 4, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?228:1">New Antiretroviral Strategies: Interview with Marcus Conant, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?228:2">3TC: Now Available Again Up To CD4 of 300</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?228:3">California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?228:4">Boston: Important Trial of Treatment Vaccine, CD4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?228:5">FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?228:6">Comment: Workable Clinical Trials [or, AIDS &quot;Confirmatory&quot; Trials: What's Wrong, and How to Move Forward Today]</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?228:7">FDA Reform: Activists' Proposals</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #227, July 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?227:1">Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?227:2">Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?227:3">Exon Amendment: Threat to AIDS Prevention and Activism?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?227:4">NAPWA Opens Pharmacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?227:5">AIDS Research &quot;Spin-off&quot; -- Ganciclovir CMV Prevention After Liver Transplantation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?227:6">Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+226"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-80</DOCNO>
<DOCOLDNO>IA017-000178-B002-137</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+230 192.33.214.13 19970106041728 text/html 6193
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+235"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #230, September 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?230:1">Acupuncture and Chinese Medicine; Interview with Tom Sinclair, L. Ac.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?230:2">Hydroxyurea and ddI: French Study Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?230:3">Thalidomide: New Expanded Access for Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?230:4">d4T Dose Clarification</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?230:5">San Francisco: Viral Load Trial Offers Free Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?230:6">National AIDS Treatment Advocates Forum, October 15-18, Los Angeles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?230:7">Next AIDS TREATMENT NEWS Delayed One Week</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?230:8">Health Insurance: Widespread Copayment Abuse</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #229, August 18, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?229:1">&quot;Confirmatory&quot; Trials: Symptom Reduction As Efficacy Measure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?229:2">FDA Warning on Raw Oysters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?229:3">ICAAC Conference, September 17-20, in San Francisco</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?229:4">Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?229:5">Alternative Medicine and HIV/AIDS: Request for Applications</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?229:6">San Francisco: AIDS TREATMENT NEWS Needs Office Space</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?229:7">House Moves to Block Internet Censorship</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?229:8">Is NIH AIDS Research in Danger?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #228, August 4, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?228:1">New Antiretroviral Strategies: Interview with Marcus Conant, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?228:2">3TC: Now Available Again Up To CD4 of 300</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?228:3">California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?228:4">Boston: Important Trial of Treatment Vaccine, CD4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?228:5">FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?228:6">Comment: Workable Clinical Trials [or, AIDS &quot;Confirmatory&quot; Trials: What's Wrong, and How to Move Forward Today]</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?228:7">FDA Reform: Activists' Proposals</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #227, July 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?227:1">Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?227:2">Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?227:3">Exon Amendment: Threat to AIDS Prevention and Activism?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?227:4">NAPWA Opens Pharmacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?227:5">AIDS Research &quot;Spin-off&quot; -- Ganciclovir CMV Prevention After Liver Transplantation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?227:6">Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #226, July 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?226:1">Combination Antiretroviral Treatment:  New Views, Evolving Practices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?226:2">Combination Treatment and Single Drugs:  Interview with Margaret Poscher, M. D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?226:3">Protease Inhibitor:  Roche Lottery Deadline July 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?226:4">Wasting Syndrome -- Affordable Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?226:5">Animal Cell Transplantation:  FDA Meeting July 13 and 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?226:6">NAC Users:  You Can Help NAC Research</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+225"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-81</DOCNO>
<DOCOLDNO>IA017-000178-B002-145</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+229 192.33.214.13 19970106041737 text/html 7226
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:17:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+234"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #229, August 18, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?229:1">&quot;Confirmatory&quot; Trials: Symptom Reduction As Efficacy Measure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?229:2">FDA Warning on Raw Oysters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?229:3">ICAAC Conference, September 17-20, in San Francisco</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?229:4">Merck Protease Inhibitor Note: Expanded Access Program Registrants Should Receive, and Return, Mailed Confirmation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?229:5">Alternative Medicine and HIV/AIDS: Request for Applications</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?229:6">San Francisco: AIDS TREATMENT NEWS Needs Office Space</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?229:7">House Moves to Block Internet Censorship</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?229:8">Is NIH AIDS Research in Danger?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #228, August 4, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?228:1">New Antiretroviral Strategies: Interview with Marcus Conant, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?228:2">3TC: Now Available Again Up To CD4 of 300</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?228:3">California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?228:4">Boston: Important Trial of Treatment Vaccine, CD4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?228:5">FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?228:6">Comment: Workable Clinical Trials [or, AIDS &quot;Confirmatory&quot; Trials: What's Wrong, and How to Move Forward Today]</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?228:7">FDA Reform: Activists' Proposals</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #227, July 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?227:1">Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?227:2">Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?227:3">Exon Amendment: Threat to AIDS Prevention and Activism?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?227:4">NAPWA Opens Pharmacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?227:5">AIDS Research &quot;Spin-off&quot; -- Ganciclovir CMV Prevention After Liver Transplantation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?227:6">Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #226, July 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?226:1">Combination Antiretroviral Treatment:  New Views, Evolving Practices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?226:2">Combination Treatment and Single Drugs:  Interview with Margaret Poscher, M. D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?226:3">Protease Inhibitor:  Roche Lottery Deadline July 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?226:4">Wasting Syndrome -- Affordable Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?226:5">Animal Cell Transplantation:  FDA Meeting July 13 and 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?226:6">NAC Users:  You Can Help NAC Research</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #225, June 16, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?225:1">Viral Load Predicts AIDS Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?225:2">Viral Load Reimbursement Information from Chiron Reimbursement Service</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?225:3">Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?225:4">PI PERSPECTIVE May 1995 Now Available from Project Inform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?225:5">HIV Pathogenesis: Teleconference June 29 in Twelve Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?225:6">Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?225:7">Internet: Pain Management Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?225:8">New York: AIDS Research Teach-In, June 24</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?225:9">San Francisco: Medical Marijuana on Viacom Cable, June 20</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?225:10">San Francisco: Sinusitis Study of Traditional Chinese Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?225:11">California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?225:12">Federal Employees: Insurance Open Season</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?225:13">AIDSWatch '95 on Capitol Hill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="ATN.cgi?225:14">World Bank in AIDS Prevention Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD><A HREF="ATN.cgi?225:15">&quot;UN50&quot; Demonstration June 25 in San Francisco</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+224"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-82</DOCNO>
<DOCOLDNO>IA017-000178-B002-156</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+228 192.33.214.13 19970106041758 text/html 6747
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:18:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+233"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #228, August 4, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?228:1">New Antiretroviral Strategies: Interview with Marcus Conant, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?228:2">3TC: Now Available Again Up To CD4 of 300</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?228:3">California: Medi-Cal Can Pay for Human Growth Hormone for Some Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?228:4">Boston: Important Trial of Treatment Vaccine, CD4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?228:5">FDA Workshop on Clinical Trial Design, September 6-7 -- Registration by Aug. 18</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?228:6">Comment: Workable Clinical Trials [or, AIDS &quot;Confirmatory&quot; Trials: What's Wrong, and How to Move Forward Today]</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?228:7">FDA Reform: Activists' Proposals</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #227, July 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?227:1">Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?227:2">Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?227:3">Exon Amendment: Threat to AIDS Prevention and Activism?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?227:4">NAPWA Opens Pharmacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?227:5">AIDS Research &quot;Spin-off&quot; -- Ganciclovir CMV Prevention After Liver Transplantation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?227:6">Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #226, July 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?226:1">Combination Antiretroviral Treatment:  New Views, Evolving Practices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?226:2">Combination Treatment and Single Drugs:  Interview with Margaret Poscher, M. D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?226:3">Protease Inhibitor:  Roche Lottery Deadline July 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?226:4">Wasting Syndrome -- Affordable Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?226:5">Animal Cell Transplantation:  FDA Meeting July 13 and 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?226:6">NAC Users:  You Can Help NAC Research</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #225, June 16, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?225:1">Viral Load Predicts AIDS Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?225:2">Viral Load Reimbursement Information from Chiron Reimbursement Service</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?225:3">Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?225:4">PI PERSPECTIVE May 1995 Now Available from Project Inform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?225:5">HIV Pathogenesis: Teleconference June 29 in Twelve Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?225:6">Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?225:7">Internet: Pain Management Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?225:8">New York: AIDS Research Teach-In, June 24</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?225:9">San Francisco: Medical Marijuana on Viacom Cable, June 20</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?225:10">San Francisco: Sinusitis Study of Traditional Chinese Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?225:11">California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?225:12">Federal Employees: Insurance Open Season</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?225:13">AIDSWatch '95 on Capitol Hill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="ATN.cgi?225:14">World Bank in AIDS Prevention Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD><A HREF="ATN.cgi?225:15">&quot;UN50&quot; Demonstration June 25 in San Francisco</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #224, June 2, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?224:1">Diarrhea, and the Experimental Treatment Saccharomyces boulardii</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?224:2">When Treatments Go Untried</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?224:3">Gallo Starts Major AIDS Research Institute in Baltimore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?224:4">Lymphoma: New TAG Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?224:5">Chinese Medicine: Where Does It Work Best in HIV/AIDS?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+223"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-83</DOCNO>
<DOCOLDNO>IA017-000178-B002-165</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+227 192.33.214.13 19970106041809 text/html 6323
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:18:30 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+232"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #227, July 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?227:1">Merck Protease Inhibitor Available to Persons with CD4 Count 50 or Less -- Must Register by August 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?227:2">Combination Treatment and Single Drugs: Interview with Margaret Poscher, M.D. (Part II of II)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?227:3">Exon Amendment: Threat to AIDS Prevention and Activism?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?227:4">NAPWA Opens Pharmacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?227:5">AIDS Research &quot;Spin-off&quot; -- Ganciclovir CMV Prevention After Liver Transplantation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?227:6">Cryptosporidium in Water: CDC Guidelines on How to Protect Yourself</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #226, July 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?226:1">Combination Antiretroviral Treatment:  New Views, Evolving Practices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?226:2">Combination Treatment and Single Drugs:  Interview with Margaret Poscher, M. D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?226:3">Protease Inhibitor:  Roche Lottery Deadline July 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?226:4">Wasting Syndrome -- Affordable Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?226:5">Animal Cell Transplantation:  FDA Meeting July 13 and 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?226:6">NAC Users:  You Can Help NAC Research</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #225, June 16, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?225:1">Viral Load Predicts AIDS Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?225:2">Viral Load Reimbursement Information from Chiron Reimbursement Service</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?225:3">Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?225:4">PI PERSPECTIVE May 1995 Now Available from Project Inform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?225:5">HIV Pathogenesis: Teleconference June 29 in Twelve Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?225:6">Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?225:7">Internet: Pain Management Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?225:8">New York: AIDS Research Teach-In, June 24</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?225:9">San Francisco: Medical Marijuana on Viacom Cable, June 20</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?225:10">San Francisco: Sinusitis Study of Traditional Chinese Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?225:11">California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?225:12">Federal Employees: Insurance Open Season</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?225:13">AIDSWatch '95 on Capitol Hill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="ATN.cgi?225:14">World Bank in AIDS Prevention Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD><A HREF="ATN.cgi?225:15">&quot;UN50&quot; Demonstration June 25 in San Francisco</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #224, June 2, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?224:1">Diarrhea, and the Experimental Treatment Saccharomyces boulardii</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?224:2">When Treatments Go Untried</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?224:3">Gallo Starts Major AIDS Research Institute in Baltimore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?224:4">Lymphoma: New TAG Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?224:5">Chinese Medicine: Where Does It Work Best in HIV/AIDS?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #223, May 19, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?223:1">New Trial Proposed for When Drugs Fail</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?223:2">Antiviral Conference Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?223:3">Abbott: Major Protest over Lack of Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?223:4">Religious Coalition Opposes Gene Patents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?223:5">California: New Drugs Added to AIDS Drug Assistance Program</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+222"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-84</DOCNO>
<DOCOLDNO>IA017-000178-B002-175</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+226 192.33.214.13 19970106041817 text/html 6193
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:18:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+231"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #226, July 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?226:1">Combination Antiretroviral Treatment:  New Views, Evolving Practices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?226:2">Combination Treatment and Single Drugs:  Interview with Margaret Poscher, M. D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?226:3">Protease Inhibitor:  Roche Lottery Deadline July 21</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?226:4">Wasting Syndrome -- Affordable Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?226:5">Animal Cell Transplantation:  FDA Meeting July 13 and 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?226:6">NAC Users:  You Can Help NAC Research</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #225, June 16, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?225:1">Viral Load Predicts AIDS Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?225:2">Viral Load Reimbursement Information from Chiron Reimbursement Service</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?225:3">Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?225:4">PI PERSPECTIVE May 1995 Now Available from Project Inform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?225:5">HIV Pathogenesis: Teleconference June 29 in Twelve Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?225:6">Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?225:7">Internet: Pain Management Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?225:8">New York: AIDS Research Teach-In, June 24</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?225:9">San Francisco: Medical Marijuana on Viacom Cable, June 20</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?225:10">San Francisco: Sinusitis Study of Traditional Chinese Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?225:11">California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?225:12">Federal Employees: Insurance Open Season</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?225:13">AIDSWatch '95 on Capitol Hill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="ATN.cgi?225:14">World Bank in AIDS Prevention Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD><A HREF="ATN.cgi?225:15">&quot;UN50&quot; Demonstration June 25 in San Francisco</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #224, June 2, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?224:1">Diarrhea, and the Experimental Treatment Saccharomyces boulardii</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?224:2">When Treatments Go Untried</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?224:3">Gallo Starts Major AIDS Research Institute in Baltimore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?224:4">Lymphoma: New TAG Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?224:5">Chinese Medicine: Where Does It Work Best in HIV/AIDS?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #223, May 19, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?223:1">New Trial Proposed for When Drugs Fail</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?223:2">Antiviral Conference Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?223:3">Abbott: Major Protest over Lack of Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?223:4">Religious Coalition Opposes Gene Patents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?223:5">California: New Drugs Added to AIDS Drug Assistance Program</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #222, May 5, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?222:1">D4T: New Clinical Data Confirms Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?222:2">Stanford Researchers Find Loss of &quot;Naive&quot; T-Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?222:3">ICC Trials: New Option on Laboratory Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?222:4">3TC Expanded Access Program: New Requirement for CD4 Less Than 100</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?222:5">Agouron Protease Inhibitor AG1343: Activity Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?222:6">AIDS Research Meetings, May 1995 and Later</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+221"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-85</DOCNO>
<DOCOLDNO>IA017-000178-B002-185</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+225 192.33.214.13 19970106041826 text/html 6452
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:18:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+230"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #225, June 16, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?225:1">Viral Load Predicts AIDS Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?225:2">Viral Load Reimbursement Information from Chiron Reimbursement Service</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?225:3">Bioelectrical Impedance Analysis (BIA) May Predict AIDS Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?225:4">PI PERSPECTIVE May 1995 Now Available from Project Inform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?225:5">HIV Pathogenesis: Teleconference June 29 in Twelve Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?225:6">Merck Protease Inhibitor Trial Seeks Persons with CD4 Count Under 50</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?225:7">Internet: Pain Management Information on World Wide Web</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?225:8">New York: AIDS Research Teach-In, June 24</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?225:9">San Francisco: Medical Marijuana on Viacom Cable, June 20</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?225:10">San Francisco: Sinusitis Study of Traditional Chinese Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?225:11">California Residents: Medi-Cal May Pay Your Private Health Insurance Premiums</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="ATN.cgi?225:12">Federal Employees: Insurance Open Season</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>13.</TD>
 <TD><A HREF="ATN.cgi?225:13">AIDSWatch '95 on Capitol Hill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>14.</TD>
 <TD><A HREF="ATN.cgi?225:14">World Bank in AIDS Prevention Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>15.</TD>
 <TD><A HREF="ATN.cgi?225:15">&quot;UN50&quot; Demonstration June 25 in San Francisco</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #224, June 2, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?224:1">Diarrhea, and the Experimental Treatment Saccharomyces boulardii</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?224:2">When Treatments Go Untried</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?224:3">Gallo Starts Major AIDS Research Institute in Baltimore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?224:4">Lymphoma: New TAG Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?224:5">Chinese Medicine: Where Does It Work Best in HIV/AIDS?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #223, May 19, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?223:1">New Trial Proposed for When Drugs Fail</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?223:2">Antiviral Conference Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?223:3">Abbott: Major Protest over Lack of Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?223:4">Religious Coalition Opposes Gene Patents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?223:5">California: New Drugs Added to AIDS Drug Assistance Program</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #222, May 5, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?222:1">D4T: New Clinical Data Confirms Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?222:2">Stanford Researchers Find Loss of &quot;Naive&quot; T-Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?222:3">ICC Trials: New Option on Laboratory Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?222:4">3TC Expanded Access Program: New Requirement for CD4 Less Than 100</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?222:5">Agouron Protease Inhibitor AG1343: Activity Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?222:6">AIDS Research Meetings, May 1995 and Later</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #221, April 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?221:1">Viral Load Success: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?221:2">Thalidomide and HIV: Several Possible Uses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?221:3">Proposal: Small Trials for Screening Antiviral Combinations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?221:4">Nerve Growth Factor: Major Trial Canceled, Revived After Protest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?221:5">Merck Protease Inhibitor: New International Contact Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?221:6">New York City: Anabolics, Wasting Symposium, May 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?221:7">International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?221:8">Congress: How to Help</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+220"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-86</DOCNO>
<DOCOLDNO>IA017-000178-B002-193</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+224 192.33.214.13 19970106041835 text/html 5558
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:18:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+229"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #224, June 2, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?224:1">Diarrhea, and the Experimental Treatment Saccharomyces boulardii</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?224:2">When Treatments Go Untried</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?224:3">Gallo Starts Major AIDS Research Institute in Baltimore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?224:4">Lymphoma: New TAG Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?224:5">Chinese Medicine: Where Does It Work Best in HIV/AIDS?</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #223, May 19, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?223:1">New Trial Proposed for When Drugs Fail</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?223:2">Antiviral Conference Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?223:3">Abbott: Major Protest over Lack of Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?223:4">Religious Coalition Opposes Gene Patents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?223:5">California: New Drugs Added to AIDS Drug Assistance Program</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #222, May 5, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?222:1">D4T: New Clinical Data Confirms Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?222:2">Stanford Researchers Find Loss of &quot;Naive&quot; T-Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?222:3">ICC Trials: New Option on Laboratory Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?222:4">3TC Expanded Access Program: New Requirement for CD4 Less Than 100</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?222:5">Agouron Protease Inhibitor AG1343: Activity Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?222:6">AIDS Research Meetings, May 1995 and Later</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #221, April 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?221:1">Viral Load Success: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?221:2">Thalidomide and HIV: Several Possible Uses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?221:3">Proposal: Small Trials for Screening Antiviral Combinations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?221:4">Nerve Growth Factor: Major Trial Canceled, Revived After Protest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?221:5">Merck Protease Inhibitor: New International Contact Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?221:6">New York City: Anabolics, Wasting Symposium, May 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?221:7">International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?221:8">Congress: How to Help</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #220, April 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?220:1">Merck Protease Inhibitor MK-639 -- Trial Cities Announced</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?220:2">ICC Trials -- Enrollment Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?220:3">3TC: Expanded Access Will Be Limited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?220:4">Infected Infant Appears to Clear HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?220:5">National AIDS Treatment Information Project</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?220:6">Topotecan Now Available for HIV, PML Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?220:7">FDA Reform in Congress: AIDS Community Absent</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?220:8">3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?220:9">Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+219"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-87</DOCNO>
<DOCOLDNO>IA017-000178-B002-202</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+223 192.33.214.13 19970106041845 text/html 5529
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:19:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+228"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #223, May 19, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?223:1">New Trial Proposed for When Drugs Fail</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?223:2">Antiviral Conference Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?223:3">Abbott: Major Protest over Lack of Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?223:4">Religious Coalition Opposes Gene Patents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?223:5">California: New Drugs Added to AIDS Drug Assistance Program</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #222, May 5, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?222:1">D4T: New Clinical Data Confirms Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?222:2">Stanford Researchers Find Loss of &quot;Naive&quot; T-Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?222:3">ICC Trials: New Option on Laboratory Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?222:4">3TC Expanded Access Program: New Requirement for CD4 Less Than 100</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?222:5">Agouron Protease Inhibitor AG1343: Activity Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?222:6">AIDS Research Meetings, May 1995 and Later</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #221, April 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?221:1">Viral Load Success: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?221:2">Thalidomide and HIV: Several Possible Uses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?221:3">Proposal: Small Trials for Screening Antiviral Combinations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?221:4">Nerve Growth Factor: Major Trial Canceled, Revived After Protest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?221:5">Merck Protease Inhibitor: New International Contact Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?221:6">New York City: Anabolics, Wasting Symposium, May 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?221:7">International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?221:8">Congress: How to Help</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #220, April 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?220:1">Merck Protease Inhibitor MK-639 -- Trial Cities Announced</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?220:2">ICC Trials -- Enrollment Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?220:3">3TC: Expanded Access Will Be Limited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?220:4">Infected Infant Appears to Clear HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?220:5">National AIDS Treatment Information Project</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?220:6">Topotecan Now Available for HIV, PML Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?220:7">FDA Reform in Congress: AIDS Community Absent</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?220:8">3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?220:9">Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #219, March 24, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?219:1">Protease Inhibitors and Beyond: Interview with David Feigal, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?219:2">Protease Inhibitors: Merck Plans Larger Trials, Expanded Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?219:3">Protease Inhibitor Consensus Statement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?219:4">Mothers March</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?219:5">ICC Trials --</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+218"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-88</DOCNO>
<DOCOLDNO>IA017-000178-B002-211</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+222 192.33.214.13 19970106041854 text/html 5760
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:19:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+227"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #222, May 5, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?222:1">D4T: New Clinical Data Confirms Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?222:2">Stanford Researchers Find Loss of &quot;Naive&quot; T-Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?222:3">ICC Trials: New Option on Laboratory Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?222:4">3TC Expanded Access Program: New Requirement for CD4 Less Than 100</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?222:5">Agouron Protease Inhibitor AG1343: Activity Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?222:6">AIDS Research Meetings, May 1995 and Later</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #221, April 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?221:1">Viral Load Success: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?221:2">Thalidomide and HIV: Several Possible Uses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?221:3">Proposal: Small Trials for Screening Antiviral Combinations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?221:4">Nerve Growth Factor: Major Trial Canceled, Revived After Protest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?221:5">Merck Protease Inhibitor: New International Contact Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?221:6">New York City: Anabolics, Wasting Symposium, May 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?221:7">International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?221:8">Congress: How to Help</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #220, April 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?220:1">Merck Protease Inhibitor MK-639 -- Trial Cities Announced</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?220:2">ICC Trials -- Enrollment Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?220:3">3TC: Expanded Access Will Be Limited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?220:4">Infected Infant Appears to Clear HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?220:5">National AIDS Treatment Information Project</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?220:6">Topotecan Now Available for HIV, PML Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?220:7">FDA Reform in Congress: AIDS Community Absent</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?220:8">3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?220:9">Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #219, March 24, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?219:1">Protease Inhibitors and Beyond: Interview with David Feigal, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?219:2">Protease Inhibitors: Merck Plans Larger Trials, Expanded Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?219:3">Protease Inhibitor Consensus Statement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?219:4">Mothers March</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?219:5">ICC Trials --</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #218, March 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?218:1">IL-2: U.S. National Institutes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?218:2">Immune Restoration -- Conference Outlines Future Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?218:3">Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?218:4">Sulfasalazine: Arthritis Drug Increases CD4 Count?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?218:5">Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?218:6">Research Meetings, March 1995</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+217"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-89</DOCNO>
<DOCOLDNO>IA017-000178-B002-220</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+221 192.33.214.13 19970106041905 text/html 5635
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:19:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+226"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #221, April 21, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?221:1">Viral Load Success: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?221:2">Thalidomide and HIV: Several Possible Uses</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?221:3">Proposal: Small Trials for Screening Antiviral Combinations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?221:4">Nerve Growth Factor: Major Trial Canceled, Revived After Protest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?221:5">Merck Protease Inhibitor: New International Contact Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?221:6">New York City: Anabolics, Wasting Symposium, May 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?221:7">International AIDS Candlelight Memorial, Sunday May 21, in 250 Cities in 47 Nations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?221:8">Congress: How to Help</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #220, April 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?220:1">Merck Protease Inhibitor MK-639 -- Trial Cities Announced</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?220:2">ICC Trials -- Enrollment Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?220:3">3TC: Expanded Access Will Be Limited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?220:4">Infected Infant Appears to Clear HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?220:5">National AIDS Treatment Information Project</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?220:6">Topotecan Now Available for HIV, PML Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?220:7">FDA Reform in Congress: AIDS Community Absent</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?220:8">3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?220:9">Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #219, March 24, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?219:1">Protease Inhibitors and Beyond: Interview with David Feigal, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?219:2">Protease Inhibitors: Merck Plans Larger Trials, Expanded Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?219:3">Protease Inhibitor Consensus Statement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?219:4">Mothers March</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?219:5">ICC Trials --</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #218, March 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?218:1">IL-2: U.S. National Institutes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?218:2">Immune Restoration -- Conference Outlines Future Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?218:3">Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?218:4">Sulfasalazine: Arthritis Drug Increases CD4 Count?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?218:5">Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?218:6">Research Meetings, March 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #217, February 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?217:1">Basic Science and Clinical Trials: Interview with</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?217:2">AIDS Clinical Trials: Why They Have Recruiting Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?217:3">Valacyclovir Study Stopped -- Worse Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?217:4">AZT: Pediatric Study Changed After Worse Monotherapy Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?217:5">Kaposi's Sarcoma: DOX-SL Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+216"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-90</DOCNO>
<DOCOLDNO>IA017-000178-B002-234</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+220 192.33.214.13 19970106041917 text/html 5433
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:19:37 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+225"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #220, April 7, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?220:1">Merck Protease Inhibitor MK-639 -- Trial Cities Announced</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?220:2">ICC Trials -- Enrollment Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?220:3">3TC: Expanded Access Will Be Limited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?220:4">Infected Infant Appears to Clear HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?220:5">National AIDS Treatment Information Project</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?220:6">Topotecan Now Available for HIV, PML Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?220:7">FDA Reform in Congress: AIDS Community Absent</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?220:8">3TC and Protease Inhibitors: Citizen's Petition Asks Faster Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?220:9">Proposal: Monitoring Program for Early Rapid Testing of New AIDS Treatments</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #219, March 24, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?219:1">Protease Inhibitors and Beyond: Interview with David Feigal, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?219:2">Protease Inhibitors: Merck Plans Larger Trials, Expanded Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?219:3">Protease Inhibitor Consensus Statement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?219:4">Mothers March</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?219:5">ICC Trials --</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #218, March 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?218:1">IL-2: U.S. National Institutes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?218:2">Immune Restoration -- Conference Outlines Future Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?218:3">Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?218:4">Sulfasalazine: Arthritis Drug Increases CD4 Count?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?218:5">Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?218:6">Research Meetings, March 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #217, February 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?217:1">Basic Science and Clinical Trials: Interview with</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?217:2">AIDS Clinical Trials: Why They Have Recruiting Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?217:3">Valacyclovir Study Stopped -- Worse Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?217:4">AZT: Pediatric Study Changed After Worse Monotherapy Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?217:5">Kaposi's Sarcoma: DOX-SL Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #216, February 12, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?216:1">Patent Office Expedites AIDS, Cancer Inventions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?216:2">AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?216:3">Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?216:4">San Francisco Area: Computerized Search for Local Clinical Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?216:5">San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?216:6">Action Alert: Balanced Budget Amendment</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+215"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-91</DOCNO>
<DOCOLDNO>IA017-000178-B002-243</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+219 192.33.214.13 19970106041929 text/html 5373
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:19:52 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+224"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #219, March 24, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?219:1">Protease Inhibitors and Beyond: Interview with David Feigal, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?219:2">Protease Inhibitors: Merck Plans Larger Trials, Expanded Access</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?219:3">Protease Inhibitor Consensus Statement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?219:4">Mothers March</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?219:5">ICC Trials --</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #218, March 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?218:1">IL-2: U.S. National Institutes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?218:2">Immune Restoration -- Conference Outlines Future Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?218:3">Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?218:4">Sulfasalazine: Arthritis Drug Increases CD4 Count?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?218:5">Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?218:6">Research Meetings, March 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #217, February 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?217:1">Basic Science and Clinical Trials: Interview with</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?217:2">AIDS Clinical Trials: Why They Have Recruiting Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?217:3">Valacyclovir Study Stopped -- Worse Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?217:4">AZT: Pediatric Study Changed After Worse Monotherapy Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?217:5">Kaposi's Sarcoma: DOX-SL Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #216, February 12, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?216:1">Patent Office Expedites AIDS, Cancer Inventions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?216:2">AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?216:3">Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?216:4">San Francisco Area: Computerized Search for Local Clinical Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?216:5">San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?216:6">Action Alert: Balanced Budget Amendment</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #215, January 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?215:1">New Information on HIV Rapid Turnover - What Does It Mean?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?215:2">Kaposi's Sarcoma: Possible Foscarnet Treatment?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?215:3">1995 Outlook: Research Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?215:4">Protease Inhibitor Task Force: Opportunity for Participation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?215:5">KS, DOX-SL: FDA Hearing February 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?215:6">FDA Advisory Committees: Hotline for Upcoming Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?215:7">International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Women, March 4 and 5</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?215:8">Notice: Next Issue Delayed One Week</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+214"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-92</DOCNO>
<DOCOLDNO>IA017-000178-B002-251</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+218 192.33.214.13 19970106041937 text/html 5637
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+223"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #218, March 3, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?218:1">IL-2: U.S. National Institutes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?218:2">Immune Restoration -- Conference Outlines Future Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?218:3">Proving Clinical Benefit in Small, Rapid Trials: Statement to National Task Force on AIDS Drug Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?218:4">Sulfasalazine: Arthritis Drug Increases CD4 Count?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?218:5">Viatical Settlement Tax Reform: Republicans Support Relief, Democrats Divided</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?218:6">Research Meetings, March 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #217, February 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?217:1">Basic Science and Clinical Trials: Interview with</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?217:2">AIDS Clinical Trials: Why They Have Recruiting Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?217:3">Valacyclovir Study Stopped -- Worse Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?217:4">AZT: Pediatric Study Changed After Worse Monotherapy Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?217:5">Kaposi's Sarcoma: DOX-SL Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #216, February 12, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?216:1">Patent Office Expedites AIDS, Cancer Inventions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?216:2">AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?216:3">Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?216:4">San Francisco Area: Computerized Search for Local Clinical Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?216:5">San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?216:6">Action Alert: Balanced Budget Amendment</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #215, January 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?215:1">New Information on HIV Rapid Turnover - What Does It Mean?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?215:2">Kaposi's Sarcoma: Possible Foscarnet Treatment?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?215:3">1995 Outlook: Research Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?215:4">Protease Inhibitor Task Force: Opportunity for Participation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?215:5">KS, DOX-SL: FDA Hearing February 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?215:6">FDA Advisory Committees: Hotline for Upcoming Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?215:7">International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Women, March 4 and 5</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?215:8">Notice: Next Issue Delayed One Week</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #214, January 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?214:1">Oral Ganciclovir Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?214:2">FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?214:3">Women and AIDS -- Unexplained Higher Risk of Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?214:4">Some Vitamins Associated with Decreased Risk of AIDS and Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?214:5">1995: Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?214:6">1995: Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?214:7">AIDS-Related Research Meetings, January and February 1995</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+213"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-93</DOCNO>
<DOCOLDNO>IA017-000178-B002-259</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+217 192.33.214.13 19970106041949 text/html 5961
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:11 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+222"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #217, February 17, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?217:1">Basic Science and Clinical Trials: Interview with</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?217:2">AIDS Clinical Trials: Why They Have Recruiting Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?217:3">Valacyclovir Study Stopped -- Worse Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?217:4">AZT: Pediatric Study Changed After Worse Monotherapy Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?217:5">Kaposi's Sarcoma: DOX-SL Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #216, February 12, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?216:1">Patent Office Expedites AIDS, Cancer Inventions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?216:2">AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?216:3">Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?216:4">San Francisco Area: Computerized Search for Local Clinical Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?216:5">San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?216:6">Action Alert: Balanced Budget Amendment</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #215, January 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?215:1">New Information on HIV Rapid Turnover - What Does It Mean?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?215:2">Kaposi's Sarcoma: Possible Foscarnet Treatment?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?215:3">1995 Outlook: Research Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?215:4">Protease Inhibitor Task Force: Opportunity for Participation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?215:5">KS, DOX-SL: FDA Hearing February 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?215:6">FDA Advisory Committees: Hotline for Upcoming Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?215:7">International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Women, March 4 and 5</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?215:8">Notice: Next Issue Delayed One Week</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #214, January 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?214:1">Oral Ganciclovir Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?214:2">FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?214:3">Women and AIDS -- Unexplained Higher Risk of Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?214:4">Some Vitamins Associated with Decreased Risk of AIDS and Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?214:5">1995: Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?214:6">1995: Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?214:7">AIDS-Related Research Meetings, January and February 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #213, December 23, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?213:1">Kaposi's Sarcoma (KS): Possible Virus Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?213:2">Kaposi's Sarcoma: DOX-SL Available to Some Patients through New Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?213:3">Wasting Syndrome: Human Growth Hormone Becoming Available-- Treatment IND</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?213:4">ACT UP Fights for Breast Cancer Drug; Funeral Procession Vs. Genentech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?213:5">&quot;AIDS Coffee Klatch&quot; Grassroots Political Organizing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?213:6">The New Congress: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?213:7">Activist Groups, Buyers' Clubs, and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?213:8">AIDS TREATMENT NEWS Selected Index Through December 23, 1994, Issue #213</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+212"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-94</DOCNO>
<DOCOLDNO>IA017-000178-B002-272</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+216 192.33.214.13 19970106042009 text/html 5963
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+221"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #216, February 12, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?216:1">Patent Office Expedites AIDS, Cancer Inventions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?216:2">AIDS, Cancer Patent Priority: Interview with Commissioner Bruce Lehman</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?216:3">Human Retroviruses and Related Infections -- Major U.S. Scientific AIDS Conference of 1995. Part I.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?216:4">San Francisco Area: Computerized Search for Local Clinical Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?216:5">San Francisco: Self-Empowerment in HIV Disease Symposium, Mar. 4</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?216:6">Action Alert: Balanced Budget Amendment</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #215, January 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?215:1">New Information on HIV Rapid Turnover - What Does It Mean?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?215:2">Kaposi's Sarcoma: Possible Foscarnet Treatment?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?215:3">1995 Outlook: Research Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?215:4">Protease Inhibitor Task Force: Opportunity for Participation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?215:5">KS, DOX-SL: FDA Hearing February 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?215:6">FDA Advisory Committees: Hotline for Upcoming Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?215:7">International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Women, March 4 and 5</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?215:8">Notice: Next Issue Delayed One Week</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #214, January 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?214:1">Oral Ganciclovir Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?214:2">FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?214:3">Women and AIDS -- Unexplained Higher Risk of Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?214:4">Some Vitamins Associated with Decreased Risk of AIDS and Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?214:5">1995: Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?214:6">1995: Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?214:7">AIDS-Related Research Meetings, January and February 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #213, December 23, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?213:1">Kaposi's Sarcoma (KS): Possible Virus Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?213:2">Kaposi's Sarcoma: DOX-SL Available to Some Patients through New Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?213:3">Wasting Syndrome: Human Growth Hormone Becoming Available-- Treatment IND</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?213:4">ACT UP Fights for Breast Cancer Drug; Funeral Procession Vs. Genentech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?213:5">&quot;AIDS Coffee Klatch&quot; Grassroots Political Organizing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?213:6">The New Congress: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?213:7">Activist Groups, Buyers' Clubs, and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?213:8">AIDS TREATMENT NEWS Selected Index Through December 23, 1994, Issue #213</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #212, December 12, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?212:1">3TC Plus AZT: Important Treatment Advance?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?212:2">Vpr -- A Viral Protein is Found to Activate HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?212:3">Untold History: Activism and Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?212:4">Computer Communication for AIDS Agencies -- HandsNet AIDS/HIV Forum</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?212:5">Threats to Ryan White, AIDS Funding: Call for Information</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+211"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-95</DOCNO>
<DOCOLDNO>IA017-000178-B002-284</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+215 192.33.214.13 19970106042017 text/html 5952
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+220"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #215, January 20, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?215:1">New Information on HIV Rapid Turnover - What Does It Mean?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?215:2">Kaposi's Sarcoma: Possible Foscarnet Treatment?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?215:3">1995 Outlook: Research Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?215:4">Protease Inhibitor Task Force: Opportunity for Participation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?215:5">KS, DOX-SL: FDA Hearing February 14</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?215:6">FDA Advisory Committees: Hotline for Upcoming Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?215:7">International Conference for People Living with HIV and AIDS, Cape Town, South Africa, March 6-10; Pre- Conference for Women, March 4 and 5</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?215:8">Notice: Next Issue Delayed One Week</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #214, January 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?214:1">Oral Ganciclovir Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?214:2">FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?214:3">Women and AIDS -- Unexplained Higher Risk of Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?214:4">Some Vitamins Associated with Decreased Risk of AIDS and Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?214:5">1995: Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?214:6">1995: Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?214:7">AIDS-Related Research Meetings, January and February 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #213, December 23, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?213:1">Kaposi's Sarcoma (KS): Possible Virus Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?213:2">Kaposi's Sarcoma: DOX-SL Available to Some Patients through New Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?213:3">Wasting Syndrome: Human Growth Hormone Becoming Available-- Treatment IND</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?213:4">ACT UP Fights for Breast Cancer Drug; Funeral Procession Vs. Genentech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?213:5">&quot;AIDS Coffee Klatch&quot; Grassroots Political Organizing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?213:6">The New Congress: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?213:7">Activist Groups, Buyers' Clubs, and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?213:8">AIDS TREATMENT NEWS Selected Index Through December 23, 1994, Issue #213</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #212, December 12, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?212:1">3TC Plus AZT: Important Treatment Advance?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?212:2">Vpr -- A Viral Protein is Found to Activate HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?212:3">Untold History: Activism and Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?212:4">Computer Communication for AIDS Agencies -- HandsNet AIDS/HIV Forum</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?212:5">Threats to Ryan White, AIDS Funding: Call for Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #211, November 18,1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?211:1">Strategy of Hope: Small, Rapid Viral-Load Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?211:2">Viral Load, Small Trials, and Immune Recovery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?211:3">Nevirapine Triple Combination: Preliminary Results Released Nov. 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?211:4">Hydroxyurea: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?211:5">The Elections: What AIDS Organizations Need to Do Now. Interview with Tom Sheridan, Sheridan Associates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?211:6">AIDS TREATMENT NEWS Talent Search: Board Members for Charitable, Internet Work</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+210"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-96</DOCNO>
<DOCOLDNO>IA017-000178-B002-292</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+214 192.33.214.13 19970106042026 text/html 6164
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+219"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #214, January 6, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?214:1">Oral Ganciclovir Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?214:2">FDA Advisory Committees Meet January 26 on Salk HIV-1 Immunogen</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?214:3">Women and AIDS -- Unexplained Higher Risk of Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?214:4">Some Vitamins Associated with Decreased Risk of AIDS and Death</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?214:5">1995: Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?214:6">1995: Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?214:7">AIDS-Related Research Meetings, January and February 1995</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #213, December 23, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?213:1">Kaposi's Sarcoma (KS): Possible Virus Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?213:2">Kaposi's Sarcoma: DOX-SL Available to Some Patients through New Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?213:3">Wasting Syndrome: Human Growth Hormone Becoming Available-- Treatment IND</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?213:4">ACT UP Fights for Breast Cancer Drug; Funeral Procession Vs. Genentech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?213:5">&quot;AIDS Coffee Klatch&quot; Grassroots Political Organizing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?213:6">The New Congress: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?213:7">Activist Groups, Buyers' Clubs, and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?213:8">AIDS TREATMENT NEWS Selected Index Through December 23, 1994, Issue #213</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #212, December 12, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?212:1">3TC Plus AZT: Important Treatment Advance?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?212:2">Vpr -- A Viral Protein is Found to Activate HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?212:3">Untold History: Activism and Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?212:4">Computer Communication for AIDS Agencies -- HandsNet AIDS/HIV Forum</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?212:5">Threats to Ryan White, AIDS Funding: Call for Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #211, November 18,1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?211:1">Strategy of Hope: Small, Rapid Viral-Load Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?211:2">Viral Load, Small Trials, and Immune Recovery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?211:3">Nevirapine Triple Combination: Preliminary Results Released Nov. 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?211:4">Hydroxyurea: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?211:5">The Elections: What AIDS Organizations Need to Do Now. Interview with Tom Sheridan, Sheridan Associates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?211:6">AIDS TREATMENT NEWS Talent Search: Board Members for Charitable, Internet Work</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #210, November 4, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?210:1">Searle Abandons Its Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?210:2">Protease Inhibitors -- Task Force Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?210:3">HIV RNA -- Time to Wake Up and Save Lives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?210:4">New AIDS Treatment Information Service, 800/HIV-0440</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?210:5">Human Growth Hormone -- Canadian Number Disconnected for U.S. Calls</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?210:6">AIDS Patents Now Available Free through Internet</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?210:7">Drugs for Infants and Children: Call for Reform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?210:8">California: AIDS Drug Assistance Program, New Drugs Proposed; Title II Public Input Sought</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?210:9">Title II National Organization Formed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?210:10">Global AIDS Summit, Paris, December 1</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+209"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-97</DOCNO>
<DOCOLDNO>IA017-000178-B002-305</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+213 192.33.214.13 19970106042034 text/html 6118
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:20:56 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+218"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #213, December 23, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?213:1">Kaposi's Sarcoma (KS): Possible Virus Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?213:2">Kaposi's Sarcoma: DOX-SL Available to Some Patients through New Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?213:3">Wasting Syndrome: Human Growth Hormone Becoming Available-- Treatment IND</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?213:4">ACT UP Fights for Breast Cancer Drug; Funeral Procession Vs. Genentech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?213:5">&quot;AIDS Coffee Klatch&quot; Grassroots Political Organizing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?213:6">The New Congress: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?213:7">Activist Groups, Buyers' Clubs, and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?213:8">AIDS TREATMENT NEWS Selected Index Through December 23, 1994, Issue #213</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #212, December 12, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?212:1">3TC Plus AZT: Important Treatment Advance?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?212:2">Vpr -- A Viral Protein is Found to Activate HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?212:3">Untold History: Activism and Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?212:4">Computer Communication for AIDS Agencies -- HandsNet AIDS/HIV Forum</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?212:5">Threats to Ryan White, AIDS Funding: Call for Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #211, November 18,1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?211:1">Strategy of Hope: Small, Rapid Viral-Load Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?211:2">Viral Load, Small Trials, and Immune Recovery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?211:3">Nevirapine Triple Combination: Preliminary Results Released Nov. 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?211:4">Hydroxyurea: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?211:5">The Elections: What AIDS Organizations Need to Do Now. Interview with Tom Sheridan, Sheridan Associates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?211:6">AIDS TREATMENT NEWS Talent Search: Board Members for Charitable, Internet Work</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #210, November 4, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?210:1">Searle Abandons Its Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?210:2">Protease Inhibitors -- Task Force Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?210:3">HIV RNA -- Time to Wake Up and Save Lives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?210:4">New AIDS Treatment Information Service, 800/HIV-0440</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?210:5">Human Growth Hormone -- Canadian Number Disconnected for U.S. Calls</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?210:6">AIDS Patents Now Available Free through Internet</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?210:7">Drugs for Infants and Children: Call for Reform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?210:8">California: AIDS Drug Assistance Program, New Drugs Proposed; Title II Public Input Sought</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?210:9">Title II National Organization Formed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?210:10">Global AIDS Summit, Paris, December 1</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #209, October 21, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?209:1">&quot;Surrogate Markers&quot;: Current Status, Future Directions (Part I)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?209:2">Maternal Transmission and Viral Load</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?209:3">Human Growth Hormone Available through Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?209:4">Protease Inhibitor: Stanford High-Dose Trial Still Enrolling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?209:5">Passive Hyperimmune Therapy: Apparent Patient Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?209:6">Alternative Treatment Research Center Receives NIH Grant</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+208"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-98</DOCNO>
<DOCOLDNO>IA017-000178-B002-315</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+212 192.33.214.13 19970106042046 text/html 6032
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+217"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #212, December 12, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?212:1">3TC Plus AZT: Important Treatment Advance?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?212:2">Vpr -- A Viral Protein is Found to Activate HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?212:3">Untold History: Activism and Growth Hormone</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?212:4">Computer Communication for AIDS Agencies -- HandsNet AIDS/HIV Forum</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?212:5">Threats to Ryan White, AIDS Funding: Call for Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #211, November 18,1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?211:1">Strategy of Hope: Small, Rapid Viral-Load Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?211:2">Viral Load, Small Trials, and Immune Recovery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?211:3">Nevirapine Triple Combination: Preliminary Results Released Nov. 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?211:4">Hydroxyurea: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?211:5">The Elections: What AIDS Organizations Need to Do Now. Interview with Tom Sheridan, Sheridan Associates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?211:6">AIDS TREATMENT NEWS Talent Search: Board Members for Charitable, Internet Work</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #210, November 4, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?210:1">Searle Abandons Its Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?210:2">Protease Inhibitors -- Task Force Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?210:3">HIV RNA -- Time to Wake Up and Save Lives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?210:4">New AIDS Treatment Information Service, 800/HIV-0440</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?210:5">Human Growth Hormone -- Canadian Number Disconnected for U.S. Calls</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?210:6">AIDS Patents Now Available Free through Internet</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?210:7">Drugs for Infants and Children: Call for Reform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?210:8">California: AIDS Drug Assistance Program, New Drugs Proposed; Title II Public Input Sought</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?210:9">Title II National Organization Formed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?210:10">Global AIDS Summit, Paris, December 1</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #209, October 21, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?209:1">&quot;Surrogate Markers&quot;: Current Status, Future Directions (Part I)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?209:2">Maternal Transmission and Viral Load</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?209:3">Human Growth Hormone Available through Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?209:4">Protease Inhibitor: Stanford High-Dose Trial Still Enrolling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?209:5">Passive Hyperimmune Therapy: Apparent Patient Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?209:6">Alternative Treatment Research Center Receives NIH Grant</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #208, October 7, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?208:1">AIDS Drug Interactions Guide Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?208:2">Patents and Biotechnology: Federal Hearings October 17 in San Diego, Comments Invited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?208:3">AIDS and Nutrition: Clarification, Additional Resources</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?208:4">KS: DOX-SL Submitted for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?208:5">Yokohama Conference: Behind U.S. Media Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?208:6">FDA Proposes Financial Disclosure for Clinical Researchers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?208:7">Grassroots Organizing: Communication Groups</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?208:8">California (and Beyond): Proposition 187 and Public Health</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+207"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-99</DOCNO>
<DOCOLDNO>IA017-000178-B002-321</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+211 192.33.214.13 19970106042054 text/html 5785
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+216"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #211, November 18,1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?211:1">Strategy of Hope: Small, Rapid Viral-Load Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?211:2">Viral Load, Small Trials, and Immune Recovery</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?211:3">Nevirapine Triple Combination: Preliminary Results Released Nov. 17</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?211:4">Hydroxyurea: Call for Information</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?211:5">The Elections: What AIDS Organizations Need to Do Now. Interview with Tom Sheridan, Sheridan Associates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?211:6">AIDS TREATMENT NEWS Talent Search: Board Members for Charitable, Internet Work</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #210, November 4, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?210:1">Searle Abandons Its Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?210:2">Protease Inhibitors -- Task Force Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?210:3">HIV RNA -- Time to Wake Up and Save Lives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?210:4">New AIDS Treatment Information Service, 800/HIV-0440</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?210:5">Human Growth Hormone -- Canadian Number Disconnected for U.S. Calls</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?210:6">AIDS Patents Now Available Free through Internet</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?210:7">Drugs for Infants and Children: Call for Reform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?210:8">California: AIDS Drug Assistance Program, New Drugs Proposed; Title II Public Input Sought</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?210:9">Title II National Organization Formed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?210:10">Global AIDS Summit, Paris, December 1</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #209, October 21, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?209:1">&quot;Surrogate Markers&quot;: Current Status, Future Directions (Part I)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?209:2">Maternal Transmission and Viral Load</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?209:3">Human Growth Hormone Available through Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?209:4">Protease Inhibitor: Stanford High-Dose Trial Still Enrolling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?209:5">Passive Hyperimmune Therapy: Apparent Patient Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?209:6">Alternative Treatment Research Center Receives NIH Grant</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #208, October 7, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?208:1">AIDS Drug Interactions Guide Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?208:2">Patents and Biotechnology: Federal Hearings October 17 in San Diego, Comments Invited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?208:3">AIDS and Nutrition: Clarification, Additional Resources</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?208:4">KS: DOX-SL Submitted for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?208:5">Yokohama Conference: Behind U.S. Media Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?208:6">FDA Proposes Financial Disclosure for Clinical Researchers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?208:7">Grassroots Organizing: Communication Groups</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?208:8">California (and Beyond): Proposition 187 and Public Health</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #207, September 16, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?207:1">New Cell Transfer, Gene Therapy Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?207:2">&quot;Access&quot; and &quot;Answers&quot;: FDA Antiviral Advisory Meeting, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?207:3">AZT, Perinatal Transmission: Unanswered Questions</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+206"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-100</DOCNO>
<DOCOLDNO>IA017-000178-B002-330</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+210 192.33.214.13 19970106042102 text/html 5497
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+215"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #210, November 4, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?210:1">Searle Abandons Its Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?210:2">Protease Inhibitors -- Task Force Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?210:3">HIV RNA -- Time to Wake Up and Save Lives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?210:4">New AIDS Treatment Information Service, 800/HIV-0440</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?210:5">Human Growth Hormone -- Canadian Number Disconnected for U.S. Calls</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?210:6">AIDS Patents Now Available Free through Internet</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?210:7">Drugs for Infants and Children: Call for Reform</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?210:8">California: AIDS Drug Assistance Program, New Drugs Proposed; Title II Public Input Sought</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?210:9">Title II National Organization Formed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?210:10">Global AIDS Summit, Paris, December 1</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #209, October 21, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?209:1">&quot;Surrogate Markers&quot;: Current Status, Future Directions (Part I)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?209:2">Maternal Transmission and Viral Load</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?209:3">Human Growth Hormone Available through Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?209:4">Protease Inhibitor: Stanford High-Dose Trial Still Enrolling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?209:5">Passive Hyperimmune Therapy: Apparent Patient Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?209:6">Alternative Treatment Research Center Receives NIH Grant</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #208, October 7, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?208:1">AIDS Drug Interactions Guide Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?208:2">Patents and Biotechnology: Federal Hearings October 17 in San Diego, Comments Invited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?208:3">AIDS and Nutrition: Clarification, Additional Resources</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?208:4">KS: DOX-SL Submitted for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?208:5">Yokohama Conference: Behind U.S. Media Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?208:6">FDA Proposes Financial Disclosure for Clinical Researchers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?208:7">Grassroots Organizing: Communication Groups</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?208:8">California (and Beyond): Proposition 187 and Public Health</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #207, September 16, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?207:1">New Cell Transfer, Gene Therapy Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?207:2">&quot;Access&quot; and &quot;Answers&quot;: FDA Antiviral Advisory Meeting, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?207:3">AZT, Perinatal Transmission: Unanswered Questions</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #206, September 2, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?206:1">AIDS Pathogenesis -- New Understanding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?206:2">Why AIDS Drug Development Has Failed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?206:3">Accelerated Approval: Statement to FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?206:4">Announcements:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?206:5">California AIDS Legislation -- Action Alerts</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+205"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-101</DOCNO>
<DOCOLDNO>IA017-000178-B002-345</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+209 192.33.214.13 19970106042115 text/html 4847
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:37 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+214"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #209, October 21, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?209:1">&quot;Surrogate Markers&quot;: Current Status, Future Directions (Part I)</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?209:2">Maternal Transmission and Viral Load</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?209:3">Human Growth Hormone Available through Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?209:4">Protease Inhibitor: Stanford High-Dose Trial Still Enrolling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?209:5">Passive Hyperimmune Therapy: Apparent Patient Benefit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?209:6">Alternative Treatment Research Center Receives NIH Grant</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #208, October 7, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?208:1">AIDS Drug Interactions Guide Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?208:2">Patents and Biotechnology: Federal Hearings October 17 in San Diego, Comments Invited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?208:3">AIDS and Nutrition: Clarification, Additional Resources</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?208:4">KS: DOX-SL Submitted for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?208:5">Yokohama Conference: Behind U.S. Media Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?208:6">FDA Proposes Financial Disclosure for Clinical Researchers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?208:7">Grassroots Organizing: Communication Groups</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?208:8">California (and Beyond): Proposition 187 and Public Health</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #207, September 16, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?207:1">New Cell Transfer, Gene Therapy Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?207:2">&quot;Access&quot; and &quot;Answers&quot;: FDA Antiviral Advisory Meeting, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?207:3">AZT, Perinatal Transmission: Unanswered Questions</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #206, September 2, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?206:1">AIDS Pathogenesis -- New Understanding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?206:2">Why AIDS Drug Development Has Failed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?206:3">Accelerated Approval: Statement to FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?206:4">Announcements:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?206:5">California AIDS Legislation -- Action Alerts</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #205, August 19, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?205:1">Human Growth Hormone Reverses Wasting in Clinical Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?205:2">Yokohama Conference Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?205:3">BARRON'S: &quot;Do We Have Too Many Drugs for AIDS?&quot;</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?205:4">Major FDA Public Meeting on Early Access, Accelerated Approval, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?205:5">Nutrition and AIDS: Interview with Kristin Weaver (Part 2)</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+204"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-102</DOCNO>
<DOCOLDNO>IA017-000178-B002-353</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+208 192.33.214.13 19970106042125 text/html 4654
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:47 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+213"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #208, October 7, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?208:1">AIDS Drug Interactions Guide Available</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?208:2">Patents and Biotechnology: Federal Hearings October 17 in San Diego, Comments Invited</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?208:3">AIDS and Nutrition: Clarification, Additional Resources</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?208:4">KS: DOX-SL Submitted for Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?208:5">Yokohama Conference: Behind U.S. Media Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?208:6">FDA Proposes Financial Disclosure for Clinical Researchers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?208:7">Grassroots Organizing: Communication Groups</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?208:8">California (and Beyond): Proposition 187 and Public Health</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #207, September 16, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?207:1">New Cell Transfer, Gene Therapy Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?207:2">&quot;Access&quot; and &quot;Answers&quot;: FDA Antiviral Advisory Meeting, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?207:3">AZT, Perinatal Transmission: Unanswered Questions</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #206, September 2, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?206:1">AIDS Pathogenesis -- New Understanding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?206:2">Why AIDS Drug Development Has Failed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?206:3">Accelerated Approval: Statement to FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?206:4">Announcements:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?206:5">California AIDS Legislation -- Action Alerts</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #205, August 19, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?205:1">Human Growth Hormone Reverses Wasting in Clinical Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?205:2">Yokohama Conference Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?205:3">BARRON'S: &quot;Do We Have Too Many Drugs for AIDS?&quot;</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?205:4">Major FDA Public Meeting on Early Access, Accelerated Approval, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?205:5">Nutrition and AIDS: Interview with Kristin Weaver (Part 2)</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #204, August 5, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?204:1">HIV RNA: New Blood Test for Individualized Therapy and Faster Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?204:2">Nutrition and AIDS: Interview with Kristin Weaver, Bay Area Nutrition Counseling Center and Clinic (BANC), at San Francisco General Hospital</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?204:3">California: MediCal Cut in Monthly Prescription Allowances Starting Oct. 1</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?204:4">Announcements, Notes</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+203"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-103</DOCNO>
<DOCOLDNO>IA017-000178-B002-364</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+207 192.33.214.13 19970106042137 text/html 4705
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:21:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+212"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #207, September 16, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?207:1">New Cell Transfer, Gene Therapy Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?207:2">&quot;Access&quot; and &quot;Answers&quot;: FDA Antiviral Advisory Meeting, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?207:3">AZT, Perinatal Transmission: Unanswered Questions</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #206, September 2, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?206:1">AIDS Pathogenesis -- New Understanding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?206:2">Why AIDS Drug Development Has Failed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?206:3">Accelerated Approval: Statement to FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?206:4">Announcements:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?206:5">California AIDS Legislation -- Action Alerts</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #205, August 19, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?205:1">Human Growth Hormone Reverses Wasting in Clinical Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?205:2">Yokohama Conference Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?205:3">BARRON'S: &quot;Do We Have Too Many Drugs for AIDS?&quot;</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?205:4">Major FDA Public Meeting on Early Access, Accelerated Approval, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?205:5">Nutrition and AIDS: Interview with Kristin Weaver (Part 2)</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #204, August 5, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?204:1">HIV RNA: New Blood Test for Individualized Therapy and Faster Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?204:2">Nutrition and AIDS: Interview with Kristin Weaver, Bay Area Nutrition Counseling Center and Clinic (BANC), at San Francisco General Hospital</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?204:3">California: MediCal Cut in Monthly Prescription Allowances Starting Oct. 1</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?204:4">Announcements, Notes</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #203, July 22, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?203:1">Zerit (d4T) Delayed; Parallel Track Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?203:2">Yokohama International Conference: Free Interactive Video Teleconference on Aug. 9  11, Ten U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?203:3">HIV and Anal Cancer: Anal Pap Smears, Early Treatment, Recommended for High-Risk Men  Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?203:4">Phenytoin (Dilantin) as Antiretroviral Treatment -- Negative Report?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?203:5">Thymomodulin Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?203:6">Immunology Book Recommended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?203:7">Interview, Kristine Gebbie, Outgoing Policy Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?203:8">Gebbie and Grassroots: Toward a Mass-Movement Organizing Style</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+202"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-104</DOCNO>
<DOCOLDNO>IA017-000178-B003-9</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+206 192.33.214.13 19970106042145 text/html 4712
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:22:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+211"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #206, September 2, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?206:1">AIDS Pathogenesis -- New Understanding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?206:2">Why AIDS Drug Development Has Failed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?206:3">Accelerated Approval: Statement to FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?206:4">Announcements:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?206:5">California AIDS Legislation -- Action Alerts</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #205, August 19, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?205:1">Human Growth Hormone Reverses Wasting in Clinical Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?205:2">Yokohama Conference Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?205:3">BARRON'S: &quot;Do We Have Too Many Drugs for AIDS?&quot;</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?205:4">Major FDA Public Meeting on Early Access, Accelerated Approval, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?205:5">Nutrition and AIDS: Interview with Kristin Weaver (Part 2)</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #204, August 5, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?204:1">HIV RNA: New Blood Test for Individualized Therapy and Faster Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?204:2">Nutrition and AIDS: Interview with Kristin Weaver, Bay Area Nutrition Counseling Center and Clinic (BANC), at San Francisco General Hospital</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?204:3">California: MediCal Cut in Monthly Prescription Allowances Starting Oct. 1</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?204:4">Announcements, Notes</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #203, July 22, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?203:1">Zerit (d4T) Delayed; Parallel Track Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?203:2">Yokohama International Conference: Free Interactive Video Teleconference on Aug. 9  11, Ten U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?203:3">HIV and Anal Cancer: Anal Pap Smears, Early Treatment, Recommended for High-Risk Men  Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?203:4">Phenytoin (Dilantin) as Antiretroviral Treatment -- Negative Report?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?203:5">Thymomodulin Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?203:6">Immunology Book Recommended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?203:7">Interview, Kristine Gebbie, Outgoing Policy Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?203:8">Gebbie and Grassroots: Toward a Mass-Movement Organizing Style</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #202, July 8, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?202:1">Thymomodulin</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?202:2">Thymomodulin Bibliography</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?202:3">Zerit (d4T) Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?202:4">Thymopentin (TP-5) Trial Starting, 34 U.S. Cities</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+201"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-105</DOCNO>
<DOCOLDNO>IA017-000178-B003-20</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+205 192.33.214.13 19970106042157 text/html 4814
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:22:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+210"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #205, August 19, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?205:1">Human Growth Hormone Reverses Wasting in Clinical Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?205:2">Yokohama Conference Overview</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?205:3">BARRON'S: &quot;Do We Have Too Many Drugs for AIDS?&quot;</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?205:4">Major FDA Public Meeting on Early Access, Accelerated Approval, September 12-13</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?205:5">Nutrition and AIDS: Interview with Kristin Weaver (Part 2)</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #204, August 5, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?204:1">HIV RNA: New Blood Test for Individualized Therapy and Faster Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?204:2">Nutrition and AIDS: Interview with Kristin Weaver, Bay Area Nutrition Counseling Center and Clinic (BANC), at San Francisco General Hospital</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?204:3">California: MediCal Cut in Monthly Prescription Allowances Starting Oct. 1</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?204:4">Announcements, Notes</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #203, July 22, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?203:1">Zerit (d4T) Delayed; Parallel Track Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?203:2">Yokohama International Conference: Free Interactive Video Teleconference on Aug. 9  11, Ten U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?203:3">HIV and Anal Cancer: Anal Pap Smears, Early Treatment, Recommended for High-Risk Men  Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?203:4">Phenytoin (Dilantin) as Antiretroviral Treatment -- Negative Report?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?203:5">Thymomodulin Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?203:6">Immunology Book Recommended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?203:7">Interview, Kristine Gebbie, Outgoing Policy Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?203:8">Gebbie and Grassroots: Toward a Mass-Movement Organizing Style</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #202, July 8, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?202:1">Thymomodulin</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?202:2">Thymomodulin Bibliography</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?202:3">Zerit (d4T) Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?202:4">Thymopentin (TP-5) Trial Starting, 34 U.S. Cities</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #201, June 17, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?201:1">Roche Protease (Proteinase) Combination Trial: Triple Combination Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?201:2">PML Treatment Update, Peptide T Possibility</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?201:3">AIDS Research Strategy: Rapid, Small Trials for Promising Treatment Leads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?201:4">Merck Protease Inhibitor Combination Trial:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?201:5">International Issues -- Newsletter Available</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+200"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-106</DOCNO>
<DOCOLDNO>IA017-000178-B003-33</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+204 192.33.214.13 19970106042217 text/html 4480
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:22:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+209"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #204, August 5, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?204:1">HIV RNA: New Blood Test for Individualized Therapy and Faster Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?204:2">Nutrition and AIDS: Interview with Kristin Weaver, Bay Area Nutrition Counseling Center and Clinic (BANC), at San Francisco General Hospital</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?204:3">California: MediCal Cut in Monthly Prescription Allowances Starting Oct. 1</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?204:4">Announcements, Notes</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #203, July 22, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?203:1">Zerit (d4T) Delayed; Parallel Track Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?203:2">Yokohama International Conference: Free Interactive Video Teleconference on Aug. 9  11, Ten U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?203:3">HIV and Anal Cancer: Anal Pap Smears, Early Treatment, Recommended for High-Risk Men  Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?203:4">Phenytoin (Dilantin) as Antiretroviral Treatment -- Negative Report?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?203:5">Thymomodulin Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?203:6">Immunology Book Recommended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?203:7">Interview, Kristine Gebbie, Outgoing Policy Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?203:8">Gebbie and Grassroots: Toward a Mass-Movement Organizing Style</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #202, July 8, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?202:1">Thymomodulin</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?202:2">Thymomodulin Bibliography</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?202:3">Zerit (d4T) Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?202:4">Thymopentin (TP-5) Trial Starting, 34 U.S. Cities</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #201, June 17, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?201:1">Roche Protease (Proteinase) Combination Trial: Triple Combination Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?201:2">PML Treatment Update, Peptide T Possibility</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?201:3">AIDS Research Strategy: Rapid, Small Trials for Promising Treatment Leads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?201:4">Merck Protease Inhibitor Combination Trial:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?201:5">International Issues -- Newsletter Available</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #200, June 3, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?200:1">Antivirals and Immune Recovery: Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?200:2">Government AIDS Research: the ACTG. Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?200:3">D4T (Stavudine): Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-107</DOCNO>
<DOCOLDNO>IA017-000178-B003-44</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+203 192.33.214.13 19970106042232 text/html 3746
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:22:52 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+208"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #203, July 22, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?203:1">Zerit (d4T) Delayed; Parallel Track Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?203:2">Yokohama International Conference: Free Interactive Video Teleconference on Aug. 9  11, Ten U.S. Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?203:3">HIV and Anal Cancer: Anal Pap Smears, Early Treatment, Recommended for High-Risk Men  Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?203:4">Phenytoin (Dilantin) as Antiretroviral Treatment -- Negative Report?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?203:5">Thymomodulin Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?203:6">Immunology Book Recommended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?203:7">Interview, Kristine Gebbie, Outgoing Policy Coordinator</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?203:8">Gebbie and Grassroots: Toward a Mass-Movement Organizing Style</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #202, July 8, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?202:1">Thymomodulin</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?202:2">Thymomodulin Bibliography</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?202:3">Zerit (d4T) Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?202:4">Thymopentin (TP-5) Trial Starting, 34 U.S. Cities</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #201, June 17, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?201:1">Roche Protease (Proteinase) Combination Trial: Triple Combination Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?201:2">PML Treatment Update, Peptide T Possibility</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?201:3">AIDS Research Strategy: Rapid, Small Trials for Promising Treatment Leads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?201:4">Merck Protease Inhibitor Combination Trial:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?201:5">International Issues -- Newsletter Available</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #200, June 3, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?200:1">Antivirals and Immune Recovery: Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?200:2">Government AIDS Research: the ACTG. Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?200:3">D4T (Stavudine): Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-108</DOCNO>
<DOCOLDNO>IA017-000178-B003-54</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+202 192.33.214.13 19970106042240 text/html 2505
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:02 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+207"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #202, July 8, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?202:1">Thymomodulin</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?202:2">Thymomodulin Bibliography</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?202:3">Zerit (d4T) Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?202:4">Thymopentin (TP-5) Trial Starting, 34 U.S. Cities</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #201, June 17, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?201:1">Roche Protease (Proteinase) Combination Trial: Triple Combination Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?201:2">PML Treatment Update, Peptide T Possibility</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?201:3">AIDS Research Strategy: Rapid, Small Trials for Promising Treatment Leads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?201:4">Merck Protease Inhibitor Combination Trial:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?201:5">International Issues -- Newsletter Available</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #200, June 3, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?200:1">Antivirals and Immune Recovery: Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?200:2">Government AIDS Research: the ACTG. Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?200:3">D4T (Stavudine): Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-109</DOCNO>
<DOCOLDNO>IA017-000178-B003-68</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+201 192.33.214.13 19970106042248 text/html 1969
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+206"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #201, June 17, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?201:1">Roche Protease (Proteinase) Combination Trial: Triple Combination Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?201:2">PML Treatment Update, Peptide T Possibility</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?201:3">AIDS Research Strategy: Rapid, Small Trials for Promising Treatment Leads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?201:4">Merck Protease Inhibitor Combination Trial:</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?201:5">International Issues -- Newsletter Available</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #200, June 3, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?200:1">Antivirals and Immune Recovery: Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?200:2">Government AIDS Research: the ACTG. Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?200:3">D4T (Stavudine): Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-110</DOCNO>
<DOCOLDNO>IA017-000178-B003-76</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?+200 192.33.214.13 19970106042256 text/html 1177
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+205"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #200, June 3, 1994</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?200:1">Antivirals and Immune Recovery: Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?200:2">Government AIDS Research: the ACTG. Interview with Michael S. Saag, M.D.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?200:3">D4T (Stavudine): Approval Recommended</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-111</DOCNO>
<DOCOLDNO>IA017-000178-B003-91</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/f/ATN.cgi?+240 192.33.214.13 19970106042304 text/html 7451
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:26 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/f/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/f/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS TREATMENT NEWS - <A HREF="ATN.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="ATN.cgi?+248"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>Issue #240, February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?240:1">Protease Inhibitors at Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?240:2">Protease Inhibitors in Human Testing: Annotated List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?240:3">Ritonavir (Abbott Protease Inhibitor) Proves Survival Benefit in Late-Stage AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?240:4">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?240:5">Vancouver International Conference: Community Booths Deadline Extended</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?240:6">FDA Antiviral Advisory Committee Meetings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?240:7">Prisoners: Send Address Updates; Contacting Organizations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?240:8">NMAC Skills Building Conference in South Africa: Facilitators Wanted</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?240:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #239, January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?239:1">NTZ: Cryptosporidiosis New Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?239:2">Viral Load: New Confirmation from Major Delavirdine Studies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?239:3">Protease Inhibitor Update: Treatment Combination Strategies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?239:4">Ritonavir: Expanded Access Begins, Warning on Drug Interactions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?239:5">Stanford NAC Study, San Francisco, Needs to Contact Screened Applicants and Participants for Followup</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?239:6">Needle Exchange: Experts Deplore Shalala Remarks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?239:7">Retroviruses Conference Notes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?239:8">DHEA and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?239:9">DHEA Clinical Experience: Interview with Jon Kaiser, M.D.</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #238, January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?238:1">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?238:2">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?238:3">AZT plus 3TC Combination Results Published</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?238:4">Opportunistic Infection Prevention: National Video Symposium, January 11</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?238:5">San Francisco: Cryptosporidiosis Water Warning</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?238:6">Computer Censorship Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?238:7">Activist Groups and PWA Coalitions, U.S. and Canada</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #237, December 22, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?237:1">Saquinavir (Invirase): First Protease Inhibitor Approved -- Reimbursement, Information Hotline Numbers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?237:2">Abbott Protease Inhibitor Lottery in January, CD4 Under 50 -- Registration Now</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?237:3">Abbott Protease Inhibitor: Early Results Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?237:4">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?237:5">Wasting Syndrome: Oral Oxandrolone Re-Released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?237:6">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?237:7">Human Retroviruses, Immune-Based, and CPCRA Meetings, Washington D.C. Late January</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?237:8">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?237:9">New York: Protease Inhibitor Forum, January 6</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="ATN.cgi?237:10">Computer Censorship: Effect on AIDS TREATMENT NEWS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="ATN.cgi?237:11">AIDS TREATMENT NEWS Selected Index</A></TD>
</TR>
</TABLE>
</UL>
<H3>Issue #236, December 1, 1995</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="ATN.cgi?236:1">Lamivudine (3TC) Approved for Combination Use with AZT</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="ATN.cgi?236:2">PMPA in Perspective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="ATN.cgi?236:3">DOXIL Approved for KS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="ATN.cgi?236:4">DOXIL Available in Government Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="ATN.cgi?236:5">New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="ATN.cgi?236:6">Identical Twins Needed to Donate Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="ATN.cgi?236:7">Medical Marijuana: 80% U.S. Voter Support</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="ATN.cgi?236:8">California: Medical Marijuana Petition Drive Begins</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="ATN.cgi?236:9">Internet Censorship: Congress Moves Toward Final Decision</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="ATN.cgi?+235"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-112</DOCNO>
<DOCOLDNO>IA017-000178-B003-98</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:1 192.33.214.13 19970106042311 text/html 2523
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?251:7.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Cryptosporidiosis: NTZ Available at Buyers' Club; Customs Holds 2nd Shipment</h3>
<P>
NTZ (nitazoxanide), an experimental drug which may be the first effective treatment against cryptosporidiosis (which causes severe diarrhea in persons with AIDS) was recently approved in Mexico, and for the first time is now available at a U.S. AIDS buyers' club, the PWA Health Group in New York. An officially approved compassionate access program recently was expanded from 100 to 150 slots. But for weeks many people who desperately needed this drug found it impossible to obtain, no matter how well connected they were. The PWA Health Group recently called people on its long list to buy NTZ, and found that half of them had died.
<P>
NTZ is inexpensive to manufacture, and is being studied for treating many parasites in developing countries. In the U.S., it is in phase I trials for cryptosporidiosis.
<P>
On June 21 a U.S. Customs office seized half of the PWA Health Group shipment of NTZ. Because such cases happen frequently and are usually resolved fairly rapidly, the PWA Health Group suggests that people contact them concerning how they might help if necessary. The shipment may have already been released by the time you receive this newsletter.
<P>
Meanwhile the PWA Health Group has enough NTZ to treat about 50 people. They require a doctor's prescription for this drug. To obtain a fact sheet on NTZ, to order the drug, or to offer to help politically if necessary, contact the PWA Health Group at 212/255-0520.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?251:7.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-113</DOCNO>
<DOCOLDNO>IA017-000178-B003-107</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:2 192.33.214.13 19970106042322 text/html 2764
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>NAC: First Controlled Trial, Positive Results</h3>
<P>
by John S. James
<P>
NAC (N-acetylcysteine), a low-cost potential treatment approved for certain non-HIV medical uses, has for years been one of the most popular &quot;alternative&quot; treatments sold by the AIDS buyers' clubs in the U.S. For many years researchers have had well-designed research protocols ready to go to scientifically test whether NAC can be helpful in HIV infection, but finding the funds for this work has been extraordinarily difficult. The first controlled trial started in late 1993 at Stanford University; now its results have been publicly reported at the May 21-24, 1996 meeting OXIDATIVE STRESS AND REDOX REGULATION: CELLULAR SIGNALING, AIDS, CANCER, AND OTHER DISEASES, at the Institut Pasteur in Paris.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0081">(1)</a> <a name="retour0081"> </a>
<P>
Although the design of this study was too limited to tell definitively if NAC improves patient survival, it did show that the condition NAC is intended to correct (low glutathione levels in blood cells) strongly predicts poor survival. NAC was found to increase glutathione levels, and possibly to improve survival. (Glutathione is an antioxidant found in all cells, and is the primary intracellular defense against oxidative stress. It is critical for energy metabolism, cell division, and other functions, and is essential for the life of the cell. Glutathione is a small peptide, consisting of three amino acids; NAC supplies cysteine, which is the limiting amino acid for the production of glutathione. In addition to the need to maintain glutathione levels to prevent oxidative damage, it is possible that low glutathione levels may accelerate HIV replication.)
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-114</DOCNO>
<DOCOLDNO>IA017-000178-B003-121</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:2.1 192.33.214.13 19970106042332 text/html 2484
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:23:53 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>History</h4>
<P>
NAC has been controversial in the U.S. medical community, because several years ago a small study conducted at the U.S. National Institutes of Health reported that NAC was not found in the blood when taken orally. Other scientists replied that the NAC was well known to be absorbed but was quickly changed by the liver into other chemicals which did not show up in the tests which were used in that study. But the case against NAC being absorbed in useful amounts is the only one that got widespread attention.
<P>
(Several years ago, this writer asked the lead researcher on the NIH NAC study how he would answer the argument that the test he used could not usefully determine bioavailability, as the NAC would be changed into related chemicals which that test would not measure. He told us that his trial was the kind required by the FDA for a pharmacokinetic study -- and that in addition his results were consistent with other reports in the literature. We did not think that this defense addressed the issue. At about that time, we were in a room with hundreds of AIDS physicians and research assistants where the NIH trial results were presented. Those doctors walked out of that room convinced that NAC was not absorbed and therefore useless. We would have thought the same thing too, if we had not talked to the parties involved. This is why most of the U.S. AIDS medical community today is convinced that NAC is not absorbed and therefore ineffective.)
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-115</DOCNO>
<DOCOLDNO>IA017-000178-B003-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:2.2 192.33.214.13 19970106042342 text/html 6773
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:24:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>The Stanford Trial</h4>
<P>
Now there is new data. The recent NAC trial was done at Stanford's Herzenberg Laboratory, one of the world's leading research groups on flow cytometry, the technology which is widely used to measure CD4 and CD8 counts, and which can also count many other kinds of cells. Flow cytometry works by treating cells so that different kinds will glow differently when exposed to a particular wavelength of light (which is usually provided by a laser). The cells move individually past the laser beam, and the fluorescence (glowing) of each is measured by a sensor and counted by computer. This technology allows cells to be divided into different populations based on many different characteristics. And by chemically reacting glutathione so that it will fluoresce, this method is also able to measure the glutathione level within each cell while simultaneously detecting if it is a CD4 cell, a CD8 cell, or some other cell type. As explained above, glutathione is a vital antioxidant in the cell -- and low intracellular glutathione is the condition which NAC is proposed to correct.
<P>
The Stanford study collected baseline data on over 200 HIV-positive volunteers; 83 of them were enrolled in a double-blind placebo-controlled trial designed primarily to test whether HIV-infected people can absorb NAC (since the earlier NIH study had raised doubts). Since all but two deaths occurred in those who entered the study with a CD4 count under 200, further survival analysis was limited to this group. Two to three years later (depending on how soon people enrolled in the trial), the researchers surveyed all subjects who contributed baseline data, to see who had survived. Some of the details of the study are complex, but basically the findings were:
<P>
(1) Low glutathione levels in CD4 T-cells mean increased risk of death. This analysis was done in those volunteers who for any reason did NOT take NAC in the study (so the researchers could see the natural-history association of mortality with glutathione levels, in the absence of treatment to restore those levels). Statistical analysis showed that those with glutathione levels equal to the group mean (0.98) had a two- to three-year survival rate of 65%. But of those with glutathione levels of 0.6, only 25% survived. The group mean itself was below normal, as glutathione levels are lower than normal in people with AIDS, as with many other serious illnesses.
<P>
(2) Oral use of NAC increases glutathione levels in blood cells. A comparison of the 27 subjects who received NAC and for whom data was available, vs. the 26 who received placebo for the 8 weeks of the formal trial, showed that those on placebo had essentially no change; but in those who took NAC, glutathione levels went up about two thirds of the way to normal. (While the amount of change was only 10-12%, it could be meaningful since glutathione levels are fairly tightly regulated by the body, and normally cannot change very much.)
<P>
(3) This study found that NAC was safe; there were no adverse effects attributed to the drug. (There have been other reports of gastrointestinal distress at high doses.)
<P>
(4) Taking NAC was associated with increased survival -- although causality could not be proved by this study. In this trial, a direct survival comparison between those assigned to take NAC vs. those assigned to placebo was not meaningful, for two reasons. First, volunteers in both groups were offered open-label NAC for six months after the 8-week formal study was completed -- and most accepted the offer. This means that most of those assigned to &quot;placebo&quot; really took almost as much NAC as those assigned to the NAC group. Since this trial was not designed to test survival, there was no one who received placebo for the whole time.
<P>
So the researchers looked at other comparisons -- which made the interpretation of the data more difficult and more uncertain. They found that on the average, the group that took NAC (for six to eight months) survived about six to eight months longer than the group that didn't take NAC.
<P>
However, this was not a comparison between randomized groups, because this trial was not designed to allow such a comparison; those who took NAC were self-selected, and it is possible that these patients were healthier, or took better care of themselves in other ways, or had a better prognosis for some other unknown reason. This means that from this trial there is no way to be sure that using NAC contributed to survival.
<P>
Therefore the investigators could only state that they see the results as consistent with the idea that NAC may improve survival. They hope to find funding as soon as possible for a proper prospective clinical trial to test this possibility.
<P>
[Note on acetaminophen (Tylenol, etc.): NAC in very large doses has long been approved by the FDA for treating poisoning caused by acetaminophen overdose. NAC is an antidote because overdoses of acetaminophen drastically deplete the glutathione in the liver, resulting in severe liver damage, and NAC provides the cysteine necessary to replenish the glutathione.
<P>
The FDA has warned heavy drinkers that alcohol use can reduce levels of glutathione, and acetaminophen can depress these levels further, causing risk of liver toxicity. Since HIV infection also causes reduced glutathione levels, Leonard Herzenberg, Ph.D., and Lenore Herzenberg, Ph.D., both of Stanford University Genetics Department and principle investigators in the NAC study described above, have long been concerned that acetaminophen or other medications which reduce glutathione levels might be harmful for persons with AIDS or HIV, and that patients and physicians could be cautious about using these drugs.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-116</DOCNO>
<DOCOLDNO>IA017-000178-B003-139</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:3 192.33.214.13 19970106042350 text/html 1603
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:24:12 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Nevirapine Approved</h3>
<P>
Nevirapine (Viramune(R)) received accelerated approval by the FDA on June 24, for use in adults in combination with other antiretrovirals. It is expected to be available in August. It is the first drug approved in a new class, the non-nucleoside reverse transcriptase inhibitors.
<P>
For more information about nevirapine, see our previous issue, <a href="/anais/f/ATN.cgi?+249">AIDS TREATMENT NEWS #249</a>, which reported on the recent FDA Antiviral Drugs Advisory Committee meeting which recommended approval. The actual approval came after our issue was published.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-117</DOCNO>
<DOCOLDNO>IA017-000178-B003-148</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:4 192.33.214.13 19970106042403 text/html 2065
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:24:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Vancouver Conference: Each Day Summarized Nightly on World Wide Web</h3>
<P>
Persons not attending the XI International Conference on AIDS (Vancouver, July 7-12) can follow the highlights in detail by taking a daily one-hour CME (continuing medical education) course, written nightly by a team of 22 practicing physicians and medical writers, and presented each day on the World Wide Web. The material is being produced by Clinical Care Options for HIV(SM), and will be presented on two different sites on the Web. Anyone throughout the world can get an immediate in-depth report on the conference through these modules -- which will remain available after the Conference.
<P>
The two sites are <a href="http://www.immunet.org/meded">http://www.immunet.org/meded</a> and <a href="http://www.cmegateway.com"> http://www.cmegateway.com</a>; the material will be identical but the presentation on the Web will be different. See the article about the CMV RETINITIS AND TREATMENT CME course on the World Wide Web (below) for more information about the different sites.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-118</DOCNO>
<DOCOLDNO>IA017-000178-B003-158</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:5 192.33.214.13 19970106042414 text/html 2143
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:24:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>SCIENCE Publishes Major AIDS Issue June 28; Full Text on Web</h3>
<P>
by John S. James
<P>
The journal SCIENCE will publish a major AIDS issue on June 28, and will release the full text that day on its Web site, <a href="http://www.sciencemag.org"> http://www.sciencemag.org</a>. This issue includes six journalistic articles, two research reports, three scientists' viewpoints (on vaccines, drug treatments, and chemokines and receptors), and an editorial. Two thousand copies will be distributed at the Vancouver conference.
<P>
Of particular note is a new picture of HIV, drawn by a leading medical illustrator based on the best current information from top scientists throughout the world.
<P>
The reporting includes a view of AIDS research based on information used by the investment community, and a table looking at the most-cited scientists among those who have published frequently.
<P>
Note to Readers: This issue of AIDS TREATMENT NEWS went to press a week early, on June 26, so that we can print copies to take to the Vancouver AIDS conference. We did not review the SCIENCE coverage, but talked to their AIDS reporter Jon Cohen.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-119</DOCNO>
<DOCOLDNO>IA017-000178-B003-166</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:6 192.33.214.13 19970106042433 text/html 3978
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:24:53 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>CMV RETINITIS AND TREATMENT CME Course on World Wide Web</h3>
<P>
by John S. James
<P>
The first AIDS/HIV CME course on the World Wide Web -- and one of the first CME courses by computer in any medical field -- begins operation on June 24. CMV RETINITIS AND TREATMENT offers one hour credit for physicians, nurses, and pharmacists; patients, advocates, and others interested can also take the course without credit. This module covers not only the approved treatments (ganciclovir and foscarnet), but also some experimental treatments and delivery systems available through clinical trials and other special programs to some patients. While the course is available throughout the world, it focuses on U.S. treatment approaches.
<P>
To prevent the material from becoming dated, this CMV module will be available for six months and then discontinued. Other AIDS-related CME modules will be online by that time.
<P>
This CMV course was written by Charles van der Horst, M.D., in a project sponsored jointly by Healthcare Communications Group and Medical Education Collaborative, and funded by an unrestricted educational grant from Roche Laboratories, Inc. The material was peer reviewed by the Clinical Care Options for HIV National Advisory Board, a panel of internationally recognized experts in HIV treatment.
<P>
Presentation on the Internet
<P>
The same material has been formatted differently and placed on two different Internet World Wide Web sites. Although the medical information is identical, there are substantial differences in the Web presentation which can affect how the end user receives the information. Because AIDS TREATMENT NEWS has a business relationship with Immunet, one of the organizations which has presented the material on the Web (see <a href="/anais/f/ATN.cgi?+247">AIDS TREATMENT NEWS #247</a>), we are uncomfortable judging or comparing two sites. But readers should know that the Immunet site was designed to work well with many different Web browsers and different Internet connections -- and &quot;to address the needs and values of three unique communities: the medical, AIDS, and Web communities,&quot; according to Lisa Nelson, the site's graphic designer. The other site, by the Medical Education Collaborative, can also be reached through a link on the home page of the American Medical Association (<a href="http://www.ama-assn.org"> http://www.ama-assn.org</a>). (Note: the period at the end of the sentence is NOT part of this or other World Wide Web addresses.)
<P>
The Immunet site is at <a href="http://www.immunet.org/meded"> http://www.immunet.org/meded</a>. The Medical Education Collaborative site can be reached through <a href="http://www.cmegateway.com"> http://www.cmegateway.com</a>.
<P>
Note: During the Vancouver conference, July 7-12, both Immunet and Medical Education Collaborative will present the same one-hour summary of each day of the conference; see separate announcement in this issue of AIDS TREATMENT NEWS.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-120</DOCNO>
<DOCOLDNO>IA017-000178-B003-177</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:7 192.33.214.13 19970106042442 text/html 1742
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Delavirdine Expanded Access Program Information on World Wide Web</h3>
<P>
On June 25 Pharmacia &amp; Upjohn, Inc. opened an Internet site on the World Wide Web for information about the expanded access program for its antiretroviral delavirdine (brand name Rescriptor(R)); this program started on April 1. The company will soon apply to the FDA for marketing approval. Delavirdine is in the same class of antiretrovirals as nevirapine, which was recently approved.
<P>
The address of the delavirdine site is <a href="http://www.pnuaids.com"> http://www.pnuaids.com</a>.
<P>
Physicians in the U.S. and Canada who would like to register patients for the expanded access program, or others who want written information, can call 800/779-0070.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-121</DOCNO>
<DOCOLDNO>IA017-000178-B003-185</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:8 192.33.214.13 19970106042450 text/html 1561
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:13 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:9.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>West Hollywood: AIDS and Chinese Medicine Conference, July 25-28</h3>
<P>
The 4th HIV/AIDS &amp; Chinese Medicine Conference will be held July 25-28 at the Wyndham Bel Age Hotel, West Hollywood, California. This is a conference for directors of Chinese medicine clinics and professional practitioners of Chinese medicine: licensed acupuncturists, medical doctors, nurses, and others who provide health care to people with HIV/AIDS.
<P>
For more information, call Howard Moffet, L.Ac., AIDS &amp; Chinese Medicine Institute, 415/282-4028, fax 415/282-2935.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:9.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-122</DOCNO>
<DOCOLDNO>IA017-000178-B003-194</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:9.1 192.33.214.13 19970106042501 text/html 7714
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:20 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:9.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3> Neuropathy: Nutrient Therapies (part 1)</h3>
<P>
by Lark Lands
<P>
[Editors note: Lark Lands, Ph.D., a well-known health educator and consultant, is the author of POSITIVELY WELL: LIVING WITH HIV AS A CHRONIC, MANAGEABLE SURVIVAL DISEASE, an 800-page book which will be published in late summer 1996. Before her current work in HIV treatment, she was employed for six years as a scientist for the MITRE Corporation, a large think tank near Washington D.C., &quot;conducting research, designing experiments, and compiling, assessing, and integrating information to provide problem resolutions and answers to government questions.&quot; When AIDS began, she was working in clinical nutrition, and has since educated people living with HIV on the importance of nutrition with this disease. She uses her professional skills to collect and organize HIV treatment information -- including not only drug therapies but also nutritional and other approaches often overlooked by the medical establishment because they do not involve proprietary drugs. She has worked with thousands of people with HIV infection to help them develop integrated treatment programs.
<P>
Dr. Lands also has had lifelong diabetes, and is an expert on diabetic neuropathy, which has been much better researched than neuropathy caused by HIV. She believes that some (not all) kinds of HIV-related neuropathy may be similar to the diabetic condition, and may respond to some of the same treatments. AIDS TREATMENT NEWS asked Dr. Lands if we could interview her on what has been learned about treating diabetic neuropathy, and how that might apply to HIV. It turned out to be more practical to publish a section of Dr. Lands' new book than to conduct a separate interview.
<P>
Readers should know that Dr. Lands emphasizes an integrated program of HIV disease management -- including antivirals and other mainstream medical treatments, nutritional approaches, and other kinds of therapy -- rather than using nutrition to treat only a specific symptom. Also, her book includes a detailed section on different kinds of HIV neuropathies. Other sections focus in detail on specific nutrients and other therapies, providing much information not included here. Unfortunately the book is not yet available. But readers should know about potential therapies which, although not conclusively proven and not officially approved, are supported by research, and have appeared to be helpful for many people.
<P>
Patients should talk with their physician before using any therapy, including nutritional treatments. Even if the physician is not familiar with or does not approve of the treatment, he or she may know about specific cautions or contraindications, due to a patient's medical condition.
<P>
The following is a small example of the useful information Dr. Lands has compiled. Her book will be an important advance in providing practical treatment information for persons with HIV disease.
<P>
[Note: POSITIVELY WELL can be ordered by calling 800/542-8102 within the U.S. and Canada (from elsewhere, call 905/672-7470), 9:00 a.m. to 5:00 p.m. Eastern time. The price is $24.95 plus shipping and handling. People can leave their name, address, phone number, and VISA or MasterCard number, which will not be charged until the book is ready to be shipped. (Remember that POSITIVELY WELL is not yet available, with estimated publication date of late summer. JSJ]
<P>
From POSITIVELY WELL: LIVING WITH HIV AS A CHRONIC, MANAGEABLE SURVIVAL DISEASE:
<P>
Although there has been virtually no research on the use of nutrient therapies for HIV-related neuropathies, there has been a fair amount of research (mostly in other countries) on their use for diabetic neuropathies. Since it appears likely that at least some of the mechanisms for the nerve damage may be similar in the two diseases (inflammation and oxidative damage to the nerves combined with B vitamin deficiencies), there is reason to believe that therapies which have proven useful for diabetics may also work for at least some people living with HIV who develop neuropathy. Many people living with HIV have reported to me that they have successfully eliminated neuropathy with some combination of the nutrient therapies discussed here. Thus, in addition to the other treatments mentioned, I would stress the importance of therapy with the B vitamins and other nutrients, especially acetyl-L-carnitine, gamma-linolenic acid, alpha-lipoic acid, magnesium, and chromium. I would definitely consider including the nutrients that have been shown to help rebuild the myelin sheath around nerves and/or improve nerve functioning such as choline, inositol, gamma linolenic acid, B6, B12, niacin, thiamine, biotin, folic acid, and magnesium.
<P>
Biotin, choline, inositol, and thiamine are B vitamins that have all been found useful in treating the peripheral and autonomic neuropathies found in diabetes and may also help with HIV-related neuropathies. In a study at the University of Athens, it was shown that regular, long-term use of biotin in diabetics was very effective both for improvement in nerve conduction and relief of pain.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0501">(2)</a> <a name="retour0501"> </a> Improvement in nerve conduction occurred after only 4-8 weeks of therapy. In this study, biotin was given via daily intramuscular injection (10 mg/day) for 6 weeks; then 3 times per week (10 mg), intramuscularly, for 6 weeks; then 5 mg/day taken orally for up to two years. The researchers hypothesize that deficiency, inactivity, or unavailability of biotin in diabetics may result in disordered activity of the biotin-dependent enzyme, pyruvate carboxylase, leading to an accumulation of pyruvate and/or a depletion of aspartate, either of which could adversely affect nervous system metabolism. There are a number of reasons why HIV-positive persons may be deficient in biotin and, thus, potentially at risk for a similar problem. It has been suggested that those with neuropathy symptoms might try 10-15 mg/day orally, taken in conjunction with the other B vitamins found useful for improving nerve function.
<P>
B12 deficiency is a known cause of neuropathy so this vitamin, along with its coworker folic acid, should certainly be included in any program aimed at eliminating this symptom. Typical symptoms of peripheral neuropathy related to B12 deficiency include the type of leg and foot pains experienced by many. B6 deficiencies are also known to cause both carpal tunnel syndrome (with symptoms of numbness, tingling, and pain in the hands and wrists) and degeneration of peripheral nerves and may be responsible for some peripheral neuropathy problems.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:9.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-123</DOCNO>
<DOCOLDNO>IA017-000178-B003-207</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:9.2 192.33.214.13 19970106042513 text/html 7213
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:9.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3> Neuropathy: Nutrient Therapies (part 2)</h3>
<P>
Choline and inositol also seem to be very important parts of the combination of vitamins needed for neuropathy resolution. Diabetic neuropathy is known to be associated with a reduction in myo-inositol levels in nerves and tissues. The decreased level of myo-inositol is believed to cause a decrease in the activity of the sodium-potassium pump and, thus, to change the sodium permeability of nerves. Both diets high in inositol and inositol supplementation have been shown to improve diabetic neuropathy. Researchers at the University of Alabama found a statistically significant improvement in nerve function in diabetics placed on a diet high in inositol. Included in the diet were high-inositol foods such as cantaloupe, peanuts, grapefruit, and whole grains. Other researchers have reported that supplementation with inositol in doses of 2-6 grams per day has resulted in improvements in neuropathy. Robert Atkins, M.D., has reported his successful use of 2-6 grams per day for reversing diabetic neuropathy, and notes that physicians at St. James Hospital in Leeds, England, have reported good results with even smaller dosages.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0502">(3)</a> <a name="retour0502"> </a>
<P>
In addition to the use of inositol itself, treatment with acetyl-L-carnitine can help raise nerve myo-inositol content. Florida researchers have found that peripheral nerve function in diabetes is linked to nerve myo-inositol content and that acetyl-l-carnitine can raise the levels of myo-inositol in the nerves of animals with experimentally induced diabetes.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0503">(4)</a> <a name="retour0503"> </a> It also apparently protects the nerve membranes from free-radical damage, as evidenced by reduced malondialdehyde levels in the animals treated with acetyl-l-carnitine.
<P>
Thiamine has also been seen to be useful in treating diabetic neuropathy. Stanley Mirski, M.D., has reported that a large percentage of his diabetic patients who suffer from neuropathy have achieved improvements with daily thiamine supplementation in doses of 50-100 mg. Using a fat-soluble form of thiamine such as thiamine tetrahydro-furfuryl disulfide may be preferable because of the relatively poor absorption of water-soluble forms of this vitamin. This type is contained in Cardiovascular Research's Allithiamine. A large number of HIV-positive people have reported to me their successful elimination of neuropathy with the combined use of the B vitamins discussed here. The information on acetyl-l-carnitine is too recent for much in the way of anecdotal reports to have surfaced, but it might be an important addition to improve the chances for successful elimination of neuropathy. Research has made it clear that people living with HIV are often deficient in carnitine.
<P>
Alpha-lipoic acid has long been used in Europe for the treatment of peripheral neuropathy in diabetics. A number of controlled clinical trials have shown its usefulness for reducing both the pain and numbness suffered by those with diabetic neuropathy, and its use for this condition is approved in Germany.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0504">(5)</a> <a name="retour0504"> </a>  Its antioxidant properties may help protect the nerves from the inflammation and oxidative damage that HIV induces, as has been shown to be true with diabetic neuropathy.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0505">(6)</a> <a name="retour0505"> </a> Because of its liver protective and antioxidant benefits, it has been included as a component of the programs of many of my clients for several years now. It may have contributed to the success of the neuropathy elimination programs some of them have used.
<P>
Gamma linolenic acid is an essential fatty acid found in borage oil, grape seed oil, black currant oil, and evening primrose oil that has been shown to be successful in reversing nerve damage in diabetics suffering from peripheral neuropathy. In a double-blind, placebo-controlled study using 480 mg of GLA daily, all the diabetics given the fatty acid experienced gradual reversal of nerve damage and improvement in the symptoms related to the peripheral neuropathy, while those on placebo gradually worsened.<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:12 #note0506">(7)</a> <a name="retour0506"> </a> It is thought that GLA may help to rebuild the myelin sheath around the nerves, thus restoring proper nerve conduction.
<P>
Magnesium is also known to be necessary for nerve conduction; deficiency is known to cause peripheral neuropathy symptoms. Thus, including optimal amounts of magnesium might contribute to elimination of neuropathy. There have also been reports of chromium deficiency causing peripheral neuropathy. I learned this too recently for chromium to have been included in most of the neuropathy therapy programs used by my clients in the past and, thus, I'm not sure what it might contribute. However, chronic infection is known to deplete body stores of chromium, so adding a dose of perhaps 200-400 mcg/day to a complete nutrient protocol might be reasonable.
<P>
In addition to all the nutrient supplements, an analysis of data coming out of the Immune Enhancement Program in Portland, Oregon, appears to show that their program, which includes Chinese herbs along with acupuncture and various other therapeutic approaches, results in improvement in neuropathy for some.
<P>
For additional information on the nutrients which might be helpful for eliminating neuropathy, including appropriate dosage ranges, see the individual nutrient entries in Chapter Six of POSITIVELY WELL, &quot;Therapeutic Basics.&quot; If you are considering supplementation with any of the B vitamins discussed above, never forget that although B vitamins are by and large non-toxic, any individual B vitamin should always be taken along with the full B complex to prevent imbalance in the body. Long-term use of very high doses of individual B vitamins taken alone, without the rest of the B complex, can induce imbalances or deficiencies in other B vitamins.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:9.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-124</DOCNO>
<DOCOLDNO>IA017-000178-B003-221</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:10 192.33.214.13 19970106042523 text/html 8330
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:9.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>World Wide Web: AIDS TREATMENT NEWS Lists Over 100 Sites</h3>
<P>
by Tadd Tobias and John S. James
<P>
As this issue goes to press, AIDS TREATMENT NEWS is opening its second Web site, the AIDS TREATMENT NEWS Internet Directory (<a href="http://www.aidsnews.org">http://www.aidsnews.org</a>). This site will help people find AIDS treatment and related information on the Internet. Also, it will report news about AIDS-relevant World Wide Web sites, and the information they have available.
<P>
The list below shows the titles of the sites we are including initially, organized by categories. We published it here to show readers the variety of information currently available on the Internet. We did not include the URLs (Internet addresses), because of limited space, and because anybody with access to the World Wide Web can visit our site (<a href="http://www.aidsnews.org">http://www.aidsnews.org</a>) and use the most current version of the list to link to any of the sites.
<P>
Please let us know about sites we overlooked, and about any other ideas for improving this directory.
<P>
<blockquote>Treatment Advocates and Information Providers
<P>
<ul> <li>  ACT UP / Golden Gate
<P>
<li>  ACT UP/Paris
<P>
<li>  ACT UP/Philadelphia
<P>
<li>  ACT UP/New York
<P>
<li>  AIDS Info BBS Database
<P>
<li>  AIDS Research Information Center
<P>
<li>  AIDS Treatment Data Network
<P>
<li>  Californians for Compassionate Use/Cannabis Buyers Club
<P>
<li>  CATTY
<P>
<li>  Critical Path AIDS Project
<P>
<li>  Hemophilia Home Page
<P>
<li>  HIVNET/GENA Information Server
<P>
<li>  Joint Project on Legal and Ethical Issues of AIDS/HIV
<P>
<li>  Mothers' Voices Home Page
<P>
<li>  NATAP (National AIDS Treatment Advocacy Project)
<P>
<li>  Outline
<P>
<li>  Project Inform
<P>
<li>  PWA Health Group
<P>
<li>  The Body
<P>
<li>  Treatment Action Group
<P>
<li>  VACTUP</ul>
<P>
Service Organizations
<P>
<ul> <li>  ACSN - AIDS Caregivers Support
<P>
<li>  AIDS Project Los Angeles
<P>
<li>  Gay Mens' Health Crisis
<P>
<li>  KAIROS Support for Caregivers
<P>
<li>  NAMES Project
<P>
<li>  Project Open Hand</ul>
<P>
Newsletters
<P>
<ul>  <li>  AIDS TREATMENT NEWS Online
<P>
<li>  Antiviral Agents Bulletin Home
<P>
<li>  CDC AIDS Daily Summary
<P>
<li>  Critical Path Project, AIDS Treatment Publications
<P>
<li>  HIV/AIDS Treatment Information
<P>
<li>  Keep Hope Alive Home Page
<P>
<li>  NAM AIDS Treatment Update</ul>
<P>
Alternative/Complementary Treatment Information
<P>
<ul> <li>  Acupuncture Home Page
<P>
<li>  ALTMED WEB Home Page
<P>
<li>  Bastyr University AIDS Research
<P>
<li>  Critical Path AIDS Project
<P>
<li>  Homeopathy Home Page
<P>
<li>  Immune Enhancement Project
<P>
<li>  Power - Program For Wellness Restoration
<P>
<li>  The Alternative Medicine Homepage
<P>
<li>  World Health Network
<P>
<li>  Yoga for HIV/AIDS</ul>
<P>
Clinical Trials Information
<P>
<ul>  <li>  AIDS Clinical Trials Information
<P>
<li>  AIDS Clinical Trials Unit at Washington University
<P>
<li>  Canadian Trials Network
<P>
<li>  CenterWatch Clinical Trials List
<P>
<li>  Clinical Trials offered in Hawaii
<P>
<li>  Critical Path AIDS Project
<P>
<li>  NAM AIDS Treatment Update
<P>
<li>  Trials Search: California HIV Clinical Trials
<P>
<li>  UCLA Care Center</ul>
<P>
Experts Online to Answer Your Questions
<P>
<ul> <li>  AIDS on line!
<P>
<li>  AMA Expert Advice
<P>
<li>  Profnet
<P>
<li>  Vanderbilt Univ. Med. Center HIV/AIDS Online Help
<P>
<li> CME (Continuing Medical Education) Online
<P>
<li>  CMV Retinitis &amp; Treatment (an online CME course)
<P>
<li>  Online HIV CME</ul>
<P>
Conferences and Abstracts, Medical Literature
<P>
<ul>  <li>  Cambridge Healthtech Institute
<P>
<li>  Establish_Online_Account (MEDLARS)
<P>
<li>  Infectious Diseases Society of America
<P>
<li>  Internet Grateful Med
<P>
<li>  National Library of Medicine - MEDLARS
<P>
<li>  Pharmaceutical Information Network
<P>
<li>  SCIENCE On-Line
<P>
<li>  XI International Conference on AIDS</ul>
<P>
Medical Sites, Miscellaneous
<P>
<ul> <li>  British Columbia Centre for Excellence in HIV and AIDS
<P>
<li>  Glossary of Terms
<P>
<li>  International Association of Physicians in AIDS Care
<P>
<li>  JAMA - HIV Site
<P>
<li>  Medscape
<P>
<li>  OncoLink, The University of Pennsylvania
<P>
<li>  Resources by Disease &amp; Condition
<P>
<li>  Roxane Pain Institute
<P>
<li>  Spinnaker
<P>
<li>  The World-Wide Web Virtual Library</ul>
<P>
Corporate Sites
<P>
<ul> <li>  Immune Network Research Ltd.
<P>
<li>  Pharmacia and Upjohn: Expanded Access ... delavirdine
<P>
<li>  Stadtlanders' HIV &amp; AIDS Focus
<P>
<li>  VSB Corp. (Viatication)
<P>
<li>  Welcome to Isis Pharmaceuticals</ul>
<P>
Children and AIDS
<P>
<ul> <li>  Children with AIDS Project
<P>
<li>  Mothers' Voices Home Page
<P>
<li>  MSSM: Adolescent AIDS Prevention
<P>
<li>  Pediatric AIDS Canada
<P>
<li>  The CANDII Program</ul>
<P>
Spiritual
<P>
<ul>  <li>  AIDS National Interfaith Network
<P>
<li>  Belly of the Buddha
<P>
<li>  The HIV/AIDS Ministries Network</ul>
<P>
Government
<P>
<ul> <li>  CDC National AIDS Clearinghouse
<P>
<li>  Food and Drug Administration
<P>
<li>  HyperDOC: U.S. National Library of Medicine
<P>
<li>  National Institute of Allergy and Infectious Diseases
<P>
<li>  National Institutes of Health
<P>
<li>  Social Security Administration
<P>
<li>  Thomas: Legislative Information on the Internet</ul>
<P>
Unconventional Theories
<P>
<ul> <li>  AIDSAuthority (including Duesberg theory) </ul>
<P>
AIDS Directories on the Web
<P>
<ul> <li>  AIDS TREATMENT NEWS Internet Directory
<P>
<li>  Emory University MedWeb: AIDS and HIV
<P>
<li>  Galaxy/EINet AIDS and HIV Resources
<P>
<li>  HIVNET AIDS Resources on the Internet
<P>
<li>  HIV: Electronic Media Information Review
<P>
<li>  JRI Health InfoWeb
<P>
<li>  Links to Other Resources
<P>
<li>  Marty Howard's HIV/AIDS Home Page
<P>
<li>  Medical Matrix-AIDS Information
<P>
<li>  New York Academy of Medicine
<P>
<li>  NOAH: AIDS and HIV Resources
<P>
<li>  Queer Resources Directory (QRD)
<P>
<li>  The World-Wide Web Virtual Library
<P>
<li>  Vanderbilt AIDS Resources
<P>
<li>  Yahoo! - Health:Diseases and Conditions</ul>
<P>
Web Search Engines
<P>
<ul><li>  Alta Vista
<P>
<li>  Architext Querying
<P>
<li>  Critical Path AIDS Project
<P>
<li>  Deja News Research Service
<P>
<li>  Internet Searching Center
<P>
<li>  Search.com</ul>
<P>
International Focus
<P>
<ul>  <li>  AIDS Surveillance in the Americas
<P>
<li>  AVERT HOME PAGE
<P>
<li>  Crusaid HIV Information Exchange
<P>
<li>  Educational Information on HIV for Singapore
<P>
<li>  European Information Center for HIV and AIDS
<P>
<li>  FQD: AIDS/HIV Resources for Filipinos
<P>
<li>  Harvard AIDS Institute
<P>
<li>  HIV/AIDS Statistics in Thailand
<P>
<li>  HIV: Electronic Media Info. Review from Australia
<P>
<li>  Hong Kong AIDS Foundation
<P>
<li>  IRCAM AIDS and HIV - informations and resources
<P>
<li>  World Health Organization</ul>
</blockquote>
<P>
[Note: <a href="http://www.aidsnews.org">http://www.aidsnews.org</a> also includes listings of sites for technical/specialized research topics, Internet free speech, and AIDS sites in French, German, Italian Spanish, and other languages. Our resource list for women and AIDS was not complete when this issue went to press, but will be in the Web site.]
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:9.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-125</DOCNO>
<DOCOLDNO>IA017-000178-B003-232</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:11 192.33.214.13 19970106042533 text/html 2971
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:25:54 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>AIDS TREATMENT NEWS</h3>
<P>
Published twice monthly
<P>
Subscription and Editorial Office:
<blockquote>P.O. Box 411256
San Francisco, CA 94141
800/TREAT-1-2 toll-free U.S. and Canada
415/255-0588 regular office number
fax: 415/255-4659
Internet: <a href="mailto: aidsnews@aidsnews.org">aidsnews@aidsnews.org</a></blockquote>
Editor and Publisher:
<blockquote>John S. James
Reader Services and Business:
Richard Copeland
Tom Fontaine
Denny Smith
Tadd Tobias</blockquote>
<P>
Statement of Purpose:
<P>
AIDS TREATMENT NEWS reports on experimental and standard treatments, especially those available now. We interview physicians, scientists, other health professionals, and persons with AIDS or HIV; we also collect information from meetings and conferences, medical journals, and computer databases. Long-term survivors have usually tried many different treatments, and found combinations which work for them. AIDS Treatment News does not recommend particular therapies, but seeks to increase the options available.
<P>
Subscription Information:
<blockquote>Call 800/TREAT-1-2
Businesses, Institutions, Professionals: $230/year.
Nonprofit organizations: $115/year.
Individuals: $100/year, or $60 for six months.
Special discount for persons with financial difficulties:
$45/year, or $24 for six months.</blockquote>
If you cannot afford a subscription, please write or call.
Outside North, Central, or South America, add air mail
postage: $20/year, $10 for six months.
Back issues available.
Fax subscriptions, bulk rates, and multiple subscriptions
are available; contact our office for details.
Please send U.S. funds: personal check or bank draft,
international postal money order, or travelers checks.
VISA, Mastercard, and purchase orders also accepted.
<P>
ISSN # 1052-4207
<P>
Copyright 1996 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
<P>
<I>
AIDS TREATMENT NEWS <BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francico, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255 - 0588 regular office number
</I>
<p>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?250:12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-126</DOCNO>
<DOCOLDNO>IA017-000178-B003-240</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?250:12 192.33.214.13 19970106042541 text/html 2828
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:04 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #250, July 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+250"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><h2>AIDS TREATMENT NEWS Issue #250, July 5, 1996</h2><br>
<P>
<CENTER>
<A HREF="ATN.cgi?250:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3> R&eacute;f&eacute;rences</h3>
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:2 #retour0081">1.</a> <a name="note0081"> </a> Herzenberg LA, De Rosa S, and Herzenberg LA. Low glutathione (GSH) Levels in CD4 T Cells Predict Poor Survival in AIDS; N-Acetylcysteine (NAC) May Improve Survival. OXIDATIVE STRESS AND REDOX REGULATION: CELLULAR SIGNALING, AIDS, CANCER, AND OTHER DISEASES, Institut Pasteur, Paris, May 21-24, 1996.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.1 #retour0501">2.</a> <a name="note0501"> </a> Koutsikos D, Agroyannis B, and Tzanatos-Exarchou H. Biotin for diabetic peripheral neuropathy. BIOMED. PHARMACOTHER. Volume 44, number 10, pages 511-514.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.2 #retour0502">3.</a> <a name="note0502"> </a> Atkins R. DR. ATKIN'S NUTRITION BREAKTHROUGH New York: William Morrow, 1981, page 194.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.2 #retour0503">4.</a> <a name="note0503"> </a> Lowitt S, Malone JI, Salem AF, and others. METABOLISM. 1995; volume 44, pages 677-680.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.2 #retour0504">5.</a> <a name="note0504"> </a> Packer L, Wiott EH, and Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. FREE RADICAL BIOLOGY &amp; MEDICINE 1995; volume 19, number 2, pages 227-250.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.2 #retour0505">6.</a> <a name="note0505"> </a> Kehler W, Kuklinski B, Ruhlman C, and Plotz C. Diabetes mellitus -- a free radical-associated disease: Effects of adjuvant supplementation of antioxidants. In: Gries FA and Wessel K (editors), THE ROLE OF ANTIOXIDANTS IN DIABETES MELLITUS: OXYGEN RADICALS AND ANTI-OXIDANTS IN DIABETES Frankfurt am Main: pmi Verl-Gruppe, 1993:33-53.
<P>
<a href="http://www.hivnet.ch/anais/f/ATN.cgi?250:9.2 #retour0506">7.</a> <a name="note0506"> </a> The Gamma Linolenic Acid Multicentre Trial Group. Treatment of diabetic neuropathy with gamma-linolenic acid. DIABETES CARE 1993; volume 16, number 1, page 8.
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-127</DOCNO>
<DOCOLDNO>IA017-000178-B003-251</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:1 192.33.214.13 19970106042553 text/html 2365
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?250:12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>New Optimism on Controlling HIV Infection</h3>
<P>
by John S. James
<P>
Today there is more optimism among leading experts about the prospects for controlling HIV infection than at any previous time in the AIDS epidemic. This change (illustrated by a recent conference, &quot;Can HIV Be Eradicated from an Infected Individual,&quot; June 12-13 in Washington, D.C., organized by the University of Amsterdam and the journal ANTIVIRAL THERAPY -- and by a major page-one article in the June 14 WALL STREET JOURNAL) does not reflect any single breakthrough, but rather a number of clinical research findings, which together are strengthening an approach to treatment strategy which began coming into public view a few months ago. It is important to understand the limitations as well as the promise of this new approach.
<P>
In late January of this year, at the Third Conference on Retroviruses and Opportunistic Infections, early data from at least two small trials suggested that, under ideal conditions, certain drug combinations could reduce all evidence of viral replication to undetectable levels in most patients. And the proportion of patients achieving this success seemed to increase over time -- the opposite of previous experience with anti-HIV drug treatments, which quickly reached a peak of viral suppression and then steadily lost effectiveness.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?250:12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-128</DOCNO>
<DOCOLDNO>IA017-000178-B003-259</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:1.1 192.33.214.13 19970106042604 text/html 6856
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Today there is more data, and from different kinds of patients, suggesting that:</h4>
<P>
1.) Under ideal conditions -- meaning that treatment is started early, using certain antiviral drug combinations, in patients who are previously untreated (at least with all of the drugs in that combination), and with patients who can and do comply with the treatment regimen by using the drugs as directed -- HIV replication in many patients can indeed be reduced to levels which are completely undetectable by any test known, for prolonged periods of time. No one knows how long this essentially complete shut-off of viral replication will last, because the trials are only running now; but in most of the patients who can achieve this suppression and who can continue using their treatments as directed, there seems to be no evidence yet that this antiviral success is coming to an end. Some people have been on treatment in the studies for well over a year.
<P>
2.) If viral replication can be reduced to undetectable levels, patients do not progress to more serious disease, in the time frame seen so far. Again, no one knows how long this will last, since there is no long-time experience yet with patients whose viral load has been greatly suppressed by drugs.
<P>
Also, there are anecdotal reports of substantial improvements in ongoing AIDS-related symptoms in some of the patients. (There is no scientific data yet on this finding, as trials designed to address this question have not yet been run).
<P>
The viral load in these patients is lower than that in long-term nonprogressors, who remain disease-free for many years, possibly indefinitely in some cases. But the number of persons who are naturally long-term nonprogressors (without treatment) is low, probably about five percent or less. By contrast, it appears that currently available drug treatments -- when used under ideal conditions -- can suppress all evidence of viral replication and disease progression in most patients, for an unknown period of time.
<P>
3.) The major problem in treating HIV has been that the virus develops resistance to all known drugs, causing treatments to lose effectiveness. It has long been known that the time required for resistant virus to develop varies greatly, depending on the drug. For example, with nevirapine (an experimental treatment recently recommended for approval by an FDA advisory committee), high-level resistance occurs very quickly if the drug is used alone. But AZT resistance develops more slowly, and some patients can use that drug for years without it happening (although there is increasing concern about people being infected with virus which has already become resistant to AZT -- and also concern that some AZT-resistant viruses may be more harmful than most non-
resistant viruses, even aside from the problem of loss of effectiveness of AZT).<br>
<P>
But now there are trials of antiviral drug combinations active enough to reduce viral replication to undetectable levels in many patients. And it is being learned that when viral replication is reduced to a low enough level, the development of drug resistance is greatly slowed, or possibly even stopped. The example of nevirapine shows how large this difference can be, since resistance develops rapidly if used as a single drug or a single addition to ongoing therapy. But in the right combinations, for patients previously untreated with any of those drugs, nevirapine appears to be useful for a long time.
<P>
4.) Like almost all treatments for infectious diseases, this approach works best when treatment is started early -- and when patients do not already have resistance to any of the drugs in the combination they are starting (either from previous use of a drug in a dose which was not effective in shutting off viral replication, or by infection with virus which was already resistant). But there is no known reason why the same approach could not also work in advanced patients who have had many previous treatments, provided that some way could be found to reduce viral load to a low enough level. The problem is that it will be more difficult to find drug combinations which can do this for persons with more advanced HIV disease. This is why it is important to develop new and more powerful drugs, and better information about how to use them in combination, and about what treatments work best for different kinds of patients.
<P>
The emerging view of experts today is that what counts is getting the viral load very low and keeping it very low, regardless of how this is achieved -- whether naturally in persons fortunate enough to be long-term nonprogressors, or by whatever antiviral combination works for the particular patient. The more advanced the illness, the higher the viral load is to start with, the more drug-resistant viruses the patient already has, and the more problems there are with continuing the drugs and using them as directed, the more difficult it will be to get the viral load low enough. To maximize potential benefit, the emerging treatment philosophy is &quot;hit hard and hit early.&quot;
<P>
How low a viral load is low enough? No one knows for sure at this time. A viral load which is and remains below the limit of detection of the Hoffmann-La Roche Amplicor HIV-1 Monitor(TM) test -- the only viral load test currently approved by the FDA -- would seem to be a reasonable goal for now; for more information, see &quot;HIV Viral Load Markers in Clinical Practice,&quot; published in NATURE MEDICINE, June 1996 (reviewed in <a href="/anais/f/ATN.cgi?+248">AIDS TREATMENT NEWS #248, June 7, 1996</a>). [As we reported in our last issue, two free tests to establish a baseline are being offered to everyone with HIV in the U.S., but only for a 60-day period beginning June 17, 1996; for more information, call 1-888-TEST-PCR.]
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-129</DOCNO>
<DOCOLDNO>IA017-000178-B003-270</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:1.2 192.33.214.13 19970106042613 text/html 2483
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Is Viral Eradication Possible?</h4>
<P>
If viral replication can be essentially completely suppressed for a long time, is it possible that the virus remaining in the body would eventually die, meaning that HIV was eliminated and the person could stop taking the drugs and would be cured? This is conceivable, but at this time there is no evidence that this is possible. Eventually some people whose virus is now being completely suppressed by antiviral drugs will try going off the drugs, and then we should find out quickly whether or not the virus comes back. (Two patients who had undetectable viral load for two months and four months did interrupt therapy, and the virus returned; this was reported by Dr. Luc Perrin, of Geneva University Hospital, at the recent HIV Eradication conference mentioned above.)
<P>
Although there is no evidence today that it is possible to eradicate HIV in an infected person, what is new is that the question is now open. Until recently, all drug regimens had been observed to fail with time; therefore, there was no possibility that any amount of those treatments could eliminate the virus. Today, with better treatments, we do not know. But even if it turns out that HIV cannot be eradicated just by suppressing it completely enough for long enough, the new results would still suggest that for many patients viral activity can be stopped for a long time, and drug efficacy maintained, with combinations of currently available drugs.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:1.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-130</DOCNO>
<DOCOLDNO>IA017-000178-B003-282</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:1.3 192.33.214.13 19970106042622 text/html 3576
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:43 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Comment: Practical Concerns</h4>
<P>
Most of the drugs being used in the new trials which appear to have largely shut off HIV replication in many patients are already widely available (in the U.S. and some other countries), by prescription or through expanded-access programs. The researchers running the trials have been unwilling to recommend particular combinations, since what counts is getting the viral load low enough, and the best drugs to use for this purpose will vary depending on the patient. Most of these regimens combine a protease inhibitor with at least two other antivirals. We will report results of particular drug combinations with particular patients as more information becomes available.
<P>
One of the practical difficulties in implementing the &quot;hit hard and hit early&quot; strategy, as the new results suggest, is that it means that people in early illness, who have no symptoms, are expected to begin long-term (possibly life-long) therapy with combinations of at least three drugs. All these drugs can have side effects -- and all are expensive, and often inconvenient to use (as most must be taken twice a day or more, some on an empty stomach, others with food, etc.) How many people will be able and willing to begin and stay on such multiple-drug treatment, when they feel completely healthy, and may understandably be inclined to leave well enough alone? How many will be able to pay for expensive treatment (especially when their insurers see that they appear entirely well)? The new results seem to suggest that everyone who is HIV-positive should be on aggressive treatment with multiple antiviral drugs. But how realistic is this?
<P>
It seems to us that the widespread use of very early, very aggressive treatment will in practice usually wait until more evidence becomes available. Much more will be known by later this year. And it is possible that persons with a naturally low viral load might need less aggressive treatment to achieve the suppression required. It is also possible that after a period of suppression, maintenance therapy might not need to be as aggressive as the initial therapy. But this is only speculation until more is known.
<P>
Meanwhile, physicians and patients should re-think the unfortunately common practice of beginning HIV treatment with AZT alone, or with other regimens not strong enough to suppress the virus sufficiently. This approach is likely to lead to resistant viruses, which might make future treatment more difficult than if the inadequate treatment had never been started at all.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-131</DOCNO>
<DOCOLDNO>IA017-000178-B003-292</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:2 192.33.214.13 19970106042640 text/html 5490
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:26:54 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:1.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Internet Free Speech Wins Court Test</h3>
<P>
by John S. James
<P>
On June 11 a U.S. District Court ruled that the key provisions of the Communications Decency Act of 1996 -- against placing &quot;indecent&quot; or &quot;patently offensive&quot; communications on computers where they might be accessible to minors -- are unconstitutional because they violate the First Amendment of the Bill of Rights. Even though it is not final because the government is likely to appeal to the Supreme Court, this 39,000-word decision is immensely important because it explains the issues and the technology in a way that the legal community can understand. (The current Supreme Court, while conservative in many areas, has generally defended free speech.)
<P>
The June 11 decision does not affect the laws against obscenity and child pornography, which remain illegal on the Internet as elsewhere. But the &quot;indecency&quot; standard is much more far-reaching and vague than obscenity. For example, unlike obscenity, indecency &quot;has not been defined to exclude works of serious literary, artistic, political or scientific value&quot; (quotation from the court decision). The new ruling essentially gives the Internet similar First Amendment protection to what books, newspapers and other print media now have, instead of imposing the much more restrictive standards now applied to broadcast radio and television, which the Communications Decency Act would have done.
<P>
The decision includes an excellent summary of the technology and history of the Internet; we learned much from it. Also impressive is its review of the recent history of the First Amendment, and explanation of the reasons free speech is important in our system of government and society. The court also noted that there are effective ways to keep unsuitable material away from children, without restricting communication among adults.
<P>
The decision took particular note of the &quot;market failure&quot; by which both broadcast and print media have largely become controlled by a few large institutions, with most peoples' participation being passive -- and how the Internet is fundamentally different, with much lower barriers for entry, and essentially the same low barriers for speakers as for listeners. The Court clearly understood that the new law would have a disproportionate effect on individual citizens and on small organizations, while large corporations could protect themselves through expensive legal defenses, and by limiting their material to the mainstream viewpoints that we now receive through the broadcast and major print media. (The Court also noted that the new law would have little effect on commercial pornographers, who already exclude children by requiring credit cards for access to their materials, and therefore would not be much affected by the CDA.)
<P>
The historic importance of this ruling cannot be overemphasized, as many experts suspect that computer communication will become as important as the printing press in human cultural development. The new law would have effectively required adults to limit their use of this medium to communications suitable for children.
<P>
The case which led to this decision was brought by dozens of organizations and companies (in two separate legal actions which were later combined), including the American Civil Liberties Union, American Library Association, American Society of Newspaper Editors, Apple Computer, Microsoft Corporation, America Online, CompuServe, The Microsoft Network, and Prodigy. AIDS organizations included AEGIS, Critical Path AIDS Project, and The Safer Sex Page.
<P>
The decision provided sound bites which were quoted again and again in the media:
<P>
&quot;The Internet may fairly be regarded as a never-ending worldwide conversation. The Government may not, through the CDA, interrupt that conversation. As the most participatory form of mass speech yet developed, the Internet deserves the highest protection from governmental intrusion.&quot;
<P>
The full text of the decision is available at various Internet sites, including <a href="http://www.aclu.org">http://www.aclu.org.</a> AIDS TREATMENT NEWS followed the development of the CDA in issues # <a href="/anais/f/ATN.cgi?227:3">227</a>, <a href="/anais/f/ATN.cgi?229:7">229</a>, <a href="/anais/f/ATN.cgi?236:9">236</a>, <a href="/anais/f/ATN.cgi?237:10">237</a>, <a href="/anais/f/ATN.cgi?238:6">238</a>, and <a href="/anais/f/ATN.cgi?240:9">240</a>.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:1.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-132</DOCNO>
<DOCOLDNO>IA017-000178-B003-301</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:3 192.33.214.13 19970106042653 text/html 1819
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:27:13 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Azithromycin Approved for Once-Weekly MAC Prophylaxis</h3>
<P>
On June 14 the FDA approved azithromycin (Zithromax(R)), adult dose 1200 mg taken once weekly, for prevention of MAC (MYCOBACTERIUM AVIUM complex) disease in persons with advanced HIV infection. According to Pfizer Inc., the new 600-mg tablets will be available in pharmacies in several weeks.
<P>
Azithromycin has been approved in the U.S. for other uses since 1992. The new approval for MAC prophylaxis should help to educate physicians about this treatment option, and also help in getting reimbursement for the drug.
<P>
According to Pfizer, its drug &quot;will be available at a lower cost than currently used MAC prevention therapies.&quot; The company has a patient assistance program to help some patients who need the drug and cannot afford it.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-133</DOCNO>
<DOCOLDNO>IA017-000178-B003-317</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:4 192.33.214.13 19970106042705 text/html 2987
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:27:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Nevirapine Recommended for Approval</h3>
<P>
On June 7 the FDA's Antiviral Drugs Advisory Committee recommended accelerated approval of nevirapine, an experimental antiretroviral currently available through an expanded-access program. The vote in favor of the drug was 8-
0. Official approval is almost certain; nevirapine will then be the first approved member of a new class of anti-HIV drugs (non-nucleoside reverse transcriptase inhibitors).
<P>
Nevirapine was recommended for use in combination with other antiretrovirals, because when the drug is used alone, viral resistance develops quickly. In triple combination with AZT plus ddI, it showed significantly greater improvement in CD4 count increase, and in viral load reduction, than AZT plus ddI plus placebo, lasting at least for the 48 weeks the trial was run.
<P>
In a separate one-year trial with previously untreated patients, those on the triple combination of nevirapine plus AZT plus ddI had an average CD4 increase of 138 at the end of the trial (computing the average increase from weeks 40-52), and the CD4 count was still increasing after one year. Without the nevirapine, those on AZT plus ddI had an increase of 81 in the same time period (weeks 40-52), and their counts were decreasing. The difference between the 138 increase and the 81 increase was statistically significant. Also, about two thirds of those receiving nevirapine plus AZT plus ddI had their viral load reduced to undetectable levels.
<P>
An in-depth article on nevirapine, by Jules Levin of the National AIDS Treatment Advocacy Project, looks in more detail at the nevirapine clinical trial results -- and at safety, drug interactions, viral resistance, status of approvals internationally, and contact information for the expanded access program. This article is available on the World Wide Web at http://www.aidsnyc.org/natap; if you do not have Internet access, you can reach Mr. Levin by fax at 718-
624-8399, or by phone at 718-624-8541.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-134</DOCNO>
<DOCOLDNO>IA017-000178-B003-330</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:5 192.33.214.13 19970106042717 text/html 2128
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:27:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Free Viral Load Tests: Remember to Dial 1 Before 888</h3>
<P>
In our last issue AIDS TREATMENT NEWS published a toll-free phone number, 1-888-TEST-PCR, for patients or physicians to call for information about the availability of free viral load tests, using the Hoffmann-La Roche test newly approved by the FDA. Two tests are being offered to everyone in the U.S. with HIV, but only during the 60-day period starting June 17.
<P>
Some calls never reached the Roche hotline, but came to private homes and businesses instead. This happened because people did not dial the '1' to indicate a long-distance call; as a result, the first seven digits of the number were taken as a local call, and the last three digits were ignored.
<P>
The '888' area code represents a new toll-free phone number, presumably instituted because the familiar '800' numbers are running out. AIDS TREATMENT NEWS normally does not publish the '1' in front of a long-distance number, since people know to dial it. The current confusion occurred because '888' toll-free numbers are new. We will include the '1' with '888' numbers we publish in the future.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-135</DOCNO>
<DOCOLDNO>IA017-000178-B003-345</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:6 192.33.214.13 19970106042729 text/html 3002
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:27:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Needlestick Exposure: CDC Recommends Three-Drug Regimen</h3>
<P>
On June 7 the U.S. Centers for Disease Control and Prevention (CDC) published revised guidelines for antiviral treatment to reduce the risk of HIV transmission due to occupational exposure, such as needlestick injury with HIV-positive blood in a hospital or laboratory. The new guidelines are provisional, as little data is available.
<P>
Because the risk of transmission is low -- only about 3 HIV infections per one thousand percutaneous exposures to HIV-infected blood, and because the antiviral drugs can have side effects, treatment is not recommended in very low risk situations (such as exposure to urine or saliva from HIV-positive persons). When treatment is recommended, it should be started very rapidly, preferably within one to two hours of exposure. The treatment suggested is indinavir (Crixivan(R)) plus AZT plus 3TC for four weeks; however, this regimen should be changed in certain cases, such as with a patient likely to be intolerant to one of those drugs or who is taking incompatible medications.
<P>
The previous recommendation for occupational exposure to HIV called for treatment with AZT. A case-control study found that this use of AZT alone was associated with a 79% reduced risk of seroconversion. There is no human data on the effectiveness of combination treatment in preventing infection due to occupational exposure to HIV (since it takes a long time to get such data, because cases of seroconversion are rare). But all that is known suggests that combination treatment will probably be more effective than AZT alone.
<P>
The complete guidelines were published in the June 7 MMWR (MORTALITY AND MORBIDITY WEEKLY REPORT, of the CDC). According to this publication, updated information about prevention of infection due to occupational exposure to HIV will be available in early 1997 from the CDC's Internet home page (<a href="http://www.cdc.gov">http://www.cdc.gov</a>), and also by fax and telephone.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-136</DOCNO>
<DOCOLDNO>IA017-000178-B003-356</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:7 192.33.214.13 19970106042738 text/html 2899
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>AIDS and Alternative Medicine: A Journalist's Perspective</h3>
<P>
by John S. James
<P>
Remarks to AIDS and Alternative Medicine: Current State of the Science, Bastyr University, Seattle, April 28, 1996:
<P>
I started AIDS TREATMENT NEWS 10 years ago, and the newsletter has now published 245 twice-monthly issues. When we started, we thought that AIDS TREATMENT NEWS would focus mainly on alternative/complementary treatments -- thinking that physicians and patients were already flooded with mainstream treatment information from journals and from industry marketing departments.
<P>
It did not turn out as expected. While some of our most important articles have been about alternative treatments -- for example, the September 1, 1995 interview with acupuncturist John Sinclair of the Immune Enhancement Project in San Francisco -- we have published many more articles about mainstream experimental treatments, or mainstream approved treatments, than about alternative approaches. Partly this is because the journals and pharmaceutical companies have done poorly in getting physicians the mainstream information they need, so most of our readers' questions concern mainstream treatments.
<P>
But also, there is much less research on alternative treatments, due to well-known funding difficulties. Research money, from government as well as from industry, is funneled preferentially into development of the most expensive treatment options -- a major though unrecognized upward pressure on the overall cost of medical care. Our reporting has been affected, because most of the new research findings have come from mainstream research. And we have felt compelled to focus on what is new, because no one has had the answer. Existing treatments, both mainstream or alternative, can be helpful, but most of the answers required to save lives will have to come from new research and development.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-137</DOCNO>
<DOCOLDNO>IA017-000178-B004-9</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:7.1 192.33.214.13 19970106042748 text/html 2215
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>What has been lost from failing to research alternative treatments?</h4>
<P>
The big Vancouver international AIDS conference will happen in two months. After one of the earlier meetings, a physician from the developing world, who had just wandered through the high-tech exhibits and research reports, commented, &quot;There is nothing for us here.&quot;
<P>
That is not surprising, since every medical tradition on Earth except for one has been excluded from any real role in developing new treatments. Only the corporate, high-tech, big-money, FDA-approved research process has been taken seriously. And this year at Vancouver there will be another issue: the unaffordability of the fruits of the big-money tradition, now that it is producing results arguably worth fighting for. Being excluded from AZT monotherapy seldom became a major concern.
<P>
But the loss is not only to the developing world, or to the excluded communities within the United States. For if there are important leads to new approaches within indigenous healing traditions -- and certainly there are -- we are unlikely to hear about them. Excluding almost everybody from the search for better treatments will slow that search greatly.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-138</DOCNO>
<DOCOLDNO>IA017-000178-B004-24</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:7.2 192.33.214.13 19970106042801 text/html 5190
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:7.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Major Problems in Drug Development</h4>
<P>
Some of the biggest problems in medical research and drug development affect mainstream and alternative alike. To simplify the recent history of drug development and approval, several years ago there were two major bottlenecks. One of them was obvious and painfully pressing, and has now largely been fixed, at least for AIDS. The other problem was more subtle, and it remains one of the major challenges for today.
<P>
When AIDS TREATMENT NEWS started reporting 10 years ago, the obvious bottleneck was in the late stage of drug development -- the later steps leading up to FDA approval. It was clear that clinical-endpoint trials were going to be required -- and that if a drug did work, it would take years for all but a few people to get it. The drug had to already look good enough that hard-nosed companies would invest many tens of millions of dollars in its development. And people could read about the drug in the newspapers, but could not get hold of it. This bottleneck, of course, affected only mainstream treatments, since anything which gets that close to approval would be considered mainstream by definition.
<P>
In most cases we do not have this problem in AIDS today. The current FDA leadership has developed regulations for accelerated approval, which allows a drug to be approved based on easily measured markers like CD4 and viral load -- and encouraged various forms of expanded access, which allow companies to provide a drug to many people before approval. The FDA now goes out of its way to find official, legal ways to make available AIDS drugs that the medical community as a whole has good reason to want to get. There are still problems, however: for example, expanded access can work commercially for some large companies, but others are uninterested, and for small companies it may be out of the question.
<P>
But the other bottleneck, early in the drug development process, has not been solved -- and it affects mainstream and alternative treatments as well. This bottleneck, which I believe is the fundamental problem in drug development today, is the difficulty of going from early work to the first credible human data on possible activity or efficacy.
<P>
In the case of mainstream treatments, the early work is usually in the laboratory. Treatment leads which show promise commonly do get published in mainstream, peer-reviewed journals. They get published because publication is the lifeblood of academic careers, so the researchers will fight to reach this stage. But then, in almost all cases, development stops cold, no matter how promising the laboratory results may be. With no human data, no one will invest millions of dollars which current rules usually require to be spent before that human data is available.
<P>
For alternative treatments, the bottleneck occurs after the treatment is already in human use, sometimes widespread human use, but there are no generally accepted scientific studies or data to support its benefit. Usually those studies never happen -- despite the obvious public health importance of researching treatments which are in widespread use, whether they work or not.
<P>
Part of the tragedy is that if a new drug or other treatment approach or idea could reach the stage of early data -- the first credible showing of activity in humans, even if less than a controlled trial -- then the existing system of drug development might respond passably well. Pharmaceutical companies, physicians, academics, and others will start being interested, and the treatment will have the momentum to carry it into further stages of research. But before it has that first credible human data, there is no sufficient evidence, no momentum, to start the ball rolling. Laboratory results, biological plausibility, or popular interest and use, have usually not been enough.
<P>
Much of the advance of medicine comes from lucky accidental discovery, in which the unexpected is allowed to reveal itself. Today's system poisons this well of potential discovery, by making research so cumbersome and expensive that it can only test ideas which already have widespread support in advance.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:7.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-139</DOCNO>
<DOCOLDNO>IA017-000178-B004-32</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:7.3 192.33.214.13 19970106042811 text/html 8441
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:33 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:7.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>What Can Be Done?</h4>
<P>
How might research be organized to overcome this particular gap between widespread use of an alternative treatment, and widely credible data showing possible activity or effectiveness? We see several possible approaches. They are relevant not only to researchers, but also to physicians, patients, advocates, public officials, and potential donors who might support research.
<P>
<li> Use of viral load. Viral load testing, now widely used although not quite yet officially approved by the FDA, has made it far easier than before to tell whether or not a drug is working as an antiviral. A major antiviral effect would ordinarily show up in a few days, or a couple weeks at most. This means that the first human trials can now be far shorter than before. The treatments that don't work could be stopped within a couple weeks -- freeing resources to continue the trials for the minority of treatments which did reduce viral load, to get long-term data for them.
<P>
<li> Developing less cumbersome and expensive ways than controlled clinical trials to get credible initial data. The U.S. National Cancer Institute has published guidelines for &quot;best case series&quot; reports from physicians who use unconventional cancer therapies. And in surgery (where randomized controlled trials of operations are now being seriously considered) -- there is also interest in improving case series reports (see THE LANCET, April 13, 1996). The purpose of using case series is not to replace clinical trials, but to help make a preliminary judgment as to what treatments should go into the trials, which will be conducted at great financial and human cost.
<P>
<li> Investigating existing obstacles to credibility. For ten years AIDS TREATMENT NEWS has been answering phone calls for information about particular treatments. Often the calls come in groups; we will suddenly get a number of calls about some particular treatment, mainstream or alternative. We have had a chance to look at what is behind the calls.
<P>
For mainstream treatments, and sometimes for nutritional approaches as well, a flurry of calls usually means that research just published in a high-status journal was reported by major newspapers or TV networks. What is driving this interest is scientific discovery.
<P>
But behind a flurry of calls about an alternative treatment, in most cases, is not a scientific advance, but a marketing campaign to make money for someone. A new incarnation of some old pill or machine is being pushed.
<P>
Recently we used the Internet's World Wide Web to do computer searches on alternative treatments. We used a search engine called Alta Vista (described below), which immediately checks over 20 million existing Web pages for whatever words we specify, and returns results immediately. About 4,000 pages include the phrase &quot;alternative medicine.&quot; But a great many of them were listings of health-food type products for sale. When we asked the search engine to eliminate all those that contained the word &quot;product&quot; or &quot;products,&quot; we got the total down to a more manageable 2,000.
<P>
The fact that a product is commercially promoted does not mean it doesn't work. But it can make it hard for us to get a sense of whether it works or not. We do not know the people behind the campaign; do they believe in their own product? Do they have evidence, and are they evaluating it well? Or are they only pursuing a marketing challenge, in which their goal is to sell as much as they can, without any need to know whether or not it works?
<P>
Occasionally a flurry of phone calls or letters results not from a commercial promotion, but from activities of a true believer. Here the credibility problem is largely the same. It is hard to tell what you can trust and what you cannot.
<P>
The pharmaceutical-industry mainstream deals with this problem by having third parties, usually academic or clinical research physicians, conduct its research. While the company pays the money, the researcher's career depends only slightly if at all on whether there are positive results -- but depends centrally on a continued reputation for objectivity.
<P>
Perhaps the alternative-treatment world could borrow this system, too. The difference would be that we will never have the money that pharmaceutical companies have, and therefore must find research strategies which are far less expensive. This is possible, since most alternative treatments are already in frequent human use, so trials are much safer than those testing a new chemical entity which no human has ever encountered before.
<P>
But the history so far is not always promising. Often academics are misused in a way which constitutes a sale of their name for use in a marketing campaign. Hungry researchers or institutions which have a public reputation are hired to do some laboratory test or other piece of the research on an alternative product -- a test which has little or nothing to do with whether the product works as claimed. The academics do their job competently, but meanwhile their name is plastered on ads or promotional articles, to make the product appear to have credibility it would not otherwise have had. This practice complicates the search for methods to do the research right.
<P>
<li> Better standardization and handling of patient data. Much could be learned without the human and material costs of trials by analysis of data already generated in medical practice. But the data needs to be computerized, in ways which avoid unnecessary inconsistencies between the records of different practices. Then the data might be pooled anonymously -- or if that was not sufficient to protect confidentiality, researchers could get statistical summaries from the different offices and analyze those.
<P>
<li> More openness to and more equal communication with indigenous and traditional healers and traditions. Usually we will have to start our learning process on their terms -- not start with trying to force what they are doing into our preconceived scientific mindset.
<P>
Ultimately, to make knowledge widely transportable and useful, we will need to find credible ways of testing proposed approaches. But these ways need to be developed in collaboration. It will often not work to bring in a preconceived piece of scientific methodology developed in other contexts and for other purposes.
<P>
One potential resource for starting this learning process is ExtraMED, a new database created by the World Health Organization, of over 200 medical journals in developing countries. These journals are excluded from Medline, Embase, and other major bibliographic databases, and therefore largely unknown to researchers in the developed world. (For more information about ExtraMED, see below).
<P>
<li> Case studies of successful medical advancement. We can learn from history and analysis of important medical advances -- in the Western scientific tradition, but in other traditions as well.
<P>
<li> Building educated donor networks. We must be ready to explain research issues to persons who could contribute major support for research, but who may want to be sure that their money does not go down the same ratholes where so much has gone already. We need to learn what it is about a research project which disposes it to success, and what disposes it to failure -- and be ready to share this knowledge with others.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:7.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:7.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-140</DOCNO>
<DOCOLDNO>IA017-000178-B004-40</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:7.4 192.33.214.13 19970106042820 text/html 2604
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:7.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Appendix: ExtraMED Database</h4>
<P>
ExtraMED is a database of over 220 biomedical journals selected by the World Health Organization as among the best in the developing world. But almost all of these journals are not indexed in Medline, Science Citation Index, or any other Western indexing service. Therefore most researchers never find out about this published research.
<P>
An eye-opening article in the August 1995 SCIENTIFIC AMERICAN, &quot;Lost Science in the Third World&quot; by staff writer W. Wayt Gibbs, compiles appalling statistics on the exclusion of developing-country research from the world's scientific literature. A handful of indexing services have come to serve as gatekeepers of whose work can reach the scientific community. They have allowed only two percent participation in science from 80 percent of the world. And the numbers have become seriously worse during the last ten years.
<P>
ExtraMED, now in its second year, claims particular strength &quot;in such topics as AIDS, tropical medicine, communicable diseases, emergency conditions, and traditional medicine.&quot; The database is distributed on CD-ROM, which stores the complete text of all pages of all articles as high-quality images -- together with a cumulative index which allows all disks to be searched with one command.
<P>
ExtraMED costs $1800 a year for 10 disks (50% less in the developing world). For more information, contact DV Trimmer, Informania Ltd., P.O. Box 1359, London W3 0ZU, England; fax 011-44-1730-265398, email <a href="mailto:100060.172@compuserve.com">100060.172@compuserve.com</a>.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:7.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?249:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-141</DOCNO>
<DOCOLDNO>IA017-000178-B004-48</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?249:8 192.33.214.13 19970106042828 text/html 3057
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #249, June 21, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+249"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #249, June 21, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:7.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>AIDS TREATMENT NEWS</h3>
<P>
Published twice monthly
<P>
Subscription and Editorial Office:
<blockquote>P.O. Box 411256
San Francisco, CA 94141
800/TREAT-1-2  toll-free U.S. and Canada
415/255-0588 regular office number
fax: 415/255-4659
Internet: <a href="mailto:aidsnews@aidsnews.org">aidsnews@aidsnews.org</a></blockquote>
Editor and Publisher:
<blockquote>John S. James</blockquote>
Reader Services and Business:
<blockquote>Richard Copeland
Tom Fontaine
Denny Smith
Tadd Tobias</blockquote>
<P>
Statement of Purpose:
<blockquote>AIDS TREATMENT NEWS reports on experimental and standard treatments, especially those available now. We interview physicians, scientists, other health professionals, and persons with AIDS or HIV; we also collect information from meetings and conferences, medical journals, and computer databases. Long-term survivors have usually tried many different treatments, and found combinations which work for them. AIDS Treatment News does not recommend particular therapies, but seeks to increase the options available.</blockquote>
<P>
Subscription Information: Call 800/TREAT-1-2
<blockquote>Businesses, Institutions, Professionals: $230/year.
Nonprofit organizations: $115/year.
Individuals: $100/year, or $60 for six months.</blockquote>
Special discount for persons with financial difficulties:
<blockquote>$45/year, or $24 for six months. If you cannot afford a subscription, please write or call.</blockquote>
Outside North, Central, or South America, add air mail postage:
<blockquote>$20/year, $10 for six months.
Back issues available.
Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details.
Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks.
VISA, Mastercard, and purchase orders also accepted.</blockquote>
<P>
ISSN # 1052-4207
Copyright 1996 by John S. James.  Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:7.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-142</DOCNO>
<DOCOLDNO>IA017-000178-B004-61</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:1 192.33.214.13 19970106042837 text/html 4235
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:28:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?249:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Viral Load Approved; Free Test Offered to All in U.S. with HIV</h3>
<P>
by John S. James
<P>
On June 3 the FDA approved the Hoffmann-La Roche Amplicor HIV-1 Monitor(TM) viral load test, the first viral load test officially approved for clinical use in the United States. (The same test has already been marketed in Europe, and in some other countries, for over a year.) And Hoffmann-La Roche announced that it will offer two free baseline tests to everyone with HIV in the U.S. (regardless of finances, and regardless of what treatments they may have used or now be using), but only during a 60-day period starting June 17.  Patients or physicians who want more information about this free testing program should call 888/TEST-PCR, a toll-free number.
<P>
It is recommended that two tests be used to establish a baseline. Because some illnesses and vaccinations can temporarily stimulate HIV (as much as 300 fold) and produce misleading viral load results, &quot;HIV RNA levels should not be measured within a month of acute illnesses or within a month after influenza and pneumococcus immunizations,&quot; according to clinical practice recommendations published this month in NATURE MEDICINE (see <a href="/anais/f/ATN.cgi?248:2">&quot;Viral Load: New Recommendations for Clinical Practice,&quot;</a> below).
<P>
The newly-approved test is based on PCR, one of three different methods for measuring viral load which have been widely used in research. (The other two methods are branched DNA, and NASBA; it is widely agreed that all three measure basically the same thing, although there can be variations in how sensitively the different methods detect a particular patient's viral subtypes. For this reason it is usually better for a patient to stay with one kind of test, not use the different tests interchangeably.)
<P>
In the U.S., viral load testing has already been available to physicians for about two years, but there have been disadvantages which appear now to have been overcome. PCR was available through &quot;home-brew&quot; tests (meaning that the laboratory which offered the service had to prepare its own reagents), and there have been questions about the quality control at some labs. In contrast, the approved PCR test is provided to the labs in a kit with the reagents strictly standardized, and now the quality control has been checked by the FDA. Also, viral load using branched-DNA technology has been and is available through Chiron Corporation, which recently applied for official FDA approval (the FDA has not acted on Chiron's application yet). The Chiron tests are reliable, but the version now available to physicians (outside of research) cannot measure viral load counts below 10,000 copies. (The newer second-generation branched-DNA test, used by researchers for about two years, can measure down to about 500 copies, and is basically equivalent to the Roche test just approved. An advantage of the Chiron test is that it has been carefully standardized to accurately measure the different subtypes of HIV found all over the world. Roche told us that its test already accurately measures the subtypes commonly found in the U.S., and that its second-generation test will include others as well.)
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?249:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-143</DOCNO>
<DOCOLDNO>IA017-000178-B004-68</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:1.1 192.33.214.13 19970106042855 text/html 4162
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:29:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Comment</h4>
<P>
Exactly what indications viral load testing would be approved for -- important for reimbursement, and perhaps even more so for improving the prevailing standard of HIV care -- has been controversial. Everyone agrees that the three major kinds of viral load testing (PCR, branched-DNA, and NASBA) do measure what they claim to measure. Everyone agrees that viral load provides important information about prognosis, that persons with a high viral load are likely to do worse. The Roche test was easily approved for these purposes.
<P>
A month ago it looked like this was all the approval this viral load test would get -- which would have given insurance companies, HMOs, and other payers an excuse to reimburse for only two viral load tests (for the baseline) in a patient's lifetime, depriving many patients' doctors of the tools to get the most benefit from protease inhibitors and other new therapies. This almost happened because, for historical reasons, the test was reviewed by the FDA's Blood Products Advisory Committee, and by the Biologics division of the FDA, which are relatively unfamiliar with HIV -- and because Roche did a poor job of presenting its case for approval to that committee.
<P>
The controversial issue was whether to also recommend the test for monitoring patients, especially for determining whether an antiviral drug or regimen is having the intended antiviral effect in a particular patient. Everything now known about HIV and antivirals strongly supports this use. But the final evidence -- a body count proving that patients who are randomly assigned to have their physician not use viral load do worse than those randomly assigned to have their physician use it -- is not yet available (such trials are under way now). Activist pressure may have helped in getting the FDA to include a statement on clinical use, although hedged:
<P>
&quot;The test has also been used as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels. The clinical significance of changes in HIV RNA measurements has not been fully established although several large studies that will more fully determine the role of comparative HIV RNA measurements in patient management are now in progress. HIV-1 RNA levels as measured by PCR were used as one of the surrogate markers in the accelerated approval process for the protease inhibitor drugs Invirase(TM), Crixivan(R), and Norvir(R), and for the reverse transcriptase inhibitor drug Epivir(TM). The utility of plasma HIV-1 RNA in surrogate endpoint determinations has not been fully established.&quot;
<P>
THE NEW YORK TIMES covered the approval accurately on June 4, but most other media reporting has been superficial. The reason is clear; much of the background on this story was not conveyed in the FDA and Roche press releases. Even the TIMES noted the concern that Roche and other companies had not applied for approval much earlier than they did -- without mentioning that a major reason for this was the lack of clarity at the FDA (and in the professional community) about what evidence would be required for approval<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-144</DOCNO>
<DOCOLDNO>IA017-000178-B004-78</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:1.2 192.33.214.13 19970106042904 text/html 2262
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:29:26 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>What You Can Do Now</h4>
<P>
We believe that everyone with HIV should get the two tests to establish a baseline; and for 60 days only (starting June 17), persons in the U.S. can get them free. (This is not charity from Roche; probably most physicians who have used viral load have used the Chiron test, and Roche clearly hopes that the free offer will get many of them to switch to its product. Roche is donating the test kits, and certain laboratories are donating their services, also clearly in the hope of future business. Patients or their HMOs, etc. will probably need to pay for the physician's office time and the blood draws.) For more information about this free test offer, call the Roche Amplicor(R) Access Program toll-free hotline, 888/TEST-PCR, between 8:30 a.m. and 5:00 p.m. Eastern time; patients can request an enrollment packet to be sent to their physician.
<P>
The same hotline will also help patients obtain reimbursement for the test after the 60-day free program.
<P>
Even if one does not plan to get further viral load testing, establishing a baseline is important because it helps with decisions about how aggressive to be with therapy, and it leaves open the option of getting tested later to see if one's viral load has changed.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-145</DOCNO>
<DOCOLDNO>IA017-000178-B004-89</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:2 192.33.214.13 19970106042913 text/html 3308
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:29:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Viral Load: New Recommendations for Clinical Practice</h3>
<P>
by John S. James
<P>
A panel of leading HIV clinicians and researchers has published interim recommendations for how to use viral load testing, based on currently available knowledge.<a href="/anais/f/ATN.cgi?248:12 #note0231">(1)</a> <a name="retour0231"> </a> The recommendations, which appear in the June 1996 issue of NATURE MEDICINE, answer common questions of physicians and patients about when to use the test and what the numbers mean. The information is current; while the recommendations represent months of work by the authors, NATURE MEDICINE published them very rapidly, about one month after receiving the manuscript.
<P>
The article summarizes the recommendations in a table:
<P>
<li> Plasma HIV RNA level that suggests initiation of treatment: More than 5,000-10,000 copies/ml and a CD4+ count/clinical status suggestive of progression; [or] &gt;30,000-50,000 regardless of laboratory/clinical status.
<P>
<li> Target level of HIV RNA after initiation of treatment: Undetectable; &lt;5,000 copies/ml is an acceptable target.
<P>
<li> Minimal decrease in HIV RNA indicative of antiviral activity: &gt;0.5 log decrease.
<P>
<li> Change in HIV RNA that suggests drug treatment failure: Return to (or within 0.3 to 0.5 log of) pretreatment value.
<P>
<li> Suggested frequency of HIV RNA measurements: At baseline, 2 measurements, 2-4 weeks apart.  Every 3 to 4 months or in conjunction with CD4+ counts.  Shorter intervals as critical decision points are neared.  3-4 weeks after initiating/changing therapy.&quot;
<P>
(For those not familiar with logarithms, a 1.0 log change means a 10-fold change; a 0.5 log change is about 3-fold; and a 0.3-log change is 2-fold. So the third of the five points quoted above means that an antiviral treatment should decrease viral load to less than a third of its starting value, for the physician to be confident that the treatment is working. Less of a decrease might have been due to testing errors, or to normal daily fluctuations in viral load.)
<P>
The NATURE MEDICINE paper also reviewed the major published research on the relationship of viral load to HIV disease progression.
<P>
The team which prepared the recommendations was convened by the International AIDS Society U.S.A.
<P>
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-146</DOCNO>
<DOCOLDNO>IA017-000178-B004-99</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:3 192.33.214.13 19970106042926 text/html 2605
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:29:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Viral Load: New Proof of Importance for Disease Staging and Prognosis</h3>
<P>
by John S. James
<P>
Research findings published May 24 <a href="/anais/f/ATN.cgi?248:12 #note0232">(2)</a> <a name="retour0232"> </a> have extended earlier work showing the importance of viral load in predicting HIV disease outcome. Measurement of plasma HIV RNA (indicating the concentration of virus in the blood) was found to be a much more accurate predictor of later illness than CD4 (T-helper) count, strongly suggesting that patients and physicians should consider viral load when making HIV treatment decisions. This data provides longer followup than for any previous study of viral load.
<P>
The research team, mostly from the University of Pittsburgh but including two members from Chiron Corporation, looked at disease outcomes in a cohort of 180 HIV-positive gay or bisexual men who were enrolled between April 1984 and March 1985 in the Pittsburgh site of the MACS study (Multicenter AIDS Cohort Study). The 180 include all who were HIV-positive when they enrolled at the Pittsburgh site, and for whom frozen plasma samples were available for testing. It is not known how long the men were infected before they enrolled.
<P>
Only 41% of the 180 volunteers received antiretroviral treatment at any time during the study. [It is important to note that the average survival times today will almost certainly be longer than those reported below, which indicate survival starting ten years ago when much less treatment was available.] [Note: Brackets are used to indicate our comments about the article -- JSJ.]
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-147</DOCNO>
<DOCOLDNO>IA017-000178-B004-110</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:3.1 192.33.214.13 19970106042936 text/html 5406
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:29:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>The data were looked at in several different ways:</h4>
<P>
<li> First, the researchers used viral load at entry into the study to divide the 180 volunteers into quartiles (four equal groups, of 45 each, with the highest, second-highest, second-lowest, and lowest viral load). They measured the viral load with a &quot;second generation&quot; bDNA test from Chiron Corporation; this test, not yet available commercially but only for research, can measure down to a cutoff of about 500 copies of HIV RNA per milliliter of plasma. (The bDNA test which has been available to practicing physicians until now has a cutoff of 10,000 copies, 20 times higher than the second-
generation test.)
<P>
Of those in the lowest viral quartile, which was 4530 copies per ml. or less, only 8% progressed to AIDS within five years. In the next quartile, 4531-13,020 copies, 26% progressed. In the second-highest quartile, 13,021 - 36,270 copies, the proportion was 49%; and in the highest quartile, above 36,270, 62% developed AIDS in five years -- almost eight times the progression rate of the lowest quartile. [These particular viral-load levels might be lower than those measured today, since these samples were processed 10 years ago with procedures not optimized to preserve them for viral load testing; it is likely that damage to the RNA led to lower counts being recorded, meaning that the numbers above are too pessimistic. One of the researchers told us that the samples in this study are likely to have suffered a 1.6-fold to 2-fold decrease in viral load counts due to how they were preserved -- meaning that the counts above may actually have been 1.6 to 2 times higher than the numbers given above.]
<P>
Looking at survival, in the lowest quartile of viral load, 5% of the volunteers died within 5 years. For the next quartile it was 10%, the second-highest quartile 25%, and in the highest quartile, 49% died within 5 years.
<P>
The increased risk of progression to AIDS, and risk of death, was still evident even ten years after this single viral load measurement.
<P>
<li> Viral load was even more predictive when the average of the first two measurements was used, instead of a single viral load test (The MACS study drew blood samples every six months). And the predictive ability was further improved by eliminating the 29 patients (out of 172 for whom two tests were available) who had an 80% or more drop in number of copies between their first and second test. (This drop probably meant that those people were still recovering from their primary HIV infection, meaning that their viral-load tests may not have properly measured the &quot;set point,&quot; or long-lasting, relatively stable viral level which remains after primary infection and seems to control the speed of disease progression.) Once these adjustments were made, those in the highest quartile (average viral load greater than 28,720, in this group) had a median survival time of only 2.5 years, with only about 5% surviving for ten years. The authors interpret this as &quot;evidence that a persistently high viral load is almost always associated with more rapid disease progression.&quot;
<P>
On the average, after statistical adjustments including both HIV RNA (viral load) and CD4 counts, the relative risk of death was 1.57 (a 57% increase) for each threefold increase in viral load.
<P>
<li> CD4 counts were much less predictive of AIDS progression and survival. When the same volunteers were divided into quartiles by CD4 count (less than 322, 322-527, 528-787, and greater than 787) the three higher quartiles showed no difference in survival, nor in progression to AIDS. Only the lowest quartile showed a worse outcome. When the 29 volunteers with an 80% or more drop in viral load were excluded, the predictive ability of the CD4 test did not improve.
<P>
In another look at CD4 count, the researchers found that 50% of those with CD4 over 500 [ten years ago], if they also had a viral load greater than 10,900, died within six years -- compared with only 5% of those with the same CD4 counts but a viral load of less than 10,900. They suggested re-evaluating the practice of using CD4 level as a trigger to begin antiretroviral therapy. [This does not affect the use of CD4 counts for starting prophylaxis for pneumocystis or other opportunistic conditions; in this situation, the CD4 level does show who is at risk.]
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-148</DOCNO>
<DOCOLDNO>IA017-000178-B004-119</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:3.2 192.33.214.13 19970106042946 text/html 4333
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Comment</h4>
<P>
This long-term followup study shows the predictive value of modern viral load testing. But in order to have the long-term progression and survival information available, the researchers necessarily had to use frozen samples collected years ago. Therefore, the particular numbers reported above should not be blindly applied today. But the conclusion that viral load testing is important for patient management -- probably considerably more important than CD4 testing for guiding antiviral therapy -- seems hard to dispute.
<P>
Even before these results were published, there was clear consensus among experts that viral load testing is valid for prognosis (predicting whether an individual is likely to do well or poorly in the future). But there has been controversy about its use for patient management, with some saying that the data to support such use is not yet available. The problem is that to get conclusive proof of the value of viral load testing for management requires randomly assigning some patients to have their physicians use viral load testing as part of their care, and randomly assigning others to not use viral load, and then looking for a statistically significant difference in the number of deaths or AIDS complications in the two groups. Such trials are now being done, but they will take time, since existing frozen samples cannot be used (as there is no way to know what a physician in the past would have done with the additional information, or how a patient would have responded to the resulting change in treatment).
<P>
We have argued elsewhere that there are fundamental problems with this kind of trial to prove the value of viral load testing. Aside from the ethical concerns, it will be hard to reach statistical proof, since antiviral therapies are still limited, and many patients in the trials will not have good access even to what does exist (as these trials do not provide or pay for treatment); if physicians cannot make effective use of the viral load information, how much difference could it make? A negative result would not show that viral load is not useful, but only that it was not useful within the limitations of the particular (and largely undefined) guidelines and therapeutic options existing at the time of the trial. How helpful is this information, when the therapies and guidelines surely will have changed considerably by the time the trial results are available? And we do not see how these trials will have the statistical power to add much to our knowledge about HOW to use viral load, when they are designed primarily to answer the go/no-go decision of whether viral load should be used in individual patient care.
<P>
There is already so much information consistently supporting the importance of viral load, that it is inconceivable that this test could be found to have no use in clinical care. Viral load testing has already become a de facto standard for those who can afford it. The problem today is to get better care out to everyone else. This is especially important now that many more treatment choices are available. Viral load will be essential for making these choices intelligently -- for example, to find out when an antiviral regimen is failing to work for a particular patient, so that different treatments can be tried instead.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-149</DOCNO>
<DOCOLDNO>IA017-000178-B004-132</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:4 192.33.214.13 19970106042955 text/html 4221
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Op Ed: Viral Load FDA Approval Delays</h3>
<P>
by David Scondras
<P>
[David Scondras served on the Boston City Council for ten years, from 1983 through 1993. He is co-founder of Search for a Cure, a Boston organization with a mission of cutting red tape, both government and corporate, which interferes with development of or access to effective treatment for HIV.]
<P>
We have good news and bad news; as this is going to press, the FDA has just approved the Roche viral load test for use by clinicians for HIV prognosis, and for monitoring the activity of antiviral therapies. The bad news is that it took much too long and were it not for the intervention of many treatment activists, the FDA's &quot;Biologics Division&quot; (Center for Biologics Evaluation and Research, CBER) very well might have made a bad decision. Delays in approvals harm those HIV positive individuals who have insurance, including Medicaid, that may not reimburse without FDA approval. And unfortunately there is a tendency for the Biologics Division to delay until they receive significant pressure from the activist community.
<P>
These problems are a direct result of the lack of experience of CBER in evaluating treatments for HIV illness, compared with the experience of the &quot;Drugs Division&quot;, (Center for Drug Evaluation and Research, CDER). The speed with which CDER moved on protease inhibitors stands in stark contrast to the delays and need for extensive advocacy campaigns at CBER.
<P>
Another example of CBER's erratic, slow and inconsistent behavior surrounds the effort to get a &quot;Treatment IND&quot; for access to the Salk therapeutic vaccine. After nearly a year of delay, CBER gave the green light for a phase III trial for this vaccine. Many people signed up since it might help, apparently has no side effects, is cost free to HIV infected people, and has very few restrictions on the use of any other therapies. However, many people who cannot get into the trial want access, so activists met with the FDA; at that meeting CBER staff made a commitment to allow an expanded access program, including Treatment IND status (the simplest legal method for getting new treatments to persons with HIV who otherwise cannot get them) for people with a CD4 count greater than 300. But when the decision arrived, it was for an open-label protocol [collecting research data] which the company specifically had said it cannot afford to undertake along with the $60 million phase III trial. We are now faced with the task of trying to get CBER staff to keep their word. This struggle continues.
<P>
The time has come to call for an HIV-positive, community-
chosen ombudsman who would have the power to appeal any decision made by the FDA divisions to Commissioner David Kessler, with the requirement that any such appeal result in a written decision by Dr. Kessler within a stated and reasonable time.
<P>
Meanwhile, as a practical matter, it is time to move decisions on HIV therapies and diagnostic tests from CBER to CDER, because at least the drug division has had ample experience with the intricacies and unique problems and needs of the HIV positive community, which is clearly lacking in the biologics division.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-150</DOCNO>
<DOCOLDNO>IA017-000178-B004-142</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:5 192.33.214.13 19970106043007 text/html 2683
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:29 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>PMPA: New Information</h3>
<P>
by John S. James
<P>
PMPA, an antiviral being developed by Gilead Sciences but not yet tested in humans, came to widespread attention last November, when a study published in SCIENCE (November 17, 1995) showed that it could block SIV (simian immunodeficiency virus) infection in macaque monkeys even when given 24 hours after exposure; PMPA protected 100% of the monkeys tested, while AZT protected none (there were 10 monkeys in each group). Now another study, presented at the Ninth International Conference on Antiviral Research in Fukushima, Japan, found that PMPA reduced SIV in chronically infected macaques by more than two logs (99%), or past the limits of detection; the virus reappeared when the drug was stopped.<a href="/anais/f/ATN.cgi?248:12 #note0233">(3)</a> <a name="retour233"> </a> Also, a 10% PMPA jell protected all four monkeys from vaginal transmission, while both of two monkeys treated with the control jell without PMPA were infected,<a href="/anais/f/ATN.cgi?248:12 #note0234">(4)</a> <a name="retour0234"> </a> suggesting the possibility of a means of preventing sexual transmission which could be controlled by women -- which would have great public-health importance. (SIV is similar to HIV; the virus is so close to HIV-2 that many believe that humans acquired HIV-2 by SIV infection from monkeys. No animal ancestor to HIV-1 is known.)
<P>
For both studies, the researchers are from Gilead, the University of Washington Regional Primate Research Center, and the National Institutes of Health. Chiron Corporation also participated in the treatment study.
<P>
Gilead Sciences plans to start human testing of PMPA in 1996.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-151</DOCNO>
<DOCOLDNO>IA017-000178-B004-151</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:6 192.33.214.13 19970106043016 text/html 3994
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:37 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:6.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>3TC: Glaxo Wellcome Broadens Patient Assistance</h3>
<P>
On May 20 Glaxo Wellcome Inc. broadened its Patient Assistance Program for Epivir(TM) (3TC, lamivudine), to no longer deny the drug to patients who qualify for their state ADAP (AIDS Drug Assistance Program) in states which have not included the drug in their program. A large majority of states already cover the drug, but several still do not. (California included 3TC in its program on April 25). 3TC was approved for combination use with AZT in November 1995.
<P>
Almost all major pharmaceutical companies have patient assistance programs for at least some of their drugs, although these vary greatly from company to company. The programs cost the companies little, since patients who receive a drug would otherwise not be customers but would go without, as they have no way otherwise to buy or obtain it. And the companies benefit by avoiding the public relations fallout that would occur from many people being denied expensive but life-critical drugs, due to their economic circumstances.
<P>
Recently there has been a problem of some companies excluding any patient whose public or private health insurance or managed care plan has rejected coverage for their drug (and sometimes also those patients whose health coverage has not yet made a decision). The pharmaceutical companies want to be sure that they are not used as the provider of last resort, allowing other institutions to refuse to pay for drugs they would otherwise have to cover. The problem is that patients then become pawns in the battles between large organizations. (This was not a major problem until recently, because traditionally it was taken for granted that if the FDA approved a treatment, it would be covered by health plans.) The problem around ADAP has been particularly acute, because of the current funding crisis for that program, and also because it ostensibly covers everyone in the state within certain income limits who needs HIV treatment, resulting in more widespread exclusion than private insurance or managed care programs, which only cover their enrolled members.
<P>
Glaxo Wellcome noted in a May 15 letter that its program &quot;was never intended or designed to serve as an alternative funding resource for inadequately funded state ADAP programs. Obviously this is a stop-gap approach to the immediate problem, and the need for a viable long-term solution grows in significance every day... This kind of solution is only going to take place as a result of collaborative efforts between government, community and industry.&quot;
<P>
Merck still has a similar policy of disqualifying patients from its patient assistance program for Crixivan(R) if they qualify for other programs which have rejected Crixivan coverage, although they will cover people up until the time a state formally rejects coverage. The Glaxo Wellcome policy was even more restrictive, excluding people until the state took a positive action allowing coverage.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:6.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-152</DOCNO>
<DOCOLDNO>IA017-000178-B004-162</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:6.1 192.33.214.13 19970106043025 text/html 2349
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:47 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h4>Comment</h4>
<P>
While Glaxo Wellcome clearly deserves credit for this change in policy, people should know that Project Inform was a key community group that undertook the difficult negotiations without which the change would not have happened. Other groups, including ACT UP/Golden Gate, had earlier pressured the company to extend its expanded access program in some states, but the extension had run out and Glaxo Wellcome had still refused to change its basic policy of excluding people in states which failed to put 3TC in their ADAP formulary.
<P>
&quot;This issue represents a growing economic tug of war between industry and government over who should be paying the bill for uninsured patients and others not adequately served by Medicaid,&quot; said Martin Delaney of Project Inform. &quot;The total cost of HIV drugs is dramatically rising with the routine use of combination therapy, the approval of protease inhibitors, and the fact that some patients who had previously rejected the available drugs are now coming in for treatment.&quot;
<P>
With the new policy on 3TC, many people have access to treatment recommended by their physicians, when they did not before. But now community groups will need to work with industry to lobby state governments, and the Federal government, at least as effectively as they have lobbied companies.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-153</DOCNO>
<DOCOLDNO>IA017-000178-B004-168</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:7 192.33.214.13 19970106043033 text/html 1907
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:30:56 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:6.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Prison: California Conference on HIV and Prison Issues, Oakland, June 27</h3>
<P>
A statewide conference on AIDS in prison will be held all day June
27, in downtown Oakland. Five workshop tracks will focus on:
<P>
<li> Education and prevention;
<li> Transitional case management;
<li> Vocational training &amp; employment;
<li> Advocacy &amp; change;
&lt;lil&gt; Legal issues.
<P>
The conference is sponsored by many organizations, including AIDS Legal Referral Panel, HIV/AIDS in Prison Project of Catholic Charities East Bay, Marin AIDS Project, Service Employees International Union Local 970, Women's AIDS Network, and WORLD. It will take place 8:30 a.m. to 5:00 p.m. June 27 at Preservation Park, 13th Street and Martin Luther King Jr. Way, in downtown Oakland; cost is $40, scholarships are available. For registration and other information call 510/834-5657 ext. 3150, or 415/255-7036, ext. 313.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:6.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-154</DOCNO>
<DOCOLDNO>IA017-000178-B004-178</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:8 192.33.214.13 19970106043042 text/html 2010
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>AIDS TREATMENT NEWS New Index Available</h3>
<P>
AIDS TREATMENT NEWS has completely rewritten its index to recent issues, covering January 1994 through May 1996. (Earlier articles were already thoroughly indexed in our three published volumes of back issues.)
<P>
This new index, 24 pages in length, represents our current judgment about which articles today still contain important information on each topic. It uses an expanded format which includes part of the article title with each entry, so that readers can see if they might be interested before looking up the article. We are using the index in house, almost always preferring it to a computer search to find the articles we are looking for.
<P>
Following our subscriber benefits policy, we have already sent the new index to everyone who began a full-rate subscription ($100 per year individual rate or greater) since January 1995. Others can buy a copy for $10. Contact AIDS TREATMENT NEWS, 800/TREAT-1-2 or 415/255-0588, or by fax at 415/255-4659.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-155</DOCNO>
<DOCOLDNO>IA017-000178-B004-189</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:9 192.33.214.13 19970106043051 text/html 2939
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>Activist Communications, Activities at Vancouver Conference</h3>
<P>
AIDS activist organizations are planning demonstrations and other communication at the XI International Conference on AIDS, July 7-12 in Vancouver. There will be a nightly world activist meetings beginning July 6 (planned for 8 p.m. at The Robson Square Conference Center, underground below the Old Courthouse, Hornby &amp; Robson Streets), possibly an informal meeting on July 5, and a march to the conference site on opening day, July 7. ACT UP chapters, including Golden Gate, New York, Paris, and Philadelphia, are sending people to the Conference; ACT UP/Golden Gate and ACT UP/Paris will have booths on site. There will also be an ACT UP press room, and probably a larger meeting room in addition. At least one activist phone number in Vancouver will have current information at all times.
<P>
For more information, contact Paul Davis, pdavis@critpath.org or Jennifer Depiero, <a href="mailto:jel@dolphin.upenn.edu">jel@dolphin.upenn.edu</a>, or call, fax, or mail either of them at ACT UP/Philadelphia, 215/731-1844, fax 215/731-1845, mail P.O. Box 15919, Middle City Station, Philadelphia PA 19103-0919.
<P>
Activists &quot;want to be inclusive in our planning process of the diversity of issues across the planet; therefore we are asking individuals and groups to help us decide what kinds of actions should be focused on during the Vancouver conference.&quot; Likely issues already being discussed include drug pricing, forced HIV testing, failed government leadership, and finding international funding (including access to treatment) for people in developing countries.
<P>
AIDS activists and organizers in developing countries are particularly invited to submit information and ideas to: Kate Krauss, ACT UP Golden Gate, <a href="mailto:kate_krauss@out.org">kate_krauss@out.org</a>, 415/252-
9200, fax 415/252-9277; or Jennifer Depiero (addresses above).
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-156</DOCNO>
<DOCOLDNO>IA017-000178-B004-196</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:10 192.33.214.13 19970106043107 text/html 8023
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:28 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>&quot;Access for All&quot;: Communication Strategy Proposal for Activists at International Conference</h3>
<P>
by John S. James
<P>
AIDS activists' communication to the public can be difficult. Because of the great diversity of issues people are working on, and because of the shallowness of most news media reporting, it is often hard for TV viewers and newspaper readers to understand where protesters are coming from, what our issues are. We need a theme or sound bite to communicate one central idea immediately, to the media and to other conference delegates as well, letting people know right away that we are on their side.
<P>
One possible theme is &quot;Access for All&quot; -- meaning access to medical care for HIV and AIDS (and other medical care as well), to information, to prevention programs, and to other services, for all the world's people. Almost everything we are now planning could fit gracefully under an Access banner:
<P>
<li> High prices of protease inhibitors and other HIV/AIDS drugs. Exorbitant drug prices cause different problems in different countries (depending on whether there is national health care, for example), but are destructive everywhere. All price issues ultimately affect people's access to medical care.
<P>
<li> Treatment access in developing countries. In past International Conferences, people from developing countries often sensed that U.S. activism pursued issues less important to them, while neglecting emergencies in their countries. &quot;Access for All&quot; means that we are going to address the problem of most of the world's people having no access to scientifically tested HIV treatments, being completely left out of all the fruits of biomedical research. One part of this problem, the lack of money for treatment in developing countries, is obvious.
<P>
Another root of this problem is the excessive focus of almost all mainstream clinical research toward high-priced, often inappropriate treatments. Is it possible that non-proprietary possibilities are not tested -- even with government or foundation money -- because proven treatments available at developing-country prices would also be used in rich countries, threatening key markets for high-priced drugs?  Could activists help prevent genocide by raising this issue at Vancouver?
<P>
<li> Research for a CURE. This issue cuts across economic lines, since no amount of money can buy a treatment that has not been discovered and developed. &quot;All&quot; includes those with money, as well as those without.
<P>
<li> Funding issues. &quot;Access for All&quot; includes money issues such as protecting Medicaid and increasing ADAP funding (U.S.), finding more money for research, and funding treatment for developing countries.
<P>
<li> Protecting medical research. &quot;Access for All&quot; includes making sure that necessary medical research is not stopped by animal-rights activists, who are now targeting AIDS in particular in order to get publicity. (This issue also cuts across economic lines, as there is no way to buy your way out of the consequences of damage to research.)
<P>
<li> Prevention. &quot;Access for All&quot; can include prevention, including vaccines, the need for vaginal microbicides or other prevention methods under the control of women, professionally designed and targeted AIDS education unimpeded by politics, and needle exchange.
<P>
<li> Information access. &quot;Access for All&quot; includes computer work (since computer communication is by far the most efficient and least expensive worldwide two-way information system). In addition, &quot;Access for All&quot; can challenge the widespread misbehavior of medical/technical journals, which often require that important work be kept secret in order to be effectively distributed. The registration fee of the International Conference could also be addressed -- the choice of such an expensive format  -- and the refusal of the Conference to release abstracts in advance (as many other conferences do, greatly improving peoples' use of scarce time at the meetings). Also included with information access is misbehavior by the media, which has often run amuck at the International Conference by latching onto a catchy theme (such as the &quot;deep kiss,&quot; or non-HIV AIDS, or excessive gloom and doom, from certain previous Conferences). Still another information issue is the need for translation of AIDS materials into different languages.
<P>
&quot;Access for All&quot; provides a unified public message to which many different issues and projects can relate. The above list is not complete, of course, but illustrates how we can take the diversity of AIDS activism and communicate it coherently to media audiences, and to Conference delegates. A major advantage of having a common theme is to help change the impression of disunity among AIDS activists. We can be working on many different problems and projects, but at the same time we are all working together.
<P>
Implementation: The first step is to agree on a common theme; &quot;Access for All&quot; is just one possibility. (&quot;Access&quot; may be too vague to communicate well. Other possibilities: &quot;Treatment for All&quot;; &quot;Medical Care for All People&quot;; ...) The agreed theme can be used in banners, signs, stickers, etc. Also, longer documents including fliers and press statements can relate this theme to the specific issues, problems, or opportunities being targeted. And when people speak to the media or address the Conference, they can relate their message to the common theme when appropriate.
<P>
We should choose a theme which will translate well, and prepare signs in many different languages, so that people will recognize their own language, and international reporters can find activists and other individuals from their country to interview. A march which includes the same sign in many languages sends a message of world activist unity, and is accessible to video and print media of many countries.
<P>
Ideally, the theme chosen should get final approval at the activist meeting the day before the conference (and perhaps also at the Community Forum). However, much of the material (signs, fliers for advance distribution, etc.) will have to be prepared in advance. The best approach might be to reach agreement soon, among those who can be contacted now. Then, in the unlikely event that the activist meeting in Vancouver decides on something different, it would be OK to have more than one theme at the Conference.
<P>
A powerful first step would be to seek agreement not only on a theme, but also on a consensus document suggesting examples of how that theme could be used. This article could serve as an early draft; feel free to circulate it to others who should be involved. Or we might decide on a different approach.
<P>
To facilitate preparation of signs and other materials, the consensus document should include translations of &quot;Access for All&quot; (or other theme we select) into many languages.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-157</DOCNO>
<DOCOLDNO>IA017-000178-B004-204</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:11 192.33.214.13 19970106043118 text/html 3059
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>AIDS TREATMENT NEWS</h3>
<P>
Published twice monthly
<P>
Subscription and Editorial Office:
<blockquote>P.O. Box 411256
San Francisco, CA 94141
800/TREAT-1-2  toll-free U.S. and Canada
415/255-0588 regular office number
fax: 415/255-4659
Internet: <a href="mailto:aidsnews@aidsnews.org">aidsnews@aidsnews.org</a></blockquote>
Editor and Publisher:
<blockquote>John S. James</blockquote>
Reader Services and Business:
<blockquote>Richard Copeland
Tom Fontaine
Denny Smith
Tadd Tobias</blockquote>
<P>
Statement of Purpose:
<blockquote>AIDS TREATMENT NEWS reports on experimental and standard treatments, especially those available now. We interview physicians, scientists, other health professionals, and persons with AIDS or HIV; we also collect information from meetings and conferences, medical journals, and computer databases. Long-term survivors have usually tried many different treatments, and found combinations which work for them. AIDS Treatment News does not recommend particular therapies, but seeks to increase the options available.</blockquote>
<P>
Subscription Information: Call 800/TREAT-1-2
<blockquote>Businesses, Institutions, Professionals: $230/year.
Nonprofit organizations: $115/year.
Individuals: $100/year, or $60 for six months.</blockquote>
Special discount for persons with financial difficulties:
<blockquote>$45/year, or $24 for six months.
If you cannot afford a subscription, please write or call.</blockquote>
Outside North, Central, or South America, add air mail postage:
<blockquote>$20/year, $10 for six months.
Back issues available.
Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details.
Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks.
VISA, Mastercard, and purchase orders also accepted.</blockquote>
<P>
ISSN # 1052-4207
Copyright 1996 by John S. James.  Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
<p>
<i>
AIDS TREATMENT NEWS<br>
Copyright 1996 by john S. James.<br>
P.O. Box 411256 - San Francisco, CA 94141<br>
800/TREAT-1-2 toll-free U.S. and Canada<br>
(+1) 415/255-0588 regular office number
</i>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?248:12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-158</DOCNO>
<DOCOLDNO>IA017-000178-B004-215</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?248:12 192.33.214.13 19970106043126 text/html 2054
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - AIDS TREATMENT NEWS Issue #248, June 7, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+248"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><H2>AIDS TREATMENT NEWS Issue #248, June 7, 1996</H2>
<P>
<CENTER>
<A HREF="ATN.cgi?248:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<h3>References</h3>
<P>
<a href="/anais/f/ATN.cgi?248:2 #retour0231">1.</a> <a name="note0231"> </a> Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, and Volberding PA. HIV viral load markers in clinical practice. NATURE MEDICINE; June 1996. Volume 2, number 6, pages 625-629.
<P>
<a href="/anais/f/ATN.cgi?248:3 #retour0232">2.</a> <a name="note0231"> </a> Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, and Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. SCIENCE May 24, 1996; volume 272, pages 1167-1190.
and
Ho, DD. Viral counts count in HIV infection. SCIENCE May 24, 1996; volume 272, pages 1124-1125.
<P>
<a href="/anais/f/ATN.cgi?248:5 #retour0233">3.</a> <a name="note0233"> </a> Bischofberger N, Tsai CC, Follis KE, and others. Antiviral efficacy of PMPA in macaques chronically infected with SIV. Ninth International Conference on Antiviral Research, Fukushima, May 19-24, 1996.
<P>
<a href="/anais/f/ATN.cgi?248:5 #retour0234">4.</a> <a name="note0234"> </a> Miller C, Rosenberg Z, and Bischofberger N. Use of topical PMPA to prevent vaginal transmission of SIV. Ninth International Conference on Antiviral Research, Fukushima, May 19-24, 1996.
<p>
<br>
<P>
</UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-159</DOCNO>
<DOCOLDNO>IA017-000178-B004-221</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:1 192.33.214.13 19970106043135 text/html 2220
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:31:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?248:12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>San Francisco: 3TC Available Now to Residents through ADAP Program</H3>
In San Francisco the Mayor's HIV Planning Council found money
unspent on other AIDS programs and used it to cover
lamivudine (Epivir(TM), 3TC) under the ADAP program (AIDS
Drug Assistance Program, for persons with limited income).
The money, $900,000, should last for the several months which
it is likely to take for California to add the drug to the
statewide ADAP formulary. 3TC was added to the ADAP formulary
for San Francisco residents on April 1. (The unspent money
totaled $1.5 million; besides the $900,000, $285,000 was
allocated to vouchers for food, clothing, taxis, and
household necessities, and the remainder went to food
programs.)
<P>
Despite early reports to the contrary, San Francisco
residents DO NOT need to already be in the ADAP program to be
eligible for Epivir. They can join the AIDS Drug Assistance
Program now. They must be San Francisco residents, be HIV
positive, and qualify under fairly generous income limits.
Also, initial reports that only the tablets are covered were
erroneous; the oral solution, which is mainly for pediatric
use and also for adults who need to use doses lower than
usual, is covered by this program as well.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?248:12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-160</DOCNO>
<DOCOLDNO>IA017-000178-B004-229</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:2 192.33.214.13 19970106043145 text/html 4982
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Protease Inhibitors: Patient Education Critical</H3>
by John S. James
<P>
It is widely agreed that successful use of the new protease
inhibitors -- especially indinavir (Crixivan(R)) from Merck &amp;
Co., and ritonavir (Norvir(TM)) from Abbott Laboratories --
will depend on effective patient education. This education is
not yet in place; for example, some important materials are
not ready yet, and some are ready but not being distributed
successfully.
<P>
One major concern is drug safety, especially drug
interactions with Abbott's ritonavir. Many drugs must not be
taken together with ritonavir, because ritonavir prevents
those drugs from being metabolized by the body, resulting in
a large overdose (not of ritonavir, but of the other drug).
Abbott has prepared a card for patients to carry, listing
some of the most important drugs to avoid; unfortunately this
card has not yet been distributed with many of the
prescriptions dispensed so far. Therefore, we are reproducing
it below, with permission [not reproduced online]. But be
sure to check with your doctor, because this list is not
complete, and it will probably change as new interaction
problems are discovered. (Merck's indinavir seems to cause
much less problem with drug interactions and with side
effects, although there are some of each.) And the different
protease inhibitors MUST NOT be combined until clinical
trials have shown whether, and how, this might be done
safely.
<P>
The other major concern, with both Merck's indinavir and
Abbott's ritonavir, is that the drugs must be used properly,
or viral resistance will develop rapidly -- and once
resistance develops to either of these drugs, then both are
likely to be much less useful (if useful at all) for that
patient, at any time in the future. (With the only other
protease inhibitor which is now approved -- saquinavir
(Invirase(TM)) from Hoffmann-La Roche -- resistance seems to
develop more slowly, so the problem is not so critical.)
Because of the resistance problem, past practices such as
casual dose reductions, &quot;drug holidays,&quot; or general laxity in
following instructions, must now be changed with the Merck
and Abbott drugs. Compliance with instructions on
prescription drugs is always a problem, and there is much
concern that patients may not comply closely enough to use
these new drugs effectively.
<P>
Also, resistance can be minimized and patients can get
maximum benefit from these drugs if they are used in
combination with other approved antiretrovirals; this keeps
the overall level of viral replication at a minimum, and
reduces the chance that a mutant virus will be resistant to
all the drugs. One combination of interest is indinavir plus
AZT plus 3TC. But combinations are likely to work best when
all of the drugs are new to the patient, so that the virus
has never seen any of them before. Since many patients have
already taken AZT for a long time, and may have virus
resistant to it, other combinations might be better for them.
Research is urgently needed to learn more about which
combinations are best for which patients.
<P>
For these reasons we believe that if people are doing fairly
well and can afford to wait, they should consider waiting
before starting protease inhibitors. In the next few months,
more will be learned about longer-term safety, and how to use
these drugs most effectively. Since most or all HIV drugs are
likely to work best the first time they are started (due to
the absence of resistant virus), it may be worth waiting in
order to get the maximum benefit out of one's first exposure
to these drugs.
<P>
But many people cannot afford to wait. If you do plan to
start using Merck's indinavir within the next few months,
while supplies are limited, you may want to start as soon as
possible, in order to have the best chance of obtaining this
drug -- see article below. (There seems to be no supply
problem with Abbott's ritonavir, however, and therefore no
occasion to hurry to get in line for it.)
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-161</DOCNO>
<DOCOLDNO>IA017-000178-B004-239</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:3 192.33.214.13 19970106043154 text/html 14021
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Indinavir (Crixivan(R)) Access and Distribution</H3>
by John S. James
<P>
Because Merck will have limited supplies of indinavir
(Crixivan), its recently approved protease inhibitor, until
new factories are running this fall -- and because this drug,
once started, should not be interrupted, in order to avoid
giving the virus opportunities to become resistant -- Merck
has set up a complex temporary distribution system. The
purpose of this system is to make sure that there is enough
drug to provide refills to everyone who starts using it.
There may be enough supply for everyone; but if there is not,
Merck will have to put new people on a waiting list, to save
enough drug to continue those who have already begun. (If
supplies do run short, Merck plans to reserve enough drug for
about 2,500 people with CD4 (T-cell) counts under 50.) Merck
now has enough drug to supply about 30,000 persons in the
U.S. for the next several months, until the new factories are
ready. (This number is likely to change depending on
international approvals and demand.)
<P>
Because of the need to track prescriptions, and because Merck
does not have the inventory available to spare enough drug to
fill the standard pharmaceutical distribution pipeline, Merck
will temporarily sell indinavir only through one mail-order
pharmacy, Stadtlanders (hotline for Crixivan, 800/238-1548)
-- and by certain special arrangements otherwise. The rest of
this article will outline how the distribution system is
supposed to work, including how Merck plans to handle a
number of special cases -- certain states, various HMOs,
Medicaid, ADAP, Federal institutions, patients in hospitals,
and persons now taking indinavir in SOME of Merck's clinical
trials (who will be offered free drug for three to five years
for a followup study, and therefore will not need to buy it).
<P>
* Patients who are already using Stadtlanders, or whose
insurance allows them to use it, should have no problem. A
simple form will be required to start a new prescription, but
the paperwork is not difficult -- and Stadtlanders has a good
reputation for customer service and followup.
<P>
Merck is encouraging physicians and patients to submit their
initial forms by fax -- although prescriptions by mail and by
phone will also be accepted. (In New York City, Stadtlanders
has opened a pharmacy in order to qualify to do mail-order
business in New York State under certain laws. But patients
still must enroll through the main phone number. Our
understanding is that the New York store will be used mainly
for mailing prescriptions to New York State Medicaid
recipients -- and for local people who may prefer to have
their prescription mailed for them for pick up there, instead
of to their home.)
<P>
The disadvantage for Stadtlanders' customers -- and for
everyone else -- is the price; Stadtlanders has a monopoly
for the next several months, and patients who pay out of
pocket for their indinavir will have to pay $5820 per year --
a markup of more than 32% over the $4400 per year which Merck
charges Stadtlanders. This is more than $1400 per year just
for the filling of the prescription (plus associated user
services, such as direct insurance billing, and calling
customers to remind them when their prescription is about to
expire). Stadtlanders told us that most of their customers
will pay prices set by their health plan, not by
Stadtlanders.
<P>
Stadtlanders also told us that their retail price has been
set at average wholesale price plus 10%. But since there are
no wholesalers in this case, with Stadtlanders buying the
drug from Merck and selling it directly to the patient, it
appears that the division between average wholesale price and
retail markup is at whatever point Stadtlanders wishes to
pick. (The &quot;average wholesale price&quot; is $15, which is a 25%
markup over Merck's price to Stadtlanders -- an average
wholesale price markup which we have been told is unusually
high for the industry.)
<P>
Merck says that antitrust laws prevent it from negotiating a
price with Stadtlanders, or from bringing any pressure on
that company to lower its price. (We talked to one lawyer
familiar with antitrust, who said that while Merck is correct
that attempts at vertical price fixing are unlawful, an
exclusive distributorship agreement may be unlawful if it
decreases competition without some other procompetitive
justification.)
<P>
* At least two other mail-order pharmacies -- Community
Prescription Service (800/842-0502), and MedExpress (800/808-
8060) have announced that they will accept orders for
indinavir, and do the paperwork to get the drug through
Stadtlanders. Others may follow, since otherwise they risk
losing much of their business to Stadtlanders, as their
clients who have to go there for indinavir may take their
other prescriptions there too, to avoid having to deal with
separate mail-order pharmacies.
<P>
* For persons in HMOs, Merck is negotiating with the HMOs and
is finding that almost all of them are willing to work with
Stadtlanders. Merck does not expect much access problem for
persons in managed care. No HMOs so far have declined to
provide indinavir -- although many have not yet made a
decision.
<P>
* For a few staff-run HMOs like Kaiser, Merck has agreed to
supply the drug directly under certain conditions, not going
through Stadtlanders. Kaiser has already received indinavir
at this time.
<P>
* For Medicaid patients, Stadtlanders is a licensed provider
in 22 states and the District of Columbia -- accounting for
over two thirds of all patients who would be placed on
therapy. In the other states, Stadtlanders is working with
The Medicine Shoppe to distribute the drug. Stadtlanders will
still get the forms, monitor patients, and report to Merck,
but will ship each patient's drug to The Medicine Shoppe,
which will then re-ship it to the patient. As of April 1, 21
states currently plan to cover indinavir, and others are
making their decisions.
<P>
* For ADAP, like Medicaid, Stadtlanders will work with the
ADAP in states where Stadtlanders cannot provide the drug
directly to determine an acceptable method of counting and
tracking patients.
<P>
* For long-term care institutions, Stadtlanders will again
act like a wholesaler. The long term care provider will need
to count and track patients and provide these numbers to
Merck.
<P>
* Federal institutions -- the Veterans Administration, the
military, the National Institutes of Health, the Public
Health Service, and Federal prisons -- will get indinavir
directly from Merck. The drug was added to the Federal supply
schedule on April 1. These institutions will have the
responsibility of tacking and counting their patients and
reporting these numbers to Merck.
<P>
* Hospital inpatients will need to take their own indinavir
into the hospital, where it will be dispensed by the hospital
pharmacy. Large AIDS hospitals will also be allowed to buy
one bottle for emergency use, for example when a patient
forgets to bring the drug when being admitted.
<P>
Note: For all users of indinavir, Merck is now preparing a
patient package insert to explain how to use the drug
correctly. But this document needs approvals from within
Merck, and then from the FDA, before it will be released.
<P>
Payment Assistance Program
<P>
Persons who have no other way to pay can apply to Merck's
patient assistance program, called SUPPORT(TM), which will
help to find payment sources the patient may have overlooked,
help advocate with payers if necessary -- or as a last resort
provide free drug to those who meet certain financial
criteria, which Merck will not reveal.
<P>
But Merck has set a policy that if a state's ADAP program
decides not to cover indinavir, then Merck will not let new
patients in that state into its patient assistance program,
no matter what their financial need. Merck is applying this
policy to all insurance programs; if an HMO or insurance
company declines to pay for indinavir, then Merck will not
let any of that plan's patients start receiving the drug
through its patient assistance program. The company is
concerned that otherwise payers will refuse to pay for its
drug, with the argument that Merck will pick up the people
who could not possibly pay out of pocket.
<P>
But if someone is already on indinavir when their state or
their plan announces that it will not pay, it would then be
clearly unethical to cut them off, so Merck will continue
them in the program in that case. (This means that if someone
has already decided that they need indinavir -- and they
might qualify for free drug under the patient assistance
program because they have a low income -- they may be able to
get into that program now, before their state or plan makes
the decision, but not be able to get in later, if their plan
should decide not to pay).
<P>
Persons in Indinavir Clinical Trials
<P>
In order to collect long-term data on indinavir use, Merck
will offer free indinavir to persons who have been in most of
its phase II and one of its phase III studies, by extending
those studies for three to five years. The phase II trials
are: protocols 004, 006, 010, 018, 019, 020, 021, 025, and
035; and the phase III trial is protocol 039. Volunteers in
these studies can get free indinavir, so they will not need
to buy it.
<P>
Those in other Merck trials (such as 033 and 037) will be
&quot;transitioned to commercial distribution&quot; when these trials
end as planned. This transition usually includes at least
eight weeks of free open-label drug, giving people time to
decide if they want to continue the treatment, and to make
arrangements to do so. Those in Merck's &quot;Advanced AIDS
Program&quot; (i.e., those who won the expanded-access lottery),
are being transitioned starting April 1.
<P>
To ensure that there will be drug supply for patients who
will be prescribed indinavir once they have completed their
study, patients will receive a card (sent by Merck to their
physician) with an 800 number on it. They must call the 800
number and give their name and social security number. The
call from the patient is important to help Merck plan for
their future drug refill needs. If a patient does not receive
this card soon, they should contact their physician.
<P>
About 12,000 persons with advanced HIV disease who failed to
win the lottery for Merck's expanded-access program are now
being sent letters explaining the distribution and patient-
assistance programs.
<P>
Comment
<P>
No one knows how well this complex distribution system will
work. Clearly it has lots of potential to work badly.
Fortunately it should be ended within a few months, allowing
indinavir to be distributed through normal channels, with
normal competition to reduce the distribution cost.
<P>
We received much of the above information on April 1, two
days before going to press, so we have had no time to deal
with many concerns, including ethical issues, which need
larger public discussion. Is it OK for Stadtlanders to be
given an absolute monopoly of a life-critical drug, be
allowed to set whatever price it wants, and then to use this
situation to set an unusually high markup? Is it OK for Merck
to wash its hands in the antitrust laws?
<P>
And what about Merck's cutting off entry to its indigent-
patient program, no matter what one's financial need, because
one's insurance plan or state ADAP program refused to pay for
indinavir? Everyone knows that the Federally funded state
programs are going to run out of money. Persons with critical
illnesses are being used as pawns in this payment dispute
among large institutions, and are being forced to take the
loss when the institutions choose not to reach agreement.
<P>
And Merck appears to be mistaken in its apparent belief that
this cutoff policy will be necessary to get the drug paid
for. Any refusal to pay for indinavir, either by private
insurance or ADAP, will not only hurt the poor, but also be a
serious hardship for many middle-class persons who would not
qualify for free drug under the patient-assistance program in
any case. Since the poor have the least political influence,
their loss as advocates for indinavir coverage would be a
disproportionately small loss of the total constituency for
reimbursement.
<P>
Also, this distribution program is full of inefficient
special arrangements which exist only to avoid crossing the
letter of some law or rule -- rules instituted with or
without good intentions, but in either case with no
comprehension of how they would actually apply in this case.
Is this bizarre and wasteful outcome just part of the price
we pay for living under an organized society and rule of law?
Or is some fix possible? Would it be different if there were
the kind of widespread political support that would certainly
exist if AIDS struck randomly at anybody?
<P>
The ultimate issue is the political failure of this country
to create a workable healthcare system. No one knows how to
transform more than half a trillion dollars of greed into
something people can live with.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-162</DOCNO>
<DOCOLDNO>IA017-000178-B004-250</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:4 192.33.214.13 19970106043205 text/html 3718
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Research at NIH: Study Panel Issues Major Report</H3>
by John S. James
<P>
On March 14 the Office of AIDS Research of the U.S. National
Institutes of Health (NIH) released an overview evaluation of
AIDS research at NIH, conducted by 114 outside experts and
representatives under Princeton virologist Dr. Arnold Levine.
A number of subpanel reports are still confidential, but are
expected to be released in April. (This writer was a
community representative on one of the subpanels, on
complementary and alternative treatments.)
<P>
The overall report (REPORT OF THE NIH AIDS RESEARCH PROGRAM
EVALUATION WORKING GROUP OF THE OFFICE OF AIDS RESEARCH
ADVISORY COUNCIL) is by far the most important ever on AIDS
research. (It is limited to U.S. National Institutes of
Health, but the U.S. funds 85% of all publicly funded AIDS
research in the world.) The evaluation's conclusions and
recommendations are unusually strong for the scientific
world, which usually covers for each other's inadequacies and
mistakes. The report is being greeted with near-universal
enthusiasm among AIDS organizations and advocates -- and
panic from some researchers who fear their funding will be
cut.
<P>
One crucial document -- the report from the clinical trials
subpanel -- is still confidential. We have heard that it will
be less threatening to pediatric researchers than the overall
report which has been published. A major controversy around
pediatric AIDS research is that it has been
disproportionately funded due to a Congressional mandate. But
there is also recognition that the area does need special
government attention, since pharmaceutical companies have
been remarkably negligent in conducting pediatric studies.
<P>
When the rest of the documentation is available, we will
report in depth on this review of AIDS research. An important
article on the initial document appeared in THE NEW YORK
TIMES on March 14.
<P>
An immediate issue is the moves in Congress to take away the
central budget authority of OAR over NIH AIDS research
(authority which Congress gave OAR in 1993 when it last
reauthorized NIH) -- returning this authority to the separate
Institutes. There is widespread concern that this change
would prevent the panel's recommendations from being
implemented, and lead to a continuation of poor overall
management and uncoordinated research efforts.
<P>
You can get a copy of the report from the World Wide Web; go
to the NIH home page, http://www.nih.gov/, and look under
News and Events. Or call 301/402-3357; or mail a request
(including your address and phone number) to Office of AIDS
Research, Building 31, room 4B54, National Institutes of
Health, Bethesda, MD 20892-2340. You can also stop by that
office for a copy.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-163</DOCNO>
<DOCOLDNO>IA017-000178-B004-259</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:5 192.33.214.13 19970106043213 text/html 2672
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Viral Load: Inconclusive FDA Hearing</H3>
by John S. James
<P>
On March 21, the FDA's Blood Products Advisory Committee
(plus members of the Antiviral Drugs Advisory Committee, the
group which usually reviews AIDS issues) met to discuss the
first application for formal FDA approval of a viral load
testing kit, for the Amplicor HIV Monitor(TM) assay of
Hoffmann-La Roche. There was little community input at this
hearing -- not because of lack of interest, but because it
was widely believed that viral load is almost certain to be
approved anyway, so community support would not be necessary.
(Viral load has long been available without formal approval,
but approval would be advantageous for a number of reasons.)
<P>
But now there is concern that while the FDA is indeed likely
to approve viral load tests, it may approve them for
prognosis only -- which managed care and insurance companies
could use as an excuse to pay for no more than one or two
tests in a patient's lifetime. That, of course, would not be
the way practicing physicians want to employ these tests.
Many physicians see them as essential for effective use of
the protease inhibitors, and for making intelligent choices
among the far greater number of combination regimens now
becoming available. But this view was not well represented at
the FDA's hearing. Some activists are now concerned that the
FDA may be about to make a serious mistake, by discouraging
the use of viral load testing to help in choosing the best
antiviral regimen for each patient.
<P>
Sometimes scientific confusion is really the projection of a
political landscape beneath. We are preparing a longer report
on the current status of viral load.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-164</DOCNO>
<DOCOLDNO>IA017-000178-B004-269</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:6 192.33.214.13 19970106043226 text/html 6109
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AZT, ddI, and ddC Combinations at FDA Advisory Hearing</H3>
by John S. James
<P>
The February 28 meeting of the FDA Antiviral Drugs Advisory
Committee asked whether the recently-available results of
four major clinical trials should change the standard use of
AZT (Retrovir(R), zidovudine), ddI (VIDEX(R), didanosine),
and ddC (HIVID(R), zalcitabine) -- especially combination use
of these antiretrovirals. Specifically, the FDA asked:
<P>
&quot;(1) Do the results of ACTG Study 175 and the other studies
[the Delta trials, CPCRA 007, and ACTG Study 152 -- which
tested various treatment approaches with AZT, ddI, and
sometimes ddC] support the safety and efficacy of didanosine
as initial therapy in persons with no prior history of
antiretroviral use? [Note: The current FDA-approved
prescribing information for didanosine (ddI) recommends that
AZT be tried first.]
<P>
&quot;(2) Do the results of these studies provide evidence that
didanosine in combination with zidovudine is clinically more
effective than didanosine monotherapy? In your discussion,
please include comments on treatment of persons with and
without a prior history of antiretroviral use.
<P>
&quot;(3) Do the results of ACTG Study 175 and other studies
support a traditional approval of HIVID (ddC) in combination
with Retrovir [AZT].&quot; [Note: ddC is currently approved for
combination use with AZT, under the FDA's accelerated
approval regulations. This means that the combination has
demonstrated benefit through markers of HIV disease
progression such as viral load or CD4 count, but the
developer, Hoffmann-La Roche, was expected to do further
clinical trials to demonstrate direct clinical benefit to
patients, such as increased survival or reduced incidence of
opportunistic infections. The FDA asked the advisory
committee to discuss and vote on whether newly available
clinical-trial results have sufficiently demonstrated
clinical benefit.]
<P>
These questions led to long and complicated discussions. Two
analyses, one of the survival data from ACTG 175, the Delta
trials, and CPCRA 007, and another based on an overview of
seven studies of ddI and AZT, compiled by Jim Neaton, Ph.D.,
of the University of Minnesota, and others, suggested that:
<P>
* Overall both AZT+ddI and AZT+ddC were better than AZT alone
in reducing the risk of death. In each of the four
combination nucleoside studies considered, the reduction in
risk of death (compared to AZT monotherapy) was greater with
AZT+ddI than with AZT+ddC.
<P>
* The effects of ddI and AZT on survival were similar both
overall and in patients who were antiretroviral naive. This
analysis included ACTG 175 but did not include ACTG 152,
which was presented for the first time the same day. (ACTG
152 is a pediatric trial in which children on AZT alone did
worse than those on at least one of the other treatments,
resulting in early closure of the AZT monotherapy arm of the
trial.)
<P>
* There are not enough data to know whether or not AZT+ddI is
more effective than ddI alone in reducing risk of disease
progression and death.
<P>
On the FDA's questions:
<P>
* The Committee voted unanimously Yes on #1, indicating that
ddI should be approved for initial treatment of HIV disease.
<P>
* The Committee voted No on #2 (meaning that there is no
proof that ddI+AZT is better than ddI alone). But the
Committee was uncomfortable with this vote, fearing that many
patients would be denied combination treatment when it is
generally believed that combination treatment is best and has
become the standard of care. It also seemed &quot;bizarre&quot; to fail
to recommend approval of AZT+ddI, when the Committee was
clearly prepared to recommend approval of AZT+ddC, and when
many believe that AZT+ddI is at least as good as AZT+ddC.
<P>
* On question #3, the Committee unanimously voted to
recommend approval of AZT+ddC for antiretroviral-naive
persons, and unanimously voted against approval for
antiretroviral-experienced persons.
<P>
[Note: In support of ddI, Bristol-Myers Squibb pointed out in
a February press release that it is less expensive than AZT
or other antiretrovirals, and will soon be available in a new
tablet which is easier for patients to use than the
formulation available until now in the U.S.]
<P>
Comment
<P>
The discussion above needs to be kept in perspective. Today
it is widely believed that 3TC is better than either ddI or
ddC for use in combination with AZT. But there is no
clinical-endpoint data on this combination yet -- only viral
load and CD4 counts -- which is why 3TC was not considered at
the February 28 hearing.
<P>
Also, all of the discussion outlined above dealt with
averages, when really there is no such thing as the average
patient. Averages may suggest which treatment to try first,
when there is no better way to guess. But if viral load tests
or other indications suggest that a treatment is not working
well for an individual, other treatments can quickly be tried
instead.
<P>
[Note: AIDS TREATMENT NEWS did not attend the February 28
hearing, and acknowledges the assistance with this article
from Mark Mascolini and from Dr. Jim Neaton.]
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-165</DOCNO>
<DOCOLDNO>IA017-000178-B004-277</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:7 192.33.214.13 19970106043235 text/html 3870
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:32:56 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Cidofovir Recommended for Approval for CMV Retinitis</H3>
by John S. James
<P>
On March 15 an FDA advisory panel unanimously recommended
approval of cidofovir for injection (Vistide(R), also known
as GS 504 intravenous, and by its chemical initials HPMPC), a
new drug for treating CMV retinitis. Panel members were
concerned about safety and lack of long-term data; but they
voted for approval because the drug has proved effective
against a condition which urgently needs more treatment
options -- effective both in newly diagnosed patients, and in
those who had failed other therapies.
<P>
Cidofovir, being developed by Gilead Sciences of Foster City,
California, is given intravenously (in the trials considered
at this meeting); however, it is used only once a week for
two weeks, and then every other week after that, so it does
not require an implanted catheter (unlike ganciclovir or
foscarnet intravenous treatment). Note: Ganciclovir has now
been approved by the FDA as an eye implant, and as orally
administered capsules, for treating CMV retinitis in certain
patients, avoiding the need for a catheter.
<P>
The main safety concern with the new drug cidofovir is kidney
toxicity; another drug, probenecid, is used to reduce this
problem, and hydration is also necessary. In one trial, two
thirds of the volunteers had adverse reactions to at least
one of the drugs.
<P>
The other major concern is that in a laboratory study,
cidofovir caused cancers in the mammary glands of female
rats. It is not known if this problem occurs in people;
however, Gilead reported that no carcinogenicity was found in
a 52-week study in primates, and that there were no cases of
non-AIDS cancers in over 500 people who have taken the drug,
and their AIDS-related cancers were consistent with controls.
Very few women have taken cidofovir in trials, so the safety
for women is unknown.
<P>
Different formulations of cidofovir is also being tested for
direct injection into the eye, and as an eyedrop for other
infections, and as a topical gel for herpes and for genital
warts.
<P>
Cidofovir is now available free of charge in the U.S. and
Canada through an expanded access program for patients with
relapsing disease who have failed or are intolerant to either
ganciclovir or foscarnet. For more information about this
program, call 800/GILEAD-5.
<P>
Note: AIDS TREATMENT NEWS did not attend the March 15
hearing. This article is largely based on coverage in the
March 18 issue of BIOCENTURY (a weekly biotechnology
newsletter delivered by fax or email, published by BioCentury
Publications Inc., in San Carlos, California), and on March
11 and March 15 press releases from Gilead. Also note the
coverage March 19 in THE NEW YORK TIMES, of a large initial
drop in Gilead's stock price which occurred when a reporter
stepped out of the meeting early and headlined old data about
the tumors in rats.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-166</DOCNO>
<DOCOLDNO>IA017-000178-B004-289</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:8 192.33.214.13 19970106043245 text/html 3098
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:33:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>California: Clinical Trials Computer Service Now Available Statewide</H3>
Trials Search, which matches a patient's confidential medical
information to over 100 HIV-related clinical trials in its
database and finds the ones for which the patient is
qualified, has been available without charge in the San
Francisco area since 1991 but is now being expanded
throughout the state. Patients complete a two-page
questionnaire giving their medical status and contact
information, and receive a list of open trials which they are
likely to be eligible to join.
<P>
Trials Search, originally developed in 1991 at Ralph K.
Davies Medical Center in San Francisco, is now operated by
the Community Consortium, an association of more than 200
physicians and other health-care professionals who provide
care for a majority of patients with HIV disease in the nine
San Francisco Bay Area counties. The expansion of the service
to Southern California was financed by the Kaiser Family
Foundation; however, the Community Consortium is still
seeking financial support for other Trials Search expenses.
<P>
Persons interested in receiving the questionnaire can call
either 800/492-5777, or 415/476-5777.
<P>
Also, the Community Consortium will make the Trials Search
software and database available to medical centers, AIDS
service organizations, and patient advocacy groups so that
searches can be done on site. In addition, the service will
be available to anyone through the Internet. (Currently it is
less useful outside of California, however, because the
database consists of trials which have sites within
California. But other medical centers could use the Trials
Search software, and enter their own database of the trials
available in their area.)
<P>
The Community Consortium also publishes the GUIDE TO HIV
CLINICAL TRIALS IN CALIFORNIA (both a Northern California and
Southern California edition), which provide in printed form
the same data in the Trials Search database. Both editions
are available now, and will be updated three times a year.
For a free copy of either guide, call either 800/492-5777, or
415/476-5777.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-167</DOCNO>
<DOCOLDNO>IA017-000178-B004-299</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:9 192.33.214.13 19970106043252 text/html 5501
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:33:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>San Francisco Protest Against Meeting Disruptions</H3>
by John S. James
<P>
On April 4, over 25 leading AIDS activists and organizers in
San Francisco -- all of them persons with HIV -- published a
letter asking a group calling itself ACT UP San Francisco to
stop disrupting public forums on treatment options for AIDS
and HIV. About a half-dozen persons identifying themselves as
ACT UP San Francisco have targeted public forums of the
Community Consortium (a local medical association which
includes the physicians who treat most of the people with HIV
in the nine San Francisco Bay Area counties), and of Project
Inform and others.
<P>
This long-simmering controversy escalated with the disruption
of a Community Consortium meeting at Davies Hospital on March
16. A scuffle occurred before the police arrived to restore
order, and speakers Donald Abrams, M.D., and Paul Volberding,
M.D., were drowned out or unable to complete their talks on
viral load and other topics.
<P>
From an ACT UP San Francisco press release after the
incident: &quot;'This game of promoting expensive, harmful drugs
by touting their temporary effects on dubious surrogate
markers like CD4 counts and blood viral load must stop now,'
demands ACT UP member Todd Swindell. 'We're dying while AIDS
research is held hostage by drug companies and the
virologists, clinicians and so-called AIDS advocates on their
payrolls. This isn't science; it's exploitation of the sick
in its most vile form.'&quot; (&quot;ACT UP SF Questions Turn Drug
Company Forum into Brawl in the Hall,&quot; ACT UP San Francisco,
March 17.)
<P>
From the April 4 activists' statement opposing the meeting
disruptions: &quot;People with AIDS have the right to choose our
own sources of information and the wisdom to know whom to
believe. We are committing ourselves now to stop any such
disruptions in the future. We need your support... Please
contact the mayor, your supervisors, the Department of Public
Health, AIDS organizations, the media, forum presenters and
especially 'ACT UP SF'. Let them know you need safety and
treatment information.&quot;
<P>
A January 15 release from ACT UP San Francisco described an
earlier incident (against a Project Inform Town Hall meeting
on January 11, 1996) as part of a series: &quot;The disruption was
the first in a planned series of attacks on mainstream AIDS
organizations in San Francisco that ACT UP SF has identified
as embroiled in conflict of interest through their acceptance
of pharmaceutical industry contributions.&quot;
<P>
Comment
<P>
The main concern has been that disruptions have been serious
enough to prevent information from being presented; people
leave and do not come back. Also, physicians and researchers
are becoming reluctant to speak in the San Francisco area.
The result is that people are prevented from getting
information they need for making treatment decisions.
<P>
ACT UP San Francisco can legitimately raise its issues,
including the excessive influence of pharmaceutical
companies, in the question and answer periods of community
forums, or by distributing flyers, or by holding its own
meetings. What is not legitimate is to prevent others from
getting the treatment information they have come to hear.
<P>
For more information on this controversy, you can obtain a
copy of the April 4 statement and list of signers from Ben
Collins, 415/558-8669, ext. 211. To reach ACT UP San
Francisco, call 415/522-2907, or call Michael Bellefountaine,
415/487-9954. Or see the debates on the Internet newsgroup
sci.med.aids -- including &quot;Demean, Dupe, Dose, Die&quot; (March
25, from &quot;DaveACTUP,&quot; strongly supportive of ACT Up San
Francisco although not signed by that organization), and
replies from Martin Delaney and others. Delaney's March 28
reply addresses the substance of the scientific disputes, as
well as the allegations of pharmaceutical-company influence.
If you cannot easily get it by computer, a copy is available
from Ben Collins, or from the Project Inform hotline,
800/822-7422 or 415/558-9051, 10 a.m. - 4 p.m. Pacific time,
Monday through Saturday. (Project Inform also has a World
Wide Web site, http://www.projinf.org.)
<P>
Note: AIDS TREATMENT NEWS often reports on the treatment
activist work of ACT UP/Golden Gate (415/252-9200). ACT
UP/Golden Gate wants the public to know that it is not
affiliated with ACT UP San Francisco. ACT UP/Golden Gate
signed the April 4 statement, and also issued its own March
28 press release condemning the meeting disruptions.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-168</DOCNO>
<DOCOLDNO>IA017-000178-B004-306</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:10 192.33.214.13 19970106043259 text/html 2271
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:33:22 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>California: AB 2812 Would Outlaw Anonymous Testing</H3>
by John S. James
<P>
A bill in the California legislature (AB 2812, Bondonaro,
Republican, Santa Barbara) would end anonymous testing in the
state by adding HIV infection to the list of diseases that
must be reported to the State Department of Health Services.
The practical result would be that many people will avoid
being tested, and miss early treatment if they are infected,
as well as missing the prevention education they would get no
matter how the test turns out. According to the Grass Roots
Networks of AIDS Project Los Angeles, &quot;AB 2812 is sponsored
by the Capitol Resources Institute, an extremely conservative
lobbying group affiliated with Focus on the Family and State
Senator Rob Hurtt. These are the same folks that support
quarantine camps for all people living with HIV and AIDS!&quot;
<P>
A hearing is scheduled for April 16 in the Assembly Health
Committee. You can help by writing to your California
Assembly representative opposing AB 2812, and by getting
others to do so.
<P>
For more information on this and other California issues, and
what you can do, call the Grass Roots Hotline at 213/993-
1680. It is a 24 hour voicemail information number, but it
lets you reach a person during business hours.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?244:11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-169</DOCNO>
<DOCOLDNO>IA017-000178-B004-319</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?244:11 192.33.214.13 19970106043319 text/html 2027
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:33:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #244, April 5, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+244"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #244, April 5, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Medications Needed Abroad</H3>
Unused medications which otherwise would be discarded can be
a lifesaver in clinics which otherwise would not have access
to them. Recently we heard about three efforts to collect
medicines for clinics abroad.
<P>
For Guatemala, the Guatemalan Association to Prevent and
Control AIDS is seeking HIV-related medications for their two
clinics in Guatemala City. Bactrim, AZT, and other drugs are
needed. For more information, contact Matt Anderson, M.D.,
Montefiore Family Health Center, 718/933-2400 (voice mail
644), or by beeper at 917/556-5046.
<P>
For South Africa, if you have medicines to donate, leave a
message with ACT UP/Golden Gate, 415/252-9200. The South
African clinics do not need Bactrim, but do need many other
medications.
<P>
And to find out about donating medicines for Cuba, contact
Alfredo Martinez-Garcia, 407/932-4482, on weekdays. His group
also needs vitamins and antibiotics. They can accept outdated
medications because many companies will exchange dated
medications for new ones.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-170</DOCNO>
<DOCOLDNO>IA017-000178-B004-329</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:1 192.33.214.13 19970106043329 text/html 5545
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:33:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?244:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Indinavir (Crixivan(R)), Merck Protease Inhibitor, Approved</H3>
by John S. James
<P>
FDA approval of indinavir, Merck's protease inhibitor, was
announced on March 14; the drug is expected to be available
by March 25. For several months, indinavir will be made
available under a temporary special distribution system,
primarily through Stadtlanders Pharmacy. Merck's price to
wholesalers will be $12 a day, or $4380 per year (retail
prices are not known as this issue of AIDS TREATMENT NEWS
goes to press). This price is significantly less than the
prices of the other two protease inhibitors now approved
(from Abbott Laboratories, and Hoffmann-La Roche).
<P>
Indinavir has been studied in more than 2,000 people. It was
approved under the FDA's accelerated approval regulations,
based on 24-week studies which showed improvements in markers
of HIV disease progression -- large viral load decreases, and
CD4 count improvements -- especially when indinavir was used
in combination with other antiretrovirals. Long-term studies
are now ongoing to test the effect of indinavir in preventing
clinical progression of HIV disease.
<P>
The package insert includes extensive prescribing
information, lists of possible side effects, and key clinical
trial results. &quot;Crixivan must be taken at intervals of 8
hours. For optimal absorption, Crixivan should be
administered without food but with water one hour before or
two hours after a meal. Alternatively, Crixivan may be
administered with other liquids such as skim milk, juice,
coffee, or tea, or with a light meal, e.g. dry toast with
jelly, juice, and coffee with skim milk and sugar; or corn
flakes, skim milk and sugar.... To insure adequate hydration,
it is recommended that the patient drink at least 1.5 liters
(approximately 48 ounces) of liquids during the course of 24
hours.&quot; Administration with grapefruit juice *decreased*
blood levels of Crixivan in one test. The dose of Crixivan is
the same whether it is used alone, or with other
antiretrovirals -- but the package insert should be checked
for instructions on combination use, e.g. with ddI. A number
of warnings and precautions, including interactions and
incompatibilities with several other drugs, are also listed
in the package insert.
<P>
It is important to take the full dose consistently as
prescribed -- without reducing the dose, skipping doses, or
taking &quot;drug holidays.&quot; But if a dose is missed, do not
double the next dose. In case of nephrolithiasis (kidney
stones or related symptoms, which have occurred in about 4%
of patients taking indinavir), a short drug interruption may
be considered.
<P>
For information on obtaining Crixivan, and on Merck's
reimbursement assistance program which is called SUPPORT(TM),
patients and physicians can call 800/927-8888, beginning
March 18.
<P>
Note: At this time, the impression among treatment advocates
is that overall, Merck's indinavir seems to be the best
choice of the three protease inhibitors now approved. Still,
those who can wait to start protease inhibitors may want to
wait until more is known about how to use them in the best
combination regimens to minimize viral resistance (which
seems to be more of a problem with the Merck and Abbott drugs
than it is with saquinavir, the Roche protease inhibitor).
But those who do want to start indinavir within the next six
to 12 months should know that there will be a limited supply
of this drug over the next several months (depending on U.S.
and international demand) -- and that those who seek indinavir
immediately may have the best chance to obtain it. Any supply
problem should end around autumn of this year, when new
manufacturing facilities are scheduled to begin production.
(We do not expect any shortage of the Roche or Abbott
protease inhibitors.)
<P>
Since it is medically inadvisable to start indinavir and then
discontinue (as that would encourage the development of
resistant viruses, reducing future usefulness of this and
certain other protease inhibitors), Merck is setting up a
system to track prescriptions in order to make sure that
refills are available for all who start using the drug.
Current plans are to accept new patients into this system on
a first-come-first-served basis.
<P>
If you expect to need indinavir in the near future, check
with your physician now about getting it. But if you can
wait, the supply and distribution problems should be over
within a year -- and the drug may be more useful then than it
would be now, since physicians will know more about how best
to use it.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?244:11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-171</DOCNO>
<DOCOLDNO>IA017-000178-B004-340</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:2 192.33.214.13 19970106043342 text/html 7980
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Ritonavir (NORVIR(TM)), Abbott Protease Inhibitor, Approved</H3>
With record speed, ritonavir (Norvir(TM)), Abbott
Laboratories' protease inhibitor, was approved by the FDA on
March 1, 1996 (one day after approval was recommended by the
FDA's Antiviral Drugs Advisory Committee) -- and was for sale
in some pharmacies within a week. For more information on the
debates at the advisory meeting which recommended this
approval, see &quot;Protease Inhibitors at FDA Advisory Hearings,&quot;
below.
<P>
Ritonavir is the only protease inhibitor which already has
proven survival benefit (the others might work just as well,
since they have comparable effects on viral load and CD4
counts, but they have not completed their clinical-endpoint
trials yet, so no data on survival are available). But
ritonavir has also raised more safety concerns than the
others. It has strong interactions with many drugs used by
persons with HIV; it should not be used concurrently with at
least 22 of them, and requires dose reduction and/or
monitoring with some others. Patients taking other
medications must consult with their physicians before
starting ritonavir. Abbott has prepared physician and patient
instructions regarding potential drug interactions.
<P>
Other concerns are that ritonavir has little safety data
beyond six months at this time. It strongly inhibits a
specific liver enzyme, which presumably is in the body for a
reason; blocking this enzyme for extended periods might cause
problems. And we have heard more anecdotal reports of side
effects with ritonavir than with the other protease
inhibitors.
<P>
There is also the problem of resistance and cross resistance
(especially cross resistance to Merck's Crixivan); this may
be minimized by optimal use of the drug -- by combining it
with two or more other antivirals, and by not missing doses
or taking &quot;drug holidays.&quot;
<P>
It is likely that many people who could afford to wait a few
months or more before starting protease inhibitors may choose
to do so. By that time, the Merck drug will also be
available; and physicians will know more about which drugs to
choose and how to make best use of them. Combinations may
work best when a patient starts all the drugs in that
combination at about the same time, without extensive prior
use of any of them.
<P>
For those considering starting ritonavir now, we note some
information from the package insert (the FDA-approved
prescribing information for physicians). This document will
be published in the PHYSICIAN'S DESK REFERENCE; meanwhile,
patients may be able to get a copy from their pharmacist or
physician.
<P>
Administration
<P>
Ritonavir is sold in two forms, capsules and oral solution.
It should be taken with meals if possible.
<P>
&quot;The recommended dosage of ritonavir is 600 mg twice daily by
mouth. Some patients experience nausea upon initiation of 600
mg b.i.d. dosing; dose escalation may provide some relief:
300 mg b.i.d. for 1 day, 400 mg b.i.d. for 2 days, 500 mg
b.i.d. for 1 day, and then 600 mg b.i.d. thereafter. In
addition, patients initiating combination regimens with
NORVIR and nucleosides may improve gastrointestinal tolerance
by initiating NORVIR alone and subsequently adding
nucleosides before completing two weeks of NORVIR
monotherapy.&quot;
<P>
&quot;Patients should be informed to take ritonavir every day as
prescribed. Patients should not alter the dose or discontinue
ritonavir without consulting their doctor. If a dose is
missed, patients should take the next dose as soon as
possible. However, if a dose is skipped, the patients should
not double the next dose.&quot;
<P>
There is no children's dose, as there have been no studies of
safety or effectiveness in children.
<P>
Drug Interactions
<P>
The package insert begins with a warning box: &quot;Co-
administration of NORVIR with certain nonsedating
antihistamines, sedative hypnotics, or anti-arrhythmics may
result in potentially serious and/or life-threatening adverse
events due to possible effects of NORVIR on the hepatic
metabolism of certain drugs. See Contraindications and
Precautions sections.&quot; Later text includes cautions and
warnings about other kinds of drugs as well.
<P>
The warnings about drug interactions are too extensive to
reproduce here. Patients and physicians should note that they
appear in different sections of the package insert, including
Special Populations -- drug-drug interactions;
Contraindications; and Precautions -- drug interactions.
<P>
Tobacco use has been found to decrease ritonavir blood levels
by 18 percent.
<P>
Adverse Events
<P>
After about three months of use of the drug in clinical
trials, &quot;the most frequently reported clinical adverse
events, other than asthenia [lack of strength, fatigue],
among patients receiving NORVIR were gastrointestinal and
neurological disturbances including nausea, diarrhea,
vomiting, anorexia [loss of appetite], abdominal pain, taste
perversion, and circumoral and peripheral paresthesias
[abnormal sensation].&quot; Tables showing percentages of patients
with dozens of other clinical and laboratory abnormalities
which might be drug related are included in the package
insert.
<P>
Because ritonavir can cause changes in some laboratory tests,
certain testing should be done to establish a baseline before
the drug is started. The testing should be repeated
periodically during therapy, or if symptoms occur, to monitor
for possible problems.
<P>
&quot;Ritonavir pharmacokinetics have not been studied in patients
with hepatic insufficiency.&quot; However, some patients with
hepatitis have been included in the clinical trials of the
drug.
<P>
Cost and Reimbursement
<P>
Ritonavir is the most expensive antiretroviral; Abbott's
charge to wholesalers is $6500 per year. We could not get the
&quot;average wholesale price&quot; (the price which wholesalers charge
pharmacies) by press time. We found some confusion about
retail prices; patients should check several pharmacies,
including mail-order or other large pharmacies serving many
persons with HIV, before making major purchasing decisions.
<P>
&quot;NORVIR is indicated in combination with nucleoside analogues
or as monotherapy for the treatment of HIV infection when
therapy is warranted.&quot; This official language from the
package insert should help in getting reimbursement from
insurance companies which use FDA approval as the basis for
their reimbursement decisions, as there are no CD4 or other
stated limits for use of ritonavir. But many managed-care
systems use their own formularies which do not include all
FDA-approved drugs, so the FDA's approval language may matter
less with them.
<P>
Because interrupting therapy can make one more likely to
develop virus resistant to this and some other protease
inhibitors, persons should avoid starting either ritonavir or
indinavir unless they expect to be able to continue without
interruptions.
<P>
For assistance in getting reimbursement for ritonavir, call
800/659-9050.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-172</DOCNO>
<DOCOLDNO>IA017-000178-B004-354</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:3 192.33.214.13 19970106043354 text/html 9187
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:12 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Protease Inhibitors at FDA Advisory Hearings</H3>
by John S. James
<P>
[Note: This writer was unable to attend the recent meetings
of the FDA advisory committees, due to the flu. AIDS
treatment writer Mark Mascolini helped with the research for
our coverage of the protease inhibitor and nucleoside analog
combination meetings.]
<P>
On February 28-March 1, four separate one-day meetings of FDA
advisory committees took place at two different sites near
Washington, D.C.
<P>
FDA advisory committees consist of outside experts (not FDA
employees) who meet when requested and advise the FDA on drug
approvals and related issues. While the FDA does not have to
follow the recommendations of the committees, it almost
always does. These meetings are important because they
usually present more information and analysis about a
potential new treatment than is available from any other
public source. (Most FDA advisory committee meetings are open
to the public, at least in large part, although sometimes
closed sessions are scheduled to review confidential
proprietary data.)
<P>
The Antiviral Drugs Advisory Committee, which reviews most
AIDS drugs seeking marketing approval, held three of the
hearings -- on recommendations for indinavir (Crixivan(R),
Merck's protease inhibitor); ritonavir (NORVIR(TM), Abbott's
protease inhibitor); and also on usage of AZT/ddI/ddC, in
view of new data from major clinical trials. Also, the
Endocrine and Metabolic Drugs Committee met separately (at
the same time as the indinavir hearing) to review the request
for approval for human growth hormone to treat AIDS-related
wasting. This article reviews the hearings on the two
protease inhibitors; the human growth hormone hearing is
examined in a separate article, below, and the meeting on new
recommendations for use of the older drugs will be covered in
a later issue of AIDS TREATMENT NEWS.
<P>
Indinavir (Crixivan) -- Merck's Protease Inhibitor
<P>
The March 1 indinavir hearing was the smoothest of the four
meetings, mainly because Merck &amp; Co. had the data and trials
it needed to support the recommendation it was asking for.
<P>
Merck was seeking (and has now been granted) clearance to
market indinavir under the FDA's &quot;accelerated approval&quot;
regulations. Accelerated approval allows an HIV treatment to
be approved based on CD4 count and viral load improvements in
clinical trials -- provided that larger trials are in place to
also prove clinical benefit to patients, such as longer
survival or fewer opportunistic infections.
<P>
About 2,000 volunteers have now taken indinavir at the
currently accepted dose (800 mg every 8 hours); 600 have
taken this dose for at least six months, and 250 for at least
a year. The main safety concerns have been an increase in
bilirubin (but without evidence of liver toxicity), and
kidney stones or related symptoms in less than three percent
of patients. The most common (but less serious) side effects
are rash, dry skin, and altered sense of taste.
<P>
Merck reported results of several trials, and they are
consistent with what was known before. More information on
specific trial results (some of which were never presented
publicly before this meeting) is available through NATAP, the
National AIDS Treatment Advocacy Project; for contact
information, see &quot;FDA Hearings: For More Information,&quot; below.
<P>
While drug interactions are much less of a problem with
indinavir than with ritonavir, indinavir does have important
interactions several other drugs. Dose adjustments are
required in some cases; other drugs cannot be used at all
with indinavir.
<P>
At the end of the day, the Committee recommended accelerated
approval for indinavir -- recommending combination treatment
when possible, but with an option for indinavir alone for
people who cannot tolerate the nucleoside analogs.
<P>
Ritonavir (NORVIR) -- Abbott's Protease Inhibitor
<P>
The February 29 meeting on ritonavir was more difficult than
the indinavir meeting. It was followed by a private late-
night meeting between Abbott and the FDA, during which final
agreements were negotiated. On the following day, Abbott
distributed a letter announcing that it would conduct trials
to provide certain additional data; and the FDA announced
that ritonavir would be approved.
<P>
The reason the Committee meeting was difficult is that while
Abbott came in with the best results so far for any HIV
treatment -- clear evidence that the drug substantially
reduced the risk of death and of opportunistic infections in
a major trial -- other important information was unavailable.
For example, there is little information on safety or
efficacy beyond six months, which is especially worrisome for
a drug with important safety concerns. There are no pediatric
data. Information is inadequate on how well the drug works in
people with earlier stages of HIV infection (the trial which
showed clinical benefit was only open to those with CD4
counts under 100).
<P>
There were many different ideas on the Committee, and much
discussion, about what proof was needed for efficacy in
earlier disease. The issue is that the accelerated approval
regulations require subsequent trials that show direct
clinical benefit to patients, to eventually back up the early
approval which is based on improvements shown in blood tests,
like CD4 count and viral load. But it has always been very
difficult -- and is now almost impossible -- to prove delayed
disease progression in persons with high CD4 counts, because
it will take many years for enough volunteers to get sick to
provide statistical proof of benefit, and people are
unwilling to stay on the same treatment that long while
better treatments are becoming available. (The proposed
&quot;symptom reduction trials&quot; to get around this problem -- see
AIDS TREATMENT NEWS #228, #229, and #231 -- have not caught on
at this time, probably because while they could provide
clinical proof of benefit quickly, they would not provide
long-term balance of risks and benefits, especially for
asymptomatic patients.)
<P>
The compromise that seemed to win wide acceptance at the FDA
advisory meeting was a long-term surrogate marker (CD4 and
viral load) and safety study, which would use the clinical
endpoints of illness and survival primarily to assure safety,
while using CD4 and viral load changes to test for durability
of response to the drug. The private meeting that evening
built on this idea, with Abbott agreeing to &quot;provide long-
term follow-up safety and clinical endpoint data from ongoing
studies M94-247 and M94-245 to assess the comparative
clinical efficacy and safety data in patients with advanced
stage disease versus patients with early stage disease.&quot;
Also, Abbott agreed &quot;to provide data from a study in patients
with higher CD4 cell counts (&gt;100 cells/microliter) looking
for durability of response by evaluating CD4 response, HIV
RNA response and safety from a study comparing ritonavir to
ritonavir+saquinavir.&quot; And Abbott agreed &quot;to participate in a
clinical study to define the safety and clinical efficacy of
ritonavir in pediatric patients.&quot;
<P>
With these agreements in place, the FDA sent Abbott an
approval letter &quot;for the use of ritonavir in combination with
nucleoside analogs or as monotherapy for treatment of HIV
infection when therapy is warranted.&quot; The labeling
(information for physicians) will describe the evidence on
which the approval is based, and the limitations of this
evidence for late-stage and also for early-stage HIV disease.
<P>
Ritonavir Comment
<P>
The key issue for the Committee seems to have been the
balancing of risks and benefits in early disease, especially
because the drug has important safety issues and no long-term
safety data. The resolution which resulted left physicians
and patients with maximum flexibility in the use of this
drug. We believe this decision was the right one -- but that
the success of this drug will depend on Abbott's ability to
educate physicians, pharmacists, and patients on how to use
ritonavir correctly, and on the company's continued ability
to rapidly conduct the research on which this education must
be based.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-173</DOCNO>
<DOCOLDNO>IA017-000178-B004-364</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:4 192.33.214.13 19970106043404 text/html 7217
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>FDA Antiviral Hearings: Community Perspectives</H3>
Dave Gilden, Gay Men's Health Crisis:
<P>
[Since we did could not attend the FDA's Antiviral Drugs
Advisory Committee hearings, we asked people who did attend
to comment on drafts of our report. Dave Gilden, editor of
TREATMENT ISSUES, sent us the following, which we found
insightful and important enough to quote in full, with his
permission.]
<P>
Gilden: &quot;My sense about the FDA is that the people there have
become convinced that a four drug combination will be highly
effective in suppressing HIV. Researchers like David Ho are
arguing that three drugs will provide long-term viral
suppression but that you need four drugs to insure that there
is no pre-treatment mutant HIV able to resist the entire drug
combination -- or to prevent eventual emergence of such virus.
<P>
&quot;The FDA is therefore determined to push the necessary drugs
through the approval process, whether the data on each one is
complete or not. The other issue affecting the FDA
deliberations is the FDA reform movement in Congress, which
the FDA is countering in part by showing how decisively it
can act when the situation calls for rapid drug approvals.
<P>
&quot;Therefore, I watched the spectacle of ritonavir getting the
kid glove treatment from FDA reviewers, and David Kessler
pushing for full approval, while I saw Serono and human
growth hormone get positively torn apart the next day. We can
expect easy treatment for nevirapine and delavirdine too,
even though the available data on these drugs' benefits is
weak indeed. These two non-nucleoside reverse transcriptase
inhibitors will then be the fourth drugs in the four-drug
regimens, along with one or two nucleoside analogs [e.g., AZT
plus 3TC, or ddI] and one or two protease inhibitors. Viral
load testing, central to optimizing and periodically
adjusting the four-drug regimens in each person, now seem to
be on the FDA fast track, too. (The Hoffmann-La Roche PCR
test will be considered by the Blood Products Advisory
Committee on March 21.)
<P>
&quot;Speaking of using two protease inhibitors, the upcoming
ritonavir/saquinavir trial assumes tremendous importance in
this four-drug scenario. I would put more money on using two
protease inhibitors, especially if there is little cross-
resistance, than adding a non-nucleoside reverse
transcriptase inhibitor. Saquinavir is extremely potent in
laboratory tests, and ritonavir may rescue its disappointing
performance in the body. [Caution -- these drugs will require
extreme dose adjustment when combined, and *must not* be used
together until safe doses are known. Near-fatal side effects
have occurred from combining protease inhibitors
inappropriately. JSJ]
<P>
&quot;In the meantime, the most treatment-savvy PWA I know is
arguing that Merck's indinavir looks better than ritonavir,
from the available data, and that we should not be swayed by
ritonavir's full approval for advanced disease. He is not
alone in this opinion. The arguments favoring indinavir are:
better safety (though neither compound has much long-term
data), better patient compliance with the recommended regimen
(important to avoid breakthrough drug-resistant HIV), fewer
evident drug-drug interactions, better CNS (central nervous
system) penetration, data indicating activity in lymph nodes,
and indications of greater durability of antiviral response
(at least as monotherapy). Abbott also has a much worse
record of working with the community, and the chances are
weak of the company now trying to fill the tremendous gaps in
our knowledge of how to use protease inhibitors. In
particular, we need to know how well the individual brands
work over the long run, when best to start protease
inhibitors (which is highly influenced by the durability of
response issue), and what to follow these compounds with
should they start to fail.&quot;
<P>
[TREATMENT ISSUES, &quot;the Gay Men's Health Crisis newsletter of
experimental AIDS therapies,&quot; is published monthly; annual
subscriptions are available for a suggested contribution of
$35 for individuals, $70 for physicians, institutions, or
international subscriptions; a full set of back issues is
available for $25. Make checks payable to GMHC, and mail to:
GMHC, Treatment Education, 129 West 20th Street, 2nd floor,
New York, NY 10011.]
<P>
Martin Delaney, Project Inform:
<P>
[The following are from a February 29 press release by
Project Inform, supporting accelerated approval of ritonavir,
but expressing caution about how the drug should be used.]
<P>
Delaney: &quot;While this [improved survival] outcome is
significant, it overlooks two other important facts from the
study. It is our understanding that the majority of the
deaths reported in this data occurred within the first six
weeks of treatment, raising questions as to whether the
outcome reflects the true longer-term effect of the drug.
More importantly, we are very concerned that the data shows a
rapid loss of antiviral activity, probably due to the
development of drug resistance, within six months when used
in this fashion. Since resistance to this drug confers
resistance to most other protease inhibitors, there is good
reason to fear that such a use of the drug may lead only to
short-term benefit followed quickly by long-term multi-drug
cross resistance to many of the key products in the field of
protease inhibitors. There is evidence that the drug can work
far better when used properly; giving too much weight to this
data may promote use of the drug in this suboptimal fashion.&quot;
<P>
&quot;We think it is critical that Abbott make clear to physicians
and patients that great care should be employed in how these
drugs are used. Simply adding them without thought to
existing therapy is unlikely to produce a lasting benefit,
while running a large risk of creating multi-drug cross
resistant strains of virus.&quot;
<P>
A position paper available through the Project Inform hotline
(800/822-7422, 10 a.m. to 4 p.m. Pacific time Monday through
Saturday) describes these concerns in greater detail, and
provides guidelines for the optimal use of protease
inhibitors, based on what is known today. It will be
published in the April 1996 issue of PI PERSPECTIVE.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-174</DOCNO>
<DOCOLDNO>IA017-000178-B004-379</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:5 192.33.214.13 19970106043414 text/html 2834
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>FDA Hearings: For More Information</H3>
The most authoritative information about each of the three
protease inhibitors now approved is the package insert for
each drug. Incidentally, Merck is planning to work with the
FDA to develop a patient's version of the package insert for
indinavir.
<P>
Later, a full transcript and also a summary of each advisory
committee hearing will be available from the FDA.
<P>
Probably the most in-depth public information at this time
about the protease inhibitors is available through Jules
Levin's National AIDS Treatment Advocacy Project; it includes
a review of each clinical trial of the drugs, and the
resulting data. If you have a World Wide Web browser, you can
receive it immediately at http://www.aidsnyc.org/natap. Jules
can also be reached by email at JuLev@aol.com, or day or
evening by phone at 718/624-8541 or by fax at 718/624-8399.
His mailing address is NATAP, 72 Orange Street, Brooklyn, NY
11201.
<P>
In addition to information from these recent hearings, NATAP
also has a 45-page booklet on the five protease inhibitors
likely to be the first available -- saquinavir (Roche),
ritonavir (Abbott), indinavir (Merck), nelfinavir (Agouron),
and VX478 (Vertex / Glaxo Wellcome). Also available is a 4-
hour videotape of NATAP's community forum on protease
inhibitors, January 6, 1996, in New York.
<P>
Note: As this issue went to press, NATAP announced a free
community forum on protease inhibitors in Los Angeles, April
13, 1996, from 1:00 p.m. to 4:40 p.m. in the Paramount
Theater, 5555 Melrose Ave. (enter at Bronson St. gate). This
event is also sponsored by Kraus Medical Partners, and Being
Alive -- and co-sponsored by 17 other AIDS organizations. For
reservations, call 800/238-7828, ext. 8145. For more
information, contact NATAP at the above computer addresses,
fax number, or phone number.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-175</DOCNO>
<DOCOLDNO>IA017-000178-B005-11</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:6 192.33.214.13 19970106043426 text/html 12884
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:47 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Human Growth Hormone Not Recommended for Approval on Narrow Advisory Panel Vote</H3>
by John S. James
<P>
On March 1, the FDA's Endocrinologic and Metabolic Drugs
Advisory Committee, meeting with outside experts including
some members of the Antiviral Drugs Advisory Committee, voted
not to recommend approval for AIDS-related wasting for
Serostim(TM), the recombinant human growth hormone produced
by Serono Laboratories, Inc. The vote was eight opposed and
seven in favor.
<P>
According to Bill Thorne from ACT UP/Golden Gate, who was the
non-voting community representative on the panel and had gone
to the hearing hoping the drug would be approved, some of
those who voted no believe that growth hormone does work for
the requested indication, but were very disappointed with the
data presented by the company. He said the Committee clearly
wanted to vote for accelerated approval -- which would have
approved the drug for marketing, but required the company to
do additional research -- but that the FDA asked the Committee
not to vote on accelerated approval, since the company had
not filed for it. Many physicians are dissatisfied with the
outcome; they know growth hormone works for some patients,
and want to be able to use it. (The drug is currently
available through a pre-approval &quot;treatment IND&quot; expanded
access program, but the paperwork for this program is
difficult.)
<P>
What were some of the concerns about the data?
<P>
* Committee members feared that the dose requested might be
too high. An FDA analyst said that the dose being sought was
twice as high as that used in treating any other condition,
and that this dose was not justified by data. Committee
members were concerned, since human growth hormone can cause
irreversible side effects. (Serono told us that all the other
dosage information was in children, who often use growth
hormone for many years -- and that no irreversible side
effects occurred in Serono's trials.)
<P>
We have been told that Serono tried to present data showing
that lower doses were inadequate, but the Committee did not
allow it to do so. According to Bill Thorne, Serono did not
seem to understand the procedure of the hearing. In the
morning, Serono presented its data (which had also been given
to members in a binder before the meeting). Then an FDA
analyst critiqued Serono's presentation. In the afternoon,
the Committee deliberated and then voted. Serono tried to
interject at that time, but was told that during the
Committee deliberations it could only respond to questions.
It was not allowed to pull out bits and pieces when that
suited its interests, after the FDA's critique. (Serono told
us that it had 60 minutes to present 40,000 pages of their
NDA -- new-drug application for marketing approval -- and that
in other hearings, advisory committees often allow companies
to address questions that arise, but this one did not.
According to Serono, they brought thousands of slides and
could easily have cleared up many of the questions.)
<P>
[Although not part of the hearing, other dosage issues were
raised in the December 1995 issue of MEDIBOLICS, a newsletter
on anabolic steroids and related medical treatments published
by Michael Mooney in West Hollywood, California. One article
indicated that Serostim appears to be deliberately formulated
to prevent people from using lower doses without throwing
some of the product away -- that Serostim, packaged in 6 mg
vials, is &quot;designed to be used within 24 hours after mixing,
when every other growth hormone product in the world,
including (Serono's) own product sold in Italy, called
Saizen, is made to last 14 days.&quot; The difference is that
Serostim left out an inexpensive preservative, meta-cresol,
and therefore could have dangerous bacterial growth if kept
over 24 hours after mixing. The article quoted an AIDS
patient in San Francisco who had &quot;constant excruciating joint
pain and random outbreaks of oil-filled cysts on my face and
upper body&quot; using 6 mg either every day or every other day,
until learning about the dosage controversy and reducing the
dose, which required him to throw part of each vial away.
<P>
Another article speculated that the oral anabolic steroid
oxandrolone (Oxandrin(R)) might work as well or better than
growth hormone at considerably less cost -- even though it
also is overpriced. Trials of oxandrolone should be finished
later this year. The article also mentions injectable
anabolics which might be very low cost alternatives for some
patients -- testosterone cypionate for $8 per month, or
nandrolone decanoate for $32 per month. (A third article in
the same issue criticizes physicians who charge $45 to $60
for each injection, when patients who are paying out of
pocket could inject themselves at home.)
<P>
MEDIBOLICS is published four times a year for $15 U.S., $22
Canada and elsewhere, P.O. Box 333, 836 N. La Cienega
Boulevard, West Hollywood, CA 90069, fax 310/659-1597, email
mmooney@a.crl.com.]
<P>
* Serono has provided Serostim to close to 900 people in its
pre-approval treatment IND program (which charges for cost
recovery, as allowed under the treatment IND regulations,
although as many as 30% of the patients have received drug
without charge through the company's indigent patient
assistance). Usually such expanded-access programs provide
important data on safety, toxicity, and the frequency of dose
reductions due to side effects. Yet Serono never mentioned
this experience in its presentation to the Committee -- even
when directly asked by Sandra Hernandez, M.D., head of the
San Francisco Department of Public Health, who served on the
Committee. (Serono told us that they did not present this
treatment IND data because it was not part of their NDA
application, due to the timing of when the NDA was filed.)
<P>
* There is little information on long-term safety and
toxicity, beyond 12 weeks -- although patients clearly need to
use growth hormone for longer than that. (Serono told us
that, of 259 volunteers enrolled in its long-term study, more
than 40% were on the drug for more than six months, and about
5% were on drug for two years or more.)
<P>
* In one of the major trials presented to the Committee,
there were actually more deaths in the treatment than in the
placebo group. Apparently this difference was not
statistically significant (meaning that it might have
resulted from chance); still it is disconcerting, and
emphasizes the need for long-term data. (Serono told us that
there were similar numbers of deaths for people while on
study -- that most of the deaths the Committee was discussing
occurred off study. In almost all cases, these people had
been off growth hormone treatment for at least three months.
Serono will continue long-term followup.)
<P>
* The Committee wondered if there is a target population that
can be identified that is likely to respond well to human
growth hormone. Or is this a treatment to use in the hope
that it will work in some percentage of the cases?
<P>
* Is the once-daily scheduling best? Or could the drug be
taken less often?
<P>
Cost
<P>
Growth hormone at the Serono dose is expected to cost between
$50,000 and $100,000 per year (Serono has not announced a
price yet); its &quot;cost recovery&quot; for the treatment IND program
charged $25 per milligram, slightly more than $50,000 per
year for the 6 mg per day the company recommends, and the
price of the approved drug will be higher than that. Serono
has said that its recombinant human growth hormone, made from
mammalian cells, is much more expensive to produce that other
recombinant human growth hormone, made from E. coli. We have
no way to evaluate this claim. We do not know how much
difference the mammalian cell derivation makes, since the E.
coli version does promote human growth over long periods of
time.
<P>
The price of human growth hormone (at least the E. coli
version) appears to be almost all profit, since a quite
similar product to increase milk production in cows costs
about two thousand times less. AIDS TREATMENT NEWS is trying
to learn why the international price has stayed so high for
so long, since recombinant human growth hormone is produced
by independent companies, and competition would normally have
led to price reductions. Incidentally, we have heard warnings
about &quot;underground&quot; human growth hormone from Eastern Europe,
which is not recombinant but prepared from cadavers, and
could carry a fatal brain infection.
<P>
Negotiations
<P>
Bill Thorne, who has been involved in three-way negotiations
between Serono, the FDA, and community activists, sees Serono
as &quot;attempting to contain whatever commitment they have in
the future [by holding out for traditional approval]. And now
the FDA is coming to doubt Serono as a source of data on its
own product, and becoming reluctant to give even accelerated
approval. The FDA does have the legal authority to grant
accelerated approval even without being asked by the sponsor,
although it is very reluctant to do so.
<P>
&quot;We need to push the FDA to take charge of this situation and
do what is right for patients -- meaning to grant accelerated
approval, whether Serono requests it or not. Activists agree
that the drug does work, and has been used in other patients
for years without any side effect so frightening we cannot
manage it, in comparison with the dangers of wasting
syndrome, which is causing many preventable deaths.&quot;
<P>
Jeff Getty, also of ACT UP/Golden Gate, is trying to
negotiate a $25,000 cap per year per patient. He has told
Serono that without the cap, activists will oppose Serono's
efforts to get traditional (vs. accelerated) approval, and
also its effort to get orphan drug status which would lock in
its monopoly for seven years.
<P>
Gina Cella of Serono told AIDS TREATMENT NEWS, &quot;Everyone
agrees that Serostim should not be denied approval; we are
all working toward that end. We are in active discussion with
the FDA; we are pleased to have the opportunity to continue
discussions with them, to respond to their questions and
present additional data as requested. We are committed to
obtaining approval for Serostim in some form, full or
accelerated approval. We are also committed to continuing
research in AIDS wasting and the use of Serostim, and will
continue additional study.&quot;
<P>
For more information on the negotiations around human growth
hormone approval, contact ACT Up/Golden Gate, 415/252-9200,
fax 415/252-9277.
<P>
Comment
<P>
To understand what happened it is necessary to look at it
from several different points of view:
<P>
* One expert physician may have summarized the views of many
by commenting that human growth hormone does something
important which no other drug does -- and that used to be
enough for approval (implying that it should still be enough
for approval in this case). He sees Serono as very good in
certain other areas, but inexperienced regarding its
presentation to this Committee.
<P>
* Most of the Committee may have agreed with that view of the
drug, in their hearts -- but their job was to decide if that
case was proven by the data placed before them, and a slim
majority could not agree that it had been proven.
<P>
* The company believes that it has the data needed to clear
up some of the Committee's concerns -- but could not include
everything in its one hour presentation, and later was not
allowed to address other concerns after they came up.
<P>
* The FDA insists that accelerated approval must not become a
safety net for drugs which fail to achieve traditional
approval. (Otherwise the usefulness of accelerated approval
could be destroyed, as payers would consider it second rate
and refuse to reimburse.)
<P>
Hopefully the company will be able to resolve enough of the
remaining issues to show the FDA's staff that Serostim can
qualify for some form of approval.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-176</DOCNO>
<DOCOLDNO>IA017-000178-B005-26</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:7 192.33.214.13 19970106043435 text/html 6284
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:34:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Consensus Statement on the Further Development of Protease Inhibitors And Human Growth Hormone</H3>
[The following consensus statement is an excellent summary of
what is needed today in AIDS treatment research. It also
reflects new common ground, after the long-running, so-called
&quot;East Coast/West Coast&quot; disputes among AIDS treatment
activists (over whether to emphasize better &quot;answers&quot; through
more rigorous clinical trials, or faster &quot;access&quot; to new
treatments by patients and physicians). David Barr of Gay
Men's Health Crisis and Martin Delaney of Project Inform
organized and led the meeting that developed this statement.
JSJ]
<P>
We, the undersigned individuals and organizations, represent
hundreds of thousands of people with HIV infection in the
United States. We are excited and hopeful that the therapies
being reviewed for approval this week (two protease
inhibitors and human growth hormone) can provide a
substantial benefit for people with HIV. However, approval of
these products is not the end of the process of drug
development. In order to provide real access and information
about how to use these drugs safely and effectively, we call
on the Food and Drug Administration, the National Institutes
of Health and the pharmaceutical industry and third-party
payers to meet the demands outlined below. Failure to do so
will seriously undermine the value that these therapies will
offer to patients today and in the future.
<P>
1) Approve both indinavir and ritonavir for people with HIV
infection for whom anti-viral treatment is indicated based on
immunologic, clinical and biological markers. Approve human
growth hormone for the treatment of wasting syndrome.
<P>
2) Whatever regulatory mechanism is used for approval,
industry and government must agree to engage in post-
marketing research to answer key unanswered questions about
safety and efficacy. In order for this research to be
effective, it will require a collaborative effort between
industry, government, academia and community heretofore
unseen in AIDS research. The commitment to engage in this
effort quickly should be of paramount importance. We insist
that a strategic plan be presented for achieving these goals
by the time of the 11th International Conference on AIDS, to
be held in Vancouver in June, 1996.
<P>
3) The following is a list of questions that we agree must be
answered as soon as possible. The list is not meant to be
exhaustive, but rather to highlight those issues we believe
are of highest priority:
<P>
* When in the course of HIV disease should anti-viral
treatment generally be initiated? * Which treatment regimens
should be used as initial therapy? * What are the best
strategies for using combinations of anti-viral drugs,
including protease inhibitors, for nucleoside-experienced
patients? * When should people switch or stop anti-viral
treatment regimens * What is the pharmacokinetic and long-
term safety profile on protease inhibitors? * To what level
must viral load be reduced and sustained to successfully halt
disease progression? * How will pediatric formulations of
protease inhibitors be developed and studied? * What is the
effect of protease inhibitors on perinatal transmission? *
What is the optimal dose of human growth hormone, alone or in
combinations?
<P>
4) Approve viral load test kits for clinical management now,
not in six months. This is essential if we are going to be
able to use these treatments effectively.
<P>
5) Provide protease drugs and growth hormone, at no cost, to
all former and current clinical trial and expanded access
program participants and collect long-term safety data from
this group. This would provide the easiest and fastest way to
get such information.
<P>
6) Promotional and educational materials must be developed
and made available to doctors, patients, pharmacists and
health educators immediately to inform them about safe and
effective use of these products particularly around issues of
compliance with treatment regimens and drug interaction
problems. Community and consumer input into the development
and distribution of such materials is essential.
<P>
7) Reimbursement decisions should be driven by clinical
and/or surrogate data from controlled clinical studies.
<P>
8) Prices for these drugs must be fair, reasonable and
sensitive to the current crisis in health care funding. Each
company must guarantee treatments to those who have no other
means of access or less than full coverage through patient
assistance programs.
<P>
9) At minimum, pharmaceutical companies must agree to provide
AIDS Drug Assistance Programs with similar rebates that are
given to Medicaid programs.
<P>
[Over 30 organizations have already signed this statement,
including AIDS Action Council, AIDS Research Alliance, AIDS
Treatment News, American Foundation for AIDS Research, Center
for AIDS Prevention Studies, Critical Path AIDS Project, Gay
Men's Health Crisis, Healing Alternatives Foundation,
National Association of People with AIDS, Pediatric AIDS
Foundation, Project Inform, PWA Health Group, San Francisco
AIDS Foundation, and Treatment Action Group.
<P>
Organizations can sign by contacting Ben Cheng or Brenda Lein
at Project Inform, 415/558-8669 ext. 221 or 214, or David
Barr at GMHC, 212/337-1904.]
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?243:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-177</DOCNO>
<DOCOLDNO>IA017-000178-B005-42</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/ATN.cgi?243:8 192.33.214.13 19970106043445 text/html 1781
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:35:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS TREATMENT NEWS - Issue #243, March 15, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="ATN.cgi?+243"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>ATN - Issue #243, March 15, 1996<BR CLEAR><HR></H2>
<CENTER>
<A HREF="ATN.cgi?243:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?242:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS and Alternative Medicine, Seattle, April 28</H3>
Bastyr University and the Bastyr University AIDS Research
Center will present AIDS and Alternative Medicine: Current
State of the Science, a continuing education program for
medical practitioners and researchers. This one-day program
will be held in Seattle on April 28 at the Washington State
Convention and Trade Center, 800 Convention Place, Seattle,
WA 98101.
<P>
Speakers include Lark Lands, Ph.D., John S. James, Candace
Pert, Ph.D., Leanna Standish, N.D., Ph.D., and others.
<P>
Registration is $125 for practitioners, $75 for students;
there is a $10 discount if paid by April 12. For more
information about registration, including continuing
education credit, call Bastyr University's Department of
Continuing Education, 206/517-3577.
<P>
<P>
<I>
AIDS TREATMENT NEWS<BR>
Copyright 1996 by John S. James.<BR>
P.O. Box 411256 - San Francisco, CA 94141<BR>
800/TREAT-1-2 toll-free U.S. and Canada<BR>
(+1) 415/255-0588 regular office number<BR>
</I><P></UL>
<HR>
<CENTER>
<A HREF="ATN.cgi?243:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="ATN.cgi?242:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-178</DOCNO>
<DOCOLDNO>IA017-000178-B005-51</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960411 192.33.214.13 19970106043454 text/html 8142
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:35:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<H3>April 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:1">Study Discounts Risk of Contracting TB on Airliners</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:2">Cambridge Biotech to Transfer Assets in Regrouping Plan</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:3">Across the USA: Pennsylvania</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:4">Hospital Sued Over AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:5">Emergence of a More Lethal Mutant HIV-1 Possible</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:6">CDC Gives Good Grade to Saliva Diagnostic Systems...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:7">Senegalese Women's Group Combats AIDS Through Training</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:8">Ultrafem to Proceed to Clinical Trials With BufferGel Technology  to Offer Women Protection Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:9">Baboon Graft Fails, But Patient Thrives</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960411:10">From Freedom to Fear: When AIDS Hits China</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:1">Sequus Pharmaceuticals Inc.: Sales of Drug for Treating AIDS-Related Cancer Gain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:2">AIDS Prevention Programs for Teenagers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:3">Abbott Laboratories</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:4">Switzerland: Abbott Test for HIV Taken Off Market</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:5">New Zidovudine Formulation Reduces Viral Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:6">HIV-1 Found in Variety of Drug Paraphernalia</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:7">Experts Call for Increased AIDS Education of African-Americans and Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:8">Thalidomide Effective for Genital Ulcer in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:9">Returning with AIDS: Supporting Rural Emigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:10">AIDS Update: Stir Up the Treatment Pot</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:1">World Wire: Ban on Abbott AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:2">Ilka Payan, 53, an Actress, Dies; Champion for Anti-AIDS Causes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:3">Maneuvers Afoot to Ax HIV Ban in Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:4">Bill Seeks to Put Federal Stamp on AIDS Memorial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:5">Good Deed Came with Possible Danger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:6">AIDS Rate Highest in Largest Prisons</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:7">How to Save Babies From AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:8">Continuous Fluconazole Protects Against Oral Candida</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:9">Kaposi's Sarcoma Study Starts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:10">M. Tuberculosis Genome to Be Sequenced</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:1">Whitman Panel Urges Needle Exchange Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:2">New Program Offers AIDS Patients Free Assistance with Tax Questions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:3">Assisted-Suicide Debate Summed Up in Opposite Actions of 2 Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:4">Internet Ad for HIV Cure Draws Restraining Order</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:5">Why Kessler Must Go</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:6">New AIDS Drug Wins Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:7">Former Blood Official Contests Probe</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:8">Schools Alter Their HIV Rules</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:9">Australia Reports on AIDS: Nef Deletions, Live Vaccines, Chinese Travelers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:10">Tuberculosis Program Changes and Treatment Outcomes in Patients with Smear-Positive Pulmonary Tuberculosis in Blantyre, Malawi</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:1">Gene Therapy and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:2">FDA Approves the Testing of Drug for AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:3">Blood Banks Adopt Stricter AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:4">The Tuberculosis Emergency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:5">Mild Cytologic Atypia Associated with CIN in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:6">Human Herpes Virus 6 Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:7">Major Opportunistic Infections Are Developing Later in HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:8">Invasive Pneumococcal Disease in a Cohort of Predominantly HIV-1 Infected Female Sex Workers in Nairobi, Kenya</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:9">Home HIV Tests Raise Issues of Counseling, Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:10">Face to Face with TB</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960401"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-179</DOCNO>
<DOCOLDNO>IA017-000178-B005-64</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960409 192.33.214.13 19970106043507 text/html 8000
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:35:26 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>April 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:1">Sequus Pharmaceuticals Inc.: Sales of Drug for Treating AIDS-Related Cancer Gain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:2">AIDS Prevention Programs for Teenagers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:3">Abbott Laboratories</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:4">Switzerland: Abbott Test for HIV Taken Off Market</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:5">New Zidovudine Formulation Reduces Viral Resistance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:6">HIV-1 Found in Variety of Drug Paraphernalia</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:7">Experts Call for Increased AIDS Education of African-Americans and Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:8">Thalidomide Effective for Genital Ulcer in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:9">Returning with AIDS: Supporting Rural Emigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960409:10">AIDS Update: Stir Up the Treatment Pot</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:1">World Wire: Ban on Abbott AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:2">Ilka Payan, 53, an Actress, Dies; Champion for Anti-AIDS Causes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:3">Maneuvers Afoot to Ax HIV Ban in Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:4">Bill Seeks to Put Federal Stamp on AIDS Memorial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:5">Good Deed Came with Possible Danger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:6">AIDS Rate Highest in Largest Prisons</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:7">How to Save Babies From AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:8">Continuous Fluconazole Protects Against Oral Candida</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:9">Kaposi's Sarcoma Study Starts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:10">M. Tuberculosis Genome to Be Sequenced</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:1">Whitman Panel Urges Needle Exchange Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:2">New Program Offers AIDS Patients Free Assistance with Tax Questions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:3">Assisted-Suicide Debate Summed Up in Opposite Actions of 2 Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:4">Internet Ad for HIV Cure Draws Restraining Order</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:5">Why Kessler Must Go</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:6">New AIDS Drug Wins Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:7">Former Blood Official Contests Probe</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:8">Schools Alter Their HIV Rules</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:9">Australia Reports on AIDS: Nef Deletions, Live Vaccines, Chinese Travelers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:10">Tuberculosis Program Changes and Treatment Outcomes in Patients with Smear-Positive Pulmonary Tuberculosis in Blantyre, Malawi</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:1">Gene Therapy and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:2">FDA Approves the Testing of Drug for AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:3">Blood Banks Adopt Stricter AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:4">The Tuberculosis Emergency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:5">Mild Cytologic Atypia Associated with CIN in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:6">Human Herpes Virus 6 Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:7">Major Opportunistic Infections Are Developing Later in HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:8">Invasive Pneumococcal Disease in a Cohort of Predominantly HIV-1 Infected Female Sex Workers in Nairobi, Kenya</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:9">Home HIV Tests Raise Issues of Counseling, Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:10">Face to Face with TB</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:1">Across the USA: Illinois</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:2">2nd-Grader Stabs 5 Others with Found Medical Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:3">Unwelcome Donations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:4">Virus Research Drawing International Attention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:5">Cognitive Impairment Linked to Early Death in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:6">No Benefits Seen in AIDS Patients After Fish Oil Supplementation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:7">EU Wants Back Money Sank into S. African AIDS Play</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:8">The Trials of a Home HIV Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:9">Case for Behavioral Studies for AIDS Prevention</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960328"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-180</DOCNO>
<DOCOLDNO>IA017-000178-B005-75</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960408 192.33.214.13 19970106043526 text/html 8010
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:35:37 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>April 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:1">World Wire: Ban on Abbott AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:2">Ilka Payan, 53, an Actress, Dies; Champion for Anti-AIDS Causes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:3">Maneuvers Afoot to Ax HIV Ban in Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:4">Bill Seeks to Put Federal Stamp on AIDS Memorial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:5">Good Deed Came with Possible Danger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:6">AIDS Rate Highest in Largest Prisons</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:7">How to Save Babies From AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:8">Continuous Fluconazole Protects Against Oral Candida</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:9">Kaposi's Sarcoma Study Starts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960408:10">M. Tuberculosis Genome to Be Sequenced</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:1">Whitman Panel Urges Needle Exchange Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:2">New Program Offers AIDS Patients Free Assistance with Tax Questions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:3">Assisted-Suicide Debate Summed Up in Opposite Actions of 2 Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:4">Internet Ad for HIV Cure Draws Restraining Order</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:5">Why Kessler Must Go</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:6">New AIDS Drug Wins Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:7">Former Blood Official Contests Probe</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:8">Schools Alter Their HIV Rules</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:9">Australia Reports on AIDS: Nef Deletions, Live Vaccines, Chinese Travelers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:10">Tuberculosis Program Changes and Treatment Outcomes in Patients with Smear-Positive Pulmonary Tuberculosis in Blantyre, Malawi</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:1">Gene Therapy and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:2">FDA Approves the Testing of Drug for AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:3">Blood Banks Adopt Stricter AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:4">The Tuberculosis Emergency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:5">Mild Cytologic Atypia Associated with CIN in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:6">Human Herpes Virus 6 Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:7">Major Opportunistic Infections Are Developing Later in HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:8">Invasive Pneumococcal Disease in a Cohort of Predominantly HIV-1 Infected Female Sex Workers in Nairobi, Kenya</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:9">Home HIV Tests Raise Issues of Counseling, Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:10">Face to Face with TB</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:1">Across the USA: Illinois</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:2">2nd-Grader Stabs 5 Others with Found Medical Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:3">Unwelcome Donations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:4">Virus Research Drawing International Attention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:5">Cognitive Impairment Linked to Early Death in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:6">No Benefits Seen in AIDS Patients After Fish Oil Supplementation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:7">EU Wants Back Money Sank into S. African AIDS Play</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:8">The Trials of a Home HIV Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:9">Case for Behavioral Studies for AIDS Prevention</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:1">Across the USA: Tennessee</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:2">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:3">Health-Insurance Measure Is Running Into Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:4">Zimbabwe's AIDS Orphans to Reach 600,000 by 2000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:5">Death Rates High Among New York Welfare Recipients--Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:6">Influenza Immunization in HIV-Positive Children Does Not Enhance HIV Replication</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:7">Zimbabwe's Maternal Mortality Deaths Rising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:8">Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:9">Rogue Science or Reality?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:10">Principals in HIV Blood Scandal Should be Summoned by Diet</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960326"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-181</DOCNO>
<DOCOLDNO>IA017-000178-B005-94</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960404 192.33.214.13 19970106043557 text/html 8116
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:36:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>April 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:1">Whitman Panel Urges Needle Exchange Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:2">New Program Offers AIDS Patients Free Assistance with Tax Questions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:3">Assisted-Suicide Debate Summed Up in Opposite Actions of 2 Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:4">Internet Ad for HIV Cure Draws Restraining Order</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:5">Why Kessler Must Go</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:6">New AIDS Drug Wins Approval</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:7">Former Blood Official Contests Probe</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:8">Schools Alter Their HIV Rules</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:9">Australia Reports on AIDS: Nef Deletions, Live Vaccines, Chinese Travelers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960404:10">Tuberculosis Program Changes and Treatment Outcomes in Patients with Smear-Positive Pulmonary Tuberculosis in Blantyre, Malawi</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:1">Gene Therapy and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:2">FDA Approves the Testing of Drug for AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:3">Blood Banks Adopt Stricter AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:4">The Tuberculosis Emergency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:5">Mild Cytologic Atypia Associated with CIN in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:6">Human Herpes Virus 6 Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:7">Major Opportunistic Infections Are Developing Later in HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:8">Invasive Pneumococcal Disease in a Cohort of Predominantly HIV-1 Infected Female Sex Workers in Nairobi, Kenya</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:9">Home HIV Tests Raise Issues of Counseling, Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:10">Face to Face with TB</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:1">Across the USA: Illinois</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:2">2nd-Grader Stabs 5 Others with Found Medical Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:3">Unwelcome Donations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:4">Virus Research Drawing International Attention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:5">Cognitive Impairment Linked to Early Death in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:6">No Benefits Seen in AIDS Patients After Fish Oil Supplementation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:7">EU Wants Back Money Sank into S. African AIDS Play</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:8">The Trials of a Home HIV Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:9">Case for Behavioral Studies for AIDS Prevention</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:1">Across the USA: Tennessee</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:2">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:3">Health-Insurance Measure Is Running Into Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:4">Zimbabwe's AIDS Orphans to Reach 600,000 by 2000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:5">Death Rates High Among New York Welfare Recipients--Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:6">Influenza Immunization in HIV-Positive Children Does Not Enhance HIV Replication</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:7">Zimbabwe's Maternal Mortality Deaths Rising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:8">Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:9">Rogue Science or Reality?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:10">Principals in HIV Blood Scandal Should be Summoned by Diet</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:1">S. Africa Insurer Offers Cover for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:2">AIDS Drug Is Approved by 4 European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:3">Review  Outlook: AIDS Babies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:4">Drawbacks of Mandatory HIV Tests, Counseling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:5">AIDS Conference Adopts Hopeful Spirit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:6">Experimental AIDS Vaccine Volunteer Infected</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:7">Anti-HIV Agent Inhibits Early Step in HIV Life Cycle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:8">Thalidomide: Facilitates Weight Gain in Persons with HIV and M. Tuberculosis Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:9">Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection--Utah, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:10">Pregnant Nurse Won't Treat HIV Patient</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960325"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-182</DOCNO>
<DOCOLDNO>IA017-000178-B005-108</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960402 192.33.214.13 19970106043610 text/html 8065
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:36:30 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>April 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:1">Gene Therapy and AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:2">FDA Approves the Testing of Drug for AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:3">Blood Banks Adopt Stricter AIDS Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:4">The Tuberculosis Emergency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:5">Mild Cytologic Atypia Associated with CIN in HIV-Positive Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:6">Human Herpes Virus 6 Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:7">Major Opportunistic Infections Are Developing Later in HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:8">Invasive Pneumococcal Disease in a Cohort of Predominantly HIV-1 Infected Female Sex Workers in Nairobi, Kenya</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:9">Home HIV Tests Raise Issues of Counseling, Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960402:10">Face to Face with TB</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:1">Across the USA: Illinois</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:2">2nd-Grader Stabs 5 Others with Found Medical Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:3">Unwelcome Donations</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:4">Virus Research Drawing International Attention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:5">Cognitive Impairment Linked to Early Death in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:6">No Benefits Seen in AIDS Patients After Fish Oil Supplementation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:7">EU Wants Back Money Sank into S. African AIDS Play</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:8">The Trials of a Home HIV Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960401:9">Case for Behavioral Studies for AIDS Prevention</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:1">Across the USA: Tennessee</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:2">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:3">Health-Insurance Measure Is Running Into Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:4">Zimbabwe's AIDS Orphans to Reach 600,000 by 2000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:5">Death Rates High Among New York Welfare Recipients--Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:6">Influenza Immunization in HIV-Positive Children Does Not Enhance HIV Replication</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:7">Zimbabwe's Maternal Mortality Deaths Rising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:8">Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:9">Rogue Science or Reality?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:10">Principals in HIV Blood Scandal Should be Summoned by Diet</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:1">S. Africa Insurer Offers Cover for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:2">AIDS Drug Is Approved by 4 European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:3">Review  Outlook: AIDS Babies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:4">Drawbacks of Mandatory HIV Tests, Counseling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:5">AIDS Conference Adopts Hopeful Spirit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:6">Experimental AIDS Vaccine Volunteer Infected</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:7">Anti-HIV Agent Inhibits Early Step in HIV Life Cycle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:8">Thalidomide: Facilitates Weight Gain in Persons with HIV and M. Tuberculosis Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:9">Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection--Utah, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:10">Pregnant Nurse Won't Treat HIV Patient</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:1">AIDS Drugs Bring Hope, High Prices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:2">Stricken, But Speaking Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:3">Fanfare: Auto Racing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:4">FDA Approves Human Testing of Preventive AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:5">Vaginal Microbicides Explored for AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:6">Leading AIDS Researcher Warns of Second Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:7">TB A Threat in Latin America, Caribbean</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:8">Advisory on Zidovudine to Reduce HIV Transmission From Mother to Infant Sent to Thousands of Health Care Providers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:9">Lamivudine Resistance May be Associated with Beneficial Effects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:10">AIDS Update: AIDS Research: Charge It</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960322"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-183</DOCNO>
<DOCOLDNO>IA017-000178-B005-118</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960328 192.33.214.13 19970106043621 text/html 8201
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:36:41 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960409"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:1">Across the USA: Tennessee</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:2">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:3">Health-Insurance Measure Is Running Into Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:4">Zimbabwe's AIDS Orphans to Reach 600,000 by 2000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:5">Death Rates High Among New York Welfare Recipients--Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:6">Influenza Immunization in HIV-Positive Children Does Not Enhance HIV Replication</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:7">Zimbabwe's Maternal Mortality Deaths Rising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:8">Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:9">Rogue Science or Reality?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960328:10">Principals in HIV Blood Scandal Should be Summoned by Diet</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:1">S. Africa Insurer Offers Cover for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:2">AIDS Drug Is Approved by 4 European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:3">Review  Outlook: AIDS Babies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:4">Drawbacks of Mandatory HIV Tests, Counseling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:5">AIDS Conference Adopts Hopeful Spirit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:6">Experimental AIDS Vaccine Volunteer Infected</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:7">Anti-HIV Agent Inhibits Early Step in HIV Life Cycle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:8">Thalidomide: Facilitates Weight Gain in Persons with HIV and M. Tuberculosis Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:9">Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection--Utah, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:10">Pregnant Nurse Won't Treat HIV Patient</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:1">AIDS Drugs Bring Hope, High Prices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:2">Stricken, But Speaking Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:3">Fanfare: Auto Racing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:4">FDA Approves Human Testing of Preventive AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:5">Vaginal Microbicides Explored for AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:6">Leading AIDS Researcher Warns of Second Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:7">TB A Threat in Latin America, Caribbean</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:8">Advisory on Zidovudine to Reduce HIV Transmission From Mother to Infant Sent to Thousands of Health Care Providers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:9">Lamivudine Resistance May be Associated with Beneficial Effects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:10">AIDS Update: AIDS Research: Charge It</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:1">TB Threat Grows Worldwide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:2">Glendening Targets $1 Million to Help Some AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:3">On Every Argentine Cellblock, Specter of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:4">Mother Whose Home Was Torched Asks Aid for Hemophiliacs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:5">Research Attacks Immune System Theory</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:6">A Menu of Rare Antibodies For Drug Firms</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:7">Morrison Says He Will Beat HIV, Fight Again</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:8">HIV Subtypes Raise Vaccine Anxieties</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:9">Outbreak of Primary and Secondary Syphilis--Baltimore City, Maryland, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:10">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:1">Dornan Says Leaders Back Him on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:2">Digest: Life Partners Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:3">Discharging HIV-Positive Service Members is Unfair and Unnecessary</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:4">The Reliable Source: Now You Know...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:5">Man Goes for Wild Ride After HIV Test Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:6">Obituary: Perry Watkins, 48, Gay Sergeant Who Won Enlistment in Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:7">All But One of Japan Hemophiliacs Take Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:8">S. Africa Insurer Launches HIV Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:9">Vaccine Drought Spurs NIAID Plan to Improve Industry Ties...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:10">Treatment of Cognitive Impairment</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960320"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-184</DOCNO>
<DOCOLDNO>IA017-000178-B005-129</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960326 192.33.214.13 19970106043632 text/html 8196
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:36:53 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960408"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:1">S. Africa Insurer Offers Cover for HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:2">AIDS Drug Is Approved by 4 European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:3">Review  Outlook: AIDS Babies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:4">Drawbacks of Mandatory HIV Tests, Counseling</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:5">AIDS Conference Adopts Hopeful Spirit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:6">Experimental AIDS Vaccine Volunteer Infected</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:7">Anti-HIV Agent Inhibits Early Step in HIV Life Cycle</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:8">Thalidomide: Facilitates Weight Gain in Persons with HIV and M. Tuberculosis Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:9">Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection--Utah, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960326:10">Pregnant Nurse Won't Treat HIV Patient</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:1">AIDS Drugs Bring Hope, High Prices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:2">Stricken, But Speaking Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:3">Fanfare: Auto Racing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:4">FDA Approves Human Testing of Preventive AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:5">Vaginal Microbicides Explored for AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:6">Leading AIDS Researcher Warns of Second Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:7">TB A Threat in Latin America, Caribbean</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:8">Advisory on Zidovudine to Reduce HIV Transmission From Mother to Infant Sent to Thousands of Health Care Providers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:9">Lamivudine Resistance May be Associated with Beneficial Effects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:10">AIDS Update: AIDS Research: Charge It</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:1">TB Threat Grows Worldwide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:2">Glendening Targets $1 Million to Help Some AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:3">On Every Argentine Cellblock, Specter of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:4">Mother Whose Home Was Torched Asks Aid for Hemophiliacs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:5">Research Attacks Immune System Theory</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:6">A Menu of Rare Antibodies For Drug Firms</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:7">Morrison Says He Will Beat HIV, Fight Again</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:8">HIV Subtypes Raise Vaccine Anxieties</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:9">Outbreak of Primary and Secondary Syphilis--Baltimore City, Maryland, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:10">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:1">Dornan Says Leaders Back Him on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:2">Digest: Life Partners Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:3">Discharging HIV-Positive Service Members is Unfair and Unnecessary</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:4">The Reliable Source: Now You Know...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:5">Man Goes for Wild Ride After HIV Test Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:6">Obituary: Perry Watkins, 48, Gay Sergeant Who Won Enlistment in Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:7">All But One of Japan Hemophiliacs Take Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:8">S. Africa Insurer Launches HIV Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:9">Vaccine Drought Spurs NIAID Plan to Improve Industry Ties...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:10">Treatment of Cognitive Impairment</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:1">Senate Votes to Repeal Requirement That GIs With AIDS Virus Be Released</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:2">'Philadelphia' Makers Settle Suit Over Source</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:3">Survival of the Nastiest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:4">Vital Statistics: AIDS Orphans</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:5">Living with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:6">Tuberculosis Rise Adds to Vietnam's AIDS Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:7">Family Role Increasing as Deaths of HIV-Positive Mothers Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:8">HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:9">National Academy of Sciences Endorses Syringe Exchange as an HIV Prevention Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:10">HIV Rate in CA Prisons Higher Than in Community</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960319"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-185</DOCNO>
<DOCOLDNO>IA017-000178-B005-140</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960325 192.33.214.13 19970106043640 text/html 8144
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:37:02 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960404"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:1">AIDS Drugs Bring Hope, High Prices</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:2">Stricken, But Speaking Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:3">Fanfare: Auto Racing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:4">FDA Approves Human Testing of Preventive AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:5">Vaginal Microbicides Explored for AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:6">Leading AIDS Researcher Warns of Second Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:7">TB A Threat in Latin America, Caribbean</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:8">Advisory on Zidovudine to Reduce HIV Transmission From Mother to Infant Sent to Thousands of Health Care Providers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:9">Lamivudine Resistance May be Associated with Beneficial Effects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960325:10">AIDS Update: AIDS Research: Charge It</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:1">TB Threat Grows Worldwide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:2">Glendening Targets $1 Million to Help Some AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:3">On Every Argentine Cellblock, Specter of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:4">Mother Whose Home Was Torched Asks Aid for Hemophiliacs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:5">Research Attacks Immune System Theory</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:6">A Menu of Rare Antibodies For Drug Firms</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:7">Morrison Says He Will Beat HIV, Fight Again</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:8">HIV Subtypes Raise Vaccine Anxieties</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:9">Outbreak of Primary and Secondary Syphilis--Baltimore City, Maryland, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:10">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:1">Dornan Says Leaders Back Him on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:2">Digest: Life Partners Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:3">Discharging HIV-Positive Service Members is Unfair and Unnecessary</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:4">The Reliable Source: Now You Know...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:5">Man Goes for Wild Ride After HIV Test Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:6">Obituary: Perry Watkins, 48, Gay Sergeant Who Won Enlistment in Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:7">All But One of Japan Hemophiliacs Take Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:8">S. Africa Insurer Launches HIV Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:9">Vaccine Drought Spurs NIAID Plan to Improve Industry Ties...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:10">Treatment of Cognitive Impairment</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:1">Senate Votes to Repeal Requirement That GIs With AIDS Virus Be Released</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:2">'Philadelphia' Makers Settle Suit Over Source</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:3">Survival of the Nastiest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:4">Vital Statistics: AIDS Orphans</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:5">Living with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:6">Tuberculosis Rise Adds to Vietnam's AIDS Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:7">Family Role Increasing as Deaths of HIV-Positive Mothers Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:8">HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:9">National Academy of Sciences Endorses Syringe Exchange as an HIV Prevention Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:10">HIV Rate in CA Prisons Higher Than in Community</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:1">Panel Backs Retinitis Drug; Gilead Stock Recovers Some</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:2">Testing Begins on AIDS Therapy Developed by Dr. Salk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:3">Experience of Doctor Vital To AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:4">Tuberculosis, Uncontrolled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:5">Impaired Immune Response After Hib Vaccination in HIV-Positive Infants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:6">Merck Discounts Its New Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:7">EEOC Permits Limited Disclosure of Employee HIV Status</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:8">Faint Hope for Drug to Tackle Deadly Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:9">Routine Immunization in HIV: Helpful or Harmful?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:10">Europe's Drug Lottery</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960318"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-186</DOCNO>
<DOCOLDNO>IA017-000178-B005-148</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960322 192.33.214.13 19970106043650 text/html 8116
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:37:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960402"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:1">TB Threat Grows Worldwide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:2">Glendening Targets $1 Million to Help Some AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:3">On Every Argentine Cellblock, Specter of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:4">Mother Whose Home Was Torched Asks Aid for Hemophiliacs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:5">Research Attacks Immune System Theory</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:6">A Menu of Rare Antibodies For Drug Firms</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:7">Morrison Says He Will Beat HIV, Fight Again</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:8">HIV Subtypes Raise Vaccine Anxieties</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:9">Outbreak of Primary and Secondary Syphilis--Baltimore City, Maryland, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960322:10">Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:1">Dornan Says Leaders Back Him on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:2">Digest: Life Partners Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:3">Discharging HIV-Positive Service Members is Unfair and Unnecessary</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:4">The Reliable Source: Now You Know...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:5">Man Goes for Wild Ride After HIV Test Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:6">Obituary: Perry Watkins, 48, Gay Sergeant Who Won Enlistment in Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:7">All But One of Japan Hemophiliacs Take Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:8">S. Africa Insurer Launches HIV Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:9">Vaccine Drought Spurs NIAID Plan to Improve Industry Ties...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:10">Treatment of Cognitive Impairment</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:1">Senate Votes to Repeal Requirement That GIs With AIDS Virus Be Released</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:2">'Philadelphia' Makers Settle Suit Over Source</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:3">Survival of the Nastiest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:4">Vital Statistics: AIDS Orphans</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:5">Living with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:6">Tuberculosis Rise Adds to Vietnam's AIDS Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:7">Family Role Increasing as Deaths of HIV-Positive Mothers Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:8">HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:9">National Academy of Sciences Endorses Syringe Exchange as an HIV Prevention Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:10">HIV Rate in CA Prisons Higher Than in Community</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:1">Panel Backs Retinitis Drug; Gilead Stock Recovers Some</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:2">Testing Begins on AIDS Therapy Developed by Dr. Salk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:3">Experience of Doctor Vital To AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:4">Tuberculosis, Uncontrolled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:5">Impaired Immune Response After Hib Vaccination in HIV-Positive Infants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:6">Merck Discounts Its New Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:7">EEOC Permits Limited Disclosure of Employee HIV Status</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:8">Faint Hope for Drug to Tackle Deadly Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:9">Routine Immunization in HIV: Helpful or Harmful?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:10">Europe's Drug Lottery</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:1">AIDS Therapy Study to Begin Among Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:2">Gilead Sciences Inc.: FDA Panel Clears Vistide; Stock Sinks on Testimony</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:3">New York Helps 600 Retain Health Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:4">FDA Put Off Making Its Decision on Drug for AIDS Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:5">Case Hurts Green Cross Profit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:6">Assessing AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:7">Guess What Kills More Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:8">Avid Gets Option to License HIV Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:9">Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:10">Growing Crisis in Paying for Care</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960315"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-187</DOCNO>
<DOCOLDNO>IA017-000178-B005-164</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960321 192.33.214.13 19970106043702 text/html 8430
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:37:22 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960401"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:1">Dornan Says Leaders Back Him on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:2">Digest: Life Partners Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:3">Discharging HIV-Positive Service Members is Unfair and Unnecessary</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:4">The Reliable Source: Now You Know...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:5">Man Goes for Wild Ride After HIV Test Results</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:6">Obituary: Perry Watkins, 48, Gay Sergeant Who Won Enlistment in Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:7">All But One of Japan Hemophiliacs Take Compromise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:8">S. Africa Insurer Launches HIV Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:9">Vaccine Drought Spurs NIAID Plan to Improve Industry Ties...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960321:10">Treatment of Cognitive Impairment</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:1">Senate Votes to Repeal Requirement That GIs With AIDS Virus Be Released</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:2">'Philadelphia' Makers Settle Suit Over Source</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:3">Survival of the Nastiest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:4">Vital Statistics: AIDS Orphans</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:5">Living with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:6">Tuberculosis Rise Adds to Vietnam's AIDS Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:7">Family Role Increasing as Deaths of HIV-Positive Mothers Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:8">HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:9">National Academy of Sciences Endorses Syringe Exchange as an HIV Prevention Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:10">HIV Rate in CA Prisons Higher Than in Community</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:1">Panel Backs Retinitis Drug; Gilead Stock Recovers Some</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:2">Testing Begins on AIDS Therapy Developed by Dr. Salk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:3">Experience of Doctor Vital To AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:4">Tuberculosis, Uncontrolled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:5">Impaired Immune Response After Hib Vaccination in HIV-Positive Infants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:6">Merck Discounts Its New Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:7">EEOC Permits Limited Disclosure of Employee HIV Status</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:8">Faint Hope for Drug to Tackle Deadly Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:9">Routine Immunization in HIV: Helpful or Harmful?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:10">Europe's Drug Lottery</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:1">AIDS Therapy Study to Begin Among Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:2">Gilead Sciences Inc.: FDA Panel Clears Vistide; Stock Sinks on Testimony</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:3">New York Helps 600 Retain Health Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:4">FDA Put Off Making Its Decision on Drug for AIDS Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:5">Case Hurts Green Cross Profit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:6">Assessing AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:7">Guess What Kills More Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:8">Avid Gets Option to License HIV Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:9">Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:10">Growing Crisis in Paying for Care</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:1">Undervaccination for hepatitis B among young men who have sex with men: San Francisco/Berkeley, California 1992-1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:2">Merck's Newly Approved AIDS Drug Is Priced 30 Percent Below Rival Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:3">FDA Sanctions Faster Blood Screening Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:4">Japanese Suits on H.I.V.-Tainted Blood Settled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:5">Report Urges Shift in AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:6">Babies Need AIDS Protection, Too</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:7">Across the USA: Rhode Island</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:8">Blood Inquiry Can Keep Memos Secret</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:9">States Debate HIV Testing in Pregnant Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:10">FDA: More Patients to Try Controversial Blood Scalding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:11">Court Expands HIV Liability for Drug Makers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:12">New Internet Sources for HIV/AIDS Treatment and Clinical Trials Information</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960314"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-188</DOCNO>
<DOCOLDNO>IA017-000178-B005-178</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960320 192.33.214.13 19970106043713 text/html 8456
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:37:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960328"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 20, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:1">Senate Votes to Repeal Requirement That GIs With AIDS Virus Be Released</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:2">'Philadelphia' Makers Settle Suit Over Source</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:3">Survival of the Nastiest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:4">Vital Statistics: AIDS Orphans</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:5">Living with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:6">Tuberculosis Rise Adds to Vietnam's AIDS Problem</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:7">Family Role Increasing as Deaths of HIV-Positive Mothers Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:8">HIV-1 Langerhans' Cell Tropism Associated with Heterosexual Transmission of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:9">National Academy of Sciences Endorses Syringe Exchange as an HIV Prevention Strategy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960320:10">HIV Rate in CA Prisons Higher Than in Community</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:1">Panel Backs Retinitis Drug; Gilead Stock Recovers Some</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:2">Testing Begins on AIDS Therapy Developed by Dr. Salk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:3">Experience of Doctor Vital To AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:4">Tuberculosis, Uncontrolled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:5">Impaired Immune Response After Hib Vaccination in HIV-Positive Infants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:6">Merck Discounts Its New Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:7">EEOC Permits Limited Disclosure of Employee HIV Status</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:8">Faint Hope for Drug to Tackle Deadly Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:9">Routine Immunization in HIV: Helpful or Harmful?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:10">Europe's Drug Lottery</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:1">AIDS Therapy Study to Begin Among Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:2">Gilead Sciences Inc.: FDA Panel Clears Vistide; Stock Sinks on Testimony</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:3">New York Helps 600 Retain Health Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:4">FDA Put Off Making Its Decision on Drug for AIDS Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:5">Case Hurts Green Cross Profit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:6">Assessing AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:7">Guess What Kills More Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:8">Avid Gets Option to License HIV Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:9">Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:10">Growing Crisis in Paying for Care</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:1">Undervaccination for hepatitis B among young men who have sex with men: San Francisco/Berkeley, California 1992-1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:2">Merck's Newly Approved AIDS Drug Is Priced 30 Percent Below Rival Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:3">FDA Sanctions Faster Blood Screening Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:4">Japanese Suits on H.I.V.-Tainted Blood Settled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:5">Report Urges Shift in AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:6">Babies Need AIDS Protection, Too</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:7">Across the USA: Rhode Island</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:8">Blood Inquiry Can Keep Memos Secret</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:9">States Debate HIV Testing in Pregnant Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:10">FDA: More Patients to Try Controversial Blood Scalding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:11">Court Expands HIV Liability for Drug Makers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:12">New Internet Sources for HIV/AIDS Treatment and Clinical Trials Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:1">Panel Offers Sharp Criticism of AIDS Research Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:2">School Parents Call Halt to Use of Book on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:3">Senate Ready to Repeal Law to Dismiss Soldiers with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:4">Book World: Infectious Pessimism</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:5">Toughing it Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:6">Specialists Help HIV Patients Live Longer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:7">U.S. Firm to Sell More AIDS Drug to France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:8">Neurological Manifestations of HIV Infection a Focus of Paris Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:9">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:10">'Lost' Files Link HIV Infections to Health Ministry Decision</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960313"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-189</DOCNO>
<DOCOLDNO>IA017-000178-B005-191</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960319 192.33.214.13 19970106043724 text/html 8454
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:37:43 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960326"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:1">Panel Backs Retinitis Drug; Gilead Stock Recovers Some</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:2">Testing Begins on AIDS Therapy Developed by Dr. Salk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:3">Experience of Doctor Vital To AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:4">Tuberculosis, Uncontrolled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:5">Impaired Immune Response After Hib Vaccination in HIV-Positive Infants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:6">Merck Discounts Its New Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:7">EEOC Permits Limited Disclosure of Employee HIV Status</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:8">Faint Hope for Drug to Tackle Deadly Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:9">Routine Immunization in HIV: Helpful or Harmful?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960319:10">Europe's Drug Lottery</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:1">AIDS Therapy Study to Begin Among Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:2">Gilead Sciences Inc.: FDA Panel Clears Vistide; Stock Sinks on Testimony</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:3">New York Helps 600 Retain Health Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:4">FDA Put Off Making Its Decision on Drug for AIDS Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:5">Case Hurts Green Cross Profit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:6">Assessing AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:7">Guess What Kills More Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:8">Avid Gets Option to License HIV Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:9">Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:10">Growing Crisis in Paying for Care</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:1">Undervaccination for hepatitis B among young men who have sex with men: San Francisco/Berkeley, California 1992-1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:2">Merck's Newly Approved AIDS Drug Is Priced 30 Percent Below Rival Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:3">FDA Sanctions Faster Blood Screening Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:4">Japanese Suits on H.I.V.-Tainted Blood Settled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:5">Report Urges Shift in AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:6">Babies Need AIDS Protection, Too</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:7">Across the USA: Rhode Island</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:8">Blood Inquiry Can Keep Memos Secret</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:9">States Debate HIV Testing in Pregnant Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:10">FDA: More Patients to Try Controversial Blood Scalding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:11">Court Expands HIV Liability for Drug Makers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:12">New Internet Sources for HIV/AIDS Treatment and Clinical Trials Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:1">Panel Offers Sharp Criticism of AIDS Research Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:2">School Parents Call Halt to Use of Book on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:3">Senate Ready to Repeal Law to Dismiss Soldiers with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:4">Book World: Infectious Pessimism</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:5">Toughing it Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:6">Specialists Help HIV Patients Live Longer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:7">U.S. Firm to Sell More AIDS Drug to France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:8">Neurological Manifestations of HIV Infection a Focus of Paris Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:9">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:10">'Lost' Files Link HIV Infections to Health Ministry Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 13, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:1">Eager for Gay History and Finding Library Allies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:2">Japanese Leaders in Logjam</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:3">Dingwall Wants Meeting to 'Renew Blood System'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:4">Somatic Growth of HIV-Positive Infants Impaired</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:5">HIV Diagnosis Before Birth on the Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:6">FDA Official Rebuts Criticism of Drug Approval Process</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:7">Gilead Sciences Makes Vistide Available in France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:8">Continued Sexual Risk Behavior Among HIV-Seropositive, Drug-Using Men--Atlanta; Washington, D.C.; and San Juan, Puerto Rico, 1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:9">Montagnier Sets Up AIDS Research Center</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:10">Marshals Pay AIDS Activists</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960312"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-190</DOCNO>
<DOCOLDNO>IA017-000178-B005-205</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960318 192.33.214.13 19970106043749 text/html 8401
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:38:04 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960325"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:1">AIDS Therapy Study to Begin Among Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:2">Gilead Sciences Inc.: FDA Panel Clears Vistide; Stock Sinks on Testimony</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:3">New York Helps 600 Retain Health Coverage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:4">FDA Put Off Making Its Decision on Drug for AIDS Wasting</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:5">Case Hurts Green Cross Profit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:6">Assessing AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:7">Guess What Kills More Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:8">Avid Gets Option to License HIV Protease Inhibitor</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:9">Neonatal Characteristics in Rapidly Progressive Perinatally Acquired HIV-1 Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960318:10">Growing Crisis in Paying for Care</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:1">Undervaccination for hepatitis B among young men who have sex with men: San Francisco/Berkeley, California 1992-1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:2">Merck's Newly Approved AIDS Drug Is Priced 30 Percent Below Rival Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:3">FDA Sanctions Faster Blood Screening Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:4">Japanese Suits on H.I.V.-Tainted Blood Settled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:5">Report Urges Shift in AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:6">Babies Need AIDS Protection, Too</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:7">Across the USA: Rhode Island</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:8">Blood Inquiry Can Keep Memos Secret</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:9">States Debate HIV Testing in Pregnant Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:10">FDA: More Patients to Try Controversial Blood Scalding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:11">Court Expands HIV Liability for Drug Makers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:12">New Internet Sources for HIV/AIDS Treatment and Clinical Trials Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:1">Panel Offers Sharp Criticism of AIDS Research Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:2">School Parents Call Halt to Use of Book on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:3">Senate Ready to Repeal Law to Dismiss Soldiers with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:4">Book World: Infectious Pessimism</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:5">Toughing it Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:6">Specialists Help HIV Patients Live Longer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:7">U.S. Firm to Sell More AIDS Drug to France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:8">Neurological Manifestations of HIV Infection a Focus of Paris Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:9">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:10">'Lost' Files Link HIV Infections to Health Ministry Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 13, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:1">Eager for Gay History and Finding Library Allies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:2">Japanese Leaders in Logjam</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:3">Dingwall Wants Meeting to 'Renew Blood System'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:4">Somatic Growth of HIV-Positive Infants Impaired</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:5">HIV Diagnosis Before Birth on the Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:6">FDA Official Rebuts Criticism of Drug Approval Process</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:7">Gilead Sciences Makes Vistide Available in France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:8">Continued Sexual Risk Behavior Among HIV-Seropositive, Drug-Using Men--Atlanta; Washington, D.C.; and San Juan, Puerto Rico, 1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:9">Montagnier Sets Up AIDS Research Center</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:10">Marshals Pay AIDS Activists</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:1">New Issue Update: Gilead Sciences</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:2">John-John Dies of AIDS at 11 Still Speaking of Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:3">Unusual Molecules Could be Key to Cancer Patients' Weight Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:4">Portraits of Lives with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:5">Thalidomide Returns With New Hope, Old Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:6">Neurex SNX-111 in the Treatment of Neuropathic Pain Caused by AIDS; Early Results Promising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:7">Identification of Levels of Maternal HIV-1 RNA Associated With Risk of Perinatal Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:8">Syringe Exchange in the United States: 1995 Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:9">JAMA, Glaxo Wellcome Create HIV/AIDS Site on Web</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960311"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-191</DOCNO>
<DOCOLDNO>IA017-000178-B005-215</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960315 192.33.214.13 19970106043800 text/html 8238
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:38:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960322"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:1">Undervaccination for hepatitis B among young men who have sex with men: San Francisco/Berkeley, California 1992-1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:2">Merck's Newly Approved AIDS Drug Is Priced 30 Percent Below Rival Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:3">FDA Sanctions Faster Blood Screening Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:4">Japanese Suits on H.I.V.-Tainted Blood Settled</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:5">Report Urges Shift in AIDS Research</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:6">Babies Need AIDS Protection, Too</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:7">Across the USA: Rhode Island</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:8">Blood Inquiry Can Keep Memos Secret</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:9">States Debate HIV Testing in Pregnant Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:10">FDA: More Patients to Try Controversial Blood Scalding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:11">Court Expands HIV Liability for Drug Makers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>12.</TD>
 <TD><A HREF="SUMM-96.cgi?960315:12">New Internet Sources for HIV/AIDS Treatment and Clinical Trials Information</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:1">Panel Offers Sharp Criticism of AIDS Research Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:2">School Parents Call Halt to Use of Book on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:3">Senate Ready to Repeal Law to Dismiss Soldiers with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:4">Book World: Infectious Pessimism</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:5">Toughing it Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:6">Specialists Help HIV Patients Live Longer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:7">U.S. Firm to Sell More AIDS Drug to France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:8">Neurological Manifestations of HIV Infection a Focus of Paris Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:9">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:10">'Lost' Files Link HIV Infections to Health Ministry Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 13, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:1">Eager for Gay History and Finding Library Allies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:2">Japanese Leaders in Logjam</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:3">Dingwall Wants Meeting to 'Renew Blood System'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:4">Somatic Growth of HIV-Positive Infants Impaired</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:5">HIV Diagnosis Before Birth on the Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:6">FDA Official Rebuts Criticism of Drug Approval Process</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:7">Gilead Sciences Makes Vistide Available in France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:8">Continued Sexual Risk Behavior Among HIV-Seropositive, Drug-Using Men--Atlanta; Washington, D.C.; and San Juan, Puerto Rico, 1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:9">Montagnier Sets Up AIDS Research Center</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:10">Marshals Pay AIDS Activists</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:1">New Issue Update: Gilead Sciences</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:2">John-John Dies of AIDS at 11 Still Speaking of Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:3">Unusual Molecules Could be Key to Cancer Patients' Weight Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:4">Portraits of Lives with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:5">Thalidomide Returns With New Hope, Old Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:6">Neurex SNX-111 in the Treatment of Neuropathic Pain Caused by AIDS; Early Results Promising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:7">Identification of Levels of Maternal HIV-1 RNA Associated With Risk of Perinatal Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:8">Syringe Exchange in the United States: 1995 Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:9">JAMA, Glaxo Wellcome Create HIV/AIDS Site on Web</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:1">Lawyer's Family In Court Over 'Philadelphia'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:2">In the Loop: Courting Clinton's Reconsideration</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:3">AIDS Data Not in Peril</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:4">AIDS Clinical Trials Lack Data on Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:5">UNAIDS Highlights Women and AIDS in New Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:6">Eight Causes Explain Most Cases of Fever in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:7">Euthanasia and Physician-Assisted Suicide in Homosexual Men with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:8">Soldiers and AIDS: All of You, Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:9">Blood, Sweat and Fears</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960308"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-192</DOCNO>
<DOCOLDNO>IA017-000178-B005-230</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960314 192.33.214.13 19970106043817 text/html 7849
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:38:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960321"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:1">Panel Offers Sharp Criticism of AIDS Research Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:2">School Parents Call Halt to Use of Book on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:3">Senate Ready to Repeal Law to Dismiss Soldiers with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:4">Book World: Infectious Pessimism</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:5">Toughing it Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:6">Specialists Help HIV Patients Live Longer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:7">U.S. Firm to Sell More AIDS Drug to France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:8">Neurological Manifestations of HIV Infection a Focus of Paris Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:9">Merck Protease Inhibitor: More News from Retroviruses Conference</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960314:10">'Lost' Files Link HIV Infections to Health Ministry Decision</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 13, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:1">Eager for Gay History and Finding Library Allies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:2">Japanese Leaders in Logjam</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:3">Dingwall Wants Meeting to 'Renew Blood System'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:4">Somatic Growth of HIV-Positive Infants Impaired</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:5">HIV Diagnosis Before Birth on the Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:6">FDA Official Rebuts Criticism of Drug Approval Process</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:7">Gilead Sciences Makes Vistide Available in France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:8">Continued Sexual Risk Behavior Among HIV-Seropositive, Drug-Using Men--Atlanta; Washington, D.C.; and San Juan, Puerto Rico, 1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:9">Montagnier Sets Up AIDS Research Center</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:10">Marshals Pay AIDS Activists</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:1">New Issue Update: Gilead Sciences</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:2">John-John Dies of AIDS at 11 Still Speaking of Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:3">Unusual Molecules Could be Key to Cancer Patients' Weight Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:4">Portraits of Lives with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:5">Thalidomide Returns With New Hope, Old Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:6">Neurex SNX-111 in the Treatment of Neuropathic Pain Caused by AIDS; Early Results Promising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:7">Identification of Levels of Maternal HIV-1 RNA Associated With Risk of Perinatal Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:8">Syringe Exchange in the United States: 1995 Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:9">JAMA, Glaxo Wellcome Create HIV/AIDS Site on Web</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:1">Lawyer's Family In Court Over 'Philadelphia'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:2">In the Loop: Courting Clinton's Reconsideration</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:3">AIDS Data Not in Peril</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:4">AIDS Clinical Trials Lack Data on Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:5">UNAIDS Highlights Women and AIDS in New Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:6">Eight Causes Explain Most Cases of Fever in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:7">Euthanasia and Physician-Assisted Suicide in Homosexual Men with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:8">Soldiers and AIDS: All of You, Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:9">Blood, Sweat and Fears</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:1">Man With AIDS Tested Negative, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:2">Physician-Aided Suicide Issue Expected Before High Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:3">Fighters to Undergo H.I.V. Testing in New Jersey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:4">In Brief: Amgen Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:5">New Drugs Raise Hope that HIV Manageable</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:6">Krever Denies Hiding Papers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:7">Japan Courts Unveil Fresh Compromise in HIV Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:8">Collapse of Communism Brings Disease Threat--WHO</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:9">Health Secretary Backs AIDS Office's Budget Authority</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:10">Danish Haemophiliacs Win in European Court</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960307"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-193</DOCNO>
<DOCOLDNO>IA017-000178-B005-244</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960313 192.33.214.13 19970106043830 text/html 7854
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:38:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960320"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 13, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:1">Eager for Gay History and Finding Library Allies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:2">Japanese Leaders in Logjam</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:3">Dingwall Wants Meeting to 'Renew Blood System'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:4">Somatic Growth of HIV-Positive Infants Impaired</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:5">HIV Diagnosis Before Birth on the Increase</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:6">FDA Official Rebuts Criticism of Drug Approval Process</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:7">Gilead Sciences Makes Vistide Available in France</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:8">Continued Sexual Risk Behavior Among HIV-Seropositive, Drug-Using Men--Atlanta; Washington, D.C.; and San Juan, Puerto Rico, 1993</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:9">Montagnier Sets Up AIDS Research Center</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960313:10">Marshals Pay AIDS Activists</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:1">New Issue Update: Gilead Sciences</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:2">John-John Dies of AIDS at 11 Still Speaking of Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:3">Unusual Molecules Could be Key to Cancer Patients' Weight Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:4">Portraits of Lives with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:5">Thalidomide Returns With New Hope, Old Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:6">Neurex SNX-111 in the Treatment of Neuropathic Pain Caused by AIDS; Early Results Promising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:7">Identification of Levels of Maternal HIV-1 RNA Associated With Risk of Perinatal Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:8">Syringe Exchange in the United States: 1995 Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:9">JAMA, Glaxo Wellcome Create HIV/AIDS Site on Web</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:1">Lawyer's Family In Court Over 'Philadelphia'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:2">In the Loop: Courting Clinton's Reconsideration</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:3">AIDS Data Not in Peril</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:4">AIDS Clinical Trials Lack Data on Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:5">UNAIDS Highlights Women and AIDS in New Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:6">Eight Causes Explain Most Cases of Fever in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:7">Euthanasia and Physician-Assisted Suicide in Homosexual Men with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:8">Soldiers and AIDS: All of You, Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:9">Blood, Sweat and Fears</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:1">Man With AIDS Tested Negative, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:2">Physician-Aided Suicide Issue Expected Before High Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:3">Fighters to Undergo H.I.V. Testing in New Jersey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:4">In Brief: Amgen Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:5">New Drugs Raise Hope that HIV Manageable</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:6">Krever Denies Hiding Papers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:7">Japan Courts Unveil Fresh Compromise in HIV Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:8">Collapse of Communism Brings Disease Threat--WHO</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:9">Health Secretary Backs AIDS Office's Budget Authority</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:10">Danish Haemophiliacs Win in European Court</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:1">AIDS Council Likely to Back Needle Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:2">Victims of Tainted Blood May Not Live to See Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:3">States Fight to Limit Federal Courts' Power Over Medicaid</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:4">White House: More AIDS Education Needed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:5">HIV Strain Resistant to New Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:6">Late-Stage AIDS Patients Susceptible to Pseudomonas Aeruginosa Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:7">HIV Prevalence High Among Male Teens Who Have Homosexual Encounters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:8">DNA Vaccine Set to Tackle HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:9">The Rolling Uncertainties of Antiprotease Prescribing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:10">Drug Program Revived</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960306"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-194</DOCNO>
<DOCOLDNO>IA017-000178-B005-260</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960312 192.33.214.13 19970106043841 text/html 7818
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:01 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960319"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:1">New Issue Update: Gilead Sciences</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:2">John-John Dies of AIDS at 11 Still Speaking of Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:3">Unusual Molecules Could be Key to Cancer Patients' Weight Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:4">Portraits of Lives with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:5">Thalidomide Returns With New Hope, Old Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:6">Neurex SNX-111 in the Treatment of Neuropathic Pain Caused by AIDS; Early Results Promising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:7">Identification of Levels of Maternal HIV-1 RNA Associated With Risk of Perinatal Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:8">Syringe Exchange in the United States: 1995 Update</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960312:9">JAMA, Glaxo Wellcome Create HIV/AIDS Site on Web</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:1">Lawyer's Family In Court Over 'Philadelphia'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:2">In the Loop: Courting Clinton's Reconsideration</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:3">AIDS Data Not in Peril</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:4">AIDS Clinical Trials Lack Data on Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:5">UNAIDS Highlights Women and AIDS in New Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:6">Eight Causes Explain Most Cases of Fever in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:7">Euthanasia and Physician-Assisted Suicide in Homosexual Men with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:8">Soldiers and AIDS: All of You, Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:9">Blood, Sweat and Fears</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:1">Man With AIDS Tested Negative, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:2">Physician-Aided Suicide Issue Expected Before High Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:3">Fighters to Undergo H.I.V. Testing in New Jersey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:4">In Brief: Amgen Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:5">New Drugs Raise Hope that HIV Manageable</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:6">Krever Denies Hiding Papers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:7">Japan Courts Unveil Fresh Compromise in HIV Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:8">Collapse of Communism Brings Disease Threat--WHO</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:9">Health Secretary Backs AIDS Office's Budget Authority</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:10">Danish Haemophiliacs Win in European Court</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:1">AIDS Council Likely to Back Needle Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:2">Victims of Tainted Blood May Not Live to See Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:3">States Fight to Limit Federal Courts' Power Over Medicaid</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:4">White House: More AIDS Education Needed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:5">HIV Strain Resistant to New Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:6">Late-Stage AIDS Patients Susceptible to Pseudomonas Aeruginosa Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:7">HIV Prevalence High Among Male Teens Who Have Homosexual Encounters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:8">DNA Vaccine Set to Tackle HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:9">The Rolling Uncertainties of Antiprotease Prescribing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:10">Drug Program Revived</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:1">Debate Over Teaching AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:2">Chiron's Eye Implant Device Is Approved for AIDS Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:3">General Denounces AIDS Policy as Unfair</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:4">Clinton Seeks Relief Funds for Disasters, AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:5">State Doctors Reject Policy on Reporting HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:6">Chronicle: Two Friends Turn Their Grief into Action and Find Compassion Along the Way</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:7">Ontario Probes Hepatitis Outbreak</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:8">New HIV Vaccine to be Tested On Humans in Sweden</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:9">A &quot;Complement-ary&quot; AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:10">HIV Prevention for Intravenous Drug Users</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960305"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-195</DOCNO>
<DOCOLDNO>IA017-000178-B005-275</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960311 192.33.214.13 19970106043853 text/html 8025
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:12 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960318"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:1">Lawyer's Family In Court Over 'Philadelphia'</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:2">In the Loop: Courting Clinton's Reconsideration</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:3">AIDS Data Not in Peril</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:4">AIDS Clinical Trials Lack Data on Adolescents</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:5">UNAIDS Highlights Women and AIDS in New Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:6">Eight Causes Explain Most Cases of Fever in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:7">Euthanasia and Physician-Assisted Suicide in Homosexual Men with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:8">Soldiers and AIDS: All of You, Out</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960311:9">Blood, Sweat and Fears</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:1">Man With AIDS Tested Negative, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:2">Physician-Aided Suicide Issue Expected Before High Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:3">Fighters to Undergo H.I.V. Testing in New Jersey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:4">In Brief: Amgen Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:5">New Drugs Raise Hope that HIV Manageable</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:6">Krever Denies Hiding Papers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:7">Japan Courts Unveil Fresh Compromise in HIV Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:8">Collapse of Communism Brings Disease Threat--WHO</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:9">Health Secretary Backs AIDS Office's Budget Authority</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:10">Danish Haemophiliacs Win in European Court</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:1">AIDS Council Likely to Back Needle Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:2">Victims of Tainted Blood May Not Live to See Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:3">States Fight to Limit Federal Courts' Power Over Medicaid</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:4">White House: More AIDS Education Needed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:5">HIV Strain Resistant to New Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:6">Late-Stage AIDS Patients Susceptible to Pseudomonas Aeruginosa Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:7">HIV Prevalence High Among Male Teens Who Have Homosexual Encounters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:8">DNA Vaccine Set to Tackle HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:9">The Rolling Uncertainties of Antiprotease Prescribing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:10">Drug Program Revived</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:1">Debate Over Teaching AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:2">Chiron's Eye Implant Device Is Approved for AIDS Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:3">General Denounces AIDS Policy as Unfair</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:4">Clinton Seeks Relief Funds for Disasters, AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:5">State Doctors Reject Policy on Reporting HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:6">Chronicle: Two Friends Turn Their Grief into Action and Find Compassion Along the Way</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:7">Ontario Probes Hepatitis Outbreak</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:8">New HIV Vaccine to be Tested On Humans in Sweden</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:9">A &quot;Complement-ary&quot; AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:10">HIV Prevention for Intravenous Drug Users</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:1">FDA Agrees to Review Test for AIDS Viral Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:2">HIV-Positive Troops Lose Special Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:3">EU Sets Prophylactics Standard</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:4">Washington  World: Supreme Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:5">Blood Transfusions Speed Conversion to Full-Blown AIDS in HIV-Infected Individuals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:6">Many HIV-Positive STD Clinic Patients Practice Unsafe Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:7">Viragen Inc. to Conduct HIV/AIDS Study with Natural Human Interferon; Company Also Forms Alliance with Leading Healthcare Provider</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:8">T-Cell Mediated Rejection of Gene-Modified HIV-Specific Cytotoxic T Lymphocytes in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:9">Tweaking T Cells with Altered Antigens</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:10">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960304"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-196</DOCNO>
<DOCOLDNO>IA017-000178-B005-290</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960308 192.33.214.13 19970106043905 text/html 8188
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960315"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 8, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:1">Man With AIDS Tested Negative, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:2">Physician-Aided Suicide Issue Expected Before High Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:3">Fighters to Undergo H.I.V. Testing in New Jersey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:4">In Brief: Amgen Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:5">New Drugs Raise Hope that HIV Manageable</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:6">Krever Denies Hiding Papers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:7">Japan Courts Unveil Fresh Compromise in HIV Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:8">Collapse of Communism Brings Disease Threat--WHO</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:9">Health Secretary Backs AIDS Office's Budget Authority</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960308:10">Danish Haemophiliacs Win in European Court</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:1">AIDS Council Likely to Back Needle Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:2">Victims of Tainted Blood May Not Live to See Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:3">States Fight to Limit Federal Courts' Power Over Medicaid</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:4">White House: More AIDS Education Needed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:5">HIV Strain Resistant to New Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:6">Late-Stage AIDS Patients Susceptible to Pseudomonas Aeruginosa Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:7">HIV Prevalence High Among Male Teens Who Have Homosexual Encounters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:8">DNA Vaccine Set to Tackle HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:9">The Rolling Uncertainties of Antiprotease Prescribing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:10">Drug Program Revived</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:1">Debate Over Teaching AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:2">Chiron's Eye Implant Device Is Approved for AIDS Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:3">General Denounces AIDS Policy as Unfair</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:4">Clinton Seeks Relief Funds for Disasters, AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:5">State Doctors Reject Policy on Reporting HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:6">Chronicle: Two Friends Turn Their Grief into Action and Find Compassion Along the Way</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:7">Ontario Probes Hepatitis Outbreak</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:8">New HIV Vaccine to be Tested On Humans in Sweden</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:9">A &quot;Complement-ary&quot; AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:10">HIV Prevention for Intravenous Drug Users</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:1">FDA Agrees to Review Test for AIDS Viral Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:2">HIV-Positive Troops Lose Special Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:3">EU Sets Prophylactics Standard</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:4">Washington  World: Supreme Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:5">Blood Transfusions Speed Conversion to Full-Blown AIDS in HIV-Infected Individuals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:6">Many HIV-Positive STD Clinic Patients Practice Unsafe Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:7">Viragen Inc. to Conduct HIV/AIDS Study with Natural Human Interferon; Company Also Forms Alliance with Leading Healthcare Provider</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:8">T-Cell Mediated Rejection of Gene-Modified HIV-Specific Cytotoxic T Lymphocytes in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:9">Tweaking T Cells with Altered Antigens</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:10">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:1">FDA to Quickly Clear Merck AIDS Drug, After Approving Abbott's Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:2">FDA Approves AIDS Drug Ritonavir in 72 Days</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:3">Hope, Concern Greet AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:4">Epidemiology: Insight Into Spread of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:5">Tokyo Minister Bares Mistakes in AIDS Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:6">Nationline: Support Threatened</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:7">Drug Holds Off HIV Damage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:8">Pomegranates Could Help in Battle Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:9">Bovine (Beta)-Lactoglobulin Modified by 3-Hydroxyphthalic Anhydride Blocks the CD4 Cell Receptor for HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:10">Helping PWAs Find Jobs</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960303"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-197</DOCNO>
<DOCOLDNO>IA017-000178-B005-300</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960307 192.33.214.13 19970106043912 text/html 8307
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960314"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:1">AIDS Council Likely to Back Needle Programs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:2">Victims of Tainted Blood May Not Live to See Report</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:3">States Fight to Limit Federal Courts' Power Over Medicaid</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:4">White House: More AIDS Education Needed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:5">HIV Strain Resistant to New Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:6">Late-Stage AIDS Patients Susceptible to Pseudomonas Aeruginosa Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:7">HIV Prevalence High Among Male Teens Who Have Homosexual Encounters</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:8">DNA Vaccine Set to Tackle HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:9">The Rolling Uncertainties of Antiprotease Prescribing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960307:10">Drug Program Revived</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:1">Debate Over Teaching AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:2">Chiron's Eye Implant Device Is Approved for AIDS Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:3">General Denounces AIDS Policy as Unfair</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:4">Clinton Seeks Relief Funds for Disasters, AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:5">State Doctors Reject Policy on Reporting HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:6">Chronicle: Two Friends Turn Their Grief into Action and Find Compassion Along the Way</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:7">Ontario Probes Hepatitis Outbreak</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:8">New HIV Vaccine to be Tested On Humans in Sweden</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:9">A &quot;Complement-ary&quot; AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:10">HIV Prevention for Intravenous Drug Users</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:1">FDA Agrees to Review Test for AIDS Viral Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:2">HIV-Positive Troops Lose Special Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:3">EU Sets Prophylactics Standard</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:4">Washington  World: Supreme Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:5">Blood Transfusions Speed Conversion to Full-Blown AIDS in HIV-Infected Individuals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:6">Many HIV-Positive STD Clinic Patients Practice Unsafe Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:7">Viragen Inc. to Conduct HIV/AIDS Study with Natural Human Interferon; Company Also Forms Alliance with Leading Healthcare Provider</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:8">T-Cell Mediated Rejection of Gene-Modified HIV-Specific Cytotoxic T Lymphocytes in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:9">Tweaking T Cells with Altered Antigens</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:10">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:1">FDA to Quickly Clear Merck AIDS Drug, After Approving Abbott's Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:2">FDA Approves AIDS Drug Ritonavir in 72 Days</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:3">Hope, Concern Greet AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:4">Epidemiology: Insight Into Spread of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:5">Tokyo Minister Bares Mistakes in AIDS Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:6">Nationline: Support Threatened</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:7">Drug Holds Off HIV Damage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:8">Pomegranates Could Help in Battle Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:9">Bovine (Beta)-Lactoglobulin Modified by 3-Hydroxyphthalic Anhydride Blocks the CD4 Cell Receptor for HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:10">Helping PWAs Find Jobs</A></TD>
</TR>
</TABLE>
</UL>
<H3></H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:1">Seattle Officials Seeking to Establish a Subsidized Natural Medicine Clinic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:2">Nationline: Needle Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:3">Baboon Marrow Won't Help Victims of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:4">Bell's Palsy is Linked with Herpes Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:5">Drug Giants Still Hunger for Biotech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:6">Plasma Facility a First in Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:7">Fighter of HIV Has a Bad Side</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:8">Gilead Sciences Announces Commencement of Topical Opthalmic Cidofovir Clinical Study by Storz</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:9">Identification of RANTES, MIP-1(alpha), and MIP-1(beta) as the Major HIV-Suppressive Factors Produced by CD8+ T Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:10">Killing Kids Softly: Rudy Crew's Dangerous AIDS Education Plan</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960301"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-198</DOCNO>
<DOCOLDNO>IA017-000178-B005-307</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960306 192.33.214.13 19970106043921 text/html 8249
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960313"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:1">Debate Over Teaching AIDS Prevention</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:2">Chiron's Eye Implant Device Is Approved for AIDS Care</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:3">General Denounces AIDS Policy as Unfair</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:4">Clinton Seeks Relief Funds for Disasters, AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:5">State Doctors Reject Policy on Reporting HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:6">Chronicle: Two Friends Turn Their Grief into Action and Find Compassion Along the Way</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:7">Ontario Probes Hepatitis Outbreak</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:8">New HIV Vaccine to be Tested On Humans in Sweden</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:9">A &quot;Complement-ary&quot; AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960306:10">HIV Prevention for Intravenous Drug Users</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:1">FDA Agrees to Review Test for AIDS Viral Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:2">HIV-Positive Troops Lose Special Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:3">EU Sets Prophylactics Standard</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:4">Washington  World: Supreme Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:5">Blood Transfusions Speed Conversion to Full-Blown AIDS in HIV-Infected Individuals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:6">Many HIV-Positive STD Clinic Patients Practice Unsafe Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:7">Viragen Inc. to Conduct HIV/AIDS Study with Natural Human Interferon; Company Also Forms Alliance with Leading Healthcare Provider</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:8">T-Cell Mediated Rejection of Gene-Modified HIV-Specific Cytotoxic T Lymphocytes in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:9">Tweaking T Cells with Altered Antigens</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:10">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:1">FDA to Quickly Clear Merck AIDS Drug, After Approving Abbott's Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:2">FDA Approves AIDS Drug Ritonavir in 72 Days</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:3">Hope, Concern Greet AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:4">Epidemiology: Insight Into Spread of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:5">Tokyo Minister Bares Mistakes in AIDS Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:6">Nationline: Support Threatened</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:7">Drug Holds Off HIV Damage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:8">Pomegranates Could Help in Battle Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:9">Bovine (Beta)-Lactoglobulin Modified by 3-Hydroxyphthalic Anhydride Blocks the CD4 Cell Receptor for HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:10">Helping PWAs Find Jobs</A></TD>
</TR>
</TABLE>
</UL>
<H3></H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:1">Seattle Officials Seeking to Establish a Subsidized Natural Medicine Clinic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:2">Nationline: Needle Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:3">Baboon Marrow Won't Help Victims of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:4">Bell's Palsy is Linked with Herpes Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:5">Drug Giants Still Hunger for Biotech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:6">Plasma Facility a First in Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:7">Fighter of HIV Has a Bad Side</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:8">Gilead Sciences Announces Commencement of Topical Opthalmic Cidofovir Clinical Study by Storz</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:9">Identification of RANTES, MIP-1(alpha), and MIP-1(beta) as the Major HIV-Suppressive Factors Produced by CD8+ T Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:10">Killing Kids Softly: Rudy Crew's Dangerous AIDS Education Plan</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:1">Abbott AIDS Drug Appears on Track for Fast Approval by FDA Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:2">Virus Linked to a Cancer in AIDS Patients Is Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:3">Why Heterosexual Sex May Spread Some HIV More Easily</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:4">'Important Finding' in AIDS Drug Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:5">Washington Wire: AIDS Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:6">Nations Differ on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:7">HIV Protein Level Tied to Babies' AIDS Risk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:8">Abbott Has No Plans to Step Up AIDS Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:9">AIDS Researchers Hit U.S. Refusal on Needle Exchanges</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:10">Are Some People Immune?</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960229"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-199</DOCNO>
<DOCOLDNO>IA017-000178-B005-318</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960305 192.33.214.13 19970106043929 text/html 8208
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960312"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:1">FDA Agrees to Review Test for AIDS Viral Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:2">HIV-Positive Troops Lose Special Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:3">EU Sets Prophylactics Standard</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:4">Washington  World: Supreme Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:5">Blood Transfusions Speed Conversion to Full-Blown AIDS in HIV-Infected Individuals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:6">Many HIV-Positive STD Clinic Patients Practice Unsafe Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:7">Viragen Inc. to Conduct HIV/AIDS Study with Natural Human Interferon; Company Also Forms Alliance with Leading Healthcare Provider</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:8">T-Cell Mediated Rejection of Gene-Modified HIV-Specific Cytotoxic T Lymphocytes in HIV-Infected Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:9">Tweaking T Cells with Altered Antigens</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960305:10">Agouron Starts Phase III Protease Inhibitor Studies</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:1">FDA to Quickly Clear Merck AIDS Drug, After Approving Abbott's Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:2">FDA Approves AIDS Drug Ritonavir in 72 Days</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:3">Hope, Concern Greet AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:4">Epidemiology: Insight Into Spread of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:5">Tokyo Minister Bares Mistakes in AIDS Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:6">Nationline: Support Threatened</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:7">Drug Holds Off HIV Damage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:8">Pomegranates Could Help in Battle Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:9">Bovine (Beta)-Lactoglobulin Modified by 3-Hydroxyphthalic Anhydride Blocks the CD4 Cell Receptor for HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:10">Helping PWAs Find Jobs</A></TD>
</TR>
</TABLE>
</UL>
<H3></H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:1">Seattle Officials Seeking to Establish a Subsidized Natural Medicine Clinic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:2">Nationline: Needle Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:3">Baboon Marrow Won't Help Victims of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:4">Bell's Palsy is Linked with Herpes Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:5">Drug Giants Still Hunger for Biotech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:6">Plasma Facility a First in Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:7">Fighter of HIV Has a Bad Side</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:8">Gilead Sciences Announces Commencement of Topical Opthalmic Cidofovir Clinical Study by Storz</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:9">Identification of RANTES, MIP-1(alpha), and MIP-1(beta) as the Major HIV-Suppressive Factors Produced by CD8+ T Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:10">Killing Kids Softly: Rudy Crew's Dangerous AIDS Education Plan</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:1">Abbott AIDS Drug Appears on Track for Fast Approval by FDA Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:2">Virus Linked to a Cancer in AIDS Patients Is Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:3">Why Heterosexual Sex May Spread Some HIV More Easily</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:4">'Important Finding' in AIDS Drug Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:5">Washington Wire: AIDS Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:6">Nations Differ on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:7">HIV Protein Level Tied to Babies' AIDS Risk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:8">Abbott Has No Plans to Step Up AIDS Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:9">AIDS Researchers Hit U.S. Refusal on Needle Exchanges</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:10">Are Some People Immune?</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:1">Surgeon Infected Patients Despite Hepatitis Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:2">Making Case for Safer Needles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:3">Bill Is Passed to Block Loss of Insurance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:4">Helping a Family Care for a Child with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:5">Public Protector or Persecutor?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:6">France Rules Out Lottery for Rare AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:7">Japan Ministry Report Fails to Answer AIDS Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:8">Voluntary Inpatient HIV Screening: Cost-Effective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:9">New Studies Say Viral Burden Tops CD4 as a Marker of HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:10">Up in Asia</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960228"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-200</DOCNO>
<DOCOLDNO>IA017-000178-B005-328</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960304 192.33.214.13 19970106043937 text/html 7943
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:39:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960311"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:1">FDA to Quickly Clear Merck AIDS Drug, After Approving Abbott's Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:2">FDA Approves AIDS Drug Ritonavir in 72 Days</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:3">Hope, Concern Greet AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:4">Epidemiology: Insight Into Spread of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:5">Tokyo Minister Bares Mistakes in AIDS Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:6">Nationline: Support Threatened</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:7">Drug Holds Off HIV Damage</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:8">Pomegranates Could Help in Battle Against AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:9">Bovine (Beta)-Lactoglobulin Modified by 3-Hydroxyphthalic Anhydride Blocks the CD4 Cell Receptor for HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960304:10">Helping PWAs Find Jobs</A></TD>
</TR>
</TABLE>
</UL>
<H3></H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:1">Seattle Officials Seeking to Establish a Subsidized Natural Medicine Clinic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:2">Nationline: Needle Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:3">Baboon Marrow Won't Help Victims of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:4">Bell's Palsy is Linked with Herpes Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:5">Drug Giants Still Hunger for Biotech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:6">Plasma Facility a First in Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:7">Fighter of HIV Has a Bad Side</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:8">Gilead Sciences Announces Commencement of Topical Opthalmic Cidofovir Clinical Study by Storz</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:9">Identification of RANTES, MIP-1(alpha), and MIP-1(beta) as the Major HIV-Suppressive Factors Produced by CD8+ T Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:10">Killing Kids Softly: Rudy Crew's Dangerous AIDS Education Plan</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:1">Abbott AIDS Drug Appears on Track for Fast Approval by FDA Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:2">Virus Linked to a Cancer in AIDS Patients Is Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:3">Why Heterosexual Sex May Spread Some HIV More Easily</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:4">'Important Finding' in AIDS Drug Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:5">Washington Wire: AIDS Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:6">Nations Differ on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:7">HIV Protein Level Tied to Babies' AIDS Risk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:8">Abbott Has No Plans to Step Up AIDS Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:9">AIDS Researchers Hit U.S. Refusal on Needle Exchanges</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:10">Are Some People Immune?</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:1">Surgeon Infected Patients Despite Hepatitis Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:2">Making Case for Safer Needles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:3">Bill Is Passed to Block Loss of Insurance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:4">Helping a Family Care for a Child with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:5">Public Protector or Persecutor?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:6">France Rules Out Lottery for Rare AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:7">Japan Ministry Report Fails to Answer AIDS Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:8">Voluntary Inpatient HIV Screening: Cost-Effective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:9">New Studies Say Viral Burden Tops CD4 as a Marker of HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:10">Up in Asia</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:1">Study Finds Clue on HIV Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:2">Japanese Blood Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:3">Nurse with H.I.V. Emphasizes Safety</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:4">Proposed French AIDS Drug Lottery Under Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:5">Overexpression of Fas Antigen Seen in Advanced HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:6">New Guidelines for PCP Prophylaxis in HIV Positive Children Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:7">HIV-Positive Substance Abusers Frequently Require Psychoactive Drug Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:8">Resistance to Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960227"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-201</DOCNO>
<DOCOLDNO>IA017-000178-B005-342</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960303 192.33.214.13 19970106043957 text/html 7962
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:40:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960308"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3></H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:1">Seattle Officials Seeking to Establish a Subsidized Natural Medicine Clinic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:2">Nationline: Needle Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:3">Baboon Marrow Won't Help Victims of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:4">Bell's Palsy is Linked with Herpes Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:5">Drug Giants Still Hunger for Biotech</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:6">Plasma Facility a First in Canada</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:7">Fighter of HIV Has a Bad Side</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:8">Gilead Sciences Announces Commencement of Topical Opthalmic Cidofovir Clinical Study by Storz</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:9">Identification of RANTES, MIP-1(alpha), and MIP-1(beta) as the Major HIV-Suppressive Factors Produced by CD8+ T Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960303:10">Killing Kids Softly: Rudy Crew's Dangerous AIDS Education Plan</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:1">Abbott AIDS Drug Appears on Track for Fast Approval by FDA Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:2">Virus Linked to a Cancer in AIDS Patients Is Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:3">Why Heterosexual Sex May Spread Some HIV More Easily</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:4">'Important Finding' in AIDS Drug Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:5">Washington Wire: AIDS Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:6">Nations Differ on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:7">HIV Protein Level Tied to Babies' AIDS Risk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:8">Abbott Has No Plans to Step Up AIDS Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:9">AIDS Researchers Hit U.S. Refusal on Needle Exchanges</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:10">Are Some People Immune?</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:1">Surgeon Infected Patients Despite Hepatitis Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:2">Making Case for Safer Needles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:3">Bill Is Passed to Block Loss of Insurance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:4">Helping a Family Care for a Child with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:5">Public Protector or Persecutor?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:6">France Rules Out Lottery for Rare AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:7">Japan Ministry Report Fails to Answer AIDS Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:8">Voluntary Inpatient HIV Screening: Cost-Effective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:9">New Studies Say Viral Burden Tops CD4 as a Marker of HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:10">Up in Asia</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:1">Study Finds Clue on HIV Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:2">Japanese Blood Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:3">Nurse with H.I.V. Emphasizes Safety</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:4">Proposed French AIDS Drug Lottery Under Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:5">Overexpression of Fas Antigen Seen in Advanced HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:6">New Guidelines for PCP Prophylaxis in HIV Positive Children Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:7">HIV-Positive Substance Abusers Frequently Require Psychoactive Drug Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:8">Resistance to Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:1">Tokyo Nears Pact With HIV Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:2">Green Cross May Pay Patients with HIV up to $190.8 Million</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:3">Possible TB Case Prompts Tests at Post Office Branch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:4">White House Criticizes Plan for Welfare</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:5">A Chance for AIDS Action</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:6">Prognostic Factors For HIV Disease Progression Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:7">Experimental Prodrug Shows Activity Against Both HIV and CMV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:8">Support Group Helps Physicians Cope with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:9">Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:10">Sleeping AIDS</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960226"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-202</DOCNO>
<DOCOLDNO>IA017-000178-B005-353</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960301 192.33.214.13 19970106044009 text/html 7912
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:40:29 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960307"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:1">Abbott AIDS Drug Appears on Track for Fast Approval by FDA Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:2">Virus Linked to a Cancer in AIDS Patients Is Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:3">Why Heterosexual Sex May Spread Some HIV More Easily</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:4">'Important Finding' in AIDS Drug Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:5">Washington Wire: AIDS Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:6">Nations Differ on HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:7">HIV Protein Level Tied to Babies' AIDS Risk</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:8">Abbott Has No Plans to Step Up AIDS Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:9">AIDS Researchers Hit U.S. Refusal on Needle Exchanges</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960301:10">Are Some People Immune?</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:1">Surgeon Infected Patients Despite Hepatitis Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:2">Making Case for Safer Needles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:3">Bill Is Passed to Block Loss of Insurance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:4">Helping a Family Care for a Child with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:5">Public Protector or Persecutor?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:6">France Rules Out Lottery for Rare AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:7">Japan Ministry Report Fails to Answer AIDS Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:8">Voluntary Inpatient HIV Screening: Cost-Effective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:9">New Studies Say Viral Burden Tops CD4 as a Marker of HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:10">Up in Asia</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:1">Study Finds Clue on HIV Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:2">Japanese Blood Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:3">Nurse with H.I.V. Emphasizes Safety</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:4">Proposed French AIDS Drug Lottery Under Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:5">Overexpression of Fas Antigen Seen in Advanced HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:6">New Guidelines for PCP Prophylaxis in HIV Positive Children Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:7">HIV-Positive Substance Abusers Frequently Require Psychoactive Drug Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:8">Resistance to Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:1">Tokyo Nears Pact With HIV Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:2">Green Cross May Pay Patients with HIV up to $190.8 Million</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:3">Possible TB Case Prompts Tests at Post Office Branch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:4">White House Criticizes Plan for Welfare</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:5">A Chance for AIDS Action</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:6">Prognostic Factors For HIV Disease Progression Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:7">Experimental Prodrug Shows Activity Against Both HIV and CMV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:8">Support Group Helps Physicians Cope with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:9">Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:10">Sleeping AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:1">Johnson's Powerful Message Is Delivered Off the Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:2">Planned Health Cuts Causing Winces</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:3">Scots Heterosexual HIV Cases Outnumber Homosexual</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:4">Forum on New AIDS Drugs to Link Phila., Other Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:5">Bay State Inmate Shifted to Texas Is Dead of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:6">Obituaries: Anti-AIDS Activist George Williams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:7">Obituaries: Pathologist, author of AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:8">The Experience of Respiratory Isolation for HIV-Infected Persons with Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:9">Prevalence of HIV Infection Among Israel's Ethiopian Immigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:10">Trials By Fire</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960223"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-203</DOCNO>
<DOCOLDNO>IA017-000178-B005-366</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960229 192.33.214.13 19970106044020 text/html 8188
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:40:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960306"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:1">Surgeon Infected Patients Despite Hepatitis Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:2">Making Case for Safer Needles</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:3">Bill Is Passed to Block Loss of Insurance</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:4">Helping a Family Care for a Child with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:5">Public Protector or Persecutor?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:6">France Rules Out Lottery for Rare AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:7">Japan Ministry Report Fails to Answer AIDS Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:8">Voluntary Inpatient HIV Screening: Cost-Effective</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:9">New Studies Say Viral Burden Tops CD4 as a Marker of HIV Disease Progression</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960229:10">Up in Asia</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:1">Study Finds Clue on HIV Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:2">Japanese Blood Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:3">Nurse with H.I.V. Emphasizes Safety</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:4">Proposed French AIDS Drug Lottery Under Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:5">Overexpression of Fas Antigen Seen in Advanced HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:6">New Guidelines for PCP Prophylaxis in HIV Positive Children Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:7">HIV-Positive Substance Abusers Frequently Require Psychoactive Drug Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:8">Resistance to Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:1">Tokyo Nears Pact With HIV Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:2">Green Cross May Pay Patients with HIV up to $190.8 Million</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:3">Possible TB Case Prompts Tests at Post Office Branch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:4">White House Criticizes Plan for Welfare</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:5">A Chance for AIDS Action</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:6">Prognostic Factors For HIV Disease Progression Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:7">Experimental Prodrug Shows Activity Against Both HIV and CMV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:8">Support Group Helps Physicians Cope with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:9">Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:10">Sleeping AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:1">Johnson's Powerful Message Is Delivered Off the Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:2">Planned Health Cuts Causing Winces</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:3">Scots Heterosexual HIV Cases Outnumber Homosexual</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:4">Forum on New AIDS Drugs to Link Phila., Other Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:5">Bay State Inmate Shifted to Texas Is Dead of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:6">Obituaries: Anti-AIDS Activist George Williams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:7">Obituaries: Pathologist, author of AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:8">The Experience of Respiratory Isolation for HIV-Infected Persons with Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:9">Prevalence of HIV Infection Among Israel's Ethiopian Immigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:10">Trials By Fire</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:1">Pa. Adds New AIDS Drug to Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:2">Airing Ads on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:3">CDC Finds Some Drug Users Still Spreading AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:4">Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:5">HHS Awards $80 Million in Ryan White Funding to 42 Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:6">Urine Therapy Devotees Flock to India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:7">Survey Finds Keys to Secondary Prevention of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:8">Serum Cortisol Levels Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:9">CDC Wants More Input Before Updating Post-Exposure Guidelines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:10">Gay Physicians Group Offers Aid to HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:11">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960222"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-204</DOCNO>
<DOCOLDNO>IA017-000178-B005-377</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960228 192.33.214.13 19970106044028 text/html 8337
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:40:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960305"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 28, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:1">Study Finds Clue on HIV Transmission</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:2">Japanese Blood Controversy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:3">Nurse with H.I.V. Emphasizes Safety</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:4">Proposed French AIDS Drug Lottery Under Attack</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:5">Overexpression of Fas Antigen Seen in Advanced HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:6">New Guidelines for PCP Prophylaxis in HIV Positive Children Proposed</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:7">HIV-Positive Substance Abusers Frequently Require Psychoactive Drug Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:8">Resistance to Protease Inhibitors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960228:9">Computer Censorship Law, ACLU Test Case, Begin February 8</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:1">Tokyo Nears Pact With HIV Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:2">Green Cross May Pay Patients with HIV up to $190.8 Million</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:3">Possible TB Case Prompts Tests at Post Office Branch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:4">White House Criticizes Plan for Welfare</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:5">A Chance for AIDS Action</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:6">Prognostic Factors For HIV Disease Progression Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:7">Experimental Prodrug Shows Activity Against Both HIV and CMV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:8">Support Group Helps Physicians Cope with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:9">Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:10">Sleeping AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:1">Johnson's Powerful Message Is Delivered Off the Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:2">Planned Health Cuts Causing Winces</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:3">Scots Heterosexual HIV Cases Outnumber Homosexual</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:4">Forum on New AIDS Drugs to Link Phila., Other Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:5">Bay State Inmate Shifted to Texas Is Dead of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:6">Obituaries: Anti-AIDS Activist George Williams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:7">Obituaries: Pathologist, author of AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:8">The Experience of Respiratory Isolation for HIV-Infected Persons with Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:9">Prevalence of HIV Infection Among Israel's Ethiopian Immigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:10">Trials By Fire</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:1">Pa. Adds New AIDS Drug to Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:2">Airing Ads on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:3">CDC Finds Some Drug Users Still Spreading AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:4">Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:5">HHS Awards $80 Million in Ryan White Funding to 42 Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:6">Urine Therapy Devotees Flock to India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:7">Survey Finds Keys to Secondary Prevention of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:8">Serum Cortisol Levels Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:9">CDC Wants More Input Before Updating Post-Exposure Guidelines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:10">Gay Physicians Group Offers Aid to HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:11">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:1">Approval of DaunoXome Set by European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:2">Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:3">Genentech to Spin Off AIDS Research Unit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:4">FDA Chief Warns Against Some Parts of Overhaul Legislation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:5">Culture, et Cetera: Excuse Me</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:6">Singapore HIV Infection Rises 29 Percent in 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:7">Teens Flush with Cash in Toilet Giveaway</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:8">HIV Antiviral Effects of Hyperbaric Oxygen Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:9">NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:10">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960221"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-205</DOCNO>
<DOCOLDNO>IA017-000178-B005-393</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960227 192.33.214.13 19970106044043 text/html 8552
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960304"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:1">Tokyo Nears Pact With HIV Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:2">Green Cross May Pay Patients with HIV up to $190.8 Million</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:3">Possible TB Case Prompts Tests at Post Office Branch</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:4">White House Criticizes Plan for Welfare</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:5">A Chance for AIDS Action</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:6">Prognostic Factors For HIV Disease Progression Identified</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:7">Experimental Prodrug Shows Activity Against Both HIV and CMV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:8">Support Group Helps Physicians Cope with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:9">Changes in Plasma HIV-1 RNA and CD4+ Lymphocyte Counts and the Risk of Progression to AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960227:10">Sleeping AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:1">Johnson's Powerful Message Is Delivered Off the Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:2">Planned Health Cuts Causing Winces</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:3">Scots Heterosexual HIV Cases Outnumber Homosexual</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:4">Forum on New AIDS Drugs to Link Phila., Other Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:5">Bay State Inmate Shifted to Texas Is Dead of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:6">Obituaries: Anti-AIDS Activist George Williams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:7">Obituaries: Pathologist, author of AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:8">The Experience of Respiratory Isolation for HIV-Infected Persons with Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:9">Prevalence of HIV Infection Among Israel's Ethiopian Immigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:10">Trials By Fire</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:1">Pa. Adds New AIDS Drug to Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:2">Airing Ads on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:3">CDC Finds Some Drug Users Still Spreading AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:4">Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:5">HHS Awards $80 Million in Ryan White Funding to 42 Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:6">Urine Therapy Devotees Flock to India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:7">Survey Finds Keys to Secondary Prevention of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:8">Serum Cortisol Levels Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:9">CDC Wants More Input Before Updating Post-Exposure Guidelines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:10">Gay Physicians Group Offers Aid to HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:11">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:1">Approval of DaunoXome Set by European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:2">Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:3">Genentech to Spin Off AIDS Research Unit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:4">FDA Chief Warns Against Some Parts of Overhaul Legislation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:5">Culture, et Cetera: Excuse Me</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:6">Singapore HIV Infection Rises 29 Percent in 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:7">Teens Flush with Cash in Toilet Giveaway</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:8">HIV Antiviral Effects of Hyperbaric Oxygen Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:9">NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:10">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:1">Genentech Inc. Forms a Firm for HIV Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:2">Chiron Will Pay About $120 Million For 49 Percent of Hoechst's Vaccine Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:3">A  Vaccine for AIDS at Least 5 Years Away</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:4">'Dreaded-Disease' Policies Rise, But Some Say They're No Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:5">Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:6">Skin Cancer and HPV 16 Infection Linked in AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:7">Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:8">Jobs at Risk for HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:9">A Kinder, Gentler War Against Hepatitis B</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:10">An Epidemic's Evolution</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960216"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-206</DOCNO>
<DOCOLDNO>IA017-000178-B006-11</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960226 192.33.214.13 19970106044052 text/html 8725
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960303"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:1">Johnson's Powerful Message Is Delivered Off the Court</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:2">Planned Health Cuts Causing Winces</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:3">Scots Heterosexual HIV Cases Outnumber Homosexual</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:4">Forum on New AIDS Drugs to Link Phila., Other Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:5">Bay State Inmate Shifted to Texas Is Dead of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:6">Obituaries: Anti-AIDS Activist George Williams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:7">Obituaries: Pathologist, author of AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:8">The Experience of Respiratory Isolation for HIV-Infected Persons with Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:9">Prevalence of HIV Infection Among Israel's Ethiopian Immigrants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960226:10">Trials By Fire</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:1">Pa. Adds New AIDS Drug to Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:2">Airing Ads on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:3">CDC Finds Some Drug Users Still Spreading AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:4">Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:5">HHS Awards $80 Million in Ryan White Funding to 42 Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:6">Urine Therapy Devotees Flock to India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:7">Survey Finds Keys to Secondary Prevention of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:8">Serum Cortisol Levels Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:9">CDC Wants More Input Before Updating Post-Exposure Guidelines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:10">Gay Physicians Group Offers Aid to HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:11">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:1">Approval of DaunoXome Set by European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:2">Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:3">Genentech to Spin Off AIDS Research Unit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:4">FDA Chief Warns Against Some Parts of Overhaul Legislation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:5">Culture, et Cetera: Excuse Me</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:6">Singapore HIV Infection Rises 29 Percent in 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:7">Teens Flush with Cash in Toilet Giveaway</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:8">HIV Antiviral Effects of Hyperbaric Oxygen Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:9">NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:10">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:1">Genentech Inc. Forms a Firm for HIV Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:2">Chiron Will Pay About $120 Million For 49 Percent of Hoechst's Vaccine Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:3">A  Vaccine for AIDS at Least 5 Years Away</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:4">'Dreaded-Disease' Policies Rise, But Some Say They're No Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:5">Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:6">Skin Cancer and HPV 16 Infection Linked in AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:7">Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:8">Jobs at Risk for HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:9">A Kinder, Gentler War Against Hepatitis B</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:10">An Epidemic's Evolution</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:1">AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:2">Remorse From a Heavyweight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:3">Sequus Drug Is Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:4">N.J. Gives Hemophiliacs Hope on AIDS Lawsuits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:5">Ryan White's Legacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:6">Answers on Blood Seem Elusive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:7">Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:8">Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:9">Gene Therapy Blocked by Strong Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:10">Tokyo Professor Accused on Perjury Over Evidence of HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:11">Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960215"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-207</DOCNO>
<DOCOLDNO>IA017-000178-B006-21</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960223 192.33.214.13 19970106044100 text/html 8680
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:22 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960301"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:1">Pa. Adds New AIDS Drug to Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:2">Airing Ads on AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:3">CDC Finds Some Drug Users Still Spreading AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:4">Health and Welfare Ministry in Japan Knew of Risk of AIDS in 1983</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:5">HHS Awards $80 Million in Ryan White Funding to 42 Cities</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:6">Urine Therapy Devotees Flock to India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:7">Survey Finds Keys to Secondary Prevention of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:8">Serum Cortisol Levels Linked to Disease Progression in AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:9">CDC Wants More Input Before Updating Post-Exposure Guidelines</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:10">Gay Physicians Group Offers Aid to HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960223:11">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:1">Approval of DaunoXome Set by European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:2">Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:3">Genentech to Spin Off AIDS Research Unit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:4">FDA Chief Warns Against Some Parts of Overhaul Legislation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:5">Culture, et Cetera: Excuse Me</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:6">Singapore HIV Infection Rises 29 Percent in 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:7">Teens Flush with Cash in Toilet Giveaway</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:8">HIV Antiviral Effects of Hyperbaric Oxygen Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:9">NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:10">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:1">Genentech Inc. Forms a Firm for HIV Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:2">Chiron Will Pay About $120 Million For 49 Percent of Hoechst's Vaccine Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:3">A  Vaccine for AIDS at Least 5 Years Away</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:4">'Dreaded-Disease' Policies Rise, But Some Say They're No Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:5">Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:6">Skin Cancer and HPV 16 Infection Linked in AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:7">Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:8">Jobs at Risk for HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:9">A Kinder, Gentler War Against Hepatitis B</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:10">An Epidemic's Evolution</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:1">AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:2">Remorse From a Heavyweight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:3">Sequus Drug Is Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:4">N.J. Gives Hemophiliacs Hope on AIDS Lawsuits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:5">Ryan White's Legacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:6">Answers on Blood Seem Elusive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:7">Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:8">Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:9">Gene Therapy Blocked by Strong Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:10">Tokyo Professor Accused on Perjury Over Evidence of HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:11">Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:1">New York to Screen Boxers for H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:2">Military HIV Ban Defended by Gingrich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:3">Today's Debate: Mandatory AIDS Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:4">Women-Friendly AIDS Protection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:5">HIV Deadly Weapon?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:6">Lawyer Gets Virulent in Case of HIV Cop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:7">Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:8">IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:9">Modified Microbe May Boost TB Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:10">The Challenge of Maternal-Infant Transmission of HIV</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960214"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-208</DOCNO>
<DOCOLDNO>IA017-000178-B006-32</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960222 192.33.214.13 19970106044110 text/html 8381
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960229"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 22, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:1">Approval of DaunoXome Set by European Countries</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:2">Patients' Groups Jump Into the Battle Over Proposals to Restructure the FDA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:3">Genentech to Spin Off AIDS Research Unit</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:4">FDA Chief Warns Against Some Parts of Overhaul Legislation</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:5">Culture, et Cetera: Excuse Me</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:6">Singapore HIV Infection Rises 29 Percent in 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:7">Teens Flush with Cash in Toilet Giveaway</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:8">HIV Antiviral Effects of Hyperbaric Oxygen Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:9">NIH Agrees to Temporary By-Pass of AIDS Office in Allocation of Grants</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960222:10">Continued Sexual Risk Behavior Among HIV Seropositive, Drug- Using Men: Atlanta, Washington D.C., San Juan, Puerto Rico</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:1">Genentech Inc. Forms a Firm for HIV Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:2">Chiron Will Pay About $120 Million For 49 Percent of Hoechst's Vaccine Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:3">A  Vaccine for AIDS at Least 5 Years Away</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:4">'Dreaded-Disease' Policies Rise, But Some Say They're No Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:5">Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:6">Skin Cancer and HPV 16 Infection Linked in AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:7">Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:8">Jobs at Risk for HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:9">A Kinder, Gentler War Against Hepatitis B</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:10">An Epidemic's Evolution</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:1">AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:2">Remorse From a Heavyweight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:3">Sequus Drug Is Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:4">N.J. Gives Hemophiliacs Hope on AIDS Lawsuits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:5">Ryan White's Legacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:6">Answers on Blood Seem Elusive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:7">Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:8">Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:9">Gene Therapy Blocked by Strong Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:10">Tokyo Professor Accused on Perjury Over Evidence of HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:11">Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:1">New York to Screen Boxers for H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:2">Military HIV Ban Defended by Gingrich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:3">Today's Debate: Mandatory AIDS Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:4">Women-Friendly AIDS Protection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:5">HIV Deadly Weapon?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:6">Lawyer Gets Virulent in Case of HIV Cop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:7">Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:8">IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:9">Modified Microbe May Boost TB Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:10">The Challenge of Maternal-Infant Transmission of HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:1">Morrison Ref HIV-Negative, Outcry for Testing Continues</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:2">Drug-Resistant TB Spreads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:3">The FDA vs. Health Exams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:4">Morrison's Partners Jolted by News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:5">Biting Case Will Be Test for HIV Law</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:6">Japan Tobacco to Start Japan HIV Drug Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:7">Japan Minister Pledges to Resolve HIV Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:8">Illinois Considering a Registry of Persons with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:9">Ribozymes Move Closer to Applications for AIDS Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:10">HIV and Dying: The Challenges of Caring</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960212"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-209</DOCNO>
<DOCOLDNO>IA017-000178-B006-47</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960221 192.33.214.13 19970106044119 text/html 8258
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960228"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 21, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:1">Genentech Inc. Forms a Firm for HIV Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:2">Chiron Will Pay About $120 Million For 49 Percent of Hoechst's Vaccine Business</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:3">A  Vaccine for AIDS at Least 5 Years Away</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:4">'Dreaded-Disease' Policies Rise, But Some Say They're No Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:5">Recurrent Varicella-Zoster Virus Infections Common in HIV-Positive Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:6">Skin Cancer and HPV 16 Infection Linked in AIDS Patient</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:7">Origin and Interstate Spread of a New York City Multidrug-Resistant Mycobacterium Tuberculosis Clone Family</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:8">Jobs at Risk for HIV-Infected Doctors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:9">A Kinder, Gentler War Against Hepatitis B</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960221:10">An Epidemic's Evolution</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:1">AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:2">Remorse From a Heavyweight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:3">Sequus Drug Is Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:4">N.J. Gives Hemophiliacs Hope on AIDS Lawsuits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:5">Ryan White's Legacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:6">Answers on Blood Seem Elusive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:7">Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:8">Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:9">Gene Therapy Blocked by Strong Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:10">Tokyo Professor Accused on Perjury Over Evidence of HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:11">Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:1">New York to Screen Boxers for H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:2">Military HIV Ban Defended by Gingrich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:3">Today's Debate: Mandatory AIDS Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:4">Women-Friendly AIDS Protection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:5">HIV Deadly Weapon?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:6">Lawyer Gets Virulent in Case of HIV Cop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:7">Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:8">IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:9">Modified Microbe May Boost TB Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:10">The Challenge of Maternal-Infant Transmission of HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:1">Morrison Ref HIV-Negative, Outcry for Testing Continues</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:2">Drug-Resistant TB Spreads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:3">The FDA vs. Health Exams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:4">Morrison's Partners Jolted by News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:5">Biting Case Will Be Test for HIV Law</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:6">Japan Tobacco to Start Japan HIV Drug Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:7">Japan Minister Pledges to Resolve HIV Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:8">Illinois Considering a Registry of Persons with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:9">Ribozymes Move Closer to Applications for AIDS Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:10">HIV and Dying: The Challenges of Caring</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:1">Medical Suspension Creates Concern</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:2">Ignoring a Proven Lifesaver</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:3">Shark, Frog Compounds Fight Sex Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:4">Medicaid Cuts Keep Many AIDS Patients from New Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:5">Clinton Signs Defense Bill, Blasts AIDS Provision</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:6">Doctor Hopes to Repeat Baboon Cell Transplant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:7">Man Accused of Giving HIV to Four is Slain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:8">Blood Supply: Possibly Tainted Product Withdrawn</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:9">Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:10">Ship to Shore</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960209"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-210</DOCNO>
<DOCOLDNO>IA017-000178-B006-62</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960216 192.33.214.13 19970106044133 text/html 8076
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:41:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960227"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:1">AIDS Deaths Continue to Rise in 25-44 Age Group, U.S. Says</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:2">Remorse From a Heavyweight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:3">Sequus Drug Is Approved</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:4">N.J. Gives Hemophiliacs Hope on AIDS Lawsuits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:5">Ryan White's Legacy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:6">Answers on Blood Seem Elusive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:7">Empiric Therapy for AIDS-Related Pneumonia Appropriate in Selected Cases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:8">Risk of Kaposi Sarcoma in Unmarried Men Similar in Pre-AIDS Era and AIDS Era</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:9">Gene Therapy Blocked by Strong Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:10">Tokyo Professor Accused on Perjury Over Evidence of HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960216:11">Mortality Due to HIV Infection Among Persons Aged 25-44 Years- United States, 1993 and 1994</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:1">New York to Screen Boxers for H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:2">Military HIV Ban Defended by Gingrich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:3">Today's Debate: Mandatory AIDS Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:4">Women-Friendly AIDS Protection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:5">HIV Deadly Weapon?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:6">Lawyer Gets Virulent in Case of HIV Cop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:7">Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:8">IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:9">Modified Microbe May Boost TB Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:10">The Challenge of Maternal-Infant Transmission of HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:1">Morrison Ref HIV-Negative, Outcry for Testing Continues</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:2">Drug-Resistant TB Spreads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:3">The FDA vs. Health Exams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:4">Morrison's Partners Jolted by News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:5">Biting Case Will Be Test for HIV Law</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:6">Japan Tobacco to Start Japan HIV Drug Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:7">Japan Minister Pledges to Resolve HIV Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:8">Illinois Considering a Registry of Persons with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:9">Ribozymes Move Closer to Applications for AIDS Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:10">HIV and Dying: The Challenges of Caring</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:1">Medical Suspension Creates Concern</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:2">Ignoring a Proven Lifesaver</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:3">Shark, Frog Compounds Fight Sex Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:4">Medicaid Cuts Keep Many AIDS Patients from New Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:5">Clinton Signs Defense Bill, Blasts AIDS Provision</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:6">Doctor Hopes to Repeat Baboon Cell Transplant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:7">Man Accused of Giving HIV to Four is Slain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:8">Blood Supply: Possibly Tainted Product Withdrawn</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:9">Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:10">Ship to Shore</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:1">Baboon Cells Fail to Thrive, But AIDS Patient Improves</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:2">2 of 6 Who Got HIV from Dentist are Alive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:3">New Proposals On Health Care Help New York</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:4">Amtrak Passenger with TB Dies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:5">AIDS Takes New Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:6">A Cure For FDA-Induced Pain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:7">HIV...and Service in the Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:8">New Strain of HIV Identified in India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:9">Detection of Virus in Vertically Exposed HIV-Antibody-Negative Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:10">Monkeys Are Not Men</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960207"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-211</DOCNO>
<DOCOLDNO>IA017-000178-B006-73</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960215 192.33.214.13 19970106044143 text/html 7932
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960226"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 15, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:1">New York to Screen Boxers for H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:2">Military HIV Ban Defended by Gingrich</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:3">Today's Debate: Mandatory AIDS Testing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:4">Women-Friendly AIDS Protection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:5">HIV Deadly Weapon?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:6">Lawyer Gets Virulent in Case of HIV Cop</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:7">Voices: Should Professional Athletes Be Required to Be Tested for the AIDS Virus?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:8">IV Drug Use Compromises Integrity of Cell Membranes Prior to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:9">Modified Microbe May Boost TB Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960215:10">The Challenge of Maternal-Infant Transmission of HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:1">Morrison Ref HIV-Negative, Outcry for Testing Continues</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:2">Drug-Resistant TB Spreads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:3">The FDA vs. Health Exams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:4">Morrison's Partners Jolted by News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:5">Biting Case Will Be Test for HIV Law</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:6">Japan Tobacco to Start Japan HIV Drug Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:7">Japan Minister Pledges to Resolve HIV Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:8">Illinois Considering a Registry of Persons with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:9">Ribozymes Move Closer to Applications for AIDS Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:10">HIV and Dying: The Challenges of Caring</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:1">Medical Suspension Creates Concern</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:2">Ignoring a Proven Lifesaver</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:3">Shark, Frog Compounds Fight Sex Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:4">Medicaid Cuts Keep Many AIDS Patients from New Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:5">Clinton Signs Defense Bill, Blasts AIDS Provision</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:6">Doctor Hopes to Repeat Baboon Cell Transplant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:7">Man Accused of Giving HIV to Four is Slain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:8">Blood Supply: Possibly Tainted Product Withdrawn</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:9">Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:10">Ship to Shore</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:1">Baboon Cells Fail to Thrive, But AIDS Patient Improves</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:2">2 of 6 Who Got HIV from Dentist are Alive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:3">New Proposals On Health Care Help New York</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:4">Amtrak Passenger with TB Dies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:5">AIDS Takes New Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:6">A Cure For FDA-Induced Pain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:7">HIV...and Service in the Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:8">New Strain of HIV Identified in India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:9">Detection of Virus in Vertically Exposed HIV-Antibody-Negative Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:10">Monkeys Are Not Men</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:1">Delco Councilman Votes Against AIDS Grant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:2">City Working to Curb Rise in Syphilis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:3">Military Misfire</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:4">Judge Bans Naming of Dentist in HIV Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:5">Race Played No Role in Closing AIDS Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:6">Chiron Viagene and Virus Research Institute Collaborate on Intracellular Gene Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:7">Clarithromycin of Benefit to AIDS Patients with Disseminated Mycobacterium Avium Complex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:8">Nontraditional Treatments Offer No Benefit to AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:9">AIDS in America: Getting Younger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:10">Private Group of AIDS Experts Work to Update Clinical Guides</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960206"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-212</DOCNO>
<DOCOLDNO>IA017-000178-B006-87</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960214 192.33.214.13 19970106044152 text/html 7976
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960223"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 14, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:1">Morrison Ref HIV-Negative, Outcry for Testing Continues</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:2">Drug-Resistant TB Spreads</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:3">The FDA vs. Health Exams</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:4">Morrison's Partners Jolted by News</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:5">Biting Case Will Be Test for HIV Law</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:6">Japan Tobacco to Start Japan HIV Drug Test</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:7">Japan Minister Pledges to Resolve HIV Issue</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:8">Illinois Considering a Registry of Persons with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:9">Ribozymes Move Closer to Applications for AIDS Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960214:10">HIV and Dying: The Challenges of Caring</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:1">Medical Suspension Creates Concern</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:2">Ignoring a Proven Lifesaver</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:3">Shark, Frog Compounds Fight Sex Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:4">Medicaid Cuts Keep Many AIDS Patients from New Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:5">Clinton Signs Defense Bill, Blasts AIDS Provision</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:6">Doctor Hopes to Repeat Baboon Cell Transplant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:7">Man Accused of Giving HIV to Four is Slain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:8">Blood Supply: Possibly Tainted Product Withdrawn</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:9">Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:10">Ship to Shore</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:1">Baboon Cells Fail to Thrive, But AIDS Patient Improves</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:2">2 of 6 Who Got HIV from Dentist are Alive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:3">New Proposals On Health Care Help New York</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:4">Amtrak Passenger with TB Dies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:5">AIDS Takes New Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:6">A Cure For FDA-Induced Pain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:7">HIV...and Service in the Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:8">New Strain of HIV Identified in India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:9">Detection of Virus in Vertically Exposed HIV-Antibody-Negative Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:10">Monkeys Are Not Men</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:1">Delco Councilman Votes Against AIDS Grant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:2">City Working to Curb Rise in Syphilis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:3">Military Misfire</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:4">Judge Bans Naming of Dentist in HIV Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:5">Race Played No Role in Closing AIDS Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:6">Chiron Viagene and Virus Research Institute Collaborate on Intracellular Gene Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:7">Clarithromycin of Benefit to AIDS Patients with Disseminated Mycobacterium Avium Complex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:8">Nontraditional Treatments Offer No Benefit to AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:9">AIDS in America: Getting Younger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:10">Private Group of AIDS Experts Work to Update Clinical Guides</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:1">AIDS Conference Offers Reasons for Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:2">New AIDS Therapies Arise, But Who Can Afford the Bill?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:3">Pharmacia  Upjohn to Cut 10 Percent of Jobs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:4">A Week of Dramatic Ups and Downs on the AIDS Front</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:5">AIDS-drug Lottery: Life-and-Death Contest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:6">New Drug Cut AIDS Deaths in Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:7">Letters to the Editor: Magic Shouldn't Compete in 1996 Olympics/Drop All This Paranoia/Not a Real Comeback</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:8">NIH Budget Trouble for AIDS Office?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:9">N.Y. Professor Puts Discredited AIDS Theory in Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:10">Infections Making a Deadly Comeback</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960205"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-213</DOCNO>
<DOCOLDNO>IA017-000178-B006-100</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960212 192.33.214.13 19970106044211 text/html 8033
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:30 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960222"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:1">Medical Suspension Creates Concern</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:2">Ignoring a Proven Lifesaver</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:3">Shark, Frog Compounds Fight Sex Disease</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:4">Medicaid Cuts Keep Many AIDS Patients from New Treatments</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:5">Clinton Signs Defense Bill, Blasts AIDS Provision</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:6">Doctor Hopes to Repeat Baboon Cell Transplant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:7">Man Accused of Giving HIV to Four is Slain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:8">Blood Supply: Possibly Tainted Product Withdrawn</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:9">Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960212:10">Ship to Shore</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:1">Baboon Cells Fail to Thrive, But AIDS Patient Improves</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:2">2 of 6 Who Got HIV from Dentist are Alive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:3">New Proposals On Health Care Help New York</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:4">Amtrak Passenger with TB Dies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:5">AIDS Takes New Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:6">A Cure For FDA-Induced Pain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:7">HIV...and Service in the Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:8">New Strain of HIV Identified in India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:9">Detection of Virus in Vertically Exposed HIV-Antibody-Negative Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:10">Monkeys Are Not Men</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:1">Delco Councilman Votes Against AIDS Grant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:2">City Working to Curb Rise in Syphilis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:3">Military Misfire</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:4">Judge Bans Naming of Dentist in HIV Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:5">Race Played No Role in Closing AIDS Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:6">Chiron Viagene and Virus Research Institute Collaborate on Intracellular Gene Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:7">Clarithromycin of Benefit to AIDS Patients with Disseminated Mycobacterium Avium Complex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:8">Nontraditional Treatments Offer No Benefit to AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:9">AIDS in America: Getting Younger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:10">Private Group of AIDS Experts Work to Update Clinical Guides</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:1">AIDS Conference Offers Reasons for Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:2">New AIDS Therapies Arise, But Who Can Afford the Bill?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:3">Pharmacia  Upjohn to Cut 10 Percent of Jobs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:4">A Week of Dramatic Ups and Downs on the AIDS Front</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:5">AIDS-drug Lottery: Life-and-Death Contest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:6">New Drug Cut AIDS Deaths in Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:7">Letters to the Editor: Magic Shouldn't Compete in 1996 Olympics/Drop All This Paranoia/Not a Real Comeback</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:8">NIH Budget Trouble for AIDS Office?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:9">N.Y. Professor Puts Discredited AIDS Theory in Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:10">Infections Making a Deadly Comeback</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:1">Drugs too Pricey for Patients?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:2">Can Post-Traumatic Stress Arise From Office Battles?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:3">Repeal Sought of HIV Provision in Defense Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:4">U.S. Experts Warn of Honduras AIDS Risk to Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:5">Congress Takes Steps to Speed FDA Approval of New Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:6">Healing a Wound Over AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:7">Case Contends AIDS Infection by Dental Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:8">Toward an Understanding of the Correlates of Protective Immunity to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:9">Was HIV Present in 1959?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:10">Antibiotic-Resistant Bacteria Take Hold in California</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960202"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-214</DOCNO>
<DOCOLDNO>IA017-000178-B006-111</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960209 192.33.214.13 19970106044220 text/html 7984
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960221"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 9, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:1">Baboon Cells Fail to Thrive, But AIDS Patient Improves</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:2">2 of 6 Who Got HIV from Dentist are Alive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:3">New Proposals On Health Care Help New York</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:4">Amtrak Passenger with TB Dies</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:5">AIDS Takes New Directions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:6">A Cure For FDA-Induced Pain</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:7">HIV...and Service in the Military</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:8">New Strain of HIV Identified in India</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:9">Detection of Virus in Vertically Exposed HIV-Antibody-Negative Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960209:10">Monkeys Are Not Men</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:1">Delco Councilman Votes Against AIDS Grant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:2">City Working to Curb Rise in Syphilis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:3">Military Misfire</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:4">Judge Bans Naming of Dentist in HIV Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:5">Race Played No Role in Closing AIDS Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:6">Chiron Viagene and Virus Research Institute Collaborate on Intracellular Gene Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:7">Clarithromycin of Benefit to AIDS Patients with Disseminated Mycobacterium Avium Complex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:8">Nontraditional Treatments Offer No Benefit to AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:9">AIDS in America: Getting Younger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:10">Private Group of AIDS Experts Work to Update Clinical Guides</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:1">AIDS Conference Offers Reasons for Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:2">New AIDS Therapies Arise, But Who Can Afford the Bill?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:3">Pharmacia  Upjohn to Cut 10 Percent of Jobs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:4">A Week of Dramatic Ups and Downs on the AIDS Front</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:5">AIDS-drug Lottery: Life-and-Death Contest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:6">New Drug Cut AIDS Deaths in Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:7">Letters to the Editor: Magic Shouldn't Compete in 1996 Olympics/Drop All This Paranoia/Not a Real Comeback</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:8">NIH Budget Trouble for AIDS Office?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:9">N.Y. Professor Puts Discredited AIDS Theory in Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:10">Infections Making a Deadly Comeback</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:1">Drugs too Pricey for Patients?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:2">Can Post-Traumatic Stress Arise From Office Battles?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:3">Repeal Sought of HIV Provision in Defense Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:4">U.S. Experts Warn of Honduras AIDS Risk to Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:5">Congress Takes Steps to Speed FDA Approval of New Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:6">Healing a Wound Over AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:7">Case Contends AIDS Infection by Dental Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:8">Toward an Understanding of the Correlates of Protective Immunity to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:9">Was HIV Present in 1959?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:10">Antibiotic-Resistant Bacteria Take Hold in California</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:1">A New AIDS Drug Yielding Optimism as Well As Caution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:2">Bills Would Repeal Provision to Expel Troops with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:3">The GOP's HIV Disgrace</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:4">Magic Returns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:5">AIDS Drug Progress Hailed, Prices Lamented</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:6">AIDS Fears Drop in U.S., Poll Shows</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:7">Romania Faces Syphilis Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:8">Inside the Beltway: AIDS and Reality</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:9">How to Ensure the Continued Resurgence of Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:10">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960201"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-215</DOCNO>
<DOCOLDNO>IA017-000178-B006-123</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960207 192.33.214.13 19970106044228 text/html 8149
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960216"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 7, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:1">Delco Councilman Votes Against AIDS Grant</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:2">City Working to Curb Rise in Syphilis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:3">Military Misfire</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:4">Judge Bans Naming of Dentist in HIV Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:5">Race Played No Role in Closing AIDS Trials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:6">Chiron Viagene and Virus Research Institute Collaborate on Intracellular Gene Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:7">Clarithromycin of Benefit to AIDS Patients with Disseminated Mycobacterium Avium Complex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:8">Nontraditional Treatments Offer No Benefit to AIDS Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:9">AIDS in America: Getting Younger</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960207:10">Private Group of AIDS Experts Work to Update Clinical Guides</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:1">AIDS Conference Offers Reasons for Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:2">New AIDS Therapies Arise, But Who Can Afford the Bill?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:3">Pharmacia  Upjohn to Cut 10 Percent of Jobs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:4">A Week of Dramatic Ups and Downs on the AIDS Front</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:5">AIDS-drug Lottery: Life-and-Death Contest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:6">New Drug Cut AIDS Deaths in Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:7">Letters to the Editor: Magic Shouldn't Compete in 1996 Olympics/Drop All This Paranoia/Not a Real Comeback</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:8">NIH Budget Trouble for AIDS Office?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:9">N.Y. Professor Puts Discredited AIDS Theory in Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:10">Infections Making a Deadly Comeback</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:1">Drugs too Pricey for Patients?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:2">Can Post-Traumatic Stress Arise From Office Battles?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:3">Repeal Sought of HIV Provision in Defense Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:4">U.S. Experts Warn of Honduras AIDS Risk to Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:5">Congress Takes Steps to Speed FDA Approval of New Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:6">Healing a Wound Over AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:7">Case Contends AIDS Infection by Dental Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:8">Toward an Understanding of the Correlates of Protective Immunity to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:9">Was HIV Present in 1959?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:10">Antibiotic-Resistant Bacteria Take Hold in California</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:1">A New AIDS Drug Yielding Optimism as Well As Caution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:2">Bills Would Repeal Provision to Expel Troops with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:3">The GOP's HIV Disgrace</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:4">Magic Returns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:5">AIDS Drug Progress Hailed, Prices Lamented</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:6">AIDS Fears Drop in U.S., Poll Shows</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:7">Romania Faces Syphilis Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:8">Inside the Beltway: AIDS and Reality</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:9">How to Ensure the Continued Resurgence of Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:10">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:1">Abbott AIDS Drug Halves Death Rate, New Study Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:2">Survival of AIDS Patients Linked to Doctors' Knowledge of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:3">Deaths from AIDS in U.S. Outpace New HIV Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:4">Army Sergeant with HIV Feels Deserted by Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:5">Students Lobby for AIDS Funds in Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:6">Japan Reports Change in Pattern of Contracting AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:7">Gilead Sciences Announces Statistically Significant Anti-HIV Activity of GS 840</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:8">Inquiry Criticizes Red Cross Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:9">CDC Study: AZT Reduces HIV Risk From Needlesticks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:10">Surveillance of Tuberculosis and AIDS Co-Morbidity--Florida, 1981-1993</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960131"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-216</DOCNO>
<DOCOLDNO>IA017-000178-B006-137</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960206 192.33.214.13 19970106044235 text/html 8136
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:42:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960215"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 6, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:1">AIDS Conference Offers Reasons for Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:2">New AIDS Therapies Arise, But Who Can Afford the Bill?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:3">Pharmacia  Upjohn to Cut 10 Percent of Jobs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:4">A Week of Dramatic Ups and Downs on the AIDS Front</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:5">AIDS-drug Lottery: Life-and-Death Contest</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:6">New Drug Cut AIDS Deaths in Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:7">Letters to the Editor: Magic Shouldn't Compete in 1996 Olympics/Drop All This Paranoia/Not a Real Comeback</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:8">NIH Budget Trouble for AIDS Office?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:9">N.Y. Professor Puts Discredited AIDS Theory in Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960206:10">Infections Making a Deadly Comeback</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:1">Drugs too Pricey for Patients?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:2">Can Post-Traumatic Stress Arise From Office Battles?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:3">Repeal Sought of HIV Provision in Defense Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:4">U.S. Experts Warn of Honduras AIDS Risk to Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:5">Congress Takes Steps to Speed FDA Approval of New Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:6">Healing a Wound Over AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:7">Case Contends AIDS Infection by Dental Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:8">Toward an Understanding of the Correlates of Protective Immunity to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:9">Was HIV Present in 1959?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:10">Antibiotic-Resistant Bacteria Take Hold in California</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:1">A New AIDS Drug Yielding Optimism as Well As Caution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:2">Bills Would Repeal Provision to Expel Troops with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:3">The GOP's HIV Disgrace</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:4">Magic Returns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:5">AIDS Drug Progress Hailed, Prices Lamented</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:6">AIDS Fears Drop in U.S., Poll Shows</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:7">Romania Faces Syphilis Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:8">Inside the Beltway: AIDS and Reality</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:9">How to Ensure the Continued Resurgence of Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:10">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:1">Abbott AIDS Drug Halves Death Rate, New Study Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:2">Survival of AIDS Patients Linked to Doctors' Knowledge of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:3">Deaths from AIDS in U.S. Outpace New HIV Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:4">Army Sergeant with HIV Feels Deserted by Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:5">Students Lobby for AIDS Funds in Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:6">Japan Reports Change in Pattern of Contracting AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:7">Gilead Sciences Announces Statistically Significant Anti-HIV Activity of GS 840</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:8">Inquiry Criticizes Red Cross Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:9">CDC Study: AZT Reduces HIV Risk From Needlesticks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:10">Surveillance of Tuberculosis and AIDS Co-Morbidity--Florida, 1981-1993</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 31, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:1">Infected With Human Virus, a Chimpanzee Develops AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:2">Better Gauge of AIDS Virus Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:3">AIDS Drug Is Reported to Reduce Virus Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:4">Ethiopia Questions Israel On Blood-Bank Dispute</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:5">For HIV-Positive, A New Dread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:6">Scientists Say Milk-Based Compound Stops HIV Spread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:7">Researchers Say Drug Combination Fights HIV Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:8">Bill Would Legalize Prescribed Marijuana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:9">Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate--United States, September-December 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:10">Responding to AIDS</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960130"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-217</DOCNO>
<DOCOLDNO>IA017-000178-B006-149</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960205 192.33.214.13 19970106044244 text/html 8019
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960214"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:1">Drugs too Pricey for Patients?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:2">Can Post-Traumatic Stress Arise From Office Battles?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:3">Repeal Sought of HIV Provision in Defense Bill</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:4">U.S. Experts Warn of Honduras AIDS Risk to Women</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:5">Congress Takes Steps to Speed FDA Approval of New Medicine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:6">Healing a Wound Over AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:7">Case Contends AIDS Infection by Dental Tools</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:8">Toward an Understanding of the Correlates of Protective Immunity to HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:9">Was HIV Present in 1959?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960205:10">Antibiotic-Resistant Bacteria Take Hold in California</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:1">A New AIDS Drug Yielding Optimism as Well As Caution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:2">Bills Would Repeal Provision to Expel Troops with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:3">The GOP's HIV Disgrace</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:4">Magic Returns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:5">AIDS Drug Progress Hailed, Prices Lamented</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:6">AIDS Fears Drop in U.S., Poll Shows</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:7">Romania Faces Syphilis Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:8">Inside the Beltway: AIDS and Reality</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:9">How to Ensure the Continued Resurgence of Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:10">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:1">Abbott AIDS Drug Halves Death Rate, New Study Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:2">Survival of AIDS Patients Linked to Doctors' Knowledge of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:3">Deaths from AIDS in U.S. Outpace New HIV Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:4">Army Sergeant with HIV Feels Deserted by Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:5">Students Lobby for AIDS Funds in Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:6">Japan Reports Change in Pattern of Contracting AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:7">Gilead Sciences Announces Statistically Significant Anti-HIV Activity of GS 840</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:8">Inquiry Criticizes Red Cross Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:9">CDC Study: AZT Reduces HIV Risk From Needlesticks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:10">Surveillance of Tuberculosis and AIDS Co-Morbidity--Florida, 1981-1993</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 31, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:1">Infected With Human Virus, a Chimpanzee Develops AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:2">Better Gauge of AIDS Virus Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:3">AIDS Drug Is Reported to Reduce Virus Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:4">Ethiopia Questions Israel On Blood-Bank Dispute</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:5">For HIV-Positive, A New Dread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:6">Scientists Say Milk-Based Compound Stops HIV Spread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:7">Researchers Say Drug Combination Fights HIV Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:8">Bill Would Legalize Prescribed Marijuana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:9">Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate--United States, September-December 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:10">Responding to AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 30, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:1">Three-Drug Therapy May Suppress HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:2">Magic Johnson Returns to NBA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:3">Cutting a Lifeline to AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:4">AZT Slashes HIV Rates in Newborns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:5">Administration to Seek Repeal of Military HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:6">HIV and DOD</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:7">Dow Closes Above 5,300 on Rate-Cut Hopes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:8">Blood Liability Put at $1-Billion</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:9">AIDS Trials Take on Peer Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:10">Fighting Infectious Disease Threats via Research: A Talk with Anthony S. Fauci</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960129"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-218</DOCNO>
<DOCOLDNO>IA017-000178-B006-161</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960202 192.33.214.13 19970106044253 text/html 8074
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960212"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:1">A New AIDS Drug Yielding Optimism as Well As Caution</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:2">Bills Would Repeal Provision to Expel Troops with H.I.V.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:3">The GOP's HIV Disgrace</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:4">Magic Returns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:5">AIDS Drug Progress Hailed, Prices Lamented</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:6">AIDS Fears Drop in U.S., Poll Shows</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:7">Romania Faces Syphilis Epidemic</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:8">Inside the Beltway: AIDS and Reality</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:9">How to Ensure the Continued Resurgence of Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960202:10">Getting Your Insurer to Cover New HIV Treatments: A Crash Course</A></TD>
</TR>
</TABLE>
</UL>
<H3>February 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:1">Abbott AIDS Drug Halves Death Rate, New Study Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:2">Survival of AIDS Patients Linked to Doctors' Knowledge of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:3">Deaths from AIDS in U.S. Outpace New HIV Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:4">Army Sergeant with HIV Feels Deserted by Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:5">Students Lobby for AIDS Funds in Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:6">Japan Reports Change in Pattern of Contracting AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:7">Gilead Sciences Announces Statistically Significant Anti-HIV Activity of GS 840</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:8">Inquiry Criticizes Red Cross Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:9">CDC Study: AZT Reduces HIV Risk From Needlesticks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:10">Surveillance of Tuberculosis and AIDS Co-Morbidity--Florida, 1981-1993</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 31, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:1">Infected With Human Virus, a Chimpanzee Develops AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:2">Better Gauge of AIDS Virus Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:3">AIDS Drug Is Reported to Reduce Virus Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:4">Ethiopia Questions Israel On Blood-Bank Dispute</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:5">For HIV-Positive, A New Dread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:6">Scientists Say Milk-Based Compound Stops HIV Spread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:7">Researchers Say Drug Combination Fights HIV Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:8">Bill Would Legalize Prescribed Marijuana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:9">Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate--United States, September-December 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:10">Responding to AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 30, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:1">Three-Drug Therapy May Suppress HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:2">Magic Johnson Returns to NBA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:3">Cutting a Lifeline to AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:4">AZT Slashes HIV Rates in Newborns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:5">Administration to Seek Repeal of Military HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:6">HIV and DOD</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:7">Dow Closes Above 5,300 on Rate-Cut Hopes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:8">Blood Liability Put at $1-Billion</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:9">AIDS Trials Take on Peer Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:10">Fighting Infectious Disease Threats via Research: A Talk with Anthony S. Fauci</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:1">Ethiopian Jews in Israeli Melee over AIDS Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:2">AIDS Discharge Clause Under Fire From Critics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:3">Lottery Emphasizes Dicey Nature of AIDS Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:4">AIDS Spreading Among Aboriginals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:5">Blood Scandal Without End</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:6">AIDS Pioneer Says Vaccine Still a Long Way Off</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:7">Gilead Sciences Announces Further Results Indicating Vistide Delays Time to Disease Progression in Patients With Relapsing CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:8">Saliva Diagnostic Systems Signs China Distributor for HIV Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:9">The Emerging Genetic Diversity of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:10">Book Review: Coming to Terms with HIV</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960126"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-219</DOCNO>
<DOCOLDNO>IA017-000178-B006-179</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960201 192.33.214.13 19970106044304 text/html 8092
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:26 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960209"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>February 1, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:1">Abbott AIDS Drug Halves Death Rate, New Study Reports</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:2">Survival of AIDS Patients Linked to Doctors' Knowledge of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:3">Deaths from AIDS in U.S. Outpace New HIV Infections</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:4">Army Sergeant with HIV Feels Deserted by Policy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:5">Students Lobby for AIDS Funds in Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:6">Japan Reports Change in Pattern of Contracting AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:7">Gilead Sciences Announces Statistically Significant Anti-HIV Activity of GS 840</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:8">Inquiry Criticizes Red Cross Officials</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:9">CDC Study: AZT Reduces HIV Risk From Needlesticks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960201:10">Surveillance of Tuberculosis and AIDS Co-Morbidity--Florida, 1981-1993</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 31, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:1">Infected With Human Virus, a Chimpanzee Develops AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:2">Better Gauge of AIDS Virus Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:3">AIDS Drug Is Reported to Reduce Virus Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:4">Ethiopia Questions Israel On Blood-Bank Dispute</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:5">For HIV-Positive, A New Dread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:6">Scientists Say Milk-Based Compound Stops HIV Spread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:7">Researchers Say Drug Combination Fights HIV Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:8">Bill Would Legalize Prescribed Marijuana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:9">Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate--United States, September-December 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:10">Responding to AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 30, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:1">Three-Drug Therapy May Suppress HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:2">Magic Johnson Returns to NBA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:3">Cutting a Lifeline to AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:4">AZT Slashes HIV Rates in Newborns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:5">Administration to Seek Repeal of Military HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:6">HIV and DOD</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:7">Dow Closes Above 5,300 on Rate-Cut Hopes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:8">Blood Liability Put at $1-Billion</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:9">AIDS Trials Take on Peer Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:10">Fighting Infectious Disease Threats via Research: A Talk with Anthony S. Fauci</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:1">Ethiopian Jews in Israeli Melee over AIDS Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:2">AIDS Discharge Clause Under Fire From Critics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:3">Lottery Emphasizes Dicey Nature of AIDS Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:4">AIDS Spreading Among Aboriginals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:5">Blood Scandal Without End</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:6">AIDS Pioneer Says Vaccine Still a Long Way Off</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:7">Gilead Sciences Announces Further Results Indicating Vistide Delays Time to Disease Progression in Patients With Relapsing CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:8">Saliva Diagnostic Systems Signs China Distributor for HIV Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:9">The Emerging Genetic Diversity of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:10">Book Review: Coming to Terms with HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:1">President to Accept HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:2">Suspect in Hypodermic Jabbing Is Declared Unfit to Stand Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:3">A New Drive For an AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:4">Grieving Siblings Need to Share AIDS Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:5">Man Wins New Trial After Court Faults Judge's AIDS Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:6">Study Finds More Children 'Cured' of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:7">Study Queries Claims that HIV Does Not Cause AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:8">Protease Inhibitors Studies Probe HIV Resistance to Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:9">English HIV and AIDS Projections Made</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:10">AIDS and Suicide</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960125"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-220</DOCNO>
<DOCOLDNO>IA017-000178-B006-193</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960131 192.33.214.13 19970106044313 text/html 7868
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960207"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 31, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:1">Infected With Human Virus, a Chimpanzee Develops AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:2">Better Gauge of AIDS Virus Reported</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:3">AIDS Drug Is Reported to Reduce Virus Levels</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:4">Ethiopia Questions Israel On Blood-Bank Dispute</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:5">For HIV-Positive, A New Dread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:6">Scientists Say Milk-Based Compound Stops HIV Spread</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:7">Researchers Say Drug Combination Fights HIV Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:8">Bill Would Legalize Prescribed Marijuana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:9">Hepatitis A Among Persons with Hemophilia Who Received Clotting Factor Concentrate--United States, September-December 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960131:10">Responding to AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 30, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:1">Three-Drug Therapy May Suppress HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:2">Magic Johnson Returns to NBA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:3">Cutting a Lifeline to AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:4">AZT Slashes HIV Rates in Newborns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:5">Administration to Seek Repeal of Military HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:6">HIV and DOD</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:7">Dow Closes Above 5,300 on Rate-Cut Hopes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:8">Blood Liability Put at $1-Billion</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:9">AIDS Trials Take on Peer Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:10">Fighting Infectious Disease Threats via Research: A Talk with Anthony S. Fauci</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:1">Ethiopian Jews in Israeli Melee over AIDS Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:2">AIDS Discharge Clause Under Fire From Critics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:3">Lottery Emphasizes Dicey Nature of AIDS Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:4">AIDS Spreading Among Aboriginals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:5">Blood Scandal Without End</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:6">AIDS Pioneer Says Vaccine Still a Long Way Off</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:7">Gilead Sciences Announces Further Results Indicating Vistide Delays Time to Disease Progression in Patients With Relapsing CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:8">Saliva Diagnostic Systems Signs China Distributor for HIV Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:9">The Emerging Genetic Diversity of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:10">Book Review: Coming to Terms with HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:1">President to Accept HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:2">Suspect in Hypodermic Jabbing Is Declared Unfit to Stand Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:3">A New Drive For an AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:4">Grieving Siblings Need to Share AIDS Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:5">Man Wins New Trial After Court Faults Judge's AIDS Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:6">Study Finds More Children 'Cured' of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:7">Study Queries Claims that HIV Does Not Cause AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:8">Protease Inhibitors Studies Probe HIV Resistance to Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:9">English HIV and AIDS Projections Made</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:10">AIDS and Suicide</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:1">Israel Dumps Blood From Ethiopians</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:2">House Compromises on Defense; White House Still Sees Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:3">Illinois Officials Want HIV List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:4">Mozambique Estimates Six Percent of Population Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:5">Taking a Big Risk for a Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:6">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:7">Therapy for Cytomegalovirus Retinitis: Still No Silver Lining</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:8">Danes' AIDS Education Criticized</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:9">Ghanaian Research Center Tackles Tough Health, Environmental Problems</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960123"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-221</DOCNO>
<DOCOLDNO>IA017-000178-B006-208</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960130 192.33.214.13 19970106044321 text/html 7884
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960206"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 30, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:1">Three-Drug Therapy May Suppress HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:2">Magic Johnson Returns to NBA</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:3">Cutting a Lifeline to AIDS Study</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:4">AZT Slashes HIV Rates in Newborns</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:5">Administration to Seek Repeal of Military HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:6">HIV and DOD</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:7">Dow Closes Above 5,300 on Rate-Cut Hopes</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:8">Blood Liability Put at $1-Billion</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:9">AIDS Trials Take on Peer Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960130:10">Fighting Infectious Disease Threats via Research: A Talk with Anthony S. Fauci</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:1">Ethiopian Jews in Israeli Melee over AIDS Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:2">AIDS Discharge Clause Under Fire From Critics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:3">Lottery Emphasizes Dicey Nature of AIDS Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:4">AIDS Spreading Among Aboriginals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:5">Blood Scandal Without End</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:6">AIDS Pioneer Says Vaccine Still a Long Way Off</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:7">Gilead Sciences Announces Further Results Indicating Vistide Delays Time to Disease Progression in Patients With Relapsing CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:8">Saliva Diagnostic Systems Signs China Distributor for HIV Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:9">The Emerging Genetic Diversity of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:10">Book Review: Coming to Terms with HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:1">President to Accept HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:2">Suspect in Hypodermic Jabbing Is Declared Unfit to Stand Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:3">A New Drive For an AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:4">Grieving Siblings Need to Share AIDS Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:5">Man Wins New Trial After Court Faults Judge's AIDS Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:6">Study Finds More Children 'Cured' of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:7">Study Queries Claims that HIV Does Not Cause AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:8">Protease Inhibitors Studies Probe HIV Resistance to Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:9">English HIV and AIDS Projections Made</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:10">AIDS and Suicide</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:1">Israel Dumps Blood From Ethiopians</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:2">House Compromises on Defense; White House Still Sees Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:3">Illinois Officials Want HIV List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:4">Mozambique Estimates Six Percent of Population Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:5">Taking a Big Risk for a Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:6">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:7">Therapy for Cytomegalovirus Retinitis: Still No Silver Lining</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:8">Danes' AIDS Education Criticized</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:9">Ghanaian Research Center Tackles Tough Health, Environmental Problems</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:1">New Issue Update: Advanced Viral</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:2">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:3">Book Review:Mary Fisher, Living Proof</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:4">Judge Curbs Insurance Firm's 'Viatical' Deals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:5">Prescription-Drug Disclosure Set Back</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:6">BC-Vietnam-Abuse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:7">Caremark International Inc.:Fourth-Quarter Loss Seen Due to $52 Million Charge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:8">HealthGate Data Unveils HealthGate, the First World Wide Web Medical Information System for Consumers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:9">Several New Drugs Shift Direction of Treatment and Research for HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:10">Xenotransplantation at a Crossroads: Prevention Versus Progress</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960119"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-222</DOCNO>
<DOCOLDNO>IA017-000178-B006-221</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960129 192.33.214.13 19970106044330 text/html 7644
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:43:52 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960205"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:1">Ethiopian Jews in Israeli Melee over AIDS Fear</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:2">AIDS Discharge Clause Under Fire From Critics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:3">Lottery Emphasizes Dicey Nature of AIDS Treatment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:4">AIDS Spreading Among Aboriginals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:5">Blood Scandal Without End</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:6">AIDS Pioneer Says Vaccine Still a Long Way Off</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:7">Gilead Sciences Announces Further Results Indicating Vistide Delays Time to Disease Progression in Patients With Relapsing CMV Retinitis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:8">Saliva Diagnostic Systems Signs China Distributor for HIV Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:9">The Emerging Genetic Diversity of HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960129:10">Book Review: Coming to Terms with HIV</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:1">President to Accept HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:2">Suspect in Hypodermic Jabbing Is Declared Unfit to Stand Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:3">A New Drive For an AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:4">Grieving Siblings Need to Share AIDS Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:5">Man Wins New Trial After Court Faults Judge's AIDS Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:6">Study Finds More Children 'Cured' of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:7">Study Queries Claims that HIV Does Not Cause AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:8">Protease Inhibitors Studies Probe HIV Resistance to Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:9">English HIV and AIDS Projections Made</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:10">AIDS and Suicide</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:1">Israel Dumps Blood From Ethiopians</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:2">House Compromises on Defense; White House Still Sees Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:3">Illinois Officials Want HIV List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:4">Mozambique Estimates Six Percent of Population Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:5">Taking a Big Risk for a Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:6">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:7">Therapy for Cytomegalovirus Retinitis: Still No Silver Lining</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:8">Danes' AIDS Education Criticized</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:9">Ghanaian Research Center Tackles Tough Health, Environmental Problems</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:1">New Issue Update: Advanced Viral</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:2">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:3">Book Review:Mary Fisher, Living Proof</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:4">Judge Curbs Insurance Firm's 'Viatical' Deals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:5">Prescription-Drug Disclosure Set Back</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:6">BC-Vietnam-Abuse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:7">Caremark International Inc.:Fourth-Quarter Loss Seen Due to $52 Million Charge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:8">HealthGate Data Unveils HealthGate, the First World Wide Web Medical Information System for Consumers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:9">Several New Drugs Shift Direction of Treatment and Research for HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:10">Xenotransplantation at a Crossroads: Prevention Versus Progress</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:1">Va. Funeral Home Agrees to Stop Charging Extra to Embalm AIDS Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:2">Hepatitis Virus Passed to Hemophiliacs in Clotting Compound, Health Officials Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:3">New Issue Update: Pharmacia  Upjohn Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:4">Scientists Aim to Recreate Immune System in AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:5">Doctors Admit Man Did Not Die of AIDS in 1959</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:6">Issue of Mandatory HIV-Testing Halts Progress on Ryan White Reauthorization</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:7">Book Review: &quot;The Second Decade of AIDS&quot;</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960118"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-223</DOCNO>
<DOCOLDNO>IA017-000178-B006-234</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960126 192.33.214.13 19970106044338 text/html 7563
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:44:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960202"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 26, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:1">President to Accept HIV Ban</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:2">Suspect in Hypodermic Jabbing Is Declared Unfit to Stand Trial</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:3">A New Drive For an AIDS Vaccine</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:4">Grieving Siblings Need to Share AIDS Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:5">Man Wins New Trial After Court Faults Judge's AIDS Precautions</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:6">Study Finds More Children 'Cured' of AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:7">Study Queries Claims that HIV Does Not Cause AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:8">Protease Inhibitors Studies Probe HIV Resistance to Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:9">English HIV and AIDS Projections Made</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960126:10">AIDS and Suicide</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:1">Israel Dumps Blood From Ethiopians</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:2">House Compromises on Defense; White House Still Sees Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:3">Illinois Officials Want HIV List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:4">Mozambique Estimates Six Percent of Population Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:5">Taking a Big Risk for a Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:6">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:7">Therapy for Cytomegalovirus Retinitis: Still No Silver Lining</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:8">Danes' AIDS Education Criticized</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:9">Ghanaian Research Center Tackles Tough Health, Environmental Problems</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:1">New Issue Update: Advanced Viral</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:2">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:3">Book Review:Mary Fisher, Living Proof</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:4">Judge Curbs Insurance Firm's 'Viatical' Deals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:5">Prescription-Drug Disclosure Set Back</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:6">BC-Vietnam-Abuse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:7">Caremark International Inc.:Fourth-Quarter Loss Seen Due to $52 Million Charge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:8">HealthGate Data Unveils HealthGate, the First World Wide Web Medical Information System for Consumers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:9">Several New Drugs Shift Direction of Treatment and Research for HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:10">Xenotransplantation at a Crossroads: Prevention Versus Progress</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:1">Va. Funeral Home Agrees to Stop Charging Extra to Embalm AIDS Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:2">Hepatitis Virus Passed to Hemophiliacs in Clotting Compound, Health Officials Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:3">New Issue Update: Pharmacia  Upjohn Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:4">Scientists Aim to Recreate Immune System in AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:5">Doctors Admit Man Did Not Die of AIDS in 1959</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:6">Issue of Mandatory HIV-Testing Halts Progress on Ryan White Reauthorization</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:7">Book Review: &quot;The Second Decade of AIDS&quot;</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:1">New Findings May Speed Trials of AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:2">AIDS Transfer Called &quot;Very Rare&quot; in Sperm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:3">City Clinics Add HIV Test to Routine Prenatal Visits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:4">Peace Corps Volunteer Sues Over Firing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:5">When Victims Need to Know</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:6">Can Animal Organs Help Make Up for the Shortage of Human Donors?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:7">Rural AIDS-HIV Increases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:8">Health Research, Once Facing a Big Budget Cut, Gets a Raise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:9">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:10">Prostitutes Spread AIDS in China</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960117"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-224</DOCNO>
<DOCOLDNO>IA017-000178-B006-248</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960125 192.33.214.13 19970106044346 text/html 7618
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:44:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960201"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 25, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:1">Israel Dumps Blood From Ethiopians</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:2">House Compromises on Defense; White House Still Sees Problems</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:3">Illinois Officials Want HIV List</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:4">Mozambique Estimates Six Percent of Population Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:5">Taking a Big Risk for a Cure</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:6">CD8 Cells: Suppressive Factors Discovered</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:7">Therapy for Cytomegalovirus Retinitis: Still No Silver Lining</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:8">Danes' AIDS Education Criticized</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960125:9">Ghanaian Research Center Tackles Tough Health, Environmental Problems</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:1">New Issue Update: Advanced Viral</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:2">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:3">Book Review:Mary Fisher, Living Proof</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:4">Judge Curbs Insurance Firm's 'Viatical' Deals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:5">Prescription-Drug Disclosure Set Back</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:6">BC-Vietnam-Abuse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:7">Caremark International Inc.:Fourth-Quarter Loss Seen Due to $52 Million Charge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:8">HealthGate Data Unveils HealthGate, the First World Wide Web Medical Information System for Consumers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:9">Several New Drugs Shift Direction of Treatment and Research for HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:10">Xenotransplantation at a Crossroads: Prevention Versus Progress</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:1">Va. Funeral Home Agrees to Stop Charging Extra to Embalm AIDS Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:2">Hepatitis Virus Passed to Hemophiliacs in Clotting Compound, Health Officials Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:3">New Issue Update: Pharmacia  Upjohn Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:4">Scientists Aim to Recreate Immune System in AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:5">Doctors Admit Man Did Not Die of AIDS in 1959</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:6">Issue of Mandatory HIV-Testing Halts Progress on Ryan White Reauthorization</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:7">Book Review: &quot;The Second Decade of AIDS&quot;</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:1">New Findings May Speed Trials of AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:2">AIDS Transfer Called &quot;Very Rare&quot; in Sperm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:3">City Clinics Add HIV Test to Routine Prenatal Visits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:4">Peace Corps Volunteer Sues Over Firing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:5">When Victims Need to Know</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:6">Can Animal Organs Help Make Up for the Shortage of Human Donors?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:7">Rural AIDS-HIV Increases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:8">Health Research, Once Facing a Big Budget Cut, Gets a Raise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:9">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:10">Prostitutes Spread AIDS in China</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 17, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:1">Justices Reject Challenge of Patent for AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:2">Doctors Tell of International Resurgence in a Variety of Infectious Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:3">Hemophiliacs Warned About Tainted Plasma</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:4">Top Educator has AIDS But Weighs New Office</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:5">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:6">Highlights</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:7">Meeting Aims to Heal AIDS Split</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:8">Neurex Launches Phase III Program for SNX-111 for...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:9">Baseball, Hotdogs, Apple Pie and HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:10">Biliary Cryptosporidiosis in HIV-infected People After the Waterborne Outbreak of Cryptosporidiosis in Milwaukee</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960116"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-225</DOCNO>
<DOCOLDNO>IA017-000178-B006-258</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960123 192.33.214.13 19970106044354 text/html 7806
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:44:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960131"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 23, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:1">New Issue Update: Advanced Viral</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:2">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:3">Book Review:Mary Fisher, Living Proof</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:4">Judge Curbs Insurance Firm's 'Viatical' Deals</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:5">Prescription-Drug Disclosure Set Back</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:6">BC-Vietnam-Abuse</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:7">Caremark International Inc.:Fourth-Quarter Loss Seen Due to $52 Million Charge</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:8">HealthGate Data Unveils HealthGate, the First World Wide Web Medical Information System for Consumers</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:9">Several New Drugs Shift Direction of Treatment and Research for HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960123:10">Xenotransplantation at a Crossroads: Prevention Versus Progress</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:1">Va. Funeral Home Agrees to Stop Charging Extra to Embalm AIDS Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:2">Hepatitis Virus Passed to Hemophiliacs in Clotting Compound, Health Officials Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:3">New Issue Update: Pharmacia  Upjohn Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:4">Scientists Aim to Recreate Immune System in AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:5">Doctors Admit Man Did Not Die of AIDS in 1959</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:6">Issue of Mandatory HIV-Testing Halts Progress on Ryan White Reauthorization</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:7">Book Review: &quot;The Second Decade of AIDS&quot;</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:1">New Findings May Speed Trials of AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:2">AIDS Transfer Called &quot;Very Rare&quot; in Sperm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:3">City Clinics Add HIV Test to Routine Prenatal Visits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:4">Peace Corps Volunteer Sues Over Firing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:5">When Victims Need to Know</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:6">Can Animal Organs Help Make Up for the Shortage of Human Donors?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:7">Rural AIDS-HIV Increases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:8">Health Research, Once Facing a Big Budget Cut, Gets a Raise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:9">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:10">Prostitutes Spread AIDS in China</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 17, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:1">Justices Reject Challenge of Patent for AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:2">Doctors Tell of International Resurgence in a Variety of Infectious Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:3">Hemophiliacs Warned About Tainted Plasma</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:4">Top Educator has AIDS But Weighs New Office</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:5">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:6">Highlights</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:7">Meeting Aims to Heal AIDS Split</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:8">Neurex Launches Phase III Program for SNX-111 for...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:9">Baseball, Hotdogs, Apple Pie and HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:10">Biliary Cryptosporidiosis in HIV-infected People After the Waterborne Outbreak of Cryptosporidiosis in Milwaukee</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:1">Needle Attack Muddies Issue of H.I.V. Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:2">Do Xenotransplants Pose a Public Health Risk?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:3">Managed Care Has Trouble Treating AIDS, Patients Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:4">Jury to Decide if Man with HIV Misled Insurer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:5">Legislation Would Allow Judges to Order HIV Tests for Suspects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:6">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:7">Innovir Reports Positive Research Results in Anti-Hepatitis B Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:8">Obituary:Jonathan Lax, Leading AIDS Activist</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:9">FDA Approves Rapid Test for Smear-Positive Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:10">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960112"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-226</DOCNO>
<DOCOLDNO>IA017-000178-B006-275</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960119 192.33.214.13 19970106044426 text/html 7551
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:44:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960130"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 19, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:1">Va. Funeral Home Agrees to Stop Charging Extra to Embalm AIDS Victims</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:2">Hepatitis Virus Passed to Hemophiliacs in Clotting Compound, Health Officials Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:3">New Issue Update: Pharmacia  Upjohn Inc.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:4">Scientists Aim to Recreate Immune System in AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:5">Doctors Admit Man Did Not Die of AIDS in 1959</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:6">Issue of Mandatory HIV-Testing Halts Progress on Ryan White Reauthorization</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960119:7">Book Review: &quot;The Second Decade of AIDS&quot;</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:1">New Findings May Speed Trials of AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:2">AIDS Transfer Called &quot;Very Rare&quot; in Sperm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:3">City Clinics Add HIV Test to Routine Prenatal Visits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:4">Peace Corps Volunteer Sues Over Firing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:5">When Victims Need to Know</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:6">Can Animal Organs Help Make Up for the Shortage of Human Donors?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:7">Rural AIDS-HIV Increases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:8">Health Research, Once Facing a Big Budget Cut, Gets a Raise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:9">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:10">Prostitutes Spread AIDS in China</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 17, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:1">Justices Reject Challenge of Patent for AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:2">Doctors Tell of International Resurgence in a Variety of Infectious Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:3">Hemophiliacs Warned About Tainted Plasma</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:4">Top Educator has AIDS But Weighs New Office</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:5">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:6">Highlights</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:7">Meeting Aims to Heal AIDS Split</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:8">Neurex Launches Phase III Program for SNX-111 for...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:9">Baseball, Hotdogs, Apple Pie and HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:10">Biliary Cryptosporidiosis in HIV-infected People After the Waterborne Outbreak of Cryptosporidiosis in Milwaukee</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:1">Needle Attack Muddies Issue of H.I.V. Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:2">Do Xenotransplants Pose a Public Health Risk?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:3">Managed Care Has Trouble Treating AIDS, Patients Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:4">Jury to Decide if Man with HIV Misled Insurer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:5">Legislation Would Allow Judges to Order HIV Tests for Suspects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:6">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:7">Innovir Reports Positive Research Results in Anti-Hepatitis B Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:8">Obituary:Jonathan Lax, Leading AIDS Activist</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:9">FDA Approves Rapid Test for Smear-Positive Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:10">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:1">Zimbabwe AIDS Toll Continues to Rise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:2">SEQUUS Pharmaceuticals Receives Approval for AMPHOCIL in Brazil, Denmark and Singapore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:3">XOMA Corp. Chooses Antifungal Compound Mycoprex for Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:4">Center for Special Immunology Announces CSI Foundation Executive Director</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:5">One-third of Argentine Convicts May Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:6">For a Change, an AIDS Success Story</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:7">Wasting Syndrome:Oral Oxandrolone Re-released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:8">Special Bulletin:  Trials Open to Enrollment.</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960403"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-227</DOCNO>
<DOCOLDNO>IA017-000178-B006-291</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960118 192.33.214.13 19970106044439 text/html 7956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:44:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960129"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 18, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:1">New Findings May Speed Trials of AIDS Drugs</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:2">AIDS Transfer Called &quot;Very Rare&quot; in Sperm</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:3">City Clinics Add HIV Test to Routine Prenatal Visits</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:4">Peace Corps Volunteer Sues Over Firing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:5">When Victims Need to Know</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:6">Can Animal Organs Help Make Up for the Shortage of Human Donors?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:7">Rural AIDS-HIV Increases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:8">Health Research, Once Facing a Big Budget Cut, Gets a Raise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:9">ACTG Clinical Trial Sites: Seven Cut, Two Added</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960118:10">Prostitutes Spread AIDS in China</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 17, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:1">Justices Reject Challenge of Patent for AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:2">Doctors Tell of International Resurgence in a Variety of Infectious Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:3">Hemophiliacs Warned About Tainted Plasma</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:4">Top Educator has AIDS But Weighs New Office</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:5">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:6">Highlights</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:7">Meeting Aims to Heal AIDS Split</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:8">Neurex Launches Phase III Program for SNX-111 for...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:9">Baseball, Hotdogs, Apple Pie and HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:10">Biliary Cryptosporidiosis in HIV-infected People After the Waterborne Outbreak of Cryptosporidiosis in Milwaukee</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:1">Needle Attack Muddies Issue of H.I.V. Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:2">Do Xenotransplants Pose a Public Health Risk?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:3">Managed Care Has Trouble Treating AIDS, Patients Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:4">Jury to Decide if Man with HIV Misled Insurer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:5">Legislation Would Allow Judges to Order HIV Tests for Suspects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:6">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:7">Innovir Reports Positive Research Results in Anti-Hepatitis B Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:8">Obituary:Jonathan Lax, Leading AIDS Activist</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:9">FDA Approves Rapid Test for Smear-Positive Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:10">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:1">Zimbabwe AIDS Toll Continues to Rise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:2">SEQUUS Pharmaceuticals Receives Approval for AMPHOCIL in Brazil, Denmark and Singapore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:3">XOMA Corp. Chooses Antifungal Compound Mycoprex for Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:4">Center for Special Immunology Announces CSI Foundation Executive Director</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:5">One-third of Argentine Convicts May Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:6">For a Change, an AIDS Success Story</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:7">Wasting Syndrome:Oral Oxandrolone Re-released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:8">Special Bulletin:  Trials Open to Enrollment.</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 3, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:1">Lawsuit Seeks to Bar U.S. From Access To AIDS Files</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:2">AIDS Funding Cut by $600,000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:3">Mission Goes Global, Grows Ever Broader</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:4">Funding for AIDS Drugs in the Spotlight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:5">An HIV-Positive Father Tells Children in a Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:6">Hepatitis Strain Rare Among U.S. Blood Donors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:7">HIV Seroprevalence Among Injection Drug Users: No Decline</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:8">Tuberculosis, AIDS, and Death Among Substance Abusers on Welfare  in New York City</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:9">Contraceptives' Role in HIV Transmission Is Examined</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:10">Isolation and Characteristics of Mycobacterium Avium Complex From Water and Soil Samples in Uganda</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960329"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-228</DOCNO>
<DOCOLDNO>IA017-000178-B006-312</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960117 192.33.214.13 19970106044451 text/html 8003
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:45:12 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960126"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 17, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:1">Justices Reject Challenge of Patent for AIDS Drug</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:2">Doctors Tell of International Resurgence in a Variety of Infectious Diseases</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:3">Hemophiliacs Warned About Tainted Plasma</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:4">Top Educator has AIDS But Weighs New Office</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:5">Across the USA: Massachusetts</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:6">Highlights</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:7">Meeting Aims to Heal AIDS Split</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:8">Neurex Launches Phase III Program for SNX-111 for...</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:9">Baseball, Hotdogs, Apple Pie and HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960117:10">Biliary Cryptosporidiosis in HIV-infected People After the Waterborne Outbreak of Cryptosporidiosis in Milwaukee</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:1">Needle Attack Muddies Issue of H.I.V. Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:2">Do Xenotransplants Pose a Public Health Risk?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:3">Managed Care Has Trouble Treating AIDS, Patients Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:4">Jury to Decide if Man with HIV Misled Insurer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:5">Legislation Would Allow Judges to Order HIV Tests for Suspects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:6">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:7">Innovir Reports Positive Research Results in Anti-Hepatitis B Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:8">Obituary:Jonathan Lax, Leading AIDS Activist</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:9">FDA Approves Rapid Test for Smear-Positive Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:10">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:1">Zimbabwe AIDS Toll Continues to Rise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:2">SEQUUS Pharmaceuticals Receives Approval for AMPHOCIL in Brazil, Denmark and Singapore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:3">XOMA Corp. Chooses Antifungal Compound Mycoprex for Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:4">Center for Special Immunology Announces CSI Foundation Executive Director</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:5">One-third of Argentine Convicts May Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:6">For a Change, an AIDS Success Story</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:7">Wasting Syndrome:Oral Oxandrolone Re-released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:8">Special Bulletin:  Trials Open to Enrollment.</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 3, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:1">Lawsuit Seeks to Bar U.S. From Access To AIDS Files</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:2">AIDS Funding Cut by $600,000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:3">Mission Goes Global, Grows Ever Broader</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:4">Funding for AIDS Drugs in the Spotlight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:5">An HIV-Positive Father Tells Children in a Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:6">Hepatitis Strain Rare Among U.S. Blood Donors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:7">HIV Seroprevalence Among Injection Drug Users: No Decline</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:8">Tuberculosis, AIDS, and Death Among Substance Abusers on Welfare  in New York City</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:9">Contraceptives' Role in HIV Transmission Is Examined</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:10">Isolation and Characteristics of Mycobacterium Avium Complex From Water and Soil Samples in Uganda</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:1">Pediatrician May Have Spread TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:2">Cancer Drugs to Get FDA Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:3">Some Blood Cells Resistant to AIDS Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:4">AIDS Community Coping With a Big Cut in Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:5">Physicians Taking A Closer Look at HIV Clearance by Neonates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:6">HIV Subtypes and Disease Transmission: Scientists Taking a Hard Look at the Data</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:7">Japan Haemophiliacs in Out-of-Court Settlement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:8">HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:9">'Shoe Leather Therapy' Is Gaining on TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:10">Drug of Choice</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960327"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-229</DOCNO>
<DOCOLDNO>IA017-000178-B006-324</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960116 192.33.214.13 19970106044501 text/html 7568
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:45:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960125"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 16, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:1">Needle Attack Muddies Issue of H.I.V. Tests</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:2">Do Xenotransplants Pose a Public Health Risk?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:3">Managed Care Has Trouble Treating AIDS, Patients Say</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:4">Jury to Decide if Man with HIV Misled Insurer</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:5">Legislation Would Allow Judges to Order HIV Tests for Suspects</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:6">Across the USA: Indiana</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:7">Innovir Reports Positive Research Results in Anti-Hepatitis B Drug Program</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:8">Obituary:Jonathan Lax, Leading AIDS Activist</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:9">FDA Approves Rapid Test for Smear-Positive Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960116:10">Lymphoma: MGBG New Studies, Compassionate Use in Earlier Disease</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:1">Zimbabwe AIDS Toll Continues to Rise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:2">SEQUUS Pharmaceuticals Receives Approval for AMPHOCIL in Brazil, Denmark and Singapore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:3">XOMA Corp. Chooses Antifungal Compound Mycoprex for Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:4">Center for Special Immunology Announces CSI Foundation Executive Director</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:5">One-third of Argentine Convicts May Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:6">For a Change, an AIDS Success Story</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:7">Wasting Syndrome:Oral Oxandrolone Re-released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:8">Special Bulletin:  Trials Open to Enrollment.</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 3, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:1">Lawsuit Seeks to Bar U.S. From Access To AIDS Files</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:2">AIDS Funding Cut by $600,000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:3">Mission Goes Global, Grows Ever Broader</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:4">Funding for AIDS Drugs in the Spotlight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:5">An HIV-Positive Father Tells Children in a Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:6">Hepatitis Strain Rare Among U.S. Blood Donors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:7">HIV Seroprevalence Among Injection Drug Users: No Decline</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:8">Tuberculosis, AIDS, and Death Among Substance Abusers on Welfare  in New York City</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:9">Contraceptives' Role in HIV Transmission Is Examined</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:10">Isolation and Characteristics of Mycobacterium Avium Complex From Water and Soil Samples in Uganda</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:1">Pediatrician May Have Spread TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:2">Cancer Drugs to Get FDA Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:3">Some Blood Cells Resistant to AIDS Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:4">AIDS Community Coping With a Big Cut in Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:5">Physicians Taking A Closer Look at HIV Clearance by Neonates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:6">HIV Subtypes and Disease Transmission: Scientists Taking a Hard Look at the Data</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:7">Japan Haemophiliacs in Out-of-Court Settlement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:8">HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:9">'Shoe Leather Therapy' Is Gaining on TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:10">Drug of Choice</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:1">Lifeline: AIDS Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:2">New Magic Act Means Handling Diverse Tasks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:3">HHS Awards Supplemental Grants for HIV/AIDS Services</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:4">U.S. Court Throws Out AIDS Privacy Award</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:5">Pneumococcal Conjugate Vaccine Safe, Immunogenic in HIV-Infected Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:6">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:7">South Africa's AIDS Play Provokes Controversy</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960111"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-230</DOCNO>
<DOCOLDNO>IA017-000178-B006-336</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960112 192.33.214.13 19970106044509 text/html 7506
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:45:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960123"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 12, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:1">Zimbabwe AIDS Toll Continues to Rise</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:2">SEQUUS Pharmaceuticals Receives Approval for AMPHOCIL in Brazil, Denmark and Singapore</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:3">XOMA Corp. Chooses Antifungal Compound Mycoprex for Development</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:4">Center for Special Immunology Announces CSI Foundation Executive Director</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:5">One-third of Argentine Convicts May Have HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:6">For a Change, an AIDS Success Story</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:7">Wasting Syndrome:Oral Oxandrolone Re-released in U.S.</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960112:8">Special Bulletin:  Trials Open to Enrollment.</A></TD>
</TR>
</TABLE>
</UL>
<H3>April 3, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:1">Lawsuit Seeks to Bar U.S. From Access To AIDS Files</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:2">AIDS Funding Cut by $600,000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:3">Mission Goes Global, Grows Ever Broader</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:4">Funding for AIDS Drugs in the Spotlight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:5">An HIV-Positive Father Tells Children in a Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:6">Hepatitis Strain Rare Among U.S. Blood Donors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:7">HIV Seroprevalence Among Injection Drug Users: No Decline</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:8">Tuberculosis, AIDS, and Death Among Substance Abusers on Welfare  in New York City</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:9">Contraceptives' Role in HIV Transmission Is Examined</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:10">Isolation and Characteristics of Mycobacterium Avium Complex From Water and Soil Samples in Uganda</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:1">Pediatrician May Have Spread TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:2">Cancer Drugs to Get FDA Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:3">Some Blood Cells Resistant to AIDS Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:4">AIDS Community Coping With a Big Cut in Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:5">Physicians Taking A Closer Look at HIV Clearance by Neonates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:6">HIV Subtypes and Disease Transmission: Scientists Taking a Hard Look at the Data</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:7">Japan Haemophiliacs in Out-of-Court Settlement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:8">HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:9">'Shoe Leather Therapy' Is Gaining on TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:10">Drug of Choice</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:1">Lifeline: AIDS Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:2">New Magic Act Means Handling Diverse Tasks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:3">HHS Awards Supplemental Grants for HIV/AIDS Services</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:4">U.S. Court Throws Out AIDS Privacy Award</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:5">Pneumococcal Conjugate Vaccine Safe, Immunogenic in HIV-Infected Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:6">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:7">South Africa's AIDS Play Provokes Controversy</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:1">Three Black Members Quit the Board of AIDS Agency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:2">New Firm Plans to Design Vaccine for Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:3">Weak Earnings Outlook Contributes to Dow's 67-Point Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:4">AIDS and Advertising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:5">Two-Drug Therapy Works in AIDS-Related Eye Ailment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:6">Chiron Corp.: Herpes Agent Clinical Trial Proves to Be Disappointing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:7">Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:8">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:9">HIV Levels May Predict Mother-to-Child</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960110"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-231</DOCNO>
<DOCOLDNO>IA017-000178-B006-349</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960403 192.33.214.13 19970106044519 text/html 7840
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:45:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960119"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>April 3, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:1">Lawsuit Seeks to Bar U.S. From Access To AIDS Files</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:2">AIDS Funding Cut by $600,000</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:3">Mission Goes Global, Grows Ever Broader</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:4">Funding for AIDS Drugs in the Spotlight</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:5">An HIV-Positive Father Tells Children in a Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:6">Hepatitis Strain Rare Among U.S. Blood Donors</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:7">HIV Seroprevalence Among Injection Drug Users: No Decline</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:8">Tuberculosis, AIDS, and Death Among Substance Abusers on Welfare  in New York City</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:9">Contraceptives' Role in HIV Transmission Is Examined</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960403:10">Isolation and Characteristics of Mycobacterium Avium Complex From Water and Soil Samples in Uganda</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:1">Pediatrician May Have Spread TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:2">Cancer Drugs to Get FDA Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:3">Some Blood Cells Resistant to AIDS Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:4">AIDS Community Coping With a Big Cut in Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:5">Physicians Taking A Closer Look at HIV Clearance by Neonates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:6">HIV Subtypes and Disease Transmission: Scientists Taking a Hard Look at the Data</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:7">Japan Haemophiliacs in Out-of-Court Settlement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:8">HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:9">'Shoe Leather Therapy' Is Gaining on TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:10">Drug of Choice</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:1">Lifeline: AIDS Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:2">New Magic Act Means Handling Diverse Tasks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:3">HHS Awards Supplemental Grants for HIV/AIDS Services</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:4">U.S. Court Throws Out AIDS Privacy Award</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:5">Pneumococcal Conjugate Vaccine Safe, Immunogenic in HIV-Infected Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:6">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:7">South Africa's AIDS Play Provokes Controversy</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:1">Three Black Members Quit the Board of AIDS Agency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:2">New Firm Plans to Design Vaccine for Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:3">Weak Earnings Outlook Contributes to Dow's 67-Point Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:4">AIDS and Advertising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:5">Two-Drug Therapy Works in AIDS-Related Eye Ailment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:6">Chiron Corp.: Herpes Agent Clinical Trial Proves to Be Disappointing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:7">Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:8">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:9">HIV Levels May Predict Mother-to-Child</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 10, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:1">Court Orders Firm to Pay Damages in Patent Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:2">In the Loop: GOP Wants $75 Million to Counsel Teens on Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:3">Nourishing the Body and Soul</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:4">Procept Initiates New Phase I/II Clinical Trial for PRO 2000 in HIV-Positive Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:5">Skating Community Hit Hard by AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:6">Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure to HIV-Infected Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:7">To Treat or Not to Treat--Approaches to Antiviral Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:8">Health-Illness Beliefs and Practices of Haitians with HIV Disease Living in Boston</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:9">Pro-Con: Should AIDS Tests Be Mandatory for Pregnant Women?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:10">Banned in the U.S.A.</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960109"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-232</DOCNO>
<DOCOLDNO>IA017-000178-B006-363</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960329 192.33.214.13 19970106044528 text/html 7738
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:45:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960118"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 29, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:1">Pediatrician May Have Spread TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:2">Cancer Drugs to Get FDA Review</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:3">Some Blood Cells Resistant to AIDS Virus</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:4">AIDS Community Coping With a Big Cut in Funding</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:5">Physicians Taking A Closer Look at HIV Clearance by Neonates</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:6">HIV Subtypes and Disease Transmission: Scientists Taking a Hard Look at the Data</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:7">Japan Haemophiliacs in Out-of-Court Settlement</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:8">HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:9">'Shoe Leather Therapy' Is Gaining on TB</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960329:10">Drug of Choice</A></TD>
</TR>
</TABLE>
</UL>
<H3>March 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:1">Lifeline: AIDS Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:2">New Magic Act Means Handling Diverse Tasks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:3">HHS Awards Supplemental Grants for HIV/AIDS Services</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:4">U.S. Court Throws Out AIDS Privacy Award</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:5">Pneumococcal Conjugate Vaccine Safe, Immunogenic in HIV-Infected Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:6">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:7">South Africa's AIDS Play Provokes Controversy</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:1">Three Black Members Quit the Board of AIDS Agency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:2">New Firm Plans to Design Vaccine for Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:3">Weak Earnings Outlook Contributes to Dow's 67-Point Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:4">AIDS and Advertising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:5">Two-Drug Therapy Works in AIDS-Related Eye Ailment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:6">Chiron Corp.: Herpes Agent Clinical Trial Proves to Be Disappointing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:7">Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:8">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:9">HIV Levels May Predict Mother-to-Child</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 10, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:1">Court Orders Firm to Pay Damages in Patent Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:2">In the Loop: GOP Wants $75 Million to Counsel Teens on Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:3">Nourishing the Body and Soul</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:4">Procept Initiates New Phase I/II Clinical Trial for PRO 2000 in HIV-Positive Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:5">Skating Community Hit Hard by AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:6">Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure to HIV-Infected Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:7">To Treat or Not to Treat--Approaches to Antiviral Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:8">Health-Illness Beliefs and Practices of Haitians with HIV Disease Living in Boston</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:9">Pro-Con: Should AIDS Tests Be Mandatory for Pregnant Women?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:10">Banned in the U.S.A.</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:11">SPECIAL BULLETIN</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960105"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-233</DOCNO>
<DOCOLDNO>IA017-000178-B006-377</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960327 192.33.214.13 19970106044538 text/html 7579
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960117"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>March 27, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:1">Lifeline: AIDS Survey</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:2">New Magic Act Means Handling Diverse Tasks</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:3">HHS Awards Supplemental Grants for HIV/AIDS Services</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:4">U.S. Court Throws Out AIDS Privacy Award</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:5">Pneumococcal Conjugate Vaccine Safe, Immunogenic in HIV-Infected Children</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:6">Curcumin: Clinical Trial Finds No Antiviral Effect</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960327:7">South Africa's AIDS Play Provokes Controversy</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:1">Three Black Members Quit the Board of AIDS Agency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:2">New Firm Plans to Design Vaccine for Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:3">Weak Earnings Outlook Contributes to Dow's 67-Point Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:4">AIDS and Advertising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:5">Two-Drug Therapy Works in AIDS-Related Eye Ailment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:6">Chiron Corp.: Herpes Agent Clinical Trial Proves to Be Disappointing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:7">Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:8">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:9">HIV Levels May Predict Mother-to-Child</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 10, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:1">Court Orders Firm to Pay Damages in Patent Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:2">In the Loop: GOP Wants $75 Million to Counsel Teens on Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:3">Nourishing the Body and Soul</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:4">Procept Initiates New Phase I/II Clinical Trial for PRO 2000 in HIV-Positive Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:5">Skating Community Hit Hard by AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:6">Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure to HIV-Infected Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:7">To Treat or Not to Treat--Approaches to Antiviral Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:8">Health-Illness Beliefs and Practices of Haitians with HIV Disease Living in Boston</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:9">Pro-Con: Should AIDS Tests Be Mandatory for Pregnant Women?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:10">Banned in the U.S.A.</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:11">SPECIAL BULLETIN</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960104"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-234</DOCNO>
<DOCOLDNO>IA017-000178-B006-388</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960111 192.33.214.13 19970106044547 text/html 8000
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960116"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 11, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:1">Three Black Members Quit the Board of AIDS Agency</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:2">New Firm Plans to Design Vaccine for Tuberculosis</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:3">Weak Earnings Outlook Contributes to Dow's 67-Point Loss</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:4">AIDS and Advertising</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:5">Two-Drug Therapy Works in AIDS-Related Eye Ailment</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:6">Chiron Corp.: Herpes Agent Clinical Trial Proves to Be Disappointing</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:7">Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:8">Major Protease Inhibitor Triple Combination Trial Begins Soon: CD4 Under 200, AZT Experienced, 3TC Naive</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960111:9">HIV Levels May Predict Mother-to-Child</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 10, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:1">Court Orders Firm to Pay Damages in Patent Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:2">In the Loop: GOP Wants $75 Million to Counsel Teens on Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:3">Nourishing the Body and Soul</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:4">Procept Initiates New Phase I/II Clinical Trial for PRO 2000 in HIV-Positive Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:5">Skating Community Hit Hard by AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:6">Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure to HIV-Infected Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:7">To Treat or Not to Treat--Approaches to Antiviral Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:8">Health-Illness Beliefs and Practices of Haitians with HIV Disease Living in Boston</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:9">Pro-Con: Should AIDS Tests Be Mandatory for Pregnant Women?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:10">Banned in the U.S.A.</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:11">SPECIAL BULLETIN</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:1">Transplant Patient Going Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:2">Judge Throws Out Lawsuit Alleging Fraud by Coram</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:3">City's Free Female Condoms Popular, Appearance Aside</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:4">Hospice Program to Serve Homeless Man with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:5">'Positive' in the Face of Living with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:6">The Safe Thalidomide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:7">'Gross Underestimation' of Occupational HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:8">HIV in the Over-50s in South London</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:9">Healthcare Needs of HIV-Infected Persons in Hospital, Outpatient, Home, and Long-Term Care Settings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:10">Predictions: New Drugs in the War on AIDS</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="SUMM-96.cgi?+960102"><IMG BORDER=0 SRC="/gif/down.gif"></A></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-235</DOCNO>
<DOCOLDNO>IA017-000178-B006-400</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960110 192.33.214.13 19970106044557 text/html 7949
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960112"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 10, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:1">Court Orders Firm to Pay Damages in Patent Case</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:2">In the Loop: GOP Wants $75 Million to Counsel Teens on Sex</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:3">Nourishing the Body and Soul</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:4">Procept Initiates New Phase I/II Clinical Trial for PRO 2000 in HIV-Positive Patients</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:5">Skating Community Hit Hard by AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:6">Case-Control Study of HIV Seroconversion in Health Care Workers After Percutaneous Exposure to HIV-Infected Blood</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:7">To Treat or Not to Treat--Approaches to Antiviral Therapy</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:8">Health-Illness Beliefs and Practices of Haitians with HIV Disease Living in Boston</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:9">Pro-Con: Should AIDS Tests Be Mandatory for Pregnant Women?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960110:10">Banned in the U.S.A.</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:11">SPECIAL BULLETIN</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:1">Transplant Patient Going Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:2">Judge Throws Out Lawsuit Alleging Fraud by Coram</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:3">City's Free Female Condoms Popular, Appearance Aside</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:4">Hospice Program to Serve Homeless Man with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:5">'Positive' in the Face of Living with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:6">The Safe Thalidomide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:7">'Gross Underestimation' of Occupational HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:8">HIV in the Over-50s in South London</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:9">Healthcare Needs of HIV-Infected Persons in Hospital, Outpatient, Home, and Long-Term Care Settings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:10">Predictions: New Drugs in the War on AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:1">Kenya's Moi Bans Sex-Education Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:2">Blood Banks Starting to Harvest Umbilical Cords</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:3">Widow of Arthur Ashe Raises Objection to Site for Monument</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:4">Touched by Royalty</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:5">Beyond the Beltway 1995: What's My Line?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:6">Appointments: The National AIDS Fund of Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:7">Is Kaposi's-Sarcoma-Associated Herpesvirus Detectable in Semen of HIV-Infected Homosexual Men?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:8">AIDS Tumor Bank</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:9">Crystal Structure of SIV Matrix Antigen and Implications for Virus Assembly</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:10">Clinton Holds First AIDS Summit</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-236</DOCNO>
<DOCOLDNO>IA017-000178-B006-411</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960109 192.33.214.13 19970106044606 text/html 6362
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960403"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>11.</TD>
 <TD><A HREF="SUMM-96.cgi?960109:11">SPECIAL BULLETIN</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:1">Transplant Patient Going Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:2">Judge Throws Out Lawsuit Alleging Fraud by Coram</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:3">City's Free Female Condoms Popular, Appearance Aside</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:4">Hospice Program to Serve Homeless Man with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:5">'Positive' in the Face of Living with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:6">The Safe Thalidomide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:7">'Gross Underestimation' of Occupational HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:8">HIV in the Over-50s in South London</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:9">Healthcare Needs of HIV-Infected Persons in Hospital, Outpatient, Home, and Long-Term Care Settings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:10">Predictions: New Drugs in the War on AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:1">Kenya's Moi Bans Sex-Education Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:2">Blood Banks Starting to Harvest Umbilical Cords</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:3">Widow of Arthur Ashe Raises Objection to Site for Monument</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:4">Touched by Royalty</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:5">Beyond the Beltway 1995: What's My Line?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:6">Appointments: The National AIDS Fund of Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:7">Is Kaposi's-Sarcoma-Associated Herpesvirus Detectable in Semen of HIV-Infected Homosexual Men?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:8">AIDS Tumor Bank</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:9">Crystal Structure of SIV Matrix Antigen and Implications for Virus Assembly</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:10">Clinton Holds First AIDS Summit</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-237</DOCNO>
<DOCOLDNO>IA017-000178-B006-424</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960105 192.33.214.13 19970106044619 text/html 4925
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:41 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960329"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 5, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:1">Patient With Baboon Marrow Goes Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:2">Work Stops at Labs and Waste Sites</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:3">Budget Talks Mired in Politics</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:4">News Summary: HIV Hope</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:5">AIDS stamp to be issued in May</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:6">Highlights: Dateline NBC</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:7">First 500,000 AIDS Cases--United States, 1995</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:8">U.N. Promotes Social Change to Fight AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:9">AIDS Update: Sharing Cells</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960105:10">A Year of Transformation in HIV/AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:1">Transplant Patient Going Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:2">Judge Throws Out Lawsuit Alleging Fraud by Coram</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:3">City's Free Female Condoms Popular, Appearance Aside</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:4">Hospice Program to Serve Homeless Man with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:5">'Positive' in the Face of Living with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:6">The Safe Thalidomide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:7">'Gross Underestimation' of Occupational HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:8">HIV in the Over-50s in South London</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:9">Healthcare Needs of HIV-Infected Persons in Hospital, Outpatient, Home, and Long-Term Care Settings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:10">Predictions: New Drugs in the War on AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:1">Kenya's Moi Bans Sex-Education Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:2">Blood Banks Starting to Harvest Umbilical Cords</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:3">Widow of Arthur Ashe Raises Objection to Site for Monument</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:4">Touched by Royalty</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:5">Beyond the Beltway 1995: What's My Line?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:6">Appointments: The National AIDS Fund of Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:7">Is Kaposi's-Sarcoma-Associated Herpesvirus Detectable in Semen of HIV-Infected Homosexual Men?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:8">AIDS Tumor Bank</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:9">Crystal Structure of SIV Matrix Antigen and Implications for Virus Assembly</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:10">Clinton Holds First AIDS Summit</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-238</DOCNO>
<DOCOLDNO>IA017-000178-B007-10</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960104 192.33.214.13 19970106044642 text/html 3598
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:46:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960327"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 4, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:1">Transplant Patient Going Home</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:2">Judge Throws Out Lawsuit Alleging Fraud by Coram</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:3">City's Free Female Condoms Popular, Appearance Aside</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:4">Hospice Program to Serve Homeless Man with AIDS</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:5">'Positive' in the Face of Living with HIV</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:6">The Safe Thalidomide</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:7">'Gross Underestimation' of Occupational HIV Infection</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:8">HIV in the Over-50s in South London</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:9">Healthcare Needs of HIV-Infected Persons in Hospital, Outpatient, Home, and Long-Term Care Settings</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960104:10">Predictions: New Drugs in the War on AIDS</A></TD>
</TR>
</TABLE>
</UL>
<H3>January 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:1">Kenya's Moi Bans Sex-Education Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:2">Blood Banks Starting to Harvest Umbilical Cords</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:3">Widow of Arthur Ashe Raises Objection to Site for Monument</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:4">Touched by Royalty</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:5">Beyond the Beltway 1995: What's My Line?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:6">Appointments: The National AIDS Fund of Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:7">Is Kaposi's-Sarcoma-Associated Herpesvirus Detectable in Semen of HIV-Infected Homosexual Men?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:8">AIDS Tumor Bank</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:9">Crystal Structure of SIV Matrix Antigen and Implications for Virus Assembly</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:10">Clinton Holds First AIDS Summit</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-239</DOCNO>
<DOCOLDNO>IA017-000178-B007-27</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?+960102 192.33.214.13 19970106044700 text/html 2130
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:47:21 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - Summary</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="/e/biblio"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>AIDS Daily Summary - <A HREF="SUMM-96.cgi?+tdm">Summary</A><BR CLEAR><HR></H2><TABLE BORDER=0 CELLPADDING=5>
<TR>
<TD VALIGN=top><A HREF="SUMM-96.cgi?+960111"><IMG BORDER=0 SRC="/gif/up.gif"></A></TD>
<TD ROWSPAN=2>
<H3>January 2, 1996</H3>
<UL>
<TABLE BORDER=0 WIDTH=85%>
<TR ALIGN=left VALIGN=top>
 <TD WIDTH=2%>1.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:1">Kenya's Moi Bans Sex-Education Book</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>2.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:2">Blood Banks Starting to Harvest Umbilical Cords</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>3.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:3">Widow of Arthur Ashe Raises Objection to Site for Monument</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>4.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:4">Touched by Royalty</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>5.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:5">Beyond the Beltway 1995: What's My Line?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>6.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:6">Appointments: The National AIDS Fund of Washington</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>7.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:7">Is Kaposi's-Sarcoma-Associated Herpesvirus Detectable in Semen of HIV-Infected Homosexual Men?</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>8.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:8">AIDS Tumor Bank</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>9.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:9">Crystal Structure of SIV Matrix Antigen and Implications for Virus Assembly</A></TD>
</TR>
<TR ALIGN=left VALIGN=top>
 <TD>10.</TD>
 <TD><A HREF="SUMM-96.cgi?960102:10">Clinton Holds First AIDS Summit</A></TD>
</TR>
</TABLE>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TR>
</TABLE>
</UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-240</DOCNO>
<DOCOLDNO>IA017-000178-B007-35</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:1 192.33.214.13 19970106044708 text/html 1212
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:47:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960402:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Across the USA: Illinois</H3>
<EM>USA Today (04/01/96) P. 12A</EM>
<P>
Florence Schieben, 75, received HIV-infected blood during
1994 hip replacement surgery and is now suing Heartland Blood
Centers.  The Aurora, Ill., blood bank has rejected her claim
that the blood was not tested correctly.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960402:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-241</DOCNO>
<DOCOLDNO>IA017-000178-B007-48</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:2 192.33.214.13 19970106044718 text/html 1773
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:47:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>2nd-Grader Stabs 5 Others with Found Medical Tools</H3>
<EM>Washington Post (03/30/96) P. H3;  Kyriakos, Marianne</EM>
<P>
A second-grader at Stanton Elementary School in Washington,
D.C., discovered a dozen lancets, needlelike medical devices, in
a field near the school and used them to stab five classmates.
Some parents are concerned that their children may have been
infected with HIV as a result.  Lancets, which are not hollow and
are not used to inject drugs, are used to prick fingers and ear
lobes when blood is drawn.  &quot;We know that in the transmission of
HIV, hollow needles are much more likely to transmit the virus
than solid needles,&quot; said Peter Hawley, medical director for the
Whitman-Walker Clinic, the area's largest AIDS clinic.  The
school's principal said several students involved in the incident
have been tested for HIV.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-242</DOCNO>
<DOCOLDNO>IA017-000178-B007-61</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:3 192.33.214.13 19970106044725 text/html 1532
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:47:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Unwelcome Donations</H3>
<EM>Washington Post (03/30/96) P. A15;  Davey, Richard J.</EM>
<P>
In a Washington Post letter to the editor, Richard J. Davey,
chief medical officer at the American Red Cross, takes issue with
a Washington Post article that suggested that some men donate
blood as a way of getting tested for HIV.  Davey objects to the
article, saying it may have unnecessarily scared people who
receive blood transfusions.  He argues that the Red Cross opposes
the practice of donating blood for the purpose of getting an HIV
test, a practice which he says could jeopardize the safety of the
blood supply.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-243</DOCNO>
<DOCOLDNO>IA017-000178-B007-75</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:4 192.33.214.13 19970106044737 text/html 1585
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:47:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Virus Research Drawing International Attention</H3>
<EM>Xinhua News Service (03/29/96)</EM>
<P>
The Harbin Veterinary Institute of the Chinese Academy of
Agricultural Science, which has gained recognition for developing
a cure for horse infectious anemia, has now attracted global
attention because of similarities between the horse virus and
HIV.  The institute developed the vaccine for the horse virus in
1982, and it remains the only vaccine to prevent the disease.
The virus is similar to HIV in its mechanism and mutability.
Researchers from Japan and the United States are seeking to
cooperate with the Chinese scientists on research to compare the
two viruses.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-244</DOCNO>
<DOCOLDNO>IA017-000178-B007-86</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:5 192.33.214.13 19970106044748 text/html 1751
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:48:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Cognitive Impairment Linked to Early Death in HIV-Infected Patients</H3>
<EM>Reuters (03/29/96)</EM>
<P>
New research shows that cognitive impairment is an
independent risk factor for early death from AIDS.  Ronald Ellis
and colleagues at the HNRC Group in San Diego reported the
results of a study of 414 HIV-positive patients.  During the
seven-year study, 106 patients died.  Risk of death was 1.2 times
greater in the globally impaired group, and 3.9 times higher in
those who were found to have cognitive-motor disorder.  In a
related study, N.C. Sacktor and colleagues in Baltimore and Los
Angeles found that a decline in psychomotor performance in HIV
patients predicted the onset of dementia, but not AIDS or death.
In another study, the incidence of multifocal leukoencephalopathy
in AIDS patients was found to be increasing.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-245</DOCNO>
<DOCOLDNO>IA017-000178-B007-100</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:6 192.33.214.13 19970106044759 text/html 1829
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:48:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>No Benefits Seen in AIDS Patients After Fish Oil Supplementation</H3>
<EM>Reuters (03/29/96)</EM>
<P>
Taking dietary supplements of fish oil for management of
advanced AIDS-related weight loss does not seem to have any
beneficial clinical effects, new research suggests.  Previous
studies in normal patients indicated that the supplements reduced
the production of interleukin-1 and tumor necrosis factor by
peripheral blood mononuclear cells.  Research also showed that
the supplements prevented interleukin-1 and tumor necrosis
anorexia in animals.  Marc K. Hellerstein and colleagues at the
University of California at San Francisco followed 20 patients
with weight loss associated with advanced HIV infection.  The
patients' body weight, percent fat, and fat-free mass stayed the
same.  Hellerstein concluded that fish oil cannot overcome
AIDS-related wasting, but may have an effect in stable AIDS
patients.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-246</DOCNO>
<DOCOLDNO>IA017-000178-B007-108</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:7 192.33.214.13 19970106044812 text/html 1475
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:48:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>EU Wants Back Money Sank into S. African AIDS Play</H3>
<EM>Reuters (03/29/96)</EM>
<P>
The European Union (EU) said on Friday that it wants the
South African health ministry to return $3.5 million it wrongly
used to fund a lavish but controversial AIDS awareness musical.
Erwan Fouere, the EU envoy to South Africa, said the money was
not authorized for the production of &quot;Sarafina 2.&quot;  Furthermore,
the EU said the ministry had used too much money for the play and
the health ministry did not follow normal procedures before
allocating the money.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-247</DOCNO>
<DOCOLDNO>IA017-000178-B007-121</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:8 192.33.214.13 19970106044824 text/html 2337
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:48:46 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>The Trials of a Home HIV Test</H3>
<EM>Business Week (03/18/96) No. 3467, P. 56;  Freundlich, Naomi; Hamilton, Joan O'C.</EM>
<P>
The first home test for HIV was developed by Elliot
Millenson in 1985, but faced opposition from AIDS activists and
the American Medical Association, and was refused for
consideration by the Food and Drug Administration (FDA) in 1987.
Now the test, which Millenson sold to Johnson &amp; Johnson in 1993,
has been submitted to the FDA and could be approved within three
months.  If approved, the test would be sold without prescription
for less than $50.  Users would mail a blood sample to a lab for
analysis.  Test results and counseling would be available over
the phone.  The change in attitude has come in part from lobbying
by J&amp;J, dissatisfaction with current testing, and the belief that
home tests will help curb HIV infection.  The FDA reviewed the
home test in 1990; however, it did not approve it, citing the
lack of face-to-face counseling.  After buying the test from
Millenson, J&amp;J launched an aggressive public relations campaign,
which was boosted by evidence that 42 percent of people at risk
for HIV would use a home test.  Some claimed that J&amp;J paid travel
expenses for doctors and AIDS activists to attend a FDA meeting
at which they supported the test; however, an investigation found
no wrongdoing, though questions about the company's methods were
raised.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960401:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-248</DOCNO>
<DOCOLDNO>IA017-000178-B007-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960401:9 192.33.214.13 19970106044842 text/html 1968
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:48:55 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - April 1, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960401"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - April 1, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Case for Behavioral Studies for AIDS Prevention</H3>
<EM>Lancet (03/16/96) Vol. 347, No. 9002, P. 750;  Rowe, Paul M.</EM>
<P>
Studies indicate that cutting rates of risky sexual behavior
in half could stop the AIDS epidemic, Thomas J. Coates, director
of the Center for AIDS Prevention Studies at the University of
California, San Francisco said in a lecture at the National
Institutes of Health.  Coates cited research that shows that
behavioral interventions can achieve such reductions.  For
example, when condom-use rules were implemented at gay sex clubs
in San Francisco, rates of unprotected sex dropped to almost
zero.  In India and Thailand, programs to educate prostitutes to
negotiate condom use led to sharp decreases in rates of venereal
disease.  Behavioral studies help explain risky sexual practices,
while scientific studies are needed to influence public policy.
Coates acknowledged that political barriers thwart research on
sexual behaviors, but noted that &quot;we're talking about things we
didn't talk about 15 years ago.&quot;
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-249</DOCNO>
<DOCOLDNO>IA017-000178-B007-146</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:1 192.33.214.13 19970106044907 text/html 1180
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:49:29 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Across the USA: Tennessee</H3>
<EM>USA Today (03/28/96) P. 11A</EM>
<P>
Tennessee's health care program Tenn-Care will cover
protease inhibitors, new AIDS drugs that experts say are
particularly promising.  Tenn-Care covers about 2,000
HIV-infected individuals.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960401:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-250</DOCNO>
<DOCOLDNO>IA017-000178-B007-151</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:2 192.33.214.13 19970106044916 text/html 1231
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:49:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Across the USA: Massachusetts</H3>
<EM>USA Today (03/28/96) P. 11A</EM>
<P>
AIDS-related deaths in Massachusetts increased 21 percent
from 1993 to 1994, and doubled from 1990 to 1994, according to a
new report.  The 1994 total was 938.  AIDS was the leading cause
of death among Hispanics in the state that year.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-251</DOCNO>
<DOCOLDNO>IA017-000178-B007-163</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:3 192.33.214.13 19970106044926 text/html 1607
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:49:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Health-Insurance Measure Is Running Into Problems</H3>
<EM>Wall Street Journal (03/28/96) P. A4</EM>
<P>
The chances of a health-insurance reform bill, aiming to
restrict insurance companies' ability to refuse coverage to
people with pre-existing conditions and guarantee continued
coverage to those who lose or change jobs, may be complicated by
amendments from Senate Republicans.  The bill's sponsors, Sens.
Nancy Kassebaum (R-Kan.) and Edward Kennedy (D-Mass.), urged
lawmakers not to amend the legislation.  Amendments may be
proposed to raise the health-insurance tax deduction for the
self-employed and to add provisions for medical savings accounts
and medical-malpractice awards.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-252</DOCNO>
<DOCOLDNO>IA017-000178-B007-179</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:4 192.33.214.13 19970106044938 text/html 1568
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Zimbabwe's AIDS Orphans to Reach 600,000 by 2000</H3>
<EM>Xinhua News Service (03/28/96)</EM>
<P>
Zimbabwe will have more than 600,000 orphans due to AIDS by
the year 2000, Margaret Mehlomakulu, deputy director of the
National AIDS Coordinating Program, said at a workshop Wednesday.
She said that AIDS would be a heavy burden on the government and
the community as they would be forced to stretch available
resources to take care of the orphans.  Mehlomakulu called for
health officials to work with the community to help prevent young
people from becoming HIV-infected.  An estimated 1 million
Zimbabweans, of a total 10.5 million, have the virus.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-253</DOCNO>
<DOCOLDNO>IA017-000178-B007-193</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:5 192.33.214.13 19970106044946 text/html 1871
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Death Rates High Among New York Welfare Recipients--Study</H3>
<EM>Reuters (03/27/96)</EM>
<P>
Rates of AIDS, tuberculosis (TB), and death are much higher
among New York City welfare recipients and applicants who have
been abusing alcohol, drugs, or both, an eight-year survey has
found.  The research, led by Lloyd Friedman of the Yale
University School of Medicine, found that between 1984 and 1992,
5.5 percent of the 858 people studied developed TB, 10 percent
had AIDS, and 21 percent died.  All 858 had a history of abusing
drugs, alcohol, or both.  The TB rate for these individuals, the
majority of whom are single black men, is nearly 15 times the
usual rate in New York City, while the AIDS rate is 10 times the
average, and the death rate is five times the usual.
Ninety-three percent of the participants agreed to undergo a
two-part medical exam, which the researchers hoped would result
in treatment for people at high risk for AIDS or TB.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-254</DOCNO>
<DOCOLDNO>IA017-000178-B007-201</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:6 192.33.214.13 19970106044954 text/html 1636
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Influenza Immunization in HIV-Positive Children Does Not Enhance HIV Replication</H3>
<EM>Reuters (03/27/96)</EM>
<P>
Although some researchers have suggested that influenza
vaccination may activate T-cells and enhance HIV replication, new
research has revealed only short-term increases in viral load in
children following immunization.  Octavio Ramillo and colleagues
at the University of Texas Southwestern Medical Center in Dallas
saw the increased HIV RNA in five of 16 children, and said the
viral load returned to baseline in four of those five children
within eight weeks.  The findings add to the evidence that the
viral burden increases after immunization more often in
HIV-positive adults than in children.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-255</DOCNO>
<DOCOLDNO>IA017-000178-B007-211</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:7 192.33.214.13 19970106045002 text/html 1672
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Zimbabwe's Maternal Mortality Deaths Rising</H3>
<EM>PANA News Service (03/27/96)</EM>
<P>
The incidence of maternal mortality has increased in
Zimbabwe as the number of HIV-infected pregnant women has risen,
a local gynecologist reported Wednesday.  Kudakwashe Kangwende
said the infant mortality rate has been made worse by pre-natal
mortality associated with HIV infection and AIDS among pregnant
women.  Kangwende said that frequent and unwarranted pregnancies
among women with AIDS contribute to the increasing maternal
mortality rate, and suggested that women with AIDS should be
allowed to have abortions.  He also said the AIDS pandemic was
causing the spread of other diseases uncommon in Zimbabwe,
including genital herpes and cervical cancer.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-256</DOCNO>
<DOCOLDNO>IA017-000178-B007-223</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:8 192.33.214.13 19970106045014 text/html 2420
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:33 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Physicians' Experience with the Acquired Immunodeficiency Syndrome as a Factor in Patients' Survival</H3>
<EM>New England Journal of Medicine (03/14/96) Vol. 334, No. 11, P. 701;  Kitahata, Mari M.;  Koepsell, Thomas D.;  Deyo, Richard A.; et al.</EM>
<P>
Mari Kitahata and colleagues examined the link between
physicians' experience with AIDS and the survival of their AIDS
patients.  They studied the cases of 403 men enrolled in a health
maintenance organization who were diagnosed with AIDS between
1984 and mid-1994.  The patients' 125 primary care physicians
were separated into three levels of AIDS experience, based on
experience with AIDS during residency training and the cumulative
number of patients with AIDS they had treated in practice.  The
authors concluded that patients cared for by doctors with the
most experience had a 31 percent lower risk of death than
patients cared for by physicians with the least experience.
Among the 224 patients diagnosed with AIDS between 1989 and 1994,
the risk of death was 43 percent lower for patients of the most
experienced doctors than for patients of the least experienced.
The study suggests that physicians who treat AIDS patients go
through a similar learning period and begin to improve their
management skills early in their experience.  The authors found
that certain methods of treatment and a tendency to follow
HIV-infected patients more closely were associated with higher
levels of physicians' experience and longer patient survival.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-257</DOCNO>
<DOCOLDNO>IA017-000178-B007-236</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:9 192.33.214.13 19970106045024 text/html 2472
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Rogue Science or Reality?</H3>
<EM>Insight (03/11/96) Vol. 12, No. 10, P. 16;  Goode, Stephen</EM>
<P>
Peter Duesberg, biology professor at the University of
California at Berkeley, member of the National Academy of
Sciences, and federal grant recipient, is criticized by many
scientists because he opposes the accepted belief that HIV causes
AIDS.  Duesberg's book &quot;Inventing the AIDS Virus&quot; outlines his
arguments and challenges his colleagues to answer them.  He says
the HIV-AIDS theory was announced hastily by federal health
officials in 1984 because groups like the National Institutes of
Health were under intense pressure to come up with an answer to
the growing AIDS epidemic.  No one questioned the connection
later, he says, because billions in federal funding was being
spent on confirming it.  Furthermore, Duesberg criticizes AIDS
researchers for abandoning long-held principles about viruses.
In other viral infections, antibodies are a sign of the body's
defense, but with HIV, antibodies are looked at as a sign that
the virus is still potent.  AIDS researcher Robert Gallo has said
that because AIDS was completely new, redefining the rules was
necessary.  Other researchers argue that HIV's ability to mutate
rapidly makes it a special case.  Duesberg says that lifestyle
factors--including drug use, repeated cases of sexually
transmitted diseases, and malnutrition--are to blame for AIDS.
Duesberg is not alone in his beliefs--the 100-member Group for
the Scientific Reappraisal of the HIV-AIDS Hypothesis supports
him.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960328:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-258</DOCNO>
<DOCOLDNO>IA017-000178-B007-251</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960328:10 192.33.214.13 19970106045035 text/html 1990
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:50:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 28, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960328"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 28, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Principals in HIV Blood Scandal Should be Summoned by Diet</H3>
<EM>Nikkei Weekly (03/11/96) Vol. 34, No. 1713, P. 6</EM>
<P>
In an editorial in the Nikkei Weekly, the authors note the
Diet's lack of involvement in Japan's tainted blood scandal,
which caused some 1,800 Japanese hemophiliacs to be infected with
HIV.  An investigation by the Ministry of Health and Welfare
revealed that contaminated blood products were distributed even
though members of government and industry knew of the HIV threat.
However, the investigation's interim report fails to answer
whether or not the ministry proposed emergency imports of safe,
heat-treated blood products.  The editors question the actions of
Takeshi Abe, who headed the AIDS task force, as well as those of
his associate, Mutsumi Kazama, and the pharmaceutical companies
who continued to ship the untreated products even after the
threat of contamination was known.  The editors claim that the
ministry investigation is not likely to provide satisfactory
answers and that the participants should testify before the Diet.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-259</DOCNO>
<DOCOLDNO>IA017-000178-B007-264</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:1 192.33.214.13 19970106045044 text/html 1546
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:51:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>S. Africa Insurer Offers Cover for HIV Infection</H3>
<EM>Financial Times (03/26/96) P. 4;  Ashurst, Mark</EM>
<P>
In South Africa, Metropolitan Life has offered the world's
first commercial life insurance policy for people with HIV.  At
least 1.5 million South Africans have the virus, though 80 percent
have not developed AIDS.  Industry observers note that the plateau
of HIV infection in developed countries could deter insurers in the
west from developing similar policies.  MetLife's coverage is
limited to people aged 15 to 55 who are in the asymptomatic
stages of HIV infection.  The maximum death benefit is $12,800.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960328:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-260</DOCNO>
<DOCOLDNO>IA017-000178-B007-279</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:2 192.33.214.13 19970106045054 text/html 1489
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:51:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Drug Is Approved by 4 European Countries</H3>
<EM>Wall Street Journal (03/26/96) P. B8</EM>
<P>
NeXstar Pharmaceuticals Inc., of Boulder, CO, announced that
Germany, the Netherlands, Finland, and Norway have cleared
DaunoXome, the company's new drug for Kaposi's sarcoma, for
marketing.  NeXstar said it would begin selling the drug in Germany
and the Netherlands within the next few weeks and that its
marketing partner in the Nordic countries would handle the drug's
sales in Finland and Norway.  The drug was previously approved in
Sweden and the United Kingdom.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-261</DOCNO>
<DOCOLDNO>IA017-000178-B007-294</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:3 192.33.214.13 19970106045117 text/html 1951
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:51:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Review &amp; Outlook: AIDS Babies</H3>
<EM>Wall Street Journal (03/26/96) P. A18</EM>
<P>
In a Wall Street Journal editorial, the authors urge the
support of an amendment to the Ryan White Care Reauthorization Act
that would require mandatory HIV testing of babies born to mothers
who were not tested.  Members of a House-Senate conference
committee are scheduled to work on the legislation on Tuesday.
Studies have shown that mothers with HIV who take AZT during
pregnancy lessen the chance of infecting their infants by
two-thirds.  Still, many mothers at risk for HIV are not tested or
treated; then, their babies are born with HIV and also often go
untreated.  AIDS activists and feminist groups have opposed
mandatory testing of newborns, arguing that it infringes on the
mother's privacy.  The authors note, however, that if the Ryan
White CARE Act is reauthorized without the Ackerman-Coburn
provision, HIV-positive infants will not be included in a measure
whose title carries the name of a child that died from the disease.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-262</DOCNO>
<DOCOLDNO>IA017-000178-B007-309</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:4 192.33.214.13 19970106045128 text/html 1799
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:51:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Drawbacks of Mandatory HIV Tests, Counseling</H3>
<EM>Philadelphia Inquirer (03/26/96) P. A8;  Smith, David Gary</EM>
<P>
In a letter to the editor in the Philadelphia Inquirer, David
Gary Smith, a physician at Abington Memorial Hospital, points out
that mandatory HIV testing of pregnant women could keep women at
risk from getting proper prenatal care.  While studies have
estimated that counseling women about being tested for HIV can
reduce HIV transmission to newborns by 66 percent, inadequate
mandatory testing, Smith says, could also have a negative impact.
Smith further notes that Philadelphia's health commissioner,
Estelle B. Richman, has led the way for maximizing the benefits of
testing and minimizing the risks of a health-care intervention by
forming an advisory board, which in December stressed the need
for effective outreach and counseling for pregnant women.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-263</DOCNO>
<DOCOLDNO>IA017-000178-B007-323</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:5 192.33.214.13 19970106045137 text/html 1504
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:51:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Conference Adopts Hopeful Spirit</H3>
<EM>Toronto Globe and Mail (03/25/96) P. A4</EM>
<P>
AIDS Researchers and health workers say the 11th International
Conference on AIDS, to be held in Vancouver, British Columbia,
will be optimistic and hopeful.  &quot;The mood among this group is
that we are taking our understanding of the virus and its effects
to unprecedented and exciting new levels,&quot; said Vancouver
researcher Michael O'Shaughnessy.  The conference will be held
July 7 to 12 and is expected to be the most significant event of
the year for researchers studying HIV.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-264</DOCNO>
<DOCOLDNO>IA017-000178-B007-335</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:6 192.33.214.13 19970106045145 text/html 1499
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Experimental AIDS Vaccine Volunteer Infected</H3>
<EM>Reuters (03/25/96)</EM>
<P>
One of 24 volunteers participating in a test of an
experimental AIDS vaccine developed by United Biomedical Inc. of
Hauppauge, NY, has been infected with HIV.  Dr. James Kahn of the
University of California, San Francisco, reports that the
individual who was infected had received four doses of the
vaccine; however, the vaccine is not thought to be the source of
infection because it does not contain live virus.  Khan notes the
trial was designed to assess the vaccine's safety, not its
efficacy.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-265</DOCNO>
<DOCOLDNO>IA017-000178-B007-351</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:7 192.33.214.13 19970106045155 text/html 1512
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Anti-HIV Agent Inhibits Early Step in HIV Life Cycle</H3>
<EM>Reuters (03/25/96)</EM>
<P>
Researchers at Sandoz in Austria and SyStemix Inc. in Palo
Alto report promising results with an experimental anti-HIV
compound called SID 791.  SID 791 is a bicyclam, which inhibits an
early step in the life cycle of HIV, presumably a step associated
with the virus' entry into cells.  Experiments in mice suggest that
the compound alone, or in combination with other antivirals, could
decrease the viral load in HIV-infected patients, and that HIV
therapy should target the virus' entry into the cell.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-266</DOCNO>
<DOCOLDNO>IA017-000178-B007-367</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:8 192.33.214.13 19970106045206 text/html 1626
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:28 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Thalidomide: Facilitates Weight Gain in Persons with HIV and M. Tuberculosis Infections</H3>
<EM>Reuters (03/25/96)</EM>
<P>
Thalidomide may help people with HIV and other infections gain
weight, researchers at New York University Medical Center and
Rockefeller University report.  Gilla Kaplan of Rockefeller
University led the study of 32 patients with HIV-1, some of whom
also had tuberculosis.  Kaplan says that tumor necrosis
factor-alpha is made by the body to defend against infection, but
it may also cause fever, weakness, and wasting.  Thalidomide,
which is known to inhibit the synthesis of TNG-alpha, might
prevent continued wasting, and even help patients gain weight,
the researchers surmised.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-267</DOCNO>
<DOCOLDNO>IA017-000178-B007-381</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:9 192.33.214.13 19970106045215 text/html 2227
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Persistent Lack of Detectable HIV-1 Antibody in a Person with HIV Infection--Utah, 1995</H3>
<EM>Morbidity and Mortality Weekly Report (03/08/96) Vol. 45, No. 9, P. 181;  Reimer, L.;  Brokopp, C.;  Mottice, S.; et al.</EM>
<P>
Last year, a patient in Utah was found to be infected with HIV
even though he tested negative for the HIV-antibody beyond the
expected &quot;window period.&quot;  The patient--who experienced fatigue,
weight loss, and a respiratory illness--had frequently donated
plasma, and each donation was also negative for the antibody.
However, his wife, who had sexual contact with a man who later
died of AIDS, tested positive for HIV.  The patient said he had
not used injection drugs, had a transfusion, or had male-to-male
sexual contact.  Blood samples from the patient were analyzed by
the Centers for Disease Control and Prevention and the Food and
Drug Administration.  Several test kits were used, and while some
showed no reaction, some showed a weak reaction, and a test for
HIV-1 p24 antigen showed positive results.  An editorial
accompanying the report says that the man probably was infected
by his wife and that the negative tests were probably a result of
an atypical host response to the virus--an occurrence which has
been reported in a small number of patients before.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960326:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-268</DOCNO>
<DOCOLDNO>IA017-000178-B039-349</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960326:10 192.33.214.13 19970106045228 text/html 2159
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 26, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960326"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 26, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Pregnant Nurse Won't Treat HIV Patient</H3>
<EM>American Medical News (03/04/96) Vol. 39, No. 9, P. 22</EM>
<P>
A federal appellate court in Alabama has affirmed summary
judgment of a hospital sued for discrimination by a pregnant
nurse who refused to treat an HIV-positive patient.  The nurse,
who was in her first trimester of pregnancy, refused to treat a
cryptococcal meningitis patient who was HIV-positive.  She was
especially concerned about contracting one of the opportunistic
diseases associated with HIV because she had gestational diabetes
and was immunocompromised.  The nurse--who was fired for her
decision, but resigned before the termination took effect--sued
the hospital four months later when she learned that it had not
assumed payment of her student loans, which was part of her
employment contract.  The hospital was granted partial summary
judgment, which the nurse appealed and the appellate court
affirmed.  The court held that the nurse failed to establish a
prima facie case of discrimination.  She did not show that
hospital rules allowed a pregnant nurse to refuse to treat an
HIV-positive patient or that the hospital policy concerning
patients with HIV resulted in disproportionate impact on pregnant
nurses.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-269</DOCNO>
<DOCOLDNO>IA017-000178-B039-359</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:1 192.33.214.13 19970106045237 text/html 1686
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:52:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Drugs Bring Hope, High Prices</H3>
<EM>Washington Post (03/25/96) P. A1;  Gillis, Justin</EM>
<P>
The recent approval of costly new AIDS drugs, which could
raise the cost of treating HIV from $2,500 a year to $12,000,
leaves cities and states in the difficult position of trying to
devise ways to help pay for them.  In the face of federal
government spending shortfalls, Maryland Gov. Parris Glendening
has promised about $1 million in additional state funds to pay
for the new drugs.  In addition, the Clinton administration has
asked Congress to approve an extra $52 million for drug payment
programs, but the request has been stymied by the budget debate.
Scientists hope the new drugs will allow HIV-infected
individuals to live longer, more productive lives.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960326:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-270</DOCNO>
<DOCOLDNO>IA017-000178-B039-371</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:2 192.33.214.13 19970106045246 text/html 1666
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:53:07 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Stricken, But Speaking Out</H3>
<EM>Philadelphia Inquirer (03/25/96) P. F5;  Reeves, Tracey A.</EM>
<P>
Since finding out in 1992 that she has HIV, Lisa Tiger has
become an AIDS activist in the American Indian community, sharing
her story and telling others that anyone can get AIDS, including
people like her from the rural middle class.  The Centers for
Disease Control and Prevention estimates that as of June 1995,
1,010 American Indians had AIDS, but people like Tiger and Miguel
Marinez of the National Native American AIDS Prevention Center
claim the figure is too low.  Daniel Simpson, an AIDS coordinator
for the Indian Health Service, says the infection rate is
underreported because AIDS is a taboo subject in the American
Indian community.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-271</DOCNO>
<DOCOLDNO>IA017-000178-B040-7</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:3 192.33.214.13 19970106045254 text/html 1331
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:53:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Fanfare: Auto Racing</H3>
<EM>Washington Post (03/25/96) P. C2</EM>
<P>
Auto racer Tim Richmond infected several women with HIV
before he died in 1989, according to the Miami Herald.
Richmond's former fiancee, LaGena Lookabill Greene, announced
last year that she had AIDS and that she was infected by
Richmond.  The Herald reported that two other of Richmond's
partners also have AIDS and that another one has died.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-272</DOCNO>
<DOCOLDNO>IA017-000178-B040-18</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:4 192.33.214.13 19970106045302 text/html 1648
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:53:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>FDA Approves Human Testing of Preventive AIDS Vaccine</H3>
<EM>Knight-Ridder/Tribune Business News (03/25/96);  Shaw, Donna</EM>
<P>
For the first time, a preventive AIDS vaccine made with HIV
DNA will be tested in uninfected people.  The vaccine, made by
Apollon Inc. and the University of Pennsylvania, will be given to
16 HIV-negative volunteers who will be followed for 18 months to
determine the vaccine's safety and efficacy.  The vaccine's two
parts--one containing the genes for the production of key HIV
proteins and the other containing genes to make viral core
proteins, will be tested separately.  Also, a DNA-based
Apollon-Penn vaccine designed to delay the onset of AIDS is now
being tested in HIV-infected individuals.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-273</DOCNO>
<DOCOLDNO>IA017-000178-B040-31</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:5 192.33.214.13 19970106045326 text/html 1567
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:53:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Vaginal Microbicides Explored for AIDS Prevention</H3>
<EM>Reuters (03/22/96)</EM>
<P>
Researchers have found several compounds that may be used as
vaginal microbicides for preventing HIV infection.  Dr. Rudi
Pauwels of the Institute for Antiviral Research in Belgium and
colleagues report that little attention has been given to the
chemical prevention of HIV infection and that spermicides with
HIV-inactivating action may have promise to block heterosexual
HIV transmission.  Nonoxynol 9 and chlorhexidine are two
virucidals being studied, and compounds that target other steps
in the viral replication cycle could be valuable as secondary
barriers.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-274</DOCNO>
<DOCOLDNO>IA017-000178-B040-42</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:6 192.33.214.13 19970106045333 text/html 1708
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:53:56 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Leading AIDS Researcher Warns of Second Epidemic</H3>
<EM>Reuters (03/22/96)</EM>
<P>
Dr. Max Essex, chairman of the Harvard AIDS Institute, warns
that the United States may be facing a second AIDS epidemic.
HIV-1B, the common HIV type in the United States and Europe, is
transmitted through injection drug use, blood products and
primary homosexual contact.  HIV-1C, -E, -D, and -A subtypes,
especially HIV-1C and HIV-E, are currently spreading rapidly in
Southeast Asia and Africa.  Essex says that these non-B strains
are transmitted primarily through vaginal intercourse, and are a
greater threat to the world's population.  Furthermore, he says
that if they took hold in the United States or Europe, they could
cause &quot;a heterosexual epidemic of significantly greater
magnitude.&quot;
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-275</DOCNO>
<DOCOLDNO>IA017-000178-B040-60</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:7 192.33.214.13 19970106045345 text/html 1708
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:54:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>TB A Threat in Latin America, Caribbean</H3>
<EM>Reuters (03/22/96);  Kenen, Joanne</EM>
<P>
Tuberculosis (TB) remains a public health problem in much of
Latin America and the Caribbean, killing more than 70,000 people
in 1995, the Pan-American Health Organization (PAHO) reported
Friday.  Of all the TB-related deaths in the Western Hemisphere
last year, 95 percent were in Latin America and the Caribbean.
The countries with the worst epidemics include Bolivia, Peru, the
Dominican Republic, and Ecuador.  PAHO estimates that less
than 70 percent of the TB patients receive complete treatment,
increasing the likelihood of resistant TB strains developing.  A
PAHO official said that even poor countries can fight the
epidemic with consistent treatment, citing Peru and Nicaragua as
examples.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-276</DOCNO>
<DOCOLDNO>IA017-000178-B040-73</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:8 192.33.214.13 19970106045354 text/html 2274
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:54:16 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Advisory on Zidovudine to Reduce HIV Transmission From Mother to Infant Sent to Thousands of Health Care Providers</H3>
<EM>Health Resources and Services Administration (03/22/96)</EM>
<P>
The Health Resources and Services Administration (HRSA)
announced Friday that it has provided its service providers with
information about offering therapy for HIV-infected pregnant
women to reduce viral transmission to their infants.  &quot;Program
Advisory: Use of Zidovudine (ZDV) to Reduce Perinatal HIV
Transmission in HRSA-Funded Programs&quot; offers useful strategies
and options for helping women to make practical decisions about
ZDV treatment.  Included in the 30-page document is a model form
to document provider counseling, patient choice for
administration of the ZDV therapy, and previous suggestions from
the U.S. Public Health Service concerning HIV testing and
counseling for infected pregnant women and ZDV use.  HRSA
Administrator Ciro V. Sumaya said, &quot;We must ensure that women are
fully informed and understand that the decision is ultimately
theirs.&quot;  According to HRSA, which works with thousands of health
care providers in such programs as the Community and Migrant
Health Centers and the Ryan White CARE Act, the guidance should
represent the standard of care for pregnant women and be followed
in all programs funded by the agency.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-277</DOCNO>
<DOCOLDNO>IA017-000178-B040-83</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:9 192.33.214.13 19970106045412 text/html 1943
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:54:33 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Lamivudine Resistance May be Associated with Beneficial Effects</H3>
<EM>Lancet (03/02/96) Vol. 347, No. 9001, P. 603;  Choo, Vivien</EM>
<P>
Patients in clinical studies develop resistance to
lamivudine (3TC) after 12 weeks of monotherapy, but do well
regardless.  This could be because the resistant strain appears
at the same time immunity against viral replication develops.
Vinayaka Prasad of Albert Einstein College of Medicine and Mark
Wainberg of McGill University conducted a study with the M184V
strain, which can be 1,000 times more resistant than the
wild-type virus to 3TC.  The researchers found that HIV
antibodies decreased seven times faster in zidovudine-treated
patients than they did in patients treated with 3TC.  This
suggests that the M184V strain may have prevented the emergence
of strains that help the virus escape attack by antibodies.  The
researchers also found that when the strain was grown in the
presence of anti-HIV agents, it prevented the emergence of
variants that were resistant to them.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960325:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-278</DOCNO>
<DOCOLDNO>IA017-000178-B040-100</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960325:10 192.33.214.13 19970106045424 text/html 1224
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:54:44 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 25, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960325"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 25, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>AIDS Update: AIDS Research: Charge It</H3>
<EM>Men's Health (03/96) Vol. 11, No. 2, P. 54</EM>
<P>
People who use the Rainbow Visa Card are now supporting AIDS
research with each purchase they make.  A percentage of all
charges made with the card is donated to nonprofit HIV and gay
and lesbian health groups.
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-279</DOCNO>
<DOCOLDNO>IA017-000178-B040-111</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:1 192.33.214.13 19970106045434 text/html 1754
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:54:56 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>TB Threat Grows Worldwide</H3>
<EM>USA Today (03/22/96) P. 1A;  Manning, Anita</EM>
<P>
Tuberculosis (TB) killed more people worldwide than ever before
in 1995, and at least 30 million will die in the next ten years
if efforts are not made to stop the epidemic.  The Centers for
Disease Control and Prevention has announced that the number of
TB cases in the United States in 1995 is expected to decline from
1994's 24,361 total; however, the World Health Organization (WHO)
said 3 million would die from the disease worldwide in 1995.  The
disease carries the threat of incurability because drug-resistant
strains thrive when medications are not taken correctly, but a
new combination therapy holds great promise to eliminate the
resistant strains.  Related Stories: Baltimore Sun (03/22) P.
14A; Philadelphia Inquirer (03/22) P. A6
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960325:10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-280</DOCNO>
<DOCOLDNO>IA017-000178-B040-122</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:2 192.33.214.13 19970106045443 text/html 1625
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:55:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Glendening Targets $1 Million to Help Some AIDS Patients</H3>
<EM>Washington Post (03/22/96) P. D2</EM>
<P>
Maryland Gov. Parris N. Glendening will allocate $1 million of
the state's budget over the next two years to help inadequately
insured individuals who are not eligible for Medicaid to afford
new AIDS drugs.  The money will cover expected shortfalls in a
federal program that helps people buy AIDS drugs, which are
promising but expensive.  Congress is currently considering a
request from the Clinton administration to provide an extra $52
million for the program, but Glendening said he wanted to act now
to make the drugs available as soon as possible.  Related Story:
Baltimore Sun (03/22) P. 2B
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-281</DOCNO>
<DOCOLDNO>IA017-000178-B040-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:3 192.33.214.13 19970106045451 text/html 2020
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:55:13 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>On Every Argentine Cellblock, Specter of AIDS</H3>
<EM>New York Times (03/22/96) P. A4;  Sims, Calvin</EM>
<P>
In Argentina, the World Health Organization (WHO) estimates that
30 percent of the 5,800 inmates in the federal prison system are
infected with HIV.  Prisoners, however, are often not found to
have the virus until they develop AIDS symptoms.  The WHO study
found that intravenous drug use and sexual activity between
inmates and inmates and outsiders are common in the prison
system.  The estimated incidence HIV infection is based on
results of voluntary tests since the Argentine law does not allow
mandatory testing of inmates.  Health officials say the rate of
HIV is probably as high in local prisons and in prisons in other
Latin American countries.  They cite the high prevalence of drug
use and prostitution before incarceration for reasons the prison
population is especially at risk.  Argentina is the only country
in the region with an AIDS treatment facility for federal
prisoners, but inmates' advocates question whether care is
actually available to every person who needs it.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-282</DOCNO>
<DOCOLDNO>IA017-000178-B040-145</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:4 192.33.214.13 19970106045502 text/html 1604
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:55:23 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Mother Whose Home Was Torched Asks Aid for Hemophiliacs</H3>
<EM>Philadelphia Inquirer (03/22/96) P. A5;  Shaw, Donna</EM>
<P>
Louise Ray, a Florida woman whose home was torched when neighbors
found out her sons had AIDS, has asked Congress to approve a $1
billion compensation package for HIV-infected hemophiliacs.
Hundreds of supporters of the measure, named after Ray's son
Ricky, who died of AIDS in 19922, rallied on the Capitol steps.
Ricky was one of an estimated 8,000 to 10,000 U.S. hemophiliacs
who were infected with HIV by tainted clotting factors.  The
measure, which would pay each HIV-infected hemophiliac $125,000,
was introduced last year, but has seen little action.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-283</DOCNO>
<DOCOLDNO>IA017-000178-B040-160</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:5 192.33.214.13 19970106045511 text/html 1873
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:55:33 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Research Attacks Immune System Theory</H3>
<EM>Wall Street Journal (03/22/96) P. B14;  Bishop, Jerry E.</EM>
<P>
Three different research teams have reported evidence that
substantiates a controversial theory about how the immune system
defends the body against disease.  If proven, the theory would
change the prevailing approach to immunology and dramatically
alter the development of anti-AIDS drugs, vaccines, and drugs to
prevent the rejection of transplants.  Immunologists have long
believed that the immune system learns to recognize and tolerate
&quot;self&quot; while attacking tissues recognized as &quot;nonself,&quot; but Polly
C.E. Matzinger of the National Institute of Allergy and
Infectious Diseases proposes an alternative theory--that the
immune system waits for a signal that somewhere in the body
tissues are dying unnatural deaths.  Her theory is not widely
accepted among the immunology community, but is being tested
nevertheless.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-284</DOCNO>
<DOCOLDNO>IA017-000178-B040-174</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:6 192.33.214.13 19970106045531 text/html 1741
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:55:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>A Menu of Rare Antibodies For Drug Firms</H3>
<EM>Investor's Business Daily (03/22/96) P. A4;  Benko, Laura B.</EM>
<P>
Finding rare antibodies needed to make certain drugs can be
difficult, but Serologicals Corp. of Atlanta, Ga. has been
stockpiling elusive proteins by increasing its donor network, and
is in some cases, cloning antibodies it collects.  The
company--which collects antibodies for hepatitis, rabies, HIV and
other diseases--has 39 donor centers, 22 of which are licensed by
the Food and Drug Administration to collect at least one type of
rare antibody.  Serological's largest product is intravenous
immune globulin, or IVIG, antibodies that boost the body's
defense against HIV, Lupus, and anemia.  The firm also clones 49
commercial antibodies, using cultures to copy single antibodies
in a laboratory.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-285</DOCNO>
<DOCOLDNO>IA017-000178-B040-189</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:7 192.33.214.13 19970106045541 text/html 1441
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:56:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Morrison Says He Will Beat HIV, Fight Again</H3>
<EM>Reuters (03/21/96)</EM>
<P>
Former heavyweight boxer Tommy Morrison says he will beat HIV and
fight again, possibly later this year.  Morrison predicted in an
interview of ESPNET SportsZone Wednesday that his HIV infection
would disappear and he would return to boxing.  He said he
believes he knows how he got the virus and how to make it
disappear--by magic.  Morrison said at the time of his retirement
that he would spend time educating children about HIV and AIDS.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-286</DOCNO>
<DOCOLDNO>IA017-000178-B040-205</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:8 192.33.214.13 19970106045552 text/html 2204
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:56:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>HIV Subtypes Raise Vaccine Anxieties</H3>
<EM>Lancet (03/02/96) Vol. 347, No. 9001, P. 603;  Rowe, Paul M.</EM>
<P>
The biology of different strains of HIV may be related to the
different ways the virus is transmitted around the globe.  Max
Essex of the Harvard AIDS Institute has reported that in
purified epithelial Langerhans cells (LC), subtype E virus grows
better than subtype B.  LCs are found in epidermis, oral and
genital mucosal epithelium, but not in rectal mucosa.  Most HIV-1
in the United States and Europe is subtype B, and in Asia and
Africa different strains predominate.  In Thailand, both E and B
subtypes are found, but E is more common, especially in those who
contract HIV via vaginal intercourse.  Beatrice Hahn of the
University of Alabama at Birmingham has reported finding hybrid
HIV-1 strains in high-risk individuals in Asia and Africa.  She
believes the mixing of previously-separate subtypes is a result
of the epidemic's growth.  Most vaccines now being developed
contain subtype B antigens, although non-B viruses predominate in
Africa and Asia, where the first trials will likely be conducted.
Non-B vaccines may have a better chance of inducing vaginal
mucosal immunity, however, because non-B viruses target LCs as
well as lymphocytes and monocytes.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-287</DOCNO>
<DOCOLDNO>IA017-000178-B040-217</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:9 192.33.214.13 19970106045602 text/html 2350
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:56:23 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Outbreak of Primary and Secondary Syphilis--Baltimore City, Maryland, 1995</H3>
<EM>Morbidity and Mortality Weekly Report (03/01/96) Vol. 45, No. 8 , P. 166</EM>
<P>
The Centers for Disease Control and Prevention, along with the
Baltimore City Health Department (BCHD) and the Maryland
Department of Health and Mental Hygiene, studied data on syphilis
cases in Baltimore City between 1992 and 1995 to determine what
trends were responsible for the outbreak there.  BCHD attempts to
notify partners and provide treatment for patients, but decreases
in personnel during the time period may have attributed to the
outbreak.  A significant increase in cocaine use in the community
is also implicated.  During the study period, the number of
self-referred patients that visited the two public sexually
transmitted disease (STD) clinics declined 12 percent, and the
number of cocaine-related deaths in Baltimore City increased 737
percent from 1990 to 1994.  An editorial note accompanying the
study suggests that the use of crack cocaine and the exchange of
sex for drugs were major factors in the syphilis epidemic in
Baltimore, as in other urban areas.  Furthermore, the authors
warn, HIV infection may be increasing as another result of the
increase in crack cocaine use and the syphilis outbreak.  The
BCHD is alerting the medical community about the outbreak,
filling STD program vacancies, and expanding surveillance
activities.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960322:10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-288</DOCNO>
<DOCOLDNO>IA017-000178-B040-235</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/e/SUMM-96.cgi?960322:10 192.33.214.13 19970106045610 text/html 2063
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:56:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>AIDS Daily Summary - March 22, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/e/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="SUMM-96.cgi?+960322"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H3>AIDS Daily Summary - March 22, 1996</H3>
<I>Centers for Disease Control and Prevention Clearinghouse<BR>Copyright 1995, Information, Inc., Bethesda, MD</I>
<BR CLEAR><HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960321:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

<H3>Rolipram: Antidepressant Used in Europe and Japan Might Have Promise Against TNF, HIV</H3>
<EM>AIDS Treatment News (03/01/96) No. 242, P. 3;  Smith, Denny</EM>
<P>
The antidepressant drug Rolipram has been found to be an active
inhibitor of tumor necrosis factor (TNF), a chemical messenger
overproduced by the immune system in some diseases, including HIV
infection.  Many AIDS symptoms--including fatigue, fever, and
dementia--that are not caused by an opportunistic infection are
associated with too much TNF.  Researchers have also suspected an
HIV/TNF feedback loop, in which TNF enhances HIV replication
while HIV progression increases TNF production.  Of the few TNF
inhibitors studied, only thalidomide--which causes side effects
in HIV-infected individuals--has been found to be clinically
valuable.  New TNF inhibitors are being developed by Celgene, but
could take years to test.  Rolipram is considered an essentially
safe drug, but laboratory tests show that the amount of the drug
necessary to inhibit TNF may not be tolerable in practice.
Clinical studies are needed to determine if the drug could be
used to treat HIV infection.
<P>
<P>
</UL>
<HR>
<CENTER>
<A HREF="SUMM-96.cgi?960322:9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="SUMM-96.cgi?960321:1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-289</DOCNO>
<DOCOLDNO>IA017-000178-B040-254</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/infomed/infostests.html 192.33.214.13 19970106045634 text/html 2369
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:56:54 GMT
Last-modified: Monday, 20-May-96 15:28:46 GMT
Content-length: 2181
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD><TITLE>HIVnet CH : Medizinische Informationen</TITLE></HEAD>

<BODY>

<BODY BGCOLOR="FFFFFF">


<A HREF="index.html"><IMG SRC="/d/gif/medinfo2.gif" BORDER=0  ALT="Medizinische Info." ALIGN=RIGHT></A><BR CLEAR=LEFT><H2>Medizinische Informationen</H2><HR>


<center>

<H3><I>Im Kanton:</I></H3>

<A HREF="#bls">BL,BS</A> / <A HREF="#be">BE</A> / <A HREF="#ge">GE</A> / <A HREF="#sg">SG</A> / <A HREF="#vd">VD</A> / <A HREF="#zh">ZH</A>
<P>
<TD ALIGN=RIGHT SIZE=275><FONT SIZE=2><I><b>Bemerkung:</b> Diese Liste umfasst ausschliesslich die Universit&auml;tsspit&auml;ler. Konsultieren Sie bitte die <A HREF="../organs/ass.html">kantonalen Auskunftstellen</A> f&uuml;r weitere Spital-Adressen.</I></FONT></TD>
</center><P>
<HR><P>


<A NAME="bls"><H3>Basel</H3></A>
<UL>
<LI><B>Information und Aids-Sprechstunde</B><br>
Universit&auml;tsklinik<br>
<I>tel (061) 265 24 31</I><P>
</UL>

<A NAME="be"><H3>Bern</H3></A>
<UL>
<LI><B>Information und Aids-Sprechstunde</B><br>
Inselspital<br>
<I>tel (031) 632 27 45</I>
</UL>

<A NAME="ge"><H3>Genf</H3></A>
<UL>
<LI><B><A HREF="http://expasy2.hcuge.ch/dmi/vih.html">Information et consultation sida</A></B><br>
H&ocirc;pital Cantonal<br>
<I>tel (022) 372 96 17</I><br>
</UL>

<A NAME="sg"><H3>St. Gallen</H3></A>
<UL>
<LI><B>Information und Aids-Sprechstunde</B><br>
Kantonsspital<br>
<I>tel (071) 261 028<br></I>
</UL>

<A NAME="vd"><H3>Waadt</H3></A>
<UL>
<LI><B>Information et consultation sida</B><br>
CHUV<br>
<I>tel (021) 314 41 41</I><P>
Policlinique m&eacute;dicale universitaire<br>
<I>tel (021) 320 34 41</I><br>
</UL>

<A NAME="zh"><H3>Z&uuml;rich</H3></A>
<UL>
<LI><B>Information und Aids-Sprechstunde</B><br>
Universit&auml;tsspital<br>
<i>tel (01) 255 23 06</i><P>
</UL>

<HR>

<i>Quelle: Aids-Hilfe Schweiz, 5.95</i>
<P>
<HR>
<P>
<CENTER>
<A HREF="/d/index.html"><IMG SRC="/d/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/d/search/index.html"><IMG SRC="/d/gif/suchen2.gif" BORDER=0 ALT="Suchen"></A>
<A HREF="/d/hivnet/index.html"><IMG ALIGN=top SRC="/d/gif/kontakte2.gif" BORDER=0 ALT="Kontakte"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-290</DOCNO>
<DOCOLDNO>IA017-000178-B040-266</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-msg.cgi?5 192.33.214.13 19970106045645 text/html 2255
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:57:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HIVNet CH - Juristische Informationen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-tdm.cgi"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>
<UL>
<H2>Juristische Informationen</H2>
<H3><I>Frage Nr 5 - 27 December, 13:12</I></H3>
<BR CLEAR>
<HR>
<TABLE CELLPADDING=10 BORDER=0>
<TR>
<TD VALIGN=top></TD>
<TD ROWSPAN=2>
<P>
<B><I>Objekt:</B></I><UL>
Kündigung
<P>
</UL>
<B><I>Frage:</B></I><UL>
Kann mein Arbeitgeber, nachdem er erfahren hat, dass ich<BR>
HIV + bin, das Arbeitsverh&auml;ltnis aufl&ouml;sen oder nicht ?<BR>
<BR>
Inwiefern sind HIV + vom Gesetz her gesch&uuml;tzt ?<BR>
<P>
</UL>
<B><I>Antwort:</B></I><UL>
Ja und nein.<BR>
<BR>
Die Aufl&ouml;sung eines Arbeitsvertrag ist im Prinzip immer m&ouml;glich wenn die K&uuml;ndigungsfristen beobachtet werden. Dies gilt genauso f&uuml;r den Arbeitgeber wie f&uuml;r den Arbeitnehmer.<BR>
<BR>
Nach schweizerischem Recht ist eine K&uuml;ndigung wegen einen HIV+ Status ganz klar missbrauchlich. Leider h&ouml;rt der Schutz des Gesetzes mit sch&ouml;nen Worten hier auf, denn Sanktionnen gibt es ausser eine finanzielle Entsch&auml;digungspflicht nicht. Das schweizer Recht kennt zum Beispiel weder die M&ouml;glichkeit eine solche K&uuml;ndigung als nichtig zu erkl&auml;ren noch ein &quot;R&uuml;ckgliederungsrecht&quot; in der ehemaligen Arbeitstelle.<BR>
<BR>
Der Schutz ist daf&uuml;r besser falls Sie wegen einer Krankheit -aslo z. B. HIV+- ganz oder teilweise verhindert sind Ihre Arbeitsleistung zu erf&uuml;llen. In diesem Fall ist eine K&uuml;ndigung nichtig. Dieser Schutz ist aber hier zeitlich gegrenzt: 30 Tage &quot;K&uuml;ndigungsschutz&quot; w&auml;hrend das erste Dienstjahr, 90 Tage vom zweiten bis zum f&uuml;nften Dienstjahr und dann 180 Tage.<BR>
<P>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="Legal-msg.cgi?4"><IMG ALIGN=right BORDER=0 SRC=/gif/down.gif></A></TD>
</TD>
</TR>
</TABLE>
<HR>
<CENTER>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
[ <A HREF="Legal-post.html">Sendung der Frage</A> ]
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-291</DOCNO>
<DOCOLDNO>IA017-000178-B040-279</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-msg.cgi?4 192.33.214.13 19970106045655 text/html 2495
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:57:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HIVNet CH - Juristische Informationen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-tdm.cgi"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>
<UL>
<H2>Juristische Informationen</H2>
<H3><I>Frage Nr 4 - 26 December, 17:07</I></H3>
<BR CLEAR>
<HR>
<TABLE CELLPADDING=10 BORDER=0>
<TR>
<TD VALIGN=top><A HREF="Legal-msg.cgi?5"><IMG ALIGN=right BORDER=0 SRC=/gif/up.gif></A></TD>
<TD ROWSPAN=2>
<P>
<B><I>Objekt:</B></I><UL>
IV
<P>
</UL>
<B><I>Frage:</B></I><UL>
Von welchem Zeitpunkt an gilt ein HIV + als IV Berechtigt.<BR>
Wie hoch sind die Leistungen der IV.<BR>
K&ouml;nnen IV Leistungen auch bezogen werden, wenn der Patient nur 6 Monate in der Schweiz ist?<BR>
<P>
</UL>
<B><I>Antwort:</B></I><UL>
HIV selbst gilt nicht direkt als IV 'berechtigt'. F&uuml;r die IV ist allgemein eine Behinderung die w&auml;hrend eine l&auml;ngere Zeit die Erw&auml;rbst&auml;tigkeit beeintr&auml;chtigt relevant. Als l&auml;ngere Zeit gilt 12 Monate, als Beeintr&auml;chtigung der Erw&auml;rbst&auml;tigkeit gilt eine Arbeitsunf&auml;higkeit von (im Durschnitt) mindestens 40%.<BR>
<BR>
Die Leistungen h&auml;ngen von drei Elemente ab: die Beitragszahlungsdauer, das durchschnittliche Einkommen und der Behinderungsgrad (25%, 50% oder 100%). Man kann f&uuml;r eine volle Invalidenrente (also mit einem Behinderungsgrad von 100%) zwischen 1980 F und 990 F pro Monat 'rechnen'.<BR>
<BR>
Eine Person die in der Schweiz seit 6 Monate ist hat im Prinzip keinen Anspruch auf IV Leistungen falls sie nicht mindestens zwischen 12 Monate (Schweizerb&uuml;rger oder ausl&auml;ndischer Staatsangeh&ouml;riger mit dessen Land die Schweiz ein Abkommen unterzeichnet hat, wie Frankreich, Deutschland, Italien, etc.) und 10 Jahre (!) Beitrage bezahlt hat.<BR>
<BR>
Achtung: falls ein Gesuch zu fr&uuml;h gestellt wird kann es vorkommen dass ein Recht auf IV Leistungen wegen mangelder Beitragszahlungsdauer endg&uuml;ltig verweigert wird! Es ist empfohlen sich gr&uuml;ndlich zu informieren.<BR>
<P>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="Legal-msg.cgi?3"><IMG ALIGN=right BORDER=0 SRC=/gif/down.gif></A></TD>
</TD>
</TR>
</TABLE>
<HR>
<CENTER>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
[ <A HREF="Legal-post.html">Sendung der Frage</A> ]
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-292</DOCNO>
<DOCOLDNO>IA017-000178-B040-295</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-msg.cgi?3 192.33.214.13 19970106045703 text/html 4956
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:57:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HIVNet CH - Juristische Informationen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-tdm.cgi"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>
<UL>
<H2>Juristische Informationen</H2>
<H3><I>Frage Nr 3 - 26 November, 11:17</I></H3>
<BR CLEAR>
<HR>
<TABLE CELLPADDING=10 BORDER=0>
<TR>
<TD VALIGN=top><A HREF="Legal-msg.cgi?4"><IMG ALIGN=right BORDER=0 SRC=/gif/up.gif></A></TD>
<TD ROWSPAN=2>
<P>
<B><I>Objekt:</B></I><UL>
Taggeldversicherung
<P>
</UL>
<B><I>Frage:</B></I><UL>
Merci f&uuml;r die Antwort zu Frage 1 (Pensionskasse).<BR>
Nun habe ich das gleiche Problem mit der Taggeldversicherung gegen Lohnausfall bei Krankheit. Was soll ich denn jetzt wieder tun?<BR>
<P>
</UL>
<B><I>Antwort:</B></I><UL>
Sorry f&uuml;r die versp&auml;tete Antwort aber wir hatten ein (entg&uuml;ltiges) Komputerproblem beim Groupe sida Gen&egrave;ve dass uns den Internet Zugang f&uuml;r eine gewisse Zeit unm&ouml;glich machte. Falls die Frage noch aktuell ist kann man manche Parallele mit der Frage N°1 ziehen (Gesundheitszustand und Antragsformular, Punkt 2 u. 3). Es wird hier betonnt dass solch eine Frage nur eine allgemeine Antwort bekommen kann. Es gilt wie immer: es lohnt sich im Zweifelfall eine Beratungstelle zu besuchen!<BR>
<BR>
Laut neuem Krankenversicherungsgesetz (KVG) gibt es nun zwei verschiedene Taggeldversicherungen gegen Lohnausfall (TGV): die eine kann man als 'soziale' TGV bezeichnen, die andere als reine private TGV.<BR>
<BR>
1. Die 'soziale' TGV ist mit dem KVG verbunden (Art. 67-77 KVG). Diese TGV ist f&uuml;r Sie freiwillig daf&uuml;r ist Ihre Aufnahme eine Pflicht f&uuml;r die Krankenkasse oder Versicherung sobald Sie diese Aufnahme beantragen.<BR>
<BR>
Die Versicherung kann aber bei der Aufnahme bestehende Krankheiten durch einen Vorbehalt ausschliessen. Solch einen Vorbehalt ist f&uuml;r maximal 5 Jahre g&uuml;ltig. Es gibt manche Ausnahmen: es wird Ihnen deshalb empfohlen dies bei einer Fachkundingen Personn zu untersuchen.<BR>
<BR>
2. Falls eine TGV mit dem Arbeitsvertrag verbunden ist, handelt es sich meistens um eine private TGV. Da kann und darf die Versicherung Ihnen die Aufnahme verweigern falls Sie HIV-positiv sind.<BR>
<BR>
Falls Sie nicht daran befragt werden m&uuml;ssen Sie noch ganz genau die Allgemeinen Bestimmungen gr&uuml;ndlich durchlesen. Es kann vorkommen dass bei der Aufnahme bestehende Krankheiten aus der Versicherung ausgeschlossen werden, auch wenn kein Aufnahmeformular verlangt ist. Eine private Versicherung hat keine Aufnahmepflicht.<BR>
<BR>
3. Es kann auch davon abh&auml;ngen wer durch die Taggeldversicherung versichert ist: Sie als individueller Arbeitnehmer (also Herr Lambda der bei der Firma Beta arbeitet) oder Sie als 'anonymer' Arbeitnehmer (also irgendeine Personn die bei der Firma Beta angestellt ist). In dem zweiten Fall werden Sie versichert unabh&auml;ngig von Ihren Gesundheitszustand.<BR>
<BR>
4. Falls Sie Arbeitsstelle wechseln gibt es oft ein Freiz&uuml;gigkeitsrecht f&uuml;r die TGV, sei sie 'sozial' oder privat.<BR>
<BR>
5. Allgemein gilt: falls Ihrer HIV-Status nur Ihnen bekannt ist (anonymer Test z. B.) dann haben Sie keinen Grund dies der Versicherung mitzuteilen. Ist dieser Status beweisbar, dann sollten Sie es im Antragsformular angeben, wenn die Frage gestellt wird. Die Leistungen k&ouml;nnen vielleicht gek&uuml;rzt werden oder es wird ein (un)begrenzten Vorbehalt angebracht: Sie vermeiden aber den Risiko dass die TGV ihnen sp&auml;ter und r&uuml;ckg&auml;nging verweigert wird, und dann oft erst wenn Sie sie eigendlich br&auml;uchten.<BR>
<BR>
6. Wird der Antragsformular nicht vertraulich behandelt (z. B. mit dem Arbeitgeber zusammen ausgef&uuml;llt) haben Sie ein Recht zur L&uuml;ge (Schutz Ihrer Privatsph&auml;re). Es wird empfohlen den Gesundheitszustand nicht im Formular anzugeben sondern dies separat dem Vertrauensarzt oder der Vertrauens&auml;rztin der Versicherung mitteilen. Die ist die Versicherung informiert dass es eine bestehende Krankheit gibt, ohne zu wissen um welche Krankheit es sich handelt.<BR>
<BR>
PS: Sie k&ouml;nnen bei der Aids-Hilfe Schweiz die Broschure &quot;von Aids biz Z, antworten auf AIDS&quot; bestellen (AHS, postfach 141, 8031 Z&uuml;rich, 01-273 42 42, aids@aids.ch). Sie enth&auml;hlt u. a. zwei Kapiteln &uuml;ber Arbeit, Versicherungen, Rechte, etc. Sie enth&auml;hlt ausserdem auch verschiedene Adressen von Beratungstellen die sich in der Deutschen Schweiz befinden.<BR>
<P>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="Legal-msg.cgi?2"><IMG ALIGN=right BORDER=0 SRC=/gif/down.gif></A></TD>
</TD>
</TR>
</TABLE>
<HR>
<CENTER>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
[ <A HREF="Legal-post.html">Sendung der Frage</A> ]
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-293</DOCNO>
<DOCOLDNO>IA017-000178-B040-315</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-msg.cgi?2 192.33.214.13 19970106045718 text/html 2348
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:57:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HIVNet CH - Juristische Informationen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-tdm.cgi"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>
<UL>
<H2>Juristische Informationen</H2>
<H3><I>Frage Nr 2 -  2 October, 16:14</I></H3>
<BR CLEAR>
<HR>
<TABLE CELLPADDING=10 BORDER=0>
<TR>
<TD VALIGN=top><A HREF="Legal-msg.cgi?3"><IMG ALIGN=right BORDER=0 SRC=/gif/up.gif></A></TD>
<TD ROWSPAN=2>
<P>
<B><I>Objekt:</B></I><UL>
Personal Computer - Wandlung
<P>
</UL>
<B><I>Frage:</B></I><UL>
Habe ich ein Recht auf Geld zur&uuml;ck, wenn eine Sache einen schweren Mangel aufweist (neuer Personal Computer l&auml;uft nicht). Im OR habe ich Recht auf Wandlung gelesen. Was bedeutet nun dies: Kann ich zum H&auml;ndler gehen und sagen:<BR>
Ich will jetzt wandeln, bitte Geld zur&uuml;ck.<BR>
<BR>
Besten Dank f&uuml;r die Antwort im voraus.<BR>
<BR>
Mfg<BR>
Peter Aregger<BR>
<P>
</UL>
<B><I>Antwort:</B></I><UL>
Ja!<BR>
<BR>
Laut Gesetz (OR art. 197) haftet der Verk&auml;ufer &quot;sowohl f&uuml;r die zugesicherten Eigenschaften als auch daf&uuml;r, dass die Sache nicht k&ouml;rperliche oder rechtliche M&auml;ngel habe, die ihren Wert oder ihre Tauglichkeit zu dem vorasugesetzten Gebrauche aufheben oder erheblich mindern&quot;.<BR>
<BR>
Es ist anzunehmen dass ein Personal Computer gekauft wird damit er ben&uuml;tzt werden kann. Sollte dies nicht der Fall seien, hatfet der Verk&auml;ufer daf&uuml;r.<BR>
<BR>
Welche M&ouml;glichkeiten gibt es dann? Entweder Sie bekommen das Geld wieder zur&uuml;ck (Wandelung, OR 205) oder Sie tauschen den Personnal Computer um (Ersatzleistung, OR 206). Dies w&auml;re wahrscheinlich die Beste L&ouml;sung falls Sie nicht Ihr Vertrauen im Verk&auml;ufer verloren haben und einen Personnel Computer brauchen!<BR>
<BR>
PS: was ist der Zusammenhang zwischen HIV/AIDS und diese Frage???<BR>
<P>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom><A HREF="Legal-msg.cgi?1"><IMG ALIGN=right BORDER=0 SRC=/gif/down.gif></A></TD>
</TD>
</TR>
</TABLE>
<HR>
<CENTER>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
[ <A HREF="Legal-post.html">Sendung der Frage</A> ]
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-294</DOCNO>
<DOCOLDNO>IA017-000178-B040-328</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/consult/Legal-msg.cgi?1 192.33.214.13 19970106045727 text/html 3087
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:57:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>HIVNet CH - Juristische Informationen</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="Legal-tdm.cgi"><IMG BORDER=0 ALIGN=right SRC="/d/gif/konsult.gif"></A>
<UL>
<H2>Juristische Informationen</H2>
<H3><I>Frage Nr 1 - 24 September, 19:05</I></H3>
<BR CLEAR>
<HR>
<TABLE CELLPADDING=10 BORDER=0>
<TR>
<TD VALIGN=top><A HREF="Legal-msg.cgi?2"><IMG ALIGN=right BORDER=0 SRC=/gif/up.gif></A></TD>
<TD ROWSPAN=2>
<P>
<B><I>Objekt:</B></I><UL>
Pensionskasse
<P>
</UL>
<B><I>Frage:</B></I><UL>
Muss ich als HIV Positiver das Pensionskassenaufnahemformular betreffend Gesundheitszustand wahrheitsgetreu ausf&uuml;llen?<BR>
<P>
</UL>
<B><I>Antwort:</B></I><UL>
Keine leichte Frage weil es unter anderem um die Rolle des Schweigens beim ausf&uuml;llen eines Gesundheitsformular geht (siehe auch Punkt 5!)<BR>
<BR>
1. Die Pensionskasse in der Sie aufgenommen werden sollen bietet das obligatorische Gesetzesminimum an. Da spielt der Gesundheitszustand keine Rolle: die Pensionskasse muss und wird Sie aufnehmen. Ein Aufnahmeformular darf in diesem Fall dementsprechend keine mit dem Gesundheitszustand verbundenen Fragen stellen.<BR>
<BR>
2. Die Pensionskasse bietet Leistungen die das obligatorische Gesetzesminimum &uuml;bersteigen. Die &uuml;berobligatorischen Leistungen kann die Pensionskasse entweder k&uuml;rzen oder mit einem bis zu 5 Jahren geltenden Vorbehalt anbringen.<BR>
<BR>
M&uuml;ssen Sie hier wahreitsgetreu das Formular ausf&uuml;llen? Falls es keinen Beweis gibt, dass Sie HIV-positiv sind (z.B. Sie haben nur einen anonymen Test gemacht) dann k&ouml;nnen Sie den Fragebogen &quot;frei&quot; ausf&uuml;llen, und falsche Auskunfte geben.<BR>
<BR>
Falls es nachweisbar ist dass Sie HIV-positiv sind, dann sollten Sie den Formular treu ausf&uuml;llen. Der Risiko ist sonst dass Ihnen Leistungen verweigert werden oder dass Sie &uuml;berhaupt von einer Zusatzversicherung (&uuml;berobligatorischer Teil) ausgeschlossen werden. (Aber: es ist auch m&ouml;glich das dies vorkommt wenn Sie das Formular wahreitsgetreu ausf&uuml;llen ...).<BR>
<BR>
3. Gibt es eine Gefahr, dass das Formular nicht vertraulich behandelt wird (Arbeitgeber, Personnalchef, etc.) dann haben Sie ein Recht (Schutz der Privatsph&auml;re) zur L&uuml;ge.<BR>
<BR>
4. Falls Sie Stelle wechseln -und dabei auch Pensionskasse- muss die neue Kasse Sie aufnehmen wie Sie sind (Freiz&uuml;gigkeit). Das bedeutet dass keine neue Vorbeh&auml;lte angebracht werden k&ouml;nnen. Geltende Vorbehalte der alten Kasse k&ouml;nnen allerdings f&uuml;r die &uuml;brigbleibende Zeit &uuml;bernommen werden.<BR>
<BR>
5. Es lohnt sich immer im Zweifelfall eine Beratungstelle zu besuchen!<BR>
<P>
</UL>
</TD>
</TR>
<TR>
<TD VALIGN=bottom></TD>
</TD>
</TR>
</TABLE>
<HR>
<CENTER>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
[ <A HREF="Legal-post.html">Sendung der Frage</A> ]
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>
</CENTER>
</UL>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-295</DOCNO>
<DOCOLDNO>IA017-000178-B040-341</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/biblio/index.html 192.33.214.13 19970106045747 text/html 3513
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:08 GMT
Last-modified: Friday, 20-Dec-96 10:29:25 GMT
Content-length: 3325
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>HivNet: Bibliotheque</TITLE>
   </HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><IMG SRC="/f/gif/bibliotheque.gif" HEIGHT=106 WIDTH=130 ALIGN=LEFT>
<A HREF="/f/webforum/index.html"><IMG SRC="/f/gif/webforum2.gif" ALT="Webforum" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/consult/index.html"><IMG SRC="/f/gif/consultation2.gif" ALT="Consultations" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" ALT="Artworks" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" ALT="Organisations" BORDER=0 HEIGHT=60 WIDTH=65 ALIGN=TOP></A>
<BR CLEAR>
</P>

<PRE>
 
 
</PRE>

<UL>
<LI><A HREF="/anais/f/ATN.cgi">AIDS TREATMENT NEWS</A>
(en anglais) </LI>

<UL>
<P>Inventaire des traitements exp&eacute;rimentaux et standards, dont ceux
disponibles &agrave; ce jour. Interviews de personnalit&eacute;s du monde
scientifique, de professionnels de la sant&eacute; ainsi que de personnes
vivant avec le Sida ou porteuses du VIH. Collection de l'information diffus&eacute;e
lors de conf&eacute;rences, dans les journaux et les bases de donn&eacute;es,
etc. </P>
</UL>

<LI><A HREF="/anais/f/SUMM-96.cgi">AIDS Daily Summary</A>
(en anglais) </LI>

<UL>
<P>Information collect&eacute;e gr&acirc;ce aux &quot;Center for Disease
Control and Prevention (CDC) National AIDS Clearinghouse&quot;. La reproduction
non commerciale des documents est autoris&eacute;e et encourag&eacute;e,
&agrave; la seule condition que la source &quot;CDC Clearinghouse&quot;
soit cit&eacute;e. Ce service public ne refl&egrave;te en aucune fa&ccedil;on
la position officielle du &quot;CDC Clearinghouse&quot;. </P>
</UL>

<LI><A HREF="/anais/f/INFOTHEQUE.cgi">INFOTHEQUE SIDA
</A>(en fran&ccedil;ais, allemand et italien) </LI>

<UL>
<P>Magazine bimestriel publi&eacute; par la Fondation &quot;Sida Info Doc
Suisse&quot; depuis septembre 1989. Les num&eacute;ros 4/95, 1/96, 2/96
et 3/96 sont disponibles dans cette bibiblioth&egrave;que. </P>
</UL>

<LI><A HREF="/anais/f/VON-AIDS.cgi">Von Aids Bis Z</A>
(en allemand et fran&ccedil;ais) </LI>

<UL>
<P>L'article &quot;Sida - Travail, assurances et s&eacute;curit&eacute;
sociale en Suisse&quot; est extrait de la brochure &laquo;Von Aids bis
Z&raquo; en cours de r&eacute;&eacute;dition. Gratuitement disponible en
imprim&eacute; pour les personnes s&eacute;ropositives ou atteintes du
Sida aupr&egrave;s de <A HREF="/pwa/index.html">&quot;PWA-Suisse&quot;</A>
052 212 47 47 et en format &eacute;lectronique sur HivNet.ch. <BR>
<BR>
</P>
</UL>

<LI><A HREF="/f/biblio/others.html">Autres publications</A>
disponibles sur Internet. </LI>

<P>
<HR></P>

<UL>
<LI><B><A HREF="/f/info/index.html">Comment</A></B>
ins&eacute;rer un texte ou une publication dans la biblioth&egrave;que
de HivNet.ch. </LI>

<LI><A HREF="/anais/admin">Ins&eacute;rer</A> un texte
ou une publication. </LI>
</UL>

<P>
<HR></P>
</UL>

<CENTER><P><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" ALT="Home" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" ALT="Rechercher" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" ALT="Contact" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=TOP></A>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-296</DOCNO>
<DOCOLDNO>IA017-000178-B040-354</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/webforum/index.html 192.33.214.13 19970106045755 text/html 1646
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:17 GMT
Last-modified: Saturday, 30-Nov-96 20:52:49 GMT
Content-length: 1456
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>HIVNet CH - Forum</TITLE>
   </HEAD>
<BODY BGCOLOR="#FFFFFF">

<IMG SRC="/f/gif/webforum.gif" ALIGN=LEFT><A HREF="/f/biblio/index.html">
</A>



<CENTER><P><A HREF="/f/biblio/index.html"><IMG SRC="/f/gif/bibliotheque2.gif" ALT="Webforum" BORDER=0  ALIGN=TOP></A><A HREF="/f/consult/index.html"><IMG SRC="/f/gif/consultation2.gif" ALT="Consultations" BORDER=0  ALIGN=TOP></A><A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" ALT="Artworks" BORDER=0  ALIGN=TOP></A><A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" ALT="Organisations" BORDER=0  ALIGN=TOP></A><BR CLEAR>
</P></CENTER>
<PRE>

</PRE>
<BR CLEAR>
<UL>
<H2>Choisissez votre forum !</H2>

<UL>
<LI><A HREF="GUESTBOOK-forum.html">Bo&icirc;te &agrave; id&eacute;es</A></LI>

<UL>
<P>Donnez-nous votre avis. D&eacute;clarations d'amour bienvenues...</P>
</UL>

<LI><A HREF="FORUM-forum.html">Bric-&agrave;-brac</A></LI>

<UL>
<P>Tout ce qui ne trouve pas sa place ailleurs est bienvenu ici.</P>
</UL>
</UL>

<P>
<HR></P>

<UL>
<LI><B><A HREF="http://www.hivnet.ch/f/info/#Participer">Ouvrez</A></B>
votre propre forum</LI>
</UL>

<CENTER><P>
<HR><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" ALT="Home" BORDER=0 ></A><A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" ALT="Rechercher" BORDER=0 ></A><A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" ALT="Contact" BORDER=0  ALIGN=TOP></A></P></CENTER>
</UL>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-297</DOCNO>
<DOCOLDNO>IA017-000178-B041-8</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/geneve/collectif/index.html 192.33.214.13 19970106045803 text/html 5693
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:26 GMT
Last-modified: Thursday, 28-Nov-96 15:42:32 GMT
Content-length: 5503
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
  <TITLE>1er D&eacute;cembre 1996</TITLE>
</HEAD>
<BODY BGCOLOR="#ffffff">

<H2><A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif"
ALIGN="RIGHT" BORDER="0"></A><BR>
<I>Collectif 1er D&eacute;cembre 1996</I></H2>

<H2 ALIGN=CENTER><HR SIZE="3" WIDTH="90%"></H2>

<P ALIGN=CENTER><IMG SRC="titre.gif" WIDTH="354" HEIGHT="89" ALIGN="BOTTOM"
NATURALSIZEFLAG="3"></P>

<P ALIGN=CENTER><TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" WIDTH=
"100%">
<TR>
<TD ROWSPAN="2" COLSPAN="2" ALIGN="CENTER"><B><I><FONT COLOR="#FF0099" SIZE=+1>Collectif 1er D&eacute;cembre<BR>
</FONT></I></B><IMG SRC="logo_ani.gif" WIDTH="113" HEIGHT="100" ALIGN="BOTTOM"
NATURALSIZEFLAG="3" ALT="Logo collectif 1er Dec; anim" BORDER="0">&nbsp;<BR>
<B><FONT SIZE=+1><A HREF="program/samedi.html">Programme du Samedi</A></FONT></B><BR>
<B><FONT SIZE=+1><A HREF="program/dimanche.html">Programme du Dimanche</A></FONT></B></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD ROWSPAN="3" COLSPAN="2" ALIGN="CENTER">&nbsp; <A HREF="affiche/affiche.html"><IMG SRC="aff_mini.gif" WIDTH="177"
HEIGHT="236" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Affiche miniature journe mondiale sida"
BORDER="0"></A>&nbsp;<BR>
<FONT SIZE=+1><A HREF="affiche/affiche.html">Grande affiche</A></FONT><BR>
<FONT SIZE=-1>Copyright: Wazzem 1996</FONT></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD ROWSPAN="2" COLSPAN="2" ALIGN="CENTER"><A HREF="http://www.yop.ch/ocom/db-sidaide.html"><IMG SRC="said_ani.gif"
WIDTH="127" HEIGHT="130" ALIGN="BOTTOM" NATURALSIZEFLAG="3" BORDER="0" 
ALT="logo SidAide"></A><BR>
<B><FONT SIZE=+1><A HREF="http://www.yop.ch/ocom/db-sidaide.html">Programme
SidAide</A></FONT></B></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</P>

<P ALIGN=CENTER><HR WIDTH="80%" SIZE="3"></P>

<H1 ALIGN=CENTER>SAMEDI 30 Novembre 1996</H1>

<P ALIGN=CENTER><B><I><FONT COLOR="#A601D0" SIZE=+3>MARCHE DE SOLIDARIT&Eacute;
</FONT></I></B></P>

<P ALIGN=CENTER><B><FONT SIZE=+2>D&eacute;part 14H00 Place Neuve<BR>
Arriv&eacute;e 16H30, Place de la Navigation</FONT></B></P>

<P ALIGN=CENTER><B><I><FONT COLOR="#D90274" SIZE=+3>Venez nombreux !</FONT></I></B></P>

<P ALIGN=CENTER><HR WIDTH="80%" SIZE="3"></P>

<BLOCKQUOTE>
  <P ALIGN=CENTER>Le collectif des associations de lutte contre le Sida (PVA-Gen&egrave;ve,
  Dialogai, Groupe Sida Gen&egrave;ve, Minist&eacute;re Sida, Aides Haute-Savoie)
  a choisi, cette ann&eacute;e, le th&eacute;me suivant:</P>
  <P ALIGN=CENTER><B><FONT COLOR="#FF0099">&quot;Un Monde, Un Espoir, <BR>
  Des Mondes, Desespoir !&quot;</FONT></B></P>
  <P ALIGN=CENTER>L'espoir de voir de nouvelles th&eacute;rapies se montrer
  &quot;prometteuses&quot;. L'espoir de sentir grandir autour de nous la
  solidarit&eacute; et le soutien. L'espoir de sentir grandir autour de nous
  la solidarit&eacute; et le soutien. L'espoir de pouvoir croire &agrave;
  nos lendemains.</P>
  <P ALIGN=CENTER>Desespoir, des in&eacute;galit&eacute;s sur le th&egrave;me
  de la sant&eacute;, des rapports Nord-Sud. D&eacute;sespoir de sentir encore
  des regards trop lourds et d'entendre des paroles charg&eacute;es de m&eacute;pris
  ou d'incompr&eacute;hension. D&eacute;sepoir d'avoir peur d'y croire.</P>
  <P ALIGN=CENTER>Pour mener &agrave; bien nos activit&eacute;s, tant dans
  le domaine de la pr&eacute;vention que dans celui de l'aide apport&eacute;e
  aux personnes touch&eacute;es par la maladie, nous sollicitons, cette ann&eacute;e
  encore, votre g&eacute;n&eacute;rosit&eacute;.</P>
  <P ALIGN=CENTER>Vous pouvez adressez vos dons &agrave; l'aide d'un bulletin
  de versement au N&deg; de compte suivant:<BR>
  CCP: 12-23084-4 compte &quot;1er D&eacute;cembre 1996&quot;</P>
  <P ALIGN=CENTER>En vous remerciant de votre confiance!</P>
</BLOCKQUOTE>

<P ALIGN=CENTER><HR WIDTH="80%" SIZE="3"></P>

<P ALIGN=CENTER><B><FONT SIZE=-1>Les organisateurs tiennent &agrave; remercier
pour leur collaboration: </FONT></B></P>

<P ALIGN=CENTER><FONT SIZE=-1>Sat Productions, l'association Entr'Aide,
Sida Info Doc Suisse, La Ville de Gen&egrave;ve, l'ADEP: Groupement des
commer&ccedil;ants des P&acirc;quis. Les Transports Publics Genevois, Th&eacute;&acirc;tre
les Montreurs d'Images, La Fanfare du Ch&acirc;teau, Les Soeurs de la perpetuelle
indulgence, Michel Besson, Marie-Claire ...., Wazzem, Association &quot;Posez
votre regard sur la vie&quot;, la Traverse, Aide Suisse contre le Sida,
ASI: Groupe d'int&eacute;r&ecirc;ts communs, les Artisans Boulangers et
P&acirc;tissiers de Gen&egrave;ve, &quot;Aujourd'hui pour Demain&quot;,
Chorale de Bons-en-Chablais, Virginie, la Tulipe d'Or, Aspasie et ceux que
nous n'avons pas eu le temps de remercier ici et un grand merci &agrave;
tous les b&eacute;n&eacute;voles.</FONT></P>

<P ALIGN=CENTER><HR WIDTH="80%" SIZE="3"></P>

<BLOCKQUOTE>
  <P ALIGN=CENTER><FONT SIZE=-1>Infographie: <A HREF="http://www.hivnet.ch/~Miguelito">Miguelito</A>,
  <A HREF="http://www.hivnet.ch/fdp/index.html">Fondation du Pr&eacute;sent</A></FONT></P>
  <P ALIGN=CENTER>&nbsp;</P>
</BLOCKQUOTE>

<P ALIGN=CENTER><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" ALIGN=
"BOTTOM" BORDER="0"></A><A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif"
ALIGN="BOTTOM" BORDER="0"></A><A HREF="/f/hivnet/index.html"><IMG SRC="/f/gif/intouch2.gif"
ALIGN="BOTTOM" BORDER="0"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-298</DOCNO>
<DOCOLDNO>IA017-000178-B041-21</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/relig.html 192.33.214.13 19970106045811 text/html 2474
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:34 GMT
Last-modified: Tuesday, 22-Oct-96 14:42:56 GMT
Content-length: 2285
Content-type: text/html
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Organisations: AIDS Ministers</TITLE>
   <META NAME="GENERATOR" CONTENT="Mozilla/3.0Gold (Win95; I) [Netscape]">
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><A HREF="http://www.hivnet.ch/f/organs/index.html"><IMG SRC="http://www.hivnet.ch/f/gif/organisations2.gif" ALT="Organisations" BORDER=0  ALIGN=RIGHT></A><ALIGN=BASELINE></P>

<H1>Aum&ocirc;niers sida</H1>

<P>
<HR></P>

<CENTER><P><A HREF="#bls">BL,BS</A> / <A HREF="#ge">GE</A> / <A HREF="#zh">ZH</A>
</P></CENTER>

<CENTER><P>
<HR><A NAME="bls"></A></P></CENTER>

<H3>Basel</H3>

<UL>
<LI><B>Aidspfarramt beider Basel<BR>
</B>Peterskirchplatz 8<BR>
CH-4051 Basel<BR>
<I>tel (061) 262 06 66<BR>
fax (061) 261 07 69</I><BR>
</LI>

<UL>
<P><I>Benedikt Gyssler, <BR>
Peter Lack,<BR>
Ines Rivera (Bereich Frauen und Kinder)</I></P>
<I></I></UL>

<LI><B>Herr Benedict H&auml;nggi<BR>
</B><I>Katholischer Aids-Seelsorger<BR>
Gef&auml;ngnis-Seelsorger<BR>
</I>Eisenstr. 46<BR>
CH-4056 Basel<BR>
<I>tel (061) 301 33 23</I><BR>
</LI>
</UL>

<P><A NAME="ge"></A></P>

<H3>Gen&egrave;ve</H3>

<UL>
<LI><B>Mme Dominique Roulin<BR>
</B><I>Pasteure<BR>
</I>CUP, av. du Mail 2<BR>
CH-1205 Gen&egrave;ve<BR>
<I>tel (022) 329 10 86</I><BR>
</LI>

<UL>
<P>lu-ve, les apr&egrave;s-midi</P>
</UL>

<P><I><A HREF="http://www.hivnet.ch/f/organs/aidsmin.html">Minist&egrave;re
Sida<BR>
</A>tel (022) 736 24 26</I><BR>
</P>
</UL>

<P><A NAME="zh"></A></P>

<H3>Z&uuml;rich</H3>

<UL>
<LI><B>Aidspfarramt<BR>
</B>Universit&auml;tsstr. 48<BR>
CH-8006 Z&uuml;rich<BR>
<I>tel (01) 255 90 55 oder 255 11 11 (Sucher &uuml;ber Zentrale)</I><BR>
</LI>

<UL>
<P>Frau Sibylle Sch&auml;r,<BR>
Herr Guido Schwitter</P>
</UL>
</UL>

<P>
<HR>Source: Aide Suisse contre le Sida, 5.95 </P>

<P>
<HR></P>

<CENTER><P><A HREF="http://www.hivnet.ch/f/index.html"><IMG SRC="http://www.hivnet.ch/f/gif/home2.gif" ALT="Home" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="http://www.hivnet.ch/f/search/index.html"><IMG SRC="http://www.hivnet.ch/f/gif/search2.gif" ALT="Rechercher" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="http://www.hivnet.ch/f/hivnet/index.html"><IMG SRC="http://www.hivnet.ch/f/gif/intouch2.gif" ALT="Contact" BORDER=0 HEIGHT=100 WIDTH=100 ALIGN=TOP></A>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-299</DOCNO>
<DOCOLDNO>IA017-000178-B041-33</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/home.html 192.33.214.13 19970106045818 text/html 2753
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:41 GMT
Last-modified: Saturday, 13-Apr-96 19:09:18 GMT
Content-length: 2563
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Organisations: Places for long-term sojourns</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Lieux d'accueil</H1><HR>


<P><center>

<A HREF="#bls">BL,BS</A> / <A HREF="#be">BE</A> / <A HREF="#ge">GE</A> / <A HREF="#ju">JU</A> / <A HREF="#sg">SG</A> / <A HREF="#vd">VD</A> / <A HREF="#zh">ZH</A>

<P></center><HR>



<A NAME="bls"><H3>Basel</H3></A>

<UL>

<LI><B>Basler Lighthouse</B><br>

Hebelstr. 90<br>

CH-4056 Basel<br>

<I>tel (061) 261 43 43<br></I><P>

<LI><B>Haus Gilgamesch</B><br>

<I>Dr. P. Joset</I><br>

Herrenweg 8<br>

CH-4054 Basel<br>

<I>tel (061) 301 38 42<br></I>

</UL>



<A NAME="be"><H3>Bern</H3></A>

<UL>

<LI><B>Wohngemeinschaft St&ouml;ckli</B><br>

Niesenblickstr.5<br>

CH-3600 Thun<br>

<I>tel (033) 231 992</I>

</UL>



<A NAME="ge"><H3>Gen&egrave;ve</H3></A>

<UL>

<LI><B>La Maison</B><br>

<I>SidAccueil</I><br>

22, ch. du Velours<br>

CH-1231 Conches<br>

<I>tel (022) 839 91 11<br>

fax (022) 346 54 55</I>

</UL>



<A NAME="ju"><H3>Jura</H3></A>

<UL>

<LI><B>Espace Bleu</B><br>

Case Postale 40<br>

CH-2800 Del&eacute;mont<br>

<I>tel (066) 224 747<br></I>

</UL>



<A NAME="sg"><H3>St. Gallen</H3></A>

<UL>

<LI><B>Wohngemeinschaft <i>'Arche'</i></B><br>

<i>Verein 'Raum f&uuml;r HIV+ und Aids-Kranke'</I><br>

Schwalbenstr. 2A<br>

CH-9001 St. Gallen<br>

<I>tel (071) 223 842 oder 221 134<br></I>

</UL>



<A NAME="vd"><H3>Vaud</H3></A>

<UL>

<LI><B>Fondation du Levant</B><br>

Av. Virgile-Rossel 20<br>

CH-1012 Lausanne<br>

<I>tel (021) 653 60 81 ou 83<br>

fax (021) 653 77 61</I>

</UL>



<A NAME="zh"><H3>Z&uuml;rich</H3></A>

<UL>

<LI><B>Anker-Huus</B><br>

Gladbachstr. 97<br>

CH-8044 Z&uuml;rich<br>

<I>tel (01) 250 71 81<br></I><P>

<LI><B>Sune-Egge</B><br>

<i>Pr. Sieber</i><br>

Konradstr. 62<br>

CH-8005 Z&uuml;rich<br>

<i>tel (01)272 24 66</i><P>

<LI><B>Z&uuml;rcher Aids-Projekte</B><br>

Turbinenstr. 10<br>

CH-8005 Z&uuml;rich<br>

<I>tel (01) 271 87 67</I><P>

<LI><B>Z&uuml;rcher Lighthouse</B><br>

Carmenstr. 42<br>

CH-8032 Z&uuml;rich<br>

<I>tel (01) 265 38 11

</UL>



<HR>

Source: Aide Suisse contre le Sida, 5.95

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-300</DOCNO>
<DOCOLDNO>IA017-000178-B041-57</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/gsg/sec1.html 192.33.214.13 19970106045836 text/html 21094
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:58:57 GMT
Last-modified: Saturday, 13-Apr-96 16:18:41 GMT
Content-length: 20903
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>GSG et Minist&egrave;re Sida: 'Mes Volont&eacute;s'</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><HR>

<H2>Dossier <i>'Mes Volont&eacute;s'</i></H2>

<H4>R&eacute;alis&eacute; par le <A HREF="index.html">Groupe Sida Gen&egrave;ve</A> et <A HREF="/f/organs/aidsmin.html">Minist&egrave;re Sida</A></H4>

<HR WIDTH=550><UL>



<A NAME="fiche1"><H3>1 - Testament biologique</H3></A>

<H4>D&eacute;finition</H4>

<UL>Le testament biologique est un acte par lequel vous pouvez faire conna&icirc;tre vos volont&eacute;s en mati&egrave;re de soins m&eacute;dicaux. Dans le contexte du sida, il n'est pas rare de souhaiter &agrave; un certain moment que l'on cesse les investigations au profit des soins de confort.<P></UL>

<H4>Utilit&eacute;</H4>

<UL>Le but d'un tel document est avant tout de faire conna&icirc;tre vos intentions. Il est toutefois important de noter qu'il permet souvent d'approfondir le dialogue avec votre m&eacute;decin traitant et vos proches. Dans le contexte du sida, ce dialogue est d'autant plus important qu'il permet de mieux cerner ce qu'on entend par acharnement th&eacute;rapeutique et le moment o&ugrave; l'on estime que commence cet acharnement.<P></UL>

<H4>Proc&eacute;d&eacute;</H4>

<UL>Il est pr&eacute;f&eacute;rable de r&eacute;diger cet acte en trois exemplaires dont un que vous remettez &agrave; votre m&eacute;decin, un que vous confiez &agrave; une personne de confiance et de r&eacute;f&eacute;rence (ami, aum&ocirc;nier, etc..) et le dernier que vous gardez pour vous-m&ecirc;me.<P>

<I><B>Remarque:</B></I><br>

Ces dispositions peuvent &ecirc;tre annul&eacute;es ou modifi&eacute;es en tout temps. Il est n&eacute;anmoins recommand&eacute; de d&eacute;truire les documents ant&eacute;rieurs dans le cas d'une nouvelle r&eacute;daction. Il ne faut pas oublier non plus de pr&eacute;venir le m&eacute;decin et la personne de r&eacute;f&eacute;rence.<P></UL>

<H4>Exemple:</H4>

<UL><I>Je, soussign&eacute;, Alexandre Borlot, apr&egrave;s m&ucirc;re r&eacute;flexion et en pleine possession de mes facult&eacute;s, en pr&eacute;sence de mon accompagnante Rolande Dumas et en accord avec ma conjointe, demande que soient consid&eacute;r&eacute;es comme l'expression de ma volont&eacute; les dispositions suivantes:<br>

Je souhaite ne pas subir d'acharnement th&eacute;rapeutique et pouvoir b&eacute;n&eacute;ficier de traitements de confort.

Dans tous les cas, je demande que mon avis soit respect&eacute;.<br>

S'il arrivait que je ne sois pas en mesure de donner mon avis (coma, troubles neurologiques, etc.), je demande que ce texte serve de document de r&eacute;f&eacute;rence et qu'il me soit uniquement administr&eacute; un traitement de confort.<P>

Fait &agrave; Gen&egrave;ve, le 23 mars 1995, Signature:</I><P></UL>



</UL><HR WIDTH=550><UL>



<A NAME="fiche2"><H3>2 - Succession et testament</H3></A>

Cett fiche a sa <A HREF="sec2.html">propre page</A>.



</UL><HR WIDTH=550><UL>



<A NAME="fiche3"><H3>3 - Enfants</H3></A>

Les voeux en forme de testament sont un acte dans lequel vous manifestez une intention dont la r&eacute;alisation d&eacute;pend avant tout de la d&eacute;cision d'une autorit&eacute;. Ainsi, si vous &ecirc;tes seul(e) &agrave; d&eacute;tenir l'autorit&eacute; parentale sur vos enfants mineurs, vous avez tout int&eacute;r&ecirc;t, dans la perspective de votre d&eacute;part, &agrave; les savoir pris en charge selon vos souhaits.<P>

Pour ce faire, vous pouvez soit dans votre testament, soit sur une feuille &agrave; part, r&eacute;diger vos souhaits quant &agrave; la prise en charge de vos enfants en argumentant le plus clairement et avec le plus de d&eacute;tails possibles les raisons de votre choix. Ces dispositions manuscrites, dat&eacute;es et sign&eacute;es sont &agrave; remettre &agrave; la Justice de Paix (cf. fiche succession) ou &agrave; une personne de confiance qui sera contrainte de les d&eacute;poser aupr&egrave;s de cette m&ecirc;me institution au plus tard lors de votre d&eacute;c&egrave;s.<P>

La d&eacute;cision finale sera prise par l'autorit&eacute; tut&eacute;laire, en l'occurrence la Chambre des tutelles, qui prend largement en compte les consid&eacute;rations et les souhaits argument&eacute;s des personnes concern&eacute;es, mais qui agit en priorit&eacute; selon ce que commande le bien de l'enfant.<P>

<I><B>Remarque:</B></I><br>

Pour tous renseignements sur les familles d'accueil et sur les questions li&eacute;es aux enfants, vous pouvez vous adresser &agrave;:<P>

Plateforme Sida et enfants, Ir&egrave;ne Girardet, <I>tel: (022) 752 46 39</I><br>

Protection de la Jeunesse, Dani&egrave;le Fournier, <I>tel: (022) 787 63 30</I><br>

<A HREF="index.html">Groupe Sida Gen&egrave;ve</A>, Brigitte Studer, <I>tel: (022) 700 15 00</I><P>



</UL><HR WIDTH=550><UL>



<A NAME="fiche4"><H3>4 - Assurances</H3></A>

Il n'est question ici que des assurances qui octroient des prestations en capital ou en rentes aux survivants ou aux b&eacute;n&eacute;ficiaires que vous auriez d&eacute;sign&eacute;s.<P>

<A NAME="fiche4par1"><H4>Pr&eacute;voyance professionnelle</H4></A>

<UL>On l'appelle plus commun&eacute;ment le deuxi&egrave;me pilier ou l'assurance li&eacute;e &agrave; la LPP (loi f&eacute;d&eacute;rale sur la pr&eacute;voyance professionnelle). Cette assurance est constitu&eacute;e d'une partie obligatoire ou l&eacute;gale dont vous &ecirc;tes au b&eacute;n&eacute;fice si vous avez &eacute;t&eacute; salari&eacute;(e) plus de trois mois et si bien &eacute;videmment le capital (montant de libre-passage) ne vous a pas d&eacute;j&agrave; &eacute;t&eacute; vers&eacute; auparavant. Elle peut &ecirc;tre, en outre, constitu&eacute;e d'une partie facultative, &agrave; savoir de prestations compl&eacute;mentaires contractuellement d&eacute;cid&eacute;es entre votre ancien employeur et la caisse de pr&eacute;voyance en question.<P>

<H4>La partie obligatoire:</H4><P>

Vous &ecirc;tes un homme:<br>

<UL><LI>Votre &eacute;pouse (veuve) recevra 60% de la rente d'invalidit&eacute; assur&eacute;e ou de la rente de vieillesse en cours pour autant qu'elle remplisse, lors de votre d&eacute;c&egrave;s, l'une des conditions suivantes:<br>

a) elle a un ou plusieurs enfants &agrave; charge,<br>

b) elle est &acirc;g&eacute;e d'au moins 45 ans et a &eacute;t&eacute; mari&eacute;e 5 ans au moins.<br>

Si elle ne remplit pas ces conditions, elle a droit &agrave; une allocation unique g&eacute;n&eacute;ralement &eacute;gale &agrave; trois rentes annuelles.<br>

<LI>La femme divorc&eacute;e touchera une rente de veuve uniquement si, lors de votre d&eacute;c&egrave;s, une indemnit&eacute; ou une pension alimentaire &eacute;tait pr&eacute;vue par le jugement de divorce et si votre mariage avait dur&eacute; 10 ans au moins.

<LI>Votre concubin(e) ne b&eacute;n&eacute;ficiera d'aucune prestation &agrave; votre d&eacute;c&egrave;s.

<LI>Votre enfant (orphelin) touchera 20% de la rente d'invalidit&eacute; ou de la rente de vieillesse jusqu'&agrave; 18 ans r&eacute;volus respectivement jusqu'&agrave; l'ach&egrave;vement de sa formation professionnelle, mais au maximum jusqu'&agrave; 25 ans.<P></UL>

Vous &ecirc;tes une femme:<br>

<UL><LI>Ni votre mari ni votre concubin(e) n'auront droit &agrave; une rente. En effet, la rente de veuf n'est pas pr&eacute;vue par la loi.

<LI>Votre enfant touchera la rente d'orphelin aux m&ecirc;mes conditions que ci-dessus.</UL>

<H4>La partie facultative:</H4><P>

Cette partie d&eacute;pend des r&egrave;glements et des statuts des caisses de pensions qui sont libres d'&eacute;largir les conditions de droit aux rentes de survivants et m&ecirc;me d'&eacute;tendre le cercle des b&eacute;n&eacute;ficiaires. Ces caisses ont de par la loi l'obligation de fournir tous les renseignements que vous pouvez leur demander: n'h&eacute;sitez pas &agrave; le faire!<P>

Vous devez conna&icirc;tre le nom de la (derni&egrave;re) caisse &agrave; laquelle vous &ecirc;tes (&eacute;tiez) affili&eacute;(e) (vous avez au moins d&ucirc; recevoir &agrave; la fin de vos rapports de travail un questionnaire de la caisse). <P>Si toutefois vous ne savez toujours pas son nom, adressez-vous &agrave; votre dernier employeur afin qu'il vous le communique. Si ce dernier ou si l'institution de pr&eacute;voyance elle-m&ecirc;me ne vous donne pas les renseignements requis, vous pouvez vous en plaindre aupr&egrave;s de l'autorit&eacute; de surveillance:<br>

</UL></UL><center>

<B>Service de surveillance des institutions de pr&eacute;voyance</B><br>

26, rue du Stand / C.P. 337<br>

1211 Gen&egrave;ve 3<br>

<I>tel: (022) 327 55 23</I>

</center><UL><UL><P>

Il est possible que le r&egrave;glement de votre caisse pr&eacute;voie qu'un capital sera vers&eacute; &agrave; des b&eacute;n&eacute;ficiaires que vous avez d&eacute;sign&eacute;s sur la proposition d'assurance. Vous pouvez en g&eacute;n&eacute;ral changer librement cette clause en d&eacute;signant d'autres b&eacute;n&eacute;ficiaires dans votre testament -en pr&eacute;cisant bien de quelle assurance il s'agit- ou par avis recommand&eacute; &agrave; votre assureur. Le r&egrave;glement de l'institution peut restreindre le cercle des b&eacute;n&eacute;ficiaires que vous pouvez d&eacute;signer. Il est donc primordial de prendre connaissance des conditions g&eacute;n&eacute;rales de votre caisse de pr&eacute;voyance.</UL></UL><HR WIDTH=200><UL>

<H4><A NAME="fiche4par2">Assurance-vie</A></H4>

<UL>Vous avez contract&eacute; une assurance-vie et vous avez d&eacute;sign&eacute; les b&eacute;n&eacute;ficiaires du capital dans le cas o&ugrave; vous d&eacute;c&eacute;deriez. Vous pouvez toujours et en tout temps annuler librement la clause et d&eacute;signer d'autres b&eacute;n&eacute;ficiaires, soit par testament, soit sur avis recommand&eacute; &agrave; l'assureur.<P>

<I><B>Remarques:</B></I><br>

<UL><LI>Si le(s) b&eacute;n&eacute;ficiaire(s) est (sont) d&eacute;sign&eacute;(s), le capital est vers&eacute; en dehors de tout droit successoral et ne fait pas partie de la part r&eacute;servataire. Si toutefois il existe des cr&eacute;anciers, ceux-ci seront d&eacute;dommag&eacute;s en priorit&eacute; sur le capital sauf si le b&eacute;n&eacute;ficiaire d&eacute;sign&eacute; est le conjoint, les descendants, les grands-parents, les p&egrave;re et m&egrave;re ainsi que les fr&egrave;res et soeurs d&eacute;sign&eacute;s.

<LI>Si le(s) b&eacute;n&eacute;ficiaires(s) n'est (ne sont) pas d&eacute;sign&eacute;(s), le capital sera vers&eacute; dans le cadre de la loi successorale en tenant compte des parts r&eacute;servataires, des actifs et des passifs de la succession. Toutefois, les personnes nomm&eacute;es dans la cat&eacute;gorie ci-dessus b&eacute;n&eacute;ficieront du capital m&ecirc;me s'ils r&eacute;pudient la succession.<P></UL></UL>



</UL><HR WIDTH=550><UL>



<A NAME="fiche5"><H3>5 - Bail</H3></A>

<H4>Epoux unis sous un r&eacute;gime matrimonial</H4>

<UL>Lorsqu'un seul des deux &eacute;poux est titulaire du bail, l'autre conjoint se voit prot&eacute;g&eacute; par la loi qui lui octroie un droit de consentement et d'action pour tous les actes concernant le logement commun ou familial. Ainsi un bailleur ne peut cong&eacute;dier une personne dont le conjoint serait d&eacute;c&eacute;d&eacute;.</UL><P>

<H4>Concubins</H4>

<UL>Le concubinage ou l'union libre ne sont pas reconnus en droit suisse. Aussi, si l'un(e) des deux concubin(e)s titulaire du bail d&eacute;c&egrave;de, l'autre partenaire n'a aucun droit sur l'appartement -qu'ils ont pourtant habit&eacute; ensemble- si celui-ci/celle-ci n'a pas &eacute;t&eacute; cosignataire du bail en question.<P>

Il est donc primordial que le/la concubin(e) puisse demander au bailleur (la r&eacute;gie) de prendre part aux effets du bail en cosignant celui-ci. Il/elle acquerra ainsi les m&ecirc;mes droits sur l'appartement mais en partagera &eacute;galement les responsabilit&eacute;s, qu'il/elle sera seul(e) &agrave; assumer lors du d&eacute;c&egrave;s de son/sa partenaire.<P></UL>

<I><B>Remarques:</B></I><br>

<UL><LI>L'h&eacute;bergement d'un(e) concubin(e) ne peut pas &ecirc;tre pris par la r&eacute;gie comme une sous-location. Il n'y a donc aucune crainte de l'annoncer et de demander qu'il figure sur le bail.

<LI>La r&eacute;gie peut toutefois requ&eacute;rir du/de la futur(e) cosignataire des garanties, telles qu'un extrait de l'Office des poursuites ou une d&eacute;claration de revenu.<P></UL>



</UL><HR WIDTH=550><UL>



<A NAME="fiche6"><H3>6 - Questions frontali&egrave;res</H3></A>

Les diff&eacute;rents &eacute;l&eacute;ments abord&eacute;s dans ces fiches s'adressent &agrave; des personnes domicili&eacute;es &agrave; Gen&egrave;ve, voire en Suisse. Le cadre l&eacute;gal est par cons&eacute;quent helv&eacute;tique, respectivement genevois.<P>

Si vous habitez sur France, les informations contenues dans ces fiches ne vous concerneront que partiellement: en effet, le droit fran&ccedil;ais r&egrave;gle diff&eacute;remment -m&ecirc;me s'il y a souvent des similitudes- la succession, la garde des enfants, les assurances ou le bail. Le droit suisse peut s'appliquer &agrave; certaines conditions: assurances sociales suisses, contrat d'assurance-vie conclu en Suisse, hospitalisation en Suisse, etc. Les informations ci-dessous sont donn&eacute;es &agrave; titre indicatives.<P>

<H4>S&eacute;curit&eacute; sociale</H4>

<UL>La plupart des prestations de la s&eacute;curit&eacute; sociale suisse peuvent &ecirc;tre vers&eacute;es en France. Il en va de m&ecirc;me des prestations vers&eacute;es pour cause de mort (rentes de veuve, orphelin).<P></UL>



<H4><A NAME="fiche6par1">Succession</A></H4>

<UL>Selon le droit fran&ccedil;ais, il existe cinq ordres d'h&eacute;ritiers, chaque ordre &eacute;cartant automatiquement de la succession les ordres suivants (l'h&eacute;riter le plus proche dans chaque ordre h&eacute;rite en priorit&eacute;); de m&ecirc;me, les liens de sang sont (nettement) privil&eacute;gi&eacute;s par rapport aux liens du mariage.<P>

Les ordres d'h&eacute;ritiers sont les suivants:<br>

1. enfants, petits-enfants, arri&egrave;re-petits-enfants,<br>

2. fr&egrave;res, soeurs, p&egrave;re, m&egrave;re et neveux/ni&egrave;ces,<br>

3. grands-parents et arri&egrave;re grands-parents,<br>

4. conjoint,<br>

5. oncles, tantes, cousin(e)s jusqu'au 6e degr&eacute;.<P>

Le droit fran&ccedil;ais conna&icirc;t &eacute;galement la r&eacute;serve. La notion est similaire &agrave; celle donn&eacute;e en droit suisse (cf. <A HREF"sec2.html#par2">fiche 2</A>). La r&eacute;serve et la quotit&eacute; disponible se d&eacute;terminent de la mani&egrave;re suivante:<br>

</UL></UL><center>

<B>H&eacute;ritiers r&eacute;servataires - <I>R&eacute;serve</I> - Quotit&eacute; disponible</B><br>

1 enfant - <I>1/2</I> - 1/2<br>

2 enfants - <I>2/3</I> - 1/3<br>

3 enfants - <I>3/4</I> -1/4<br>

<B>En l'absence d'enfants:</B><br>

M&egrave;re ou p&egrave;re - <I>1/4</I> - 3/4<br>

M&egrave;re et p&egrave;re - <I>1/2</I> - 1/2<P>

</center><UL><UL>

Le testament existe sous trois forme: olographe (cf. <A HREF="sec2.html#par3">fiche2</A>), authentique (devant notaire) ou mystique (rare).<P></UL>

<H4><A NAME="fiche6par2">Quelques adresses utiles</A></H4>

<UL>

<li>Num&eacute;ro vert <B>Sida Info Service</B>: <I>05 36 66 36</I>

<li>Num&eacute;ro azur <B>Sida Info Droit</B>: <I>36 63 66 36</I> (tous les mardis de 17H &agrave; 22H)

<li><B>Affaires notariales</B>: <I>(161) 44 52 33 46</I> (tous les mardis et jeudis de 15H &agrave; 19H)

<li><B>AIDES Haute-Savoie</B>:<br>

10, rue Baron de Lo&euml; - B.P.33, F-74102 Annemasse, <I>tel: 50 87 20 00</I><br>

5, ave Chevesnes - B.P. 135, F-74004 Annecy, <I>tel: 50 52 74 85</I>

<li><B>AIDES Savoie</B>:<br>

B.P. 106, F-73001 Chamb&eacute;ry, <I>tel: 79 85 50 34</I>

<li><B>AIDES Ain</B>:<br>

31, rue de l'H&ocirc;tel-de-Ville, F-01130 Nantua, <I>tel: 74 24 64 34</I><br>

4, rue Cr&egrave;ve-Coeur, F-01100 Bourg-en-Bresse, <I>tel: 74 75 07 07</I>

<li><B>AIDES Lyon Rh&ocirc;ne-Alpes</B>:<br>

2, rue Chavanne, F-69001 Lyon, <I>tel: 72 07 04 70</I>

<li><B>Groupement des frontaliers</B>:<br>

Immeuble "La Crois&eacute;e", 50, rue de Gen&egrave;ve - B.P. 35, F-74103 Annemasse Cedex, <I>tel: 50 37 34 97</I></UL><P>



</UL><HR WIDTH=550><UL>



<A NAME="fiche7"><H3>7 - Service fun&egrave;bre et fun&eacute;railles</H3></A>

<H4>Les derni&egrave;res volont&eacute;s</H4>

<UL>Il est important de savoir que l'on peut signaler ses derni&egrave;res volont&eacute;s en ce qui concerne ses fun&eacute;railles. Comme pour un testament, il suffit de les exprimer sur une feuille manuscrite, dat&eacute;e et sign&eacute;e.<P>

On peut y faire figurer:<br><ul>

<li>son d&eacute;sir ou non d'&ecirc;tre incin&eacute;r&eacute;(e). Dans ce cas, si l'on souhaite que les cendres soient d&eacute;pos&eacute;es ou r&eacute;pandues en un endroit pr&eacute;cis, il est n&eacute;cessaire de le sp&eacute;cifier.

<li>on peut formuler ses d&eacute;sirs quant au choix ou non d'une c&eacute;r&eacute;monie, de l'officiant, de la musique qui y sera jou&eacute;e, des textes qui y seront lus, etc.

<li>il est enfin possible de pr&eacute;parer soi-m&ecirc;me les textes des faire-part diffus&eacute;s par voie de presse.</UL><P>

Il ne s'agit ici que d'exemples et l'on peut tout &agrave; fait, si cela est souhait&eacute;, ne pr&eacute;voir aucune disposition.<P>

<I><B>Remarques:</B></I><br><UL>

<li>Il est possible &eacute;galement de faire figurer ces dispositions parmi celles qui r&egrave;glent sa succession (testament).

<li>Il peut &ecirc;tre utile de d&eacute;signer une personne (conjoint(e), concubin(e), proche) pour effectuer toutes les d&eacute;marches n&eacute;cessaires (p.ex. pour signaler le d&eacute;c&egrave;s &agrave; l'employeur, au bailleur, aux assurances, &agrave; la banque, etc.).</UL></UL><P>

<H4><A NAME="fiche7par2">Fun&eacute;railles</A></H4>

<UL>Dans le canton de Gen&egrave;ve, les fun&eacute;railles peuvent &ecirc;tre prises en charge par la communes de domicile (voire d'origine). Certaines communes assument tous les frais d'inhumation, d'autres le font seulement pour les personnes dans le besoin. Les communes d'Avusy, Bellevue, Confignon, Genthod et Soral ne prennent en charge aucun frais aff&eacute;rent aux fun&eacute;railles. Il est donc pr&eacute;f&eacute;rable de s'informer &agrave; la mairie de la commune de domicile avant d'entreprendre des d&eacute;marches aupr&egrave;s des pompes fun&egrave;bres.<P>

La Ville de Gen&egrave;ve assure gratuitement les fun&eacute;railles, l'inhumation ou l'incin&eacute;ration de toute personne n&eacute;e, d&eacute;c&eacute;d&eacute;e, domicili&eacute;e ou propri&eacute;taire sur son territoire, qu'elle soit d&eacute;munie ou non. Ce service est assur&eacute; par:<br></UL></UL><center>

<B>Pompes Fun&egrave;bres Officielles de la Ville de Gen&egrave;ve</B><br>

4, rue du Vieux-March&eacute;<br>

1207 Gen&egrave;ve<br>

<I>(022) 735 91 50</I><P></center><UL><UL>

Ce service comprend la fourniture du cercueil, la mise en bi&egrave;re, le d&eacute;p&ocirc;t dans une chambre mortuaire, le transfert jusqu'au lieu de culte, l'acheminement sur un cimeti&egrave;re de la Ville, le service des porteurs, le creusage et le comblement de la fosse, respectivement l'incin&eacute;ration et l'urne pour les cendres.<P>

Toutes les prestations suppl&eacute;mentaires &agrave; celles ci-dessus sont factur&eacute;es en plus.<P>

<I><B>Remarque :</B></I><br>

Les personnes de passage, notamment celles qui sont en traitement dans les cliniques et les h&ocirc;pitaux sis sur la commune de Gen&egrave;ve, restent &agrave; la charge de leur commune de domicile.<P></UL>

<H4><A NAME="fiche7par3">D&eacute;c&egrave;s &agrave; l'&eacute;tranger</A></H4>

<UL>Il peut arriver qu'un d&eacute;c&egrave;s survienne &agrave; l'&eacute;tranger et que l'on doive rapatrier le corps en Suisse. Le plus simple est de s'adresser aux pompes fun&egrave;bres du lieu du d&eacute;c&egrave;s qui organiseront le rapatriement en Suisse, y.c. pour les d&eacute;marches administratives. En absence de pompes fun&egrave;bres, s'adresser &agrave; la mairie du lieu ou &agrave; la repr&eacute;sentation suisse la plus proche.<P>

D&egrave;s l'arriv&eacute;e du corps en Suisse, prendre imm&eacute;diatement contact avec les pompes fun&egrave;bres locales pour r&eacute;gler les questions administratives (pour Gen&egrave;ve: pompes fun&egrave;bres officielles de la Ville).
</UL>
</UL>

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-301</DOCNO>
<DOCOLDNO>IA017-000178-B041-70</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/gsg/sec2.html 192.33.214.13 19970106045845 text/html 15927
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:59:06 GMT
Last-modified: Saturday, 13-Apr-96 16:20:14 GMT
Content-length: 15736
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>GSG et Minist&egrave;re Sida: 'Mes Volont&eacute;s'</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations" ALIGN=RIGHT></A><ALIGN=BASELINE><HR>

<H2>Dossier <i>'Mes Volont&eacute;s'</i></H2>

<H4>R&eacute;alis&eacute; par le <A HREF="index.html">Groupe Sida Gen&egrave;ve</A> et <A HREF="/f/organs/aidsmin.html">Minist&egrave;re Sida</A></H4>

<HR WIDTH=550><UL>

<A NAME="fiche2"><H3>2 - Succession et Testament</H3></A>

<I>La succession &agrave; cause de mort est la transmission de l'ensemble des droits (propri&eacute;t&eacute;, possession, gage, etc.) et obligations (contrat, reconnaissance de dette, etc.) d'un d&eacute;funt &agrave; un ou plusieurs h&eacute;ritiers. Cela signifie que votre h&eacute;ritier ne re&ccedil;oit pas seulement des actifs mais h&eacute;rite &eacute;galement des dettes que vous avez contract&eacute;es de votre vivant.</I><P>



<H4>Les h&eacute;ritiers l&eacute;gaux</H4>

<UL>Vous avez, de votre vivant, le choix et la possibilit&eacute; de r&eacute;gler votre succession et de d&eacute;signer ou non vos h&eacute;ritiers. Si vous ne le faites pas (si, par exemple, vous ne r&eacute;digez aucun testament), vos h&eacute;ritiers sont d'ores et d&eacute;j&agrave; d&eacute;sign&eacute;s par la loi. C'est pourquoi, on les appelle h&eacute;ritiers l&eacute;gaux. Ce sont, dans l'ordre dans lequel ils sont appel&eacute;s &agrave; vous succ&eacute;der:<br>

<UL><li>votre conjoint survivant (&agrave; savoir seulement la personne unie sous un r&eacute;gime matrimonial),

<li>vos enfants (y compris les enfants adoptifs et reconnus) ou leurs descendants (1&egrave;re parent&egrave;le),

<li>en l'absence de ceux ci-dessus, vos parents ou leurs descendants (2&egrave;me parent&egrave;le),

<li>en l'absence de ceux ci-dessus, vos grands-parents ou leurs descendants (3&egrave;me parent&egrave;le).<P></UL>

Leurs droits &agrave; la succession sont ainsi pr&eacute;vus par la loi:<br>

<UL><li>Si vous laissez un conjoint et des enfants, le conjoint re&ccedil;oit la 1/2 de votre succession, vos enfants, l'autre 1/2,

<li>Si vous laissez un conjoint et vos p&egrave;re et m&egrave;re, le conjoint re&ccedil;oit les 3/4 de la succession, vos parents, le 1/4,

<li>Si vous laissez un conjoint et des fr&egrave;res et soeurs, le conjoint re&ccedil;oit les 3/4 de la succession, vos fr&egrave;res et soeurs, le 1/4,

<li>Si vous &ecirc;tes veuf/veuve ou divorc&eacute;(e) et ne laissez que des enfants, ceux-ci re&ccedil;oivent toute la succession (part &eacute;gale &agrave; chaque enfant),

<li>Si vous &ecirc;tes c&eacute;libataire et ne laissez que p&egrave;re et m&egrave;re, ceux-ci re&ccedil;oivent toue la succession.</UL></UL>



<H4>Les h&eacute;ritiers institu&eacute;s</H4>

<UL>Si toutefois vous d&eacute;sirez que l'attribution et le partage de votre succession se fasse diff&eacute;remment, vous pouvez d&eacute;signer vous-m&ecirc;me vos h&eacute;ritiers. C'est pourquoi, on appelle ces derniers h&eacute;ritiers institu&eacute;s. Un(e) concubin(e), un(e) ami(e), une personne morale (association, fondation, soci&eacute;t&eacute; anonyme, ...) de m&ecirc;me qu'un enfant pas encore con&ccedil;u ou n&eacute;, peuvent &ecirc;tre d&eacute;sign&eacute;s en qualit&eacute; de successeurs.<P>

Dans le m&ecirc;me sens, un h&eacute;ritier l&eacute;gal peut &eacute;galement &ecirc;tre institu&eacute;. Cependant, l'h&eacute;ritier institu&eacute; paiera des droits de succession d'autant plus &eacute;lev&eacute; qu'il sera &eacute;loign&eacute; dans son degr&eacute; de parent&eacute; ou sans lien avec la personne de laquelle il h&eacute;rite.</UL>



<A NAME="par2"><H4>Les h&eacute;ritiers r&eacute;servataires</H4></A>

<UL>Si vous avez le choix de d&eacute;signer qui vous voulez comme h&eacute;ritier, vous devez n&eacute;anmoins savoir que certains membres de votre famille peuvent faire valoir leurs droits sur la succession, du fait que la loi leur donne une priorit&eacute; sur les autres h&eacute;ritiers que vous avez institu&eacute;s. On les appelle h&eacute;ritiers r&eacute;servataires. Ce sont:<br>

<UL><li>votre conjoint survivant dont la r&eacute;serve couvre la 1/2 de la succession,

<li>vos descendants dont la r&eacute;serve couvre les 3/4 de la succession,

<li>vos p&egrave;re et m&egrave;re dont la r&eacute;serve couvre la 1/2 de la succession.</UL><P>

<I><B>Exemple:</B></I><br>

<I>Paul, dont les p&egrave;re et m&egrave;re sont encore en vie, a institu&eacute; par testament ordinaire son ami Robert comme h&eacute;ritier de tous ses biens. Les parents de Paul ont la possibilit&eacute;, s'ils le veulent, d'agir en justice &agrave; l'encontre de Robert afin de r&eacute;duire sa part &agrave; la quotit&eacute; disponible (part dont Paul pouvait l&eacute;galement disposer &agrave; sa convenance) qui, en l'occurrence, ne couvre que la moiti&eacute; de la succession de Paul.</I><P>

La situation varie essentiellement selon le concours des h&eacute;ritiers r&eacute;servataires appel&eacute;s &agrave; succ&eacute;der. A titre d'information, nous publions ce petit tableau:<P>

</UL></UL><center>

<B><I>survivants</I> - part(s) l&eacute;gale(s) - <I>part(s) r&eacute;servataire(s)</I> - quotit&eacute; disponible</B><br>

<li><I>un conjoint (seul h&eacute;ritier)</I> - totalit&eacute; - <I>1/2</I> - 1/2

<li><I>un conjoint + des enfants</I> - 1/2 + 1/2 - <I>2/8 + 3/8</I> - 3/8

<li><I>un conjoint + p&egrave;re et/ou m&egrave;re</I> - 3/4 +1/4 - <I>3/8 + 1/8</I> - 1/2

<li><I>un conjoint + fr&egrave;re(s) et/ou soeur(s)</I> - 3/4 + 1/4 - <I>3/8 + nulle</I> - 5/8

<li><I>des enfants (seuls h&eacute;ritiers)</I> - totalit&eacute; - <I>3/4</I> - 1/4

<li><I>p&egrave;re et/ou m&egrave;re (seuls h&eacute;ritiers)</I> - totalit&eacute; - <I>1/2</I> - 1/2

<li><I>p&egrave;re ou m&egrave;re + fr&egrave;re(s) et soeur(s)</I> - totalit&eacute; - <I>1/4 + nulle</I> - 3/4

<li><I>fr&egrave;re(s) et soeur(s) (seuls h&eacute;ritiers)</I> - totalit&eacute; - <I>nulle</I> - totalit&eacute;<P></center><UL><UL>

<I><B>Remarques:</B></I><br><UL>

<li>Des dispositions testamentaires qui ne respectent pas les quotit&eacute;s r&eacute;servataires ne sont pas nulles. Toutefois un h&eacute;ritier r&eacute;servataire l&eacute;s&eacute; (ou son successeur) peut, dans le d&eacute;lai d'un an &agrave; compter du jour o&Ugrave; il a pris connaissance des dispositions en question, intenter une action en r&eacute;duction et en restitution afin de recevoir sa r&eacute;serve.

<li>Peuvent &eacute;galement &ecirc;tre l'objet d'actions en r&eacute;duction et en restitution des donations ex&eacute;cut&eacute;es dans les cinq ann&eacute;es ant&eacute;rieures &agrave; votre d&eacute;c&egrave;s (les pr&eacute;sents d'usage except&eacute;s) ou toutes ali&eacute;nations faites dans l'intention manifeste d'&eacute;luder les r&egrave;gles concernant la r&eacute;serve.

<li>La loi donne la possibilit&eacute; au disposant de favoriser le conjoint survivant qui h&eacute;rite en concours avec ses enfants en lui accordant l'usufruit de la totalit&eacute; de la succession. Cet usufruit remplace la part l&eacute;gale du conjoint et se r&eacute;duit, en cas de remariage, de la r&eacute;serve des enfants.

<li>La part successorale du conjoint survivant d&eacute;pend pour la plupart des cas du r&eacute;gime matrimonial des &eacute;poux et ne peut donc &ecirc;tre d&eacute;termin&eacute;e qu'apr&egrave;s dissolution du r&eacute;gime matrimonial en question.</UL><P></UL>

<H4>L'Hex&eacute;r&eacute;dation</H4><UL>

Vous pouvez d&eacute;sh&eacute;riter un h&eacute;ritier r&eacute;servataire (exh&eacute;r&eacute;dation) dans seulement deux cas:<br>

1. si celui-ci vous a gravement l&eacute;s&eacute;, vous ou l'un de vos proches (assassinat, meurtre, l&eacute;sions corporelles graves, vol, abus de confiance, etc.), ou s'il a gravement manqu&eacute; &agrave; ses devoirs de famille pr&eacute;vus express&eacute;ment par la loi (devoirs r&eacute;ciproques des &eacute;poux, devoirs liant les parents aux enfants, etc.). Les motifs exacts doivent figurer dans le testament afin d'&eacute;carter tout doute sur les causes de l'exh&eacute;r&eacute;dation.<br>

2. si celui-ci s'av&egrave;re insolvable et r&eacute;pond par cons&eacute;quent d'un ou de plusieurs actes de d&eacute;faut de biens &agrave; son encontre, dont le montant total d&eacute;passe le quart de la part auquel il aurait l&eacute;galement droit si vous n'aviez pas r&eacute;dig&eacute; de testament.<P>

<B>A d&eacute;faut d'h&eacute;ritiers institu&eacute;s ou l&eacute;gaux, c'est la collectivit&eacute; publique d&eacute;sign&eacute;e par le canton de votre dernier domicile qui aura qualit&eacute; d'h&eacute;riti&egrave;re.</B><P>



</UL>

<H4><A NAME="par3">Le testament</A></H4><UL>

C'est l'acte par lequel vous pouvez faire conna&icirc;tre vos volont&eacute;s en mati&egrave;re successorale. Celui-ci peut prendre plusieurs formes:<P>

<B>1. Le testament ordinaire ou olographe</B><br>est de loin le plus r&eacute;pandu. Il doit, pour &ecirc;tre valable, avoir &eacute;t&eacute; &eacute;crit, sign&eacute; et dat&eacute; manuellement. Par "dat&eacute;", on entend la mention du lieu, du jour, du mois et de l'ann&eacute;e o&Ugrave; le testament est &eacute;tabli. Il peut &ecirc;tre r&eacute;dig&eacute; dans n'importe quelle langue.<br>

Il est pr&eacute;f&eacute;rable d'&eacute;viter ratures et corrections qui rendraient le texte illisible de m&ecirc;me que les adjonctions (le cas &eacute;ch&eacute;ant, il faut au moins les signer et les dater) qui peuvent nuire &agrave; l'interpr&eacute;tation de vos derni&egrave;res volont&eacute;s.<br>

Un tel acte est valable aussi longtemps qu'il n'a pas &eacute;t&eacute; r&eacute;voqu&eacute;. Il peut &ecirc;tre annul&eacute; en tout temps ou remplac&eacute; par un autre.<br>

Vous pouvez conserver vous-m&ecirc;me ce testament ou le remettre &agrave; une personne digne de confiance. Vous avez le choix &eacute;galement de le d&eacute;poser chez un notaire ou aupr&egrave;s de l'autorit&eacute; ci-dessous:<P>

</UL></UL><center><b>Justice de Paix</b><br>

5, rue des Chaudronniers<br>

1204 Gen&egrave;ve<br>

<I>tel: (002) 319 26 61</I><P></center><UL><UL>

<I><B>Remarques:</B></I><br>

<UL><li>Un testament ne peut &ecirc;tre r&eacute;dig&eacute; que par une seule personne qui ne r&egrave;gle que sa propre succession (les testaments en commun ne sont pas admis !).

<li>Un testament ne peut pas &ecirc;tre r&eacute;dig&eacute; par une personne &acirc;g&eacute;e de moins de 18 ans r&eacute;volus (majorit&eacute; civile, d&egrave;s 1996).

<li>Une personne sous tutelle n'a pas besoin de l'approbation du tuteur.

<li>Le d&eacute;p&ocirc;t d'un testament aupr&egrave;s de la Justice de Paix est gratuit pour le testateur. En revanche, les h&eacute;ritiers de la succession devront s'acquitter d'un &eacute;molument (env. Frs 150.--) et de frais calcul&eacute;s en fonction du montant de la succession.

<li>Quelle que soit la personne &agrave; laquelle vous confiez votre testament, celle-ci est de toute fa&ccedil;on contrainte de le remettre &agrave; la Justice de Paix apr&egrave;s votre d&eacute;c&egrave;s.<P></UL>

<I><B>Exemple d'un testament olographe:</B></I><br>

<I>Moi, Jeanne Ducommun, n&eacute;e le 3 f&eacute;vrier 1954 et domicili&eacute;e &agrave; Gen&egrave;ve l&egrave;gue mon seul collier en or jaune &agrave; mon amie Th&eacute;r&egrave;se Paquier, n&eacute;e le 23 juin 1953 et domicili&eacute;e &agrave; Bernex. Par ailleurs, j'institue mon fils Nicolas, h&eacute;ritier de la totalit&eacute; du restant de mes biens.<P>

Je r&eacute;voque toutes dispositions ant&eacute;rieures &agrave; ce pr&eacute;sent acte.<P>

Fait &agrave; Gen&egrave;ve, le 27 avril 1995. Signature</I><P>

<B>2. Le testament public ou authentique</B><br>est un acte r&eacute;dig&eacute;, &agrave; Gen&egrave;ve, par un notaire auquel vous avez pr&eacute;alablement communiqu&eacute; vos volont&eacute;s et qui apr&egrave;s vous l'avoir fait lire et signer, le date et le signe lui-m&ecirc;me en pr&eacute;sence de deux t&eacute;moins qui apposent &eacute;galement leur signature.<P>

Ce testament est valable tant qu'il n'a pas &eacute;t&eacute; remplac&eacute; par un autre testament, quelle que soit sa forme.<P>

<I><B>Remarques:</B></I><br>

Ne peuvent concourir en qualit&eacute; de notaire ou de t&eacute;moins:<br><UL>

<li>votre conjoint,

<li>vos descendants, ascendants, fr&egrave;res et soeurs ainsi que leurs conjoints,

<li>les personnes qui ne savent ni lire ni &eacute;crire,

<li>les personnes priv&eacute;es de l'exercice de leurs droits civils (mineurs, interdits),</UL>

Le notaire et les t&eacute;moins de m&ecirc;me que leurs ascendants, descendants, fr&egrave;res et soeurs ou conjoints ne peuvent pas &ecirc;tre institu&eacute;s h&eacute;ritiers.<P>

<B>3. Le testament oral</B><br>est un testament extraordinaire qui n'est admis que si vous &ecirc;tes emp&ecirc;ch&eacute; de tester dans une des deux formes ci-dessus et que vous vous trouviez dans l'imminence d'une mort li&eacute;e &agrave; un accident ou &agrave; une affection mortelle impr&eacute;visible et aigu&euml; qui n&eacute;cessite le recours &agrave; cette forme de testament.<br>

Vos derni&egrave;res volont&eacute;s sont alors communiqu&eacute;es verbalement et simultan&eacute;ment &agrave; deux t&eacute;moins qui s'empressent de les mettre par &eacute;crit, de les dater, de les signer et de les d&eacute;poser aupr&egrave;s de la Justice de Paix.<br>

Ce testament perd sa validit&eacute; 14 jours apr&egrave;s que vous avez recouvr&eacute; la possibilit&eacute; d'utiliser une forme ordinaire.<P></UL>



<H4><A NAME="par4">Le pacte successoral</A></H4>

<UL>C'est un contrat que vous pouvez passer avec vos h&eacute;ritiers ou un tiers sur votre succession future. Vous continuez &agrave; disposer librement de vos biens comme dans un testament avec la garantie que l'autre partie accepte d'&ecirc;tre institu&eacute;e h&eacute;riti&egrave;re ou au contraire qu'elle renonce &agrave; la totalit&eacute; ou &agrave; une partie de ses pr&eacute;tentions successorales.<P>

Ce pacte est conclu devant notaire et sign&eacute; par lui et par les parties concern&eacute;es et ce, en pr&eacute;sence de deux t&eacute;moins.<P>

Il peut &ecirc;tre r&eacute;sili&eacute; en tout ou partie par l'accord de toutes les parties mais il peut &eacute;galement &ecirc;tre annul&eacute; par vous seul si le b&eacute;n&eacute;ficiaire commet apr&egrave;s la signature du pacte un d&eacute;lit grave &agrave; votre &eacute;gard ou manque &agrave; ses devoirs de famille envers vous.<P></UL>



<H4><A NAME="par5">La succession de personnes &eacute;trang&egrave;res</A></H4>

<UL>Si vous &ecirc;tes &eacute;tranger domicili&eacute; en Suisse et que vous d&eacute;c&eacute;dez en Suisse sans avoir r&eacute;dig&eacute; de testament, votre succession sera r&eacute;gl&eacute;e en principe selon le droit suisse (les biens situ&eacute;s &agrave; l'&eacute;tranger pouvant &ecirc;tre soumis au droit successoral de l'Etat concern&eacute;). Vous avez toutefois la possibilit&eacute; de soumettre votre succession au droit de l'Etat dont vous avez la nationalit&eacute;, si vous en manifestez la volont&eacute; dans votre testament.<P>

(cf. &eacute;galement la fiche sur les <A HREF="sec1.html#fiche6">questions frontali&egrave;res</A>)

</UL></UL></UL>

<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/hivnet/index.html"><IMG ALIGN=top SRC="/f/gif/intouch2.gif" BORDER=0 ALT="Contact"></A>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-302</DOCNO>
<DOCOLDNO>IA017-000178-B041-107</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/d/ 192.33.214.13 19970106045927 text/html 1880
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:59:49 GMT
Last-modified: Monday, 23-Dec-96 16:18:07 GMT
Content-length: 1692
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>HIVNet CH</TITLE>
   </HEAD>
<BODY BGCOLOR="#FFFFFF">

<P>
<FONT SIZE=-1>[ <A HREF="http://www.hivnet.ch/f/">Fran&ccedil;ais</A> ] [ <A HREF="http://www.hivnet.ch/e/">English</A> ] [ Deutsch ]
</FONT>
<CENTER>
<P>
<IMG SRC="/gif/hivnet.gif" HEIGHT=95 WIDTH=316>
<BR>
<IMG SRC="/gif/titred.gif" HEIGHT=25 WIDTH=418></P></CENTER>
<CENTER>
<TABLE WIDTH="80%" >
<TR ALIGN=CENTER>
<TD><A HREF="/d/biblio/"><IMG SRC="/d/gif/bibliothek.gif" ALT="Bibliothek" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/d/webforum/"><IMG SRC="/d/gif/webforen.gif" ALT="WebForen" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/d/consult/"><IMG SRC="/d/gif/berat.gif" ALT="Konsultation" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>
</TR>

<TR ALIGN=CENTER>
<TD><A HREF="/d/organs/l"><IMG SRC="/d/gif/organisationen.gif" ALT="Organisationen" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/d/art/"><IMG SRC="/d/gif/artworks.gif" ALT="Artworks" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD><A HREF="/d/search/"><IMG SRC="/d/gif/suchen.gif" ALT="Suchen" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>
</TR>

<TR ALIGN=CENTER>
<TD></TD>

<TD><A HREF="/d/info/"><IMG SRC="/d/gif/intouch.gif" ALT="Info" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=CENTER></A></TD>

<TD></TD>
</TR>
</TABLE>
</CENTER>
</UL>
<PRE>
</PRE>
<P><FONT SIZE=-1><CENTER>Mit der Unterst&uuml;tzung des Bundesamt f&uuml;r Gesundheit, der Stiftung Aids Info Doku Schweiz und vom Staat Genf.
<P>

Copyright 1991-1996 <A HREF="http://www.hivnet.ch/d/fdp.html">Fondation
du Pr&eacute;sent</A> und die Autoren</FONT></P></CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-303</DOCNO>
<DOCOLDNO>IA017-000178-B041-121</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/e/ 192.33.214.13 19970106045936 text/html 2284
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 04:59:58 GMT
Last-modified: Monday, 23-Dec-96 16:16:52 GMT
Content-length: 2096
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
  <TITLE>HIVNet CH</TITLE>
  <META NAME="GENERATOR" CONTENT="Adobe PageMill 2.0 Mac">
</HEAD>
<BODY BGCOLOR="#ffffff">

<P>
<FONT SIZE=-1>[ <A HREF="http://www.hivnet.ch/f/">Fran&ccedil;ais</A> ] [ <A HREF="/d">Deutsch</A> ] [ English ]</FONT>
<P ALIGN=CENTER><IMG SRC="gif/hivnet.gif" WIDTH="316" HEIGHT="95" ALIGN=
"BOTTOM" NATURALSIZEFLAG="3">
<CENTER><IMG SRC="/e/gif/titree.gif"></CENTER>
<P>
<CENTER><TABLE WIDTH="80%">
<TR ALIGN="CENTER">
<TD ALIGN="CENTER"><A HREF="/e/biblio/index.html"><IMG SRC="/e/gif/bibliotheque.gif" WIDTH="130"
HEIGHT="106" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Library" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="/e/webforum/index.html"><IMG SRC="/e/gif/webforum.gif" WIDTH="130" HEIGHT=
"106" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Forum" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><IMG SRC="/e/gif/consultation.gif" WIDTH="130" HEIGHT="106" ALIGN="BOTTOM"
NATURALSIZEFLAG="3" ALT="Advice"><BR><FONT SIZE=-1><A HREF="/f/consult">french</A> and <A HREF="/d/consult">german</A></FONT></TD></TR>
<TR ALIGN="CENTER">
<TD ALIGN="CENTER"><A HREF="/e/organs/index.html"><IMG SRC="/e/gif/organisations.gif" WIDTH="130"
HEIGHT="106" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Organisations" BORDER=
"0"></A></TD>
<TD ALIGN="CENTER"><A HREF="/e/art/index.html"><IMG SRC="/e/gif/artworks.gif" WIDTH="130" HEIGHT=
"106" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Fun Art" BORDER="0"></A></TD>
<TD ALIGN="CENTER"><A HREF="/e/search/index.html"><IMG SRC="/e/gif/search2.gif"  ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Search" BORDER="0"></A></TD></TR>
<TR ALIGN="CENTER">
<TD></TD>
<TD ALIGN="CENTER"><A HREF="/e/info/index.html"><IMG SRC="/e/gif/intouch.gif" ALIGN="BOTTOM" NATURALSIZEFLAG="3" ALT="Info" BORDER="0"></A></TD>
<TD></TD></TR>
</TABLE></CENTER>




<P ALIGN=CENTER><FONT SIZE=-1>
With the support of the Swiss Ministry of Public Health, The <I>Fondation Aids Info Doku Schweiz</I> and the State of Geneva
<P></CENTER>
<CENTER>
Copyright 1991-1996 <A HREF="/fdp/">Fondation
du Pr&eacute;sent</A> and the Authors</FONT></CENTER>
<BR>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-304</DOCNO>
<DOCOLDNO>IA017-000178-B041-138</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/biblio/ 192.33.214.13 19970106045951 text/html 3513
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:00:07 GMT
Last-modified: Friday, 20-Dec-96 10:29:25 GMT
Content-length: 3325
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>HivNet: Bibliotheque</TITLE>
   </HEAD>
<BODY BGCOLOR="#FFFFFF">

<P><IMG SRC="/f/gif/bibliotheque.gif" HEIGHT=106 WIDTH=130 ALIGN=LEFT>
<A HREF="/f/webforum/index.html"><IMG SRC="/f/gif/webforum2.gif" ALT="Webforum" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/consult/index.html"><IMG SRC="/f/gif/consultation2.gif" ALT="Consultations" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" ALT="Artworks" BORDER=0 HEIGHT=59 WIDTH=65 ALIGN=TOP></A>
<A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" ALT="Organisations" BORDER=0 HEIGHT=60 WIDTH=65 ALIGN=TOP></A>
<BR CLEAR>
</P>

<PRE>
 
 
</PRE>

<UL>
<LI><A HREF="/anais/f/ATN.cgi">AIDS TREATMENT NEWS</A>
(en anglais) </LI>

<UL>
<P>Inventaire des traitements exp&eacute;rimentaux et standards, dont ceux
disponibles &agrave; ce jour. Interviews de personnalit&eacute;s du monde
scientifique, de professionnels de la sant&eacute; ainsi que de personnes
vivant avec le Sida ou porteuses du VIH. Collection de l'information diffus&eacute;e
lors de conf&eacute;rences, dans les journaux et les bases de donn&eacute;es,
etc. </P>
</UL>

<LI><A HREF="/anais/f/SUMM-96.cgi">AIDS Daily Summary</A>
(en anglais) </LI>

<UL>
<P>Information collect&eacute;e gr&acirc;ce aux &quot;Center for Disease
Control and Prevention (CDC) National AIDS Clearinghouse&quot;. La reproduction
non commerciale des documents est autoris&eacute;e et encourag&eacute;e,
&agrave; la seule condition que la source &quot;CDC Clearinghouse&quot;
soit cit&eacute;e. Ce service public ne refl&egrave;te en aucune fa&ccedil;on
la position officielle du &quot;CDC Clearinghouse&quot;. </P>
</UL>

<LI><A HREF="/anais/f/INFOTHEQUE.cgi">INFOTHEQUE SIDA
</A>(en fran&ccedil;ais, allemand et italien) </LI>

<UL>
<P>Magazine bimestriel publi&eacute; par la Fondation &quot;Sida Info Doc
Suisse&quot; depuis septembre 1989. Les num&eacute;ros 4/95, 1/96, 2/96
et 3/96 sont disponibles dans cette bibiblioth&egrave;que. </P>
</UL>

<LI><A HREF="/anais/f/VON-AIDS.cgi">Von Aids Bis Z</A>
(en allemand et fran&ccedil;ais) </LI>

<UL>
<P>L'article &quot;Sida - Travail, assurances et s&eacute;curit&eacute;
sociale en Suisse&quot; est extrait de la brochure &laquo;Von Aids bis
Z&raquo; en cours de r&eacute;&eacute;dition. Gratuitement disponible en
imprim&eacute; pour les personnes s&eacute;ropositives ou atteintes du
Sida aupr&egrave;s de <A HREF="/pwa/index.html">&quot;PWA-Suisse&quot;</A>
052 212 47 47 et en format &eacute;lectronique sur HivNet.ch. <BR>
<BR>
</P>
</UL>

<LI><A HREF="/f/biblio/others.html">Autres publications</A>
disponibles sur Internet. </LI>

<P>
<HR></P>

<UL>
<LI><B><A HREF="/f/info/index.html">Comment</A></B>
ins&eacute;rer un texte ou une publication dans la biblioth&egrave;que
de HivNet.ch. </LI>

<LI><A HREF="/anais/admin">Ins&eacute;rer</A> un texte
ou une publication. </LI>
</UL>

<P>
<HR></P>
</UL>

<CENTER><P><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" ALT="Home" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" ALT="Rechercher" BORDER=0 HEIGHT=100 WIDTH=100></A>
<A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" ALT="Contact" BORDER=0 HEIGHT=106 WIDTH=130 ALIGN=TOP></A>
</P></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-305</DOCNO>
<DOCOLDNO>IA017-000178-B041-154</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/webforum/ 192.33.214.13 19970106050001 text/html 1646
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:00:23 GMT
Last-modified: Saturday, 30-Nov-96 20:52:49 GMT
Content-length: 1456
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
   <TITLE>HIVNet CH - Forum</TITLE>
   </HEAD>
<BODY BGCOLOR="#FFFFFF">

<IMG SRC="/f/gif/webforum.gif" ALIGN=LEFT><A HREF="/f/biblio/index.html">
</A>



<CENTER><P><A HREF="/f/biblio/index.html"><IMG SRC="/f/gif/bibliotheque2.gif" ALT="Webforum" BORDER=0  ALIGN=TOP></A><A HREF="/f/consult/index.html"><IMG SRC="/f/gif/consultation2.gif" ALT="Consultations" BORDER=0  ALIGN=TOP></A><A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" ALT="Artworks" BORDER=0  ALIGN=TOP></A><A HREF="/f/organs/index.html"><IMG SRC="/f/gif/organisations2.gif" ALT="Organisations" BORDER=0  ALIGN=TOP></A><BR CLEAR>
</P></CENTER>
<PRE>

</PRE>
<BR CLEAR>
<UL>
<H2>Choisissez votre forum !</H2>

<UL>
<LI><A HREF="GUESTBOOK-forum.html">Bo&icirc;te &agrave; id&eacute;es</A></LI>

<UL>
<P>Donnez-nous votre avis. D&eacute;clarations d'amour bienvenues...</P>
</UL>

<LI><A HREF="FORUM-forum.html">Bric-&agrave;-brac</A></LI>

<UL>
<P>Tout ce qui ne trouve pas sa place ailleurs est bienvenu ici.</P>
</UL>
</UL>

<P>
<HR></P>

<UL>
<LI><B><A HREF="http://www.hivnet.ch/f/info/#Participer">Ouvrez</A></B>
votre propre forum</LI>
</UL>

<CENTER><P>
<HR><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" ALT="Home" BORDER=0 ></A><A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" ALT="Rechercher" BORDER=0 ></A><A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" ALT="Contact" BORDER=0  ALIGN=TOP></A></P></CENTER>
</UL>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-306</DOCNO>
<DOCOLDNO>IA017-000178-B041-169</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/consult/ 192.33.214.13 19970106050011 text/html 2247
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:00:34 GMT
Last-modified: Tuesday, 03-Dec-96 16:04:58 GMT
Content-length: 2058
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet CH - Conseils</title></head>







<BODY BGCOLOR="FFFFFF">



<IMG ALIGN=left SRC="/f/gif/consultation.gif">

<CENTER>

<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>

<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>

<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>

<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>

</CENTER>

<BR CLEAR>

<PRE>



</PRE>

<UL>



<H1>Conseils</H1>





<UL>
Conseils de sant&eacute;, informations juridiques et dialogue avec les associations en lutte contre le Sida. 
<P>
Ce service traite les questions et les r&eacute;ponses de <B>fa&ccedil;on anonyme</B>.



<UL>

<P>

<B>

<LI><A HREF="Medic-forum.html">Conseils de sant&eacute;</A>

<P>

<LI><A HREF="Legal-forum.html">Informations juridiques</A>

<P>

<LI><A HREF="pvage-forum.html">Dialogue</A> avec l'association "Personnes Vivant Avec", Gen&egrave;ve 

</B>

</UL>

<P>



Les conseils sont donn&eacute;s uniquement &agrave; titre informatif.<B> Ils ne remplacent en aucun cas une consultation médicale ou juridique aupr&egrave;s d'un praticien autoris&eacute;</B>.

<P>

</UL>

<A HREF="http://expasy2.hcuge.ch/dmi/">La Division des Maladies Infectieuses</A> de l'Hôpital Cantonal Universitaire de Genève donne les conseils de sant&eacute;. 
<P>
L'association <A HREF="/gsg/">Groupe Sida Genève</A> donne les informations juridiques.
<P>
L'association <A HREF="/pvage/index.html">"Personnes Vivant Avec"</A> &agrave; Gen&egrave;ve r&eacute;pond aux demandes faites sur son espace.
<P>

<HR>



<CENTER>

<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>

<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" BORDER=0 ALT="Rechercher"></A>

<A HREF="/f/info/index.html"><IMG SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>

</CENTER>



</UL>



</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT18-B27-307</DOCNO>
<DOCOLDNO>IA017-000178-B041-181</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/organs/ 192.33.214.13 19970106050020 text/html 6466
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:00:41 GMT
Last-modified: Monday, 23-Dec-96 16:29:46 GMT
Content-length: 6278
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>HIVNet CH: Organisations</TITLE></HEAD>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/organisations.gif" WIDTH="130" HEIGHT="106" >
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" WIDTH="65" HEIGHT="59"  BORDER=0 ALT="Artworks"></A>
</CENTER>
<BR CLEAR>
<PRE>

 

</PRE>
<UL>
<UL>


<H2>Organisations actives dans le domaine HIV/SIDA</H2>

<P>
<B>Organisations pr&eacute;sentes sur ce serveur</B><P>



<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/dialogai/index.html">Dialogai</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/gsg/index.html">Groupe Sida Gen&egrave;ve<BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/pwa/index.html">PWA</A> - F&eacute;d&eacute;ration suisse PWA (People With Aids) et <A HREF="/pvage/index.html">PVA Gen&egrave;ve</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/sids/index.html">Sida Info Doc Suisse</A><BR><IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline>Lettre mensuelle d'information <A HREF="/migrants/index.html">Migrants contre le Sida / VIH</A><BR>

<IMG SRC="/gif/puce_bleue.gif"  WIDTH="10" HEIGHT="10"   HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/fdp/index.html">La Fondation du Pr&eacute;sent - Gen&egrave;ve</A><BR>
<P>
<IMG SRC="/gif/puce_bleue.gif" HSPACE=5 BORDER=0 ALIGN=baseline><A HREF="/geneve/collectif/index.html">Programme du 1er D&eacute;cembre 1996, Gen&egrave;ve</A><BR>

<P>
<HR WIDTH=150>
<P>

<B>Organisations suisses - Index</B>
<P>
<TABLE BORDER=2 CELLPADDING=10>

<TR>

<TD ALIGN=CENTER><H1>A</H1>
<TD><LI><A HREF="ass.html"><B>AHS</B> (ASS)</A></B><I> - Aids Hilfe Schweiz und Kantonale Aids-Hilfen</I><BR>
<LI><A HREF="relig.html#bls"><B>Aidspfarramt</B> (Aum&ocirc;niers Sida)</A><I> beider Basel</I><BR>
<LI><A HREF="relig.html#zh"><B>Aidspfarramt</B> (Aum&ocirc;niers Sida)</A><I> (Z&uuml;rich)</I><BR>
<LI><B><A HREF="home.html#zh">Anker-Huus</A></B><I> (Wohnprojekte, Z&uuml;rich)</I><BR>
<LI><A HREF="ass.html"><B>ASS</B> (AHS)</A> - Aide Suisse contre le Sida, Antennes cantonales de l'ASS<BR>
<LI><B>Fondation <A HREF="child.html#vd">As'Trame</A></B><I> (Sida et enfants, Vaud)</I><BR>
<LI><A HREF="relig.html"><B>Aum&ocirc;niers Sida</B></A>
</TR>

<TR>
<TD ALIGN=CENTER><H1>B</H1>
<TD>
<LI><B><A HREF="home.html#bls">Basler Lighthouse</A></B><I> (Wohnprojekte, B&acirc;le)</I><BR>
<LI><B><A HREF="ofsp.html">BAG</A></B><I> - Budesamtes f&uuml;r Gesundheitswesen</I><BR>
</TR>

<TR>
<TD ALIGN=CENTER><H1>D</H1>
<TD><LI><B><A HREF="/dialogai/index.html">Dialogai</A></B><I> (Association homosexuelle, GE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>E</H1>
<TD><LI><B><A HREF="home.html#ju">Espace Bleu</A></B><I> (Lieu d'accueil, JU)</I><BR>
<LI><B>Association <A HREF="child.html#ge">ESPER</A></B><I> (Sida et enfants, GE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>G</H1>
<TD><LI><B><A HREF="child.html#ju">GSE</A> - Groupe Sida Enfants</B><I> (JU)</I>
<LI><B><A HREF="/gsg/index.html">GSG</A> - Groupe Sida Gen&egrave;ve</B><I> (Antenne de l'ASS)</I>
<LI><B><A HREF="child.html#ge">GSG</A> - Groupe Sida Gen&egrave;ve</B><I> (Sida et enfants)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>H</H1>
<TD><LI><B><A HREF="home.html#bls">Haus Gilgamesch</A></B><I> (Wohnprojekte, BS)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>K</H1>
<TD><LI><B><A HREF="child.html#zh">Aids</A> und Kind <I>(ZH)</I> 
</TR>


<TR>
<TD ALIGN=CENTER><H1>L</H1>
<TD><LI><B>Fondation du <A HREF="home.html#vd">Levant</A></B><I> (Lieu d'accueil, VD)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>M</H1>
<TD><LI><B>La <A HREF="home.html#ge">Maison</A></B><I> (Lieu d'accueil, GE)</I>
<LI><B><A HREF="/migrants/index.html">Migrants contre le Sida/VIH</A></B><I>
<LI><B><A HREF="/ministere-sida/">Minist&egrave;re Sida</A></B><I> (Aum&ocirc;niers sida, GE)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>O</H1>
<TD><LI><B><A HREF="ofsp.html">OFSP</A></B><I> - Office F&eacute;d&eacute;ral de la Sant&eacute; Publique</I>
</TR>



<TR>
<TD ALIGN=CENTER><H1>P</H1>
<TD><LI><B><A HREF="relig.html#ge">Pasteure:</A> Mme Dominique Roulin</B><I> (GE)</I><BR><UL> et aupr&egrave;s de <B><A HREF="/ministere-sida/">Minist&egrave;re Sida</A></B><I> (Aum&ocirc;niers sida, GE)</I></UL>
<LI><B><A HREF="child.html#ge">Plateforme</A> 'Sida et Enfants'</B><I> (GE)</I>
<LI><B>Fondation du <A HREF="/f/fdp/index.html">Pr&eacute;sent</A></B><I>(Information, GE)</I>
<LI><B><A HREF="/pvage/index.html">PVA</A> - Gen&egrave;ve</B><I> (Antenne de PWA Suisse)</I>
<LI><B><A HREF="/pwa/index.html">PWA</A> Schweiz</B><I> (Schw. Verein der </i>People With Aids<i>)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>S</H1>
<TD><LI><B><A HREF="relig.html#bls">Seelsorge:</A> Herr Benedict H&auml;nggi</B><I> (BS)</I>
<LI><B><A HREF="/sids/index.html">SIDS</A> Sida Info Doc Suisse</B><I></I>
<LI><B><A HREF="home.html#zh">Sune-Egge</A></B><I> (Wohnprojekte, ZH)</I>
</TR>


<TR>
<TD ALIGN=CENTER><H1>W</H1>
<TD><LI><B><A HREF="home.html#sg">Wohngemeinschaft</A> 'Arche'</B><I> (Wohnprojekte, SG)</I>
<LI><B><A HREF="home.html#be">Wohngemeinschaft</A> St&ouml;ckli</B><I> (Wohnprojekte, BE)</I>
</TR>

<TR>
<TD ALIGN=CENTER><H1>Z</H1>
<TD><LI><B><A HREF="home.html#zh">Z&uuml;rcher Aids Projekte</A></B><I> (Wohnprojekte, ZH)</I>
<LI><B><A HREF="home.html#zh">Z&uuml;rcher Lighthouse</A></B><I> (Wohnprojekte, ZH)</I>
</TR>
</TABLE>
</UL>
</UL>
<P>
<HR>
<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" WIDTH="100" HEIGHT="100"   BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search.gif" WIDTH="100" HEIGHT="100"   BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-308</DOCNO>
<DOCOLDNO>IA017-000178-B041-196</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/search/ 192.33.214.13 19970106050031 text/html 2023
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:00:52 GMT
Last-modified: Monday, 02-Dec-96 09:43:42 GMT
Content-length: 1835
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD>

<TITLE>HIVNet: Rechercher</TITLE>

</HEAD>



<BODY BGCOLOR="FFFFFF">

<IMG ALIGN=left SRC="/f/gif/search.gif">
<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<UL>
<H2>Recherche de documents</H2>
<FORM ACTION="/anais/f/bin/search.cgi" METHOD=post>

<B>contenant</B> le ou les mots suivants
<BR>
<UL><I>(exemple: DDI 3TC SAQUINAVIR)</I><BR>
<INPUT NAME=and SIZE=40></UL><BR>

contenant <B>au moins</B> un des mots suivants,

<BR><UL><INPUT NAME=or SIZE=40></UL><BR>

<B>ne contenant pas</B> le ou les mots suivants,

<UL><INPUT NAME=not SIZE=40></UL>

<P>

dans les publications suivantes (à sélectionner)
<P>
<UL>
<TABLE BORDER=0>
<TR>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="ATN"> AIDS TREATMENT NEWS</TD>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="SUMM-96"> AIDS Daily Summary</TD>
</TR>
<TR>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="INFOTHEQUE"> INFOTHEQUE SIDA</TD>
<TD><INPUT TYPE=checkbox NAME=dbname VALUE="VON-AIDS"> Von Aids bis Z</TD>
</TR>
</TABLE>
</UL>
<P>

<I><INPUT TYPE="submit" VALUE="     Recherche!     "></I><P>
</UL>
</FORM>


<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>
</CENTER>

</BODY>
</HTML>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-309</DOCNO>
<DOCOLDNO>IA017-000178-B041-208</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/infomed/index.html 192.33.214.13 19970106050039 text/html 1537
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:01 GMT
Last-modified: Saturday, 30-Nov-96 17:42:00 GMT
Content-length: 1347
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>HIVNet CH - Informations medicales</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<CENTER>
<A HREF="/f/biblio/index.html"><IMG ALIGN=top SRC="/f/gif/bibliotheque2.gif" BORDER=0 ALT="Bibliotheque"></A>
<A HREF="/f/webforum/index.html"><IMG ALIGN=top SRC="/f/gif/webforum2.gif" BORDER=0 ALT="Webforum"></A>
<A HREF="/f/consult/index.html"><IMG ALIGN=top SRC="/f/gif/consultation2.gif" BORDER=0 ALT="Consultations"></A>
<A HREF="/f/art/index.html"><IMG ALIGN=top SRC="/f/gif/artworks2.gif" BORDER=0 ALT="Artworks"></A>
<A HREF="/f/organs/index.html"><IMG ALIGN=top SRC="/f/gif/organisations2.gif" BORDER=0  ALT="Organisations"></A>
</CENTER>
<BR CLEAR>
<PRE>

</PRE>
<UL>


<H2>Informations m&eacute;dicales</H2>
<HR>
<UL>
<LI>Informations m&eacute;dicales et tests anonymes <A HREF="infostests.html">en Suisse</A>
<LI><A HREF="http://expasy2.hcuge.ch/dmi/etude.html">Informations sur les recherches th&eacute;rapeutiques</A> en cours &agrave; l'H&ocirc;pital Cantonal Universitaire de Gen&egrave;ve (HCUG).
</UL>
<P>
<HR>
<P>
</UL>

<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-310</DOCNO>
<DOCOLDNO>IA017-000178-B041-221</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/latex/avril.html 192.33.214.13 19970106050047 text/html 882
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:09 GMT
Last-modified: Saturday, 30-Nov-96 18:14:35 GMT
Content-length: 693
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD><TITLE>Les Aventures du Latex</TITLE></HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" BORDER=0  ALT="Artworks" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Les aventures du Latex</H1><HR>


<CENTER>
<A HREF="denis.html"><IMG HSPACE=5  BORDER=0 SRC="/gif/right.gif"></A>
<P>
<H2>Avril </H2>




<IMG BORDER=1 ALIGN=center SRC="avril.gif"><p>

<P>
<HR>
<P>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-311</DOCNO>
<DOCOLDNO>IA017-000178-B041-228</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/latex/denis.html 192.33.214.13 19970106050057 text/html 1118
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:20 GMT
Last-modified: Saturday, 30-Nov-96 18:15:07 GMT
Content-length: 929
Content-type: text/html
</DOCHDR>
<HTML>

<HEAD><TITLE>Les Aventures du Latex</TITLE></HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" BORDER=0  ALT="Artworks" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Les aventures du Latex</H1><HR>


<CENTER>
<A HREF="avril.html"><IMG HSPACE=5 BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="petitr.html"><IMG HSPACE=5  BORDER=0 SRC="/gif/right.gif"></A>

<P>
<H2>Jean-Claude Denis</H2>


<IMG BORDER=1 ALIGN=top SRC="denis1.gif"><HR WIDTH=100>

<center>
(A suivre ...)
</center>

<!-- <IMG BORDER=1 ALIGN=top SRC="denis2.gif"><HR WIDTH=100>

<IMG BORDER=1 ALIGN=top SRC="denis3.gif"><P>-->

<P>
<HR>
<P>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-312</DOCNO>
<DOCOLDNO>IA017-000178-B041-239</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/latex/petitr.html 192.33.214.13 19970106050105 text/html 1027
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:28 GMT
Last-modified: Saturday, 30-Nov-96 18:22:28 GMT
Content-length: 838
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>Les Aventures du Latex</TITLE></HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" BORDER=0  ALT="Artworks" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Les aventures du Latex</H1><HR>


<CENTER>
<A HREF="denis.html"><IMG HSPACE=5 BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="vaninnis.html"><IMG HSPACE=5  BORDER=0 SRC="/gif/right.gif"></A>

<P>
<H2>Petit-Roulet</H2>


<IMG BORDER=1 ALIGN=top SRC="petitr1.gif"><!-- <HR WIDTH=100>

<IMG BORDER=1 ALIGN=top SRC="petitr2.gif">--><P>

<P>
<HR>
<P>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Contact"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-313</DOCNO>
<DOCOLDNO>IA017-000178-B041-253</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/anim/petitr.html 192.33.214.13 19970106050114 text/html 520
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:37 GMT
Last-modified: Friday, 19-Apr-96 21:05:24 GMT
Content-length: 333
Content-type: text/html
</DOCHDR>
<html>
<head>
<title>Petit-Roulet (Les Aventures du Latex)</title>
<body>
<center>
<H2>Petit-Roulet</H2>
<em>Les Aventures du Latex</em>
<P>
<HR>
<P>
<table border=10>
<ROW>
<td>
<img vspace=10 hspace=10 src="doit.cgi">
</td>
</ROW>
</table>
<p>
Et, c'est reparti pour un <a href="petitr.html">tour</a> !!!
</center>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B27-314</DOCNO>
<DOCOLDNO>IA017-000178-B041-266</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/art/latex/vaninnis.html 192.33.214.13 19970106050124 text/html 995
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:01:45 GMT
Last-modified: Saturday, 30-Nov-96 18:21:32 GMT
Content-length: 806
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Les Aventures du Latex</TITLE>
</HEAD>

<BODY BGCOLOR="FFFFFF">

<A HREF="/f/art/index.html"><IMG SRC="/f/gif/artworks2.gif" BORDER=0  ALT="Artworks" ALIGN=RIGHT></A><ALIGN=BASELINE><H1>Les aventures du Latex</H1><HR>


<CENTER>
<A HREF="petitr.html"><IMG HSPACE=5 BORDER=0 SRC="/gif/left.gif"></A>

<P>
<H2>Beno&icirc;t van Innis</H2>
<IMG BORDER=1 ALIGN=center SRC="vaninnis.gif"><p>

<center>
&quot;Après le dîner, Monsieur de Kerckhove leur offrit un préservatif&quot;
</center>
<P>
<HR>
<P>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-315</DOCNO>
<DOCOLDNO>IA017-000178-B041-276</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/pwa/projet_ecoles/finhaut.html 192.33.214.13 19970106050138 text/html 2719
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:02:00 GMT
Last-modified: Sunday, 05-May-96 12:59:50 GMT
Content-length: 2531
Content-type: text/html
</DOCHDR>
<html>
<head><title>T&eacute;moignage &agrave; Finhaut (Valais, Suisse)</title>
</head>
<body background="fond.gif">
<center><h2>T&eacute;moignage &agrave; Finhaut</h2>
<h3>Valais, Suisse</h3></center>
<hr size=5 width=75%>
<p>
<center><a href="Finhfoto.html"><img src="Finhaut1.gif"></a><br>
<font size=1>Photo Christian Rochat; L'illustr&eacute;</font>
<p>Corinne et Michel t&eacute;moignent aupr&egrave;s d'&eacute;leves en classe de neige.</center>
<p>
<hr size=5 width=75%>
<p>
A la demande d'une &eacute;cole, Corinne et Michel sont all&eacute;s t&eacute;moigner de leur vie de s&eacute;ropositif aupr&egrave;s d'une classe de neige.
<p>
Les enfants, entre 12 et 14 ans, peuvent poser toutes les questions qu'ils veulent aux intervenants. Ceux-ci essayent de r&eacute;pondre &agrave; chaque demande, le plus simplement possible, tout en se r&eacute;servant le droit de garder le silence sur un sujet difficile. Lorsque cela arrive, et  c'est tr&egrave;s rare, les t&eacute;moignants expliquent pourquoi ils le font (sujet trop douloureux, deuil r&eacute;cent, incertitude sur la r&eacute;ponse &agrave; donner, etc...).
<p>
Il peut para&icirc;tre pr&eacute;matur&eacute; de parler du Sida &agrave; des jeunes de 12 &agrave; 14 ans. Eh bien non.<br>
Les modes d'infections et la pr&eacute;vention m&eacute;dicale sont d&eacute;crits par un medecin, une infirmi&egrave;re ou par un service sp&eacute;cialis&eacute;. Nos t&eacute;moignages &eacute;voquent essentiellement la vie en tant que s&eacute;rpositif et, si le sujet est abord&eacute; par les &eacute;l&egrave;ves, &eacute;galement la pr&eacute;vention m&eacute;dicale.
Nous nous appliquons &agrave; &eacute;voquer les cons&eacute;quences d'une infection par le VIH/SIDA et toutes les contraintes que cela implique. 
<p>
Les questions des enfants &agrave; ce sujet sont tr&egrave;s pr&eacute;cises et directes. L&agrave; o&ugrave; un adulte tourne autour du pot, le suicide par exemple, l'enfant posera la question franchement (Quand on vous a dit que vous aviez le sida, est-ce que vous avez pens&eacute; &agrave; vous suicider?).

Les buts vis&eacute;s sont: une pr&eacute;vention g&eacute;n&eacute;rale, diminuer l'exclusion, donner l'occasion aux &eacute;l&egrave;ves de parler avec une personne s&eacute;ropositive et bien d'autres.
<p>
<hr size=5>
<center><font size=2>Mis en page par <a href="http://www.hivnet.ch/~Miguelito">Miguelito</a><br>
Vos <a href="mailto: Miguelito@hivnet.ch">questions</a> sont les bienvenues.</font></center>   








</body>
</html>
</DOC>
<DOC>
<DOCNO>WT18-B27-316</DOCNO>
<DOCOLDNO>IA017-000178-B041-287</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/consult/Medic-forum.html 192.33.214.13 19970106050149 text/html 1498
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:02:09 GMT
Last-modified: Saturday, 30-Nov-96 18:06:16 GMT
Content-length: 1308
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet.CH - Conseils de Santé</title></head><BODY BGCOLOR="FFFFFF"><A HREF="index.html"><IMG BORDER=0 ALIGN=right SRC="/f/gif/consultation.gif"></A><UL><H2>Conseils de Santé</H2><H3><I>Page principale</I></H3><BR CLEAR><HR><P><UL>Cette page vous permet de poser une question de santé et d'obtenir un conseilde <B>façon anonyme</B>.
<P><UL><LI><A HREF="Medic-tdm.cgi">Acc&eacute;der</A> &agrave;  la liste des questions et conseils déjà post&eacute;s<P><LI><A HREF="Medic-post.html">Poster</A> votre question</UL><P>Ce service est fourni en collaboration avec la <A HREF="http://expasy2.hcuge.ch/dmi/">Division des Maladies Infectieuses</A> (DMI) de l'Hôpital Cantonal Universitaire de Genève et ne constitue ni ne remplace une consultation m&eacute;dicale.<P><B>Sur rendez-vous</B>, toute personne s&eacute;ropositive peut obtenir une consultation m&eacute;dicale sp&eacute;cialis&eacute;e au DMI.<br>T&eacute;l. (41 22) 37 29 617 - du lundi au vendredi de 8h &agrave; 18 heures. </UL><P><HR><P><CENTER><A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A><A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A><A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A></CENTER></BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-317</DOCNO>
<DOCOLDNO>IA017-000178-B041-298</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/consult/Legal-forum.html 192.33.214.13 19970106050204 text/html 1280
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:02:26 GMT
Last-modified: Saturday, 30-Nov-96 18:04:19 GMT
Content-length: 1090
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet.CH - Informations juridiques</title></head>

<BODY BGCOLOR="FFFFFF">
<A HREF="index.html"><IMG BORDER=0 ALIGN=right SRC="/f/gif/consultation.gif"></A>

<UL>
<H2>Conseils juridiques</H2>

<H3><I>Page principale</I></H3>
<BR CLEAR>
<HR>
<P>

<UL>
Cette page vous permet de poser une question juridique et en particulier dans le
domaine des assurances sociales et d'obtenir une réponse anonyme. Vous avez aussi la possibilité de consulter les informations fournies précédemment.
<P>
<UL>
<LI><A HREF="Legal-tdm.cgi">Consulter</A> la liste des questions/réponses déjà post&eacute;es
<P>
<LI><A HREF="Legal-post.html">Poster</A> une question
</UL>
<P>
Ce service est fourni en collaboration avec le <A HREF="/gsg/"> Groupe sida Gen&egrave;ve</A>.
<P>
</UL>
<P>
<HR>

<P>
<CENTER>
<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>
<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>
<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-318</DOCNO>
<DOCOLDNO>IA017-000178-B041-313</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/f/consult/pvage-forum.html 192.33.214.13 19970106050212 text/html 1529
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:02:34 GMT
Last-modified: Saturday, 30-Nov-96 18:05:03 GMT
Content-length: 1339
Content-type: text/html
</DOCHDR>
<html><head><title>HIVNet.CH - Questionnaire Personnes Vivant Avec</title></head>



<BODY BGCOLOR="FFFFFF">

<A HREF="index.html"><IMG BORDER=0 ALIGN=right SRC="/f/gif/consultation.gif"></A>



<UL>

<H2>Personnes Vivant Avec</H2>



<H3><I>Page principale</I></H3>

<BR CLEAR>

<HR>

<P>



<UL>

Cette page vous permet de poser une question aux Personnes Vivant Avec et d'obtenir une r&eacute;ponse de <FONT SIZE=-1>FAÇON ANONYME</FONT><I></I>.

<P>

<UL>

<LI><A HREF="pvage-tdm.cgi">Acc&eacute;der</A> &agrave;  la liste des questions  déjà post&eacute;es

<P>

<LI><A HREF="pvage-post.html">Poster</A> votre question

</UL>

<P>

Ce service est fourni en collaboration avec  <A HREF="/pvage/index.html">PVA - Gen&egrave;ve</A> qui s'engage &agrave; r&eacute;pondre dans les meilleurs d&eacute;lais.
<P>

PVA - Gen&egrave;ve accueille toutes les personnes d&eacute;sirant avoir un entretien avec un membre de l'association
<P>
Demandez un rendez-vous par t&eacute;l&eacute;phone au (+41 22) 700 15 31. 

</UL>

<P>

<HR>



<P>

<CENTER>

<A HREF="/f/index.html"><IMG SRC="/f/gif/home2.gif" BORDER=0 ALT="Home"></A>

<A HREF="/f/search/index.html"><IMG SRC="/f/gif/search2.gif" BORDER=0 ALT="Rechercher"></A>

<A HREF="/f/info/index.html"><IMG ALIGN=top SRC="/f/gif/intouch.gif" BORDER=0 ALT="Info"></A>

</CENTER>

</BODY>

</HTML>

</DOC>
<DOC>
<DOCNO>WT18-B27-319</DOCNO>
<DOCOLDNO>IA017-000178-B041-344</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?+tdm 192.33.214.13 19970106050237 text/html 736
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Index</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>
<H2>INFOTHEQUE SIDA - Index<BR CLEAR><HR></H2>
<UL><UL TYPE=DISC><LI><A HREF="INFOTHEQUE.cgi?+9504">Aids Infotheque 4/95, Jul 1995</A>
<LI><A HREF="INFOTHEQUE.cgi?+9601">Infoth&egrave;que SIDA 01/96</A>
<LI><A HREF="INFOTHEQUE.cgi?+9602">Infoth&egrave;que SIDA 02/96</A>
<LI><A HREF="INFOTHEQUE.cgi?+9603">Infoth&egrave;que SIDA 03/96</A>
</UL></UL>
<HR>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-320</DOCNO>
<DOCOLDNO>IA017-000178-B041-360</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:1 192.33.214.13 19970106050248 text/html 3289
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Kommentar</I><br>Prof. Dr. med. Beat Roos</H3><br>
<I>Ehemaliger Direktor des Bundesamtes f&uuml;r Gesundheitswesen (1983 bis 1990)</I><P>
<UL>
Als wir 1983 im Bundesamt f&uuml;r Gesundheitswesen (BAG) mit dem ersten Schweizer konfrontiert waren, der an einem Kaposi Sarkom litt, wussten wir: die neue und r&auml;tselhafte Krankheit Aids gab es auch bei uns. Kaposi, dieser bis dahin seltene b&ouml;sartige Tumor, rasch zu einer "Schwulenkrankheit" gemacht, von der wir aus den Vereinigten Staaten Kenntnis hatten, weckte b&ouml;se Ahnungen. Bald darauf entdeckte Luc Montagnier am Pasteur Institut in Paris das "Human Immunodeficiency Virus" (HIV); es wurde rasch klar, dass dieses sexuell &uuml;bertragbare Virus die neue Krankheit ausl&ouml;ste, und der Kaposi-Tumor nur eines von vielen m&ouml;glichen Symptomen von Aids war. Da sah sich 1985 das BAG veranlasst, alle Haushalte der Schweiz in einer Brosch&uuml;re zu orientieren und aufgrund des Epidemiengesetzes eine eine nationale Pr&auml;ventions-Kampagne zu starten.<P>
In dieser fr&uuml;hen Zeit von Aids ist in der Schweiz gelungen, was viele diesem etwas langsamen, etwas konservativen und etwas zugekn&ouml;pften Land nicht zugetraut hatten: staatliche Einrichtungen vernetzten sich mit den Gef&auml;hrdeten und Betroffenen, mit nichtstaatlichen Organisationen, z. B. Vereinigungen von Homosexuellen, in einer Geschwindigkeit und einer direkten Art, wie wir es noch nicht erlebt hatten. Wir hatten begriffen: Wir m&uuml;ssen handeln.<P>
Weil es kaum Vorbilder gab f&uuml;r die Projekte, die n&ouml;tig waren, handelten wir nach dem Prinzip von Trial and Error, evaluierten und korrigierten schnell, was sich bew&auml;hrte und was nicht, und versuchten, gewonnenes Know-how zu b&uuml;ndeln und weiterzugeben, national und international.<P>
Und heute? Was ist in den langen Jahren aus Vorstellungskraft, Fantasie und Mut, was aus den unkonventionellen Ideen geworden, dem Willen, Kontroversen und Angriffe auszuhalten, der Risikobereitschaft, tabuisierte Themen &ouml;ffentlich zu er&ouml;rtern? Heute ist Aids selbstverst&auml;ndlich da. Aber nicht mehr pr&auml;sent. Wir leben damit.<P>
Wenn ich der Aids-Hilfe und ihren Verb&uuml;ndeten, aber auch den verantwortlichen Gesundheitsbeh&ouml;rden in unserem Lande und den Politikern etwas w&uuml;nsche, ist es: nicht einfach damit leben, nicht in Rou-tine erstarren, nicht m&uuml;de werden, nicht resignieren, nicht verwalten.<br>
K&auml;mpfen!<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-321</DOCNO>
<DOCOLDNO>IA017-000178-B041-371</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.1 192.33.214.13 19970106050259 text/html 13435
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:18 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>10 Jahre Aids-Hilfe Schweiz</I><br>Christian Schneeberger</H3>
<I>Aids-Aktivist der ersten Stunde und Vorstands mitglied der Aids-Hilfe Schweiz 1988-1993</I><P>
<UL>
<B>Die Aids-Hilfe Schweiz (AHS) kann mit Stolz auf ihre zehnj&auml;hrige Geschichte zur&uuml;ckblicken: die Epidemie scheint in der Schweiz unter Kontrolle; die Bev&ouml;lkerung ist informiert und sensibilisiert, die Kurve der Neuansteckungen flacht ab. Die Zusammenarbeit mit den Beh&ouml;rden und mit den (organisierten) Betroffenen funktioniert, trotz gelegentlichen Reibungen, besser als anderswo. Das Pr&auml;servativ ist enttabuisiert und breit bewerbbar; im Drogenbereich sind - vereinzelt - saubere Spritzen sogar schon in Gef&auml;ngnissen erh&auml;ltlich. Die STOP AIDS-Kampagne wie auch die zielgruppenorientierten Pr&auml;ventionsaktivit&auml;ten stossen, von gelegentlichen St&ouml;rman&ouml;vern aus traditionalistisch-konservativen Kreisen abgesehen, auf breite Akzeptanz in Gesellschaft und Politik und finden auch international grosse Anerkennung. Und sogar das Problem der aus Unkenntnis, Vorurteil und &Auml;ngsten gespeisten Diskriminierung und Ausgrenzung von Infizierten und Erkrankten hat an Virulenz verloren.</B><P>
Wohl die wenigsten der Pioniere, die im Fr&uuml;hsommer 1985 die Gr&uuml;ndung der AHS in die Wege leiteten, h&auml;tten damals diese Erfolge f&uuml;r m&ouml;glich gehalten. Seit zwei Jahren schon hatten zun&auml;chst Ger&uuml;chte und aufgeregte Schlagzeilen, dann erste Fakten &uuml;ber die in Amerika grassierende "Schwulenseuche" zu heftigen Debatten und ersten (Pr&auml;ventions-) Aktivit&auml;ten in den Organisationen der Homosexuellen gef&uuml;hrt. Die Schwulen sahen durch die neue Krankheit nicht nur ihre k&ouml;rperliche Integrit&auml;t, sondern auch j&uuml;ngst erk&auml;mpfte Freir&auml;ume und erste Ans&auml;tze zu gr&ouml;sserer gesellschaftlicher Akzeptanz gef&auml;hrdet.<br>
Diese doppelte Bedrohung und die entsprechende pers&ouml;nliche und soziale Betroffenheit der Homosexuellen war die zentrale Triebkraft bei der Gr&uuml;ndung der AHS. Als Pate hatte das weitsichtige und fr&uuml;h engagierte Bundesamt f&uuml;r Gesundheitswesen (BAG) mit sanftem Druck das Vorhaben eines nationalen Zusammenschlusses gef&ouml;rdert: es w&uuml;nschte sich statt vieler lokaler Gruppen und Gr&uuml;ppchen einen einzigen, kompetenten Ansprechpartner. Dieser sollte zudem durch seine N&auml;he zu den anzusprechenden Bev&ouml;lkerungskreisen den anlaufenden Pr&auml;ventionsbem&uuml;hungen Glaubw&uuml;rdigkeit verleihen, da man richtig erkannte, dass angesichts einer langen Tradition von Ausgrenzung und Verfolgung das Vertrauen in staatliche Instanzen bei den in erster Linie betroffenen Randgruppen und Minderheiten wohl nicht besonders gross sein konnte.<P>
<H4>Das (andere) Drei-S&auml;ulen-Konzept</H4>
Faktisch ergab sich damit eine Dreiteilung der Verantwortlichkeiten: Medizin und Wissenschaft - der dritte Partner - lieferten den jeweils aktuellsten Wissensstand als Grundlage f&uuml;r die Pr&auml;ventionsbotschaften; die staatlichen Instanzen - in erster Linie das BAG - sorgten f&uuml;r die politische Unterst&uuml;tzung und f&uuml;r das n&ouml;tige Geld; die Aids-Hilfe organisierte - in engem Kontakt mit den Zielgruppen - die optimale Umsetzung der Projekte und stellte gleichzeitig sicher, dass Bed&uuml;rfnisse der Betroffenen rasch wahrgenommen und ber&uuml;cksichtigt werden konnten.<P>
<H4>Ein Lernmodell anstelle der Repression</H4>
Von Anfang an war man sich einig, dass repressive Massnahmen weder praktikabel noch erfolgsversprechend waren. Man setzte auf Verhaltens&auml;nderungen. Ausgehend von der Theorie des sozialen Lernens galt es, ohne unn&ouml;tige &Auml;ngste zu sch&uuml;ren, mit m&ouml;glichst wenigen einpr&auml;gsamen Kernbotschaften mitzuteilen, wie sich die &Uuml;bertragung des Virus verhindern l&auml;sst.<br>
"Mit den Betroffenen f&uuml;r die Betroffenen" hiess die Strategie, die sich auch bei der Ausweitung auf neue Zielgruppen, Drogenabh&auml;ngige, Sexgewerbe, bew&auml;hrte. Die jeweiligen Kernaussagen ("Im Minimum e Gummi drum", "Kein Spritzentausch", "Bei mir immer mit"), die ab 1987 im wesentlichen auch die STOP AIDS-Kampagne pr&auml;gten, sind Allgemeingut geworden.<br>
Da solches, auf Verhaltensanpassungen im Sexualbereich zielendes Lernen aber nur in einem offenen und m&ouml;glichst angstfreien Klima dauerhafte Erfolge verspricht, musste parallel dazu an der Schaffung eines entsprechenden Umfeldes gearbeitet werden - was noch heute von fundamentalistischen Kreisen als Werbung f&uuml;r Homosexualit&auml;t, Prostitution, Drogensucht und freie Liebe missverstanden wird.<br>
In der Tat d&uuml;rfte die Bedrohung durch Aids den gesellschaftlichen Wandel der letzten zehn Jahre, wenn nicht urs&auml;chlich bestimmt, so doch mitgepr&auml;gt oder beschleunigt haben: vom Stellenwert der Sexualaufkl&auml;rung in den Schulen &uuml;ber die wachsende Akzeptanz homosexueller Lebensformen bis hin zur breiten Unterst&uuml;tzung radikal neuer Ans&auml;tze in der Drogenpolitik.<P>
<H4>Schwierige Umsetzung</H4>
Auch wenn sich die Erfolge durchaus eingestellt haben: ohne Schwierigkeiten und R&uuml;ckschl&auml;ge ging es nicht. Auf allen drei Ebenen - Politik, Medizin und "Basis" - waren 1985 nur Vereinzelte informiert und motiviert: es galt f&uuml;r die Vork&auml;mpfer in jedem der Bereiche m&ouml;glichst breite Mehrheiten zu gewinnen.<br>
Die &Uuml;berzeugungsarbeit bei den Zielgruppen rieb sich vor allem an Verdr&auml;ngungsmechanismen. Die angestrebte Dauerpr&auml;senz mit Pr&auml;ventionsbotschaften liess sich nur schwer durchsetzen: die st&auml;ndige Konfrontation mit der Bedrohung war und ist schwer zu ertragen. Andererseits versuchten verschiedene Gruppen, im wesentlichen ohne Erfolg, die Aids-Hilfe f&uuml;r die Verfolgung eigener Ziele zu instrumentalisieren.<br>
Nicht zu erreichen war die erhoffte "Unit&eacute; de Doctrine" von Seiten der Wissenschaft. Nicht nur Aussenseiter &agrave; la Duesberg verunsicherten die &Ouml;ffentlichkeit, auch innerhalb der Standesorganisationen legten sich Mediziner quer, denen die liberale Stossrichtung der Kampagne und - vor allem - der Einbezug der Betroffenen zu schaffen machte.<br>
Die radikalsten Gegner der Kampagne gruppierten sich in der Aids-Aufkl&auml;rung Schweiz und lobbyierten nicht nur in medizinischen Kreisen, sondern vor allem auch auf politischer Ebene f&uuml;r ihre Sicht der Dinge. Das BAG, als Amt zu politischer Zur&uuml;ckhaltung verpflichtet, und zudem - mit Druck von oben und unten - in einer unkomfortablen Sandwichposition, konnte diesen Aktivit&auml;ten nur wenig entgegensetzen.<P>
<H4>Der Weg hin zur Mehrheit</H4>
Die Bedrohung durch Aids beschr&auml;nkte sich inzwischen l&auml;ngst nicht mehr auf "Risikogruppen", die Notwendigkeit der seit 1987 angelaufenen Kampagnen f&uuml;r die Gesamtbev&ouml;lkerung war im Grundsatz unbestritten. Doch die langwierige und m&uuml;hselige Konsensfindung in den politischen und<br>
medizinischen Gremien - man denke etwa an die (im R&uuml;ckblick kaum mehr nachvollziehbaren) Auseinandersetzungen um die Spritzenabgabe - f&uuml;hrten bei der AHS zu einer Neudefinierung ihrer Rolle.<br>
Da die st&auml;ndigen Angriffe die Umsetzung der Pr&auml;ventionskampagnen immer wieder verz&ouml;gerten, oder im schlimmsten Fall ganz blockierten und mehr und mehr auch die Zielgruppenarbeit behinderten, entwickelte die AHS - &uuml;ber die urspr&uuml;ngliche Funktion als basisnahe Struktur hinaus - Eigeninitiative im gesellschaftspolitischen Bereich. Diese Neupositionierung f&uuml;hrte aber bald zu Zielkonflikten.<P>
<H4>Der Wandel zur Heterosexualisierung von Aids</H4>
Unter dem Druck politischer Attacken wurde, auch von der AHS - der Schreibende schliesst sich ein - eine "Heterosexualisierung" der Krankheit vorangetrieben. Nur eine glaubhaft gemachte Bedrohung der Gesamtbev&ouml;lkerung schien das Fliessen der Gelder sicherzustellen, die eine Weiterf&uuml;hrung der dringend n&ouml;tigen Pr&auml;ventionsarbeit erm&ouml;glichten. Dieser Paradigmenwechsel hatte Folgen. Eine - im Bild der &Ouml;ffentlichkeit - von schwulen Aktivisten gepr&auml;gte Aids-Hilfe erwies sich in dieser Strategie als Handikap. Die Betroffenenkompetenz der Anf&auml;nge, die N&auml;he zu marginalisierten Gruppen waren immer weniger gefragt. Man brauchte jetzt Anw&auml;lte bei der Mehrheit.<br>
Mit dem Schlagwort der "Professionalisierung" wurden die aus der Basis rekrutierten Exponenten der Aids-Hilfe mehr und mehr durch institutionsnahe Personen ersetzt: als Galionsfiguren w&auml;hlte man Politikerinnen und Politiker und mehrheitstaugliche Lobbyisten mit Einfluss und Verbindungen - und bei den AHS-Mitarbeitern und Mitarbeiterinnen wurde inhaltliche Kompetenz im urspr&uuml;nglichen Sinne einer "Verankerung bei den Zielgruppen" im Vergleich zu formalen Qualifikationen immer unwichtiger.<P>
<H4>Die regionalen Aids-Hilfen</H4>
Schon bald nach der Gr&uuml;ndung der AHS entstanden spontan erste lokale, regionale und kantonale Aids-Hilfen, zun&auml;chst - und in den meisten gr&ouml;sseren St&auml;dten - erneut unter Federf&uuml;hrung homosexueller Aktivisten, dann aber immer mehr auf Initiative von Gesundheitspolitikern, Beh&ouml;rden und sozialen Organisationen. Bereits Mitte 1987 war ein nahezu fl&auml;chendeckendes Netz vorhanden. Die Grundaufgabe war, in &Uuml;bereinstimmung mit den Vorstellungen von AHS und BAG, relativ klar: Umsetzung der Pr&auml;ventionskonzepte vor Ort und vor allem: Beratung, Betreuung, Begleitung (BBB). Damit ersch&ouml;pfte sich allerdings die Gemeinsamkeit schon weitgehend.<br>
So unterschiedlich die Gr&uuml;ndungsumst&auml;nde, so unterschiedlich die formalen und finanziellen Strukturen: die Aids-Hilfen waren als Vereine neu gegr&uuml;ndet, als staatliche Fach- und Stabstellen eingesetzt oder an bestehende Strukturen angeh&auml;ngt worden; sie waren kantonal oder gar &uuml;berkantonal, lokal oder regional t&auml;tig; sie waren relativ komfortabel dotiert oder mussten ohne einen Rappen &ouml;ffentlicher Gelder auskommen.<br>
Versuche, diesem Wildwuchs Herr zu werden, verliefen mehr oder weniger im Sand; das f&ouml;deralistisch organisierte Gesundheitswesen erwies sich s&auml;mtlichen Koordinierungsbem&uuml;hungen gegen&uuml;ber als resistent. Und die AHS - obschon inzwischen als Dachverband konstituiert - fand, angesichts all ihrer neuen Aufgaben, immer weniger Zeit und Energie, sich um diese Basis zu k&uuml;mmern.<br>
Und so werkelten die regionalen Aids-Hilfen vor sich hin, bis heute unbestritten engagiert und fast durchwegs kompetent im Bereich BBB, ansonsten allenfalls in den grossen Zentren mehr als nur punktuell pr&auml;sent. F&uuml;r eine kontinuierliche Pr&auml;ventions- und Lobby-Arbeit fehlten die personellen und finanziellen Ressourcen ebenso wie die Unterst&uuml;tzung von oben. Und wie auf nationaler Ebene wurden - so sie &uuml;berhaupt je vorhanden waren - die wegsterbenden und ersch&ouml;pften basisnahen Gr&uuml;nder immer &ouml;fter durch zielgruppenferne Profis ersetzt.<P>
<H4>Zur&uuml;ck zu den Wurzeln</H4>
Inzwischen wird die von der AHS mitgetragene Schwerpunktverlagerung auf die Zielgruppe "Gesamtbev&ouml;lkerung" kritisch hinterfragt. Auch wenn die im November 1994 in der Weltwoche gerittene Attacke ("Der Mythos der heterosexuellen Aids-Epidemie") das Kind wohl mit dem Bade aussch&uuml;ttet - eine generelle Entwarnung ist mit Bestimmtheit nicht angesagt -, sind manche dort ge&auml;usserten &Uuml;berlegungen auch f&uuml;r die Schweiz bedenkenswert.<br>
Die Aids-Hilfe Schweiz, die zur Zeit intensiv an einer "Vision 2000" arbeitet, muss sich ernsthaft &uuml;berlegen, ob die in den letzten Jahren erfolgte Neuorientierung der Weisheit letzter Schluss war und ob die Zukunft der AHS wirklich in der geplanten Ausweitung der Aktivit&auml;ten &uuml;ber das Thema Aids hinaus - hin zu einer f&uuml;hrenden Rolle im gesamten Bereich von "Sexual Health" - liegen soll.<br>
Gerade auch im R&uuml;ckblick auf die Erfolge der ersten zehn Jahre, auf die die AHS mit Recht stolz sein darf, m&uuml;sste man sich auf die urspr&uuml;nglichen St&auml;rken zur&uuml;ckbesinnen und - mit den Betroffenen, f&uuml;r die Betroffenen - eine vielleicht weniger gloriose, aber umso notwendigere Zukunft nahe der Basis suchen: die kantonalen Aids-Hilfen und die noch immer in erster Linie unter Aids leidenden und an Aids sterbenden Schwulen und Drogenabh&auml;ngigen w&uuml;ssten es ihr zu danken.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-322</DOCNO>
<DOCOLDNO>IA017-000178-B041-380</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.2 192.33.214.13 19970106050307 text/html 7077
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:29 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>

 
<H3><I>Wie man den Kampf gegen Aids bei schwulen M&auml;nnern doch noch verliert</I><br>Roger Staub,</H3>
<I>Delegierter f&uuml;r Aidsfragen des Kantons Z&uuml;rich, Gr&uuml;ndungs- und Vorstandsmitglied der Aids-Hilfe Schweiz 1985-1987</I><P>
<UL>
<B>"Ich bin 50, homosexuell und habe Aids." Mit diesen Worten pr&auml;sentierte sich am 2. Juli 1985 der Fernsehjournalist Andr&eacute; Ratti der &Ouml;ffentlichkeit als neuer Pr&auml;sident der Aids-Hilfe Schweiz. Die Aids-Hilfe Schweiz war einen Monat zuvor von den Schwulenorganisationen der Schweiz in Z&uuml;rich gegr&uuml;ndet worden. Andr&eacute; Ratti stellte sich an die Spitze einer Organisation, die der weiteren Ausbreitung von HIV bei allen Betroffenengruppen (damals sagten die meisten noch "Risikogruppen") Einhalt gebieten und Betroffenen helfen wollte.</B><P>
F&uuml;r die Pr&auml;ventionsarbeit bei schwulen M&auml;nnern entwickelte die Aids-Hilfe Schweiz unter F&uuml;hrung von Herbert Riedener das "Drei-S&auml;ulen-Konzept": Hot Rubber (Pr&auml;ventionsmittel) - Safer Sex (Pr&auml;ventionswissen) - Rede mitenand (Beratung und gegenseitige Unterst&uuml;tzung). Die Entwicklung dieses Konzepts und dessen Umsetzung geh&ouml;ren zu den wichtigsten Leistungen der Aids-Hilfe Schweiz: Die Erfolge waren schon nach wenigen Jahren messbar; verschiedene Untersuchungen des Institut Universitaire de M&eacute;decine Sociale et Pr&eacute;ventive in Lausanne belegen dies eindr&uuml;cklich. Die WHO (Weltgesundheitsorganisation) erachtete die Hot Rubber-Kampagne als so beispielhaft, dass ich sie am "World Summit of Health Ministers" 1988 in London als innovatives Beispiel vorstellen durfte.<P>
<H4>Nicht bei den Anfangserfolgen stehenbleiben</H4>
Ich bin rund um HIV und Aids strikte gegen jede Verwendung von Kriegsvokabular. Mir dr&auml;ngt sich aber doch folgender Vergleich auf: Wenn wir uns mit diesen Anfangserfolgen begn&uuml;gen und "nach ersten gewonnenen Schlachten auch den Krieg f&uuml;r gewonnen erkl&auml;ren", werden wir den Kampf ge-gen HIV bei M&auml;nnern, die mit M&auml;nnern Sex haben, verlieren:<br>
Erstens, weil es heute keineswegs mehr darum geht, mit Safer Sex anzufangen, sondern Safer Sex stabil ins Verhaltensrepertoire eines jeden Mannes, der mit M&auml;nnern Sex hat, einzubauen und beizubehalten. Dass die &uuml;ber 80% der Schwulen, die Safer Sex leben, dabei bleiben (k&ouml;nnen), daf&uuml;r brauchen sie Motivation und Unterst&uuml;tzung. Das kostet Zeit, Geld und Energie. Vor allem f&uuml;r die Aids-Hilfe Schweiz.<br>
Zweitens kennen auch diejenigen M&auml;nner die Safer Sex-Botschaft, die sich (noch) nicht nach ihr richten. Das Wissen ist da. Dass aber Wissen<br>
alleine nicht ausreicht, ist eine Binsenwahrheit. Jetzt m&uuml;ssen uns die Umst&auml;nde, unter denen Unsafe Sex vorkommt, interessieren. Die Leitfrage muss heissen: K&ouml;nnen wir diese Umst&auml;nde so ver&auml;ndern, dass sie seltener zu "unsafem" Verhalten f&uuml;hren?<br>
Drittens haben wir ein Problem mit den jungen Schwulen: F&uuml;r viele von ihnen ist Aids eine Krankheit der &auml;lteren Schwulen. Sie kennen kaum HIV-infizierte M&auml;nner und haben keine aidskranken, gleichaltrigen Freunde. Die Jungen von heute nehmen die Pr&auml;vention nicht wahr als an sie, sondern an die &auml;lteren gerichtet. Pr&auml;vention wird die Jungen nur erreichen, wenn sie nicht weiterhin von "Alten" f&uuml;r "Junge", sondern von Jungen mit Jungen entwickelt und gestaltet wird.<br>
Viertens sind es nicht nur gutausgebildete, relativ gut verdienende M&auml;nner, die die (Party-) Szenen unserer St&auml;dte frequentieren, die sich nicht (immer) sch&uuml;tzen, sondern auch &auml;rmere, weniger gebildete, verklemmtere, j&uuml;ngere und &auml;ltere M&auml;nner. Aidspr&auml;vention muss zu ihnen gebracht werden, dahin, wo diese M&auml;nner sich treffen! Keine Aids-Hilfe kann warten, bis Einzelne und Gruppen von M&auml;nnern, die nicht zu den jungen und selbstbewussten Schwulen unserer St&auml;dte geh&ouml;ren, auf die Gesch&auml;ftsstelle kommen und "ihre" Pr&auml;vention einfordern.<br>
Und f&uuml;nftens werden wir zur Kenntnis nehmen m&uuml;ssen, dass vieles, was gestern eine gute Idee war und Wirkung zeigte, heute nicht nur veraltet und ohne Effekt, sondern sogar schlicht falsch sein k&ouml;nnte.<br>
Die Aids-Hilfe Schweiz hat nach den Erfolgen der ersten Jahre bei Schwulen im Engagement nachgelassen und viele Ressourcen in andere Bereiche, bei anderen Gruppen investiert. Mit dem neu gestarteten "MSM-Projekt" besteht wieder Hoffnung, dass der Kampf gegen Aids bei M&auml;nnern, die mit M&auml;nnern Sex haben, nicht verloren wird. Aber nur, wenn ausreichende Mittel eingesetzt werden: ausreichend f&uuml;r die Arbeit in einem Teil der Bev&ouml;lkerung, der immer noch 40% der Neuerkrankungen an Aids stellt, in dem immer noch jede dritte Neuinfektion vorkommt, der noch bis vor wenigen Jahren von der Gesellschaft massiv diskriminiert wurde.<P>
<H4>Von der Ver&auml;nderung des Verhaltens zur Ver&auml;nderung der Verh&auml;ltnisse</H4>
Zur Aidspr&auml;vention muss der politische Kampf f&uuml;r gen&uuml;gende Mittel ebenso geh&ouml;ren wie die Umorientierung der Arbeit von der Verhaltensebene des Einzelnen auf die Verh&auml;ltnisse, in denen Schwule heute leben (m&uuml;ssen). Mehr von der gleichen Pr&auml;vention wie in den letzten Jahren wird nichts mehr bringen. Wir brauchen heute Neues und Unterst&uuml;tzung daf&uuml;r, dass die Verbesserung der Verh&auml;ltnisse, in denen all jene leben, die wir erreichen wollen, imperativ zur Pr&auml;vention geh&ouml;rt.<br>
Eine Aids-Hilfe, die ihren Namen verdient, muss zusammen mit den Schwulen nicht nur f&uuml;r Toleranz, sondern f&uuml;r Akzeptanz der Menschen, die gleichgeschlechtlich lieben, einstehen. Zur Akzeptanz geh&ouml;rt, dass diese Menschen mit ad&auml;quaten Mitteln versorgt werden, dass ihre Leben durch HIV nicht st&auml;rker gef&auml;hrdet werden als die Leben der Menschen, die heterosexuell lieben. Menschen in und um Aids-Hilfen, die dies nicht einsehen wollen (oder k&ouml;nnen), haben in Andr&eacute; Rattis Aids-Hilfe nichts verloren!<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-323</DOCNO>
<DOCOLDNO>IA017-000178-B042-7</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.3 192.33.214.13 19970106050320 text/html 6455
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Den Fixerinnen und Fixern fehlte eine Lobby</I><br>
Prof. Dr. med. Peter Grob,</H3><br>
<I>Departement f&uuml;r Innere Medizin Universit&auml;tsspital Z&uuml;rich, Mitglied des Vorstandes der AHS 1987-1990</I><P>
<UL>
<B>Die Geschichte der AHS ist eine Geschichte der Aufkl&auml;rung, der Hilfe an Betroffene, der Verhinderung von Diskriminierung. Sie begann mit homosexuellen M&auml;nnern, die sich aktiv gegen Aids einsetzten und ihren Kampf mit den gesellschaftlichen Dimensionen der Krankheit verkn&uuml;pften. Sie wurde m&ouml;glich durch die solidarische Unterst&uuml;tzung von Personen aus Kultur, Wirtschaft und Politik. &Auml;hnlich und doch anders pr&auml;sentiert sich die Geschichte der AHS aus dem Blickwinkel der Menschen, die Drogen spritzen.</B><P>
Mit einer Verz&ouml;gerung von ein, zwei Jahren wurde deutlich, dass auch sie von der HIV-Epidemie stark betroffen waren. Den intraven&ouml;s Drogenkonsumierenden fehlte jedoch eine Lobby; einzig eine kleine Gruppe von Sozial- und Drogenarbeitern/-innen sowie Verantwortliche und Mitarbeiter/innen einiger Drogeninstitutionen setzten sich f&uuml;r die HIV-Pr&auml;vention bei Drogenkonsumenten/-innen ein. Allerdings waren sie auf verschiedene Gruppen aufgesplittert und auch uneins in ihren politischen Standpunkten. Die AHS ergriff die Initiative, um diese verschiedenen Bem&uuml;hungen zu koordinieren.<P>
Mit finanzieller Unterst&uuml;tzung des BAG entstanden bei der AHS und bei einer Reihe von kantonalen Aids-Hilfen Arbeitsgruppen und Projekte, die sich speziell mit den Problemen der HIV-Pr&auml;vention bei Drogenkonsumenten/-innen befassten. In hartn&auml;ckiger Kleinarbeit liessen sich verschiedene Erfolge verzeichnen, so im Bereich der Information der Bev&ouml;lkerung, in der Betreuung und Beratung und auch im Kampf gegen Diskriminierung. Die Erf&uuml;llung der hochgesteckten Ziele stiess aber oft an Grenzen.<P>
Die Aids-Pr&auml;vention im Drogenbereich wurde f&uuml;r die AHS nie zu einem eigentlichen Schwerpunkt ihrer Arbeit. Heute ist sie sogar eher als Stiefkind zu bezeichnen. Man wurde sich bewusst, dass die Drogensucht selbst ein komplexes und schwer l&ouml;sbares Problem darstellt, mit Implikationen weit &uuml;ber die Aidsproblematik hinaus. Die AHS &uuml;bernahm die Betreuung des Flash-Box-Projektes; in Genf betreibt die Groupe Sida Gen&egrave;ve einen Spritzenbus; einzelne kantonale Aids-Hilfen betreuen in Gef&auml;ngnissen Gefangene, von denen ein Grossteil Drogen konsumiert. In ihrer Beratungs- und Betreuungsarbeit sind die Mitarbeiter/innen der kantonalen Aids-Hilfen zudem h&auml;ufig mit Fragen und Problemen rund um HIV und Drogenkonsum konfrontiert.<P>
<H4>L&uuml;cken in der Drogen- und Aids-Pr&auml;vention</H4>
Mit den Diskussionen um Platzspitz und Letten ist die Drogenproblematik in der Schweiz in den Mittelpunkt des &ouml;ffentlichen Interesses ger&uuml;ckt. Viele neue Hilfsstrukturen sind entstanden oder befinden sich in Planung. Trotzdem gibt es in der Drogen- und Aidspr&auml;vention noch eine Reihe von L&uuml;cken auszuf&uuml;llen. Dazu einige Gedanken:<P>
Das Drogenproblem nimmt bei der Bev&ouml;lkerung, den Parteien und den Beh&ouml;rden zwar einen wichtigen Platz ein, doch beschr&auml;nken sich die Diskussionen auf einzelne Aspekte. Dazu geh&ouml;rt der Schutz der Bev&ouml;lkerung vor der Kriminalit&auml;t der Drogenh&auml;ndler wie auch der Fixer/innen. In aller Eile wurden neue Gef&auml;ngnispl&auml;tze geschaffen, Gesetze versch&auml;rft und ordnungspolizeiliche Massnahmen zur Aufl&ouml;sung offener Drogenszenen ergriffen. Ein weiterer Aspekt der Diskussion befasst sich mit dem Ausbau der &Uuml;berlebenshilfe f&uuml;r schwers&uuml;chtige Drogenkonsumenten/-innen. In vielen Kantonen entstanden Notschlaf-, Kontakt- und Anlaufstellen, Pl&auml;tze f&uuml;r Entz&uuml;ge und begleitetes Wohnen; teilweise wurden auch Verteilernetze f&uuml;r Spritzen und Nadeln ausgebaut. In andern Kantonen passierte jedoch wenig.<br>
F&uuml;r ganz wesentliche Bereiche der Drogenpr&auml;vention bleiben zurzeit nur Brosamen &uuml;brig. Dazugeh&ouml;rt die Hilfe an die Drogenkonsumenten/-innen, die noch nicht sozial ausgestiegen sind und denen auch Kriminalit&auml;t fern ist. Diese Gruppe umfasst 15 000 bis 20 000 der gesch&auml;tzten Zahl von 20 000 bis 30 000 Drogenkonsumenten/-innen in der Schweiz.<P>
<H4>Teufelskreis fr&uuml;her durchbrechen</H4>
Im heutigen Umfeld ist der Kontakt zu dieser wichtigsten Zielgruppe f&uuml;r eine fr&uuml;he Schadensbegrenzung praktisch verlorengegangen. Diese Menschen sind einmal mehr in den Untergrund vertrieben, versuchen im geheimen zu leben und zu &uuml;berleben, &uuml;ber mehrere Zwischenstationen des Drogenhandels Stoff und saubere Spritzen zu beschaffen. Ihr Lebensgleichgewicht ist prek&auml;r labil, gepr&auml;gt durch Angst vor dem Abgleiten und leider auch von Selbst&uuml;bersch&auml;tzung. Zu ihnen muss Kontakt gefunden werden.<P>
Dies kann nur passieren, wenn Drogenkonsumenten/-innen ihre Sucht nicht mehr verheimlichen m&uuml;ssen. Der bekannte Teufelskreis der sozialen Ausgrenzung muss fr&uuml;her durchbrochen werden, nicht erst auf der Stufe der Notschlafstellen, der unmenschlichen Spritzenautomaten und der staatlichen Drogenabgabe. Der Staat tut sehr viel und kann nicht viel mehr. Die Bev&ouml;lkerung ist gefordert. Hier kann die AHS auf vielen Ebenen einen wichtigen Beitrag leisten. Dieser Wunsch ist begleitet von einem grossen Dank an die AHS f&uuml;r ihre bisherige Arbeit.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-324</DOCNO>
<DOCOLDNO>IA017-000178-B042-18</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.4 192.33.214.13 19970106050328 text/html 7459
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:03:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>'Et les personnes touch&eacute;es commen&ccedil;aient &agrave; parler'</I><br>Philippe Esnault</H3>
<I>Dialogai, Gen&egrave;ve</I><P>
<UL>
<B>Il y a dix ans, Carlos, mon ami, s'&eacute;teignait dans un silence de mort, foudroy&eacute; par une maladie dont personne n'osait encore articuler le nom. Fort d'une impuissance &agrave; laquelle je ne pouvais me r&eacute;signer, je me pr&eacute;sentais donc quelques jours plus tard aupr&egrave;s de Dialogai, groupe homosexuel, mais qui arborait d&eacute;j&agrave; en 1985, sur le bulletin que j'avais trouv&eacute; dans un bar, le logo "antenne de l'Aide suisse contre le sida".</B><P>
La maladie prit ainsi un nom, et ce fut le d&eacute;but d'un parcours que je n'avais jamais envisag&eacute; pour ma vie, devenir un militant autour d'une maladie que personne n'avait os&eacute; imaginer.<br>
Quelques mois auparavant, l'Aide suisse contre le sida s'&eacute;tait constitu&eacute;e, autour de la souffrance et du t&eacute;moignage de son premier pr&eacute;sident, Andr&eacute; Ratti, qui devait d&eacute;c&eacute;der quelques mois plus tard en laissant &agrave; ses successeurs un lourd h&eacute;ritage. C'est &agrave; cette p&eacute;riode que je commen&ccedil;ais donc mon apprentissage de la vie associative, fort des espoirs d'une lutte radicale contre l'extension de ce qui devenait une &eacute;pid&eacute;mie, et de l'optimisme qui pr&eacute;valait, en cette p&eacute;riode, sur les capacit&eacute;s de la science. La nature de mon engagement reposait surtout sur l'information des personnes les plus expos&eacute;es afin de les inciter &agrave; se pr&eacute;munir contre une &eacute;ventuelle contamination. Je voulais aussi offrir aux personnes d&eacute;j&agrave; touch&eacute;es une &eacute;coute et un soutien actif. Pour ce faire, il &eacute;tait n&eacute;cessaire de refuser les clich&eacute;s culpabilisateurs encore vivaces. Je me transformais donc, tour &agrave; tour, en distributeur de capotes, en r&eacute;pondant t&eacute;l&eacute;phonique, en oreille attentive ou en main tendue. J'avais 20 ans, encore jeune et beau d'une vie qui &eacute;cl&ocirc;t, mais &eacute;galement touch&eacute; au plus profond de moi par un virus que je ne parvenais &agrave; nommer qu'au travers de mon engagement.<P>
<H4>Et puis V&eacute;ronique, Christian, Jean-Marie, Marc-Philippe sont partis vers l'ailleurs, emportant avec eux quelques espoirs ...</H4>
La t&acirc;che devenait alors plus ardue. Elle n&eacute;cessitait une action sur plusieurs fronts. Les vraies questions apparurent enfin, lorsque l'on se rendit compte que la maladie ne choisissait pas ses victimes en fonction de leur moralit&eacute;. L'&eacute;pid&eacute;mie prenait alors vraiment une dimension sociale et politique. L'Aide suisse contre le sida s'agitait elle aussi de soubresauts id&eacute;ologiques sans doute incontournables, et les personnes touch&eacute;es commen&ccedil;aient &agrave; parler, mais encore de fa&ccedil;on discr&egrave;te, au sein des organisations.<br>
Un jour, au milieu d'une r&eacute;union de professionnels que nous &eacute;tions devenus, j'entendis quelqu'un parler de ces "gens-l&agrave;" marquant ainsi par le simple langage, le foss&eacute; qui s&eacute;pare les s&eacute;ropositifs des s&eacute;ron&eacute;gatifs. L'action &agrave; entreprendre devenait ainsi bien plus profonde et ambitieuse que de distribuer des capotes en comptant les morts.<P>
<H4>Et puis Bruno, Claude-Eric, Didier et les autres s'en sont all&eacute;s ...</H4>
Un jour, j'ai rencontr&eacute; Elham, et nous avons mesur&eacute; ensemble la longueur du foss&eacute;. Il fallait exister, au-del&agrave; des d&eacute;rives comptables que nous ressentions trop lourdement au sein des antennes de l'Aide suisse contre le sida. P.W.A Suisse naissait de trop &eacute;touffer.<P>
<H4>Et puis Elham, Ren&eacute;, Sylvano, Pietro et les autres s'en sont all&eacute;s ...</H4>
Cela fait plus de dix ann&eacute;es que je vis avec un virus, dix ann&eacute;es que je d&eacute;pense une &eacute;nergie &agrave; esp&eacute;rer que la maladie ne soit plus un obstacle pour vivre le mieux possible en ouvrant le regard sur le monde. Les espoirs du d&eacute;but ont &eacute;t&eacute; rang&eacute;s au placard, et suivant l'air du temps, le sida est devenu une cause honorable. Mais qu'en est-il des d&eacute;rives discriminatoires que subissent les personnes atteintes, en Suisse mais &eacute;galement de par le monde entier. En dix ans, l'ASS a su former, il faut le reconna&icirc;tre, un rassemblement unanime autour du pr&eacute;servatif, mais il demeure un symbole bien d&eacute;risoire face &agrave; une &eacute;pid&eacute;mie qui touche aussi &agrave; l'&acirc;me.<P>
<H4>Et puis Mich&egrave;le, R&eacute;my, Michel et les autres sont partis.</H4>
O&ugrave; sont donc les id&eacute;es fortes qui rassemblent, dans un d&eacute;sir commun d'une soci&eacute;t&eacute; plus respectueuse des personnes, qu'elles soient bien portantes ou malades? O&ugrave; sont les &eacute;nergies pour affirmer et d&eacute;fendre clairement une appartenance &agrave; un projet courageux au niveau national? J'ai bien peur que la solidarit&eacute; tant d&eacute;clam&eacute;e dans les premi&egrave;res ann&eacute;es se conjugue pour le futur &agrave; une attitude bien charitable, avec d&icirc;ners de gala, congr&egrave;s politesses et petits fours dans la bouche.<P>
<H4>Et puis Sylvie, Fran&ccedil;ois et les autres sont partis.</H4>
Pourtant, des choses ont chang&eacute;, plus de personnes osent aujourd'hui parler de leur situation, les langues se d&eacute;lient. Les personnes vivant avec le sida seront encore l&agrave;, pour les ann&eacute;es &agrave; venir, ne l'oublions pas! Dix ans en novembre prochain que Carlos est mort, dix ans d'engagement dans la lutte contre le sida, dix ans d'espoirs et de d&eacute;senchantements, dix ans de militantisme, dix ann&eacute;es de vie intime avec le virus, dix ans d'ASS.<br>
J'ai 31 ans aujourd'hui, un peu plus vieux mais toujours plein d'&eacute;nergie de d'enthousiasme pour la vie. Cependant, je m'&eacute;puise au coeur d'une organisation dont je n'arrive plus &agrave; sentir battre le coeur. Alors &agrave; la fin de cette ann&eacute;e, j'ai d&eacute;cid&eacute; de changer de navire sans changer de cap, parce que je n'ai pas d'autre ambition que de rester fid&egrave;le &agrave; mes convictions et &agrave; mes amis et amies disparus! Pour le sida comme pour le reste, il me reste l'imagination. Bonne continuation &agrave; tous!<P>
</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-325</DOCNO>
<DOCOLDNO>IA017-000178-B042-34</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.5 192.33.214.13 19970106050341 text/html 5820
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:03 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Les malades du sida sont indociles</I><br>Dr m&eacute;d. Bernard Hirschel</H3>
<I>H&ocirc;pital cantonal universitaire de Gen&egrave;ve, division des maladies infectieuses</I><P>
<UL>
<B>En 1987, alors que j'&eacute;tais &agrave; Washington pour une des premi&egrave;res conf&eacute;rences sur le sida, j'ai lu dans le "Washington Post"  - qui publiait le compte rendu d'un sondage men&eacute; aupr&egrave;s des m&eacute;decins am&eacute;ricains - que beaucoup d'entre eux avaient peur de soigner des sid&eacute;ens. Seul dans ma chambre d'h&ocirc;tel, j'ai &eacute;crit l'unique lettre de lecteur de ma vie "Why I Treat Patients with Aids". Pourquoi je soigne des malades du sida? Pour de nombreuses raisons, mais tout d'abord pour les malades eux-m&ecirc;mes.<P></B>
J'appr&eacute;ciais alors et j'appr&eacute;cie toujours autant d'avoir affaire &agrave; des patients qui connaissent leur maladie presqu'aussi bien que les m&eacute;decins, ce qui permet &agrave; un v&eacute;ritable partenariat de s'&eacute;tablir. Les contacts avec des organisations d'entraide comme P.W.A et avec l'ASS sont &eacute;galement caract&eacute;ris&eacute;s par cet esprit de partenariat.<P>
<H4>Un nouveau regard</H4>
Et nous en avons appris des choses! Par exemple, &agrave; porter un nouveau regard sur l'h&ocirc;pital, avec ses lacunes et ses difficult&eacute;s. Probl&egrave;mes relatifs au secret m&eacute;dical, manque de confort des chambres, possibilit&eacute;s restreintes de soins corporels individuels, rigidit&eacute; des horaires, probl&egrave;mes de contact avec les autres malades, dispersion des responsabilit&eacute;s entre traitements stationnaires et traitements ambulatoires, manque de communication entre m&eacute;decins, et bien d'autres choses encore.<br>
Les malades du sida sont souvent indociles et de ce fait pas toujours faciles &agrave; vivre. Mais c'est quand m&ecirc;me gr&Acirc;ce &agrave; leurs critiques que des d&eacute;ficiences peuvent &ecirc;tre d&eacute;cel&eacute;es et, parfois, &eacute;limin&eacute;es. Souvent, mais pas toujours, la volont&eacute; de r&eacute;forme est frein&eacute;e pour des raisons financi&egrave;res. Il n'est par exemple pas possible chez nous de loger tous les patients dans des chambres &agrave; un ou deux lits. D'un autre c&ocirc;t&eacute;, glisser le billet contenant le diagnostic sida dans une enveloppe pour qu'il ne saute pas aux yeux du premier venu ne va s&ucirc;rement pas ruiner l'h&ocirc;pital!<P>
<H4>Les besoins des malades du sida</H4>
Par leur int&eacute;r&ecirc;t et leurs revendications, les personnes touch&eacute;es ont &eacute;galement largement contribu&eacute; au d&eacute;veloppement de nouveaux m&eacute;dicaments. Entre la synth&egrave;se d'une mol&eacute;cule et la mise sur le march&eacute; d'un m&eacute;dicament, il s'&eacute;coule g&eacute;n&eacute;ralement de longues ann&eacute;es. Pendant les ann&eacute;es 60 et 70, les efforts de recherche visaient en priorit&eacute; &agrave; minimiser le risque des effets secondaires, d'o&ugrave; un tr&egrave;s long travail de d&eacute;veloppement. Personne ne songeait alors &agrave; acc&eacute;l&eacute;rer le processus. Le sida, une maladie mortelle contre laquelle il n'y a longtemps eu aucun rem&egrave;de, a chamboul&eacute; ce cours.<br>
Des profanes int&eacute;ress&eacute;s, en particulier aux Etats-Unis (l'Europe est plut&ocirc;t &agrave; la tra&icirc;ne ici), participent d&eacute;sormais activement &agrave; l'effort de recherche - du d&eacute;veloppement au test clinique de m&eacute;dicaments. Le processus est complexe et exige une multitude de d&eacute;marches: recherche de la strat&eacute;gie la plus prometteuse, mise au point de protocoles de recherche d&eacute;taill&eacute;s, recrutement et motivation de volontaires, sans oublier la collecte de fonds aupr&egrave;s des sources publiques et priv&eacute;es pour financer le travail. Mener de front parall&egrave;lement toutes ces d&eacute;marches permet de gagner du temps. Les premiers m&eacute;dicaments v&eacute;ritablement efficaces entreront dans la phase des tests cliniques en 1995. Bien s&ucirc;r, nous aurions pr&eacute;f&eacute;r&eacute; que cette phase d&eacute;bute cinq ans plus t&ocirc;t, mais sans l'entraide mentionn&eacute;e, on n'en serait m&ecirc;me pas l&agrave; aujourd'hui.<P>
<H4>Le "mod&egrave;le sida"</H4>
Peut-on s'inspirer du "mod&egrave;le sida", bas&eacute; sur l'entraide, pour d'autres maladies? Bien s&ucirc;r, l'int&eacute;r&ecirc;t du public et des m&eacute;dias serait diff&eacute;rent, le financement de la recherche aussi. Quoi qu'il en soit, des organisations d'entraide potentielles, il y en a beaucoup, en particulier pour certains cancers. Nous nous r&eacute;jouissons de constater que les exp&eacute;riences faites dans la lutte contre le sida portent, &agrave; cet &eacute;gard, leurs premiers fruits.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:2.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-326</DOCNO>
<DOCOLDNO>IA017-000178-B042-48</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:2.6 192.33.214.13 19970106050351 text/html 5097
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:11 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Riassunto</I><br>Christian Schneeberger</H3>
<I>Volontario anti-Aids, membro del comitato dell'Aiuto Aids Svizzero dal 1988 al 1993</I><P>
<UL>
<B>Tra successi e insuccessi, l'Aiuto Aids Svizzero compie 10 anni. Considerazioni critiche in occasione di questo traguardo.<P></B>
Quando l'Aids cominci&Ograve; a diffondersi, gli uomini omosessuali videro minacciata la loro integrit&agrave; fisica e la loro accettazione sociale da poco conquistata con grandi difficolt&agrave;. Questa doppia minaccia &egrave; all'origine della creazione dell'AAS. L'obiettivo dell' Ufficio federale della sanit&agrave; pubblica (UFSP) - padrino dell'AAS - era di istituire un'organizzazione nazionale che fungesse da interlocutore competente e unico e che potesse conferire credibilit&agrave; agli sforzi di prevenzione attraverso il contatto diretto con le persone minacciate e colpite dalla malattia.<P>
Ne risult&Ograve; una tripartizione delle responsabilit&agrave;: medicina e scienza fornivano le basi per i messaggi preventivi; le istanze statali si occupavano del supporto politico e delle finanze e l'Aiuto Aids - in collaborazione con i gruppi bersaglio - si impegnava a favore dell'attuazione dei progetti.<P>
Sulla base della teoria dell'apprendimento sociale, pochi messaggi molto pregnanti dovevano illustrare con chiarezza come impedire la trasmissione del virus. Gli omosessuali furono i promotori della strategia che ebbe come motto "Con le persone e per le persone colpite dalla malattia", strategia che venne ripresa ed estesa al mondo della droga e della prostituzione. Dato che per ottenere il successo auspicato nel campo della sessualit&agrave; l'apprendimento doveva poter contare su un clima aperto, si adott&Ograve; una linea di discorso chiara, che le cerchie fondamentaliste interpretarono a torto come una propaganda a favore dell'omosessualit&agrave;, della prostituzione, della tossicodipendenza e dell'amore libero.<P>
Visto che le numerose critiche ritardavano o addirittura bloccavano l'attuazione delle misure preventive, ostacolando il lavoro dei gruppi bersaglio, l'AAS decise di concentrare gli sforzi a livello socio-politico. Questo atteggiamento provoc&Ograve; non pochi conflitti d'opinione. Per rispondere agli attacchi, si cerc&Ograve; di reagire con un'"eterosessualizzazione" della malattia: solo una minaccia evidente per l'intera popolazione sembrava potesse garantire i finanziamenti necessari. Questo nuovo orientamento ebbe delle conseguenze: infatti i gruppi marginalizzati vennero, via via, sempre pi&ugrave; trascurati, preferendo coinvolgere in questa causa esponenti esterni credibili all'opinione pubblica. Gli esponenti reclutati in un primo tempo tra gli addetti ai lavori e le persone colpite dal male, vennero sostituiti da politici e gruppi d'interesse autorevoli.<P>
Nel 1987 esisteva gi&agrave; una rete di antenne regionali dell'Aiuto Aids che si occupavano dell'attuazione delle misure preventive a livello locale e soprattutto della realizzazione dei tre obiettivi fondamentali della prevenzione: consulenza, assistenza e accompagnamento. Ogni sezione era organizzata in modo indipendente ed era inquadrata in strutture diverse. Tutti i tentativi volti al conferimento di una forma unitaria fallirono. La struttura federalistica del settore della sanit&agrave; ostacol&Ograve; non poco gli sforzi di coordinamento e l'AAS, in considerazione dei suoi nuovi compiti, ebbe sempre meno tempo ed energia da dedicare alle antenne dell'Aiuto Aids.<P>
L'Aiuto Aids Svizzero, che sta lavorando a un progetto intitolato "Visione 2000", deve riflettere con attenzione: il nuovo orientamento &egrave; l'ultima possibilit&agrave; a disposizione? Ripercorrendo i successi conseguiti duranti i primi dieci anni di attivit&agrave;, l'organizzazione - con le persone e per le persone colpite dalla malattia - dovrebbe riavvicinarsi nuovamente alla base, ossia alle persone comuni: le sezioni cantonali dell'Aiuto Aids e gli omosessuali e i tossicodipendenti malati di Aids e in fase terminale - sempre ancora coinvolti in prima linea - sapranno apprezzare uno sviluppo in questo senso.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-327</DOCNO>
<DOCOLDNO>IA017-000178-B042-59</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:3.1 192.33.214.13 19970106050400 text/html 5167
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:23 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Bibliothek:</I><br>10 Jahre Aids-Hilfe Schweiz</H3>
<I></I><P>

<H4>Die STOP AIDS-Story 1987-1992</H4>
Aids-Hilfe Schweiz, Bundesamt f&uuml;r Gesundheitswesen (Hrsg.)<br>
<I>Z&uuml;rich u. Bern, 1993, 117 S., Fr. 10.-</I><P>
<UL>
Seit 1987 begleitet die STOP AIDS-Kampagne die Schweizerinnen und Schweizer manchmal etwas lauter, manchmal etwas leiser. Evaluationen und politische Reaktionen haben gezeigt, dass die Kampagne im allgemeinen gut ankommt und die Adressaten erreicht. Wer einen &Uuml;berblick &uuml;ber diesen Teil der Geschichte der Aids-Hilfe Schweiz bekommen m&ouml;chte, ist mit diesem Buch gut beraten. Farbige Reproduktionen zeigen auch alle wichtigen Plakate usw.<br>
Wie mache ich eine sinnvolle, mehrj&auml;hrige Pr&auml;ventionskampagne aus einem Guss? Die Antwort findet sich in der STOP AIDS-Story.<P>
<I>Zu beziehen bei: Aids Info Docu Schweiz Postfach 3001 Bern</I><P>
</UL><HR WIDTH=100>
<H4>HIV-Pr&auml;vention in der Schweiz. Ziele, Strategien, Massnahmen</H4>
Bundesamt f&uuml;r Gesundheitswesen, Eidgen&ouml;ssische Kommission f&uuml;r Aidsfragen (Hrsg.)<br>
<I>Bern, EDMZ, 1993,  289 S., Fr. 20.-, Kurzfassung gratis</I><P>
<UL>
Das umfangreiche Handbuch erl&auml;utert das aktualisierte nationale Konzept zur Aidsbek&auml;mpfung bei der allgemeinen Bev&ouml;lkerung und bei einer Reihe von speziellen Zielgruppen die Pr&auml;ventionsziele und zeigt, wie sich diese Ziele erreichen lassen.<br>
"HIV-Pr&auml;vention in der Schweiz" liegt in einer ausf&uuml;hrlichen Fassung als Ringordner und in einer Kurzfassung als Brosch&uuml;re vor und ist in Deutsch, Franz&ouml;sich, Italienisch und Englisch erh&auml;ltlich. Die Kurzfassung erg&auml;nzt die Kapitel zur zielgruppenspezifischen Pr&auml;vention (Ziele, Strategien, Massnahmen) mit Angaben wie Zust&auml;ndigkeit (z.B. BAG, AHS usw.), Koordinationsgremium (z.B. Creativteam der STOP AIDS-Kampagne/AHS), Aktionstr&auml;ger (z.B. Betroffenenorganisationen/BAG/Berufsverb&auml;nde) und Finanzierung (Private/BAG und/oder Kantone).<P>
<I>Zu beziehen bei: Aids Info Docu Schweiz, Postfach, 3001 Bern</I><P>
</UL><HR WIDTH=100>
<H4>Act Up: Feuer unterm Arsch.<br>
Die Aids-Aktionsgruppen in Deutschland und den USA</H4>
Andreas Salmen (Hrsg.)<br>
<I>Berlin, Deutsche Aids-Hilfe, Aids-Forum D.A.H. Sonderband, 1991, 127 S.</I><P>
<UL>
Aids-Aktionsgruppen mit ihrem vehementen &ouml;ffentlichen Eintreten f&uuml;r die B&uuml;rgerrechte von Menschen mit HIV/ Aids und f&uuml;r deren optimale medizinische und therapeutische Versorgung haben in den letzten Jahren das Bild von Aids-Selbsthilfe in der &Ouml;ffentlichkeit zunehmend bestimmt - Grund genug, sich ihrer Geschichte, ihren Themen und ihren Aktionsformen zu widmen. Mich&&aelig;Elig;el Callen und Dan Turner stellen die Geschichte der People With Aids Coalition dar. 1983 gegr&uuml;ndet, stellt sie mit ihrer fr&uuml;hen Selbstorganisation von direkt Betroffenen eine wichtige Grundlage f&uuml;r die Bildung &ouml;ffentlich agierender Aktionsgruppen dar. Cindy Patton analysiert in ihren Betrachtungen der "Aids-Industrie" nicht nur das Handeln staatlicher Aids-Organisationen und der offiziellen Forschung, sie kritisiert auch die Entwicklung der privaten Aids-Serviceorganisationen. Beide Aufs&auml;tze stellen eine gute Grundlage f&uuml;r das Verst&auml;ndnis der Notwendigkeit von Aktionsgruppen dar. 1987 wurde in New York die erste ACT UP-Gruppe gegr&uuml;ndet.  Dokumentiert wird hier die Gr&uuml;ndungsrede von Larry Kramer. Es folgen Texte von Vito Russos, Mich&&aelig;Elig;el Callens, David Leavitt, Mark Harrington und Peter Staley. Bernd Vielhaber, Mitarbeiter des Berliner Pflegevereins HIV e.V., beschreibt schliesslich die spezifischen Probleme und M&auml;ngel der medizinischen Versorgung von Menschen mit HIV/Aids in der Bundesrepublik.<P>
Es bleibt zu hoffen, dass dieser Band noch mehr Betroffenen als bisher den Mut verschafft, sich &ouml;ffentlich zu &auml;ussern und ihre Probleme darzustellen. Aids ist kein Thema der allgemeinen Medien mehr, der Neuigkeitswert der "Seuche" ist  dahin - es sei denn, wir machen Krankheit und unsere Situation durch unser Handeln zum Thema.<P>
<I>... aus der Einleitung von<br>
Andreas Salmen</I><P>
</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:2.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-328</DOCNO>
<DOCOLDNO>IA017-000178-B042-69</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:3.2 192.33.214.13 19970106050414 text/html 16507
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:34 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Neue Publikationen</I></H3>
<HR>
<P>

<A NAME="1">Andr&eacute; Glucksmann</A><br>
<H4>Der Stachel der Liebe.<br>
Ethik im Zeitalter von Aids</H4><br>
<I>Aus dem Franz&ouml;sischen von Eva Moldenhauer<br>
M&uuml;nchen, Artemis & Winkler, 1995, 283 S., Fr. 44.-</I><P>
<UL>
Wer &uuml;ber Aids nachdenkt, ger&auml;t rasch in eine Ausweglosigkeit. Aids ist zwar keine Krankheit wie andere Krankheiten. Aber Aids ist auch eine Krankheit und mu&szlig; immer auch als solche gedacht werden. F&uuml;r Aids als eine individuelle Krankheit interessiert sich Andr&eacute; Glucksmann jedoch nicht. Aids ist f&uuml;r ihn vielmehr eine gigantische Metapher des Ungl&uuml;cks. Glucksmann verleiht Aids eine ungeheuerliche Gr&ouml;&szlig;e und macht aus einer Krankheit ein soziales Verh&auml;ngnis vom Rang der Atombombe. Nicht nur das Liebesleben der Menschen sei durch Aids nachhaltig zerst&ouml;rt. Unm&ouml;glich geworden sei durch Aids auch das soziale Miteinander der Menschen. Nicht etwa rhetorisch, sondern ganz verzweifelt fragt Glucksmann: "Wie soll man zusammenleben, wenn jeder f&uuml;r sich, wie f&uuml;r die anderen, ein Miniatur-Tschernobyl ist?" Man sieht: Aids geh&ouml;rt f&uuml;r Glucksmann zu den letzten Dingen, und als solches ist Aids nicht bew&auml;ltigbar, weder kollektiv noch individuell. Weil die anderen &uuml;ber Aids weniger gro&szlig; denken als er, ist es ihm auch ein Leichtes, gegen sie zu polemisieren. Alle, die im vergangenen Jahrzehnt daran gearbeitet haben, die Ausbreitung der HIV-Infektion einzud&auml;mmen, die Politiker und ihre Helfershelfer, die Psys und Sozs, h&auml;tten nichts anderes getan, als Aids zu bagatellisieren, sch&ouml;nzureden und das Problem der Ausbreitung der HIV-Infektion zu erledigen.<br>
Glucksmann zufolge haben all die teuren Pr&auml;ventionskampagnen die Ausbreitung der HIV-Infektion nicht einzud&auml;mmen vermocht. Ihr eigentlicher, von niemand durchschauter Zweck liege in der Verleugnung von Aids "als einer generischen Krankheit, die &uuml;ber allen schwebt und das Ganze bedroht". Gewi&szlig;, die Pr&auml;ventionskampagnen waren bislang unter der Allgemeinbev&ouml;lkerung nicht sehr erfolgreich. Trotzdem macht es sich Glucksmann etwas zu leicht, wenn er deren Erfolg nur an dem Gebrauch bzw. Nichtgebrauch des Kondoms mi&szlig;t. Er fetischisiert das Kondom zum einzigen Mittel der Pr&auml;vention. Dabei &uuml;bersieht er wie so viele, da&szlig; es vielf&auml;ltige andere M&ouml;glichkeiten gibt, mit denen man sich und andere vor einer HIV-Infektion sch&uuml;tzen kann. Abgelesen werden kann das an dem Verhalten homosexueller M&auml;nner. Gleichwohl trifft Glucksmann durch sein Insistieren auf die Eigengesetzlichkeit der Liebe den Kern der Widerst&auml;nde gegen den Gebrauch des Kondoms. Zwischen dem, was wir uns als Praxis der Liebe vorstellen, und den aus der Aids-Logik abgeleiteten Notwendigkeiten herrscht nach wie vor eine brisante Ungleichzeitigkeit. Das Kondom steht als etwas Drittes zwischen den Liebenden, und dieses Dritte ist, da innig mit den Gefahren von Aids verkn&uuml;pft, negativ aufgeladen und wird deshalb oft genug als St&ouml;rendes aus der Liebespraxis ausgeschieden. Diese Gedanken sind allerdings nicht ganz so neu, wie Glucksmann sie pr&auml;sentiert.<br>
Auch in seiner Ethik ist Glucksmann nicht gerade originell. Man fragt sich angesichts des Zustandes der Welt, ob es wirklich des Einbrechens von Aids in diese bedurfte, um den auf dem Klappentext herausgestellten ethischen Grundsatz aufzustellen: "Handle so, da&szlig; du, soweit irgend m&ouml;glich, sowohl diejenigen, die du liebst, als auch die Menschheit sch&uuml;tzt". Dieses Postulat geh&ouml;rte auch schon vor dem Erscheinen des Buches von Glucksmann zum Bestand ethischer S&auml;tze in unserer Kultur. Und sogar manche der von ihm gescholtenen Aids-Technokraten sind von diesem ethischen Impuls geleitet. Sie zerbrechen sich die K&ouml;pfe &uuml;ber die Bedingungen einer m&ouml;glichst breiten Durchsetzung einer solchen Ethik des sexuellen Handelns im Zeichen von Aids. Ganz unmittelbar schlagen sich Abertausende von HIV-infizierten Frauen und M&auml;nnern mit diesem Anspruch herum. Sie versuchen die Liebe und die Leidenschaft zu retten und zugleich das geliebte Objekt zu sch&uuml;tzen. Ihre Sexualit&auml;t gleicht in der Tat einem Drahtseilakt. Glucksmann, der nur das Mi&szlig;lingen der Pr&auml;vention ins Visier nimmt, scheint gebannt darauf zu warten, da&szlig; einer dieser Artisten des Lebens abst&uuml;rzt und dabei jemanden infiziert. Das verleiht seinem Text ein unangenehmes Aroma und bringt seinen Autor in die N&auml;he eines Voyeurs des Ungl&uuml;cks.<br>
Zu assimilieren ist das durch die HIV-Infektion ausgel&ouml;ste Drama nicht. Das f&uuml;hrt aber keineswegs durchg&auml;ngig zum Negieren der Infektiosit&auml;t durch die Infizierten, wie das Glucksmann unterstellt. "Wem das Todesurteil verk&uuml;ndet wird", so schreibt er, "kann es entweder &uuml;berh&ouml;ren oder nichts anderes mehr h&ouml;ren.<br>
Im ersten Fall entscheidet man sich f&uuml;r ein Leben &agrave; la Cyril Collard, das sich nur darum k&uuml;mmert zu leben. Im zweiten Fall konzentriert man sich wie Herv&eacute; Guibert auf einen Tod, der nichts hinter sich l&auml;&szlig;t. In beiden Perspektiven erscheint die Vorstellung, irgend etwas zu sch&uuml;tzen, als haltlos und, angesichts der Intensit&auml;t des inneren Dramas, als unpassend." Was aber, wenn es noch einen dritten Fall gibt; einen Fall, der gar nicht so selten ist? In diesem dritten Fall lebt man nolens volens mit dem Bewu&szlig;tsein, vor der Zeit zu sterben und versucht, so weit das m&ouml;glich ist, sich um sich und andere zu sorgen, wozu auch geh&ouml;rt, diese zu sch&uuml;tzen. M&ouml;glich ist das nur, weil auch die HIV-Infizierten die Gewi&szlig;heit ihres Todes phasenweise zu verleugnen imstande sind. Damit n&auml;hern sie sich den anderen, die sich, den Tod verleugnend, f&uuml;r unsterblich halten, zeitweise wieder an.<br>
Da&szlig; es die M&ouml;glichkeit gibt, auch im Wissen des vorzeitigen Sterbens nach dem von Glucksmann aufgestellten ethischen Grundsatz zu handeln, bezeugen zahlreiche Texte von HIV-Infizierten und Aids-Kranken. Von diesen wollte er jedoch nichts wissen. Glucksmann hat auch gar keinen Text &uuml;ber Aids geschrieben, sondern einen Text, in dem er Aids zur Illustration seiner pessimistischen Ansicht &uuml;ber die unrettbar verlorene Welt ben&uuml;tzt. Der Text von Glucksmann ist eine philosophische Instrumentalisierung von Aids, die, wie alle Instrumentalisierungen dieser Krankheit, letztendlich auf die Kranken und Infizierten zur&uuml;ckschl&auml;gt.<P>
<I>Martin Dannecker</I><P></UL>

</UL><HR WIDTH=550><UL>

<A NAME="2"><H4>Illegale Drogen in der Schweiz 1990-1993</H4></A>
Schweizerische Fachstelle f&uuml;r Alkohol- und andere Drogenprobleme (SFA) im Auftrag des Bundesamtes f&uuml;r Gesundheitswesen<br>
<I>Z&uuml;rich, Seismo, 1995, 240 S., Fr. 24.-</I><P>
<UL>
Das Buch liefert eine leserfreundliche Gesamtbetrachtung zur schweizerischen Drogenproblematik in den turbulenten Jahren 1990-1993. Es ist dem Bundesamt f&uuml;r Gesundheitswesen hoch anzurechnen, dass es mit diesem Buch und weiteren Publikationen den Wissensstand in Drogenfragen in allen involvierten Kreisen anheben will - u.a. auch als Grundvoraussetzung zur notwendigen Versachlichung der nach wie vor intensiv gef&uuml;hrten Drogendebatte. Die Frage bleibt: Kommen die sorgf&auml;ltig recherchierten Berichte und Fakten am "richtigen" Ort rechtzeitig an? Den engagierten Fachleuten und Betroffenen ist die Problematik h&auml;ufig schon vertraut, und Bestandesaufnahmen haben den Nachteil, dass sie schon am Publikationstag nicht mehr ganz aktuell sind.<br>
Trotzdem d&uuml;nkt mich diese Buch wertvoll als Teilchen der gemeinsamen Anstrengungen zur &Uuml;berwindung irrationaler Bew&auml;ltigungsstrategien und zur Entwicklung einer vern&uuml;nftigen und menschlichen Drogenpolitik.<P>
<I>Thomas Kessler</I><P></UL>

</UL><HR WIDTH=550><UL>

<H4><A NAME="3">Freundschaft - Liebe - Sexualit&auml;t.</A><br>
Grundlagen und Praxisbeispiele f&uuml;r die Arbeit mit geistig behinderten Frauen und M&auml;nnern<br>
Daniela Dittli, Hans Furrer</H4>
<I>Luzern, SZH Schweizerische Zentralstelle f&uuml;r Heilp&auml;dagogik, 1994, 102 S., Fr. 28.20</I><P>
<UL>
Wie schon aus dem Titel ersichtlich, enth&auml;lt das vorliegende Buch sowohl einen theoretischen Teil mit grunds&auml;tzlichen &Uuml;berlegungen zur Sexualit&auml;t als auch eine Sammlung von Lektionsvorschl&auml;gen zu verschiedenen Themenbereichen. Die Materialien des praxisbezogenen Teils sind f&uuml;r leicht bis mittelschwer entwicklungsbeeintr&auml;chtigte Frauen und M&auml;nner gedacht. Im theoretischen Teil werden die gesellschaftliche Funktion der Sexualit&auml;t und ihre Geschichte sowie die psychosexuelle Entwicklung beschrieben. Es wird auf die Zusammenh&auml;nge zwischen verschiedenen Entwicklungsbereichen eingegangen und im speziellen auf Behinderung als Entwicklungsbeeintr&auml;chtigung. Am Ende des theoretischen Teils wird versucht, den Zusammenhang zwischen Sexualit&auml;t und innerpsychischen und &auml;usseren Entwicklungsbeeintr&auml;chtigungen aufzuzeigen.<br>
Anhand von f&uuml;nfzehn konkreten Lektionsbeispielen wird im zweiten Teil dargestellt, wie der Themenkomplex "Freundschaft - Liebe - Sexualit&auml;t" in Gruppen von geistig behinderten Frauen und M&auml;nnern erarbeitet werden kann. Die Autoren gehen dabei von erwachsenenbildnerischen Prinzipien aus und geben viele grunds&auml;tzliche methodische Hinweise, die meines Erachtens nicht nur f&uuml;r dieses Gebiet wertvoll sind. Themen wie Kenntnisse der Sexualorgane, Gebrauch des Pr&auml;servativs usw. werden nicht isoliert als Fertigkeit vermittelt, sie sind eingebettet in Lektionen &uuml;ber Partnerschaft, Kennenlernen des eigenen K&ouml;rpers, Z&auml;rtlichkeit, Verh&uuml;tung, Aids, Selbstbefriedigung, Heirats- und Kinderwunsch, u.a. Eine kommentierte Literatur- und Materialliste sowie Arbeitsmaterialien (Kopiervorlagen, Arbeitsanleitungen) bieten den PraktikerInnen konkrete Hilfe.<br>
Alles in allem ein interessantes, gut lesbares Buch mit vielen Anregungen f&uuml;r die Praxis. Es besticht durch eine durchdachte Begriffswahl und ein ausgepr&auml;gtes Bewusstsein im Umgang mit geschlechts- und rollenspezifischen Themen.<P>
<I>Bea Vonlanthen Minnig</I><P></UL>

</UL><HR WIDTH=550><UL>

<A NAME="4"><H4>Aids und &Ouml;konomie</H4></A>
Willy Oggier, Bernhard J. G&uuml;ntert (Hrsg.)<br>
<I>Schweizerische Gesellschaft f&uuml;r Gesundheitspolitik (SGGP), Muri, 1995, 140 S., Fr. 36.-</I><P>
<UL>
Die Herausgeber wollen mit diesem Buch die Skepsis gegen&uuml;ber &ouml;konomischen Analysen und Fragestellungen in der Gesundheitspolitik abbauen. Zehn Autoren &auml;ussern sich in unabh&auml;ngigen Aufs&auml;tzen. Ihre &Uuml;berlegungen haben hohe Aktualit&auml;t und politische Relevanz.<br>
Im ersten Teil offeriert z. B. B. Somaini eine "Kochbuch-Anleitung" f&uuml;r zeitgem&auml;sses Projekt-Management sowie eine Innenansicht der Funktionsweise der &ouml;ffentlichen Administration. Seine Diagnose von Visionslosigkeit, administrativem Versagen, von Angst und pers&ouml;nlichem Machstreben deckt sich mit den fundierten &ouml;konomischen &Uuml;berlegungen von M. Pedergnana. Er kritisiert, dass die chaotische Situation um Aids bis in die 90er Jahre "dilettantisch" gemanaged wurde und dass "unbequeme" &Ouml;konomInnen bewusst von der Diskussion ausgeschlossen blieben. Hochbrisant ist seine These, das sich einige der Veranwortlichen vom vorzeitigen Aids-Tod der Fixer und Schwulen gar einen gesellschaftlichen Nutzen versprachen.<br>
Es geh&ouml;rt zur Aufgabe der &Ouml;konomie, Kosten-Nutzen-&Uuml;berlegungen anzustellen. Im zweiten Teil des Buches kommen die Grenzen und Probleme der &Ouml;konomie zu Tage: zu intangiblen Kosten wie Leid und Schmerz k&ouml;nnen die &Ouml;konomInnen keine Aussagen machen. Hingegen lassen sich direkte (Behandlungs-) Kosten und indirekte Kostenfolgen  (z. B. Ausfall von "volkswirtschaftlichen Nutzen-Potential") aufrechnen und als "objektive" Entscheidungsgrundlage oder als Anhaltspunkte f&uuml;r Vergleiche verwenden. Wie dies geschehen k&ouml;nnte und wo die Problematik liegt, wird in f&uuml;nf Beitr&auml;gen diskutiert.<br>
Es gelingt den Herausgebern, &ouml;konomische &Uuml;berlegungen als n&uuml;tzliche Entscheidungsgrundlage darzustellen und konkrete Verbesserungen zu offerieren. Eine redaktionelle F&uuml;hrung durch das Buch und ein Anhang mit Erl&auml;uterungen und Definitionen der verwendeten &ouml;konomischen und medizinischen Fachbegriffe w&auml;ren eine willkommene Lesehilfe.<P>
<I>Olivier L&uuml;thold</I><P></UL>

</UL><HR WIDTH=550><UL>

<A NAME="5"><H4>Aids. Information f&uuml;r die Schule</H4></A>
Erziehungsdirektion des Kantons Z&uuml;rich, Pestalozzianum (Hrsg.)<br>
<I>Z&uuml;rich, Lehrmittelverlag, 2. &uuml;berarb. Aufl. 1995, 104 S. + Anhang, Fr. 35.-</I><P>
<I>Zu beziehen bei: 
Lehrmittelverlag des Kantons Z&uuml;rich, R&auml;ffelstr. 32, Postfach, 8045, Z&uuml;rich<br>
tel. 01 462 98 15, fax. 01 462 99 61</I><P>

</UL><HR WIDTH=550><UL>

<A NAME="6"><H4>Kissing doesn't kill: Greed and indifference do</H4></A>
Lizentiatsarbeit, Theologische Fakult&auml;t der Universit&auml;t<br>
Peter Lack<br>
<I>Freiburg i.&Uuml;., 1995, 150 S.</I><P>
<UL>
Ein Pl&auml;doyer f&uuml;r die sozialethische Betrachtung von sexuell &uuml;bertragbaren Krankheiten (STD) und grunds&auml;tzliche &Uuml;berlegungen zum Kranksein veranschaulicht am Beispiel von HIV/AIDS.<P>
<i>Zu beziehen bei: Peter Lack, Place du Petit-St-Jean 19<br>
1700 Fribourg</i><P></UL>

</UL><HR WIDTH=550><UL>

<A NAME="7"><H4>Die stille und die schrille Szene.<br>Erfahrungen von
Schwulen im Alltag</H4></A>
Udo Rauchfleisch<br>
<I>Freiburg i.B., Herder, 1995, 192 S., Fr. 16.80</I><P>
<UL>
Udo Rauchfleisch, Professor an der Psychiatrischen Uniklinik in Basel, versucht anhand von Erfahrungsberichten verschiedener M&auml;nner ein paar Aspekte der Schwulenszene zu beleuchten. Diesen bescheidenen Anspruch l&ouml;st er ein. Mehr allerdings nicht. Irgendwelche &uuml;ber die einzelnen Berichte hinausgehenden Gedanken oder Schlussfolgerungen finden sich nicht. Und das ist schade. Denn das Buch bleibt so auf der Ebene eines zuf&auml;llig zusammengest&uuml;ckelten Albums.<br>
Konkret unterteilen sich die Texte in die sechs Kapitel: Coming-out, Beziehung, Kirche, Gewalt, Schwule in der &Ouml;ffentlichkeit und Alter. In diesen Kapiteln &auml;ussern sich jeweils drei schwule M&auml;nner mit ihren Erfahrungen. Wer als "Schwuler im fortgeschrittenen Stadium" etwas erfahren m&ouml;chte zu speziellen Aspekten schwulen Lebens, wird entt&auml;uscht. Das einzige vorstellbare Zielpublikum, das profitieren kann, sind (junge) M&auml;nner im Coming-out. Sie lesen in K&uuml;rze einiges &uuml;ber lebensnahe M&ouml;glichkeiten, ein schwules Leben zu f&uuml;hren. Fraglich ist allerdings, ob diese Gruppe ein Buch ersteht mit dem Titel "Die stille und die schrille Szene", ein Titel, der in ziemlich losem Zusammenhang steht mit dem Inhalt.<P>
<I>Thomas Trachsel</I><P></UL>

</UL><HR WIDTH=550><UL>

<A NAME="8"><H4>Die AIDS-Pr&auml;ventionsanstrengungen in sechs ostschweizerischen Kantonen und im F&uuml;rstentum Liechtenstein</H4></A>
Willy Oggier, Bernhard G&uuml;ntert<br>
<I>St. Gallen, Forschungsgruppe f&uuml;r Management im Gesundheitswesen an der Hochschule St. Gallen, 1994, 63 S., gratis</I><P><UL>
Ausf&uuml;hrliche Besprechung in der n&auml;chsten Ausgabe.<P></UL>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:3.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-329</DOCNO>
<DOCOLDNO>IA017-000178-B042-82</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:3.3 192.33.214.13 19970106050424 text/html 8521
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:46 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Graue Literatur</I></H3>
<P>

<H4>5th International Conference on Aids, Montreal, Quebec, 4-9 June, 1989</H4>
<I>Ottawa : International Development Research Centre, 1989, 2 Bde.</I><P><UL>
Eine wichtige Quelle f&uuml;r einen &Uuml;berblick &uuml;ber die weltweite Entwicklung von Aids-Hilfsorganisationen sind die Berichtsb&auml;nde der j&auml;hrlichen Internationalen Aids-Konferenzen. Wir geben im folgenden einige kurze Hinweise auf dort behandelte Themen:<br>
Im Berichtsjahr 1989 (und in den darauf folgenden Jahren) arbeitet die WHO auf internationaler Ebene eng mit Privatorganisationen (NGOs) zusammen, tauscht mit einer Vielzahl von ihnen Informationen aus, benutzt diese Stellen, um geeignetes Pr&auml;ventionsmaterial zu vertreiben und als Focus, um die Informationen f&uuml;r das Global Programme on AIDS (GPA) zu kanalisieren. Zusammenarbeit unter NGO's und Regierungen existiert bereits und entwickelt sich im Bereich der nationalen Aids-Programme rasch weiter.<br>
F&uuml;r die Rolle von Freiwilligen-Organisationen (z.B. Rotes Kreuz) in Entwicklungsl&auml;ndern zeigt das Beispiel von Belize deutlich, dass ohne direkten Einsatz dieser Organisationen die dortigen Regierungen ihre Ziele nicht erfolgreich erreichen k&ouml;nnen: effiziente Aids-Information f&uuml;r die sexuell aktive Bev&ouml;lkerung, &Auml;nderung des Lebensstils, des Sexualverhalten und der Sexualpraktiken etc. Da sie sich aus der Gesellschaft rekrutieren und mit ihr vertraut sind, bringt ihnen die Bev&ouml;lkerung volles Vertrauen entgegen.<br>
Aus den USA wird vor allem &uuml;ber die Arbeit von Freiwilligen berichtet, die Direktbetroffenen helfen: Abgabe von Gratismahlzeiten, Beratung, Betreuung, Rechtsdienst, finanzielle Unterst&uuml;tzung etc.<P>
<I>AME</I><P></UL>

<HR WIDTH=550>

<H4>6th International Conference on Aids. San Francisco, 20-24, June 1990</H4>
<I>San Francisco, 1990, 3 Bde.</I><P><UL>
In den USA gelingt unter Einbezug von NGO's die Durchf&uuml;hrung von nationalen Programmen eher. Staatliche Organisationen haben die finanziellen Ressourcen und die gesundheitspolitischen Erfahrungen, aber ihnen fehlen der Zugang und die Glaubw&uuml;rdigkeit bei Personen mit Risikoverhalten.<P>
<I>AME</I><P></UL>

<HR WIDTH=550>

<H4>7th International Conference on Aids: Science challenging AIDS. Florence, 16-21, June 1991</H4>
<I>Roma : Istituto superiore di sanit&agrave;, 1991, 3 Bde.</I><P><UL>
Sogenannte "Assistance Programms" in den USA beinhalten eine finanzielle Starthilfe und eine intensive Unterst&uuml;tzung in organisatorischen Fragen. Dies kann die F&auml;higkeit  von NGO's, HIV-Pr&auml;ventionsprogramme auf lokaler Ebene durchzuf&uuml;hren, enorm erh&ouml;hen. Die CBO's (= Community based organizations) haben bereits Netzwerke gebildet, um ihr Wissen und ihre Erfahrungen auszutauschen und um an Programm- und Politikentwicklung teilzuhaben.<br>
Um Randgruppen in Indien mit Aids-Informationsmaterialien zu erreichen, spielen lokale NGO's eine wichtige Rolle. Sie k&ouml;nnen diese Gruppen besser erreichen als die zentrale Regierung, und dank ihrer Flexibilit&auml;t sind sie auch f&auml;hig, speziell f&uuml;r diese konzipierte Pr&auml;ventions-Botschaften zu vermitteln.<P>
<I>AME</I><P></UL>

<HR WIDTH=550>

<H4>8th International Conference on Aids - 3th STD World Congress. Amsterdam, 19-24, July 1992</H4>
<I>Amsterdam: CONGREX Holland B.V., 1992, 3 Bde.</I><P><UL>
In den USA erhalten Minority's NGO's Unterst&uuml;tzung aus lokalen Mitteln; sobald sie sich etabliert haben, werden sie auch von Staat und privaten Organisationen unterst&uuml;tzt. Das "American Red Cross" zeigt ein strategisches Vorgehen f&uuml;r langfristige Planung: NGO's - auch mit kleinem Budget - k&ouml;nnen Pr&auml;ventionsprogramme f&uuml;r HIV-Positive entwickeln. Der Schl&uuml;ssel dazu ist die M&ouml;glichkeit, sehr individuelle Beratung und Betreuung zu bieten.<br>
Europas Netzwerk-Strukturen sind entscheidend f&uuml;r die Unterst&uuml;tzung der gesellschaftlichen Entwicklungen in den L&auml;ndern Zentral- und Osteuropas, die z.Zt. rapiden sozialen &Auml;nderungen unterliegen. Durch die Unterst&uuml;tzung der Betroffenen selbst und durch &Uuml;berwinden der sozialen, kulturellen und ideologischen Barrieren konnten Grundlagen f&uuml;r gemeinsame Strategien entwickelt werden, die auf Menschenrechten und Selbstbewusstsein basieren.<br>
In Peru gr&uuml;ndeten medizinisches Personal und andere Freiwillige eine NGO mit dem Ziel, die Gesellschaft &uuml;ber Aids aufzukl&auml;ren. Ohne Geld und trotz sozialer und &ouml;konomischer Krise zeigt dieses Beispiel, dass gut ausgebilete Berufsleute eine Organisation schaffen k&ouml;nnen, die die Gesundheitssituation des Landes im Hinblick auf Aids beeinflussen kann.<br>
Aus Afrika wurde gefordert, dass eine Evaluation der von NGO's durchgef&uuml;hrten Projekte erste Priorit&auml;t hat. Ohne Evaluationsbericht, klar definierte Strukturen und einen detaillierten Aktionsplan sollten keine finanziellen Mittel verteilt werden.<P>
<I>AME</I><P></UL>

<HR WIDTH=550>

<H4>9th International Conference on Aids -  4th STD World Congress. Berlin, 6-11, June 1993</H4>
<I>Berlin : Institut f&uuml;r Klinische und Experimentelle Virologie der Freien Universit&auml;t Berlin, 1993, 2 Bde.</I><P><UL>
In Europa (F, E, GB) liegt das Schwergewicht der Arbeitsgebiete der NGO's im Aufbau von Selbsthilfegruppen, Peer-Groups und in der Integrierung von HIV-Positiven.<br>
In Isr&&aelig;Elig;el gilt die Aufmerksamkeit vorallem der Information und Pr&auml;vention. Mit einem Pr&auml;ventionsprojekt, bei dem durch medizinisches Personal oder Studenten informiert wird, konnte ein grosser Teil der Bev&ouml;lkerung erreicht werden.<br>
In Russland wird in allen Bereichen vor allem die internationale Zusammenarbeit gef&ouml;rdert (z. B. ein Quilt Project in Zusammenarbeit mit dem Names Project San Francisco).<br>
Berichte aus S&uuml;damerika (Brasilien, Kolumbien) besagen, dass die nationalen Aids-Hilfen landesweit Niederlassungen eingerichtet haben und besonders die Freiwilligen-Arbeit f&ouml;rdern.<P>
<I>AME</I><P></UL>

<HR WIDTH=550>

<H4>10th International Conference on AIDS - International Conference on STD. Yokohama, 7-12,  August 1994</H4>
<I>Yokohama, 1994, 3 Bde.</I><P><UL>
W&auml;hrend die Beitr&auml;ge aus den europ&auml;ischen Staaten (GB, CH, D, F, GR, P) zum Thema NGO's und ihrer Arbeit &uuml;ber die Ausbildung von Freiwilligen Helfern, Fundraising, Selbsthilfegruppen, Betreuung von HIV-Positiven/Aids-Kranken, Rolle der Massenmedien berichten, liegt der Schwerpunkt der Berichte aus S&uuml;damerika (Peru, Argentinien, Brasilien) auf dem Versuch, die Informationsvermittlung zu dezentralisieren (Aufkl&auml;rungskampagne in den Schulen nicht nur in der Hauptstadt, Ausbildung von med. Personal, Lehrern, Betreuern). Hier zeichnet sich klar ab, dass nur ein gemeinsamer Effort von NGO's, privaten Firmen und der Regierung einen bedeutenden Einfluss bei der Aids-Bek&auml;mpfung haben kann.<br>
In Afrika (Lesotho, Tanzania, Guinea, Uganda, S&uuml;dafrika) wird - z.T. stark gepr&auml;gt von der politischen Situation - ebenfalls die Zusammenarbeit der NGO's mit dem medizinischen Personal und den PWAs angestrebt. In Guinea z.B. ist daraus ein Aids Info Center entstanden.<br>
In Asien sind die vorherrschenden Themen die Sicherheit der Blut-Banken, der Schutz des medizinischen Personals und der Bev&ouml;lkerung, die Etablierung von Selbshilfegruppen, Information, Beratung/Betreuung der Patienten (Hot-Lines) und die Epidemie-&Uuml;berwachung.<P>
<I>AME</I></UL><P>


</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-330</DOCNO>
<DOCOLDNO>IA017-000178-B042-96</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:4.1 192.33.214.13 19970106050435 text/html 39075
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:04:54 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<A NAME="1">J. Ruffi&eacute;, J.-C. Sournia</A><BR>
<H4>Les &eacute;pid&eacute;mies dans l'histoire de l'homme</H4>
<I>Paris, Flammarion, 1995, 302 p.</I><BR><UL>
Un essai d'anthropologie m&eacute;dicale, passionnant par bien des c&ocirc;t&eacute;s, mais dont le chapitre consacr&eacute; au sida para&icirc;t avoir &eacute;t&eacute; &eacute;crit &agrave; la h&acirc;te. D'abord parce qu'il ne dit rien que nous ne sachions d&eacute;j&agrave;, ensuite et surtout parce que ses auteurs utilisent malencontreusement le terme de &quot;sidatiques&quot; pour d&eacute;signer les personnes touch&eacute;es. Et cela alors qu'ils ne semblent aucunement partager les phobies des inventeurs de ce substantif sulfureux puisqu'ils se prononcent sans ambiguit&eacute; contre les peurs irraisonn&eacute;es et les vell&eacute;it&eacute;s de marquage ou de mise &agrave; l'&eacute;cart des s&eacute;ropositifs.
Le r&ocirc;le de transformateur social jou&eacute; par le sida passe aux oubliettes. Aucune mention n'est faite des avanc&eacute;es
obtenues dans le partage du savoir m&eacute;dical, de la transformation des rapports entre m&eacute;decins et patients, de la fonction novatrice du r&eacute;seau associatif, du r&ocirc;le cl&eacute; de la pr&eacute;vention...<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="2"><H4>Le sida, images de l'&eacute;pid&eacute;mie</H4></A>
<I>Gen&egrave;ve, OMS, 1995, 148 p., 32 FS (22,40 FS dans les PVD)</I><BR><UL>
Enfin un ouvrage global sur le sida dont les auteurs r&eacute;ussissent
&agrave; &eacute;viter les pi&egrave;ges des compromis consensuels
et de la marginalisation des pays du tiers monde. Un ouvrage qui,
de surcro&icirc;t, tranche sur la fadeur habituelle des publications
munies du sceau de l'officialit&eacute;, pose avec vigueur et
empathie les vraies questions, n'h&eacute;site pas &agrave; mettre
en &eacute;vidence les obstacles culturels, sociaux et &eacute;conomiques
&agrave; la ma&icirc;trise de l'&eacute;pid&eacute;mie, dessine
les grands traits de ce qui devrait &ecirc;tre fait dans l'urgence.<P>
M&ecirc;me s'il contient de nombreuses donn&eacute;es chiffr&eacute;es
et, en particulier, un bilan de la dynamique de l'&eacute;volution
du sida dans toutes les r&eacute;gions du monde, ce livre n'a
rien d'un rapport ou d'un compte-rendu exhaustif. Concret, proche
de la vie, il propose une suite ordonn&eacute;e d'instantan&eacute;s
sur la situation actuelle. Apr&egrave;s un bref bilan des connaissances
sur le sida et ses modes de transmission, les auteurs se penchent
sur les questions clefs. Pourquoi la propagation du VIH se poursuit-elle
&agrave; l'allure de 6000 nouvelles infections quotidiennes? Comment
faire face &agrave; ce d&eacute;fi majeur?<P>
Les auteurs constatent que &quot;c'est la pauvret&eacute; qui
marque &agrave; la fois la ligne de moindre r&eacute;sistance
et constitue l'un des plus puissants moteurs de propagation du
sida&quot;. D&eacute;nuement extr&ecirc;me du tiers monde avec
ses effets pervers sur le plan de la sant&eacute; publique: migrations
de travailleurs, enfants abandonn&eacute;s, tourisme sexuel, privation
de connaissances et de moyens de protection... Poches de mis&egrave;re
du monde d&eacute;velopp&eacute;: aux Etats-Unis, les afro-am&eacute;ricains
supportent 28% des cas de sida alors qu'ils ne repr&eacute;sentent
que 12% de la population. La subordination de la femme s'inscrit
aussi largement dans un contexte de pauvret&eacute; et compte
parmi les obstacles majeurs &agrave; la pr&eacute;vention. Tout
comme les d&eacute;nis et, en particulier, le d&eacute;ni culturel
de l'homosexualit&eacute; qui persiste &agrave; divers degr&eacute;s
un peu partout dans le monde.<P>
Les mesures d'isolement, le d&eacute;pistage obligatoire, induisent
une s&eacute;curit&eacute; trompeuse favorable &agrave; la diss&eacute;mination
du virus. A ce propos, c'est tr&egrave;s opportun&eacute;ment
qu'est rappel&eacute; l'&eacute;chec de la politique de Cuba qui,
en 1993, a fini par renoncer aux mesures d'isolement obligatoire
des s&eacute;ropositifs. Autre mauvais exemple: les fiches d'inspection
sanitaire d&eacute;livr&eacute;es aux prostitu&eacute;es dans
certaines villes d'Allemagne et qui n'ont d'autre effet que d'encourager
les rapports non prot&eacute;g&eacute;s.<P>
Comment faire face, comment briser la synergie de ces fl&eacute;aux
que sont l'homophobie, la pauvret&eacute;, le ch&ocirc;mage, la
toxicomanie? Dans la mesure o&ugrave; il y a prise de conscience
de la n&eacute;cessit&eacute; d'une mobilisation et o&ugrave;
les moyens financiers sont disponibles, des r&eacute;ussites sont
possibles, dans le domaine de la pr&eacute;vention comme dans
celui de la prise en charge des personnes touch&eacute;es. Ce
livre en d&eacute;crit plusieurs. En Ethiopie, en Tanzanie, en
Tha&icirc;lande, en Grande-Bretagne. Mais ces succ&egrave;s restent
dramatiquement insuffisants et, pour l'instant, le cri d'alarme
lanc&eacute; par l'OMS ne semble &ecirc;tre &eacute;cout&eacute;
que d'une oreille distraite par la plupart des d&eacute;cideurs
de notre plan&egrave;te. Or, comme le souligne &agrave; propos la pr&eacute;face de cet ouvrage, &quot;d'ici
la fin de la d&eacute;cennie, le total cumul&eacute; des personnes
infect&eacute;es pourrait s'&eacute;lever &agrave; 40 millions,
plus que la totalit&eacute; des morts de la Seconde Guerre mondiale.&quot;
Ni l'optimisme, ni la banalisation paresseuse ne sont donc aujourd'hui
de mise.<P>
<I>RCh</I><BR>
<BR>

</UL><HR>

<A NAME="3">Luc Montagnier (&eacute;dit.)<BR></A>
<H4>Sida, les faits, l'espoir</H4>
<I>Paris, MED Editions, 1995 (9&egrave;me &eacute;dition), 64 p., 43 FF</I><BR><UL>
Cet ouvrage, con&ccedil;u sous la forme de dessins comment&eacute;s,
propose une bonne information de base accessible &agrave; chacun.
Le contenu a &eacute;t&eacute; mis &agrave; jour pour la neuvi&egrave;me
fois et il semble, h&eacute;las, que la distance entre la r&eacute;alit&eacute;
et l'espoir n'ait gu&egrave;re diminu&eacute; au cours de cette
derni&egrave;re d&eacute;cennie, malgr&eacute; l'am&eacute;lioration
du traitement de certaines complications du sida.<P>

</UL><HR>

<A NAME="4">Caroline Gr&eacute;co<BR></A>
<H4><I>'Julien, toi qui pr&eacute;f&egrave;res les hommes'</I></H4>
<I>Paris, Crit&eacute;rion, 1995, 59 FF</I><BR><UL>
Une m&egrave;re, confront&eacute;e &agrave; l'homosexualit&eacute;
de son fils Julien, raconte son itin&eacute;raire compliqu&eacute;.
De la sid&eacute;ration &agrave; l'acceptation, en passant par
la solitude face &agrave; un mari se prot&eacute;geant par le
d&eacute;ni et par les difficult&eacute;s &agrave; aborder un
&quot;autre monde&quot;. &quot;Autre monde&quot; per&ccedil;u
avec les oeill&egrave;res des pr&eacute;jug&eacute;s et des clich&eacute;s.
Comment est-ce possible, alors que mon fils n'a pas le geste eff&eacute;min&eacute;?<P>
Il a pourtant fallu passer par l'effort de compr&eacute;hension
de ce qui, finalement ne se choisit pas et ne s'explique pas.
Cette m&egrave;re a d&ucirc; changer ses rep&egrave;res, accepter
comme normal ce qui l'horrifiait. Son t&eacute;moignage est surtout
destin&eacute; aux parents qui se trouveraient dans une semblable
situation. T&eacute;moignage singulier qui a, certes, des limites
dans l'exemplarit&eacute; m&ecirc;me si la diversit&eacute; des
sensibilit&eacute;s et des comportements homosexuels est mise
en &eacute;vidence &agrave; travers les portraits de quelques
amis de Julien. Et des limites aussi dans la tol&eacute;rance
et l'acceptation de ceux qui n'entreraient pas dans le sch&eacute;ma
d'une homosexualit&eacute; lisse, les travestis et les &quot;folles&quot;
dont la m&egrave;re et le fil s'accordent pour en avoir horreur...<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="5"><H4>Amour, sexualit&eacute;, sida.</H4></A>
R&eacute;flexions autour des r&eacute;sultats d'une enqu&ecirc;te
en milieu &eacute;tudiant parisien<BR>
<I>Parts, IDUP, 1994, 152 p.</I><BR><UL>
Cette enqu&ecirc;te men&eacute;e en milieu universitaire avec
la participation active des &eacute;tudiants avait pour objectif,
outre la connaissance des repr&eacute;sentations et des comportements,
de contribuer aux r&eacute;flexions autour de la sexualit&eacute;
dans le cadre oblig&eacute; de la pr&eacute;vention cibl&eacute;e
du sida. Ce livre en pr&eacute;sente les r&eacute;sultats et les
conclusions. Il est introduit par un prologue contextuel qui comporte
un rappel de la situation &eacute;pid&eacute;miologique dans le
monde et en France, une revue des enqu&ecirc;tes sur la sexualit&eacute;
men&eacute;es en France, un article sur quelques aspects historiques
et sociaux de l'amour et de la sexualit&eacute;. L'auteur de ce
dernier, Maryse Jaspard, rappelle opportun&eacute;ment que &quot;la
responsabilisation de l'individu est conditionnelle &agrave; l'existence
d'un degr&eacute; de libert&eacute; face aux prescriptions&quot;.<P>
Les r&eacute;sultats de l'enqu&ecirc;te sont pr&eacute;sent&eacute;s
et comment&eacute;s pour chaque th&egrave;me trait&eacute; (&acirc;ge
du premier rapport, amour et sexualit&eacute;, information et
comportements pr&eacute;ventifs, attitude face aux malades. Une
synth&egrave;se essaye de d&eacute;terminer la marge entre la
connaissance th&eacute;orique du risque statistique et la perception
de la r&eacute;alit&eacute; individuelle du risque. Elle souligne
la mani&egrave;re dont la notion de &quot;groupes &agrave; risque&quot;
a fonctionn&eacute; dans l'inconscient collectif, en incitant
&agrave; reporter le danger sur les &quot;autres&quot;, les &quot;d&eacute;prav&eacute;s&quot;.
Une autre question, pos&eacute;e par les diff&eacute;rences entre
&eacute;tudiants et &eacute;tudiantes, est celle du r&ocirc;le
des messages pr&eacute;ventifs qui pourraient avoir eu pour effet
une &quot;...tendance &agrave; maintenir, voire accro&icirc;tre,
la distance qui s&eacute;pare les deux sexes dans l'univers amoureux?&quot;<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="6">Andr&eacute; Ruffiot, Jean Martin (&eacute;dit.)</A><BR>
<H4>Les familles face au sida</H4>
<I>Paris, Dunod, 328 p., 145 FF, 44,50 FS</I><BR><UL>
Fruit d'une collaboration entre le laboratoire de psychologie
clinique et pathologique de l'Universit&eacute; Pierre-Mend&egrave;s-France
de Grenoble et diverses institutions lausannoises (Institut de
M&eacute;decine sociale et pr&eacute;ventive, ProFamilia..) cet
ouvrage a pour objectif de mettre en relation la famille avec
l'ensemble des probl&egrave;mes induits par l'irruption du sida.
R&eacute;sultat d'un travail collectif, il apporte des &eacute;clairages
tr&egrave;s divers, souvent contradictoires, &agrave; la mesure
des sensibilit&eacute;s, des convictions et des pratiques d'auteurs
tous sp&eacute;cialistes du sida mais dont les approches de cette
probl&eacute;matique apparaissent heureusement &eacute;clectiques.
Abord&eacute; pour la premi&egrave;re fois de mani&egrave;re aussi
globale, le th&egrave;me des familles face au sida aurait mal
support&eacute; des conclusions p&eacute;remptoires et d&eacute;finitives.
On saura gr&eacute; aux &eacute;diteurs d'avoir su &eacute;viter
ce pi&egrave;ge en nous proposant la mati&egrave;re et les grands
axes d'un d&eacute;bat dont on ne peut que souhaiter l'&eacute;largissement
et l'approfondissement. En pointant les principaux questionnements,
en transmettant exp&eacute;riences et initiatives, les contributions
&agrave; ce livre illustrent l'extr&ecirc;me complexit&eacute;
du sujet, la gravit&eacute; des enjeux &eacute;thiques, les risques
de d&eacute;rapage...<P>
L'ouvrage comporte six parties. La premi&egrave;re se penche sur
le concept de famille, son inscription dans l'histoire, ses liens
avec la sant&eacute; publique. La seconde aborde le noeud de probl&egrave;me,
celui du secret destructeur, de la collision entre la norme familiale
traditionnelle et les pratiques per&ccedil;ues comme d&eacute;valorisantes
- et donc stigmatis&eacute;es - de l'homosexualit&eacute; ou de
la toxicomanie souvent r&eacute;v&eacute;l&eacute;es par le VIH.
Comment aider &agrave; rompre un silence choisi par le s&eacute;ropositif
pour se prot&eacute;ger et prot&eacute;ger sa famille et qui est
en m&ecirc;me temps source d'aggravation de la souffrance (isolement,
non-communication) et porteur des ingr&eacute;dients d'une crise
majeure en cas de r&eacute;v&eacute;lation brutale? La troisi&egrave;me
partie, qui nous a paru la moins ouverte, pour ne pas dire floue
et nostalgique quant aux &quot;id&eacute;aux familiaux&quot; qu'elle
v&eacute;hicule ici ou l&agrave;, envisage les conditions d'un
retour vers la famille. Le d&eacute;sir d'enfant (grossesse, adoption)
est d&eacute;battu dans une quatri&egrave;me partie alors que
la cinqui&egrave;me partie traite de l'interface famille - pr&eacute;vention.
Nous en avons appr&eacute;ci&eacute; le ton critique et novateur,
en particulier celui de la contribution de Philippe Mocellin qui
met en garde contre les confusions entre le discours de valorisation
du concept de famille et le discours id&eacute;ologique des d&eacute;fenseurs
des valeurs dites &quot;traditionnelles&quot; et insiste sur la
n&eacute;cessit&eacute; d'une approche moins individualiste de
la pr&eacute;vention, en particulier &quot;&agrave; partir de
l'existence de r&eacute;elles communaut&eacute;s de soutien, au
sens familial du terme, dispos&eacute;es &agrave; prendre en charge
leur propre destin&eacute;e pour lutter contre l'&eacute;pid&eacute;mie&quot;.
Une derni&egrave;re partie est consacr&eacute;e &agrave; l'accompagnement
et &agrave; l'&eacute;coute des familles confront&eacute;es &agrave;
la maladie.<P>
Il est &eacute;videmment impossible, dans le lit de Procuste d'une
recension, de rendre compte, de la richesse et de la vari&eacute;t&eacute;
des opinions exprim&eacute;es et des pistes dessin&eacute;es.
Nous nous limiterons &agrave; en mentionner quelques unes, tout
en nous interrogeant sur quelques questions absentes de cet ouvrage.<br>
Tr&egrave;s pragmatique, Jean Martin, dans une contribution sur
les perspectives de sant&eacute; publique, insiste sur &quot;le
grand d&eacute;fi&quot; qui est de &quot;faire oeuvre de capacitation
des parents et des familles, tout en &eacute;vitant le paternalisme
ou l'endoctrinement&quot;. Il pr&eacute;conise une meilleure int&eacute;gration
des personnes touch&eacute;es (PVA) par un dialogue qui &eacute;vite
les effets d&eacute;l&eacute;t&egrave;res d'id&eacute;es doctrinales
sur ce qui serait normal et ne le serait pas. A propos du secret
m&eacute;dical, il pr&ocirc;ne une pratique m&eacute;diane entre
celles de la Su&egrave;de et de la France: les partenaires stables
(conjoints mari&eacute;s, concubins) pourraient se voir notifier
le statut s&eacute;rologique de leur compagne ou de leur compagnon
qui refuseraient de le dire, la confidentialit&eacute; n'&eacute;tant
pas rompue quand il y a relations multiples.<P>
Andr&eacute; Ruffiot, sur un autre registre, insiste sur la n&eacute;cessit&eacute;
d'une r&eacute;flexion &agrave; propos des phobies relatives &agrave;
l'homosexualit&eacute;. Il rel&egrave;ve avec justesse que, si
le sida pose tant de probl&egrave;mes du c&ocirc;t&eacute; de
la famille, c'est d'abord par la &quot;honte&quot; qu'il induit,
&quot;cons&eacute;quence d'une id&eacute;ologie morale entretenue
par la soci&eacute;t&eacute;&quot; et qu'il est important d'&eacute;radiquer.<P>
Cette piste, fondamentale, aurait m&eacute;rit&eacute; sans doute
un peu plus d'attention de la part des contributeurs de cet ouvrage.
Peu d'entre eux semblent en effet, ne serait-ce que de mani&egrave;re
implicite, prendre au s&eacute;rieux la d&eacute;finition large
de la famille selon l'OMS rappel&eacute;e pourtant au d&eacute;but
du livre: &quot;tout groupe de personnes li&eacute;es par des
sentiments de confiance, de soutien mutuel et par un destin commun&quot;.
Curieusement, si la souffrance de la famille (au sens traditionnel)
face &agrave; un fils gay est souvent &eacute;voqu&eacute;e, jamais
il n'est question de la souffrance du compagnon &eacute;ventuel
de ce fils, jamais ne sont mentionn&eacute;s les effets de la
situation de non droit familial de ce compagnon dont le sort -
int&eacute;gration ou rejet - d&eacute;pend du seul bon vouloir
d'une famille h&eacute;las trop souvent heureuse de se d&eacute;barrasser
de celui qui tend &agrave; personnifier la &quot;honte&quot;.
Entre sida et famille, la relation est ambivalente, variable dans
le temps et dans l'espace, int&eacute;grative et rejetante, g&eacute;n&eacute;ratrice
d'amour et de haine. Cet ouvrage le laisse percevoir, il d&eacute;montre
aussi la persistance de tabous, r&eacute;v&egrave;le une sorte
de pluralit&eacute; confusionnelle du ressenti de la famille,
d&eacute;voile les mouvements contraires de la m&eacute;lancolie
qui paralyse et du courage humaniste qui transforme.<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="7">Evelyne Chevalier</A><BR>
<H4>Sida et entreprises</H4>
Enqu&ecirc;te en C&ocirc;te d'Ivoire<BR>
<I>Amb&eacute;rieu, Impact SIDA &amp; Entreprises, 1994, 50 FF</I><BR><UL>
Comment les entreprise de la C&ocirc;te d'Ivoire prennent-elles
en charge le sida, sachant que cette maladie touche, en ville,
des travailleurs actifs dont seuls 8% b&eacute;n&eacute;ficient
de prestations sociales? Quels sont les acteurs qui se mobilisent,
ceux qui ne le font pas? Quelles r&eacute;ponses peuvent offrir
les entreprises face au d&eacute;fi du sida? Ce sont l&agrave;
les pistes explor&eacute;es par Evelyne Chavalier dans ce livre
bien document&eacute; et surprenant &agrave; bien des &eacute;gards.<P>
Impact SIDA &amp; Entreprises<BR>
107, rue de la R&eacute;publique<BR>
F 01500 Amb&eacute;rieu<P></UL>

<HR>

<A NAME="8">Daniel Welzer-Lang, Pierre Dutey, Michel Dorais<BR></A>
<H4>La peur de l'autre en soi - Du sexisme &agrave; l'homophobie</H4>
<I>Montr&eacute;al, VLB, 1995</I><BR><UL>
A une &eacute;poque o&ugrave; la l&eacute;gitimit&eacute; de la
revendication de droits &eacute;gaux pour les homosexuels commence
&agrave; &ecirc;tre reconnue, il est surprenant de constater l'absence
presque totale, en France, de litt&eacute;rature sur le th&egrave;me
de l'homophobie. Un silence enfin rompu par cet ouvrage de niveau
universitaire, construit autour des travaux engag&eacute;s par
un groupe d'&eacute;tudes anthropologiques de l'Universit&eacute;
Lumi&egrave;re de Lyon et une recherche post-doctorale d'un collaborateur
du Centre qu&eacute;b&eacute;cois de coordination sur le sida.<P>
Interrogations sur la d&eacute;finition et les racines de l'homophobie,
&eacute;clairages provenant de divers champs professionnels, points
de vue divergents aussi. Une premi&egrave;re partie passe en revue
les recherches et th&eacute;ories, jette un regard critique sur
certaines approches de la culture et de la science. Une deuxi&egrave;me
partie rend compte de diverses enqu&ecirc;tes et questionne sur
les pratiques homophobes et sexistes.<P>
Sujet tabou car susceptible de d&eacute;voiler la face cach&eacute;e
du masculin? Pour Daniel Welzer-Lang l'&eacute;tude de l'homophobie
constitue une clef de la compr&eacute;hension du rapport hommes
- femmes. En hi&eacute;rarchisant les diff&eacute;rences, le sexisme
a construit ses antichambres (service militaire...), ses rites
(football...) ses territoires virils (&quot;la maison des hommes&quot;),
terreaux o&ugrave; poussent la crainte et le m&eacute;pris auto
protecteur de l'Autre. Avec ses paradoxes car prendre du plaisir
entre hommes constitue l'interdit supr&ecirc;me, les r&eacute;fractaires
&eacute;tant exclus symboliquement de la communaut&eacute; masculine
&quot;normale&quot;. Michel Dorais se demande si la recherche
des &quot;causes&quot; de l'homosexualit&eacute; ne rel&egrave;ve
pas de la science fiction et ne donne pas plus d'information sur
les pr&eacute;jug&eacute;s des chercheurs que sur le ph&eacute;nom&egrave;ne &eacute;tudi&eacute;. D'o&ugrave; une
critique vigoureuse des th&egrave;ses essentialistes, auxquelles
est assimil&eacute; le freudisme dont les adeptes &quot;semblent
avoir pass&eacute; &agrave; c&ocirc;t&eacute; d'une explication
g&eacute;n&eacute;rale non seulement de l'homosexualit&eacute;
mais de l'orientation sexuelle&quot;. Et le choix d'une approche
constructiviste qui renonce &agrave; la vaine recherche des causes
de l'homosexualit&eacute;, consid&eacute;r&eacute;e comme une
orientation ne posant pas probl&egrave;me en soi et envisag&eacute;e
surtout comme le produit de facteurs externes. Ce qu'il importe
de cerner, ce sont les causes de la stigmatisation de l'homosexualit&eacute;.<P>
Relevons enfin l'&eacute;tude de Pierre Dutey sur les diff&eacute;rents
sens de l'homophobie &agrave; travers la litt&eacute;rature et
les cinq textes des &quot;enqu&ecirc;tes et pratiques&quot;: enqu&ecirc;te
et r&eacute;flexions sur les fonctions psychiques de l'homophobie
(Christophe Gentaz), les causes de l'invisibilit&eacute; des lesbiennes
dans les repr&eacute;sentations sociales (Fran&ccedil;oise Guillemaut),
les limites des &eacute;volutions quant &agrave; la tol&eacute;rance
sociale de l'homosexualit&eacute; en Allemagne (Mich&&aelig;Elig;el Bochow),
la reprise du discours sexiste par des gays de la droite extr&ecirc;me
(Claude Lesselier), les cons&eacute;quences de l'homophobie sur
le d&eacute;veloppement des adolescents homosexuels (Bill Ryanet
Jean-Yves Frappier).<P>
Un ouvrage qui trace des pistes novatrices sur un terrain encore
min&eacute; par les pr&eacute;jug&eacute;s. Et qui bousculera
sainement tous ceux qui ne craignent pas de revoir leur copie.<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="9"><H4>Un voile sur l'amour</H4></A>
Enqu&ecirc;te sur les attitudes des jeunes face au sida<BR>
<I>Strasbourg, Presses Universitaires de Strasbourg, 1994, 108 p., 60 FF</I><BR><UL>
Comment les jeunes per&ccedil;oivent-ils le sida et ceux qui en
sont atteints? Qu'en savent-ils exactement et que font-ils pour
se prot&eacute;ger? Comment jugent-ils les messages qui leur sont
adress&eacute;s? Int&egrave;grent-ils ce risque dans leur vie
intime? Telles sont quelques unes des questions auxquelles ces
deux enqu&ecirc;tes men&eacute;es aupr&egrave;s de jeunes dans
le d&eacute;partement du Bas-Rhin s'efforcent de r&eacute;pondre.<P>

</UL><HR>

<A NAME="10">Cl&eacute;ment Olivier</A><BR>
<H4>L'amour assassin</H4>
<I>Montr&eacute;al, L'Homme - Stank&eacute;, 1994, 172 p., 99 FF, 33,50 FS</I><BR><UL>
Bouscul&eacute; par sept ans de lutte d&eacute;sesp&eacute;r&eacute;e
contre le sida, ce m&eacute;decin a &eacute;prouv&eacute; le besoin
d'&eacute;crire un &quot;livre th&eacute;rapeutique&quot;. Pour
lui-m&ecirc;me, en r&eacute;v&eacute;lant ses tourments; pour
les soignants, en proposant ce qu'il estime &ecirc;tre &quot;un
outil de compr&eacute;hension et de partage&quot;.<P>
Comme point de d&eacute;part &agrave; sa r&eacute;flexion pour
une vision qu'il juge &quot;globale et plus g&eacute;n&eacute;reuse&quot;,
Cl&eacute;ment Olivier utilise, la relation de situations r&eacute;elles
cens&eacute;es refl&eacute;ter le quotidien du sida.<P>
Des situations choisies pourtant, qui reviennent sous la plume
de ce m&eacute;decin comme pour d&eacute;montrer ce que serait
l'environnement d&eacute;prav&eacute; du sida, le caract&egrave;re
&quot;monstrueux&quot; de la maladie, l'aspect &quot;hideux&quot;
de certains patients. Le choix des termes ne traduit-il pas la
peur et le d&eacute;sarroi de ce m&eacute;decin? Que signifie
ce sentiment de &quot;terreur&quot; face &agrave; certain &quot;spectacle&quot;,
ce qualificatif d'&quot;univers r&eacute;pugnant&quot; appliqu&eacute;
&agrave; une situation de d&eacute;tresse extr&ecirc;me, ce nom
de &quot;fant&ocirc;me&quot; accol&eacute; &agrave; un malade?
Quant &agrave; cette histoire d'&quot;archange&quot;, &quot;r&eacute;incarnation
m&ecirc;me de l'image que je me fais de satan&quot;, &quot;pr&eacute;dateur&quot;
qui ne pense qu'&agrave; se venger en contaminant six femmes,
elle comblera ceux qui alimentent leur fonds de commerce du fantasme
de la s&eacute;ropositivit&eacute; comme bombe &agrave; retardement
de terroristes insaisissables. On croisera aussi dans ce recueil
d'&quot;histoires repr&eacute;sentatives&quot; une dame qui vend
des seringues contamin&eacute;es, un homosexuel &agrave; tendances
masochistes qui fait preuve &quot;d'insouciance absolue dans la
tol&eacute;rance la plus grande&quot; et fr&eacute;quente des
&quot;bars de troisi&egrave;me ordre&quot;, un gamin provocateur
infect&eacute; par une fille qui a d&eacute;j&agrave; fait tomber
10 copains sous son charme, un petit gar&ccedil;on incarnant la
victime par opposition aux &quot;hommes pervers qui jouissent
du mal&quot;.<P>
Est-ce pour compenser le malaise &eacute;vident qu'il &eacute;prouve
devant la souffrance et la mort de ses patients que Cl&eacute;ment
Olivier prend finalement le parti du m&eacute;pris et de l'agressivit&eacute;
moralisante? N'est-il pas permis de se poser quelques questions
sur la nature de l'&quot;humanisme&quot; dont il est fait &eacute;talage
par l'auteur. Relevons encore la cruaut&eacute; stupide de quelques
sentences glan&eacute;es dans ce livre: &quot;quand on a si peur
de mourir, c'est qu'on a toujours eu peur de vivre&quot;, &quot;on
meurt comme on a v&eacute;cu&quot;. M&ecirc;me l'angoisse du mourir
et les circonstances d'une fin de vie deviennent ici p&eacute;ch&eacute;s,
jauges de la d&eacute;cence morale. Quelle qualit&eacute; d'accompagnement
peut &eacute;merger de ce d&eacute;ficit d'empathie? On s'interrogera
tout de m&ecirc;me sur la signification de la pr&eacute;face de
l'abb&eacute; Pierre et de la postface de Johanne de Montigny,
sp&eacute;cialiste des soins palliatifs...<P>
RCh<BR>

</UL><HR>

<A NAME="11">Frank Hagenbucher-Saripanti</A>
<H4>Repr&eacute;sentation du sida et m&eacute;decine traditionnelle
dans la r&eacute;gion de Pointe Noire (Congo)</H4>
<I>Paris, ORSTOM, 1994, 107 p., 80 FF</I><BR><UL>
En &eacute;voquant les repr&eacute;sentations du sida qui &eacute;mergent
dans cette r&eacute;gion d'Afrique noire, l'auteur s'interroge
sur la simultan&eacute;it&eacute; des d&eacute;buts de l'&eacute;pid&eacute;mie
et de la progression apparente d'une maladie de peau d&eacute;nomm&eacute;e
mwanza dont les similitudes avec les manifestations dermatologiques
du VIH orientent fr&eacute;quemment le diagnostic traditionnel
vers des confusions et des amalgames. Les propos d'informateurs
de terrain sont &eacute;clair&eacute;s par leur mise en rapport
avec l'&eacute;volution actuelle des repr&eacute;sentations de
la maladie et des m&eacute;decines traditionnelles. Changement
et innovation visent &agrave; conformer la tradition &agrave;
une &eacute;thique nouvelle et &agrave; une conception moderne
de la sant&eacute;.<P>

</UL><HR>

<A NAME="12">Georges Math&eacute;</A>
<H4>SIDA: sceau, sexe, science</H4>
<I>Paris, La Coutellerie, 1995, 100 FF</I><BR><UL>
Pr&eacute;sent&eacute; comme un &quot;canc&eacute;rologue d'envergure
internationale&quot;, Georges Math&eacute; appara&icirc;t dans
ce livre comme un pol&eacute;miste obscur et violent. Son parti
pris semble &ecirc;tre celui de la provocation et du scandale.
Le dessein de r&eacute;v&eacute;ler ce qui &quot;nous est dissimul&eacute;
par les instances officielles&quot; se traduit par une op&eacute;ration
de r&egrave;glement de compte avec ses coll&egrave;gues m&eacute;decins
et chercheurs et s'exprime dans une logorrh&eacute;e d&eacute;nonciatrice
de &quot;complots&quot; aux motivations vari&eacute;es: financi&egrave;res,
nationalistes, sexuelles (ceux qui oeuvrent &agrave; d&eacute;velopper
la fornication comme acte culturel!), honorifiques...<P>
A propos de sexualit&eacute; et de toxicomanie, Georges Math&eacute;
ne fait pas dans la dentelle. En s'insurgeant, par exemple, contre
le fait que le test &agrave; l'hormone femelle ne soit pas pratiqu&eacute;
sur les donneurs de sang afin de d&eacute;pister leur &eacute;ventuelle
homosexualit&eacute;! En insinuant encore que, quand les hommes
de l'art s'emparent de la sensibilit&eacute; gay, quand les politiciens
officialisent les couples homos, il y aurait &quot;risque d'induire
ce contre quoi ils pr&eacute;tendent lutter: un v&eacute;ritable
racisme.&quot; D'autre part, &quot;de l'homosensualit&eacute;
- n&eacute;ologisme utilis&eacute; par Georges Math&eacute; pour
en souligner le caract&egrave;re orgiaque! - &agrave; la drogue,
il y a d'autant moins de diff&eacute;rence qu'un quart des homosensuels
se droguent, et qu'un quart des toxicomanes se livrent aux pratiques
homosensuelles.&quot; Tout est donc tr&egrave;s simple: le sevrage
pur et dur, avec l'aide de diverses substances pharmacologiques
(m&eacute;thadone exclue), d'un accompagnement social et d'un
suivi m&eacute;dical. Il conviendrait m&ecirc;me d'agir en amont:
les boissons contenant de la coca ainsi que les &quot;poppy-seed
cokes&quot; (douceur servie dans les restaurants suisses!) pourraient
d&eacute;r&eacute;gler le fornix des enfants et cr&eacute;er ainsi
une d&eacute;pendance pr&eacute;coce &agrave; toutes les drogues
r&eacute;cr&eacute;atives.<P>
Georges Math&eacute; s'en prend violemment &agrave; l'establishment
scientifique. Allant jusqu'&agrave; &eacute;crire que les centres
sp&eacute;cialis&eacute;s n'auraient qu'un seul but: &quot;caser
des m&eacute;decins, fils et gendres de patrons, qui n'ont, pour
autant, trouv&eacute; de postes dans les h&ocirc;pitaux universitaires,
et concentrer suffisamment de malades pour les essais th&eacute;rapeutiques.&quot;<P>
L'Acad&eacute;mie de m&eacute;decine est qualifi&eacute;e d'&quot;archa&iuml;que&quot;,
les scientifiques sont tourn&eacute;s en d&eacute;rision sous
le vocable de &quot;s&ccedil;avants&quot; (sic), Jean-Paul L&eacute;vy,
directeur de l'Agence Nationale de Recherche sur le Sida est accus&eacute;
d'aller recruter des chercheurs &agrave; l'&eacute;tranger et
de s'aligner sur les programmes am&eacute;ricains. Globalement
si &quot;la m&eacute;decine n'a pas encore sombr&eacute;&quot;,
elle se voit reprocher de faire fausse route. Georges Math&eacute;,
s&eacute;duit par les th&egrave;ses de Peter Duesberg sans s'y
rallier enti&egrave;rement (il ne peut accepter la th&eacute;orie
selon laquelle le VIH1 ne joue aucun r&ocirc;le &agrave; l'origine
du sida), opte pour une approche immunog&eacute;n&eacute;tique
dont nous laisserons l'appr&eacute;ciation &agrave; la communaut&eacute;
scientifique.<P>
Un livre au langage abscons, chaotique et sulfureux, qui m&ecirc;le
indistinctement frustrations, col&egrave;res et fantasmes &agrave;
un savoir de canc&eacute;rologue. Si le coup de col&egrave;re
est rat&eacute;, le brouillage est en tout cas r&eacute;ussi.
D&eacute;solant.<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="13">Gilles M&eacute;dioni</A><BR>
<H4><I>Cyril Collard</I></H4>
<I>Paris, Flammarion, 1995, 192 p., 89 FF</I><BR><UL>
Montage bien construit de t&eacute;moignages, d'interviews, d'anecdotes,
d'extraits de presse et d'&eacute;crits de Collard, ce livre fait-il
vraiment le point d&eacute;finitif et objectif sur l'auteur des
Nuits fauves, comme le sugg&egrave;re la pri&egrave;re d'ins&eacute;rer?<P>
Il nous a plut&ocirc;t paru, &agrave; travers les appr&eacute;ciations
contradictoires et souvent passionn&eacute;es dont cet ouvrage
a le m&eacute;rite de se faire l'&eacute;cho, qu'une certaine
fr&eacute;n&eacute;sie tend &agrave; l'emporter sur la r&eacute;flexion
et l'analyse. Outrances et tentatives de r&eacute;cup&eacute;ration
id&eacute;ologique ne sont-ils pas des r&eacute;actions presque
naturelles dans un environnement &eacute;motionnel, de surcro&icirc;t
brouill&eacute; par un battage m&eacute;diatique auquel chacun
semble vouloir prendre sa petite part?<P>
La biographie de ce voyou de bonne famille n'aurait probablement
jamais g&eacute;n&eacute;r&eacute; le trouble et le scandale sans
&quot;l'aveu&quot; d'un rapport sexuel non prot&eacute;g&eacute;,
l'un des partenaires (Cyril Collard en l'occurrence) connaissant
sa s&eacute;ropositivit&eacute; et la dissimulant &agrave; l'autre.
Th&egrave;me clef des Nuits fauves, roman autobiographique puis
film &agrave; succ&egrave;s sorti &agrave; la fin de 1992. Th&egrave;me
sensible aussi puisque brisant un tabou jud&eacute;o-chr&eacute;tien
pour les uns, t&eacute;moignant de la confusion affective, sexuelle
et id&eacute;ologique de notre &eacute;poque pour les autres.
Aveu re&ccedil;u tant&ocirc;t comme preuve de droiture, tant&ocirc;t
comme signant un comportement criminel. Au point que le psychanalyste
Tony Anatrella y voit l'&eacute;tape d'un cheminement vers une
esp&eacute;rance mystique alors que Dominique Jamet appr&eacute;hende
Cyril Collard comme un &quot;criminel irresponsable&quot;. Entre
le h&eacute;ros r&eacute;dempteur et le coupable originel, quelle
place reste-t-il pour les al&eacute;as de l'acte amoureux, la
reconnaissance de leur l&eacute;gitimit&eacute;?<P>
Question qui vient heurter de front nos ambitions et nos illusions
s&eacute;curitaires... Le livre de Gilles M&eacute;dioni, loin
d'&ecirc;tre d&eacute;finitif &agrave; cet &eacute;gard, a le
m&eacute;rite de nous livrer les pi&egrave;ces &eacute;parses
et contradictoires du dossier embarrassant que Cyril Collard a
jet&eacute; &agrave; la figure d'une soci&eacute;t&eacute; mal
pr&eacute;par&eacute;e &agrave; l'accepter sans d&eacute;tour.<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="14">Jean-Luc Maxence</A><BR>
<H4>Les &eacute;crivains sacrifi&eacute;s des ann&eacute;es sida</H4>
<I>Paris, Bayard, 1995, 132 p.</I><BR><UL>
Avec sa subjectivit&eacute;, sa croyance, ses col&egrave;res &agrave;
propos d'une &eacute;poque dont il estime certains horizons d&eacute;sax&eacute;s,
Jean-Luc Maxence se propose d'&eacute;voquer quelques &eacute;crivains
d'une g&eacute;n&eacute;ration sacrifi&eacute;e par le sida. Pour
les faire revivre avec nous. Pour analyser leurs oeuvres comme
r&eacute;v&eacute;latrices du monde d'aujourd'hui.<P>
M&ecirc;me s'il lui semble percevoir chez Guy Hocquenghem ou chez
Herv&eacute; Guibert une &quot;nostalgie religieuse&quot;, une
&quot;tentation de saintet&eacute;&quot;, l'auteur met en garde
contre les relectures acrobatiques qui recherchent &agrave; tout
prix de la transcendance dans les oeuvres &eacute;crites sous
l'emprise du sida. Il est vrai que cette maladie rend les &eacute;crivains
graves, &quot;philosophes par n&eacute;cessit&eacute;&quot; et
les incite au refus des subterfuges, des enluminures, des d&eacute;n&eacute;gations.
Il oblige surtout &agrave; un langage de v&eacute;rit&eacute;, &agrave; une sorte
de mise &agrave; nu de l'essentiel de l'&ecirc;tre. La pens&eacute;e
sida remet en cause certaines valeurs et certains tabous de la
modernit&eacute; avec, en particulier, ce retour oblig&eacute;
d'une mort &eacute;vacu&eacute;e m&ecirc;me si, comme le rel&egrave;ve
Jean-Luc Maxence, les &eacute;crivains atteints &quot;nous sugg&egrave;rent
tous d'accepter la mort comme aspect essentiel de la vie, mais
nous avouent tous ne pas y parvenir&quot;. Beaucoup d&eacute;noncent
aussi la violence de l'univers hospitalier, jouant alors le r&ocirc;le
de r&eacute;formateurs des conditions de soins.<P>
L'auteur, tout au long de cette promenade litt&eacute;raire, ne
dissimule ni ses sympathies, ni ses aversions. S&eacute;v&egrave;re
&agrave; l'&eacute;gard des &quot;exc&egrave;s morbides&quot;
de Cyrill Collard, &quot;&eacute;crivain secondaire artificiellement
grandi&quot;, s&eacute;duit au contraire par Pascal de Duve, son
jeu verbal, ses clins d'oeil ironiques, sa mort joyeuse &quot;car
il a t&eacute;moign&eacute; de la beaut&eacute; des choses jusqu'au
bout&quot; ou par Guy Hocquenghem &agrave; l'&quot;imaginaire
&eacute;pique&quot;. Un mod&egrave;le de &quot;lutteur&quot;,
par opposition au &quot;d&eacute;serteur&quot; que serait Collard.
Jugement temp&eacute;r&eacute; par l'interrogation sur la possible
participation du d&eacute;r&egrave;glement des sens au &quot;m&ecirc;me
d&eacute;sir de puret&eacute; existentielle&quot;...<BR>
Relevons enfin la pr&eacute;sence, dans ce panorama litt&eacute;raire
qui ne pr&eacute;tend pas &agrave; l'exhaustivit&eacute;, de Michel
Foucault, Jean-Paul Aron, Conrad Detrez, Alain-Emmanuel Dreuilhe.<P>
<I>RCh</I><BR>

</UL><HR>

<A NAME="15">Denis Ledogar<BR></A>
<H4>Face au sida, le courage d'esp&eacute;rer</H4>
<I>Paris, Bayard, 1995</I><BR><UL>
T&eacute;moignage d'un pr&ecirc;tre catholique, aum&ocirc;nier
et accompagnant de personnes touch&eacute;es par le sida dans
un grand centre hospitalier de Strasbourg. R&eacute;cits de vie,
r&eacute;cits de deuils. Mais, surtout, r&eacute;flexion humaniste
et critique.<P>
Humaniste quand Denis Ledogar plaide pour une lecture de l'Evangile
qui ne donne pas le droit &agrave; l'homme de juger ou de punir
quiconque. Ou qu'il d&eacute;nonce les tentations d'une dictature
d&eacute;clarant la guerre au sida en imposant l'abstinence hors
mariage, en isolant les s&eacute;ropositifs, en d&eacute;livrant
un insigne attestant de la s&eacute;ron&eacute;gativit&eacute;.
Il y aurait l&agrave; &quot;confiscation inflexible de tout ce
qui est humain.&quot;<P>
Critique, l'auteur &quot;en a marre de se faire engueuler&quot;
&agrave; propos de l'attitude de sa propre Eglise. Celle-ci s'est
&quot;&eacute;loign&eacute;e des hommes&quot;, elle est &quot;&agrave;
c&ocirc;t&eacute; de la plaque&quot;, elle &quot;doit se prononcer
sans fard sur les r&eacute;alit&eacute;s r&eacute;v&eacute;l&eacute;es
par le sida&quot;, en particulier l'homosexualit&eacute;. Ce pr&ecirc;tre
hors du commun ose dire, y compris lors de c&eacute;r&eacute;monies
fun&egrave;bres, que l'amour entre deux hommes peut &ecirc;tre
&quot;authentique et profond.&quot;<P>
Un livre probe et chaleureux qui sait aussi ne pas tomber dans
le pi&egrave;ge des vertus morales qu'induirait le sida: la souffrance
est d&eacute;shumanisation. L'Eglise se doit aussi de respecter
les non croyants, refuser d'op&eacute;rer un tri entre bons et
mauvais malades &quot;car je n'ai jamais entendu les malades se
critiquer mutuellement, comparer leur situation, se d&eacute;livrer
ou se refuser des dipl&ocirc;mes de malchance ou d'innocence.&quot;<P>
<I>RCh</I><BR>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:3.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-331</DOCNO>
<DOCOLDNO>IA017-000178-B042-109</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:4.2 192.33.214.13 19970106050445 text/html 14403
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Litt&eacute;rature<I> 'grise'</I></H3>

<H4>Anthropologie et sida. Bilan et perspectives. Rencontre de mai 1994. Pr&eacute;sentation des d&eacute;bats</H4>
<i>Aix-en-Provence - Toulouse, LEHA, AMADES, 1995, 52 p.</i><P>
<UL>
R&eacute;sum&eacute; d'une rencontre de r&eacute;flexion sur les apports de la recherche anthropologique &agrave; la connaissance de l'&eacute;pid&eacute;mie de sida. Comme le souligne le Professeur Jean Benoist en introduction "...Aussi les sciences sociales, pour l'essentiel, se placent-elles au niveau de la maladie telle qu'elle se passe en un lieu donn&eacute;, dans un sous-ensemble social et culturel pr&eacute;cis. Quitte ensuite &agrave; comparer, &eacute;tendre ou restreindre la validit&eacute; de ce qui a &eacute;t&eacute; trouv&eacute;. Grande est alors la perplexit&eacute; du biologiste, devant ce qui lui para&icirc;t une collection de faits sans synth&egrave;se!".<P>
<I>Laboratoire d'Ecologie<br>
humaine et d'Anthropologie<br>
Universit&eacute; d'Aix-Marseille III<br>
Pavillon de Lanfant<br>
346, route des Alpes<br>
F 13100 Aix-en-Provence<br></I>

</UL><HR WIDTH=550>

<H4><i>Bernard Champaloux</i><br>Les pratiques de gestion du capital sant&eacute; chez les personnes atteintes par le VIH</H4>
<i>Aix-en-Provence, LEHA, 1993, 96 p.</i><P>
<UL>
Comment celui &agrave; qui une autorit&eacute; m&eacute;dicale reconnue annonce une s&eacute;ropositivit&eacute; au VIH &eacute;labore-t-il la gestion de son capital sant&eacute;? Cette recherche en anthropologie de la maladie se penche sur diverses repr&eacute;sentations de l'infection, sur le recours aux th&eacute;rapeutes, sur les pratiques profanes visant tant &agrave; renforcer l'organisme qu'&agrave; adopter des attitudes mentales susceptibles de contrecarrer l'&eacute;volution de la maladie.<P>
<I>Laboratoire d'Ecologie<br>
humaine et d'Anthropologie<br>
Universit&eacute; d'Aix-Marseille III<br>
Pavillon de Lanfant<br>
346, route des Alpes<br>
F 13100 Aix-en-Provence<br></I>

</UL><HR WIDTH=550>

<H4>Rapport du s&eacute;minaire "HIV Prevention and Care Training Course"</H4>
<i>Paris, M&eacute;decins du Monde, 1995, 8 p. plus annexes</i><P>
<UL>
R&eacute;sum&eacute; - en fran&ccedil;ais - d'un s&eacute;minaire qui avait pour objet l'information sur les probl&egrave;mes tels qu'ils se posent dans cette r&eacute;gion d'Afrique et la formation  des formateurs de terrain.<P>
<I>M&eacute;decins du Monde<br>
62, rue Marcadet<br>
F 75018 Paris<br>
T&eacute;l&eacute;phone (00331) 44 92 15 15<br>
Fax 44 92 99 99<br></I>

</UL><HR WIDTH=550>

<H4>Premier s&eacute;minaire sur la pr&eacute;vention du VIH aupr&egrave;s des Maghr&eacute;bins vivant en Europe: rencontre euro-maghr&eacute;bine. Rapport final</H4>
<i>Strasbourg, Aides Alsace, 1993, 68 p.</i><P>
<UL>
Compte-rendu d'un s&eacute;minaire centr&eacute; sur la pr&eacute;vention aupr&egrave;s des Maghr&eacute;bins: &eacute;change d'exp&eacute;riences, d&eacute;veloppement d'un r&eacute;seau, stimulation des activit&eacute;s internationales, &eacute;laboration d'une politique sp&eacute;cifique.<P>
<I>Aides Alsace<br>
47, rue de la Course<br>
F 67000 Strasbourg<br>
T&eacute;l&eacute;phone (0033) 88 75 73 63<br>
Fax 88 75 15 91<br></I>

</UL><HR WIDTH=550>

<H4>Pr&eacute;vention du sida.<br>
R&eacute;alisation d'une action aupr&egrave;s de personnes prostitu&eacute;es</H4>
<i>Rapport d'&eacute;valuation<br>
Nancy, Antigone, 1995, 16 p.</i><P>
<UL>
Evaluation d'un projet ayant pour objectifs de construire un observatoire des activit&eacute;s prostitutionnelles, de traiter les questions de sant&eacute; publique li&eacute;es &agrave; la prostitution et de d&eacute;velopper un relais social (permanences hospitali&egrave;res, contacts sur le terrain, accompagnement social &agrave; la demande).<P>

</UL><HR WIDTH=550>

<H4>Trois r&eacute;cits de vie</H4>
<i>Nancy, Antigone, 1993, 15 p.</i><P>
<UL>
Trois t&eacute;moignages de personnes s&eacute;ropositives, prostitu&eacute;es et marginalis&eacute;es.<P>
<I>Antigone<br>
Espace Camille Mathis<br>
Bo&icirc;te postale 376<br>
F 54007 Nancy Cedex<br>
T&eacute;l&eacute;phone (0033) 83 36 44 58<br>
Fax (0033) 83 37 28 01<br></I>

</UL><HR WIDTH=550>

<H4>Sida et sciences sociales</H4>
<i>Paris, CERMES, 1994, 60 p.</i><P>
<UL>
Cette plaquette contient l'expos&eacute; et la m&eacute;thodologie d'une quinzaine de recherches men&eacute;es entre 1986 et 1994. Elles recouvrent les th&egrave;mes sida et soci&eacute;t&eacute;, vie quotidienne avec le VIH, diversit&eacute;s et innovation de la prise en charge, mobilisation et action associative.<br>
Une publication qui d&eacute;montre la vari&eacute;t&eacute;, la qualit&eacute; et l'utilit&eacute; des travaux relevant des sciences sociales. Un outil pr&eacute;cieux pour les acteurs de terrain, dont le travail ne saurait que gagner en efficacit&eacute; s'ils prenaient mieux en consid&eacute;ration les incertitudes, les contradictions, les maladresses de leurs r&eacute;ponses. La spontan&eacute;it&eacute; et le pragmatisme ont besoin d'un regard critique et r&eacute;fl&eacute;chi, d'analyses qui aident &agrave; la compr&eacute;hension des probl&egrave;mes. Et non de ces essais qui ne font qu'annoncer "l'imminence de catastrophes non ma&icirc;trisables" et &agrave; propos desquels les &eacute;diteurs de cette plaquette prennent vigoureusement leurs distances.<P>
<I>RCh<P>
CERMES<br>
Centre de recherche m&eacute;decine, maladie et sciences sociales<br>
201, rue de Vaugirard<br>
F 75015 Paris<br>
T&eacute;l&eacute;phone (00331) 44 49 64 80<br>
Fax 44 49 64 99<br></I>

</UL><HR WIDTH=550>

<H4><i>P. Adam, G. Paicheler, A. Queman</i><br>Prospective sida 2010<br>
Projet de base d'analyse<br>
Volet psychologique, social et culturel</H4>
<i>Paris, CERMES, 1995, 106 p.</i><P>
<UL>
Ce rapport dresse un panorama synth&eacute;tique de l'&eacute;tat de la recherche portant sur les aspects psychologiques, sociaux et culturels du sida en France. Les trois grands domaines d'&eacute;tude constituent les chapitres du cadre pr&eacute;ventif g&eacute;n&eacute;ral de la lutte contre le sida, les milieux et les groupes cibles, les personnes atteintes.<P>
<I>CERMES<br>
201, rue Vaugirard<br>
F 75015 Paris<br></I>

</UL><HR WIDTH=550>

<H4><i>Genevi&egrave;ve Paicheler</i><br>Le public face &agrave; la menace du sida. Interpr&eacute;tation des connaissances et prise de conscience du risque</H4>
<i>Paris, CERMES, 1994, 182 p.</i><P>
<UL>
Cette recherche se situe &agrave; l'interface entre la prise de conscience du danger de la maladie et les conduites permettant une meilleure adaptation au risque. Elle se donne pour perspective la compr&eacute;hension des processus complexes qui lient actions et prise de conscience. Ceci dans le but de permettre la d&eacute;finition de strat&eacute;gies de communication mieux adapt&eacute;es aux attentes des gens.<P>
<I>CERMES<br>
201, rue Vaugirard<br>
F 75015 Paris<br></I>

</UL><HR WIDTH=550>

<H4><i></i><br>Premi&egrave;res rencontres europ&eacute;ennes de professionnels de la sant&eacute;: sexualit&eacute; et sant&eacute;</H4>
<i>Paris, Arches, 1994, 155 p.</i><P>
<UL>
Ces actes reproduisent les interventions de professionnels de la sant&eacute; de sept pays europ&eacute;ens: trois de l'Ouest, quatre de l'Est. Seules deux interventions - fran&ccedil;aises - sont centr&eacute;es sur le sida.<br>
Une conf&eacute;renci&egrave;re roumaine, Diana Manea, illustre la persistance des m&eacute;thodes autoritaires et r&eacute;pressives dans certains Etats ex-communistes: la pr&eacute;vention de la contamination du VIH impliquerait des mesures diff&eacute;renci&eacute;es selon le statut s&eacute;rologique, "la lutte contre la toxicomanie et l'homosexualit&eacute;" &eacute;tant s&eacute;rieusement pr&ocirc;n&eacute;e comme un moyen de pr&eacute;server les "personnes saines"...<br>
C'est dire le chemin qu'il reste &agrave; parcourir et la vigilance que devraient manifester les institutions internationales et les ONG sollicit&eacute;es pour financer des actions qui s'inscriraient dans la philosophie d'une toute puissance des injonctions &eacute;tatiques en mati&egrave;re de sant&eacute; publique.<P>
<I>RCh<P>
ARCHES<br>
14, rue Tiphaine<br>
F 75015 Paris<br>
T&eacute;l./fax (00331) 45 77 36 82<br></I>

</UL><HR WIDTH=550>

<H4><i>L'usage de drogues et l'&eacute;pid&eacute;mie du VIH</i><br>Cadre de r&eacute;f&eacute;rence pour la pr&eacute;vention</H4>
<i>Montr&eacute;al, CQCS, 1994, 44 p.</i><P>
<UL>
Ce cadre de r&eacute;f&eacute;rence est con&ccedil;u &agrave; l'attention des intervenants des r&eacute;seaux de sant&eacute; et des services sociaux. Il s'inscrit dans une double perspective de pr&eacute;vention de l'usage des drogues et de diminution des risques li&eacute;s &agrave; cet usage. Le Qu&eacute;bec a mis en oeuvre une strat&eacute;gie globale et int&eacute;gr&eacute;e de pr&eacute;vention dont ce document expose les grandes orientations, trace un bilan et montre les diverses initiatives sp&eacute;cifiques.<P>
<I>Centre qu&eacute;b&eacute;cois de<br>
coordination sur le sida<br>
3655, rue Saint-Urbain<br>
Montr&eacute;al (Qu&eacute;bec)<br>
H2X 2P4<br>
T&eacute;l&eacute;phone (514) 873-9890<br>
Fax (514) 873-9997<br></I>

</UL><HR WIDTH=550>

<H4><i>R. Mendes-Leite, P.-O. de Busscher</i><br>Microg&eacute;ographie "sexographique" des back-rooms parisiennes: appropriation de l'espace et gestion de la sexualit&eacute; face au VIH</H4>
<i>Paris, GREH, 1995, 82 p.</i><P>
<UL>
Ce rapport s'applique &agrave; la recherche socio-anthropologique concernant les pratiques de rencontres des gais dans divers &eacute;tablissements et leur rapport &agrave; la pr&eacute;vention du sida. Il comporte deux parties: la premi&egrave;re, outre l'enqu&ecirc;te ethnographique, inclut une analyse critique de la litt&eacute;rature scientifique sur les questions de la sexualit&eacute; anonyme, du multipartenariat, des pratiques sodomasochistes. La seconde partie est centr&eacute;e sur les recommandations qui d&eacute;coulent de la recherche de terrain dans la perspective d'une am&eacute;lioration de la pr&eacute;vention. Recommandations pr&eacute;cieuses qui mettent judicieusement en garde &agrave; propos des effets d&eacute;l&eacute;t&egrave;res de certains discours de "bon sens" et insistent aussi sur la n&eacute;cessit&eacute; de varier la pr&eacute;sentation visuelle et textuelle des messages &eacute;crits, leur r&eacute;&eacute;dition sous la m&ecirc;me forme ne tenant pas compte de la bri&egrave;vet&eacute; de l'effet sur le client r&eacute;gulier des lieux de rencontre.<P>
<I>Association GREH<br>
3bis, rue Orfila<br>
F 75020 Paris<br>
T&eacute;l&eacute;phone (00331) 40 33 09 37<br>
Fax 46 36 41 23<br></I>

</UL><HR WIDTH=550>

<H4>Les travailleurs sexuels et la consommation de crack</H4>
<i>Paris, IREP, 1994, 65 p.</i><P>
<UL>
Cette recherche a &eacute;t&eacute; men&eacute;e aupr&egrave;s des femmes consommatrices de cracks, h&eacute;ro&iuml;nomanes, qui se prostituent dans divers quartiers de Paris, dans le but d'identifier de nouvelles strat&eacute;gies pr&eacute;ventives et soignantes. Ses auteurs estiment en conclusion que l'information ne suffit pas &agrave; garantir l'adoption syst&eacute;matique de comportements &agrave; risques r&eacute;duits, qu'il est essentiel de consid&eacute;rer les pratiques sexuelles et sanguines en relation avec l'environnement dans lequel &eacute;voluent les sujets. D'o&ugrave; la demande d'actions de pr&eacute;vention et de soins s'appuyant sur le travail de rue, sur des structures d'accueil &agrave; seuil bas, sur la cr&eacute;ation de liens fonctionnels entre ces modes d'intervention et les h&ocirc;pitaux dans le but de rendre les soins accessibles aux consommateurs les plus marginalis&eacute;s.<P>
<I>IREP<br>
Institut de Recherche en<br>
Epid&eacute;miologie de la pharmacod&eacute;pendance<br>
45, rue des Saints-P&egrave;res<br>
F 75270 Paris Cedex 06<br>
T&eacute;l&eacute;phone (00331) 46 07 10 29<br>
Fax 46 07 11 29<br></I>

</UL><HR WIDTH=550>

<H4>Les Cahiers noirs de l'HCUG</H4>
<i>Gen&egrave;ve, Dialogai - PVA-Gen&egrave;ve, 1995,  28 p. plus annexes</i><P>
<UL>
Les dysfonctionnements de l'h&ocirc;pital confront&eacute; au sida vus &agrave; travers des t&eacute;moignages d'usagers et de proches. Ce document contient aussi des &eacute;l&eacute;ments de r&eacute;flexion &agrave; propos de l'&eacute;thique hospitali&egrave;re et des rapports soignants-soign&eacute;s et propose des pistes pour am&eacute;liorer la prise en charge des patients VIH et mettre en place une approche plus humaniste et moins exclusivement technique.<P>
<I>Dialogai<br>
Case postale 27<br>
1211 Gen&egrave;ve 7<br>
T&eacute;l&eacute;phone (022) 340 00 00<br>
Fax  340 03 98<P>
PVA Gen&egrave;ve<br>
17, rue Pierre-Fatio<br>
1204 Gen&egrave;ve<br>
T&eacute;l&eacute;phone (022) 700 15 31<br></I>

</UL><HR WIDTH=550>

<H4><i>D&eacute;partement de l'Is&egrave;re</i><br>Programme triennal de lutte contre le sida (1994-1996)</H4>
<i>Bilan descriptif d'activit&eacute; 1994</i><P>
<UL>
La programmation triennale d'un d&eacute;partement fran&ccedil;ais<br>
pilote pour r&eacute;pondre aux besoins et aux manques inventori&eacute;s en 1992 et la description des activit&eacute;s engag&eacute;es l'an dernier.<br>
<I>Office d&eacute;partemental dePr&eacute;vention du Sida<br>
23, avenue Albert 1er de Belgique<br>
F 38100 Grenoble<br>
T&eacute;l&eacute;phone (0033) 76 87 62 40<br>
</I><br>

</UL>
</UL>


</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-332</DOCNO>
<DOCOLDNO>IA017-000178-B042-118</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:4.3 192.33.214.13 19970106050452 text/html 5922
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Revues, journaux</H3><HR>

<H4>Population. Sexualit&eacute; et sciences sociales</H4>
<i>Paris, INED - PUF, 1993,<br>
430 p., 130 FF</i><P>
<UL>
Longtemps exclue du champ des sciences sociales, la sexualit&eacute; retrouve peu &agrave; peu ses dimensions historiques, ethnographiques, anthropologiques, sociologiques. Le biologisme freudien, enracin&eacute; dans une th&eacute;orie universaliste des pulsions sexuelles, ne permettait gu&egrave;re d'envisager le comportement sexuel sous l'angle d'une production sociale. Or, seuls les outils des sciences sociales permettent de comprendre l'h&eacute;t&eacute;rog&eacute;n&eacute;it&eacute; temporelle, spatiale, tribale de ce comportement.<P>
Ce recueil d'&eacute;tudes et de r&eacute;flexion, centr&eacute; autour des r&eacute;sultats de l'Analyse des comportements sexuels en France (ACSF), t&eacute;moigne de l'importance de la recherche en sciences sociales dans le contexte de la pr&eacute;vention du sida. En mod&eacute;lisant l'&eacute;pid&eacute;mie et les comportements sexuels, l'ACSF a permis de cerner l'extr&ecirc;me diversit&eacute; des personnalit&eacute;s sexuelles, de d&eacute;terminer que le rythme des changements de comportements &eacute;taient plus lent que suppos&eacute;, d'identifier les r&eacute;seaux de "confidents" qui permettent aux individus de parler plus facilement de leur sexualit&eacute;.<P>
Un chapitre est consacr&eacute; sp&eacute;cifiquement au sida. Il comporte des &eacute;tudes traitant de la pr&eacute;valence et des facteurs favorisants des comportements de pr&eacute;vention, de la structure d'un mod&egrave;le pr&eacute;visionnel ainsi qu'une critique des mod&egrave;les d'analyse des comportements &agrave; risque qui sugg&egrave;re, en conclusion, des pistes qui pourraient s'appuyer sur la recherche micro-&eacute;conomique et psychosociologique.<P>
<I>RCh</I><P>

</UL><HR WIDTH=550>

<H4>Les r&eacute;seaux de sant&eacute;</H4>
<i>Marseille, Pr&eacute;venir 27, 1994, 194 p., 130 FF</i><P>
<UL>
La notion de r&eacute;seau est singuli&egrave;rement r&eacute;actualis&eacute;e par le cloisonnement induit par des sp&eacute;cialisations de plus en plus pointues. Elle semble r&eacute;pondre aux nouveaux besoins sanitaires et sociaux qui se manifestent aujourd'hui, en particulier dans le secteur complexe de la prise en charge du sida.<br>
Ce num&eacute;ro de Pr&eacute;venir analyse la nature et les diverses fonctions des r&eacute;seaux. Quelle est leur l&eacute;gitimit&eacute;, selon quels modes fonctionnent-ils, quels enjeux sous-tendent-ils?<br>
Face &agrave; la complexit&eacute; de la demande, le r&eacute;seau permet une complexification des r&eacute;ponses. Celles-ci sont nombreuses et diverses en mati&egrave;re de fili&egrave;res de soins comme dans le domaine des r&eacute;seaux de sant&eacute;.<P>
<I>Pr&eacute;venir CVM<br>
Bo&icirc;te postale 92<br>
F 13362 Marseille Cedex 10<br>
T&eacute;l&eacute;phone (0033) 91 23 40 78</I><P>

</UL><HR WIDTH=550>

<H4>Sida: l'ampleur de la pand&eacute;mie. L'impact socio-&eacute;conomique du sida</H4>
<i>Paris, Futuribles, No 194, 1995, 96 p., 70 FF</i><P>
<UL>
Ce num&eacute;ro comporte trois &eacute;tudes. L'une, sign&eacute;e Jean-Baptiste Brunet, analyse les perspectives de l'&eacute;pid&eacute;mie en Europe et conclut, comme hypoth&egrave;se la plus probable, au passage &agrave; une situation end&eacute;mique "avec une extension lente et progressive de l'infection dans la population h&eacute;t&eacute;rosexuelle, associ&eacute; au maintien d'un risque &eacute;lev&eacute; pour les populations qui sont d&eacute;j&agrave; les plus touch&eacute;es". Patrick Festy, dans une &eacute;tude consacr&eacute;e &agrave; l'avenir de la population africaine, insiste sur les difficult&eacute;s sp&eacute;cifiques des perspectives &agrave; long terme. Les modes de contamination rendent al&eacute;atoires les mod&egrave;les calqu&eacute;s sur la situation europ&eacute;enne et, en l'&eacute;tat actuel de l'information, la marge d'incertitude autorise autant &agrave; dire que l'&eacute;pid&eacute;mie se r&eacute;sorbera d'elle m&ecirc;me qu'elle entra&icirc;nera un recul durable, voire l'extinction, de la population africaine. Les cons&eacute;quences globales (d&eacute;mographiques, sociales, &eacute;thiques, &eacute;conomiques) du sida, sur lesquelles se penche un collectif d'auteurs, restent presque aussi incertaines en raison des probl&egrave;mes qu'elles soul&egrave;vent, en particulier ceux li&eacute;s au d&eacute;veloppement &eacute;conomique et ses liens avec la sant&eacute;. La volont&eacute; de faire de la lutte contre le sida une priorit&eacute;, affirm&eacute;e lors du sommet de Paris du 1er d&eacute;cembre 1994, se traduira-t-elle par des r&eacute;ponses ad&eacute;quates sur le terrain?<P>
<I>RCh<P>
Diffusion en Suisse:<br>
Librairie du Boulevard<br>
35, rue de Carouge<br>
1205 Gen&egrave;ve<br>
T&eacute;l&eacute;phone (022) 328 70 54<br>
Fax 780 62 31<P></I>


</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:4.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-333</DOCNO>
<DOCOLDNO>IA017-000178-B042-128</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:4.4 192.33.214.13 19970106050501 text/html 3009
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Mat&eacute;riel d'information</H3><HR>

<H4>Outils de pr&eacute;vention du sida en Communaut&eacute; fran&ccedil;aise</H4>
<i>Bruxelles, Agence Pr&eacute;vention Sida, 1995, 28 p.</i><P>
<UL>
Un catalogue complet des outils de pr&eacute;vention  recommand&eacute;s en Belgique francophone &agrave; destination des relais (enseignants, &eacute;ducateurs, relais m&eacute;dicaux et sociaux),  et du public (jeunes, adultes, personnes s&eacute;ropositives et leur entourage).<P>
<I>Agence de Pr&eacute;vention du Sida<br>
4&eacute;, rue de H&&&&aelig;Elig;elig;Elig;erne<br>
B 1040 Bruxelles<br>
T&eacute;l&eacute;phone (0..) 2 627 75 11<br>
Fax  2 627 75 12<br></I>

</UL><HR WIDTH=550>

<H4>M&eacute;mento sida, abr&eacute;g&eacute;</H4>
<i>Bruxelles, Infor Sida, 1994, 28 p., gratuit</i><P>
<UL>
Imprim&eacute; sur des fiches cartonn&eacute;es, facile &agrave; consulter, &agrave; la fois complet et succinct, ce M&eacute;mento aidera tous ceux qui recherchent les meilleures r&eacute;ponses, &agrave; la fois claires et nuanc&eacute;es.<P>

</UL><HR WIDTH=550>

<H4>L'accueil de l'enfant s&eacute;ropositif</H4>
<i>Montpellier, R&eacute;seau VIH-Enfant, 1995, 80 p., gratuit en payant les frais d'envoi</i><P>
<UL>
Cette brochure, prim&eacute;e au concours Troph&eacute;es Hospitalia 1994, est destin&eacute;e aux travailleurs sociaux et aux personnels des structures d'accueil de l'enfance. Dans des chapitres qui traitent des parents, des enfants, des lieux de vie, de l'accueil, du secret professionnel, elle r&eacute;pond aux principaux probl&egrave;mes et aborde aussi les questions r&eacute;ponses qui demandent d&eacute;lib&eacute;ration et examen de cas en cas. Un outil exemplaire pour pr&eacute;venir les d&eacute;rapages &agrave; l'&eacute;cole et dans les espaces sociaux susceptibles de se trouver "confront&eacute;s" &agrave; des enfants s&eacute;ropositifs.<P>
Diffusion:<br>
<I>Arcat Sida<br>
13, boulevard de Rochechouart<br>
F 75009 Paris<br>
T&eacute;l&eacute;phone (00331) 49 70 85 90<br>
Fax 49 70 85 99<P></I>

</UL>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-334</DOCNO>
<DOCOLDNO>IA017-000178-B042-139</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:5 192.33.214.13 19970106050509 text/html 9194
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:31 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Videos (Deutsch)</H3><HR>

<H4>Ich lebe gern, ich sterbe gern</H4>
<i>Claudia Acklin, CH 1989, 75 Min.</i><P>
<UL>
Der Name Andr&eacute; Ratti wird in unserem Land (und vielleicht auch ein bisschen dar&uuml;ber hinaus) mit dem Thema Aids und Aids-Hilfe verbunden bleiben, solange dieses eines ist. Er hat im Juli 1985 mit seinem &Ouml;ffentlichen Bekenntnis in der Tagesschau "Ich... bin 50 Jahre alt, homosexuell, und ich habe Aids" der unheimlichen Krankheit ein Gesicht gegeben, hat sie medienf&auml;hig gemacht. Und von da an lebte Ratti mit und gegen Aids und auf den absehbaren Tod hin.<P>
Wie er das tat, versuchte Claudia Acklin von Bekannten, Freunden Rattis zu erfahren. Denn sie hat ihn selber nicht gekannt, ist erst nach seinem Tod auf den "Mythos Ratti" aufmerksam geworden. Ihn zu ergr&uuml;nden, ist sie angetreten. Gelungen ist es ihr nicht: Zwar gibt es in ihrem Film wohltuend sachliche, relativierende &Auml;usserungen &uuml;ber ihn, insgesamt aber "weht da etwas zuviel Weihrauch", wie es ein Befragter selber sagt.<P>
Ratti hat sein Leben und sein Sterben inszeniert, er mochte die Pose und die grosse Geste. Claudia Acklin, so ist zu vermuten, ist ihm (posthum) auf den Leim gekrochen.<P>
Ratti aber h&auml;tte ihr Film vermutlich gefallen.<P>
Zu beziehen bei:<br>
<I>Megaherz<br>
Weststr. 77<br>
8003 Z&uuml;rich<br>
Tel. 01 462 86 80</I><P>

</UL><HR WIDTH=550>

<H4>... und das Leben geht weiter ... (And the Band Played On)</H4>
<i>Roger Spottiswood (Regie), mit Matthew Modine, Richard Gere, Phil Collins<br>
CONNEXION Film, VMP VIPRO Video, 1994, 135 Min., Fr. 39.90</i><P>
<UL>
Nach 1977 treten seltsame Krankheitsf&auml;lle auf: Menschen sterben an Krankheiten, die normalerweise harmlos sind oder bis anhin nur unter ganz bestimmten Bedingungen auftraten. Anfangs der 80er Jahre nehmen die Erkrankungen sprunghaft zu, und vor allem homosexuelle M&auml;nner sind davon betroffen.<P>
Die Gesundheitsbeh&ouml;rde sieht sich zum Handeln veranlasst: Sie beruft ein Team von Wissenschaftlern, das mit wenig Mitteln das Ausmass der Epidemie, m&ouml;gliche Ursachen und Therapien untersuchen soll. Mit grossem Enthusiasmus nimmt das Team die Arbeit auf. Schon bald muss es jedoch erkennen, dass die Krankheit ihre T&uuml;cken hat: Die republikanische Regierung bleibt w&auml;hrend Jahren tatenlos. Und die am h&auml;ufigsten Betroffenen stellen sich quer, weil sie hinter den be&auml;ngstigenden Meldungen reaktion&auml;re Propaganda wittern, die ihnen die neu gewonnene sexuelle Freiheit vermiesen soll.<P>
Die Verfilmung des gleichnamigen Buches von Randy Shilts ist recht gut gelungen ist. Dass dabei das Geschehen aus der Sicht der Wissenschaftlergruppe dargestellt ist, verleiht dem Film die n&ouml;tige Distanz.<P>
Stellenweise wird leider etwas zu dick aufgetragen, so dass ernste Szenen Gefahr laufen, l&auml;cherlich zu wirken. Der Film ist nicht zuletzt auch darum sehenswert, weil er einen der ersten Versuche der Filmindustrie Hollywoods darstellt, das heikle Thema zu verfilmen. Pikant dabei: Auf der Leinwand erscheinen SchauspielerInnen, die bis dahin Himmel und H&ouml;lle in Bewegung gesetzt hatten, nicht mit dem Aids- respek-tive dem Schwulenmilieu in Verbindung gebracht zu werden ...<P>
<I>Lars Hangartner<br>
Erh&auml;ltlich im Fachhandel</I><P>

</UL><HR WIDTH=550>

<H4>Zero Patience</H4>
<i>John Greyson, Zero Patience Productions Ltd., Canada, 1993, 97 Min.,<br>
ú 16.- und ú 3.- Versand</i><P>
<UL>
Ein Musical &uuml;ber ein so ernstes Thema wie Aids? Und dazu erst noch eines, das zum Lachen ist, um nicht zu sagen: zum Totlachen? Das h&ouml;rt sich provozierend geschmacklos, politisch unkorrekt an. In der Tat geniesst es "Zero Patience" f&ouml;rmlich, Tabus zu verletzen. Da reden etwa zwei Hinterteile miteinander, da singen drei M&auml;nner unter der Dusche &uuml;ber das Problem einer pl&ouml;tzlichen Erektion, da tanzen Blutk&ouml;rperchen einen ansteckenden Conga - als ob das die selbstverst&auml;ndlichste Sache der Welt w&auml;re.<P>
Obschon aber alles eine absolut entwaffnende Ironie umspielt, ist das Anliegen des Films sehr viel ernster (und aufrichtiger) als in so manchem "seri&ouml;sen" Betroffenheitsdrama &agrave; la Hollywood.<P>
Denn indem Autor und Regisseur John Greyson Tabus bricht, bricht er auch eine Lanze: Er befreit die Thematik vom moralisierenden Zeigefinger und gibt so den Blicke frei auf ein Virus, das sowohl bei den Nichtinfizierten als auch bei Betroffenen Scheuklappen zur Folge hat.<P>
Am Anfang des Films lesen Schulkinder aus "Tausendundeine-Nacht" vor. In der Folge nimmt der Film selbst, obwohl in der Gegenwart spielend, immer m&auml;rchenhaftere Z&uuml;ge an. Im Mittelpunkt steht Sir Richard Burton, der verb&uuml;rgte viktorianische Sexologe, der unsterblich ist, seit er vom Jungbrunnen getrunken hat und jetzt am Naturgeschichtlichen Museum Tiere ausstopft. F&uuml;r eine Ausstellung &uuml;ber die Urspr&uuml;nge von Aids folgt er den Spuren jenes Mannes, der die Seuche nach Amerika eingeschleppt haben soll. Diesen "Patient Zero", wie ihn die Mediziner nennen, stellt sich Burton als gewissenlosen Triebmenschen vor - bis er leibhaftig vor ihm steht.<P>
In "Zero Patience" werden Zeiten, sexuelle Ausrichtungen und Ideologien ziemlich wild durcheinandergewirbelt. Das erfordert ein Publikum mit mehr als null Geduld, soll es den irren Twists bis zum Schluss folgen.<P>
Nicht minder kunterbunt mutet der Stilmix an: Es ist, als h&auml;tten sich Monty Python, Esther Williams, Jarman, Cocteau und Woody (aus "Everything You Always Wanted To Know About Sex") zu einer Wohlt&auml;tigkeits-Travestieparty mit dem Motto "The HIV Horror Picture Show" eingefunden.<P>
Unter dem Flitter stecken jedoch ungeschminkte Wahrheiten: wie die Medien unsere Sicht von Aids pr&auml;gen oder wie schnell wir bereit sind, jemanden zum S&uuml;ndenbock zu stempeln, um alle Verantwortung von uns weisen zu k&ouml;nnen. Aids, das macht "Zero Patience" deutlich, ist letztlich auch eine Geschichte von "Zero Tolerance".<P>
Roland Vogler,<I> "Tages-Anzeiger" vom 15.5.1995</I><P>
<I>Bezugsadresse:<br>
Dangerous to know<br>
66 Offley Road<br>
Kennington Oval<br>
GB - London SW9 0LS<br>
<P></I>

</UL><HR WIDTH=550>

<H4>The Karate Kids in Goldtooth. An Adventure Film on Substance Abuse Prevention</H4>
<i>Derek Lamb und Kai Pindal<br>
Street Kids International, Toronto, 1995, 27 Min., $ 80.-</i><P>
<UL>
Die Geschichte vom kleinen Jungen Karate und seiner Schwester Nina ber&uuml;hrt und w&uuml;hlt auf. Es ist die Geschichte von "Street Kids", in der Alkohol, Drogen, Prostitution zum Alltag geh&ouml;ren. Gef&auml;hrdete Jugendliche, vor allem in L&auml;ndern der Dritten Welt, sollen angeregt werden, &uuml;ber ihr Leben auf der Strasse nachzudenken und zu reden.<P>
Der b&ouml;se Dealer "Goldzahn" verf&uuml;hrt den Strassenjungen Karate mit L&ouml;sungsmitteln, Pillen und Gratis-Joints, bis er ihn in Abh&auml;ngigkeit gefangen hat. Resozialisierungsversuche scheitern, die Warnungen seiner Schwester Nina will er nicht h&ouml;ren. Karate st&uuml;rzt immer weiter ab und kann sich nicht mehr aus den F&auml;ngen von Goldzahn befreien.<P>
Erst nachdem Karate realisiert, dass Goldzahn seine Schwester in die Prostitution getrieben hat, setzt er sich zur Wehr. F&uuml;r seine Schwester kommt die Rettung zu sp&auml;t - sie stirbt. Karate - gel&auml;utert - baut sich ein neues Leben auf, diesmal ohne Drogen.<P>
Der Film ist f&uuml;r europ&auml;ische Augen sehr plakativ, vereinfachend und teilweise moralisierend. Die Welt ist aufgeteilt in B&ouml;se und Gute, Verf&uuml;hrer und Verf&uuml;hrte, Opfer und T&auml;ter. Didaktisch gut und informativ ist der Begleittext auf der Kasetteninnenseite. Die Ben&uuml;tzer erhalten Hinweise zur Vorf&uuml;hrung, z. B. dass der Film in eine Diskussion eingebettet sein sollte. Anregungen zur Diskussion, Startfragen und allgemeine &Uuml;berlegungen zur Suchtpr&auml;vention stehen alle unter dem Motto der Produzenten:<br>
<I>"Unser Job ist es, junge Menschen zu ermutigen, Selbstverantwortung zu &uuml;bernehmen."</I><P>
<I>Claus Herger<P>
Zu beziehen bei:<br>
Street Kids International<br>
398 Adelaide Street West,<br>
Suite 1000, 10th floor<br>
Toronto<br>
Canada M5V 1S7<br>
<P>
</I>

</UL>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:4.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-335</DOCNO>
<DOCOLDNO>IA017-000178-B042-152</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:6 192.33.214.13 19970106050521 text/html 14265
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:40 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Vid&eacute;os (Fran&ccedil;ais)</H3><HR>

<H4>Temps d'amour</H4>
<i>Production: Minist&egrave;re de l'Education Nationale<br>
R&eacute;alisation: Patrick Volson<br>
VHS SECAM couleur,<br>
34 minutes, 1994</i><P>
<UL>
Ce film se propose de sensibiliser les adolescents &agrave; l'amour, &agrave; la relation &agrave; l'autre et &agrave; la nouvelle responsabilit&eacute; qui d&eacute;coule de la transmissibilit&eacute; du VIH. Il est accompagn&eacute; d'un riche livret p&eacute;dagogique.<br>
Le sc&eacute;nario est construit de mani&egrave;re &agrave; permettre aux adolescents d'exprimer leur ressenti - le ras de bol des uns, la peur des autres, les diff&eacute;rences de sensibilit&eacute; entre filles et gar&ccedil;ons...  -  et &agrave; inscrire le message de responsabilit&eacute; dans la progression dramatique d'une histoire impliquant les jeunes eux-m&ecirc;mes. Une approche de bon augure, la communication d&eacute;livr&eacute;e par les pairs &eacute;tant normalement mieux int&eacute;gr&eacute;e que les discours injonctifs.   Les interrogations qui charpentent le film, le langage dominant, appartiennent aux lyc&eacute;ens; le savoir des sp&eacute;cialistes adultes n'intervient que ponctuellement, par le biais d'interviews r&eacute;alis&eacute;s par les adolescents.<br>
Pourtant, la cr&eacute;dibilit&eacute; de cette habilet&eacute; p&eacute;dagogique pr&eacute;sente quelques failles. L'officialit&eacute; du discours peine &agrave; se dissimuler, les difficult&eacute;s ou les r&eacute;voltes des protagonistes semblent souvent n'avoir d'autre r&ocirc;le que de servir &agrave; une r&eacute;cup&eacute;ration de trop bon aloi. C'est lisse, trop souvent superficiel,  parfois plus proche du registre de la publicit&eacute; que de celui des interrogations existentielles qu'impliquerait la gravit&eacute; du sujet. Les acteurs repr&eacute;sentent aussi une cat&eacute;gorie d'adolescents plut&ocirc;t privil&eacute;gi&eacute;e: celle qui a un bon savoir de base, celle dont les parents sont des interlocuteurs, celle qui ne semble avoir gu&egrave;re de raison de zoner. Est-ce vraiment l&agrave; qu'il convient de cibler en priorit&eacute;? Ce film oublie aussi l'homosexualit&eacute; - curieuse pr&eacute;vention que celle qui fait ressentir leur exclusion aux ados gays -  et... les personnes touch&eacute;es!  Les spectateurs n'auront d'autre vision de la s&eacute;ropositivit&eacute; que celle de la peur, la peur d'un des protagonistes d'avoir &eacute;t&eacute; contamin&eacute; suite &agrave; un rapport non prot&eacute;g&eacute;!  La crainte du voyeurisme peut-elle justifier cette mise &agrave; distance du r&eacute;el humain de l'&eacute;pid&eacute;mie?<P>
<I>RCh</I><P>
<I>Minist&egrave;re de l'Education Nationale<br>
Direction des Lyc&eacute;es et Coll&egrave;ges<br>
F 75000 Paris<br>
T&eacute;l&eacute;phone (00331)  49 55 11 18</I><P>

</UL><HR WIDTH=550>

<H4>Sida, paroles de l'un &agrave; l'autre</H4>
<i>Production: M de S Films,<br>
R&eacute;alisation: Paule Muxel, Bertrand de Solliers<br>
Film 35 mm, disponible en cassette vid&eacute;o VHS PAL ou SECAM, 73 minutes, 1993,<br>
100 FF.</i><P>
<UL>
Pour les conditions d'obtention du film, contacter l'adresse ci-dessous (une copie du dossier de presse peut &ecirc;tre demand&eacute;e &agrave; Sida Info Doc)<br>
"...et ce film nous a empoign&eacute;, nous a emport&eacute;. Il y a mille fa&ccedil;ons de regarder les gens, vous savez, et il y a mille fa&ccedil;ons de les filmer. Godard disait qu'il y avait une morale dans la fa&ccedil;on de placer la cam&eacute;ra. Ce film est magnifique parce qu'on ne voit pas des individus mais des personnes. Tout cela est montr&eacute; avec une gr&Acirc;ce, une compr&eacute;hension qui font na&icirc;tre la tendresse. Et tout &agrave; coup, on se sent intime avec ces gens l&agrave;. Ils sont nous."<br>
C'est Jeanne Moreau qui s'exprimait en ces termes &agrave; propos de "Sida, paroles de l'un &agrave; l'autre" lors d'une intervention sur France 3, fin novembre 1993. Et il n'est pas de meilleurs termes pour exprimer la qualit&eacute; de ce film qui donne la parole &agrave; des personnes s&eacute;ropositives. Et qui la donne pleinement, sans effets de montage, sans fioritures, sans trucage et, surtout, sans ce rationnement insupportable du temps, &agrave; la fa&ccedil;on des clips. Un film qui laisse toute sa place &agrave; l'&eacute;motion, &agrave; la r&eacute;volte, &agrave; la col&egrave;re, &agrave; la dignit&eacute;, &agrave; la peur, &agrave; la vie. Et qui interroge aussi avec une force rassurante sur les mirages et la superficialit&eacute; d'une soci&eacute;t&eacute; qui &eacute;crase et exclut tout ce qui ne se calque pas sur ses mythes pr&eacute;fabriqu&eacute;s. Une le&ccedil;on sur le sens de l'existence, &agrave; l'oppos&eacute; de l'id&eacute;ologie des "gagnants", et qui met aussi en pi&egrave;ces les discours normatifs de certains experts en pr&eacute;vention. Est-ce parce que tout devient horriblement compliqu&eacute; et difficile avec la s&eacute;ropositivit&eacute; que le regard devient plus ac&eacute;r&eacute;, la sensibilit&eacute; plus forte, l'horizon plus large? Comme si la vie prenait soudain sa v&eacute;ritable dimension quand la mort n'est plus occult&eacute;e. Un film qui donne enfin &agrave; r&eacute;fl&eacute;chir et qui, &agrave; ce titre, devrait &ecirc;tre consid&eacute;r&eacute; comme un instrument essentiel de communication par les relais de pr&eacute;vention, y compris et surtout dans les &eacute;coles.<P>
<I>RCh</I><P>

</UL><HR WIDTH=550>

<H4>Une histoire qui n'a pas de fin</H4>
<i>Production: M de S Films/Plan&egrave;te Cable<br>
R&eacute;alisation: Paule Muxel, Bertrand de Solliers<br>
Film 35 mm, disponible aussi en cassette vid&eacute;o VHS PAL ou SECAM sous-titr&eacute;e en anglais, 100 minutes, 1994, 100 FF.</i><P>
<UL>
Pour les conditions d'obtention du film, contacter l'adresse ci-dessous (une copie du dossier de presse peut &ecirc;tre demand&eacute;e &agrave; Sida Info Doc)<br>
En adoptant une approche analogue &agrave; celle de "Sida, paroles de l'un &agrave; l'autre", ce film donne la parole &agrave; des "professionnels" en rapport avec des personnes touch&eacute;es par le sida: infirmiers, aides-soignants, assistants sociaux, m&eacute;decins, chercheurs. Le tournage, tr&egrave;s sobre, est centr&eacute; sur les seuls intervenants: paroles, silences, mouvements du visage. Tous sont film&eacute;s dans une voiture en mouvement.<br>
Le temps pour chacun d'essayer de dire son ressenti, d'exprimer  les doutes, les remises en question, les col&egrave;res qu'alimentent les contacts avec les patients et la confrontation avec la logique technique des structures de soins. La vari&eacute;t&eacute; des t&eacute;moins, de par leurs fonctions et de par leurs sensibilit&eacute;s, donne une authenticit&eacute; qui &eacute;meut et questionne tout &agrave; la fois. Intensit&eacute; et difficult&eacute; de la relation avec les malades, peur, exclusion, tentation du jugement, interrogation sur le soigner et le gu&eacute;rir, le curatif et le palliatif. Probl&egrave;me aussi pour le m&eacute;decin qui voit son d&eacute;sir de puissance battu en br&egrave;che par l'&eacute;chec annonc&eacute;, &eacute;chec si difficilement pronon&ccedil;able. Et quel sens donner &agrave; ces morts, ces deuils sans fin?  Questions &eacute;thiques aussi, par exemple &agrave; propos des toxicomanes "&agrave; qui on ne donne jamais la parole alors qu'on n'arr&ecirc;te pas de parler d'eux". Ou &agrave; propos du m&eacute;decin face &agrave; une personne s&eacute;ropositive qui aurait un comportement dangereux pour son partenaire et refuserait de l'avertir.<br>
Un praticien nous dit le chemin qu'il a parcouru avec un de ses patients se trouvant dans cette situation, chemin complexe et compr&eacute;hensif, et qui "ne peut pas &ecirc;tre de l'ordre de la d&eacute;lation".<br>
Un film pr&eacute;cieux pour aider soignants et accompagnants &agrave; mieux se situer dans l'univers d'une maladie incurable et r&eacute;voltante. Et que l'on peut qualifier sans exag&eacute;ration d'outil de base &agrave; toute formation dans ce domaine.<P>
<I>RCh</I><P>

</UL><HR WIDTH=550>

<H4>Sida, paroles de familles</H4>
<i>Production: M de S Films<br>
R&eacute;alisation: Paule Muxel,<br>
Bertrand de Solliers<br>
Film 35 mm, disponible aussi en cassette vid&eacute;o VHS PAL ou SECAM sous-titr&eacute;e en anglais, 100 minutes, disponible d&egrave;s juillet 1995, prix &agrave; d&eacute;terminer (env. 100 FF).</i><P>
<UL>
Pour les conditions d'obtention du film, contacter l'adresse ci-dessous (une copie du dossier de presse peut &ecirc;tre demand&eacute;e &agrave; Sida Info Doc)<br>
Ce film est le dernier de la trilogie de Paule Muxel et Bertrand de Solliers. Il sera disponible en juillet 1995. L'introduction au synopsis dit: "Il s'agit de rencontrer des familles toutes impliqu&eacute;es directement par la disparition d'un de leurs proches, de la maladie du sida. Questions autour de l'absence, des liens de la filiation, de la m&eacute;moire et de la relation humaine, du sens de la vie et de la mort. Ces personnes nous font partager leurs r&eacute;flexions sur la culpabilit&eacute; individuelle et collective, sur leur sens de l'accompagnement, de leur lutte pour la vie, &agrave; chaque fois &agrave; partir de leur exp&eacute;rience personnelle, de ce qui a &eacute;t&eacute; travers&eacute;, &eacute;prouv&eacute;, compris."<P>
<I>M de S Films<br>
23, rue Etienne Marcel<br>
F 75001 Paris<br>
T&eacute;l&eacute;phone (00331) 40 39 94 39<br>
Fax 40 39 94 59</I><P>

</UL><HR WIDTH=550>

<H4>Le Chant des Pistes, M&eacute;decines traditionnelles, cultures et sida<br>
S&eacute;minaire de Bamako, f&eacute;vrier 1994</H4>
<i>Production: OPALS, CNRS (URA 882/UPR 3121),<br>
Le Chant des Pistes, R&eacute;alisation: A. Epelboin, M. Haby</i><P>
<UL>
Ce film pr&eacute;sente des extraits d'interventions et des interviews de chercheurs, de m&eacute;decins, de gu&eacute;risseurs, de th&eacute;rapeutes traditionnels venant du Cameroun, du Congo, de la C&ocirc;te d'Ivoire, de France, du Gabon et du S&eacute;n&eacute;gal r&eacute;unis en s&eacute;minaire &agrave; Bamako. Rencontre surprenante et qui t&eacute;moigne de l'urgence &agrave; utiliser les gu&eacute;risseurs &agrave; la fois comme relais de la pr&eacute;vention (leaders d'opinion qui touchent 85% de la population) et comme compl&eacute;ment d'une m&eacute;decine allopathique mal implant&eacute;e et pauvre en moyens. Un film dont la vision ne peut &ecirc;tre que vivement recommand&eacute;e &agrave; toute personne impliqu&eacute;e dans la coop&eacute;ration avec des pays de l'Afrique subsaharienne.<P>
<I>RCh</I><P>

</UL><HR WIDTH=550>

<H4>Pour cause de sida</H4>
<i>Production:  WIN - OPALS<br>
R&eacute;alisation: Benedicte Gelle, Hubert Martin, Dominique Nasplezes, Fred Sekyewa<br>
Octobre 1994</i><P>
<UL>
L'Ouganda, c'est aujourd'hui environ 1,5 millions de personnes infect&eacute;es par le VIH sur 17 millions d'habitants. C'est aussi un pays d'Afrique qui a &eacute;t&eacute; parmi les premiers &agrave; prendre conscience de la gravit&eacute; de l'&eacute;pid&eacute;mie et de la n&eacute;cessit&eacute; d'une action pr&eacute;ventive. Ce film propose un bilan de la situation en 1994, en mettant en avant le d&eacute;sastre humain g&eacute;n&eacute;r&eacute; par le sida qui n'&eacute;pargne l&agrave;-bas aucune famille et dont les effets destructeurs m&eacute;riteraient d'interpeller les responsables politiques au plus haut niveau. Les interventions humanitaires, et en particulier celle de M&eacute;decins du Monde, sont infiniment pr&eacute;cieuses mais ne sauraient r&eacute;parer les d&eacute;g&Acirc;ts &eacute;conomiques et sociaux (villages d&eacute;peupl&eacute;s, &eacute;lites d&eacute;cim&eacute;es, cultures abandonn&eacute;es) du sida. V&eacute;ritable cercle infernal car, comme le souligne un des intervenants de ce film, mis&egrave;re et sida sont synonymes et, sans aide mat&eacute;rielle, il sera impossible de faire changer les comportements facilitant la propagation du VIH. Un bon film de sensibilisation, qui ne fait d'ailleurs pas que dans la noirceur et montre les extraordinaires capacit&eacute;s d'entraide et de mobilisation de gens pourtant d&eacute;pourvus de presque tout moyen.
<P>
<I>RCh<P>
OPALS<br>
Organisation Pan-Africaine de lutte contre le sida<br>
15-21, rue de l'Ecole de<br>
M&eacute;decine<br>
F 75006 Paris<br>
T&eacute;l&eacute;phone (00331) 43 26 72 28<br>
Fax 43 29 70 93</I><P>

</UL><HR WIDTH=550>

<H4>L'h&eacute;patite B, on peut s'en passer</H4>
<i>Production:  CFA et SB SmithKline Beecham, Unit&eacute; vaccins 1994</i><P>
<UL>
Ce film tr&egrave;s court, tourn&eacute; dans le cadre de la campagne fran&ccedil;aise "Camion Forum H&eacute;patite B", met l'accent sur l'actualit&eacute; d'une vaccination contre l'h&eacute;patite B, non seulement des populations jug&eacute;es jusqu'ici &agrave; haut risque, mais des nouveaux-n&eacute;s et de  l'ensemble des adolescents. L''ignorance de ces derniers sur cette maladie est illustr&eacute;e par les interviews introductives.<P>
<I>CFA<br>
Comit&eacute; Fran&ccedil;ais pour<br>
l'Adolescence<br>
33, rue de la Chapelle<br>
F 75018 Paris<br>
T&eacute;l&eacute;phone (00331) 42 09 99 18</I><P>

</UL>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-336</DOCNO>
<DOCOLDNO>IA017-000178-B042-162</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:7 192.33.214.13 19970106050530 text/html 3715
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:05:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3>Theater</H3><HR>

<H4><I>Harvey Fierstein, </I><br>Leo und ich</H4>
<i>aus der Trilogie "Safe Sex"<br>Eine Produktion der Theater-Falle Basel, Regie: Michael Luiser</i><P>
<UL>
Der "Krimi" ist gelaufen, auf der Leinwand folgt der Abspann, begleitet von typischer Filmmusik. So endet "Leo und ich" von der TheaterFalle Basel, und mit Fernsehwerbung und Film hat das Theaterst&uuml;ck auch begonnen.<br>
Eine Frau f&auml;hrt mit ihrem Kind vor ein Haus in Basel und verschwindet im Eingang. Jetzt verschwindet auch die Filmleinwand, und man sieht die Frau auf der B&uuml;hne in einem Wohnzimmer. Es ist die Wohnung von Leo, der an Aids gestorben ist. Marion, die Frau, war mit Leo verheiratet. Sp&auml;ter lebte Leo mit seinem Freund Arthur zusammen, der nun ebenfalls das Zimmer betritt. Die beiden Hinterbliebenen wissen nicht recht, wie sie miteinander umgehen sollen. Wer hat mehr Anspruch auf Leo - die Ehefrau, von der sich Leo getrennt hat, oder Arthur, der Leo gepflegt und beim Sterben begleitet hat?<P>
Im Publikum weiss man zun&auml;chst nicht so genau, wie man seine Sympathien verteilen soll. Ist Marion denn nicht immer noch beleidigt, weil ihr Mann sich mit einem anderen Mann davonmachte? Am Schluss sieht alles anders aus, doch diese Pointe darf man hier nicht verraten. Denn "Leo und ich" des Amerikaners Harvey Fierstein ist ein "well made play", eine spannungsvoll aufgebaute Stunde Theater mit guten Rollen. Effektvoll ist auch die Kombination von Theater und Film.<P>
Dass "Leo und ich" im Rahmen der Aids-Pr&auml;vention und als "Ermutigung zum Leben" angepriesen wird, mag seltsam anmuten. Im Grunde genommen handelt dieses  St&uuml;ck von der Not "inexistenter" schwuler Beziehungen. Es geht in diesem St&uuml;ck nicht zentral um Aids, sondern es geht um Menschen und um den Umgang mit verschiedenen Tabuthemen. So k&auml;mpft Arthur, Leo's Freund, um die Existenz seiner Beziehung zu Leo. Als schwuler Mann erh&auml;lt nicht er die Kondolenzkarten, sonders Leos Ex-Frau. Leos Tod f&uuml;hrt Arthur mit aller Deutlichkeit vor Augen, dass seine Beziehung, seine Liebe zu Leo nicht zur Kenntnis genommen bzw. verdr&auml;ngt und tabuisiert wird. Er selbst scheint in dieser Gesellschaft gar nicht zu existieren.<P>
Schon allein die Auseinandersetzung mit dieser Thematik verstehe ich als ein St&uuml;ck Aids-Pr&auml;vention.<br>
Das St&uuml;ck richtet sich an Erwachsene und Jugendliche ab 15 Jahren. Durch den Inhalt wird das Erleben nicht auf die intellektuelle Ebene der Diskussion gelenkt, sondern auf das Heraussp&uuml;ren der eigenen Betroffenheit.<P>
<I>Marcello Schumacher</I><P><br>
Das St&uuml;ck "Leo und ich" kann &uuml;ber die TheaterFalle Basel,  Ruth Widmer, Wiesendamm 24, 4057 Basel, gekauft werden.<P>

</UL>
</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-337</DOCNO>
<DOCOLDNO>IA017-000178-B042-172</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:8.1 192.33.214.13 19970106050540 text/html 5686
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:06:01 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>



<H3><I>PD Dr. med. M. Opravil</I><br>&Uuml;bersicht &uuml;ber therapeutische Studien bei HIV-Infizierten in der Schweiz</H3>
<i>Abteilung Infektionskrankheiten und Spitalhygiene, Universit&auml;tsspital, 8091 Z&uuml;rich</i><P>
<UL>

<H4>Delavirdine-Kombinationsstudie [Z&uuml;rich, Genf]<P></H4>
Multinationale, randomisierte, plazebokontrollierte Phase III-Studie mit dem Nicht-Nukleosid-Reverse-Transkriptase-Inhibitor Delavirdine (U-90152), kombiniert mit Zidovudin (AZT).<br>
Dauer 24 Monate. Einschluss: Patienten mit symptomatischer HIV-Infektion und CD4-Zellen <350/´l, mit oder ohne vorg&auml;ngige AZT-Therapie.<P>

<H4>Saquinavir-Kombinationsstudie bei HIV-Infektion [ausgew&auml;hlte Zentren]</H4>
Multinationale, randomisierte, plazebokontrollierte Phase III-Studie mit dem Proteasehemmer Saquinavir (Ro 31-8959) in4Armen:AZT/AZT+DDC/ AZT+Saquinavir/AZT+DDC+Saquinavir. Dauer mind. 20 Monate.<br>
Einschluss: Patienten mit CD4-Zellen 50-350/´l, die noch nie eine anti-HIV-Therapie oder nur kurz AZT (<16 Wochen) erhielten.<P>

<H4>Lamivudine/Loviride/Zidovudin-Kombinationsstudie bei HIV-Infektion</H4>
Multinationale, randomisierte, plazebokontrollierte Phase III-Studie in<br>
3 Armen (Verh&auml;ltnis 1:2:1):AZT/AZT +Lamivudine (3TC)/AZT+Lamivudin + Loviride (R089439) &uuml;ber 12 Monate. Einschluss: Patienten mit CD4-Zellen 25-250/´l, die entweder noch nie oder  mit AZT (+ fakultativ zus&auml;tzlich DDC oder DDI) behandelt wurden.<P>

<H4>Stavudine bei HIV-Infektion [alle Zentren]</H4>
Offene Verabreichung von Stavudine (d4T) bei Patienten, bei denen AZT, DDI und DDC nicht vertragen wurden, kontraindiziert sind, oder darunter eine Verschlechterung der HIV-Infektion auftrat ("named patient program").<P>

<H4>Prophylaxe der oropharyngealen Candidiasis mit Fluconazol<br>[Lausanne, Bern]</H4>
Prospektive, randomisierte, plazebokontrollierte Studie, die den Einfluss von Fluconazol (1 x pro Woche) auf Rezidivrate der Candidiasis und auf die Resistenzentwicklung untersucht.<P>

<H4>Therapie der resistenten oropharyngealen Candidiasis mit Fluconazol [Lausanne, Bern]</H4>
Prospektive Pilotstudie, die Wirksamkeit und Vertr&auml;glichkeit von hochdosiertem Fluconazol bei Candidiasis untersucht, die auf die &uuml;blichen Dosen von Fluconazol resistent ist.<P>

<H4>Orales Ganciclovir bei CMV-Retinitis [ausgew&auml;hlte Zentren]</H4>
Prospektive Studie mit oralem Ganciclovir (3 g/Tag) bei Patienten, die sich in der Dauersuppressionsphase der Therapie der CMV-Retinitis befinden und bei denen die intraven&ouml;se Gabe der Medikamente nicht m&ouml;glich ist.<P>

<H4>Ern&auml;hrungsstudie im Bereich HIV [Basel]</H4>
An HIV-infizierten Personen mit einem K&ouml;rpergewicht im unteren Normbereich oder Gewichtsverlust soll untersucht werden, wie sich Ern&auml;hrungsberatung und Nahrungsmittelzus&auml;tze auf Krankheitsverlauf, Eiweissstoffwechsel und Lebensqualit&auml;t auswirken.<P>

<H4>HIV "Non-Progressoren"-Studie</H4>
Prospektive multizentrische Studie zur Untersuchung medizinischer, psychosozialer und biologischer Aspekte der HIV-Infektion bei asymptomatischen, seit l&auml;nger als 6 Jahren infizierten Personen ohne retrovirale Therapie mit z. Z. >500 CD4-Zellen/´l. Das Ziel ist die Identifizierung von Faktoren, die den g&uuml;nstigen Verlauf erkl&auml;ren k&ouml;nnten. Information &uuml;ber Tel. 077-35 03 76 (Mo-Fr, 9-19 Uhr).<P>

<H4>Gyn&auml;kologische Vorsorgeuntersuchungen bei HIV-positiven Frauen</H4>
Prospektive Erfassung der gyn&auml;kologischen Erkrankungen (besonders Cervixcarcinom) bei Patientinnen der Schweiz. HIV-Kohortenstudie durch j&auml;hrliche Untersuchung in Zusammenarbeit mit Frauen&auml;rzten. Die betroffenen Patientinnen sollen einer fr&uuml;hzeitigen Behandlung zugef&uuml;hrt werden.<P>

<H4>K-639 Proteasehemmer-Kombinationsstudie bei bisher unbehandelten HIV-Infizierten [Z&uuml;rich]</H4>
Multinationale, randomisierte, placebokontrollierte Phase III-Studien mit dem Proteasehemmer MK-639 (L-735,524) und AZT in 3 Armen: MK-639/MK-639+AZT/AZT. Alle klinischen Stadien, keine akute Aids-Erkrankung. CD4-Zellen 50-500/´l. Laufzeit: 12 Monate plazebokontrolliert, weitere 6 Monate open-label MK-639 mit beliebiger antiretroviraler Therapie.<P>

<H4>Ern&auml;hrung; CETORNAN-Studie [Genf]</H4>
Wendet sich an seropositive Personen, die mehr als 150 CD4/´l und einen Gewichtsverlust von 5% oder mehr ihres Normalgewichts aufweisen. Die Studie vergleicht die Entwicklung der Ern&auml;hrungssituation, der Muskelfunktion und von immunologischen Parametern bei Patienten, die zus&auml;tzlich Glutamin erhalten, eine Aminos&auml;re, die f&uuml;r ihre regulierende Rolle bei der Proteinsynthese bekannt ist. Dauer: 12 Wochen. Laufende Rekrutierung.<P>

</UL>


</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-338</DOCNO>
<DOCOLDNO>IA017-000178-B042-184</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:8.2 192.33.214.13 19970106050551 text/html 5838
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:06:13 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Luc Perrin</I><br>Eine Studie aus dem Programm der Kommission zur Kontrolle der Aids-Forschung</H3>
<i>Laboratoire Central de Virologie, Gen&egrave;ve</i><P>
<UL>
Kann ein fr&uuml;her Einsatz von Zidovudin bei einer HIV-Infektion den Ausbruch von Krankheitssymptomen verz&ouml;gern?<br>
Zidovudin war weltweit das erste Medikament, das gegen den Aidserreger HIV Wirkung zeigte. War es zuerst n&ouml;tig, die optimale Dosierung mit den minimalsten Nebenwirkungen festzulegen, versucht man heute, den besten Zeitpunkt f&uuml;r den Beginn einer Therapie mit diesem Mittel zu finden.<P>
Um die Wirkungsweise eines Medikamentes zu beurteilen, sind sogenannte doppelblinde, placebokontrollierte Studien n&ouml;tig. Je mehr Teilnehmer man f&uuml;r eine solche Untersuchung gewinnen kann, umso aussagekr&auml;ftiger wird sie. Dies ist bei der HIV-Infektion nicht einfach, denn ersten sind die Zahlen der Infizierten in Europa (im Gegensatz etwa zu Afrika) relativ klein und zweitens kann die Phase, in der der Patient zwar HIV-infiziert, aber ohne Symptome bleibt, im Mittel um die 10 Jahre dauern. Diese beiden Tatsachen machen es schwierig, genaue Aussagen &uuml;ber ein zu testendes Medikament zu erhalten. In der Schweiz bietet die HIV-Kohortenstudie eine gute Grundlage f&uuml;r solche Studien, denn mit ihrer Hilfe wird der Kontakt der &Auml;rzte zu einer grossen Zahl von HIV-positiven Menschen gew&auml;hrleistet. Um aber die Zahl der Beobachtungen noch zu vergr&ouml;ssern, werden sogenannte multizentrische Studien durchgef&uuml;hrt. Dies kann heissen, dass sich zum Beispiel alle Universit&auml;tskliniken der Schweiz nach einem einheitlichen Schema beteiligen. Noch informativer werden die Resultate, wenn verschiedene Kliniken in verschiedenen L&auml;ndern teilnehmen.<P>
Die vorliegende Studie wurde deshalb multizentrisch durchgef&uuml;hrt. Dabei beschr&auml;nkte man sich nicht nur auf die Schweiz, sondern man arbeitete mit Forschern aus Australien, Belgien, D&auml;nemark, Frankreich, Italien und Portugal zusammen.<br>
Als zuverl&auml;ssig gelten Studien, die randomisiert, doppelblind und placebokontrolliert durchgef&uuml;hrt werden. Randomisiert heisst, dass die Teilnehmer nach dem Zufallsprinzip der einen oder anderen Gruppe zugeteilt werden, doppelblind bedeutet, dass weder Arzt noch Patient weiss, ob das verabreichte Pr&auml;parat echt oder ein Placebo ist. Ein Placebo ist ein wirkstofffreies, &auml;usserlich aber nicht vom Original unterscheidbares "Scheinmedikament".<P>
<H4>Hintergrund:</H4>
AZT (Zidovudin bzw. Retrovir(r)) war weltweit erste Medikament, das die Vermehrung des HI-Virus bremsen kann. Es hemmt die Wirkung des Virus-Enzyms "Reverse Transkriptase", das zur Virusvermehrung notwendig ist. Diese Hemmung ist allerdings nicht total, so dass es die Virusvermehrung nicht vollst&auml;ndig zum erliegen bringen kann.<P>
W&auml;hrenddem man noch vor kurzer Zeit davon ausgegangen ist, das Virus "schlummere" in der Latenzphase zwischen Ansteckung und Ausbruch der ersten Aids-Symptome, und k&ouml;nnen somit kaum am Auftreten von klinischen Symptomen beteiligt sein, zeigen neuere Forschungen, das eine kontinuierliche Virusvermehrung stattfindet.<P>
Deshalb stellt sich erneut die Frage, ob es sinnvoll ist, schon fr&uuml;h mit der AZT-Behandlung anzufangen. Die fr&uuml;heste Phase w&auml;re die sogenannte "prim&auml;re HIV-Infektion" (PHI), als dieman die ersten Wochen nach der Ansteckung bezeichnet.<P>
<H4>Befunde:</H4>
77 Studienteilnehmer mit PHI wurden regelm&auml;ssig untersucht. Dabei wurden sie in einer fr&uuml;hen Phase nach der Ansteckung behandelt. Sie erhielten w&auml;hrend 6 Monaten entweder  zweimal t&auml;glich 250 mg Zidovudin oder ein Placebo (also das Scheinmedikament ohne Wirkstoff). Dabei traten w&auml;hrend der durchschnittlich 15monatigen Beobachtungsdauer 8 F&auml;lle von opportunistischen Infektionen auf. Diese betrafen in 7 F&auml;llen Teilnehmer aus der Placebogruppe und in einem Fall jemanden aus der Zidovudingruppe. Es zeigte sich ebenfalls, dass die Zahl der CD4-Lymphozyten, die als entscheidend f&uuml;r den Gesundheitszustand gilt, bei der Gruppe mit Zidovudin h&ouml;her lag. Dieser Zustand hielt nach Beendigung der 6 Monate dauernden Behandlung bei der Zidovudingruppe bis zu 2 Jahre an. Zidovudin zeigt also eine deutliche Wirkung.<P>
<H4>Wie weiter mit Zidovudin?</H4>
Zidovudin wurde als Medikament gew&auml;hlt, weil es zu Beginn der Studie als Standardtherapie galt. Noch immer gilt es als Mittel der Wahl bei Patienten, die vorg&auml;ngig noch mit keinem anderen Medikament behandelt wurden. Inzwischen zeichnet sich aber ab, dass Zidovudin als alleiniges Therapeutikum nicht optimal ist. In Kombination mit anderen Wirkstoffen kann eine drastischere Hemmung der Virusvermehrung erreicht werden, w&auml;hrend dabei keine oder schw&auml;chere Nebenwirkungen auftreten.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-339</DOCNO>
<DOCOLDNO>IA017-000178-B042-200</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:8.3 192.33.214.13 19970106050604 text/html 2315
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:06:26 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Kommission zur Kontrolle der Aids-Forschung (Hrsg.)</I><br>Resultate einiger Projekte aus dem Nationalen Aids-Forschungs-Programm</H3>
<i>Bern, Kommission zur Kontrolle der Aids-Forschung und Bundesamt f&uuml;r Gesundheitswesen, 1995, 60 S., gratis</i><P>
<UL>
Das Bundesamt f&uuml;r Gesundheitswesen (BAG) und die Kommission zur Kontrolle der Aids-Forschung (KKAF) informieren &uuml;ber die vom Bund unterst&uuml;tzte Aids-Forschung in der Schweiz.<P>
Eine Brosch&uuml;re zeigt an 10 ausgew&auml;hlten Projekten, wie die vom Parlament bewilligten Gelder zum Einsatz kommen und welche Resultate bis jetzt erreicht wurden. Selbstverst&auml;ndlich sind unter den gesamthaft 150 unterst&uuml;tzten Projekten noch viele andere, die interessante Resultate vorweisen, doch sind sie oft wissenschaftlich so komplex, dass sie dem medizinischen Laien kaum zug&auml;nglich gemacht werden k&ouml;nnen.<P>
Das Fazit dieses kurzen Rechenschaftsberichts geht dahin, dass mit  den investierten Geldern wesentliche Fortschritte erreicht wurden. Es wird auch klar, dass die Schweiz innerhalb der internationalen Forschungsgemeinschaft zum Thema Aids durchaus wichtige Beitr&auml;ge leisten kann.<P>
Zu beziehen bei:<br>
<I>Dr. Giampiero Trezzini<br>
Sekret&auml;r der Kommission zur Kontrolle der Aids-Forschung<br>
BAG, Postfach<br>
3097 Liebefeld</I><P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-340</DOCNO>
<DOCOLDNO>IA017-000178-B042-212</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:8.4 192.33.214.13 19970106050618 text/html 7054
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:06:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Y. Cao et al.</I><br>Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection</H3>
<i>New Engl J Med 1995; 332:201-8.</i><P>
<UL>
Die Pathogenese der HIV-Infektion ist komplex und h&auml;ngt von einer Vielzahl von Faktoren ab, ausgehend sowohl von der infizierten Person wie auch vom Virus selbst. Nach der Serokonversion bleibt die Mehrzahl der Patienten w&auml;hrend einer l&auml;ngeren Zeitperiode asymptomatisch, entwickelt aber im Mittel nach zehn Jahren Symptome im Zusammenhang mit einer schwerwiegenden Sch&auml;digung des Immunsystems. Die Zahl der CD4-Zellen gilt zur Zeit als der wichtigste prognostische Faktor und sie erlaubt, das Stadium des Patienten im Krankheitsverlauf zu bestimmen und entsprechende prophylaktische und therapeutische Massnahmen vorzuschlagen. Im Verlauf der letzten Jahre wurde eine kleine Gruppe von Patienten gefunden, die schon seit l&auml;ngerer Zeit seropositiv ist, ohne Krankheitszeichen oder eine Abnahme der Aktivit&auml;t des Immunsystems zu zeigen: Die "long-term survivors" oder Nonprogessoren. Der Anteil an solchen Patienten ist nicht genau bekannt. Je nach Kriterien kann man von einem Anteil zwischen 5% und 10% ausgehen. Die vorhanden Daten reichen noch nicht, um zu sagen, ob die Nichtprogression ein definitiver Zustand ist oder ob es sich um ein sehr langsames Fortschreiten handelt, das letztlich auch zur Krankheit f&uuml;hrt.<br>
Die seropositiven Nonprogressoren sind sowohl f&uuml;r die klinische wie auch f&uuml;r die Grundlagenforschung von sehr grossem Interesse. Man kann davon ausgehen, dass es eine grunds&auml;tzlich Erkl&auml;rung f&uuml;r diese Ph&auml;nomene gibt, die auch f&uuml;r andere Patienten n&uuml;tzlich w&auml;ren. Die Autoren dieser Studie haben zehn seropositive Patienten rekrutiert, die seit 10 bis 15 Jahren eine normale und stabile Anzahl von CD4-Zellen aufweisen. Keiner der Patienten zeigte Symptome im Zusammenhang mit seiner HIV-Infektion. Virologische, immunologische und genetische Aspekte wurden innerhalb dieses Kollektivs untersucht.<P>
Die Vir&auml;mie ist bei diesen Patienten sehr tief. Im Vergleich zu progredienten Patienten ist die Zahl der im Blut oder in den Lymphozyten gefundenen Viren bei sechs sehr niedrig oder nicht messbar. Bei vier Patienten betr&auml;gt die Anzahl der RNS-Kopien (viruseigene Erbsubstanz) zwischen 839 und 11549 Kopien pro Milliliter Plasma. Im Vergleich dazu findet man bei Patienten mit CD4-Zahlen unter 200 / ´l einen mittleren Wert von 580'000 Kopien pro Milliliter Plasma; bei Patienten mit CD4-Werten zwischen 200 und 500 / ´l betr&auml;gt der mittlere Wert 71'000 Kopien. Eine der wesentlichen Charakteristiken der Nonprogressoren besteht somit darin, dass die Vir&auml;mie im Verlaufe der Jahre sehr niedrig bleibt. Es werden drei Hypothesen vorgeschlagen, um dieses Ph&auml;nomen zu erkl&auml;ren. Erstens k&ouml;nnten die CD4-Zellen dieser Patienten f&uuml;r eine Infektion weniger empfindlich sein. Zweites k&ouml;nnte bei diesen Patienten das Immunsystem st&auml;rker reagieren und damit die virale Replikation in Schach halten. Drittens k&ouml;nnte es sich beim Virus um einen weniger aggressiven Stamm handeln, so dass die Infektion latent bleibt, ohne das Immunsystem nachhaltig zu sch&auml;digen.<P>
Die CD8- ("Partnerzellen" von CD4) und CD4-Lymphozyten k&ouml;nnen isoliert und im Labor untersucht werden. Zellen von Nonprogressoren sowie Zellen von Patienten mit Symptomen von Immunsch&auml;den wurden mit verschiedenen St&auml;mmen von HIV infiziert. Unter experimentellen Bedingungen waren die CD4-Zellen der Nonprogressoren einer Infektion gegen&uuml;ber klar widerstandsf&auml;higer als diejenigen von Progressoren. In einem weiteren Schritt des Experiments entfernt man die CD8-Zellen aus dem Kulturmedium und stellt dann fest, dass die Resistenz der CD4-Zellen gegen eine HIV-Infektion verlorengeht. Wenn man diesen Hemmungseffekt misst, stellt man fest, dass die CD8 der Nonprogressoren wesentlich wirksamer sind als diejenigen der Progressoren. Die Resistenz gegen die Infektion ist nicht eine ausschliessliche Eigenschaft der CD4-Zellen, vielmehr beruht diese auf einem dynamischen Geschehen, in dem die CD8-Zellen eine Partnerrolle spielen. Zus&auml;tzliche Untersuchungen zeigen, dass ein direkter Kontakt zwischen CD4 und CD8 nicht notwendig ist, sondern dass ein l&ouml;slicher Faktor (Cytokin?) von den CD8-Zellen produziert wird. Diese Faktor, welcher f&uuml;r die Pathogenese und eine eventuelle Therapie von h&ouml;chstem Interesse ist, konnte bis jetzt noch nicht identifiziert werden.<P>
Zus&auml;tzlich zu dieser starken zellul&auml;ren Abwehr gegen das HIV zeigen die Nonprogressoren auch eine gute humorale Reaktion (Antik&ouml;rperbildung) gegen das Virus. Im Gegensatz zu den Progressoren verf&uuml;gen die Nonprogressoren &uuml;ber sehr aktive neutralisierende Antik&ouml;rper, die zur Eliminierung des zirkulierenden Virus beitragen.<P>
Eine genetische Analyse der Patienten konnte keine gemeinsamen Charakteristiken nachweisen. Dabei ist zu ber&uuml;cksichtigen, dass ein Kollektiv von zehn Personen zu klein ist, um zu diesem Aspekt g&uuml;ltige Aussagen machen zu k&ouml;nnen.<P>
Diese Studie zeigt klar die Bedeutung der Immunantwort gegen das HIV bei den Nonprogressoren. Im Rahmen anderer Arbeiten zur Dynamik der Infektion zeigt sich, dass die Immunantwort zweifellos einen Schl&uuml;sselfaktor bei der Nonprogression darstellt, indem sie die virale Replikation hemmen kann. Ein von den CD8-Zellen produzierter Faktor scheint in diesem Gleichgewicht eine wichtige Rolle zu spielen. Eine Frage bleibt vorl&auml;ufig noch unbeantwortet: Kann man mit Hilfe einer antiretroviralen Behandlung, oder in Zukunft durch Einsatz des Faktors, die Vir&auml;mie auf unter 10'000 Kopien pro Milliliter Plasma reduzieren und dadurch den klinischen Effekt der Nonprogression erreichen? Diese Hypothesen lassen hoffen, doch es ist noch einiges an Grundlagen- und klinischer Forschung n&ouml;tig, bevor eine wirksame Therapie zur Verf&uuml;gung steht.<P>

</UL>

</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9504:8.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-341</DOCNO>
<DOCOLDNO>IA017-000178-B042-222</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9504:8.5 192.33.214.13 19970106050629 text/html 5005
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:06:52 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Aids Infotheque 4/95, Jul 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9504"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A>

<IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif">

<H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2>
<I>Das Magazin der Aids Info Docu Schweiz<BR>
Le magazine de Sida Info Doc Suisse</I>
<BR CLEAR>


<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>


<H3><I>Dr. Therese Stutz Steiger</I><br>Europ&auml;ische Parlamentarische Konferenz &uuml;ber HIV und Aids: Fortsetzung dringend n&ouml;tig</H3>
<i>Bundesamt f&uuml;r Gesundheitswesen, Leiterin der Abteilung<br>
Gesundheitsf&ouml;rderung</i><P>
<UL>
<B>Am 19. und 20. Mai haben in Barcelona 50 Parlamentarier und Parlamentarierinnen der "Standing Conference of European Parliamentarians on HIV/AIDS" getagt.</B><P>
Die Konferenz war die Antwort auf die Resolution eines Treffens in London 1993, welche die Institutionen der Europ&auml;ischen Union auffordert, sich an einer st&auml;ndigen Konferenz zu beteiligen, um die interparlamentarische Zusammenarbeit innerhalb der EU und im europ&auml;ischen Raum zu vertiefen. Ziel der Konferenz war ein umfassender Update: &uuml;ber neuste wissenschaftliche Erkenntnisse zu informieren, diePr&auml;ventionsmassnahmen in den einzelnen L&auml;ndern zu erl&auml;utern und zu vergleichen so-wie die Rolle von Beh&ouml;rden und nicht-staatlichen Organisationen (NGO's) auszuleuchten. Im Programm waren deshalb s&auml;mtliche "klassischen" Themen zu finden; behandelt wurden sie weitgehend von bekannten Experten und Expertinnen, die &uuml;ber lang-j&auml;hrige Erfahrung in der Aids-Arbeit verf&uuml;gen.<P>
<B>Die Schweiz als Musterland der Pr&auml;vention gefragt.</B> Die Schweiz wurde eingeladen, obwohl nicht Mitglied der EU, weil sie in der Aidspr&auml;vention und im Umgang mit dem Drogenproblem in verschiedener Hinsicht als Modellfall gilt und Schrittmacherdienste leistet. Die Pr&auml;sidentin und der Pr&auml;sident der Kommissionen f&uuml;r  soziale Sicherheit und Gesundheit beider R&auml;te, die Nationalr&auml;tin und &Auml;rztin Ruth Gonseth und St&auml;nderat Thomas Onken, nahmen an der Konferenz teil. Fran&ccedil;oise Dubois-Arber, Institut f&uuml;r Sozial- und Pr&auml;ventivmedizin der Universit&auml;t Lausanne, pr&auml;sentierte einen vergleichenden &Uuml;berblick &uuml;ber die Evaluation der Aids-pr&auml;vention in Europa.<P>
Neben den EU-Parlamentariern waren Fachleute aus den Gesundheitsministerien und aus verschiedenen NGO's vertreten. Am ersten Morgen fanden drei Hauptbl&ouml;cke zu den Themen: "Scientific Update, HIV/AIDS Education and Prevention und Governement Responses and the Role of the Voluntary Sector" statt, anschliessend sechs Workshops. Im Anschluss an ei- nen weiteren Block &uuml;ber die&ouml;ko-nomischen Folgen von HIV wur-de &uuml;ber die Schlussdeklaration der Konferenz debattiert. Die Public Health Foundation in London soll unter der &Auml;gide derst&auml;n-digen Konferenz folgendenwich-tige Gebiete weiter bearbeiten:<br>
Sexualerziehung, Rolle der ehrenamtlichen Organisationen, medizinische, biologische und psychosozialeForschung, psycho-soziale und wirtschaftliche Auswirkungen von HIV/AIDS, Hilfe und Unterst&uuml;tzung von HIV-Tr&auml;gern und Familien, Auswirkun-gen auf intraven&ouml;s Drogenabh&auml;ngige, auf M&auml;nner, die mit M&auml;nnern Sex haben, auf Frauen und Familien, HIV/Aids-Gesetzgebung, HIV/Aids im Gef&auml;ngnis.<P>
<B>Die Weiterf&uuml;hrung der Konferenz ist gew&auml;hrleistet.</B> Das gesammelte Wissen und die Erfahrungen sollen anderenKontinenten und Kulturen zur Verf&uuml;gung stehen. Die Themen sollen in den Parlamenten nicht "einschlafen", und die Regierungen sollen die bestm&ouml;gliche Verwendung der Mittel f&uuml;r Hilfe und Behandlung sowie die gr&ouml;sstm&ouml;gliche Effizienz bei der Pr&auml;vention und der Forschung sicherstellen, immer in enger Zusammenarbeit mit Betroffenen und denAids-Hilfe-Organisationen.<P>
St&auml;nderat Onken und Nationalr&auml;tin Gonseth erkl&auml;rten, in den zwei Tagen viel profitiert und gelernt zu haben, was sie in der Schweiz fruchtbar machen m&ouml;chten. Es sei wertvoll gewesen, sich einmal mit der Aidsproblematik so vertieft zu besch&auml;ftigen. Sie pl&auml;dierten f&uuml;r eine Fortsetzung der Konferenz alle zwei Jahre, wobei sie sich vielen Parlamentariern in der Meinung anschlossen, sie solle m&ouml;glichst ohne neue Strukturen auskommen.<P>

</UL>
</UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-342</DOCNO>
<DOCOLDNO>IA017-000178-B042-238</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:1.1 192.33.214.13 19970106050639 text/html 4255
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Commentaire</H3><BLOCKQUOTE><I>Dr med. Ruedi Osterwalder, Pr&eacute;sident de la sous-commission Sant&eacute; et Affaires sociales de la Commission f&eacute;d&eacute;rale charg&eacute;e du sida</I><P>Le VIH d&eacute;voile peu &agrave; peu ses secrets: on conna&icirc;t maintenant son mat&eacute;riel g&eacute;n&eacute;tique et les prot&eacute;ines qu'il produit. Cette prouesse est due &agrave; un immense engagement financier et &agrave; l'inlassable travail fourni par des milliers de personnes au sein de la communaut&eacute; internationale des chercheurs. Malgr&eacute; cette focalisation des &eacute;nergies, personne n'a encore trouv&eacute; de vaccin. Et personne n'a trouv&eacute; de m&eacute;dicaments permettant de combattre le virus et de gu&eacute;rir la maladie qui en r&eacute;sulte: le sida. Mais la recherche explore sans cesse de nouvelles voies. Il est certain cependant que nous atteindrons un jour nos objectifs.<P>Comme son nom l'indique, le sida est une maladie du syst&egrave;me immunitaire. Ce syst&egrave;me est une n&eacute;buleuse complexe, un r&eacute;seau compos&eacute; de centaines d'&eacute;l&eacute;ments. Quantit&eacute; de composants sont encore inconnus &agrave; ce jour et de nombreuses interactions restent voil&eacute;es de myst&egrave;re. Mais des &eacute;tudes men&eacute;es ces derni&egrave;res ann&eacute;es ont montr&eacute; que le syst&egrave;me nerveux central avait une certaine influence sur le syst&egrave;me immunitaire. Et comme le cerveau fait partie int&eacute;grante du syst&egrave;me nerveux central, les chercheurs essayent de d&eacute;terminer si le bien-&ecirc;tre ou le stress pourraient dynamiser ou affaiblir le syst&egrave;me immunitaire.<P>En d'autres termes, l'esprit dicte-t-il sa loi au corps? Les r&eacute;sultats sont contradictoires. Mais pour l'instant, personne n'a r&eacute;ussi &agrave; d&eacute;montrer qu'un &eacute;tat psychologique favorable pouvait par exemple faire remonter de mani&egrave;re sensible le taux de lymphocytes T CD4. Et personne ne sait si on pourra le d&eacute;montrer un jour. <P>Faut-il alors supprimer des traitements les mesures d'ordre psychologique? Certes non! M&ecirc;me si les chiffres restent muets, l'impact du  mental  est r&eacute;el. On sait depuis longtemps que l'&ecirc;tre humain n'est pas une machine: il ne r&eacute;sulte pas de la somme de ses composants. D'ailleurs, le ph&eacute;nom&egrave;ne des maladies psychosomatiques est connu depuis belle lurette. Qu'importe si les r&eacute;sultats biochimiques ne sont pas probants! Seul compte l'&ecirc;tre humain, qui doit rester au centre des pr&eacute;occupations. Il faut donc continuer de veiller &agrave; l'&eacute;tat psychologique des malades car des mesures cibl&eacute;es peuvent am&eacute;liorer son &eacute;tat g&eacute;n&eacute;ral. En d'autres termes, nous n'avons pas le droit d'abandonner &agrave; eux-m&ecirc;mes ceux qui nous sont proches!</BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9504:8.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-343</DOCNO>
<DOCOLDNO>IA017-000178-B042-248</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:1.2 192.33.214.13 19970106050648 text/html 4193
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:10 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Kommentar</H3><BLOCKQUOTE><I>Dr. med. Ruedi Osterwalder, Pr&auml;sident der Subkommission Gesundheit und Soziales der Eidg. Kommission f&uuml;r Aidsfragen</I><P> Das HIV hat uns manches gelehrt. Das winzige Virus wurde analysiert, man kennt den Aufbau seiner Erbsubstanz und alle Eiweisse, die es produziert. Dies wurde m&ouml;glich, weil die internationale Forschergemeinschaft sich mit einem gewaltigen Einsatz von Arbeitsleistung und finanziellen Ressourcen ans Werk gemacht hat, weil sich tausende von Menschen auf den  Punkt  HIV konzentriert haben.<P>Trotz all dieses Aufwands war es aber noch nicht m&ouml;glich, eine Impfung oder ein Medikament gegen das Virus bzw. gegen das von ihm ausgel&ouml;ste Aids zu entwickeln. Die Forschung ist aber dauernd daran, neue Wege zu suchen, und man wird in vielen kleinen Schritten das Ziel sicher erreichen.<P>Der kritische Punkt im ganzen Krankheitsgeschehen ist das Immunsystem. Allerdings: hier von einem  Punkt  zu reden, ist nicht angebracht. Vielmehr stellt das Ganze ein riesiges Netzwerk dar, mit vermutlich hunderten von Komponenten, die l&auml;ngst nicht alle entdeckt und erkl&auml;rt sind. Und auch &uuml;ber die Interaktionen dieser einzelnen Zellen und Stoffe bestehen noch viele Unklarheiten. Die Forschung konnte in den letzten Jahren zeigen, dass das ZNS  unser Nervensystem  gewisse Einfl&uuml;sse auf das Immunsystem aus&uuml;bt. Und weil dazu auch das Gehirn geh&ouml;rt, versucht man zu ergr&uuml;nden, ob Fakten wie Befindlichkeit oder Stress dazu f&uuml;hren k&ouml;nnen, das Immunsystem anzukurbeln oder vielleicht auch zu schw&auml;chen. <P>Kann uns die Psyche vor Krankheit retten? Die Resultate sind widerspr&uuml;chlich, und niemand konnte bis jetzt zeigen, dass durch psychische Beeinflussung z.&nbsp;B. die Zahl der CD4-Zellen wieder so angestiegen w&auml;re, dass man von einer echten Verbesserung der Situation h&auml;tte sprechen k&ouml;nnen. Ob dies je gelingen wird, ist zur Zeit fraglich.<P>Muss man also das Kapitel  Psyche  sang- und klanglos abschreiben? Gewiss nicht! Die Tatsache, dass es bisher nicht gelungen ist, ihren Einfluss auf das Immunsystem in einzelnen biochemischen Aspekten messbar zu machen, bedeutet &uuml;berhaupt nichts. L&auml;ngst hat man ja erkannt, dass der Mensch keine Maschine ist, nicht bloss aus der Summe der einzelnen Teile besteht. Dazu geh&ouml;rt, dass wir die Psyche pflegen, ganz besonders unter so schwierigen Umst&auml;nden wie bei Krankheit. Das Ph&auml;nomen von psychosomatischen Zusammenh&auml;ngen ist bekannt. Ob sich dies letztlich in einem Messresultat dokumentieren l&auml;sst, ist unwichtig. Wichtig ist der Mensch, der im Zentrum steht und dessen Gesamtsituation sich durch gezielte psychische Interventionen verbessern l&auml;sst. Oder kurz gesagt: Wir d&uuml;rfen die Seele so oder so nicht verk&uuml;mmern lassen!</BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-344</DOCNO>
<DOCOLDNO>IA017-000178-B042-263</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:2.1 192.33.214.13 19970106050657 text/html 15962
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:19 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Immunit&eacute;, syst&egrave;me nerveux et psychisme - le point des connaissances.</H3><BLOCKQUOTE><I>Prof. Dr&nbsp;med. P.&nbsp;J. Grob, division d'immunologie clinique, d&eacute;partement de m&eacute;decine interne, h&ocirc;pital universitaire de Zurich.</I><P><B>La psycho-neuro-immunologie, science qui &eacute;tudie le lien entre l'immunologie et la neurobiologie, s'est d&eacute;velopp&eacute;e ces 20&nbsp;derni&egrave;res ann&eacute;es. Les chercheurs tentent d'&eacute;lucider les interactions entre le syst&egrave;me nerveux central et le syst&egrave;me immunitaire de l'organisme. La moisson de r&eacute;sultats est importante, mais les r&eacute;ponses sont parfois contradictoires, et difficiles &agrave; interpr&eacute;ter. Comme la presse grand public soul&egrave;ve de grands espoirs en &eacute;voquant l'influence b&eacute;n&eacute;fique du psychisme sur le syst&egrave;me immunitaire, le moment est venu d'analyser la situation d'un point de vue scientifique.</B><P>Pour des raisons de place, nous nous contenterons de mentionner les deux th&egrave;ses les plus populaires:<P><UL><LI>le stress affaiblit le syst&egrave;me immunitaire, rend malade, aggrave une maladie ou acc&eacute;l&egrave;re son d&eacute;roulement, et transforme par exemple une s&eacute;ropositivit&eacute; en un sida d&eacute;clar&eacute;.<P><LI>les mesures antistress renforcent le syst&egrave;me immunitaire, rendent la maladie moins grave, repoussent l'apparition de certains sympt&ocirc;mes, et retardent par exemple le d&eacute;veloppement d'un sida d&eacute;clar&eacute;.</UL><P><B>Le syst&egrave;me psycho-neuro-immuno-endocrinologique</B><P>Les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire <A HREF="INFOTHEQUE.cgi?9601:2.1#note1" NAME="retour1">(1)</A>, m&ecirc;me si bien des questions restent ouvertes. La communication au sein de ces syst&egrave;mes passe par l'interm&eacute;diaire d'un grand nombre de  messagers , ou  m&eacute;diateurs , dont les hormones. L'hormone CRH par exemple (Corticotropin Releasing Hormon), produite par l'hypothalamus, est une des premi&egrave;res r&eacute;ponses de l'organisme en cas de stress.<P>De fait, les fonctions du syst&egrave;me immunitaire peuvent &ecirc;tre modifi&eacute;es par le biais de plusieurs syst&egrave;mes:<P><UL><LI>syst&egrave;me neuro-sympathique (cat&eacute;cholamine)<BR><LI>syst&egrave;me limbique ou cerveau pal&eacute;omammalien (GABA  ou d&eacute;riv&eacute; de l'acide glutamique, s&eacute;rotonine, peptides opio&iuml;des<BR><LI>appareil hypotalamo-hypophysaire (ACTH), et par les surr&eacute;nales (corticost&eacute;ro&iuml;des).</UL> <P>Le syst&egrave;me immunitaire &agrave; son tour lib&egrave;re des substances complexes, les cytokines (comme l'interleukine 1&nbsp;&agrave;&nbsp;3, l'interf&eacute;ron), qui ont une influence sur cette communication entre les syst&egrave;mes (r&eacute;troaction). Mais si ces substances peuvent moduler l'activit&eacute; de certaines fonctions, elles ne peuvent pas renforcer directement la totalit&eacute; du syst&egrave;me immunitaire ou l'affaiblir. Elles agissent sur des combinaisons complexes de fonctions. Quand l'effet de la r&eacute;action se dissipe, le balancier revient presque toujours vers un point d'&eacute;quilibre (r&eacute;gulation hom&eacute;ostasique), si aucune mesure extr&ecirc;me n'est prise.<P><B>Des exp&eacute;riences contradictoires sur les animaux</B> <P>Ces informations sont avant tout le r&eacute;sultat d'exp&eacute;riences men&eacute;es sur des animaux soumis &agrave; des stress extr&ecirc;mes (&eacute;lectrochocs, mouvements de va-et-vient) ou op&eacute;r&eacute;s afin de mettre ponctuellement hors circuit certaines parties du cerveau. Si la physiologie est complexe, les liens entre maladies et stress sont &eacute;galement d&eacute;routants, comme le prouvent les deux &eacute;tudes qui suivent. <P><BR><OL><LI>70&nbsp;% d'une population de souris s&eacute;lectionn&eacute;es g&eacute;n&eacute;tiquement d&eacute;veloppent spontan&eacute;ment un diab&egrave;te, une maladie dans laquelle des processus auto-immunes jouent un grand r&ocirc;le. En soumettant ces souris &agrave; un stress important (immobilisation, rotations, parcage) la maladie appara&icirc;t plus t&ocirc;t, en 60&nbsp;&agrave;&nbsp;110 jours, et plus souvent (W.R.&nbsp;Carter et al.; Diabetologia&nbsp;30: 674, 1987). En d'autres termes, le stress a des effets n&eacute;gatifs.<P><LI>80&nbsp;% des souris appartenant &agrave; des souches particuli&egrave;res d&eacute;veloppent une polyarthrite assez grave quand on leur injecte du collag&egrave;ne, un des composants du tissu conjonctif. Si on soumet ces souris &agrave; un stress important (changement de cage 6&nbsp;fois par jour,  parcage), la maladie appara&icirc;t moins souvent et son degr&eacute; de gravit&eacute; est moindre. Si l'on renforce encore le stress en mettant les souris en pr&eacute;sence d'un chat, afin qu'elles d&eacute;veloppent une peur panique, on diminue le nombre de cas de polyarthrite (Rogers et al., Art. Rheum.&nbsp;23: 1337, 1980). En d'autres termes, le stress a des effets positifs.<P></OL>On le voit, ces deux &eacute;tudes sont contradictoires. En g&eacute;n&eacute;ral, dans les discussions, l'&eacute;tude cit&eacute;e est fonction de la th&egrave;se que l'on d&eacute;fend.<P><B>Des &eacute;tudes sur l'homme peu probantes</B><P>Bien entendu, nos connaissances dans ce domaine en m&eacute;decine humaine sont encore tr&egrave;s lacunaires. Les principaux messagers et m&eacute;diateurs mentionn&eacute;s plus haut ne peuvent par exemple pas &ecirc;tre mesur&eacute;s dans le sang, mais dans les organes seulement. Deux &eacute;tudes r&eacute;centes men&eacute;es &agrave; Zurich ont tent&eacute; de faire le point. L'une a pour th&egrave;me  L'influence du psychisme sur le syst&egrave;me immunitaire et sur l'apparition d'une maladie chez une personne en bonne sant&eacute;  <A HREF="INFOTHEQUE.cgi?9601:2.1#note2" NAME="retour2">(2)</A>; l'autre examine  L'influence du psychique sur le d&eacute;roulement d'une maladie pour laquelle des processus immunologiques jouent un r&ocirc;le cl&eacute;  <A HREF="INFOTHEQUE.cgi?9601:2.1#note3" NAME="retour3">(3)</A>.<P>Ces deux &eacute;tudes tiennent compte des travaux publi&eacute;s dans les revues scientifiques s&eacute;rieuses du monde entier. <P>La premi&egrave;re &eacute;tude porte sur l'examen de personnes initialement en bonne sant&eacute;: 42&nbsp;ont &eacute;t&eacute; soumises &agrave; des situations de stress exog&egrave;ne (d&eacute;c&egrave;s du partenaire, examen, soins donn&eacute;s &agrave; des proches gravement malades, mission en space-shuttle, etc.), 16&nbsp;pr&eacute;sentaient des caract&eacute;ristiques particuli&egrave;res dans leur personnalit&eacute;, et 9&nbsp;ont &eacute;t&eacute; expos&eacute;es &agrave; des situations exp&eacute;rimentales stressantes ou relaxantes. Malheureusement, cette &eacute;tude ne permet pas de tirer des conclusions g&eacute;n&eacute;rales: ni le d&eacute;roulement des cas, ni les situations psychologiques au d&eacute;but de l'&eacute;tude, ni l'&eacute;tat de sant&eacute; des personnes &agrave; la fin de l'&eacute;tude n'&eacute;taient identiques. De plus, trop de param&egrave;tres ont &eacute;t&eacute; utilis&eacute;s: 91&nbsp;proc&eacute;d&eacute;s diff&eacute;rents pour l'&eacute;valuation du psychisme, 68&nbsp;pour &eacute;tudier l'immunit&eacute;. R&eacute;sultat: cette &eacute;tude prouve simplement que le stress subjectif ou objectif (l&agrave; encore, il existe des douzaines de d&eacute;finitions) peut provoquer des augmentations ou des diminutions discr&egrave;tes de certaines valeurs immunitaires (anticorps dans la salive, stimulation de certaines cellules immunitaires) dans des proportions variables, pour un laps de temps variable  mais le plus souvent court  et avec une constance variable puisque dans certains cas, aucune fluctuation n'a &eacute;t&eacute; observ&eacute;e.<P>D'autres travaux semblent indiquer que les modifications immunologiques sont associ&eacute;es &agrave; certaines caract&eacute;ristiques de la personnalit&eacute; (peur, d&eacute;pression, solitude, ou attitude positive, personnalit&eacute; dynamique, soutien social, etc.). Les changements observ&eacute;s &eacute;taient toutefois tous de faible amplitude et d&eacute;passaient &agrave; peine la norme. En fait, les param&egrave;tres immunitaires analys&eacute;s et les modifications observ&eacute;es n'entreraient plus en ligne de compte aujourd'hui. Les preuves sont donc insuffisantes pour que l'on puisse &eacute;tablir un lien de cause &agrave; effet entre la personnalit&eacute; et l'apparition d'une maladie. En outre, la bri&egrave;vet&eacute; du temps d'observation ne permet pas non plus des d&eacute;ductions scientifiques rigoureuses.<P>La deuxi&egrave;me &eacute;tude porte sur des patients d&eacute;j&agrave; atteints de maladies dans lesquelles le syst&egrave;me immunitaire joue un r&ocirc;le essentiel: maladies auto-immunes (35&nbsp;cas) comme l'enc&eacute;phalite am&eacute;ricaine de Saint-Louis ou la polyarthrite chronique (9), le diab&egrave;te sucr&eacute; (12), la scl&eacute;rose en plaque (4), la maladie de Basedow ou goitre exophtalmique (5), la maladie de Crohn et la colite ulc&eacute;reuse (5), le syndrome malin (14), l'asthme bronchitique (4), diverses maladies (2) et maladies infectieuses (19), dont l'infection par le VIH (10 cas). L&agrave; encore, pour les 74&nbsp;cas sous revue, 64&nbsp;syst&egrave;mes d'&eacute;valuation de l'&eacute;tat phychique ont &eacute;t&eacute; utilis&eacute;s, presque jamais le m&ecirc;me, et 46&nbsp;param&egrave;tres diff&eacute;rents ont &eacute;t&eacute; employ&eacute;s pour analyser le syst&egrave;me immunitaire de 27&nbsp;des cas. La plupart de ces param&egrave;tres sont d'ailleurs obsol&egrave;tes aujourd'hui. L'examen clinique est &eacute;galement incomplet puisque seuls certains aspects ont &eacute;t&eacute; pris en compte. Conclusion: ces travaux ne permettent pas non plus d'affirmer que le psychisme a une influence sur le d&eacute;roulement de la maladie. Certes, un certain nombre de cas semblent indiquer un lien possible entre le stress et l'&eacute;volution de la maladie, mais d'autres &eacute;tudes n'aboutissent pas &agrave; la m&ecirc;me conclusion.<P>Que penser de tout cela ? L'interpr&eacute;tation de r&eacute;sultats souvent controvers&eacute;s laisse le champ libre &agrave; quantit&eacute; d'hypoth&egrave;ses et d'affirmations p&eacute;remptoires comme:  Le stress est dangereux . Mais en l'&eacute;tat actuel des connaissances, affirmer au contraire que  le stress prot&egrave;ge  n'a rien de farfelu, puisque le syst&egrave;me immunitaire est con&ccedil;u pour supporter le stress et qu'il est tout &agrave; fait capable de s'adapter et d'apprendre. Bref, nous manquons de preuves irr&eacute;futables pour les deux hypoth&egrave;ses, mais aucune ne peut &ecirc;tre enti&egrave;rement rejet&eacute;e &agrave; l'heure actuelle. <P>D'un point de vue scientifique cependant, les deux th&eacute;ories n'ont pas grand sens, car elles sont &agrave; la fois trop simples et trop dogmatiques. Il suffit d'observer par exemple le d&eacute;roulement d'une infection par le virus VIH pour se rendre compte de la complexit&eacute; de la situation. Les s&eacute;ropositifs passent d'une hyperstimulation de leur syst&egrave;me immunitaire au d&eacute;but de l'infection &agrave; un affaiblissement des fonctions immunitaires au fil de la maladie. Un syst&egrave;me immunitaire affaibli devrait pouvoir &ecirc;tre stimul&eacute;. C'est l&agrave; que le b&acirc;t blesse, car cette stimulation ne fait qu'accro&icirc;tre la prolif&eacute;ration du virus. Il faudrait donc inhiber le syst&egrave;me immunitaire! Dans cette optique, il est sans doute faux de dire que le stress aggrave la maladie, comme il est faux de dire que des mesures antistress renforcent le syst&egrave;me immunitaire et am&eacute;liorent le cours de la maladie. Ceci dit, si des facteurs psychiques avaient v&eacute;ritablement une influence nette sur le syst&egrave;me immunitaire, il faudrait redoubler de pr&eacute;cautions pour ne causer aucun tort.<P><B>Quelles conclusions tirer ?</B><P>A mon avis,  &ecirc;tre bien dans sa t&ecirc;te  est un des buts de l'existence, quel que soit l'&eacute;tat de sant&eacute;. Quand on est touch&eacute; par une maladie grave, l'entourage du patient, l'&eacute;quipe soignante et les psychologues s'efforcent d'aider le malade &agrave; rester en harmonie avec lui-m&ecirc;me. Les contacts humains, l'engagement social sont alors d&eacute;terminants. Mais d'autres mesures peuvent aider, comme la m&eacute;ditation ou d'autres techniques choisies en fonction des go&ucirc;ts et des affinit&eacute;s de chacun. Si ces mesures aident un malade &agrave; mieux supporter son sort, elles sont importantes et justes. Mais si elles sont li&eacute;es &agrave; une promesse d'am&eacute;lioration de l'&eacute;tat de sant&eacute;, d'interruption de la maladie, voire de gu&eacute;rison, elles deviennent sujettes &agrave; caution. Ce principe est valable tout particuli&egrave;rement pour les s&eacute;ropositifs. Certes, ils ont besoin qu'on les aide &agrave; supporter leur destin. Mais il serait inacceptable de consid&eacute;rer comme fautif un s&eacute;ropositif qui aurait refus&eacute; le soutien  psychologique propos&eacute;. Non seulement, il risquerait de se sentir coupable, &agrave; tort, mais son entourage. parfois dogmatique, pourrait le lui reprocher. Le soutien psychologique destin&eacute; &agrave; l'origine &agrave; aider le patient peut alors se retourner contre lui. <P><I>Sources:</I><P><FONT SIZE=2><A HREF="INFOTHEQUE.cgi?9601:2.1#retour1" NAME="note1">1. -</A> Sternber, E.M., moderator: The stress response and the regulation of inflammatory disease. Ann intern Med 1992; 117: 854-866<P><A HREF="INFOTHEQUE.cgi?9601:2.1#retour2" NAME="note2"> 2. -</A> Hodel, L., Grob, P.J.: Psyche und Immunit&auml;t (5 Uebersichtstabellen, 91 Literaturangaben). Schweiz Med Wochenschr 1993; 123: 2323 - 2341<P><A HREF="INFOTHEQUE.cgi?9601:2.1#retour3" NAME="note3">3. -</A> Ganzoni, Ch. (Dissertation unter Leitung von Prof. P.J. Grob, 1995: Psyche, Immunit&auml;t und Krankheitsverlauf - Eine Literatur&uuml;bersicht (12 &Uuml;bersichtstabellen, 85 Literaturangaben).</FONT></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-345</DOCNO>
<DOCOLDNO>IA017-000178-B042-278</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:2.2 192.33.214.13 19970106050711 text/html 13146
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Immunit&auml;t, Nervensystem und Psyche  was weiss man heute?</H3><BLOCKQUOTE><I>Prof. Dr.&nbsp;med. P.&nbsp;J.&nbsp;Grob, Abteilung Klinische Immunologie, Departement Innere Medizin, Universit&auml;tsspital Z&uuml;rich</I><P><B>Psychoneuroimmunologie, eine Verbindung zwischen der Immunologie und der Neurobiologie, ist eine Wissenschaft, die sich im Verlauf der letzten 20&nbsp;Jahre entwickelt hat. Die Forscher untersuchen, wie sich das zentrale Nervensystem und die Immunabwehr gegenseitig beeinflussen. Man hat zwar viele Erkenntnisse gesammelt, manche davon sind aber widerspr&uuml;chlich und schwierig zu interpretieren. Nachdem nicht zuletzt die Laienpresse oft viel Hoffnungen auf eine g&uuml;nstige Beeinflussung des Immunsystems durch die Psyche weckt, soll im folgenden der Stand der Dinge aus der Sicht des Wissenschafters skizziert werden.</B><P>Der K&uuml;rze wegen sollen nur zwei Hypothesen erw&auml;hnt sein, die viele Anh&auml;nger haben und denen oft nachgelebt wird: <P>Stress schw&auml;cht das Immunsystem, macht krank, oder verschlimmert eine Krankheit, respektive beschleunigt z.&nbsp;B. das Auftreten von Aids bei HIV-Infizierten <P>Antistress st&auml;rkt das Immunsystem und mildert einen schweren Krankheitsverlauf, respektive verz&ouml;gert z. B. das Auftreten von Aids. Dazu ein Kommentar. <P><B>Das Psycho-Neuro-Immunendokrinologische Netzwerk</B><P>Die gegenseitigen Beeinflussungsm&ouml;glichkeiten von Psyche, endokrinem System, Immunsystem und zentralem Nervensystem (ZNS) sind auf physiologischer, anatomischer und molekularbiologischer Ebene gesichert <A HREF="INFOTHEQUE.cgi?9601:2.2#note01" NAME="retour01">(1)</A>, wenn auch noch mit vielen offenen Fragen. Die Kommunikation innerhalb dieser Teilsysteme erfolgt &uuml;ber eine grosse Zahl von Signal- und Botenstoffen. Ausgel&ouml;st durch Stress werden z.&nbsp;B. vom Hirn  Stress -Hormone wie das Corticotropin releasing hormon (CRF) gebildet. Sowohl &uuml;ber das sympathische Nervensystem (Catecholamine) oder die Neuropeptide, wie &uuml;ber das limbische System ( central autonome arousal system ): GABA, Opioide, Serotonin usw. und die hypotalamisch-hypophys&auml;re Achse (z.&nbsp;B.&nbsp;ACTH) sowie, vermittelt z.&nbsp;B. durch Hormone der Nebennierenrinde (Kortikosteroide), k&ouml;nnen Funktionen des Immunsystems moduliert werden. <P>Vom Immunsystem wiederum werden komplexe Stoffe, sogenannte Zytokine (z.&nbsp;B. Interleukine-1 bis&nbsp;3, Interferone usw.), freigesetzt, die wiederum die obgenannten Kommunikationen beeinflussen (R&uuml;ckkoppelung). Modulieren heisst aber kaum je generelle Immunstimulation (St&auml;rkung) oder generelle Immundepression (Schw&auml;chung), sondern komplexe Kombinationen von Immunfunktionen, die gest&auml;rkt oder auch geschw&auml;cht werden. Charakteristisch ist dabei, dass die erw&auml;hnte Regulation und Gegenregulation, nach meist kurzen Ausschl&auml;gen in die eine oder andere Richtung fast immer wieder zu einem Gleichgewicht (Hom&ouml;ostase) f&uuml;hrt, sofern nicht extreme Massnahmen ergriffen werden. <P>Diese Erkenntnisse sind vor allem in Tierexperimenten erarbeitet worden, teils durch extreme Stresssituationen (Elektroschocks, Schwingbewegungen usw.) oder sogar durch punktuelle Ausschaltung von Hirnzentren usw. Bez&uuml;glich Krankheitsmodellen seien zwei Beispiele erw&auml;hnt: <P>Genetisch speziell selektionierte M&auml;use entwickeln zu 30-70&nbsp;% innert 60-110&nbsp;Tagen spontan die Zuckerkrankheit, eine Erkrankung, bei der autoimmunologische Vorg&auml;nge wesentlich sind. Durch grossen Stress (unbeweglich machen, Rotationen, zusammenpferchen) tritt die Krankheit etwas fr&uuml;her und etwas h&auml;ufiger auf (W.R. Carter et&nbsp;al.; Diabetologia 30: 674, 1987). Das hiesse also: Stress schadet. <P>Durch Injektion von Kollagen, einem Gewebsbestandteil, kann in bestimmten M&auml;usest&auml;mmen in 70-80&nbsp;% eine recht schwere Polyarthritis erzeugt werden. Durch grossen Stress (t&auml;glich 6mal K&auml;figwechsel, zusammenpferchen) tritt die Krankheit weniger h&auml;ufig und nur leicht auf. Verst&auml;rkt man den Stress durch Todesangst (Katze), tritt kaum eine Krankheit auf (Rogers et al., Art. Rheum. 23: 1337, 1980). Das hiesse also: Stress n&uuml;tzt. <P>Die Beispiele zeigen, wie komplex Einfl&uuml;sse von Stress sein k&ouml;nnen. Je nach Einstellung wird jeweils nur die eine oder andere Arbeit zitiert.<P><B>Wenig Erkenntnisse beim Menschen</B><P>Verst&auml;ndlicherweise ist unser Wissensstand beim Menschen viel kleiner und noch sehr unvollst&auml;ndig; z.&nbsp;B. k&ouml;nnen die meisten der wichtigen erw&auml;hnten Botenstoffe nicht im Blut, sondern nur in den Organen selbst gemessen werden. Um einen &Uuml;berblick zu gewinnen, wurden in Z&uuml;rich zwei Arbeiten gemacht, mit den Themen: <P>Einfluss der Psyche auf das Immunsystem und die Krankheitsentstehung beim Gesunden <A HREF="INFOTHEQUE.cgi?9601:2.2#note02" NAME="retour02">(2)</A> und<P>Einfluss der Psyche auf den Verlauf von Krankheiten, bei denen immunologische Vorg&auml;nge wesentlich sind <A HREF="INFOTHEQUE.cgi?9601:2.2#note03" NAME="retour03">(3)</A>. <P>In beiden Arbeiten wurde die weltweit bestehende Literatur aus anerkannten wissenschaftlichen Journalen ber&uuml;cksichtigt.<P>Bei der ersten Analyse mit Ausgangspunkt gesunder Menschen gingen 42&nbsp;Studien von  von aussen definierten  Stresssituationen (Partnerverlust, Examen, Pflege von schwerkranken Angeh&ouml;rigen, Space-Shuttle-Mission u.&nbsp;a.) aus, 16 von bestimmten Pers&ouml;nlichkeitsmerkmalen und 9 von experimentellen Stresssituationen oder von Entspannungsbem&uuml;hungen. Da sich die Studien im Design, der psychischen Ausgangssituation, der Beurteilung der Psyche (91 verschiedene Verfahren), der Immunit&auml;t (68 verschiedene Parameter) und auch bez&uuml;glich dem biologischen Resultat (verschiedene  Endpunkte  von Gesundheit/Krankheit) stark unterschieden, lassen sich nur wenige generelle Schlussfolgerungen ziehen: <BR>Subjektiver oder objektiver Stress (es gibt Dutzende verschiedener Definitionen) k&ouml;nnen mit diskreten Steigerungen oder Erniedrigungen einzelner Immungr&ouml;ssen (z.&nbsp;B. Antik&ouml;rper im Speichel, Stimulierbarkeit bestimmter Immunzellen) einhergehen, dies in verschiedenem Ausmass, von unterschiedlicher, meist kurzer Dauer und nicht in allen Arbeiten best&auml;tigt. <P>In anderen Studien ergaben sich Anhaltspunkte daf&uuml;r, dass die erw&auml;hnten immunologischen Ver&auml;nderungen auch mit bestimmten Pers&ouml;nlichkeitsmerkmalen (Angst, Depressivit&auml;t, Einsamkeit,  good coping ,  power motive syndrome , soziale Unterst&uuml;tzung u.&nbsp;a.) assoziiert sein k&ouml;nnen. Den immunologischen Ver&auml;nderungen war gemeinsam, dass sie sich in einem relativ engen Bereich bewegten und die Norm kaum oder h&ouml;chstens marginal &uuml;berschritten. Keinem der analysierten Immunparameter und keiner der beobachteten Ver&auml;nderungen wird heute eine anerkannte Aussagekraft zugeordnet. Belege f&uuml;r eine Beziehung zur Krankheitsentstehung ergaben sich kaum; meist waren auch die Beobachtungszeiten sehr kurz. <P>Die zweite Analyse betraf Patienten mit Erkrankungen, bei denen Immunvorg&auml;nge wesentlich sind, wie  Autoimmunkrankheiten  (35 Studien), davon u.&nbsp;a. Saint-Louis-Enzephalitis&nbsp;(SLE)und chronische Polyarthritis&nbsp;(9), Diabetes mellitus&nbsp;(12), Multiple Sklerose&nbsp;(4), Morbus Basedow&nbsp;(5), Morbus Crohn und Colitis ulcerosa&nbsp;(5), sowie Malignome&nbsp;(14), Asthma bronchiale&nbsp;(4), andere Krankheiten&nbsp;(2) und Infektionskrankheiten (19&nbsp;Studien), davon 10&nbsp;betreffend HIV-Infektionen. In den 74&nbsp;Studien wurden 64&nbsp;verschiedene Verfahren zur Beurteilung psychischer Faktoren angewandt, kaum je dieselben. Zur Beurteilung des Immunsystems dienten in 27&nbsp;Arbeiten 46&nbsp;verschiedene Immunparameter, die grosse Mehrzahl mit heute kaum anerkannter Aussagekraft. Bei der klinischen Verlaufsbeurteilung wurden meist nur Teilaspekte ber&uuml;cksichtigt. Auch diese Arbeiten geben keine schl&uuml;ssigen Hinweise darauf, dass psychische Einfl&uuml;sse den Krankheitsverlauf ver&auml;ndern. Viele Studien weisen zwar auf m&ouml;gliche Zusammenh&auml;nge zwischen Stress und Krankheitsgeschehen hin, andere aber nicht.<P>Die Interpretationen der oft kontroversen Resultate lassen Raum f&uuml;r viele Hypothesen  wie z.&nbsp;B.  Stress schadet . Auch die vom heutigen Wissensstand durchaus vertretbare gegenteilige Hypothese,  Stress sch&uuml;tzt und hilft , k&ouml;nnte sich ableiten lassen, ist doch das Immunsystem f&uuml;r Stress angelegt, lern- und ausserordentlich adaptationsf&auml;hig. F&uuml;r beide Hypothesen fehlen Beweise, sie k&ouml;nnen aber auch nicht ganz ausgeschlossen werden. <P>Wissenschaftlich gesehen machen beide wenig Sinn, da zu einfach und dogmatisch. Dies l&auml;sst sich besonders gut anhand der HIV-Infektionen zeigen. HIV-Infizierte zeigen anf&auml;nglich eine Hyperstimulation des Immunsystems und sp&auml;ter eine zunehmende Einschr&auml;nkung von Immunfunktionen. Liegt sie vor, m&uuml;sste man das Immunsystem stimulieren. Stimulierte Immunfunktionen sind aber eine wesentliche Voraussetzung f&uuml;r eine verst&auml;rkte Virusproduktion. Man m&uuml;sste also das Immunsystem inhibieren. In diesem Licht ist es offensichtlich, dass wahrscheinlich keine der beiden Hypothesen G&uuml;ltigkeit hat. W&uuml;rde eine zutreffen, respektive k&ouml;nnte das Immunsystem durch psychische Einfl&uuml;sse wesentlich beeinflusst werden, w&auml;re mit gr&ouml;sster Vorsicht vorzugehen, um keinen Schaden anzurichten.<P><B>Was sind die Konsequenzen?</B><P>Dazu ein paar pers&ouml;nliche Aussagen: Das psychische Wohlergehen ist wichtiges Ziel eines jeden Menschen, ob gesund oder krank. Die Kontaktpersonen und die medizinischen und psychologischen Betreuer versuchen mitzuhelfen, das Wohlergehen zu f&ouml;rdern. Wichtig dabei sind vor allem menschliche Zuneigung und soziales Engagement. Auch andere Massnahmen psychologischer Natur wie Meditation k&ouml;nnen helfen, je nach individueller Verfassung und Neigung. Dienen sie dazu, dass ein kranker Mensch sein Schicksal besser bew&auml;ltigt, sind sie wichtig. Fragw&uuml;rdig wird, wenn Bem&uuml;hungen zur Verbesserung des psychischen Wohlergehens mit Versprechungen verbunden sind, die Gesundheit werde gesichert, das Fortschreiten einer Krankheit gelindert oder sogar gestoppt. Dies gilt ganz besonders bei HIV-Infizierten. Sie brauchen und verdienen jede m&ouml;gliche Hilfe, um ihr Schicksal besser zu ertragen. Nicht akzeptabel ist, einen betroffenen Menschen mit dem Fortschreiten seiner Krankheit zum Versager zu stempeln, weil er die angebotene psychologische Hilfe (Methode) nicht recht befolgt habe. Dies verursacht dem Betroffenen nicht nur ungerechtfertigte Schuldgef&uuml;hle, sondern kann bewirken, dass eine ideologisierte Umgebung das Dogma des  Selbstverschuldens  &uuml;bernimmt. Was als Hilfe gedacht ist, kann sich damit zum Schaden wenden.<P><I>Literaturverzeichnis</I><P><FONZ SIZE=2><A HREF="INFOTHEQUE.cgi?9601:2.2#retour01" NAME="note01">1. -</A> Sternber, E.M., moderator: The stress response and the regulation of inflammatory disease. Ann intern Med 1992; 117: 854-866<P><A HREF="INFOTHEQUE.cgi?9601:2.2#retour02" NAME="note02">2. -</A> Hodel, L., Grob, P.J.: Psyche und Immunit&auml;t (5 &Uuml;bersichtstabellen, 91 Literaturangaben) Schweiz Med Wochenschr 1993;123:2323-2341<P><A HREF="INFOTHEQUE.cgi?9601:2.2#retour03" NAME="note03">3. -</A> Ganzoni, Ch. (Dissertation unter Leitung von Prof. P.J. Grob), 1995: Psyche, Immunit&auml;t und Krankheitsverlauf - Eine Literatur&uuml;bersicht (12 &Uuml;bersichtstabellen, 85 Literaturangaben).</FONT></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-346</DOCNO>
<DOCOLDNO>IA017-000178-B042-292</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:2.3 192.33.214.13 19970106050719 text/html 6735
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:41 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Interventions psychologiques et syst&egrave;me immunitaire</H3><BLOCKQUOTE><I>G. H&uuml;sler, J.P. Cousse Institut de Psychologie, Universit&eacute; de Fribourg, Suisse</I><P>Il s' av&egrave;re que les interventions psychologiques ont des effets favorables sur le bien-&ecirc;tre et sur certains param&egrave;tres immunitaires. H&uuml;sler (1995) a trouv&eacute; des tendances  semblables dans une m&eacute;taanlyse (analyse sur des donn&eacute;es de plusieurs &eacute;tudes) portant sur des interventions psychologiques chez des personnes s&eacute;ropositives et atteintes du Sida. Certaines des &eacute;tudes ayant int&eacute;gr&eacute; une forme de la relaxation syst&eacute;matique, notent un plus grand effet sur les param&egrave;tres immunitaires (plus on pratique la relaxation, plus certains param&egrave;tres s'am&eacute;liorent). <BR>Cette relation est aussi d&eacute;montr&eacute;e par une m&eacute;taanalyse de van Roods, Bogaards, Goulmy, van Houwelingen (1992) qui ont decrit dix &eacute;tudes sur la relaxation. Ex: l' augmentation de IgA de salive et des NK (natural killer) est liee &agrave; la relaxation et l' activation des cellules est plus grande (PHA monte) <P>Les r&eacute;sultats sur les &eacute;tudes de sport montrent les effets suivants: Compar&eacute;s avec les groupes de contr&ocirc;le, les groupes d'intervention permettent des ralentissements de chute de param&egrave;tres immunitaires notamment les CD4 ou du ratio (CD4/CD8). D'apr&egrave;s les recherches actuelles, nous pouvons admettre que grace aux interventions psychologiques et sportives,  il y a une certaine probabilit&eacute; que le stress psychologique diminue - le cortisol baisse avec l'effet suivant sur  le syst&egrave;me immunitaire: les CD4 les NK augment et se stabilisent pour un certain temps. <P><B>Il y a des possibilit&eacute;s.</B> <P>Dans le cadre de Perspectives Plus (un r&eacute;seau d'aide psychologique dans toute la Suisse, soutenu par l'Office f&eacute;d&eacute;ral de la sant&eacute; publique, (H&uuml;sler, 1993, 1995) nous r&eacute;pondons aux demandes de personnes anxieuses ou au bord de l'&eacute;puisement &eacute;motionnel. Ces personnes, nous pouvons souvent les consid&eacute;rer comme ayant subi une effraction par le virus et harcel&eacute;es par celui-ci. En fait nous pourrions appliquer le concept de stress post traumatique (PTST) aux patients VIH, comme on a pu le faire avec le cancer (Archinard, Savary, 1995). Le PTST &eacute;tant &quot;un trouble anxieux&quot; durable cons&eacute;cutif &agrave; un ou des traumatismes. Dans le cas du sida se pr&eacute;cise la r&eacute;p&eacute;tition des &quot;petits&quot; chocs, par le rappel des &quot;limitations&quot;, qui entravent par exemple la spontan&eacute;it&eacute; de s'exprimer ou de faire un projet. S'ajoute aussi ce que l'on pourrait appeler le traumatisme continu: &quot;&ccedil;a ne va pas s'arranger&quot;, sorte de mouvement de &quot;ressac&quot;, qui permet difficilement de tenir l'&eacute;quilibre.<P>Si pour certains patients le terme PSTD n'est pas appropri&eacute;, nous pouvons affirmer par contre, que les n&eacute;cessaires performances que doivent accomplir les s&eacute;ropositifs pour maintenir une vie normale, occasionnent une somme de stress souvent sup&eacute;rieure aux capacit&eacute;s de r&eacute;cup&eacute;ration; d'o&ugrave; la menace d'effondrement psychologique et somatique.<P>Nous avons donc choisi de centrer notre aide psychologique sur la personne rendue vuln&eacute;rable par son sida (et moins sur l'histoire de sa vuln&eacute;rabilit&eacute;), en pensant que le v&eacute;cu traumatique ou stressant doit s'int&eacute;grer (et non dominer) dans les domaines psychologiques, sociaux et biologiques.<BR>Nous devons admettre, m&ecirc;me si certains indices cliniques portent &agrave; le croire, que nous ne savons pas encore grand chose sur la port&eacute;e du travail psychologique pour contribuer &agrave; une meilleure stabilit&eacute; somatique et immunitaire. Par ailleurs, la recherche faite par le patient pour &quot;recadrer&quot; les traumatismes et att&eacute;nuer les offensives du stress, semble &ecirc;tre une combinaison d&eacute;licate qu' il essaie de d&eacute;chiffrer ou contr&ocirc;ler avec une probabilit&eacute; de succ&egrave;s limit&eacute;. Notre aide psychologique est sans doute un facteur de reconstruction symbolique et pragmatique. Nous esp&eacute;rons, gr&acirc;ce aux recherches actuelles ou &agrave; venir, de combiner notre contribution avec les approches  biologiques pour une meilleure stabilit&eacute; psychologique et immunologique des patients. <P><I>Bibliographie<BR></I><I><BR></I><I>Archinard, S. D., Savary, P.A. (1995). Les &eacute;tats de stress posttraumatique (PTSD) en m&eacute;decine. M&eacute;decine et Hygi&egrave;ne, n  2069. <BR></I><I><BR></I><I>H&uuml;sler, G., Hemmerlein, G., Perrez, M., Plancherel, B. (1993). L' intervention psychologique br&egrave;ve fribourgeoise pour s&eacute;ropositifs (IPBF) - un mod&egrave;le.<BR></I><I><BR></I><I>H&uuml;sler , G. (1995). Rapport annuelle 1994. Perspectives Plus. Universit_ de Fribourg. <BR></I><I><BR></I><I>Van Roods, Y.R., Bogaards, M., Goulmy, E, van Houwelingen, H.C. (1992). The effects of stress and relaxation on the in vitro immune response in man: A meta-analytic study. Journal of Behavioral Medecine, 16 (2), 163-181.</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-347</DOCNO>
<DOCOLDNO>IA017-000178-B042-306</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:2.4 192.33.214.13 19970106050729 text/html 5865
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:07:51 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Immunit&agrave;, sistema nervoso e psiche  cosa ne sappiamo oggi?</H3><BLOCKQUOTE><I>Prof. Dr. P.J. Grob, Divisione immunologia clinica, Reparto di medicina interna, ospedale dell'Universit&agrave; di Zurigo</I><P><B>La psiconeuroimmunologia, una combinazione di immunologia e neurobiologia, &egrave; una branca scientifica che &egrave; andata sviluppandosi negli ultimi 20&nbsp;anni. I ricercatori stanno studiando i meccanismi attraverso i quali il sistema nervoso centrale e le difese immunitarie si influenzano reciprocamente. Sebbene siano molte le cognizioni acquisite in questo campo, buona parte di esse sono tuttavia contraddittorie e di difficile interpretazione.<BR></B><B>Avvenendo spesso che la stampa, e non soltanto essa, susciti molte speranze a proposito di un favorevole influsso della psiche sul sistema immunitario, &egrave; necessario delineare brevemente qui di seguito lo stato attuale delle conoscenze da un punto di vista prettamente scientifico.</B><P><B>Basso livello di conoscenza dell'essere umano<BR></B><BR>Il nostro bagaglio attuale di cognizioni inerenti all'essere umano &egrave; ancora relativamente modesto e molto incompleto; ad esempio, la maggior parte degli importanti messaggeri non sono misurabili nel sangue, ma solo negli organi stessi. Allo scopo di acquisire una visione d'insieme pi&ugrave; completa, sono stati eseguiti a Zurigo due lavori di ricerca aventi come tema:<P>Influenza della psiche sul sistema immunitario e sulla genesi della malattia nella persona sana.<P><OL><LI>Influenza della psiche sul decorso di malattie in cui i processi immunologici sono essenziali.<P><LI>In entrambi i lavori si &egrave; tenuto conto della bibliografia internazionale esistente tratta da pubblicazioni scientifiche ufficiali.</OL><P>Le interpretazioni dei risultati spesso controversi lasciano spazio a molte ipotesi, come ad es. &quot;lo stress &egrave; dannoso&quot;. Ma in base allo stato conoscitivo attuale se ne potrebbe dedurre anche l'ipotesi contraria e perfettamente sostenibile &quot;lo stress protegge e aiuta&quot;, in quanto il sistema immunitario &egrave; predisposto allo stress e possiede straordinarie capacit&agrave; di apprendimento e adattamento. Nessuna delle due ipotesi &egrave; dimostrabile, ma non per questo &egrave; possibile escluderle.<P>Da un punto di vista scientifico, entrambe appaiono improbabili perch&eacute; troppo semplici e dogmatiche; lo si pu&ograve; osservare in modo particolare nelle infezioni da virus HIV. Le persone che l'hanno contratto mostrano inizialmente un'iperstimolazione del sistema immunitario, seguita poi da una crescente diminuzione delle funzioni immunitarie. Se ci&ograve; si verifica, si dovrebbe stimolare il sistema immunitario. Ma le funzioni immunitarie, se stimolate, costituiscono la premessa di un rafforzamento dell'attivit&agrave; virale. Si dovrebbe allora inibire il sistema immunitario. Sotto questo aspetto appare evidente che probabilmente nessuna delle due ipotesi &egrave; valida. Qualora una di esse risultasse vera o se il sistema immunitario dovesse subire notevoli influenze di tipo psichico, si dovrebbe allora procedere con la massima cautela allo scopo di evitare dei danni.<P><B>Quali le conseguenze ?</B><P>Il benessere psichico &egrave; l'obiettivo primario di qualsiasi essere umano, sia egli sano o malato. Le persone che sono a contatto con il malato nonch&eacute; i medici e gli psicologi che lo assistono si sforzano di contribuire a stimolare il benessere psichico, nel qual caso sono soprattutto importanti la simpatia e l'impegno sociale. Anche altri interventi di natura psicologica come ad esempio la meditazione possono essere di aiuto e avere una certa importanza, semprech&eacute; essi mettano chi soffre in condizione di affrontare meglio il proprio destino. Molto discutibili sono invece tutte quelle forme di assistenza, intese a migliorare il benessere psichico, pi&ugrave; o meno legate a promesse di una salute sicura, di rallentamento o magari di arresto del progresso di una malattia. Inaccettabile &egrave; il fatto di dare del &quot;fallito&quot; a una persona la cui malattia si aggrava per non aver osservato alla lettera i metodi psicologici proposti. Ci&ograve; potrebbe indurre nel malato non soltanto ingiustificati sensi di colpa, ma addirittura far s&igrave; che in un ambiente ideologizzato venga adottato il dogma della &quot;colpa autoindotta&quot;, trasformando cos&igrave; in danno ci&ograve; che era stato concepito come ausilio.</BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-348</DOCNO>
<DOCOLDNO>IA017-000178-B042-318</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.1 192.33.214.13 19970106050737 text/html 2111
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:00 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Psychoimmunologie </H3><BLOCKQUOTE><B>P. Kaschka und H. N. Aschauer (Hrsg.)</B> <BR><I>Stuttgart, Thieme, 1990, 202&nbsp;S., Fr. 45.-</I><P>Die Herausgeber sagen es im Vorwort selbst:  Das vorliegende Buch besch&auml;ftigt sich als erstes deutschsprachiges Werk mit dem Thema der Interaktionen zwischen Zentralnervensystem, neuroendokrinem System und Immunsystem. Es erhebt keinen Anspruch auf Vollst&auml;ndigkeit oder Endg&uuml;ltigkeit.  Zudem ist es sehr auf die Psychiatrie zugeschnitten, und selbst der einzige Artikel im Zusammenhang mit HIV tr&auml;gt den Titel  Psychiatrische Auff&auml;lligkeiten im Verlauf der HIV-Infektion . Damit ist es bestenfalls f&uuml;r einige Fachleute interessant, und f&uuml;r sie d&uuml;rfte es wohl eher ein Klassiker sein.<BR><I><BR></I><I>ATP</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-349</DOCNO>
<DOCOLDNO>IA017-000178-B042-331</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.2 192.33.214.13 19970106050749 text/html 2620
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Biopsychologie von Stress und emotionalen Reaktionen.</H3><BLOCKQUOTE><B>G&uuml;nter Debus, Gisela Erdmann, Konrad Wolfgang Kallus</B><BR><I>Ans&auml;tze interdisziplin&auml;rer Forschung G&ouml;ttingen, Hogrefe, 1995, 356 S., DM 46.80</I><P>Dieses Buch ist dem 60. Geburtstag von Willhelm Hanke, einem angesehenen biologisch orientierten Psychologen, gewidmet und wohl von ihm nahestehenden Autoren redigiert. Der erste Satz des Geleitworts lautet:  Es gibt hunderte wenn nicht tausende von Buch- und Zeitschriftenpublikationen, die verschiedene Aspekte von Stress behandeln, und die Emotionen als Ursachen, Mediatoren oder Konsequenzen oder als direkte oder indirekte Indikatoren eines Stresszustandes einbeziehen.  Und so ist es. Im vorliegenden Buch beginnen alle Kapitel mit  Psychologie in Zusammenarbeit mit ... Biometrie, Verhaltensbiologie, Physiologie, Verhaltenspharmakologie, biologische Psychiatrie und Umweltwissenschaften .<P>Der Schreibende sah in diesem Buch zwar viel Aufschlussreiches, was es sehr lesenswert macht; es enth&auml;lt indessen nur andeutungsweise neue wissenschaftliche Erkenntnisse der Psycho-Neuro-Immuno-Endokrinologie, einem jungen, faszinierenden Gebiet, f&uuml;r das mehrere spezielle Fachzeitschriften existieren.<P><I>Prof. Dr. med. P. J. Grob<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-350</DOCNO>
<DOCOLDNO>IA017-000178-B043-13</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.3 192.33.214.13 19970106050804 text/html 3793
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:20 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Immunantwort und Psyche</H3><BLOCKQUOTE><B>Diether G.R. Findeisen, Lothar Pickenhain</B><BR><I>Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH, 1990, 125&nbsp;S., Fr.&nbsp;29.-<BR></I><BR> Der Mensch und seine Umwelt stellen eine sich wechselseitig beeinflussende Einheit dar  (S.&nbsp;13). Dieser Satz ist in den einleitenden Gedanken zu finden. Der rein naturwissenschaftlichen Betrachtungsweise der neueren Medizin stellen sie eine Medizin gegen&uuml;ber, die das Subjekt bzw. die Einheit von Organismus und Umwelt ber&uuml;cksichtigt, wie sie etwa in der antiken Medizin und in anderen Kulturkreisen bekannt ist. <P>Fortschritte und Erfolge bei der Behandlung der k&ouml;rperlichen Sch&auml;den, so die beiden emeritierten Medizin-Professoren, werden durch die Vernachl&auml;ssigung psychischer (psychosozialer) Sch&auml;digungen erkauft, die &uuml;ber den Stressmechanismus oder chronische psychische Belastungen zu Erkrankungen f&uuml;hren. Somit liegt das Buch geradlinig im Zeitgeist.<BR> <BR>Exemplarisch wird die These am Beispiel der Immunabwehr dargelegt. Im Kapitel  Der Mensch in seiner Umwelt  wird &uuml;ber die Systembeziehung Organismus und Umwelt der Mensch als ein sich selbstorganisierendes Subsystem  Selbst  vom  Nicht-Selbst  abgegrenzt. Die Verbindung beider wird durch das Immun- und Nervensystem garantiert, und die Kommunikation dieser beiden Systeme wird durch endokrinologische Zwischenglieder (Hormone, Transmitter) sichergestellt.<P><BR>Der zweite Teil des Buches befasst sich mit den St&ouml;rungen zwischen Individuum und Umwelt und der Gesunderhaltung des Systems Mensch. Gesundheit ist das Fliessgleichgewicht zwischen Organismus und Umwelt. Kommt es zu &uuml;berm&auml;ssigen Umwelteinwirkungen, bzw. reichen die Abwehr- und Verarbeitungsmechanismen nicht mehr aus, kommt es zu St&ouml;rungen. Unvermeidlich f&uuml;hrt das zum Begriff Stress. Die Wirkmechanismen von Stress werden vor allem auf der psychologischen Seite, bzw. in ihren Wirkungen auf das Immunsystem, erl&auml;utert. Der psychischen Seite der Stressverarbeitung, bzw. den Verarbeitungsmechanismen, wie sie mit dem Begriff  Coping  verbunden sind, und der dahinter stehenden 20j&auml;hrigen Forschung wird leider keine Zeile gewidmet.<P>Der letzte Teil, der sich mit der Gesunderhaltung befasst, ist weit weniger pr&auml;gnant und bleibt bei den g&auml;ngigen Tips zur  Stabilisierung des Immunsystems  stehen.<P><I>Dr. Gebhard H&uuml;sler</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-351</DOCNO>
<DOCOLDNO>IA017-000178-B043-24</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.4 192.33.214.13 19970106050814 text/html 2309
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:36 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Der Einflu&szlig; von Hypnose und Stre&szlig; auf das Blutbild.</H3><BLOCKQUOTE><B>Walter Bongartz</B><BR><I>Psychoh&auml;matologische Studien Frankfurt a.M., Lang, 1996, 299&nbsp;S., Fr.&nbsp;77.-</I><P>Das Manuskript diese Arbeit wurde an der Universit&auml;t Konstanz 1993 als Habilitationsschrift akzeptiert. Es ist sicher kein Buch, das dem Laien interessante Informationen vermitteln kann. Und auch der Fachmann findet kaum Revolution&auml;res. Die Resultate sind in manchen F&auml;llen zwar signifikant (was wohl nicht meinen kann, von biologischer Relevanz); oft sind sie widerspr&uuml;chlich und lassen sich nur mit Hypothesen interpretieren. Eingehend stellt das Buch methodologische Schwierigkeiten, wie etwa die Messung von Stress, dar.<BR> <BR>Wer glaubt, im vorliegenden Band eine Entscheidungshilfe f&uuml;r oder gegen Hypnosetherapien zu finden, muss entt&auml;uscht werden. Es ist eine der vielen akademischen Arbeiten, deren Titel zuviel verspricht.<P><I>ATP<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-352</DOCNO>
<DOCOLDNO>IA017-000178-B043-39</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.5 192.33.214.13 19970106050828 text/html 1991
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Stress und Stressbew&auml;ltigung.</H3><BLOCKQUOTE><B>Klaus Klein, Forschungsstelle f&uuml;r Gesundheitserziehung der Universit&auml;t K&ouml;ln (Hrsg.)<BR></B><I>Baltmannsweiler, Schneider (Reihe Praktische Gesundheitsf&ouml;rderung, Bd. 5), 1995, 33&nbsp;S., Fr.&nbsp;19.80<BR></I><BR>Arbeitsmaterialien in Theorie und Praxis f&uuml;r Lehrer, Kursleiter und Dozenten<BR><I><BR></I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>Hinweis</H3><BLOCKQUOTE><B>Eine von Dr. Peter Brauchli (Institut f&uuml;r Verhaltenswissenschaft der ETH Z&uuml;rich)</B><P>zusammengestellte Liste mit weiteren Literaturangaben zum Thema kann bei der Aids Info Docu bezogen werden.<BR></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:3.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-353</DOCNO>
<DOCOLDNO>IA017-000178-B043-53</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:3.6 192.33.214.13 19970106050837 text/html 1877
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:08:59 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Verhaltenstraining zur Stressbew&auml;ltigung.</H3><BLOCKQUOTE><B>Angelika Wagner-Link</B><BR><I>M&uuml;nchen, Pfeiffer, 1995, 235&nbsp;S., Fr. 38.<BR></I><BR>Arbeitsbuch f&uuml;r Therapeuten und Trainer<BR></BLOCKQUOTE><P><HR SIZE=3 WIDTH=80%><P><H3>Stress und Stressbew&auml;ltigung.</H3><BLOCKQUOTE><B>Zentralstelle f&uuml;r psychologische Information und Dokumentation Trier (Hrsg.)</B><BR><I>Trier, Universit&auml;t Trier, 1991-1992, 3 Bde., ca. DM 95.-- + Porto<BR></I><I><BR></I> Eine Spezialbibliographie deutschsprachiger Literatur<BR></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-354</DOCNO>
<DOCOLDNO>IA017-000178-B043-65</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.1.1 192.33.214.13 19970106050849 text/html 3306
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:08 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Kondome quer durchs Curriculum</H3><BLOCKQUOTE><B>Ian Harvey</B><BR><I>M&uuml;lheim an der Ruhr, Verlag an der Ruhr, 1995, 71&nbsp;S., Fr.&nbsp;29.80</I><P> Kondome quer durchs Curriculum  ist eine Mappe mit einzelnen Bl&auml;ttern, die das Thema   Kondom  aus verschiedenen Blickwinkeln bearbeitet, geeignet f&uuml;r die Schule beziehungsweise f&uuml;r den Unterricht mit Jugendlichen, aber auch f&uuml;r Eltern oder JugendarbeiterInnen. Das Buch bietet Hilfe, das Thema Kondom in den verschiedensten Zusammenh&auml;ngen aufzugreifen: in der Mathematik, Musik, Kunst, Geographie, Geschichte, Sprache, etc.<P>Der Aufbau ist einfach, klar und phantasievoll: In der Mathematik zum Beispiel werden Formeln erarbeitet, die den Prozentsatz von ungewollten Schwangerschaften in verschiedenen  europ&auml;ischen L&auml;ndern errechnen, in der Geographie werden die Anbaugebiete von Kautschuk vorgestellt usw. Zu jedem Unterrichtsfach stehen verschiedene Arbeitsbl&auml;tter zur Verf&uuml;gung, mit denen die Jugendlichen in Gruppen arbeiten k&ouml;nnen; f&uuml;r die Lehrperson gibt es jeweils Infobl&auml;tter mit Hintergrundinformationen und L&ouml;sungen zu den Arbeitsbl&auml;ttern.<P>Ich finde die Idee sehr gut und sinnvoll, das Thema Kondom und damit auch die Themen Verh&uuml;tung, sexuell &uuml;bertragbare Krankheiten und Sexualit&auml;t, aus dem Fach Biologie herauszuholen und es in allen m&ouml;glichen Unterrichtsf&auml;chern zu behandeln. Der Aufbau und die Aufmachung des Buches sind ansprechend, informativ und kreativ.<P>Allgemein wirft dieses Buch die Frage auf, wie in der Schule aktuelle und gesellschaftlich wichtige Themen bearbeitet und gelehrt werden sollen und k&ouml;nnen. Vernetzung, beziehungsweise f&auml;cher&uuml;bergreifendes Lehren, ist angesprochen, ebenso wie die Verantwortung jeder Lehrperson bez&uuml;glich der Vermittlung von Themen, die mit ihrem Fach nicht traditionell verbunden und potentiell tabuisiert sind.<P><I>Regina Meier</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:3.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-355</DOCNO>
<DOCOLDNO>IA017-000178-B043-79</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.1.2 192.33.214.13 19970106050857 text/html 3348
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:20 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Sexualerziehung in den deutschsprachigen Schulen des Kantons Bern.</H3><BLOCKQUOTE><B>Amt f&uuml;r Bildungsforschung der Erziehungsdirektion des Kantons Bern (Hrsg.) </B><BR><I>Inhalte, Methoden, Rahmenbedingungen - Ergebnisse einer Umfrage Bern, ED Kt. Bern, 1995, 45&nbsp;S.&nbsp;+&nbsp;Anhang, Fr.&nbsp;3.</I><P>Als Grundlage dieses Berichtes dient ein Fragebogen zur Sexualerziehung, der im Dezember 1993 an 250&nbsp;Lehrerinnen und Lehrer des deutschsprachigen Teils des Kantons Bern versandt wurde. Zus&auml;tzlich wurden 30&nbsp;Sch&uuml;lerinnen und Sch&uuml;ler des 8.&nbsp;und 9.&nbsp;Schuljahres befragt. Der Fragebogen zur Sexualerziehung enthielt Fragen<P><UL><LI>zum Inhalt und den Methoden des Sexualunterrichts<LI>zur Vorbereitung des Sexualunterrichts<LI>zu den Bestimmungen zur Sexualerziehung im Kanton Bern<LI>zur Lehrperson.</UL><P>Im ersten Teil des Berichtes werden die Grundlagen zur Sexualerziehung im Kanton Bern er&ouml;rtert, im zweiten Teil die Anlage und die Durchf&uuml;hrung der Umfrage aufgezeigt. Der dritte Teil pr&auml;sentiert die Ergebnisse.<P>Ich empfehle diesen Bericht vor allem den Verantwortlichen f&uuml;r die Aus- und Weiterbildung von Lehrkr&auml;ften. Es erschreckt in Anbetracht der Wichtigkeit der Themen - Aids, Verh&uuml;tung, Liebe, Sexualit&auml;t -, dass weit &uuml;ber die H&auml;lfte der Lehrpersonen ihre Ausbildung im Fach Sexualerziehung als  &uuml;berhaupt nicht  und  ungen&uuml;gend  bezeichnen. <P>Eine zweite Auff&auml;lligkeit sind die Methoden, die in der Sexualerziehung angewendet werden. Vorherrschend sind da  Information durch die Lehrperson  und  Klassengespr&auml;ch  genannt. Gerade in der Sexualerziehung w&auml;ren jedoch kreative M&ouml;glichkeiten wie etwa Werkstattunterricht dringend notwendig.<P><I>Velia H. Stoppa</I><P><I>Zu beziehen bei: <BR></I><I>Erziehungsdirektion des Kantons Bern Amt f&uuml;r Bildungsforschung <BR></I><I>Sulgeneckstrasse 70 3005 Bern<BR></I><I>Tel. 031 633 85 11 Fax 031 633 83 55<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-356</DOCNO>
<DOCOLDNO>IA017-000178-B043-90</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.1.3 192.33.214.13 19970106050906 text/html 1582
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Freundschaft, Liebe, Sexualit&auml;t.<BR>Arbeitshilfen f&uuml;r den Religions- und Ethikunterricht in der Sekundarstufe&nbsp;1</H3><BLOCKQUOTE><B>Rainer Gaedt</B><BR><I>G&ouml;ttingen, Vandenhoeck&nbsp;&amp;&nbsp;Ruprecht, 1995, 197&nbsp;S., Fr.&nbsp;33.30</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.1.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-357</DOCNO>
<DOCOLDNO>IA017-000178-B043-103</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.1.4 192.33.214.13 19970106050918 text/html 1690
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:37 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Sexualp&auml;dagogische Jungenarbeit</H3><BLOCKQUOTE><B>Reinhold Munding K&ouml;ln</B>, <BR><I>Bundeszentrale f&uuml;r gesundheitliche Aufkl&auml;rung, 1995, 77&nbsp;S., gratis</I><P><I>zu beziehen bei:<BR></I><I>Bundeszentrale f&uuml;r gesundheitliche Aufkl&auml;rung (BZgA)<BR></I><I>Ostmerheimer Str. 200; D-51101 K&ouml;ln<BR></I><I>Tel. 0049 221 899 20</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-358</DOCNO>
<DOCOLDNO>IA017-000178-B043-115</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.2.1 192.33.214.13 19970106050927 text/html 2930
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Mein Kind ist so und nicht anders.<BR>Erfahrungen und Ansichten einer Mutter zur homosexuellen Lebensweise ihres Kindes</H3><BLOCKQUOTE><B>Anke M. Bartels</B><BR><I>D&uuml;sseldorf, Econ, 1995, 207&nbsp;S., Fr.&nbsp;34.</I><P>Ein Buch von Eltern f&uuml;r Eltern homosexueller Kinder, ein erfrischend neuer Weg, um das Thema Homosexualit&auml;t zu beleuchten. Zwar hat die Autorin mit einer Arbeit zur Homosexualit&auml;t in Psychologie abgeschlossen, im vorliegenden Buch aber verzichtet sie weitestgehend auf Theorien.<P>Viel lieber erz&auml;hlt sie von ihrer eigenen Kindheit und Jugend, wie sie diese erlebt und empfunden hat, und was sie bei der Erziehung ihrer eigenen Kinder besser machen wollte. Dann berichtet sie von ihrer lesbischen Tochter Cathrin, ihren ersten Beobachtungen und Vermutungen, dem Coming-out der Tochter, wie sie als Mutter anf&auml;nglich M&uuml;he hatte, der lesbischen Lebensweise im Haus den gleichen Platz einzur&auml;umen, wie er f&uuml;r eine  normale  Beziehung selbstverst&auml;ndlich ist. Schliesslich folgen Reaktionen von Verwandten und Bekannten, Erfahrungen in anderen L&auml;ndern und mit anderen Eltern homosexueller Kinder und Beschreibungen der homosexuellen Subkultur Norddeutschlands, denn die Autorin hat mit ihrer Tochter zusammen viele Szenelokale besucht.<P>Das Buch liest sich leicht. Durch die grosse Palette an Gedanken und Erlebnissen, die darin vorkommen, klingen Bartels immer wieder eigene Erfahrungen und Erinnerungen an  und pl&ouml;tzlich wird Homosexualit&auml;t zu einer sehr realen und normalen Sache.<P><I>R&ouml;bi Berger</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.1.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-359</DOCNO>
<DOCOLDNO>IA017-000178-B043-125</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.2.2 192.33.214.13 19970106050936 text/html 3260
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:09:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Mitten ins Herz<BR>Eine Mutter erz&auml;hlt vom Coming-out ihres Sohnes</H3><BLOCKQUOTE><B>Rob Forman Dew</B><BR><I>Hamburg, Kabel, 1995, 238&nbsp;S., Fr.&nbsp;35.</I><P> Mitten ins Herz  ist die Geschichte Rob Forman Dews und ihrer Familie, deren Leben aus der allt&auml;glichen Bahn geworfen wird, als der Sohn Stephen der Familie er&ouml;ffnet, er sei schwul.  Indem Eltern von Geburt ihrer Kinder an voraussetzen, sie werden sich heterosexuell entwickeln, gef&auml;hrden sie deren Chancen auf eine gl&uuml;ckliche Zukunft.  Die Autorin ist eine sehr genaue Frau. Sie beschreibt ihre Gef&uuml;hle und Beobachtungen &auml;usserst pr&auml;zis. Da l&auml;sst sich nicht schummeln: Wer nicht mitdenkt, liest nicht mehr weiter.<P> Durch das, was Stephen in seinem Leben alles erreichen w&uuml;rde, hatten wir gehofft, uns selber ein Denkmal zu schaffen, und diese Chance schien nun vertan. In Stephens Kindern und Enkelkinder hatten wir gehofft, Unsterblichkeit zu erlangen. Nat&uuml;rlich sage ich mir heute, dass Stephen es im Leben durchaus zu etwas bringen kann und vielleicht sogar Kinder haben wird, aber mit unserer Unsterblichkeit ist es ein f&uuml;r allemal vorbei. <P>Das M&uuml;hsame: Die Autorin liebt verschachtelte Geschichten. Immer wieder blendet sie zur&uuml;ck, erz&auml;hlt von fr&uuml;heren Begebenheiten, die pl&ouml;tzlich von Belang werden, bringt abschnittlange Vergleiche von Gef&uuml;hlen und Naturereignissen, um nicht falsch verstanden zu werden. Das alles mag zwar gut gemeint sein, macht das Buch aber oft schwer lesbar. Schliesslich ist der &Uuml;bersetzer ein paar Mal &uuml;berfordert: Die verschachtelten S&auml;tze gehen nicht mehr auf, und die amerikanische Satzstellung schl&auml;gt &uuml;berm&auml;ssig durch.<P>Das Gute: Die Pr&auml;zision, mit der sich die Autorin auszudr&uuml;cken pflegt, bringt manch diffuses Gef&uuml;hl oder Wissen auf den Punkt.<P><I>R&ouml;bi Berger</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-360</DOCNO>
<DOCOLDNO>IA017-000178-B043-138</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.2.3 192.33.214.13 19970106050945 text/html 1724
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:10:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Sexualit&auml;t, Lebensformen, Liebe</H3><BLOCKQUOTE><B>Wilfried H&auml;rle, Reiner Preul (Hrsg.)</B><BR><I>Marburg, Elwert (Reihe Marburger Jahrbuch Theologie, Bd.&nbsp;7), 1995, 135&nbsp;S., Fr.&nbsp;42.-</I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>Bisexualit&auml;t</H3><BLOCKQUOTE><B>Francis H&uuml;sers, Almut K&ouml;nig</B><BR><I>Stuttgart, Thieme, 1995, 164&nbsp;S., Fr.&nbsp;34.-</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.2.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-361</DOCNO>
<DOCOLDNO>IA017-000178-B043-156</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.2.4 192.33.214.13 19970106050957 text/html 2183
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:10:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Abschied von der sexuellen Revolution. <BR>Liebe und Sexualit&auml;t der  Nach-68er-Generation  in Zeiten von Aids </H3><BLOCKQUOTE><B>Hans Bardeleben, Ralf Fieberg, Bruno W. Reimann</B><BR><I>Berlin, Sigma (Reihe Ergebnisse sozialwissenschaftlicher Aids-Forschung, Bd.&nbsp;15), 1995, 316&nbsp;S.,</I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>Strichpunkt. Theoretische &Uuml;berlegungen und Situationsbericht zur Stricherszene Bahnhof Bern. </H3><BLOCKQUOTE><B>Franz-Othmar Schaad, Judith Lorenz</B><BR><I>Diplomarbeit Solothurn, H&ouml;here Fachschule f&uuml;r Soziale Arbeit, 3. Aufl., 1995, 126 S., Fr. 35.-</I><P><I>Bezug: Strichpunkt,<BR>Postfach 364; 4566 Kriegstetten<P>Ausleihe:<BR>Studien- und Bildungsbibliothek des SLS in Solothurn<BR>Schweizerisches Sozialarchiv, Z&uuml;rich<BR>Stadt- und Universit&auml;tsbibliothek, Bern</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.3.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-362</DOCNO>
<DOCOLDNO>IA017-000178-B043-169</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.3.1 192.33.214.13 19970106051007 text/html 2705
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:10:27 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Bittere Naturmedizin</H3><P><B>Roland Bettschart et al.</B><BR><I>K&ouml;ln, Kiepenheuer &amp; Witsch, 1995, 926&nbsp;S., DM&nbsp;49.80</I><P>Die Alternativmedizin boomt. Sch&auml;tzungen aus Deutschland sagen, dass bis zu einem Drittel aller Aufwendungen im Medizinbereich in diese Sparte fliessen. Aber bekommen die Patienten auch einen reellen Gegenwert f&uuml;r ihr Geld? Die Szene ist undurchsichtig: Mediziner mit Zusatzausbildung bieten ihre Hilfe an, Heilpraktiker mischen mit und auch Scharlatane machen sich breit. Zudem gibt es f&uuml;r die Mehrzahl der zur Frage stehenden Methoden kaum kontrollierte Studien, die Gesichertes &uuml;ber ihre Wirksamkeit aussagen.<P>Die Autoren, darunter auch Reinhard Saller, Professor f&uuml;r Naturheilkunde am Departement f&uuml;r Innere Medizin am Universit&auml;tsspital Z&uuml;rich, haben die Riesenaufgabe gepackt und eine vermutlich fast vollst&auml;ndige &Uuml;bersicht der bekannten Alternativmethoden zusammengestellt. Geordnet nach Krankheitssymptomen werden sie jeweils bewertet. Von  zweckm&auml;ssig  &uuml;ber  wenig zweckm&auml;ssig  bis  abzuraten  sind sie klassifiziert. <P>Falls man Alternativtherapien nicht mit dem behandelnden Arzt abspricht, sollte zumindest dieses Buch konsultiert werden. Es kann helfen, Sch&auml;den zu vermeiden, seien sie k&ouml;rperlicher oder finanzieller Art.<P><I>ATP</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.2.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.3.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-363</DOCNO>
<DOCOLDNO>IA017-000178-B043-183</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.3.2 192.33.214.13 19970106051018 text/html 2192
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:10:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.4.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Kooperation und Rivalit&auml;t in der spitalexternen Gesundheitsversorgung. <BR>Quartierbezogene Dienste in Z&uuml;rich</H3><BLOCKQUOTE><B>Monica Budowski, Waltraut Schmied Mattanza</B><BR><I>Z&uuml;rich, Seismo, 1995, 168&nbsp;S., Fr.&nbsp;29.-</I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>The Cellular Basis of Central Nervous System HIV-1 Infection and the Aids Dementia Complex </H3><BLOCKQUOTE><B>Richard W. Price, John J. Sidtis (Hrsg.)</B><BR><I>New York, Haworth Press (Journal of Neuro-Aids, Volume&nbsp;1, Number&nbsp;1), 1996, 173&nbsp;S.</I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>Neuropsychologische Untersuchungen zur kognitiven Leistungsf&auml;higkeit HIV-infizierter Patienten</H3><BLOCKQUOTE><B>Marcia Coutinho Krahforst</B><BR><I>Berlin, VWF (Reihe Akademische Abhandlungen zur Psychologie), 1995, 171&nbsp;S., Fr.&nbsp;78.-</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.3.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.4.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-364</DOCNO>
<DOCOLDNO>IA017-000178-B043-198</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.4.1 192.33.214.13 19970106051037 text/html 3672
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:10:49 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.4.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Menschen mit Aids pflegen: i.v. DrogengebraucherInnen </H3><BLOCKQUOTE><B>Michael Ewers, Winnie Weicht (Hrsg.)</B> <BR><I>Frankfurt&nbsp;a.M., Mabuse, 1995, 225&nbsp;S., Fr.&nbsp;36.</I><P>Dieses Buch gibt in knapper Form detaillierte Auskunft zum Thema, und &uuml;berall strahlt grosse praktische Vertrautheit mit den Problemen durch. Elf Autoren, Frauen und M&auml;nner mit jahrelanger Berufserfahrung in Drogenarbeit, berichten von folgenden Standpunkten aus: Krankenpflege, Medizin, Sozialarbeit, Hauswirtschaft, Ern&auml;hrungslehre und Organisation von Selbsthilfegruppen bis hin zu vernetzten Behandlungs- und F&uuml;rsorgeinstitutionen in deutschen Grossst&auml;dten. Drei Verfasser schildern ihre eigene Betroffenheit als Drogenkonsumenten und Kranke und beschreiben ihre Erfahrungen mit Verwahrlosung, Kriminalit&auml;t, Gef&auml;ngnis und Therapie.<P>Der Leser findet eine vielf&auml;ltige &Uuml;bersicht &uuml;ber die Drogen- und Aidsproblematik und die damit verbundene k&ouml;rperliche, psychische, soziale und spirituelle Not  lebensnahe und realistische Schilderungen der Schwere und Gr&ouml;sse der Probleme, welche die HIV-Infizierten und Aidspatienten, ihre Angeh&ouml;rigen und unsere ganze Gesellschaft betreffen.<P>Grundlage des Buches sind tiefes Verst&auml;ndnis und Akzeptanz des drogenabh&auml;ngigen Mitmenschen. &Uuml;berall wird die allgemeine Erfahrung deutlich, dass Ernstnehmen des Patienten und geduldiges Eingehen auf seine pers&ouml;nlichen Bed&uuml;rfnisse und Sorgen kurz- und langfristig der erfolgreichere Weg sind  besser als die Forderung nach einer grunds&auml;tzlichen &Auml;nderung des Lebensstils und theoretisch w&uuml;nschbarer totaler Drogenabstinenz, welche f&uuml;r die Betroffenen in ihrer Bedr&auml;ngnis als erste Schritte nicht realisierbar sind.<P>Eingehend sind die Schwierigkeiten und gangbaren L&ouml;sungen im Alltag von Pflege und Behandlung erw&auml;hnt, vom Spritzenabszess bis zur Unterst&uuml;tzung des hilflos und verwirrt gewordenen Schwerkranken und zur Sterbebegleitung.<P>Dem Buch mit hohem praktischem und ideellem Wert sind viele aufmerksame Leser zu w&uuml;nschen. Es ist zu hoffen, dass solche Hilfsbereitschaft und Hilfsf&auml;higkeit immer klarer das Bewusstsein unserer Zeit erf&uuml;llt.<P><I>Dr. med. Walter Munz<BR></I><I>Sune-Egge, Z&uuml;rich</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.3.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.4.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-365</DOCNO>
<DOCOLDNO>IA017-000178-B043-215</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.4.2 192.33.214.13 19970106051046 text/html 1941
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:09 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.4.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.5.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Arbeit, Ausbildung und Qualifikation f&uuml;r Drogengebraucher in Substitutionsbehandlung</H3><BLOCKQUOTE><B>Heino St&ouml;ver (Hrsg.)</B><BR><I>Berlin, Deutsche Aids-Hilfe&nbsp;e.V. (Reihe Aids-Forum D.A.H., Bd.&nbsp;XIX), 176&nbsp;S., gratis</I><P><I>zu beziehen bei:<BR></I><I>Deutsche Aids-Hilfe e.V.<BR></I><I>Dieffenbachstrasse 33; 10967 Berlin<BR></I><I>Tel. 0049 306 900 870</I></BLOCKQUOTE><p><hr size=3 width=80%><p><H3>Die Berner Drogenszene </H3><BLOCKQUOTE><B>Norman Braun, Andreas Diekmann, Jonas Peter Weber, Claudia Zahner</B><BR><I>Bern, Paul Haupt, 1995, 135&nbsp;S., Fr.&nbsp;38.-</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.4.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:4.5.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-366</DOCNO>
<DOCOLDNO>IA017-000178-B043-230</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:4.5.1 192.33.214.13 19970106051055 text/html 3044
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:17 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.4.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Mein Gott AIDS</H3><BLOCKQUOTE><B>Markus Commer&ccedil;on</B><BR><I>Augsburg, Pattloch, 1995, 144&nbsp;S., Fr.&nbsp;29.80</I><P> Schreiben Sie Ihre Geschichte mit Gott! Sie haben doch eine , riet ihm der Lektor des Verlags, und Markus Commer&ccedil;on schrieb. Es ist sein drittes Coming-out; als schwul und HIV-infiziert hat er sich schon fr&uuml;her dem Leserpublikum vorgestellt. Hier nun bekennt er sich zu seinem Glauben an Gott, zu dem er sich  schutzsuchend und vertrauensvoll  wendet mit seiner allzumenschlichen Frage nach dem Sinn seines Lebens. Allzumenschlich, ja gr&ouml;sstenteils r&uuml;hrend, ist dementsprechend sein Buch. Ausgehend von einer biographischen Notiz skizziert er tagebuchartig, wie er  mit Aids lebt, liebt, leidet und glaubt.  Ein Regenbogen von Assoziationen und Gef&uuml;hlen. <P>Wer aufgrund des vielverspechenden Titels tiefsch&uuml;rfende theologische Reflexionen erwartet, wird sicher entt&auml;uscht. Das Buch hat mich dennoch beeindruckt. Hier schreibt eine empfindsame kindliche Seele, die in ihrer Biographie mit Aids alle erdenklichen Tiefen und H&ouml;henfl&uuml;ge erlebt hat, ihr kleines ABC des Lebens. Die Botschaft ist einfach: wo die Seele an der Sinnsuche scheitert, offenbart sich ihr das Geheimnis Gottes, der ihn liebt und der es gut mit ihm meint. Was das Leben mit Aids angeht, k&ouml;nnte er unbedarfte Leser aufkl&auml;ren, doch verliert Commer&ccedil;on sich in Banalit&auml;ten. Das ist streckenweise &auml;rgerlich, manchmal erschreckend. St&auml;rker sind dann wieder die letzten Kapitel &uuml;ber Sterben und Tod. Dennoch w&uuml;rde ich dieses Buch niemandem schenken, der noch Anspr&uuml;che ans Lesen stellt. <BR><I><BR></I><I>Ruedi Weber</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.4.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-367</DOCNO>
<DOCOLDNO>IA017-000178-B043-243</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.1 192.33.214.13 19970106051104 text/html 6298
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.5.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Le sida et les fragilit&eacute;s fran&ccedil;aises: nos r&eacute;actions face &agrave; l'&eacute;pid&eacute;mie</H3><BLOCKQUOTE><B>Jean de Savigny</B><BR><I>Paris, Albin Michel, 1995, 377 p., 125 FF</I><P>Ancien directeur de la d&eacute;funte Agence fran&ccedil;aise de lutte contre le sida, Jean de Savigny se propose avec ce livre d'alimenter le d&eacute;bat sur l'organisation de la lutte contre l'&eacute;pid&eacute;mie et son impact sur la soci&eacute;t&eacute;. Il nous livre le regard d'un expert qui s'est form&eacute; sur le terrain - il n'avait aucune exp&eacute;rience de la pr&eacute;vention lors de sa nomination ! - et dont la situation actuelle, &agrave; l'&eacute;cart des structures sp&eacute;cialis&eacute;es, lui facilite une prise de distance critique face aux opinions pr&eacute;con&ccedil;ues et aux st&eacute;r&eacute;otypes.  Tour &agrave; tour sont abord&eacute;s les divers aspects de la lutte contre le virus, l'&eacute;valuation de l'efficacit&eacute; pr&eacute;ventive, le choc social, les menaces hors des fronti&egrave;res de l'Occident.<P>D'embl&eacute;e, l'auteur estime que ni l'incrimination de la transmission, ni la violation du secret m&eacute;dical pour identifier et avertir les partenaires, ne sont compatibles avec l'appel &agrave; la responsabilisation de tous ceux qui prennent des risques, ind&eacute;pendamment de leur statut s&eacute;rologique. Il se montre plus critique &agrave; l'&eacute;gard d'autorit&eacute;s qui, choisissant de noircir le mal, brandissent une menace g&eacute;n&eacute;rale cens&eacute;e convaincre chacun d'adopter des comportements ad&eacute;quats. C'est vers les groupes les plus expos&eacute;s que devrait se diriger en priorit&eacute; la pr&eacute;vention; ni les h&eacute;t&eacute;rosexuels, ni les jeunes ne feraient partie de ces groupes, &eacute;tant cependant entendu que &quot;&nbsp;tout citoyen peut se mettre dans une situation &agrave; risques&nbsp;&quot;. C'est l&agrave;, pr&eacute;cis&eacute;ment, la grande difficult&eacute; d'une politique contrainte &agrave; hi&eacute;rarchiser ses cibles sans pour autant oublier la population g&eacute;n&eacute;rale. Et qui ne peut, de surcro&icirc;t, occulter l'impact d&eacute;mobilisateur sur l'opinion de la mise en &eacute;vidence des populations les plus touch&eacute;es.  Ces contraintes impliquent une action &quot;&nbsp;sur le fil du rasoir&nbsp;&quot;, d'autant plus efficace qu'elle saura &eacute;viter les demi-mensonges tactiques et prendre les initiatives qui s'imposent. A cet &eacute;gard, Jean de Savigny souligne les cons&eacute;quences d&eacute;sastreuses de la r&eacute;f&eacute;rence exclusive aux relations h&eacute;t&eacute;rosexuelles dans les campagnes destin&eacute;es aux jeunes: &quot;&nbsp;...le jeune qui se d&eacute;couvre homosexuel a toute chance de mener ses premi&egrave;res exp&eacute;riences avant d'avoir re&ccedil;u une information sur l'homosexualit&eacute; et les risques de contamination. Tout cela explique que le quart des malades homosexuels a entre 20 et 30 ans, ce qui signifie une contamination pendant l'adolescence!&nbsp;&quot; Les insuffisances concernent aussi la toxicomanie. La p&eacute;nalisation de l'usage des stup&eacute;fiants a longtemps entrav&eacute; les actions sp&eacute;cifiques avec, pour r&eacute;sultat, que la majorit&eacute; des nouvelles contaminations des 20-29 ans est attribu&eacute;e aujourd'hui aux &eacute;changes de seringues.<P>A ces r&eacute;serves pr&egrave;s, l'approche pr&eacute;ventive fond&eacute;e sur la responsabilisation est jug&eacute;e globalement positive. L'auteur estime que &quot;&nbsp;tous les voyants sont au vert&nbsp;&quot; et fait un sort &agrave; la &quot;&nbsp;soi-disant acc&eacute;l&eacute;ration de la diffusion de l'&eacute;pid&eacute;mie dans la population h&eacute;t&eacute;rosexuelle&nbsp;&quot;, m&ecirc;me si &quot;&nbsp;&agrave; l'int&eacute;rieur du contingent total des nouveaux contamin&eacute;s - globalement en baisse - un r&eacute;&eacute;quilibrage est observ&eacute; entre les h&eacute;t&eacute;rosexuels en augmentation relative et les autres cat&eacute;gories&nbsp;&quot;. Ce qui ne saurait justifier une baisse de vigilance puisque les r&eacute;sultats obtenus renforcent au contraire les arguments en faveur d'un effort soutenu.<P>Sur le th&egrave;me des &eacute;branlements sociaux induits par le sida, le lecteur ne restera pas indiff&eacute;rent  aux r&eacute;flexions de l'ancien directeur de l'AFLS, &eacute;clairage mod&eacute;r&eacute;, critique, contestable aussi,  d'un univers parfois emport&eacute; par l'urgence et les convictions oblig&eacute;es. Et face &agrave; l'effort d&eacute;risoire de solidarit&eacute; internationale (l'aide globale &eacute;quivaut &agrave; deux mois et demi de d&eacute;penses sida en France), c'est la question cruciale d'une perte de la guerre men&eacute;e contre le sida dans le tiers monde qui est pos&eacute;e en conclusion.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:4.5.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.2"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-368</DOCNO>
<DOCOLDNO>IA017-000178-B043-266</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.2 192.33.214.13 19970106051116 text/html 2134
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:38 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Le sida </H3><BLOCKQUOTE><I>Toulouse, Editions Milan, 1995, 64 p., 15 FF<BR></I><BR>L'essentiel du sida en 64 pages pour le lecteur press&eacute;. Pari insens&eacute;, pari r&eacute;ussi pourtant gr&acirc;ce &agrave; la comp&eacute;tence sans faille d'Arcat-Sida conjugu&eacute;e &agrave; une pr&eacute;sentation s&eacute;duisante et &eacute;minemment pratique. Rien ne manque des aspects historiques, pr&eacute;ventifs, m&eacute;dicaux, sociaux, de l'infection &agrave; VIH; chaque chapitre est r&eacute;sum&eacute;; un index, un glossaire, une courte bibliographie facilitent l'orientation et engagent &agrave; une exploration plus pointue. Seule &eacute;tranget&eacute;, la page consacr&eacute;e aux  associations &agrave; l'&eacute;tranger oublie la Belgique, le Qu&eacute;bec et la Suisse...<P><I>Rch<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.1"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.3"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-369</DOCNO>
<DOCOLDNO>IA017-000178-B043-278</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.3 192.33.214.13 19970106051125 text/html 2423
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:48 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Les sciences sociales face au sida</H3><BLOCKQUOTE><B>Jean-Pierre Dozon, Laurent Vudal</B><BR><I>Paris, Orstom Editions, 1995, 304 p.<BR></I><BR><B>Cas africains autour de l'exemple ivoirien</B><P>Les sciences humaines revendiquent, au m&ecirc;me titre que la m&eacute;decine, leur pleine part dans la recherche men&eacute;e autour du sida. Aucune strat&eacute;gie pr&eacute;ventive ne peut se satisfaire de la diffusion neutre de conseils &quot;&nbsp;techniques&nbsp;&quot; en oubliant les repr&eacute;sentations sociales qui se forgent autour de la maladie. Entre l'universalit&eacute; des principes &eacute;thiques, heureusement rappel&eacute;s par Fran&ccedil;oise H&eacute;ritier-Aug&eacute;, et les sp&eacute;cificit&eacute;s culturelles, l'articulation fait parfois probl&egrave;me. Cet ouvrage, qui reproduit les actes d'un atelier qui s'est tenu en 1993 en C&ocirc;te d'Ivoire, stimule une meilleure prise de conscience tout en d&eacute;busquant pr&eacute;jug&eacute;s et a priori culturels qui rendent souvent probl&eacute;matiques la coop&eacute;ration euro-africaine.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.2"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.4"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-370</DOCNO>
<DOCOLDNO>IA017-000178-B043-293</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.4 192.33.214.13 19970106051135 text/html 3387
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:11:57 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Comment vivre avec une personne atteinte par le virus du sida ?</H3><BLOCKQUOTE><B>Pierre Kneip</B><A HREF="INFOTHEQUE.cgi?9601:5.4#noteX1" NAME="retourX1">*</A><BR><I>Paris, Editions Josette Lyon, 1995, 198 p., 78 FF</I><P>&quot;&nbsp;Soutenir et accompagner ceux qui soutiennent et accompagnent&nbsp;&quot;, tel est l'objectif de ce livre. Directeur du service d'aide t&eacute;l&eacute;phonique Sida Info Service (SIS), Pierre Kneip estime que la formation du proche passe par un apprentissage et un d&eacute;conditionnement propres &agrave; d&eacute;gager la maladie individuelle de la gangue sociale dont elle serait prisonni&egrave;re et du silence paradoxal dont elle s'entoure.<P>A partir de situations concr&egrave;tes et repr&eacute;sentatives, souvent illustr&eacute;es par des extraits anonymis&eacute;s de questions pos&eacute;es &agrave; SIS, l'auteur passe en revue le traumatisme de l'annonce de la s&eacute;ropositivit&eacute;, la gestion du secret, les crises en s&eacute;rie qui &eacute;maillent la vie, les attitudes face &agrave; la mort. Le processus de mise en proximit&eacute; fait appel &agrave; la relation humaine, &agrave; la capacit&eacute; de se mettre &agrave; la hauteur de l'interlocuteur tout en &eacute;vitant de lui dire n'importe quoi ou de lui sugg&eacute;rer des mod&egrave;les &eacute;trangers &agrave; sa sensibilit&eacute;: pens&eacute;e positive, attitude h&eacute;ro&iuml;que, confusion entre droit et devoir de savoir. Mettre en confiance, ne pas c&eacute;der &agrave; des mod&egrave;les pr&eacute;&eacute;tablis, &eacute;viter les tentations maladroitement bienveillantes ou les abus captateurs, telles sont les lignes de force qui guident les r&eacute;ponses propos&eacute;es par  cet ouvrage &eacute;minemment utile et qui pourrait servir, aussi, d'appui &agrave; la formation des r&eacute;pondants des permanences t&eacute;l&eacute;phoniques.<P><I>RCh<BR></I><BR><A HREF="INFOTHEQUE.cgi?9601:5.4#retourX1" NAME="noteX1">*</A> Pierre Kneip est d&eacute;c&eacute;d&eacute; du sida le 2 d&eacute;cembre 1995.<BR></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.3"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.5"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-371</DOCNO>
<DOCOLDNO>IA017-000178-B043-307</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.5 192.33.214.13 19970106051144 text/html 3352
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:05 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Un amour s&eacute;rodiff&eacute;rent </H3><BLOCKQUOTE><B>Isabelle Muller</B><BR><I>Paris, Seuil, 1995, 203 p., 95 FF</I><P>Sans pr&eacute;tentions litt&eacute;raires, ce t&eacute;moignage relate le parcours insolite de l'amour d'une femme s&eacute;ron&eacute;gative pour un homme s&eacute;ropositif. Une exp&eacute;rience rare, qui ne pr&eacute;tend pas &agrave; l'exemplarit&eacute;, mais qui r&eacute;v&egrave;le avec acuit&eacute; les rapports ambivalents du ressenti intellectuel et de l'emportement &eacute;motionnel. Et qui met aussi en &eacute;vidence la souffrance d'une confrontation quotidienne avec la mort et le deuil annonc&eacute;s. La peur du virus qui tend &agrave; se confondre avec la peur culpabilisante vis-&agrave;-vis de celui qui en est porteur. Le d&eacute;ni, tant&ocirc;t utile parce qu'il prot&egrave;ge, tant&ocirc;t dangereux quand il conduit &agrave; l'&quot;&nbsp;amour &agrave; mort&nbsp;&quot; de rapports temporairement sans protection. La solitude du proche, r&eacute;duit au silence de la pudeur, mis parfois &agrave; l'&eacute;cart, cloisonn&eacute; dans une s&eacute;ron&eacute;gativit&eacute; qui le rend irr&eacute;m&eacute;diablement diff&eacute;rent de l'&ecirc;tre aim&eacute;. La haine du virus, la col&egrave;re contre ceux qui en parlent avec toute l'objectivit&eacute; du d&eacute;tachement scientifique et toute la cruaut&eacute; du d&eacute;tachement &eacute;motionnel.<P>Un livre qui ne donne pas dans l'h&eacute;ro&iuml;sme, souligne au contraire la difficult&eacute; de vivre avec et &agrave; proximit&eacute; du virus, quand l'amour et la tendresse se heurtent &agrave; l'angoisse omnipr&eacute;sente des &quot;&nbsp;calculs lugubres&nbsp;&quot;. Le sida bouleverse tragiquement la vie; il n'engage pas plus au d&eacute;tachement qu'il ne m&eacute;rite d'&ecirc;tre banalis&eacute; au rang de l'&eacute;v&eacute;nement ordinaire. Isabelle Muller nous le rappelle en &eacute;voquant son amour extraordinaire et singuli&egrave;rement &eacute;prouvant.<P><I>RCh.<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.4"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-372</DOCNO>
<DOCOLDNO>IA017-000178-B043-321</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.6 192.33.214.13 19970106051152 text/html 3791
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:14 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Ev&eacute;nements quotidiens et bien-&ecirc;tre &agrave; l'adolescence: vers de nouvelles strat&eacute;gies d'&eacute;ducation pour la sant&eacute;</H3><BLOCKQUOTE><B>Daniel Cordonier</B><BR><I>Gen&egrave;ve, M&eacute;decine et Hygi&egrave;ne, 1995, 224 p., 44 FS</I><P>Souhaitant jeter un pont entre l'univers des chercheurs et celui des praticiens, Daniel Cordonier propose une strat&eacute;gie d'&eacute;ducation &agrave; la sant&eacute; fond&eacute;e sur l'&eacute;tude de la vie quotidienne des jeunes &agrave; travers une approche &eacute;v&eacute;nementielle. Une enqu&ecirc;te, men&eacute;e aupr&egrave;s de plusieurs centaines d'adolescents valaisans, a servi de base &agrave; l'analyse de la perception et des effets des &eacute;v&eacute;nements quotidiens sur les composantes de leur bien-&ecirc;tre et de la place accord&eacute;e aux &eacute;v&eacute;nements touchant la sant&eacute; physique par rapport aux autres &eacute;v&eacute;nements. A l'oppos&eacute; des &quot;&nbsp;&eacute;v&eacute;nements pr&eacute;gnants&nbsp;&quot; que sont les relations avec le sexe oppos&eacute; et les loisirs, les probl&egrave;mes de sant&eacute; physique sont ressentis &agrave; la fois comme peu importants et moins ma&icirc;trisables. Des r&eacute;sultats qui apparaissent en contradiction avec les pr&eacute;missent des mod&egrave;les pr&eacute;ventifs &eacute;tablissant un lien entre bien-&ecirc;tre et absence de maladie. Ce qui conduit l'auteur &agrave; pr&eacute;coniser la construction des actions pr&eacute;ventives comme &quot;&nbsp;&eacute;v&eacute;nements&nbsp;&quot; susceptibles, de surcro&icirc;t, d'&ecirc;tre modul&eacute;s en fonction des variables de la perception propres &agrave; l'&acirc;ge, au sexe, aux situations sociales. Conscient des ambigu&iuml;t&eacute;s normatives d'une approche apparent&eacute;e, par certains traits, &agrave; la strat&eacute;gie publicitaire, Daniel Cordonier propose de la compl&eacute;ter par un &quot;&nbsp;p&ocirc;le p&eacute;dagogique&nbsp;&quot; qui devrait aider les adolescents &agrave; g&eacute;rer leur bien-&ecirc;tre dans un espace de pouvoir pr&eacute;servant autonomie et libert&eacute; d'action.<BR>Les pistes th&eacute;oriques et pratiques dessin&eacute;es dans cet ouvrage appellent d&eacute;bat et exploration, ce d'autant plus que rien n'est dit quant &agrave; l'articulation entre strat&eacute;gie &eacute;v&eacute;nementielle et pr&eacute;vention des MST et du sida.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.5"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.7"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-373</DOCNO>
<DOCOLDNO>IA017-000178-B043-336</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.7 192.33.214.13 19970106051201 text/html 4392
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:24 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Le mort et moi et nous</H3><BLOCKQUOTE><B>Patrick Baudy, Marie-Th&eacute;r&egrave;se Gatt, Bernard Paillard</B><I><BR></I><I>Paris, Textuel, 1995, 170 p., 125 FF<BR></I><BR>Est-ce vraiment le d&eacute;ni de la mort qui fait question dans nos soci&eacute;t&eacute;s? N'est-ce pas le d&eacute;ficit de sociabilit&eacute;, la difficult&eacute; &agrave; recr&eacute;er des liens pour mieux vivre, qu'il conviendrait plut&ocirc;t d'interroger?<P>De disciplines et d'exp&eacute;riences diverses, les auteurs de ce livre apportent des &eacute;clairages parfois nouveaux sur les rapports de la finitude avec la modernit&eacute;.<P>Si la d&eacute;shumanisation que l'on ressent aujourd'hui autour de la mort appelle correction, toutes les recettes ne sont pas bonnes &agrave; prendre. Ainsi, le pari de la &quot;&nbsp;bonne mort&nbsp;&quot;, du &quot;&nbsp;mourir comme dans une image&nbsp;&quot; peut aboutir &agrave; de dramatiques d&eacute;sillusions. Exhumer des rituels ancr&eacute;s dans des id&eacute;ologies disparues rel&egrave;ve de l'artifice. Escamoter le deuil brise les liens sociaux et m&egrave;ne &agrave; l'exil psychologique.<P>Humaniser les rapports, c'est tout &agrave; la fois contester la dislocation impos&eacute;e aux individus et inventer de liens et des rituels porteurs de sens pour les groupes qui les pratiquent. Ainsi se trouve mis en cause, dans ce contexte, le morcellement des corps &agrave; l'h&ocirc;pital, qui a pour effet de briser les personnes; la confiscation des d&eacute;pouilles par la famille l&eacute;gale, qui laisse les compagnons homosexuels seuls face &agrave; leurs souvenirs, est &eacute;galement &eacute;voqu&eacute;. Parmi les pistes &agrave; suivre, l'accent est mis sur la r&eacute;habilitation du relationnel, vraie sp&eacute;cificit&eacute; des soins palliatifs; le Patchwork des noms est appr&eacute;hend&eacute; comme un rituel qui plonge dans la modernit&eacute; et ferait du sida &quot;&nbsp;l'un des grands moments fondateurs de l'histoire sociale&nbsp;&quot;.<P>Le d&eacute;ni de sa propre mort - il y a, selon un des auteurs, &quot;&nbsp;de la sagesse dans l'id&eacute;e de ne pas se souvenir que l'on doit mourir&nbsp;&quot; - ne saurait &ecirc;tre confondu avec l'indiff&eacute;rence &agrave; l'&eacute;gard des vivants confront&eacute;s &agrave; la mort. C'est, semble-t-il, ce que souhaite d&eacute;montrer ce livre, plaidoyer collectif en faveur de l'&eacute;mergence de nouvelles solidarit&eacute;s, d'un humanisme mieux ancr&eacute; dans les diversit&eacute;s des vies d'aujourd'hui. En annexe, des fragments de textes litt&eacute;raires et philosophiques donnent une profondeur temporelle impressionnante aux interrogations de l'homme autour de la mort. Il y a 35 si&egrave;cles, Gilgamesh disait d&eacute;j&agrave; son d&eacute;sespoir et sa peur de mourir. Thomas More, en 1516, dans l'Utopie, pr&eacute;conisait le recours &agrave; l'euthanasie si &quot;la maladie n'est pas seulement incurable mais s'accompagne de souffrances vraiment atroces et incessantes.&quot;<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.6"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.8"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-374</DOCNO>
<DOCOLDNO>IA017-000178-B044-2</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.8 192.33.214.13 19970106051209 text/html 5215
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:32 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Vivre le deuil au jour le jour: la perte d'une personne proche</H3><BLOCKQUOTE><B>Christophe Faur&eacute;</B><BR><I>Paris, Albin Michel, 1995, 250 p., 110 FF</I><P>M&eacute;decin psychiatre ayant tr&egrave;s t&ocirc;t &eacute;t&eacute; confront&eacute; au sida et aujourd'hui sp&eacute;cialis&eacute; en soins palliatifs, Christophe Faur&eacute; souligne d'embl&eacute;e que la recette du &quot;&nbsp;bon deuil&nbsp;&quot; n'existe pas. Normatifs, reposant sur des pr&eacute;suppos&eacute;s et des croyances, les modes d'emploi peuvent aller &agrave; fin contraire, se r&eacute;v&eacute;ler d&eacute;vastateurs. Le deuil est un v&eacute;cu qui appartient &agrave; chaque individu et qui ne peut s'abstraire d'une multitude de facteurs sp&eacute;cifiques comme la nature des relations avec le d&eacute;funt, le parcours de la maladie et de l'accompagnement, les circonstances de la mort. D'o&ugrave; la nocivit&eacute; de ces id&eacute;es re&ccedil;ues telles que la pr&eacute;tendue n&eacute;cessit&eacute; d'une rupture avec le pass&eacute;, l'affirmation que le deuil est affaire de volont&eacute;, le soi-disant danger qu'il y aurait &agrave; parler du d&eacute;funt ou &agrave; exprimer ses &eacute;motions, la foi qu'il suffirait de laisser faire le temps, facteur d'oubli...<P>Cette m&eacute;connaissance de la r&eacute;alit&eacute; du deuil, l'auteur l'a v&eacute;cue avec violence quand il a &eacute;t&eacute; confront&eacute; &agrave; l'absence de toute structure d'&eacute;coute des proches en milieu hospitalier et, comme volontaire de l'association AIDES, quand il a pris conscience que le deuil, avec ses r&eacute;percussions impitoyables, &quot;&eacute;tait un aspect fondamental dans la prise en compte globale de la r&eacute;alit&eacute; de l'&eacute;pid&eacute;mie.&quot;<P>Aider &agrave; se confronter au deuil, ce n'est donc pas, pour Christophe Faur&eacute;, proposer un mod&egrave;le de pr&ecirc;t &agrave; porter mais faciliter une meilleure compr&eacute;hension de ce processus. Son livre y contribue avec talent et conviction. Il offre les rep&egrave;res th&eacute;oriques indispensables et d&eacute;finit avec rigueur des concepts souvent mal per&ccedil;us par le profane tel celui du &quot;&nbsp;travail&nbsp;&quot; de deuil. Il expose les &quot;&nbsp;&eacute;tapes du deuil&nbsp;&quot; en mettant en garde contre une appr&eacute;hension trop rigide de ce qui n'est qu'une construction pour rendre un processus plus intelligible, ces &eacute;tapes n'&eacute;tant valables qu'en &quot;&nbsp;g&eacute;n&eacute;ral&nbsp;&quot; et susceptibles de se chevaucher. Un chapitre est consacr&eacute; &agrave; diverses cat&eacute;gories de pertes: conjoint, enfants, adolescents, parents, d&eacute;c&egrave;s par suicide; un autre se penche sur la clarification et la pratique de la relation d'aide. A propos des deuils compliqu&eacute;s, la r&eacute;f&eacute;rence &agrave; celui devenu chronique et pathologique de la reine Victoria est d'autant plus int&eacute;ressante que l'attitude de la souveraine r&eacute;ussit, durant plusieurs g&eacute;n&eacute;rations, &agrave; s'imposer comme r&eacute;f&eacute;rence sociale! Il est vrai que, du deuil oblig&eacute; et sans fin du mod&egrave;le victorien au deuil occult&eacute; d'aujourd'hui,  il y a comme un cheminement contraire. Mais la s&eacute;duction moderne pour les routes d'&eacute;vitement est-elle finalement moins troublante que l'attirance pour les impasses? Or, Gabriel Faur&eacute; nous rappelle de mani&egrave;re imag&eacute;e que, &quot;&nbsp;pour sortir du tunnel, il est indispensable d'y entrer.&nbsp;&quot; D'o&ugrave; l'importance d'en conna&icirc;tre la topographie et les obstacles et d'avoir &agrave; disposition les mains tendues qui aideront &agrave; d&eacute;couvrir une sortie dont la lumi&egrave;re n'effacera pas le souvenir de l'&ecirc;tre aim&eacute;.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.7"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.9"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-375</DOCNO>
<DOCOLDNO>IA017-000178-B044-12</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.9 192.33.214.13 19970106051216 text/html 3914
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:39 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Couples homophiles: le droit &agrave; l'existence ? <BR>R&eacute;flexion &eacute;thique sur le statut actuel des homophiles</H3><BLOCKQUOTE><I>Lausanne, Institut d'Ethique Sociale, 1995, 68 p., 25 FS<BR></I><BR>En janvier 1995, une rencontre organis&eacute;e par le Minist&egrave;re pour les probl&egrave;mes conjugaux et familiaux de l'Eglise &eacute;vang&eacute;lique r&eacute;form&eacute;e de Berne-Jura et l'Institut d'Ethique Sociale se proposait de d&eacute;battre des droits qui devraient &ecirc;tre accord&eacute;s aux couples de m&ecirc;me sexe. Les deux expos&eacute;s pr&eacute;sent&eacute;s dans ce cadre forment le noyau de cette publication.<BR> <BR>Wolfgang Lienemann pr&eacute;sente un point de vue th&eacute;ologique qui s'inscrit dans le courant moderniste: une critique objective des traditions bibliques, et en particulier de Paul, l'incite &agrave; mettre en &eacute;vidence les notions d'Amour et de responsabilit&eacute; &agrave; l'&eacute;gard de la corpor&eacute;it&eacute;, propres &agrave; r&eacute;habiliter la sexualit&eacute;, celle-ci &eacute;tant susceptible de relever du &quot;satanique&quot; dans la mesure o&ugrave; son exercice s'opposerait au service de Dieu et de notre prochain. Soucieux de consensus au sein d'une Eglise d&eacute;chir&eacute;e par des opinions apparemment inconciliables, l'auteur plaide pour l'adh&eacute;sion  au droit moderne et pour &quot;l'int&eacute;gration l&eacute;gale au droit de la famille d'un partenariat enregistr&eacute;, dans une forme qui se rapproche beaucoup du mariage, tout en restant clairement distincte de celui-ci...&quot;<P>Annemarie Geissb&uuml;hler nous propose un aper&ccedil;u des questions juridiques soulev&eacute;es par la p&eacute;tition &quot;les m&ecirc;mes droits pour les couples de m&ecirc;me sexe&quot;: mise en &eacute;vidence des disparit&eacute;s de traitement induites par le r&eacute;gime actuel de non-reconnaissance, inventaire des mises &agrave; jour qu'impliquerait l'extension aux homosexuels du principe de l'&eacute;galit&eacute; devant la loi et de l'inviolabilit&eacute; de la dignit&eacute; humaine.<BR>Plusieurs documents sont propos&eacute;s en annexe, dont le texte de la p&eacute;tition &quot;les m&ecirc;mes droits pour les couples de m&ecirc;me sexe&quot; et quelques prises de position sur l'homosexualit&eacute; &eacute;manant d'Eglises de la mouvance protestante suisse. Un dossier utile pour un d&eacute;bat qui peine encore &agrave; s'extirper des retranchements dans lesquels une tradition s&eacute;culaire l'avait confin&eacute;.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.8"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.10"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-376</DOCNO>
<DOCOLDNO>IA017-000178-B044-24</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.10 192.33.214.13 19970106051224 text/html 3796
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:46 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>L'amour et le pr&eacute;servatif</H3><BLOCKQUOTE><B>Tony Anatrella</B><BR><I>Paris, Flammarion, 1995, 150 p., 120 FF</I><P>Psychanalyste et pr&ecirc;tre, Tony Anatrella r&egrave;gle ses comptes avec les campagnes de pr&eacute;vention du sida, coupables de nous &quot;inciter &agrave; la r&eacute;gression&quot; et de &quot;nous y maintenir&quot;, de &quot;d&eacute;velopper l'id&eacute;e que l'autre est dangereux&quot;, d' &quot;imposer l'homosexualit&eacute; comme un mod&egrave;le social&quot; et de bien d'autres intentions mal&eacute;fiques. En confondant - sciemment ? - la prise en compte des sexualit&eacute;s marginales avec leur promotion officielle, en se livrant &agrave; des manipulations contestables (humour d'auteurs de BD interpr&eacute;t&eacute; au premier degr&eacute;, d&eacute;rives isol&eacute;es d&eacute;crites comme repr&eacute;sentatives, recours s&eacute;lectif &agrave; des t&eacute;moignages de patients en psychanalyse...), en m&ecirc;lant interrogations l&eacute;gitimes et pol&eacute;miques de bas &eacute;tage, en nous faisant prendre pour iconoclastes des questions d&eacute;sarmantes de banalit&eacute;, l'auteur semble s'ing&eacute;nier &agrave; torpiller la r&eacute;flexion de fond qu'il pr&eacute;tend mener. La conception relationnelle de la sexualit&eacute; qui nous est propos&eacute;e appara&icirc;t finalement comme un paravent &agrave; une entreprise de r&egrave;glement de comptes &agrave; l'&eacute;gard de ceux qui n'entrent pas dans le moule psychanalytique et th&eacute;ologique bricol&eacute; pour la bonne cause. Le langage abscons permet tant&ocirc;t de mieux emballer un discours insultant et blessant, tant&ocirc;t de donner une caution &quot;scientifique&quot; &agrave; des exhortations id&eacute;ologiques. Ainsi, &agrave; propos du discours sur le pr&eacute;servatif qui  &quot;entretient cet id&eacute;alisme du moi qui l'emp&ecirc;che d'acc&eacute;der &agrave; une conscience morale (puisqu'il n'y a pas de manque), et qui le fait hurler de souffrance &agrave; l'&eacute;coute d'une parole significative, car celle-ci manifeste l'espace et la faille du manque, source du d&eacute;sir. Il est difficile de sortir de l'attachement maternel, structure de l'omnipotence, pour se diff&eacute;rencier afin d'&ecirc;tre relativis&eacute; par la parole du p&egrave;re.&quot;<BR>&nbsp;<BR>N'y-a-t-il pas l&agrave;, finalement, mati&egrave;re &agrave; un d&eacute;solant dialogue de sourds?<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.9"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.11"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-377</DOCNO>
<DOCOLDNO>IA017-000178-B044-38</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.11 192.33.214.13 19970106051233 text/html 1918
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:12:55 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Essais th&eacute;rapeutiques et  &eacute;tudes cliniques</H3><BLOCKQUOTE><B>Jean-Pierre Le Floch, L&eacute;on Perlemuter</B><BR><I>Paris, Masson, 1995, 472 p., 180 FF</I><P>Cet ouvrage se propose de r&eacute;pondre aux besoins des acteurs professionnels intervenants dans le d&eacute;roulement d'une &eacute;tude. Il traite de la construction d'une &eacute;tude, de sa conception jusqu'au recueillement des donn&eacute;es, du suivi, des probl&egrave;mes sp&eacute;cifiques, des crit&egrave;res &eacute;thiques et l&eacute;gaux, de la gestion des anomalies et de la terminaison de l'&eacute;tude. </BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.10"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.12"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-378</DOCNO>
<DOCOLDNO>IA017-000178-B044-50</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.12 192.33.214.13 19970106051244 text/html 1927
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:06 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.13"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Vivre son mourir</H3><BLOCKQUOTE><B>Isabelle Delisle</B><BR><I>Ottawa, Mortagne, 1995, 336 p., 49 FF</I><P>Ouvrage &eacute;trangement illumin&eacute; qui conviendra &agrave; ceux que l'&eacute;vocation incantatoire du bonheur, de la lumi&egrave;re, du bien supr&ecirc;me, de l'harmonie, de l'accomplissement, du positif et de la &quot;vraie&quot; vie ne finit pas par lasser. Magie divinatoire et philosophie b&eacute;ate pour &quot;s'approprier la mort comme une gerbe de fleurs&quot;, recettes s&eacute;raphiques pour  personnes dot&eacute;es d'un solide app&eacute;tit de bonheur...<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.11"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.13"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-379</DOCNO>
<DOCOLDNO>IA017-000178-B044-64</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.13 192.33.214.13 19970106051254 text/html 3687
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:15 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.14"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Le t&eacute;moin myope Regards sur le sida</H3><BLOCKQUOTE><B>Cyrille Koupernik</B><BR><I>Paris, L'Harmattan, 1995, 190 p.</I><P>De quelques mutations sociales induites par le sida, vues &agrave; travers la lorgnette d'un collectionneur de coupures de journaux. Si le t&eacute;moin collectif est jug&eacute; myope, l'auteur est-il pour autant un analyste innocent, impartial, capable de se situer hors du noeud d'enjeux de pouvoir et de basses intrigues? Il nous propose en tout cas un ouvrage &agrave; l'ambiance lourde, m&eacute;lange de peur et de clairvoyance, ambivalent dans les r&eacute;ponses sugg&eacute;r&eacute;es comme dans les convictions morales exprim&eacute;es en filigrane. Pr&eacute;senter la &quot;sexualit&eacute; libre&quot; comme un parcours qui m&egrave;ne &quot;&agrave; cet Enfer sur terre&quot;, demander la censure, voire l'interdiction, des &eacute;changes par Minitel et des petites annonces sp&eacute;cialis&eacute;es, c'est oublier les effets pervers et l'efficacit&eacute; illusoire d'une approche pr&eacute;ventive qui commence par juger et finit par infantiliser. Mais le rappel des messages contradictoires ou des pr&eacute;visions erron&eacute;es qui &eacute;maillent l'histoire du sida ne devrait pas manquer d'inciter &agrave; la r&eacute;flexion les amateurs de positions carr&eacute;es et d&eacute;finitives. Il y a aussi les ph&eacute;nom&egrave;nes de r&eacute;cup&eacute;ration id&eacute;ologique et Cyrille Koupernik a mille fois raison de mettre en garde contre certaines d&eacute;rives utilitaristes, telle celle qui appr&eacute;hende le sida africain comme une sorte de r&eacute;gulation inesp&eacute;r&eacute;e des naissances.<P>Pamphl&eacute;taire, par son style, par ses approximations, par sa mani&egrave;re d'utiliser les citations, ce livre refl&egrave;te pourtant un effort d'ouverture vers des pistes peu famili&egrave;res &agrave; son auteur. Celui-ci a l'honn&ecirc;tet&eacute; de dire n'avoir &quot;aucune comp&eacute;tence particuli&egrave;re pour parler du SIDA&quot; et d'avouer &ecirc;tre &quot;fascin&eacute; par le pr&eacute;sent&quot; pour r&ecirc;ver &quot;comme r&ecirc;ve un psychiatre: il essaye de r&eacute;cr&eacute;er la vie &agrave; partir du dit et du non-dit.&quot; Exercice p&eacute;rilleux, non d&eacute;pourvu d'int&eacute;r&ecirc;t et... de bizarreries!<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.12"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.14"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-380</DOCNO>
<DOCOLDNO>IA017-000178-B044-77</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.14 192.33.214.13 19970106051305 text/html 2188
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:25 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.13"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.15"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Une mort africaine <BR>Le sida au quotidien</H3><BLOCKQUOTE><B>Hubert Prolongeau</B><BR><I>Paris, Le Seuil, 1995</I><P>Le quotidien du sida en Ouganda. Un reportage de terrain, intelligent et empathique, qui sait situer les noeuds d'une trag&eacute;die face &agrave; laquelle les initiatives humanitaires de l'Occident s'&eacute;puisent dans le d&eacute;couragement et l'insuffisance de moyens. La sant&eacute; en Ouganda, c'est six dollars par t&ecirc;te et par an! Et le sida dans le monde, c'est 92% des budgets de recherche pour 8% des malades. Chiffres impitoyables, mis en exergue dans ce livre, et dont la communaut&eacute; internationale ne semble, jusqu'ici, prendre connaissance qu'avec un haussement d'&eacute;paule g&ecirc;n&eacute;. Esp&eacute;rons que ce t&eacute;moignage aide &agrave; surmonter cette coupable l&eacute;thargie.<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.13"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.15"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-381</DOCNO>
<DOCOLDNO>IA017-000178-B044-94</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.15 192.33.214.13 19970106051312 text/html 2681
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:35 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.14"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.16"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Sang contamin&eacute;<BR>Priorit&eacute;s d'Etat et d&eacute;cisions politiques</H3><BLOCKQUOTE><B>Jacques Roux</B><BR><I>Montpellier, Espaces 34, 1995, 236 p., 98 FF</I><P>Le Professeur Jacques Roux &eacute;tait Directeur g&eacute;n&eacute;ral de la Sant&eacute; publique de 1981 &agrave; 1985, &agrave; l'&eacute;poque de l'affaire du sang contamin&eacute;. Il figure parmi les quatre personnalit&eacute;s inculp&eacute;es et condamn&eacute;es &agrave; l'issue d'un proc&egrave;s controvers&eacute;.<P>Son point de vue pr&eacute;sente l'int&eacute;r&ecirc;t de remonter aux racines, multiples et tortueuses, d'une bien &eacute;trange affaire. Une affaire brouill&eacute;e par l'&eacute;motion, brouill&eacute;e par une certaine irresponsabilit&eacute; politicienne, brouill&eacute;e par l'insurmontable contradiction entre exigence l&eacute;gitime de qualit&eacute; et restrictions budg&eacute;taires. Le style pond&eacute;r&eacute;, le parti pris humaniste de l'auteur, renforcent la cr&eacute;dibilit&eacute; d'un t&eacute;moignage qui donne, d'abord, &agrave; penser sur les dysfonctionnements et les blocages de notre soci&eacute;t&eacute;. Car si drame il y a eu, celui-ci ne semble s'&ecirc;tre sold&eacute;, pour l'instant que par un proc&egrave;s sacrificiel et la mise sous boisseau de quelques questions fondamentales...<P><I>RCh<BR></I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.14"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.16"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-382</DOCNO>
<DOCOLDNO>IA017-000178-B044-109</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.16 192.33.214.13 19970106051320 text/html 1849
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:42 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.15"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.17"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>De la syphilis au sida <BR>Cinq si&egrave;cles de m&eacute;moire litt&eacute;raire de V&eacute;nus</H3><BLOCKQUOTE><B>Jean Goens</B><BR><I>Bruxelles, Presses Interuniversitaires Europ&eacute;ennes, 1995, 230 p., 160 FF</I><P>Cet ouvrage envisage la dimension socio-culturelle des maladies v&eacute;n&eacute;riennes dans leur &eacute;volution chronologique au travers des &eacute;crits litt&eacute;raires. Histoire essentiellement consacr&eacute;e &agrave; la syphilis. Un &eacute;pilogue aborde le sida et le retour de la peur.</BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.15"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:5.17"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-383</DOCNO>
<DOCOLDNO>IA017-000178-B044-121</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:5.17 192.33.214.13 19970106051328 text/html 2759
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:50 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.16"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Un mal imaginaire</H3><BLOCKQUOTE><B>Maxime Montel</B><BR><I>Paris, Editions de Minuit, 1994, 111p., 65 FF</I><P>Maxime Montel, dans un langage qui lui est propre, nous livre une r&eacute;flexion d&eacute;capante sur le sida. Sans complaisance, parlant d'une r&eacute;alit&eacute; qu'il conna&icirc;t plus que bien, il nous invite &agrave; laisser tomber nos illusions.<P> ...nous sommes condamn&eacute;s &agrave; vivre &agrave; pic au-dessus du non-&ecirc;tre, pos&eacute;s sur une fracture, entre ce qui vit et ce qui est mort. <P>Ou, plus loin:  Comment pourrions-nous ne pas osciller sans cesse entre folie et raison, otages de nos propres corps tromp&eacute;s, victimes d'une surexposition permanente &agrave; l'in&eacute;luctable: l'&eacute;vidence de notre disparition? <P>L'auteur parcourt ainsi le chemin qui m&egrave;ne de la vie &agrave; la mort, nous obligeant sans cesse &agrave; ne pas nous mentir. Rien n'&eacute;chappe &agrave; son scalpel. Il parle aussi du t&eacute;moignage:  T&eacute;moigner n'appartient &agrave; personne. T&eacute;moigner n'est pas de notre pouvoir. Chacun de nous n'est qu'un exemple &agrave; proposer. Il faudrait ajouter bout &agrave; bout toutes nos histoires... <P>Puis, au d&eacute;tour d'une page, le ton change, l'&eacute;motion, la tendresse s'encha&icirc;nent autour de textes offerts &agrave; ses amis disparus.<P>Un petit livre &agrave; lire et relire...<P><I>Dominique Roulin</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.16"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:6"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT18-B27-384</DOCNO>
<DOCOLDNO>IA017-000178-B044-131</DOCOLDNO>
<DOCHDR>
http://hivnet.unige.ch:80/anais/INFOTHEQUE.cgi?9601:6 192.33.214.13 19970106051336 text/html 3236
HTTP/1.0 200 OK
Server: Netscape-Communications/1.1
Date: Monday, 06-Jan-97 05:13:58 GMT
Content-type: text/html
</DOCHDR>
<HTML>
<HEAD><TITLE>INFOTHEQUE SIDA - Infoth&egrave;que SIDA 01/96</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">
<A HREF="/anais/search"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Search2.gif"></A>
<A HREF="INFOTHEQUE.cgi?+9601"><IMG ALIGN=RIGHT BORDER=0 SRC="/gif/Bibliotheque2.gif"></A><IMG ALIGN=left BORDER=0 SRC="INFOTHEQUE/gif/marge.gif"><H2>AIDS INFOTHEK - INFOTHEQUE SIDA</H2><I>Das Magazin der Aids Info Docu Schweiz<BR>Le magazine de Sida Info Doc Suisse</I><BR CLEAR><p><center><b><i>les interactions entre le psychisme, le syst&egrave;me endocrinien, le syst&egrave;me immunitaire et le syst&egrave;me nerveux central existent bel et bien au niveau physiologique, anatomique et au niveau de la biologie mol&eacute;culaire, m&ecirc;me si bien des questions restent ouvertes.</i></b></center><p><CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.17"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:7.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
<UL>
<H3>Publications r&eacute;centes</H3><BLOCKQUOTE>Les ouvrages ci-apr&egrave;s nous sont parvenus ou sont parus trop tardivement pour que nous puissions en rendre compte dans cette Infoth&egrave;que. Nous nous r&eacute;servons d'y revenir dans une prochaine &eacute;dition.<P><B>Le g&eacute;n&eacute;raliste et son patient</B><BR>Monique Gu&eacute;rin<BR><I>Paris, Flammarion, collection Dominos, 1995, 128 p., 39 FF</I><P><B>Banque de donn&eacute;es sant&eacute; publique</B><BR><I>Rennes, ENSP, 1995, 3 volumes 256, 291 et 135 p., 500 FF</I><P><B>Douleur et m&eacute;decine, la fin d'un oubli</B> <BR>Isabelle Baszanger<BR><I>Paris, Seuil, 1995, 467 p., 155 FF</I><P><B>Faire l'&eacute;ducation sexuelle &agrave; l'&eacute;cole <BR></B>Marie-Paule Desaulniers<BR><I>Montr&eacute;al, Editions Nouvelles, 180 p., 142 FF</I><P><B>Emotions: essai sur le corps et le social</B> <BR>Paul Dumouchel<BR><I>Le Plessis-Robinson, Synth&eacute;labo, 1995, 230 p., 84 FF</I><P><B>Contes des vies rus&eacute;es</B> <BR>Nordim Za&iuml;mi<BR><I>Paris, L'Harmattan, 1995</I><P><B>Intelligence et pratique du social<BR></B><B>La m&eacute;thode marketing au service des associations</B><BR>Bernard Dobiecki<BR><I>Gen&egrave;ve, Editions des Deux Continents, 1995, 210 p., 39;- FS</I><P><B>Traits d'union<BR></B><B>La communication associative en pratique</B><BR>Albert-Luc Hearing<BR><I>Gen&egrave;ve, IES, 1995, 180 p., 33.- FS</I><P><B>Les anges de Masilia</B><BR>Gilles Granouillet<BR><I>Montpellier, Espaces 34, collection Espace Th&eacute;&ecirc;tre, 1995, 96 p., 64 FF</I><P><B>L'infection &agrave; VIH. Savoir et comprendre</B><BR>Didier Sicard, Jean-Marie Faucher<BR><I>Montpellier, Espaces 34, 1996, 180 p. env., 90 FF env.</I><P><B>Communication et &eacute;motion. Essais de microsociologie relationnelle</B><BR>Simon Laflamme<BR><I>Paris, L'Harmattan, 1995, 192 p., 95 FF</I></BLOCKQUOTE></UL>
<HR>
<CENTER>
<A HREF="INFOTHEQUE.cgi?9601:5.17"><IMG BORDER=0 SRC="/gif/left.gif"></A>
<A HREF="INFOTHEQUE.cgi?9601:7.1"><IMG BORDER=0 SRC="/gif/right.gif"></A>
</CENTER>
</BODY>
</HTML>
</DOC>
